assay_id,curated_by,tid,assay_tissue,assay_category,description,doc_id,assay_type,assay_test_type,assay_organism,assay_tax_id,assay_strain,assay_cell_type,assay_subcellular_fraction
1,Autocuration,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,11087,B,,,,,,
2,Autocuration,22226,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,684,F,,,,,,
3,Autocuration,22226,,,,15453,B,,,,,,
4,Autocuration,104729,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,17841,B,,Bos taurus,9913.0,,,
5,Intermediate,80001,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),17430,F,,Homo sapiens,9606.0,,143B,
6,Intermediate,80001,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),17430,F,,Homo sapiens,9606.0,,143B,
7,Intermediate,80001,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,13799,F,,Mus musculus,10090.0,,143B,
8,Expert,80001,,,In vitro cell cytotoxicity was determined against 143B cell line,17774,F,,Homo sapiens,9606.0,,143B,
9,Intermediate,80001,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,3801,F,,Homo sapiens,9606.0,,143B,
10,Intermediate,80001,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,17430,F,,Homo sapiens,9606.0,,143B,
11,Intermediate,80001,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,17430,F,,Homo sapiens,9606.0,,143B,
12,Expert,80001,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,17774,F,,Homo sapiens,9606.0,,143B,
13,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,F,,Staphylococcus aureus,1280.0,,,
14,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,F,,Staphylococcus aureus,1280.0,,,
15,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,F,,Staphylococcus aureus,1280.0,,,
16,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",11324,F,,Staphylococcus aureus,1280.0,,,
17,Expert,100122,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,11347,A,,Rattus norvegicus,10116.0,,,
18,Autocuration,12054,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),16474,B,,,,,,
19,Autocuration,12054,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,10091,B,,,,,,
20,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),16474,B,,,,,,
21,Autocuration,12054,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),16474,B,,,,,,
22,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),16474,B,,,,,,
23,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,16474,B,,,,,,
24,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,16474,B,,,,,,
25,Autocuration,22226,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",14352,B,,,,,,
26,Autocuration,12054,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,5646,B,,Oryctolagus cuniculus,9986.0,,,
27,Autocuration,12054,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),5646,B,,Oryctolagus cuniculus,9986.0,,,
28,Autocuration,12426,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,10997,B,,,,,,
29,Autocuration,12054,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,6309,B,,soya bean,3847.0,,,
30,Autocuration,12054,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,167,B,,Glycine max,3847.0,,,
31,Autocuration,12054,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,167,B,,Glycine max,3847.0,,,
32,Autocuration,12054,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,11087,B,,Glycine max,3847.0,,,
33,Autocuration,12054,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,11087,B,,Glycine max,3847.0,,,
34,Autocuration,12054,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,13622,B,,Glycine max,3847.0,,,
35,Autocuration,12054,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,13622,B,,Glycine max,3847.0,,,
36,Autocuration,22226,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,11347,A,,Rattus norvegicus,10116.0,,,
37,Autocuration,22226,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,5926,B,,Escherichia coli,562.0,,,
38,Autocuration,22226,,,Dissociation constant with dimeric 16S rRNA RNA construct B,4567,B,,,,,,
39,Intermediate,22222,,,Dissociation constant towards 16S rRNA construct A,3782,B,,,,,,
40,Intermediate,22222,,,Dissociation constant towards 16S rRNA construct B,3782,B,,,,,,
41,Expert,100263,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,4466,B,,Escherichia coli,562.0,,,
42,Expert,100263,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,6592,B,,Escherichia coli,562.0,,,
43,Autocuration,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,B,,,,,,
44,Autocuration,13053,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,B,,,,,,
45,Autocuration,20001,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,13163,B,,Homo sapiens,9606.0,,,
46,Autocuration,20001,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,13163,B,,Homo sapiens,9606.0,,,
47,Expert,12971,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10691,B,,Rattus norvegicus,10116.0,,,
48,Expert,12971,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10691,B,,Rattus norvegicus,10116.0,,,
49,Expert,12971,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10691,B,,Rattus norvegicus,10116.0,,,
50,Expert,12971,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10691,B,,Rattus norvegicus,10116.0,,,
51,Autocuration,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),898,B,,,,,,
52,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),912,B,,,,,,
53,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,912,B,,,,,,
54,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,912,B,,,,,,
55,Autocuration,104740,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,15103,B,,Rattus norvegicus,10116.0,,,Membranes
56,Intermediate,80002,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,5116,F,,Homo sapiens,9606.0,,1A9,
57,Autocuration,104835,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,14578,F,,Rattus norvegicus,10116.0,,Oocytes,
58,Autocuration,104821,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,14578,F,,Rattus norvegicus,10116.0,,Oocytes,
59,Autocuration,104848,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,14578,F,,Rattus norvegicus,10116.0,,Oocytes,
60,Expert,80002,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,4787,F,,Homo sapiens,9606.0,,1A9,
61,Intermediate,80002,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,4787,F,,Homo sapiens,9606.0,,1A9,
62,Intermediate,80002,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,3547,F,,Homo sapiens,9606.0,,1A9,
63,Intermediate,80002,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,3547,F,,Homo sapiens,9606.0,,1A9,
64,Intermediate,80002,,,Effective dose of compound against replication of 1A9 cell line was evaluated,6726,F,,Homo sapiens,9606.0,,1A9,
65,Expert,80002,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,3455,F,,Homo sapiens,9606.0,,1A9,
66,Intermediate,80002,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),5726,F,,Homo sapiens,9606.0,,1A9,
67,Intermediate,80002,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,5726,F,,Homo sapiens,9606.0,,1A9,
68,Intermediate,80002,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,5726,F,,Homo sapiens,9606.0,,1A9,
69,Intermediate,80002,,,Inhibitory activity against Taxol resistant 1A9 cell lines,3395,F,,Homo sapiens,9606.0,,1A9,
70,Expert,80002,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,3415,F,,Homo sapiens,9606.0,,1A9,
71,Expert,80002,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,3415,F,,Homo sapiens,9606.0,,1A9,
72,Expert,80002,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,17099,F,,Homo sapiens,9606.0,,1A9,
73,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,17099,F,,Homo sapiens,9606.0,,1A9,
74,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,17099,F,,Homo sapiens,9606.0,,1A9,
75,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,17099,F,,Homo sapiens,9606.0,,1A9,
76,Intermediate,81072,,,Inhibitory concentration against Jurkat cells,17721,F,,Homo sapiens,9606.0,,Jurkat,
77,Intermediate,22226,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1229,F,,,,,,
78,Expert,100121,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,11347,A,,Rattus norvegicus,10116.0,,,
79,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",17117,B,,,,,,
80,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",17117,B,,,,,,
81,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",17117,B,,,,,,
82,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11375,B,,Candida albicans,5476.0,,,Microsomes
83,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11375,B,,Candida albicans,5476.0,,,Microsomes
84,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11375,B,,Saccharomyces cerevisiae,4932.0,,,Microsomes
85,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11375,B,,Saccharomyces cerevisiae,4932.0,,,Microsomes
86,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",11375,B,,Sus scrofa,9823.0,,,Microsomes
87,Autocuration,11231,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",791,B,,Rattus norvegicus,10116.0,,,
88,Autocuration,11231,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",791,B,,Rattus norvegicus,10116.0,,,
89,Autocuration,11231,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",791,B,,Rattus norvegicus,10116.0,,,
90,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",11375,B,,Rattus norvegicus,10116.0,,,Microsomes
91,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",11375,B,,Rattus norvegicus,10116.0,,,Microsomes
92,Autocuration,12083,Liver,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",153,B,,Rattus norvegicus,10116.0,,,Microsomes
93,Expert,11377,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),8269,B,,,,,,
94,Expert,11377,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,8269,B,,,,,,
95,Expert,81020,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,17653,F,,Homo sapiens,9606.0,,HepG2,
96,Intermediate,81020,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,14277,F,,Homo sapiens,9606.0,,HepG2,
97,Intermediate,81020,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1717,F,,Homo sapiens,9606.0,,HepG2,
98,Intermediate,81020,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,14091,F,,Homo sapiens,9606.0,,HepG2,
99,Intermediate,81020,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,14091,F,,Homo sapiens,9606.0,,HepG2,
100,Expert,50606,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,17653,F,,Hepatitis B virus,10407.0,,,
101,Intermediate,81020,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,13105,F,,Homo sapiens,9606.0,,HepG2,
102,Intermediate,81020,,,Concentration required to inhibit 50% of 2.2.15 cell line,1717,F,,Homo sapiens,9606.0,,HepG2,
103,Intermediate,81020,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,13105,A,,Homo sapiens,9606.0,,HepG2,
104,Intermediate,50587,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,13600,F,,Homo sapiens,9606.0,,2.2.15,
105,Intermediate,50587,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,13467,F,,Homo sapiens,9606.0,,2.2.15,
106,Expert,50606,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",17477,F,,Hepatitis B virus,10407.0,,2.2.15,
107,Intermediate,50587,,,In vitro anti-HBV activity in 2.2.15 cells,1593,F,,Homo sapiens,9606.0,,2.2.15,
108,Intermediate,50587,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1593,F,,Homo sapiens,9606.0,,2.2.15,
109,Intermediate,50587,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,15089,F,,Homo sapiens,9606.0,,2.2.15,
110,Intermediate,50587,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,15089,F,,Homo sapiens,9606.0,,2.2.15,
111,Intermediate,50587,,,Cytotoxicity in 2.2.15 cells,1593,F,,Homo sapiens,9606.0,,2.2.15,
112,Intermediate,50587,,,Cytotoxicity in 2.2.15 cells; Not determined,1593,F,,Homo sapiens,9606.0,,2.2.15,
113,Intermediate,50587,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,13600,F,,Homo sapiens,9606.0,,2.2.15,
114,Intermediate,50587,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,13467,F,,Homo sapiens,9606.0,,2.2.15,
115,Intermediate,50587,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,13467,F,,Homo sapiens,9606.0,,2.2.15,
116,Intermediate,81020,,,Antiviral activity against HBV was determined in 2.215 cell line,14764,F,,Homo sapiens,9606.0,,HepG2,
117,Autocuration,22226,,,Inhibition of 20-HETE synthesis in human renal microsomes,6531,B,,Homo sapiens,9606.0,,,Microsomes
118,Autocuration,22226,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,17322,B,,,,,,
119,Intermediate,80612,,,Inhibitory concentration against 2008 (ovarian) cells,17072,F,,Homo sapiens,9606.0,,2008,
120,Intermediate,80612,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,16936,F,,Homo sapiens,9606.0,,2008,
121,Intermediate,80612,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),16936,F,,Homo sapiens,9606.0,,2008,
122,Intermediate,80612,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,17146,F,,Homo sapiens,9606.0,,2008,
123,Intermediate,80612,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,17146,F,,Homo sapiens,9606.0,,2008,
124,Intermediate,80613,,,In vitro inhibition of 2008/R ovarian cancer cell line,10797,F,,Homo sapiens,9606.0,,2008/R,
125,Intermediate,80613,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,10797,F,,Homo sapiens,9606.0,,2008/R,
126,Intermediate,80614,,,In vitro inhibition of 2008/S ovarian cancer cell line,10797,F,,Homo sapiens,9606.0,,2008/S,
127,Intermediate,80614,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,10797,F,,Homo sapiens,9606.0,,2008/S,
128,Expert,100256,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,4823,B,,Homo sapiens,9606.0,,,
129,Intermediate,100256,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,12912,B,,Homo sapiens,9606.0,,,
130,Expert,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome,2957,B,,,,,,
131,Expert,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,2957,B,,,,,,
132,Intermediate,100256,,,Inhibitory activity against 20S proteosome,3260,B,,,,,,
133,Autocuration,22226,,,Compound was tested for inhibitory activity against tryptase,3451,B,,Homo sapiens,9606.0,,,
134,Intermediate,81020,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,13885,F,,Homo sapiens,9606.0,,HepG2,
135,Intermediate,81020,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,13885,F,,Homo sapiens,9606.0,,HepG2,
136,Autocuration,22226,,,Compound was tested for the inhibition of Alpha-glucosidase,3676,B,,,,,,
137,Autocuration,235,,,Inhibitory concentration against human neutrophil elastase (HNE),6043,B,,,,,,
138,Autocuration,22226,Heart,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,11140,F,,Rattus norvegicus,10116.0,,,
139,Autocuration,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,10543,F,,,,,,
140,Expert,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,10543,F,,,,,,
141,Autocuration,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,10543,B,,,,,,
142,Expert,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,10543,F,,,,,,
143,Intermediate,80360,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,11365,F,,Mus musculus,10090.0,,P338,
144,Intermediate,80360,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,11365,F,,Mus musculus,10090.0,,P338,
145,Intermediate,80384,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,11803,F,,Homo sapiens,9606.0,,PBL,
146,Autocuration,22226,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,11803,F,,Ovis aries,9940.0,,,
147,Autocuration,22226,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,11803,F,,Ovis aries,9940.0,,,
148,Autocuration,191,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),12278,B,,,,,,
149,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,8249,F,,Homo sapiens,9606.0,,,
150,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,8249,F,,Homo sapiens,9606.0,,,
151,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,8249,F,,Homo sapiens,9606.0,,CCRF-CEM,
152,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,8249,F,,Homo sapiens,9606.0,,CCRF-CEM,
153,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,8249,F,,Homo sapiens,9606.0,,CCRF-CEM,
154,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,8249,F,,Homo sapiens,9606.0,,CCRF-CEM,
155,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,8249,F,,Homo sapiens,9606.0,,,
156,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,8249,F,,Homo sapiens,9606.0,,,
157,Autocuration,104290,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,16992,B,,,,,,
158,Intermediate,50264,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,10543,F,,Streptococcus pyogenes,1314.0,,,
159,Intermediate,50527,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),17833,F,,Human herpesvirus 3,10335.0,,,
160,Expert,50527,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,17290,F,,vericilla zoster virus,10335.0,,HEL,
161,Intermediate,50527,,,Antiviral activity against 07/1 strain of VZV; ND: No data,17290,F,,vericilla zoster virus,10335.0,,,
162,Intermediate,50527,,,Antiviral activity against 07/1 strain of VZV; ND=No data,17290,F,,vericilla zoster virus,10335.0,,,
163,Intermediate,50145,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",10932,F,,escherichia cloac,561.0,,,
164,Autocuration,22226,,,Ratio of Ki at A2 to Ki at A1 receptors,9707,B,,,,,,
165,Expert,11143,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",2346,B,,Candida albicans,5476.0,,,
166,Expert,18077,,,"Inhibition of 1,3-beta-glucan synthase",2205,B,,Candida glabrata CBS 138,284593.0,,,
167,Intermediate,80609,,,Inhibition of growth of 1-87 human tumor cell line,11900,F,,Homo sapiens,9606.0,,1-87 tumor cell line,
168,Expert,12166,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,14864,B,,Rattus norvegicus,10116.0,,,
169,Autocuration,100171,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),16474,B,,Glycine max,3847.0,,,
170,Autocuration,100171,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,16474,B,,Glycine max,3847.0,,,
171,Autocuration,100171,,,% inhibition against soybean 1-lipoxygenase (SLO),16474,B,,Glycine max,3847.0,,,
172,Autocuration,100171,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,16474,B,,Glycine max,3847.0,,,
173,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,3094,B,,Glycine max,3847.0,,,
174,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,3094,B,,Glycine max,3847.0,,,
175,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,3094,B,,Glycine max,3847.0,,,
176,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,3094,B,,Glycine max,3847.0,,,
177,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,3094,B,,Glycine max,3847.0,,,
178,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,3094,B,,Glycine max,3847.0,,,
179,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,3094,B,,Glycine max,3847.0,,,
180,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,3094,B,,Glycine max,3847.0,,,
181,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,3094,B,,Glycine max,3847.0,,,
182,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,3094,B,,Glycine max,3847.0,,,
183,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,3094,B,,Glycine max,3847.0,,,
184,Autocuration,22226,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,10413,B,,Mus musculus,10090.0,,,
185,Intermediate,80049,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),16929,F,,Mus musculus,10090.0,,C3H 10T1/2,
186,Intermediate,22226,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1229,F,,,,,,
187,Autocuration,11489,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),16587,B,,,,,,
188,Autocuration,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),16587,B,,,,,,
189,Autocuration,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,16587,B,,,,,,
190,Autocuration,11489,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,16587,B,,,,,,
191,Autocuration,11862,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,16587,B,,,,,,
192,Expert,12347,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,8058,F,,Bos taurus,9913.0,,,
193,Expert,100120,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,9065,B,,Rattus norvegicus,10116.0,,,
194,Expert,100120,Adrenal gland,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,8865,B,,Rattus norvegicus,10116.0,,,
195,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase,9066,B,,Rattus norvegicus,10116.0,,,
196,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase,8394,B,,Rattus norvegicus,10116.0,,,
197,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,8394,B,,Rattus norvegicus,10116.0,,,
198,Autocuration,10328,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,6431,B,,,,,,
199,Autocuration,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,6431,B,,,,,,
200,Autocuration,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,6431,B,,,,,,
201,Autocuration,11134,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,9295,F,,,,,,
202,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,B,,,,,,
203,Autocuration,11134,,,Compound was tested in vitro for inhibition of 12-LO human platelet,13622,B,,,,,,
204,Autocuration,11134,,,Inhibitory concentration against human platelet 12-lipoxygenase,12079,F,,,,,,
205,Autocuration,11134,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,13622,B,,,,,,
206,Autocuration,11134,,,Inhibitory concentration against human platelet 12-lipoxygenase,12079,F,,Homo sapiens,9606.0,,,
207,Expert,11835,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,13500,B,,,,,,
208,Expert,11601,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,13723,B,,,,,,
209,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),16474,B,,,,,,
210,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase,1630,B,,,,,,
211,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,167,B,,,,,,
212,Autocuration,11134,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),16474,B,,,,,,
213,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,167,B,,,,,,
214,Autocuration,11134,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,16474,B,,,,,,
215,Autocuration,11601,,,Inhibitory activity towards porcine 12-lipoxygenase,10091,B,,,,,,
216,Autocuration,11601,,,Tested for inhibition against porcine 12-LO,11966,B,,,,,,
217,Autocuration,12052,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,951,B,,,,,,
218,Autocuration,12052,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,10997,B,,,,,,
219,Expert,12052,,,In vitro inhibition of rat platelet 12-lipoxygenase,10193,B,,,,,,
220,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,B,,,,,,
221,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,10193,B,,,,,,
222,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,10193,B,,,,,,
223,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,10193,B,,,,,,
224,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,10193,B,,,,,,
225,Autocuration,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,11087,B,,,,,,
226,Intermediate,80007,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,15569,F,,Homo sapiens,9606.0,,41M,
227,Expert,80007,,,In vitro antitumor activity against 41M cell line.,12989,F,,Homo sapiens,9606.0,,41M,
228,Intermediate,80007,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,16745,F,,Homo sapiens,9606.0,,41M,
229,Intermediate,80007,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,15569,F,,Homo sapiens,9606.0,,41M,
230,Expert,80007,,,In vitro antitumor activity against 41McisR cell line.,12989,F,,Homo sapiens,9606.0,,41M,
231,Expert,80007,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,12989,F,,Homo sapiens,9606.0,,41M,
232,Intermediate,80007,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,16745,F,,Homo sapiens,9606.0,,41M,
233,Expert,84,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),6210,B,,Homo sapiens,9606.0,,,
234,Expert,68,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),6210,B,,Homo sapiens,9606.0,,,
235,Expert,68,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),6226,B,,,,,,
236,Expert,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,17855,B,,,,,,
237,Expert,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,17855,B,,,,,,
238,Expert,10201,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,17855,B,,,,,,
239,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",10413,B,,,,,,
240,Autocuration,11303,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",10413,B,,Escherichia coli,562.0,,,
241,Autocuration,11303,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",10413,B,,Escherichia coli,562.0,,,
242,Autocuration,11303,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",10413,B,,Escherichia coli,562.0,,,
243,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",10413,B,,,,,,
244,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",10413,B,,,,,,
245,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
246,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",7587,B,,Sus scrofa,9823.0,,,
247,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
248,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
249,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
250,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
251,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
252,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
253,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
254,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",7587,B,,Sus scrofa,9823.0,,,
255,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
256,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
257,Autocuration,11303,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",7323,B,,,,,,
258,Autocuration,22226,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",7587,B,,Sus scrofa,9823.0,,,
259,Autocuration,22226,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",7587,B,,Sus scrofa,9823.0,,,
260,Expert,100249,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,13750,B,,Saccharomyces cerevisiae,4932.0,,,
261,Autocuration,22226,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,7662,B,,Rattus norvegicus,10116.0,,,
262,Autocuration,22226,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,7662,B,,Rattus norvegicus,10116.0,,,
263,Autocuration,22226,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",7662,B,,Rattus norvegicus,10116.0,,,
264,Autocuration,104698,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",12211,F,,,,,,
265,Autocuration,104698,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",12211,F,,,,,,
266,Intermediate,20033,Ileum,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,12211,F,,Cavia porcellus,10141.0,,,
267,Expert,10623,,,Stimulatory activity of intragastric pressure was tested in the rat,12211,F,,,,,,
268,Autocuration,121,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,15453,B,,,,,,
269,Autocuration,22226,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),11884,F,,Rattus norvegicus,10116.0,,,
270,Autocuration,12688,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,7185,F,,,,,,
271,Expert,121,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,6876,B,,Homo sapiens,9606.0,,,
272,Expert,121,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,6876,B,,Homo sapiens,9606.0,,,
273,Autocuration,12198,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,11863,F,,,,,,
274,Autocuration,12198,,,Inhibition constant of high-affinity 5-HT uptake,11863,B,,,,,,
275,Autocuration,12198,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,11863,F,,,,,,
276,Autocuration,12198,,,Maximum rate was determined for high affinity transport of 5-HT,11863,F,,,,,,
277,Autocuration,104714,,,Compound was tested for agonistic activity against 5-HT uptake,4639,F,,,,,,
278,Expert,10577,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,15796,B,,,,,,
279,Expert,105,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,15796,B,,Bos taurus,9913.0,,,
280,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,12801,B,,Rattus norvegicus,10116.0,,,
281,Autocuration,104744,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,12801,B,,,,,,
282,Autocuration,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,12120,B,,,,,,Membranes
283,Autocuration,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,12120,B,,,,,,Membranes
284,Autocuration,104744,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,11963,B,,,,,,
285,Autocuration,51,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,11701,F,,,,,,
286,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
287,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
288,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
289,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),16394,F,In vivo,,,,,
290,Intermediate,105570,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,11574,F,,Cavia porcellus,10141.0,,,
291,Autocuration,279,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
292,Autocuration,107,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,15363,B,,,,,,
293,Expert,12687,,,Efficacy against 5-hydroxytryptamine 2A receptor,15363,F,,Rattus norvegicus,10116.0,,,
294,Expert,12687,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,15329,F,,,,,,
295,Expert,12687,,,Relative potency towards 5-HT2A receptor of rat tail artery,15329,F,,,,,,
296,Expert,12687,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,15329,F,,,,,,
297,Expert,12687,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,15329,F,,,,,,
298,Autocuration,12687,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,15329,F,,,,,,
299,Expert,12687,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,15329,F,,,,,,
300,Intermediate,20033,Ileum,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,273,F,,Cavia porcellus,10141.0,,,
301,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),273,F,,Cavia porcellus,10141.0,,,
302,Intermediate,20033,Ileum,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,273,F,,Cavia porcellus,10141.0,,,
303,Autocuration,10623,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,12092,B,,,,,,
304,Expert,10623,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1317,F,,Rattus norvegicus,10116.0,,,
305,Expert,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,12409,B,,,,,,
306,Autocuration,22226,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,11126,B,,Gallus gallus,9031.0,,,
307,Autocuration,22226,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,11126,F,,Homo sapiens,9606.0,,,
308,Autocuration,22226,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,11126,F,,Homo sapiens,9606.0,,,
309,Autocuration,80156,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,11126,B,,Homo sapiens,9606.0,,HL-60,
310,Autocuration,22226,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,11126,B,,Homo sapiens,9606.0,,,
311,Autocuration,22226,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,11126,B,,Homo sapiens,9606.0,,,
312,Autocuration,104703,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,17807,B,,Homo sapiens,9606.0,,Oocytes,
313,Intermediate,100256,,,Chymotryptic inhibitory activity against 26S proteasome,16575,F,,,,,,
314,Intermediate,100256,,,Inhibitory activity against 26S proteasome degradation of IkB,15407,B,,,,,,
315,Intermediate,81034,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,10797,F,,Homo sapiens,9606.0,,A2780,
316,Intermediate,81034,,,In vitro inhibition of 2780/S ovarian cancer cell line,10797,F,,Homo sapiens,9606.0,,A2780,
317,Autocuration,22226,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,3469,F,,Homo sapiens,9606.0,,,
318,Intermediate,22222,,,Association constant for binding to AATT 28-mer AATT hairpin,16037,B,,,,,,
319,Intermediate,22222,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,16037,B,,,,,,
320,Intermediate,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,16037,B,,,,,,
321,Intermediate,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,16037,B,,,,,,
322,Autocuration,22226,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),16524,F,,Homo sapiens,9606.0,,,
323,Autocuration,22226,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),16524,F,,Homo sapiens,9606.0,,,
324,Autocuration,22226,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,16524,F,,Homo sapiens,9606.0,,,
325,Autocuration,22226,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,16758,F,,Cricetulus griseus,10029.0,,,
326,Autocuration,22226,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,16758,F,,Cricetulus griseus,10029.0,,,
327,Autocuration,22226,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,16758,F,,Cricetulus griseus,10029.0,,,
328,Autocuration,241,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,14360,B,,,,,,
329,Expert,241,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,14360,B,,Homo sapiens,9606.0,,,
330,Autocuration,22226,,,Selectivity ratio of ID50 in liver and heart,9964,B,,Rattus norvegicus,10116.0,,,
331,Autocuration,12132,,,"Selectivity, ratio of relative ID50 in liver and heart",9964,B,,,,,,
332,Autocuration,12132,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,9964,B,,,,,,
333,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,B,,,,,,
334,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,B,,,,,,
335,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,B,In vivo,,,,,
336,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,F,In vivo,,,,,
337,Autocuration,22226,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",9964,B,,,,,,
338,Autocuration,12132,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,9964,B,,,,,,
339,Autocuration,22226,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",9964,B,,Homo sapiens,9606.0,,,
340,Autocuration,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,9964,B,,,,,,
341,Autocuration,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,9964,F,,,,,,
342,Autocuration,12132,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",9964,B,,,,,,
343,Autocuration,22226,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",9964,B,,Rattus norvegicus,10116.0,,,
344,Autocuration,12132,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,9964,B,In vivo,,,,,
345,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",9964,B,,,,,,
346,Autocuration,22226,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",9964,B,,Rattus norvegicus,10116.0,,,
347,Autocuration,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",9964,B,,,,,,
348,Autocuration,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",9964,F,,,,,,
349,Autocuration,22226,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",3796,B,,Rattus norvegicus,10116.0,,,
350,Autocuration,19690,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,4251,B,,Escherichia coli,562.0,,,
351,Autocuration,19690,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,4251,B,,Escherichia coli,562.0,,,
352,Autocuration,19690,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,4251,B,,Escherichia coli,562.0,,,
353,Autocuration,19690,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,4251,B,,Escherichia coli,562.0,,,
354,Autocuration,19690,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,166,B,,,,,,
355,Autocuration,19690,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,17861,B,,,,,,
356,Autocuration,19690,,,Inhibition constant against 3-dehydroquinate synthase,166,B,,,,,,
357,Autocuration,19690,,,Association rate constant against 3-dehydroquinate synthase,166,B,,,,,,
358,Autocuration,19690,,,Rate constant against 3-dehydroquinate synthase,166,B,,,,,,
359,Autocuration,22226,,,Inhibitory activity against fuc-TVII,3548,B,,,,,,
360,Autocuration,12236,Liver,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
361,Autocuration,12236,Liver,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
362,Autocuration,12236,Liver,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
363,Autocuration,12236,Liver,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
364,Autocuration,12236,Liver,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
365,Autocuration,12236,Liver,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
366,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
367,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
368,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
369,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
370,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,9877,B,,Rattus norvegicus,10116.0,,,Microsomes
371,Autocuration,104832,,,Inhibitory activity against 3-phosphoglycerate kinase.,3003,B,,,,,,
372,Autocuration,104832,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,3003,B,,,,,,
373,Autocuration,104832,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",3003,B,,,,,,
374,Expert,10612,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,17185,B,,Homo sapiens,9606.0,,,
375,Intermediate,80616,,,Cytotoxicity on 3677 melanoma cells,6072,F,,Homo sapiens,9606.0,,3677 melanoma cell line,
376,Intermediate,80616,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,6072,F,,Homo sapiens,9606.0,,3677 melanoma cell line,
377,Intermediate,80617,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,5018,F,,Mus musculus,10090.0,,MC-38,
378,Intermediate,22226,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,2852,F,,Homo sapiens,9606.0,,,
379,Autocuration,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,8663,F,,,,,B16,
380,Autocuration,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,8663,F,,,,,B16,
381,Expert,12464,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,3245,F,,Human rhinovirus 14,12131.0,,,
382,Intermediate,50085,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,3245,F,,Human rhinovirus sp.,169066.0,,,
383,Intermediate,50679,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,3877,F,,human rhinovirus type 14,169066.0,,,
384,Intermediate,50679,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,3877,F,,human rhinovirus type 14,169066.0,,,
385,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,F,,Human rhinovirus 14,12131.0,,,
386,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,F,,Human rhinovirus 14,12131.0,,,
387,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,5861,F,,Human rhinovirus 14,12131.0,,,
388,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,5861,F,,Human rhinovirus 14,12131.0,,,
389,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,13748,F,,Enterovirus,12059.0,,,
390,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,13748,F,,Enterovirus,12059.0,,,
391,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,13748,F,,Enterovirus,12059.0,,,
392,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,13748,F,,Enterovirus,12059.0,,,
393,Expert,12464,,,Inhibition of human rhinovirus 3C protease,13748,B,,Human rhinovirus B,147712.0,,,
394,Autocuration,22226,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,17699,B,,Homo sapiens,9606.0,,,
395,Intermediate,80619,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),7145,F,,Mus musculus,10090.0,,3EM 37,
396,Intermediate,80619,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),7145,F,,Mus musculus,10090.0,,3EM 37,
397,Intermediate,80619,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),7145,F,,Mus musculus,10090.0,,3EM 37,
398,Intermediate,80619,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),7145,F,,Mus musculus,10090.0,,3EM 37,
399,Intermediate,80619,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,7145,F,,Mus musculus,10090.0,,3EM 37,
400,Intermediate,80619,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,7145,F,,Mus musculus,10090.0,,3EM 37,
401,Intermediate,80620,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,5325,F,,Mus musculus,10090.0,,3LL cell line,
402,Intermediate,80620,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,5325,F,,Mus musculus,10090.0,,3LL cell line,
403,Expert,80620,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,5325,F,,Mus musculus,10090.0,,3LL cell line,
404,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
405,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
406,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
407,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
408,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
409,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
410,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
411,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
412,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
413,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
414,Intermediate,80620,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,16169,F,,Mus musculus,10090.0,,3LL cell line,
415,Intermediate,80620,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,16169,F,,Mus musculus,10090.0,,3LL cell line,
416,Intermediate,80620,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,16169,F,,Mus musculus,10090.0,,3LL cell line,
417,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,16169,F,,Mus musculus,10090.0,,3LL cell line,
418,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
419,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
420,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
421,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
422,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
423,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
424,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
425,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
426,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
427,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
428,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
429,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,16169,F,,Mus musculus,10090.0,,3LL cell line,
430,Intermediate,80621,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,15547,F,,Homo sapiens,9606.0,,3LLD122,
431,Autocuration,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,8663,F,,,,,,
432,Autocuration,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,8663,F,,,,,,
433,Autocuration,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,8663,F,,,,,,
434,Autocuration,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,8663,F,,,,,,
435,Intermediate,80951,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,4504,F,,Mus musculus,10090.0,,NIH3T3,
436,Intermediate,80951,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,4504,F,,Mus musculus,10090.0,,NIH3T3,
437,Expert,11169,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,12695,F,,,,,NIH3T3,
438,Intermediate,80951,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,12695,F,,Mus musculus,10090.0,,NIH3T3,
439,Intermediate,80951,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,12695,F,,Mus musculus,10090.0,,NIH3T3,
440,Expert,80951,,,Effective dose against murine 3T3 fibroblasts cells,17642,F,,Mus musculus,10090.0,,NIH3T3,
441,Expert,80951,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,17642,F,,Mus musculus,10090.0,,NIH3T3,
442,Expert,80951,,,Cytotoxic effect on 3T3 cells,12340,F,,Mus musculus,10090.0,,NIH3T3,
443,Expert,80951,,,Cytotoxic effect on 3T3 cells,12340,F,,Mus musculus,10090.0,,NIH3T3,
444,Intermediate,80951,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,12716,F,,Mus musculus,10090.0,,NIH3T3,
445,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,6277,F,,Mus musculus,10090.0,,NIH3T3,
446,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,6277,F,,Mus musculus,10090.0,,NIH3T3,
447,Expert,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,6277,F,,Mus musculus,10090.0,,NIH3T3,
448,Expert,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,6277,F,,Mus musculus,10090.0,,NIH3T3,
449,Intermediate,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,6277,F,,Mus musculus,10090.0,,NIH3T3,
450,Expert,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,6277,F,,Mus musculus,10090.0,,NIH3T3,
451,Expert,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,6277,F,,Mus musculus,10090.0,,NIH3T3,
452,Intermediate,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,6277,F,,Mus musculus,10090.0,,NIH3T3,
453,Expert,80951,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,17780,F,,Mus musculus,10090.0,,NIH3T3,
454,Autocuration,104860,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,12751,F,,Mus musculus,10090.0,,,
455,Expert,80951,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,12380,F,,Mus musculus,10090.0,,NIH3T3,
456,Intermediate,80951,,,Inhibitory activity against 3T3 cell line,14892,F,,Mus musculus,10090.0,,NIH3T3,
457,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,12695,F,,Mus musculus,10090.0,,NIH3T3,
458,Expert,11169,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,12695,F,,,,,,
459,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,12695,F,,Mus musculus,10090.0,,NIH3T3,
460,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,12695,F,,Mus musculus,10090.0,,NIH3T3,
461,Expert,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,12695,F,,,,,,
462,Expert,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,12695,F,,,,,,
463,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,6277,F,,Mus musculus,10090.0,,NIH3T3,
464,Expert,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,6277,F,,Mus musculus,10090.0,,NIH3T3,
465,Expert,9,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,4959,F,,Homo sapiens,9606.0,,NIH3T3,
466,Expert,9,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),4959,F,,Homo sapiens,9606.0,,NIH3T3,
467,Expert,188,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,4959,F,,Homo sapiens,9606.0,,NIH3T3,
468,Expert,188,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),4959,F,,Homo sapiens,9606.0,,NIH3T3,
469,Intermediate,80951,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,12082,F,,Mus musculus,10090.0,,NIH3T3,
470,Intermediate,80951,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,12082,F,,Mus musculus,10090.0,,NIH3T3,
471,Intermediate,80951,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,12082,F,,Mus musculus,10090.0,,NIH3T3,
472,Intermediate,80951,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,12082,F,,Mus musculus,10090.0,,NIH3T3,
473,Intermediate,80951,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,2643,F,,Mus musculus,10090.0,,NIH3T3,
474,Expert,80951,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,11926,F,,Mus musculus,10090.0,,NIH3T3,
475,Intermediate,80951,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,15204,A,,Mus musculus,10090.0,,NIH3T3,
476,Expert,80951,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,15992,F,,Mus musculus,10090.0,,NIH3T3,
477,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,16279,F,,Mus musculus,10090.0,,NIH3T3,
478,Intermediate,80951,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,F,,Mus musculus,10090.0,,NIH3T3,
479,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,F,,Mus musculus,10090.0,,NIH3T3,
480,Intermediate,80951,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,F,,Mus musculus,10090.0,,NIH3T3,
481,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,F,,Mus musculus,10090.0,,NIH3T3,
482,Intermediate,80951,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),16279,F,,Mus musculus,10090.0,,NIH3T3,
483,Expert,80951,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,12831,F,,Mus musculus,10090.0,,NIH3T3,
484,Intermediate,80951,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,13497,F,,Mus musculus,10090.0,,NIH3T3,
485,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,F,,,,,3T3-L1,
486,Intermediate,80006,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,13618,F,,Mus musculus,10090.0,,3T3-L1,
487,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,11902,F,,Mus musculus,10090.0,,3T3-L1,
488,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,11902,F,,Mus musculus,10090.0,,3T3-L1,
489,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,11902,F,,Mus musculus,10090.0,,3T3-L1,
490,Intermediate,80006,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",14840,F,,Mus musculus,10090.0,,3T3-L1,
491,Intermediate,80006,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",14840,F,,Mus musculus,10090.0,,3T3-L1,
492,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,13715,F,,,,,3T3-L1,
493,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,13715,F,,,,,3T3-L1,
494,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,F,,,,,3T3-L1,
495,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,13715,F,,,,,3T3-L1,
496,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,F,,,,,3T3-L1,
497,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,13715,F,,,,,3T3-L1,
498,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,13715,F,,,,,3T3-L1,
499,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,13715,F,,,,,3T3-L1,
500,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,F,,,,,3T3-L1,
501,Expert,80006,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,13715,F,,,,,3T3-L1,
502,Expert,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,F,,,,,3T3-L1,
503,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,13715,F,,,,,3T3-L1,
504,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,F,,,,,3T3-L1,
505,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,13715,F,,,,,3T3-L1,
506,Expert,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,F,,,,,3T3-L1,
507,Expert,80006,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,F,,,,,3T3-L1,
508,Expert,80006,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,13715,F,,,,,3T3-L1,
509,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,13715,F,,,,,3T3-L1,
510,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,13715,F,,,,,3T3-L1,
511,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,13715,F,,,,,3T3-L1,
512,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,13715,F,,,,,3T3-L1,
513,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,13715,F,,,,,3T3-L1,
514,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,13715,F,,,,,3T3-L1,
515,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,13715,F,,,,,3T3-L1,
516,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,13715,F,,,,,3T3-L1,
517,Expert,11214,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,6411,F,,,,,3T3-L1,
518,Intermediate,80006,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,6411,F,,Mus musculus,10090.0,,3T3-L1,
519,Expert,11214,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,6411,F,,,,,3T3-L1,
520,Expert,80006,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,3966,F,,Mus musculus,10090.0,,3T3-L1,
521,Intermediate,80006,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,3966,F,,Mus musculus,10090.0,,3T3-L1,
522,Expert,80006,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,15556,F,,Mus musculus,10090.0,,3T3-L1,
523,Expert,80006,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,5845,F,,Mus musculus,10090.0,,3T3-L1,
524,Expert,80006,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,14422,F,,Mus musculus,10090.0,,3T3-L1,
525,Expert,80006,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,5845,F,,Mus musculus,10090.0,,3T3-L1,
526,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,14508,F,,Mus musculus,10090.0,,3T3-L1,
527,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,14508,F,,Mus musculus,10090.0,,3T3-L1,
528,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,14508,F,,Mus musculus,10090.0,,3T3-L1,
529,Intermediate,80622,,,Inhibitory activity against rat fibroblast (3Y1) cell line,6349,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
530,Expert,80622,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,15899,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
531,Expert,80622,,,Cytotoxicity in 3Y1 cells.,15899,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
532,Expert,80622,,,Cytostatic effect in 3Y1 cells.,15899,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
533,Intermediate,80622,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",15899,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
534,Expert,80622,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,17038,F,,Rattus norvegicus,10116.0,,3Y1 cell line,
535,Autocuration,22226,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,12421,B,,,,,,
536,Autocuration,22226,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,12947,B,,,,,,
537,Autocuration,22226,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,12947,B,,,,,,
538,Expert,11607,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,4896,B,,Sus scrofa,9823.0,,,
539,Autocuration,11607,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,6148,B,,,,,,
540,Autocuration,11607,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,16432,B,,,,,,
541,Expert,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,4978,B,,,,,,
542,Expert,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),4978,B,,,,,,
543,Autocuration,11607,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,3723,B,,,,,,
544,Autocuration,11607,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),3518,B,,,,,,
545,Autocuration,11607,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,4164,B,,,,,,
546,Autocuration,11607,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,3518,B,,,,,,
547,Expert,11607,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,4164,B,,Sus scrofa,9823.0,,,
548,Autocuration,11607,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,3518,B,,,,,,
549,Autocuration,11607,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),3518,B,,,,,,
550,Autocuration,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,4978,B,,,,,,
551,Autocuration,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),4978,B,,,,,,
552,Autocuration,104733,,,Binding affinity against melatonin (MT1) receptor (pC1),6455,B,,,,,,
553,Autocuration,22226,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,2222,B,,,,,,
554,Autocuration,22226,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,13020,B,,,,,,
555,Autocuration,22226,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,13021,B,,,,,,
556,Autocuration,10619,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,14532,B,,,,,,
557,Autocuration,10619,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,14118,B,,,,,,
558,Autocuration,51,Hippocampus,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,11884,B,,,,,,
559,Expert,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,13969,B,,,,,,
560,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor,13392,B,,,,,,
561,Expert,51,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,14430,B,,,,,,
562,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12248,B,,,,,,
563,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,B,,,,,,
564,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
565,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
566,Autocuration,51,Hippocampus,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
567,Autocuration,51,Hippocampus,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
568,Autocuration,51,Hippocampus,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
569,Autocuration,51,Hippocampus,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,B,,,,,,
570,Autocuration,51,Hippocampus,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",11799,B,,,,,,
571,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,14331,B,,Rattus norvegicus,10116.0,,,Membranes
572,Expert,51,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,11884,B,,Bos taurus,9913.0,,,
573,Autocuration,51,Hippocampus,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,14331,B,,,,,,
574,Autocuration,51,Hippocampus,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,11701,B,,,,,,
575,Expert,51,Hippocampus,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,11701,B,,,,,,
576,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,12248,B,,,,,,
577,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,12248,B,,,,,CHO,
578,Expert,51,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12248,B,,,,,,
579,Expert,51,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,12249,B,,,,,,
580,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12248,B,,,,,CHO,
581,Expert,51,Hippocampus,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",11799,B,,,,,,
582,Autocuration,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,634,B,,,,,,
583,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
584,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
585,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
586,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,9995,B,,,,,,
587,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,9995,B,,,,,,
588,Expert,51,Hippocampus,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,12210,B,,,,,,
589,Expert,51,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,13311,B,,,,,,
590,Expert,51,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",2331,B,,Homo sapiens,9606.0,,CHO,
591,Autocuration,51,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1375,F,,Cavia porcellus,10141.0,,,
592,Autocuration,51,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1375,F,,Cavia porcellus,10141.0,,,
593,Autocuration,51,Hippocampus,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,11574,F,,Cavia porcellus,10141.0,,,
594,Autocuration,51,Ileum,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,12867,B,,Cavia porcellus,10141.0,,,
595,Autocuration,51,Ileum,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,B,,Cavia porcellus,10141.0,,,
596,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,12867,B,,Cavia porcellus,10141.0,,,
597,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,B,,Cavia porcellus,10141.0,,,
598,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,12867,B,,Cavia porcellus,10141.0,,,
599,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,12867,B,,Cavia porcellus,10141.0,,,
600,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11574,B,,Cavia porcellus,10141.0,,,
601,Autocuration,51,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,13114,B,,Cavia porcellus,10141.0,,,
602,Autocuration,51,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,13181,B,,Cavia porcellus,10141.0,,,
603,Autocuration,106,Hippocampus,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10639,B,,Cavia porcellus,10141.0,,,
604,Autocuration,106,Hippocampus,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10639,F,,Cavia porcellus,10141.0,,,
605,Autocuration,11863,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11883,B,,Cricetulus griseus,10029.0,,CHO,
606,Autocuration,51,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,17785,B,,,,,,
607,Autocuration,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1558,F,,,,,HeLa,
608,Autocuration,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1558,F,,,,,HeLa,
609,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,15740,F,,,,,,
610,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,17624,F,,,,,CHO,
611,Expert,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,17624,F,,,,,CHO,
612,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,17624,F,,,,,CHO,
613,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,17624,F,,,,,CHO,
614,Expert,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
615,Expert,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
616,Autocuration,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,17624,B,,,,,CHO,
617,Autocuration,51,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,14256,F,,,,,,
618,Expert,51,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,3445,B,,Homo sapiens,9606.0,,HeLa,
619,Expert,51,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,3445,B,,Homo sapiens,9606.0,,HeLa,
620,Expert,51,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,17200,B,,Homo sapiens,9606.0,,CHO,
621,Expert,51,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,17200,B,,Homo sapiens,9606.0,,CHO,
622,Autocuration,51,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,15180,F,,,,,,
623,Autocuration,51,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,15180,F,,,,,,
624,Autocuration,51,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,F,,,,,,
625,Autocuration,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,F,,,,,CHO,
626,Expert,51,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),2759,F,,Homo sapiens,9606.0,,CHO,
627,Autocuration,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),2759,F,,,,,CHO,
628,Expert,51,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),2759,F,,Homo sapiens,9606.0,,CHO,
629,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,F,,,,,CHO,
630,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),2759,F,,,,,CHO,
631,Expert,51,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),2759,F,,Homo sapiens,9606.0,,CHO,
632,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),2759,F,,,,,CHO,
633,Expert,51,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),2759,F,,Homo sapiens,9606.0,,CHO,
634,Expert,51,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,3445,F,,Homo sapiens,9606.0,,,
635,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,F,,Homo sapiens,9606.0,,,
636,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",5272,F,,Homo sapiens,9606.0,,,
637,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",5272,F,,Homo sapiens,9606.0,,,
638,Autocuration,51,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,F,,,,,CHO,
639,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,F,,,,,CHO,
640,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,17624,F,,,,,CHO,
641,Expert,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,17624,F,,,,,CHO,
642,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,17624,F,,,,,CHO,
643,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,17624,F,,,,,CHO,
644,Autocuration,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,F,,,,,CHO,
645,Autocuration,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,17624,F,,,,,CHO,
646,Expert,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,F,,,,,CHO,
647,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,17624,F,,,,,CHO,
648,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,17624,F,,,,,CHO,
649,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,17624,F,,,,,CHO,
650,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,F,,,,,,
651,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,F,,,,,,
652,Autocuration,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,6563,F,,,,,,
653,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,F,,,,,HEK293,
654,Expert,51,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",6876,F,,Homo sapiens,9606.0,,,
655,Expert,51,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",6876,F,,,,,,
656,Expert,51,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,5272,F,,Homo sapiens,9606.0,,,
657,Expert,51,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,5272,F,,Homo sapiens,9606.0,,,
658,Autocuration,51,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,F,,,,,,
659,Expert,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",5548,F,,,,,,
660,Autocuration,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,F,,,,,,
661,Autocuration,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",5548,F,,,,,,
662,Expert,51,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",5929,F,,,,,,
663,Expert,51,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",5929,F,,Homo sapiens,9606.0,,,
664,Expert,51,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",5929,F,,Homo sapiens,9606.0,,,
665,Autocuration,51,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",16245,F,,,,,,
666,Expert,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",5640,F,,,,,,
667,Autocuration,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",5640,F,,,,,,
668,Autocuration,51,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,14509,F,,,,,CHO,
669,Expert,51,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,14509,F,,,,,CHO,
670,Autocuration,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,B,,,,,,
671,Autocuration,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,B,,,,,,
672,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,F,,,,,,
673,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",6563,F,,,,,,
674,Autocuration,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,6563,F,,,,,,
675,Expert,51,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,6563,F,,Homo sapiens,9606.0,,,
676,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,F,,,,,,
677,Expert,51,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,5272,F,,Homo sapiens,9606.0,,,
678,Expert,51,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,F,,Homo sapiens,9606.0,,,
679,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",5272,F,,Homo sapiens,9606.0,,,
680,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,5272,F,,Homo sapiens,9606.0,,,
681,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,5272,F,,Homo sapiens,9606.0,,,
682,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",5272,F,,Homo sapiens,9606.0,,,
683,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",5272,F,,Homo sapiens,9606.0,,,
684,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,5272,F,,Homo sapiens,9606.0,,,
685,Expert,51,,,Inhibition of human 5-hydroxytryptamine 1A receptor,16146,B,,Homo sapiens,9606.0,,,
686,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
687,Expert,105,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,13706,B,,,,,HEK293,
688,Autocuration,51,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,15250,B,,,,,CHO,
689,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,F,,,,,CHO,
690,Expert,51,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,6861,B,,,,,,
691,Expert,51,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,17200,B,,Homo sapiens,9606.0,,,
692,Autocuration,51,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
693,Autocuration,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
694,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
695,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
696,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
697,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
698,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,12058,F,In vivo,Rattus norvegicus,10116.0,,,
699,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
700,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
701,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
702,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
703,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
704,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,12058,F,In vivo,Rattus norvegicus,10116.0,,,
705,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
706,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
707,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,12058,F,In vivo,Rattus norvegicus,10116.0,,,
708,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
709,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,12058,F,In vivo,Rattus norvegicus,10116.0,,,
710,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,12058,F,In vivo,Rattus norvegicus,10116.0,,,
711,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,12058,F,In vivo,Rattus norvegicus,10116.0,,,
712,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,12058,F,In vivo,Rattus norvegicus,10116.0,,,
713,Autocuration,105093,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,11440,B,,,,,,
714,Autocuration,11923,Hypothalamus,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,6238,B,,,,,,
715,Autocuration,10577,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10046,B,,,,,,
716,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10046,B,,,,,,
717,Expert,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10046,B,,,,,,
718,Autocuration,55,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",167,B,,,,,,
719,Autocuration,55,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",167,B,,,,,,
720,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),11520,F,,,,,,
721,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,F,,,,,,
722,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,F,,,,,,
723,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,11520,F,,,,,,
724,Autocuration,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,135,F,,Cavia porcellus,10141.0,,,
725,Autocuration,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,135,F,,Cavia porcellus,10141.0,,,
726,Autocuration,55,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,11311,B,,Cavia porcellus,10141.0,,,
727,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10193,B,,Cavia porcellus,10141.0,,,
728,Expert,55,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,12281,B,,Homo sapiens,9606.0,,,
729,Autocuration,55,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
730,Autocuration,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,12576,F,,,,,,
731,Autocuration,17087,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,12281,B,,,,,,
732,Autocuration,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,12576,F,,,,,,
733,Expert,55,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,11089,B,,Sus scrofa,9823.0,,,
734,Expert,12166,,,In vitro inhibition of rat 5-Lipoxygenase,11006,B,,,,,,
735,Expert,12166,,,Inhibitory activity against 5-Lipoxygenase,11481,B,,Rattus norvegicus,10116.0,,,
736,Expert,12166,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,10864,B,,,,,RBL-1,
737,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,B,,,,,RBL-1,
738,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,11311,B,,,,,RBL-1,
739,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,11311,B,,,,,,
740,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
741,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,11006,B,,,,,,
742,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,3595,B,,,,,RBL-1,
743,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,11311,B,,,,,,
744,Autocuration,22226,,,Ratio of IC50 against 5-LO and COX,11481,B,,Rattus norvegicus,10116.0,,,
745,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,11006,B,,,,,,
746,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,11006,B,,,,,,
747,Autocuration,12166,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,11311,B,,,,,,
748,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,11006,F,,,,,,
749,Autocuration,120,Prostate gland,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,4288,B,,,,,,
750,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,7587,B,,Columba livia,8932.0,,,
751,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,7587,B,,Columba livia,8932.0,,,
752,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,7587,B,,Columba livia,8932.0,,,
753,Autocuration,10732,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,11249,B,,,,,,
754,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,8003,F,,Rattus norvegicus,10116.0,,,
755,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),8003,F,,Rattus norvegicus,10116.0,,,
756,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),8003,F,,Rattus norvegicus,10116.0,,,
757,Expert,10576,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,12416,B,,,,,,
758,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,16293,B,,,,,,
759,Autocuration,22226,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
760,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
761,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
762,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
763,Autocuration,104744,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,B,,,,,,
764,Autocuration,104744,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,B,,,,,,
765,Autocuration,104744,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,10085,B,,,,,,
766,Autocuration,104744,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,9841,B,,,,,,Membranes
767,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,8822,B,,Rattus norvegicus,10116.0,,,
768,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,9806,B,,Rattus norvegicus,10116.0,,,
769,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,9806,B,,Rattus norvegicus,10116.0,,,
770,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,8868,B,,,,,,
771,Autocuration,104744,Hippocampus,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,9036,B,,,,,,
772,Autocuration,104744,Hippocampus,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,11374,B,,,,,,
773,Autocuration,104744,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,10881,B,,,,,,
774,Autocuration,104744,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,8822,B,,,,,,
775,Autocuration,104744,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,9806,B,,Rattus norvegicus,10116.0,,,
776,Autocuration,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,15463,B,,,,,,
777,Autocuration,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,15463,B,,,,,,
778,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,B,,,,,,
779,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,B,,,,,,
780,Autocuration,104744,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,8569,B,,,,,,
781,Autocuration,104744,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,10062,B,,Rattus norvegicus,10116.0,,,
782,Autocuration,104744,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,4771,B,,,,,,
783,Autocuration,104744,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,B,,,,,,
784,Autocuration,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,B,,,,,,
785,Autocuration,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,10062,B,,,,,,
786,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,15463,B,,,,,,
787,Autocuration,104744,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,15463,B,,,,,,
788,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,9098,B,,,,,,
789,Autocuration,22226,,,Affinity for 5-hydroxytryptamine 1 receptor,3070,B,,Rattus norvegicus,10116.0,,,
790,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,14542,B,,,,,,
791,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,14542,B,,,,,,
792,Autocuration,104744,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,6398,B,,,,,,
793,Autocuration,104744,Brain,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1344,B,,,,,,
794,Autocuration,104744,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,11963,B,,,,,,
795,Autocuration,22226,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,8908,B,,Rattus norvegicus,10116.0,,,
796,Autocuration,104744,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,9098,B,,,,,,
797,Autocuration,104744,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,8841,B,,Rattus norvegicus,10116.0,,,
798,Autocuration,22226,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,8814,B,,Rattus norvegicus,10116.0,,,
799,Autocuration,104744,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,11752,B,,,,,,
800,Autocuration,104744,Brain,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,11642,B,,,,,,
801,Autocuration,104744,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,11642,B,,,,,,
802,Autocuration,104744,Brain,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,9231,B,,,,,,
803,Autocuration,104744,Brain,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,11351,B,,,,,,
804,Autocuration,22226,,,Compound was tested for binding affinity against 5-HT1 receptor,4639,B,,,,,,
805,Autocuration,22226,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1205,B,,,,,,
806,Expert,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10025,B,,,,,,
807,Autocuration,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",13241,F,,,,,,
808,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,16245,F,In vivo,,,,,
809,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,16245,F,In vivo,,,,,
810,Autocuration,10576,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,12438,F,,,,,,
811,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,16245,F,In vivo,,,,,
812,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,16245,F,In vivo,,,,,
813,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,15740,F,,,,,,
814,Autocuration,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,15535,F,,,,,,
815,Expert,51,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,15535,F,,,,,,
816,Autocuration,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,15535,F,,,,,,
817,Expert,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,9888,B,,,,,,
818,Autocuration,10576,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10085,B,,,,,,
819,Autocuration,10576,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10085,B,,,,,,
820,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,17331,B,,,,,,Membranes
821,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10845,B,,Rattus norvegicus,10116.0,,,
822,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10845,B,,Rattus norvegicus,10116.0,,,
823,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10845,B,,,,,,
824,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10845,B,,Rattus norvegicus,10116.0,,,
825,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10845,B,,Rattus norvegicus,10116.0,,,
826,Expert,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,13730,B,,,,,,
827,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,13508,B,,,,,,
828,Expert,10576,Hippocampus,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,13508,B,,,,,,
829,Expert,10576,Hippocampus,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,B,,,,,,
830,Autocuration,10576,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,4671,B,,,,,,
831,Expert,10576,Hippocampus,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,13631,B,,,,,,
832,Autocuration,10576,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,12438,B,,,,,,
833,Autocuration,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10483,B,,,,,,
834,Autocuration,10576,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10483,B,,,,,,
835,Intermediate,10576,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,12352,B,,,,,,
836,Autocuration,10576,Hippocampus,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,14732,B,,,,,,
837,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,11049,B,,Rattus norvegicus,10116.0,,,
838,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,11049,B,,Rattus norvegicus,10116.0,,,
839,Expert,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",13657,B,,,,,,
840,Autocuration,10576,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,11473,B,,,,,,
841,Autocuration,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,2014,B,,,,,,
842,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,3086,B,,,,,,
843,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,B,,,,,,
844,Expert,10576,Hippocampus,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10922,B,,,,,,
845,Expert,10576,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,13346,B,,,,,,
846,Expert,10576,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,15311,B,,,,,,
847,Autocuration,10576,Hippocampus,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10922,B,,,,,,
848,Autocuration,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10025,B,,,,,,
849,Expert,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10025,B,,,,,,
850,Autocuration,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,9742,B,,,,,,
851,Autocuration,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,9742,F,,,,,,
852,Expert,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,12304,B,,,,,,
853,Autocuration,10576,Hippocampus,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,15789,B,,,,,,
854,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",9912,B,,,,,,
855,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",9912,B,,,,,,
856,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",9912,B,,,,,,
857,Expert,10576,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,16693,B,,,,,,
858,Expert,10576,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,13276,B,,,,,,
859,Autocuration,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,12678,B,,,,,,
860,Autocuration,10576,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,11825,B,,,,,,
861,Expert,10576,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,12443,B,,,,,,
862,Expert,10576,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,13830,B,,,,,,
863,Expert,10576,Hippocampus,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,14286,B,,,,,,
864,Expert,10576,Hippocampus,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,14356,B,,Rattus norvegicus,10116.0,,,
865,Autocuration,10576,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,15306,B,,,,,,
866,Expert,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),15306,B,,,,,,
867,Expert,10576,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,
868,Autocuration,10576,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",3651,B,,,,,,
869,Autocuration,10576,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,14331,F,,,,,,
870,Autocuration,10576,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,14331,F,,,,,,
871,Expert,10576,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,14178,B,,Rattus norvegicus,10116.0,,,
872,Expert,10576,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10639,B,,Rattus norvegicus,10116.0,,,
873,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,B,,,,,,
874,Expert,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1348,B,,Rattus norvegicus,10116.0,,,
875,Autocuration,10576,Hippocampus,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,13605,B,,,,,,
876,Autocuration,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,17624,B,,,,,CHO,
877,Autocuration,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,F,,,,,CHO,
878,Autocuration,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,17624,F,,,,,CHO,
879,Autocuration,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,15267,B,,,,,,
880,Autocuration,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,16532,B,,,,,,
881,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",6563,F,,,,,,
882,Autocuration,51,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,4751,B,,,,,CHO,
883,Autocuration,51,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,15463,B,,,,,,
884,Autocuration,51,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),3805,B,,,,,,
885,Autocuration,51,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5640,B,,,,,,
886,Autocuration,51,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,6563,B,,,,,,
887,Autocuration,51,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,5548,B,,,,,,
888,Autocuration,51,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,6347,B,,,,,,
889,Autocuration,51,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,F,,,,,HEK293,
890,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,13047,B,,,,,,
891,Autocuration,51,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,15740,B,,,,,,
892,Expert,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",5640,F,,,,,,
893,Autocuration,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",5640,F,,,,,,
894,Expert,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,17211,B,,,,,HeLa,
895,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,4751,B,,,,,CHO,
896,Expert,51,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
897,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,4707,B,,,,,,
898,Expert,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,13910,B,,Homo sapiens,9606.0,,,
899,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,16190,B,,,,,HeLa,
900,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16633,B,,,,,,
901,Autocuration,51,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,11898,B,,,,,CHO,
902,Autocuration,51,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11898,B,,,,,CHO,
903,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,14331,B,,,,,,
904,Expert,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,17624,B,,,,,CHO,
905,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,17624,B,,,,,CHO,
906,Autocuration,51,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,3307,B,,,,,,
907,Expert,51,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,6563,B,,Homo sapiens,9606.0,,CHO,
908,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,14165,B,,,,,,
909,Autocuration,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,5732,B,,,,,,
910,Expert,51,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,13366,B,,,,,,
911,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,17626,B,,,,,,
912,Expert,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,6588,B,,,,,HeLa,
913,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,16209,B,,,,,,
914,Autocuration,51,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,15463,B,,,,,,
915,Autocuration,51,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,15463,B,,,,,,
916,Autocuration,51,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,14770,B,,,,,,
917,Autocuration,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),16245,B,,,,,Cell line,
918,Autocuration,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),16245,B,,,,,,
919,Autocuration,51,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,5548,B,,,,,,
920,Expert,51,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5548,B,,,,,,
921,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,5548,B,,,,,,
922,Expert,51,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,6876,B,,,,,,
923,Autocuration,51,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,2598,B,,,,,,
924,Expert,51,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,17785,B,,,,,,
925,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,6013,B,,,,,,
926,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,5929,B,,,,,,
927,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16633,B,,,,,,
928,Autocuration,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1558,B,,,,,,
929,Expert,51,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,16026,B,,,,,,
930,Autocuration,51,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,12469,B,,,,,,
931,Expert,51,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,B,,Homo sapiens,9606.0,,,
932,Autocuration,51,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,B,,,,,,
933,Autocuration,51,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,3935,B,,,,,,
934,Autocuration,51,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,15818,B,,,,,,
935,Autocuration,51,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
936,Expert,51,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,13729,F,,,,,CHO-K1,
937,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,15413,B,,,,,,
938,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),15413,B,,,,,,
939,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),15413,B,,,,,,
940,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,15413,B,,,,,,
941,Expert,51,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,3445,B,,Homo sapiens,9606.0,,HeLa,
942,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,15740,B,,,,,,
943,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,15740,B,,,,,,
944,Autocuration,51,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,17626,B,,,,,,
945,Expert,51,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,4234,B,,Homo sapiens,9606.0,,,
946,Expert,51,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,5640,B,,,,,,
947,Expert,51,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,5272,B,,Rattus norvegicus,10116.0,,,
948,Autocuration,51,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,4622,B,,,,,CHO,
949,Expert,51,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,17085,B,,,,,,
950,Autocuration,51,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,3025,B,,,,,,
951,Expert,51,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,15315,B,,,,,,
952,Autocuration,51,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,15267,B,,,,,,
953,Autocuration,51,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,17158,B,,,,,HeLa,
954,Expert,51,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,14214,B,,Homo sapiens,9606.0,,HeLa,
955,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,17133,B,,,,,,
956,Autocuration,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,16532,B,,,,,,
957,Expert,51,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,2391,B,,Homo sapiens,9606.0,,,
958,Autocuration,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,14447,B,,,,,,
959,Autocuration,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,14447,B,,,,,,
960,Autocuration,51,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,15086,B,,,,,,
961,Expert,51,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,13051,B,,Homo sapiens,9606.0,,,
962,Autocuration,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",16026,F,,,,,,
963,Expert,51,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,17085,B,,,,,,
964,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,17133,B,,,,,,
965,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,17133,B,,,,,,
966,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,B,,,,,HeLa,
967,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,17211,B,,,,,HeLa,
968,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,B,,,,,HeLa,
969,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,17211,B,,,,,HeLa,
970,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,F,,,,,,
971,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,F,,,,,,
972,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",16394,F,,,,,,
973,Autocuration,51,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,16394,F,In vivo,,,,,
974,Autocuration,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,16394,B,,,,,,
975,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,15740,F,,,,,,
976,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,15740,F,,,,,,
977,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,15740,B,,,,,,
978,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,F,,,,,HEK293,
979,Expert,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",5640,F,,,,,,
980,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",5640,F,,,,,,
981,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",5640,F,,,,,,
982,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",5640,F,,,,,,
983,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,2759,F,,,,,CHO,
984,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",16394,F,,,,,,
985,Expert,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",16394,F,,Homo sapiens,9606.0,,,
986,Expert,51,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,3445,F,,Homo sapiens,9606.0,,,
987,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,4316,B,,,,,CHO,
988,Expert,51,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,4316,B,,,,,,
989,Expert,51,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,15180,F,,Homo sapiens,9606.0,,,
990,Expert,51,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,15180,F,,Homo sapiens,9606.0,,,
991,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,F,,,,,,
992,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,F,,,,,,
993,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,15042,F,,,,,,
994,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,F,,,,,,
995,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,F,,,,,,
996,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,15042,F,,,,,,
997,Autocuration,51,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,15042,F,,,,,,
998,Expert,51,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,F,,Homo sapiens,9606.0,,HeLa,
999,Expert,51,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,F,,Homo sapiens,9606.0,,HeLa,
1000,Expert,51,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,15180,F,,Homo sapiens,9606.0,,HeLa,
1001,Autocuration,51,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",16245,F,,,,,,
1002,Autocuration,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,F,,,,,,
1003,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,17296,F,,,,,HEK293,
1004,Autocuration,51,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),2759,F,,,,,CHO,
1005,Autocuration,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,2759,F,,,,,CHO,
1006,Expert,51,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),2759,F,,Homo sapiens,9606.0,,CHO,
1007,Autocuration,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),2759,F,,,,,CHO,
1008,Expert,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,15419,F,,,,,,
1009,Autocuration,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,15419,F,,,,,,
1010,Autocuration,51,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",16026,F,,,,,,
1011,Expert,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1414,B,In vitro,,,,,
1012,Expert,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1414,B,In vitro,,,,,
1013,Autocuration,51,,,Binding activity radioligand.,12861,B,,,,,,
1014,Autocuration,51,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,B,,,,,,
1015,Autocuration,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,5104,B,,,,,,
1016,Autocuration,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,5105,B,,,,,,
1017,Autocuration,51,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,16312,B,,,,,,
1018,Expert,51,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,15180,B,,Homo sapiens,9606.0,,,
1019,Autocuration,51,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,5033,B,,,,,,
1020,Expert,51,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,16909,B,,Homo sapiens,9606.0,,CHO,
1021,Autocuration,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,2590,F,,,,,,
1022,Autocuration,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,2590,F,,,,,,
1023,Expert,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,16394,B,,,,,,
1024,Expert,51,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,4540,B,,Homo sapiens,9606.0,,HEK293,
1025,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,17296,B,,,,,HEK293,
1026,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,17296,B,,,,,HEK293,
1027,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,15779,B,,,,,HEK293,
1028,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,15779,B,,,,,HEK293,
1029,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,15779,B,,,,,HEK293,
1030,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,6166,B,,,,,,
1031,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,15779,B,,,,,HEK293,
1032,Autocuration,51,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,4199,B,,,,,HEK293,
1033,Autocuration,51,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,15316,B,,,,,,
1034,Autocuration,51,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,14875,B,,,,,,
1035,Expert,51,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,14727,B,,,,,HeLa,
1036,Expert,51,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,14727,B,,,,,,
1037,Autocuration,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,15146,B,,,,,HEK293,
1038,Autocuration,51,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,5213,B,,,,,HEK293,
1039,Autocuration,51,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,16429,B,,,,,,
1040,Expert,51,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,15042,B,,Homo sapiens,9606.0,,HeLa,
1041,Autocuration,51,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,14818,B,,,,,HEK293,
1042,Autocuration,51,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",4829,B,,,,,HEK293,
1043,Expert,51,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,17200,B,,,,,,
1044,Autocuration,51,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,13051,B,,Homo sapiens,9606.0,,,
1045,Autocuration,106,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,5486,B,,,,,,
1046,Autocuration,105,,,Binding affinity against 5-HT1D receptor,5254,B,,,,,,
1047,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1A receptor,5254,B,,,,,,
1048,Autocuration,107,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,15331,B,,,,,,
1049,Autocuration,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,13506,B,,Homo sapiens,9606.0,,,
1050,Autocuration,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,15267,B,,,,,,
1051,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,16616,F,In vivo,,,,,
1052,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,16616,F,In vivo,,,,,
1053,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,16616,F,In vivo,,,,,
1054,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,16616,F,,Mus musculus,10090.0,,,
1055,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,16616,F,,Mus musculus,10090.0,,,
1056,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,16616,F,,Mus musculus,10090.0,,,
1057,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,16616,F,,Mus musculus,10090.0,,,
1058,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,16616,F,,Mus musculus,10090.0,,,
1059,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,16616,F,,Mus musculus,10090.0,,,
1060,Autocuration,11863,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10297,B,,,,,,
1061,Expert,11863,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,13704,B,,,,,,
1062,Expert,11863,Hippocampus,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10297,B,,Mus musculus,10090.0,,,
1063,Autocuration,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10297,B,,,,,,
1064,Expert,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10297,B,,Mus musculus,10090.0,,,
1065,Autocuration,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,10297,B,,,,,,
1066,Autocuration,11863,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,217,B,,,,,,
1067,Expert,11863,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10297,B,,Mus musculus,10090.0,,,
1068,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,4921,B,,Sus scrofa,9823.0,,,
1069,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,4921,B,,Sus scrofa,9823.0,,,
1070,Autocuration,51,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,4996,B,,Sus scrofa,9823.0,,,
1071,Autocuration,51,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,12918,B,,Sus scrofa,9823.0,,,
1072,Autocuration,51,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,5333,B,,Sus scrofa,9823.0,,,
1073,Autocuration,51,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,4437,B,,Sus scrofa,9823.0,,,
1074,Autocuration,51,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1742,B,,Sus scrofa,9823.0,,,
1075,Expert,51,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,16688,B,,Sus scrofa,9823.0,,,
1076,Autocuration,51,,,Binding activity radioligand.,12861,B,,Sus scrofa,9823.0,,,
1077,Expert,51,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,12861,B,,Sus scrofa,9823.0,,,
1078,Autocuration,51,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,12861,B,,Sus scrofa,9823.0,,,
1079,Expert,10624,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,12490,B,,,,,,
1080,Expert,51,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,11828,B,,Sus scrofa,9823.0,,,
1081,Autocuration,51,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,11866,B,,Sus scrofa,9823.0,,,
1082,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,12827,B,,Sus scrofa,9823.0,,,
1083,Autocuration,51,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,12918,B,,Sus scrofa,9823.0,,,
1084,Expert,51,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,12919,F,,Sus scrofa,9823.0,,,
1085,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,13047,B,,Oryctolagus cuniculus,9986.0,,,
1086,Expert,10576,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,15796,B,,Rattus norvegicus,10116.0,,,
1087,Expert,10576,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",3651,B,,Rattus norvegicus,10116.0,,,
1088,Autocuration,10576,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,188,B,,,,,,
1089,Expert,10576,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,Membranes
1090,Expert,10576,Hippocampus,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,Membranes
1091,Autocuration,10576,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,B,,,,,,
1092,Expert,10576,Hippocampus,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,17167,B,,Rattus norvegicus,10116.0,,,
1093,Autocuration,10576,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,14776,B,,,,,,
1094,Expert,10576,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,12158,B,,,,,,
1095,Autocuration,10576,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,13481,B,,,,,,
1096,Autocuration,10576,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,B,In vitro,,,,,
1097,Autocuration,10576,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10210,B,,,,,,
1098,Autocuration,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10205,B,,,,,,Membranes
1099,Autocuration,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10205,B,,,,,,Membranes
1100,Expert,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10205,B,,,,,,Membranes
1101,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,12280,B,,Rattus norvegicus,10116.0,,,
1102,Expert,10576,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,17386,B,,,,,,
1103,Expert,10576,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,13654,B,,,,,,
1104,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,14423,B,,,,,,
1105,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,15412,B,,,,,,
1106,Autocuration,10576,Hippocampus,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,B,,,,,,
1107,Expert,10576,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,4101,B,,Rattus norvegicus,10116.0,,,
1108,Autocuration,10576,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10062,B,,,,,,
1109,Autocuration,10576,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,6238,B,,,,,,
1110,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,16273,B,,,,,,
1111,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,11139,B,,,,,,
1112,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,16796,B,,,,,,
1113,Expert,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9548,B,,Rattus norvegicus,10116.0,,,
1114,Autocuration,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10381,B,,,,,,
1115,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,13408,B,,,,,,
1116,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,13825,B,,Rattus norvegicus,10116.0,,,
1117,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,11147,B,,,,,,
1118,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10552,B,,,,,,
1119,Autocuration,10576,Striatum,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10552,B,,,,,,
1120,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,17136,B,,Rattus norvegicus,10116.0,,,Membranes
1121,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,5778,B,,Rattus norvegicus,10116.0,,,Membranes
1122,Autocuration,10576,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,13481,B,,,,,,
1123,Autocuration,10576,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,13481,B,,,,,,
1124,Intermediate,10576,Hippocampus,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,13630,B,,,,,,
1125,Expert,10576,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,16245,B,,,,,,
1126,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,14509,B,,,,,,
1127,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,14509,B,,,,,,
1128,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,14509,B,,,,,,
1129,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,14509,B,,,,,,
1130,Expert,10576,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,14256,B,,,,,,
1131,Autocuration,10576,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,11139,B,,,,,,
1132,Expert,10576,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,11047,B,,Rattus norvegicus,10116.0,,,
1133,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,11047,B,,Rattus norvegicus,10116.0,,,
1134,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,11047,B,,Rattus norvegicus,10116.0,,,
1135,Expert,10576,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,2395,B,,Rattus norvegicus,10116.0,,CHO-K1,
1136,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,9699,B,,,,,,
1137,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,12028,B,,Rattus norvegicus,10116.0,,,
1138,Autocuration,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,12028,B,,,,,,
1139,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,5815,B,,,,,,
1140,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,16616,B,,,,,,
1141,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,5815,B,,,,,,
1142,Autocuration,10576,Hippocampus,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",2761,B,,,,,,
1143,Expert,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,13133,B,,,,,,
1144,Autocuration,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10444,B,,,,,,
1145,Expert,10576,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,13278,B,,Rattus norvegicus,10116.0,,,
1146,Autocuration,10576,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,15874,B,,,,,,
1147,Autocuration,10576,Striatum,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10552,B,,,,,,Membranes
1148,Autocuration,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),11130,B,,,,,,
1149,Autocuration,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),11130,B,In vivo,,,,,
1150,Autocuration,10576,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,14542,B,,,,,,
1151,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,13670,B,,Rattus norvegicus,10116.0,,,
1152,Expert,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,9888,B,,,,,,
1153,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,3678,B,,Rattus norvegicus,10116.0,,,Membranes
1154,Autocuration,10576,Hippocampus,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,11332,B,,,,,,
1155,Autocuration,10576,Hippocampus,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,11332,B,,,,,,
1156,Expert,10576,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1185,B,,,,,,
1157,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,2014,B,,,,,,
1158,Autocuration,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1185,B,,,,,,
1159,Expert,10576,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,14429,B,,,,,,
1160,Expert,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",16288,B,,,,,,
1161,Expert,10576,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,5432,B,,Rattus norvegicus,10116.0,,,
1162,Autocuration,10576,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,14429,B,,,,,,
1163,Expert,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,13672,B,,,,,,
1164,Expert,10576,Hippocampus,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,B,,,,,,
1165,Autocuration,10576,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,11296,B,,,,,,
1166,Expert,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,14749,B,,,,,CHO,
1167,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,15086,B,,,,,,
1168,Autocuration,10576,Hippocampus,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,13462,B,,,,,,
1169,Autocuration,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,15363,B,,,,,,
1170,Autocuration,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,15363,B,,,,,,
1171,Autocuration,10576,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10796,B,,,,,,
1172,Expert,10576,Brain,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,12816,B,,,,,,
1173,Expert,10576,Hippocampus,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,13542,B,,,,,,
1174,Expert,10576,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,13308,B,,,,,,
1175,Expert,10576,Hippocampus,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,13541,B,,,,,,
1176,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10058,B,,,,,,
1177,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10058,B,,,,,,
1178,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10058,B,,,,,,
1179,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10058,B,,,,,,
1180,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10058,B,,,,,,
1181,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10058,B,,,,,,
1182,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10058,B,,,,,,
1183,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10058,B,,,,,,
1184,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10058,B,,,,,,
1185,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10058,B,,,,,,
1186,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10058,B,,,,,,
1187,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10058,B,,,,,,
1188,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10058,B,,,,,,
1189,Expert,10576,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10058,B,,Rattus norvegicus,10116.0,,,
1190,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10058,B,,,,,,
1191,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10058,B,,,,,,
1192,Expert,10576,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,12879,B,,,,,,
1193,Expert,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,11964,B,,,,,,
1194,Autocuration,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),11964,B,,,,,,
1195,Autocuration,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),11964,B,,,,,,
1196,Expert,10576,Brain,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9548,B,,,,,,
1197,Expert,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,9098,B,,,,,,
1198,Autocuration,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,9098,B,,,,,,
1199,Autocuration,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,9098,B,,,,,,
1200,Expert,10576,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,13248,B,,,,,CHO,
1201,Expert,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,3147,B,,,,,,
1202,Expert,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,13949,B,,,,,,
1203,Autocuration,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11883,B,,,,,CHO,
1204,Autocuration,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),11883,B,,,,,,
1205,Expert,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,11883,B,,Rattus norvegicus,10116.0,,,
1206,Expert,10576,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,15535,B,,,,,,Membranes
1207,Autocuration,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,15535,B,,,,,,
1208,Autocuration,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,15535,B,,,,,,
1209,Expert,51,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,16372,B,,Homo sapiens,9606.0,,CHO,
1210,Expert,10576,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,14608,B,,,,,,
1211,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,4795,B,,Rattus norvegicus,10116.0,,,
1212,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,13863,B,,,,,,
1213,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,13863,B,,,,,,
1214,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,13863,B,,,,,,
1215,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,13863,B,,,,,,
1216,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,13863,B,,,,,,
1217,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,13863,B,,,,,,
1218,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,13863,B,,,,,,
1219,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,13863,B,,,,,,
1220,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,13863,B,,,,,,
1221,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,13863,B,,,,,,
1222,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,13863,B,,,,,,
1223,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,13863,B,,,,,,
1224,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,13863,B,,,,,,
1225,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,13863,B,,,,,,
1226,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,13863,B,,,,,,
1227,Autocuration,10576,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,9742,B,,,,,,
1228,Autocuration,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,12073,B,,,,,,
1229,Autocuration,10576,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,4101,B,,,,,,
1230,Autocuration,10576,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,15360,B,,,,,,
1231,Autocuration,10576,Hippocampus,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,11576,B,,,,,,
1232,Expert,10576,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,5834,B,,,,,,
1233,Expert,10576,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,2395,B,,Rattus norvegicus,10116.0,,CHO-K1,
1234,Autocuration,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1375,B,,,,,,
1235,Autocuration,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1375,B,,,,,,
1236,Autocuration,10576,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),3967,B,,,,,,
1237,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,12884,B,,,,,,
1238,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,2343,B,,,,,,
1239,Autocuration,10576,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",11511,B,,,,,,
1240,Expert,10576,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",11511,B,,Rattus norvegicus,10116.0,,,
1241,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,16394,F,In vivo,,,,,
1242,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),16394,F,In vivo,,,,,
1243,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),16394,F,In vivo,,,,,
1244,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),16394,F,In vivo,,,,,
1245,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),16394,F,In vivo,,,,,
1246,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),16394,F,In vivo,,,,,
1247,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),16394,F,In vivo,,,,,
1248,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),16394,F,In vivo,,,,,
1249,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),16394,F,In vivo,,,,,
1250,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),16394,F,In vivo,,,,,
1251,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),16394,F,In vivo,,,,,
1252,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),16394,F,In vivo,,,,,
1253,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),16394,F,In vivo,,,,,
1254,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),16394,F,In vivo,,,,,
1255,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,16394,F,In vivo,,,,,
1256,Expert,10576,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,Membranes
1257,Autocuration,10576,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,16796,B,,,,,,
1258,Autocuration,10576,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,16796,B,,,,,,
1259,Autocuration,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,15629,B,,,,,,
1260,Autocuration,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",13241,F,,,,,,
1261,Expert,10576,Hippocampus,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,12073,B,,,,,,
1262,Autocuration,10576,Hippocampus,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,14286,B,,,,,,
1263,Autocuration,10576,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,14542,B,,,,,,
1264,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,13630,F,,,,,,
1265,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,13630,F,,,,,,
1266,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,13630,F,,,,,,
1267,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,13630,F,,,,,,
1268,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,13630,F,,,,,,
1269,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,13630,F,,,,,,
1270,Expert,10576,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,13630,F,,Rattus norvegicus,10116.0,,,
1271,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,13630,F,,,,,,
1272,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,13630,F,,,,,,
1273,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,13630,F,,,,,,
1274,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,13630,F,,,,,,
1275,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,13630,F,,,,,,
1276,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,13630,F,,,,,,
1277,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,13630,F,,,,,,
1278,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,13630,F,,,,,,
1279,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,13630,F,,,,,,
1280,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,13630,F,,,,,,
1281,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,13630,F,,,,,,
1282,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,13630,F,,,,,,
1283,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,13630,F,,,,,,
1284,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,13630,F,,,,,,
1285,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,13630,F,,,,,,
1286,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,13630,F,,,,,,
1287,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,13630,F,,,,,,
1288,Autocuration,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,9783,B,,,,,,
1289,Expert,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,9783,B,,,,,,
1290,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,14331,B,,Rattus norvegicus,10116.0,,,Membranes
1291,Expert,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,15260,B,,,,,,
1292,Autocuration,10576,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,15260,B,,,,,,
1293,Autocuration,10576,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,15260,B,,,,,,
1294,Expert,10576,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,
1295,Autocuration,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,15629,B,,,,,,
1296,Autocuration,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,15086,B,,,,,,
1297,Expert,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,5717,F,,,,,,
1298,Autocuration,10576,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,12652,B,,,,,,
1299,Autocuration,10576,Hippocampus,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,14608,B,,,,,,
1300,Autocuration,10576,Hippocampus,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,B,,,,,,
1301,Autocuration,10576,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,B,,,,,,
1302,Expert,10576,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,15247,B,,Rattus norvegicus,10116.0,,,
1303,Expert,10576,Hippocampus,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,17529,B,,,,,,
1304,Autocuration,10576,Hippocampus,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,14826,B,,,,,,
1305,Autocuration,10576,Hippocampus,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,14826,B,,,,,,
1306,Autocuration,10576,Hippocampus,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,13241,B,,,,,,
1307,Autocuration,10576,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,14093,B,,,,,,
1308,Autocuration,10576,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,14093,B,,,,,,
1309,Autocuration,10576,Brain,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,14442,B,,,,,,
1310,Autocuration,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,9919,B,,,,,,
1311,Autocuration,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,9919,B,,,,,,
1312,Autocuration,10576,Hippocampus,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,11440,B,,,,,,
1313,Autocuration,10576,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,11257,B,,,,,,
1314,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10330,B,,,,,,
1315,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,17331,B,,Rattus norvegicus,10116.0,,,
1316,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,16567,B,,,,,,
1317,Expert,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",12058,B,,Rattus norvegicus,10116.0,,,
1318,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,9699,B,,,,,,
1319,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,9547,B,,,,,,
1320,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10330,B,,,,,,
1321,Autocuration,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,14331,B,,,,,,
1322,Expert,10576,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,14060,B,,Rattus norvegicus,10116.0,,,
1323,Autocuration,10576,Hippocampus,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,14744,B,,,,,,
1324,Autocuration,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,13506,B,,,,,,
1325,Expert,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,B,,,,,,
1326,Expert,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,B,,,,,,
1327,Expert,10576,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10062,B,,,,,,
1328,Autocuration,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,12073,B,,,,,,
1329,Autocuration,106,,,GTPgammaS radioligand binding assay,14875,B,,,,,,
1330,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,2391,B,,,,,,
1331,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,2391,F,,,,,,
1332,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,2391,F,,,,,,
1333,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,2391,B,,,,,,
1334,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,2391,B,,,,,,
1335,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,2391,F,,,,,,
1336,Expert,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,17211,B,,,,,HeLa,
1337,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,17211,B,,,,,HeLa,
1338,Expert,106,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
1339,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,16190,B,,,,,CHO,
1340,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,14165,B,,,,,,
1341,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,14165,B,,,,,,
1342,Expert,106,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,4234,B,,Homo sapiens,9606.0,,,
1343,Expert,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,6328,B,,,,,,
1344,Autocuration,106,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,14770,B,,,,,,
1345,Autocuration,106,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,2598,B,,,,,,
1346,Expert,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,6897,B,,,,,,
1347,Autocuration,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,6897,B,,,,,,
1348,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,6013,B,,,,,,
1349,Expert,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,5843,B,,,,,,
1350,Expert,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,14454,B,,,,,,
1351,Autocuration,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,16209,B,,,,,,
1352,Autocuration,106,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,3935,B,,,,,,
1353,Expert,106,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,13729,F,,,,,CHO-K1,
1354,Expert,106,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,14251,F,,,,,,
1355,Expert,106,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,17085,B,,,,,,
1356,Autocuration,106,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,3025,B,,,,,,
1357,Expert,106,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,15315,B,,,,,,
1358,Expert,106,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,14214,B,,Homo sapiens,9606.0,,,
1359,Expert,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,3804,B,,Homo sapiens,9606.0,,,
1360,Expert,106,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,2391,B,,Homo sapiens,9606.0,,,
1361,Expert,106,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,4175,B,,Homo sapiens,9606.0,,,
1362,Autocuration,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,17296,B,,,,,CHO,
1363,Expert,106,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,17085,B,,,,,,
1364,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,17211,B,,,,,HeLa,
1365,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,17211,B,,,,,HeLa,
1366,Autocuration,106,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,17211,B,,,,,HeLa,
1367,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,15926,B,,Homo sapiens,9606.0,,,
1368,Autocuration,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,16312,B,,,,,CHO-K1,
1369,Expert,106,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,5843,B,,,,,,
1370,Autocuration,106,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,5843,B,,,,,,
1371,Expert,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,16312,B,,,,,CHO-K1,
1372,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor,15926,B,,Homo sapiens,9606.0,,,
1373,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor,15926,B,,Homo sapiens,9606.0,,,
1374,Expert,106,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,4540,B,,Homo sapiens,9606.0,,CHO,
1375,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,6166,B,,,,,,
1376,Autocuration,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,17296,B,,,,,CHO,
1377,Autocuration,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,17296,B,,,,,CHO,
1378,Autocuration,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,17296,B,,,,,CHO,
1379,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,B,,,,,CHO,
1380,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,B,,,,,CHO,
1381,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,15779,B,,,,,CHO,
1382,Autocuration,106,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,4199,B,,,,,CHO,
1383,Expert,106,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,14875,B,,Homo sapiens,9606.0,,,
1384,Autocuration,106,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,15146,B,,,,,CHO,
1385,Autocuration,106,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,5213,B,,,,,,
1386,Autocuration,106,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,14818,B,,,,,CHO,
1387,Autocuration,106,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",4829,B,,,,,CHO,
1388,Expert,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,14454,F,,,,,,
1389,Expert,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,14454,F,,,,,,
1390,Autocuration,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",14875,F,,,,,CHO,
1391,Autocuration,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",14875,F,,,,,CHO,
1392,Autocuration,105,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",15250,F,,,,,,
1393,Autocuration,105,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,15250,B,,,,,CHO,
1394,Autocuration,17105,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,15086,B,,,,,,
1395,Autocuration,106,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,3025,F,,Oryctolagus cuniculus,9986.0,,,
1396,Autocuration,106,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,14998,B,,Oryctolagus cuniculus,9986.0,,,
1397,Intermediate,106,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",14998,B,,Oryctolagus cuniculus,9986.0,,,
1398,Autocuration,106,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,14998,B,,Oryctolagus cuniculus,9986.0,,,
1399,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,13969,B,,,,,,
1400,Intermediate,10577,,,Binding affinity for 5-hydroxytryptamine 1B receptor,13392,B,,,,,,
1401,Expert,10577,Striatum,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,3651,B,,Rattus norvegicus,10116.0,,,
1402,Expert,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10025,B,,,,,,
1403,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,13863,B,,,,,,
1404,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,13863,B,,,,,,
1405,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,13863,B,,,,,,
1406,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,13863,B,,,,,,
1407,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,13863,B,,,,,,
1408,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,13863,B,,,,,,
1409,Autocuration,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,4622,B,,,,,,
1410,Intermediate,10576,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,14911,B,,,,,,
1411,Autocuration,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,12678,B,,,,,,
1412,Expert,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,12678,B,,,,,,
1413,Expert,10576,Hippocampus,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,14235,B,,,,,,
1414,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,14949,B,,,,,,
1415,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,14949,B,,,,,,
1416,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,14949,B,,,,,,
1417,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,14949,B,,,,,,
1418,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,14949,B,,,,,,
1419,Expert,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,16118,B,,,,,,
1420,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,3268,B,,,,,,
1421,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,3268,B,,,,,,
1422,Expert,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,16117,B,,,,,,
1423,Expert,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,9783,B,,,,,,
1424,Autocuration,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,9783,B,,,,,,
1425,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,14356,B,,Rattus norvegicus,10116.0,,,
1426,Autocuration,10576,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,15740,F,,,,,,
1427,Autocuration,10576,Hippocampus,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,12306,B,,,,,,
1428,Expert,10576,Hippocampus,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,13348,B,,Rattus norvegicus,10116.0,,,
1429,Autocuration,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10394,B,,,,,,
1430,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,15260,B,,,,,,
1431,Expert,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,B,,,,,,
1432,Intermediate,10576,Hippocampus,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,15260,F,,,,,,
1433,Autocuration,10576,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,12851,B,,,,,,
1434,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,2148,B,,Rattus norvegicus,10116.0,,,
1435,Expert,10576,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,13134,B,,,,,,
1436,Autocuration,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,12462,B,,,,,,
1437,Expert,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,12462,B,,,,,,
1438,Autocuration,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,12462,B,,,,,CHO,
1439,Expert,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,11933,B,,,,,,
1440,Autocuration,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,11933,B,,,,,,
1441,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,403,B,,Rattus norvegicus,10116.0,,,
1442,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,15538,B,,,,,,
1443,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,15538,B,,,,,,
1444,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,15538,B,,,,,,
1445,Intermediate,10576,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,12464,B,,,,,,
1446,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1455,B,,,,,,
1447,Autocuration,10576,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,12652,B,,,,,,
1448,Autocuration,10576,Hippocampus,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,12639,B,,,,,,
1449,Expert,10576,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,13949,B,,,,,,
1450,Expert,10576,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,12463,B,,Rattus norvegicus,10116.0,,,
1451,Expert,10576,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,14829,B,,,,,,
1452,Autocuration,10576,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,14829,B,,,,,,
1453,Autocuration,10576,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,12092,B,,,,,,
1454,Autocuration,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,403,B,,,,,,
1455,Autocuration,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,403,B,,,,,,
1456,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,3967,B,,,,,,
1457,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,12771,B,,Rattus norvegicus,10116.0,,,
1458,Autocuration,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,15086,B,,,,,,
1459,Autocuration,10576,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,14909,B,,,,,,
1460,Expert,10576,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,14949,B,,,,,,
1461,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,2309,B,,Rattus norvegicus,10116.0,,,
1462,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,4170,B,,,,,,
1463,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,11642,B,,Rattus norvegicus,10116.0,,,
1464,Autocuration,10576,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,11642,B,,,,,,
1465,Autocuration,10576,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,12953,B,,,,,,
1466,Autocuration,10576,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,12953,B,,,,,,
1467,Expert,10576,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,12953,B,,,,,,
1468,Expert,10576,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",12903,B,,,,,CHO,
1469,Expert,10576,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,12536,B,,,,,,
1470,Autocuration,10576,,,The inhibition activity of 5-HT1A at 1 uM,10058,B,,,,,,
1471,Expert,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",12902,B,,,,,CHO-K1,
1472,Expert,10576,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,14057,B,,,,,,
1473,Autocuration,10576,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,11296,B,,,,,,
1474,Autocuration,10576,Hippocampus,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,B,,,,,,
1475,Expert,10576,Hippocampus,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,11296,B,,,,,,
1476,Expert,10576,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,16616,F,,Rattus norvegicus,10116.0,,,Membranes
1477,Expert,10576,Hippocampus,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",16616,F,,Rattus norvegicus,10116.0,,,Membranes
1478,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,16567,B,,,,,,
1479,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,16567,B,,,,,,
1480,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,16567,B,,,,,,
1481,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,16567,B,,,,,,
1482,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,17136,B,,,,,,
1483,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,17136,B,,,,,,
1484,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,16616,B,,Rattus norvegicus,10116.0,,,
1485,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,17331,B,,,,,,
1486,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,17331,B,,,,,,
1487,Expert,10576,Hippocampus,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,17167,B,,Rattus norvegicus,10116.0,,,
1488,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,15740,F,,,,,,
1489,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,15740,F,,,,,,
1490,Autocuration,10576,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,4671,B,,,,,,
1491,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10058,B,,,,,,
1492,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10058,B,,,,,,
1493,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10058,B,,,,,,
1494,Autocuration,10576,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,12073,B,,,,,,
1495,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),2759,B,,,,,,
1496,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),2759,F,,,,,,
1497,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),2759,B,,,,,,
1498,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),2759,F,,,,,,
1499,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,2759,F,,,,,,
1500,Autocuration,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,B,,,,,,
1501,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,9737,B,,,,,,
1502,Expert,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,5717,F,,,,,,
1503,Autocuration,10576,Hippocampus,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,12253,B,,,,,,
1504,Autocuration,10576,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,14025,B,,,,,,
1505,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10425,B,,,,,,
1506,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,14998,B,,,,,,
1507,Autocuration,10576,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,13694,B,,,,,,
1508,Autocuration,10576,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,13694,B,,,,,,
1509,Autocuration,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,4342,B,,,,,,
1510,Expert,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,12936,B,,Rattus norvegicus,10116.0,,,
1511,Expert,10576,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,13144,B,,Rattus norvegicus,10116.0,,,
1512,Expert,10576,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,13343,B,,,,,,
1513,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,12132,B,,,,,,
1514,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,15419,B,,,,,,
1515,Autocuration,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1479,B,,,,,,
1516,Expert,10576,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,14287,B,,,,,,
1517,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor,13116,B,,,,,,
1518,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,2759,B,,Rattus norvegicus,10116.0,,,Membranes
1519,Autocuration,10576,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,2759,B,,,,,,
1520,Expert,10576,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",14748,B,,,,,,
1521,Autocuration,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,12304,B,,,,,,
1522,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,12409,B,,Rattus norvegicus,10116.0,,,
1523,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,12409,B,,Rattus norvegicus,10116.0,,,
1524,Autocuration,10576,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,13267,B,,,,,,
1525,Autocuration,10576,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,15194,B,,,,,,
1526,Expert,10576,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,14256,B,,,,,,
1527,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,16567,B,,,,,,
1528,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,15740,F,,,,,,
1529,Expert,12687,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,13278,B,,Rattus norvegicus,10116.0,,,
1530,Expert,10626,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1970,B,,,,,,Membranes
1531,Autocuration,10576,Brain,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10034,B,,,,,,
1532,Autocuration,51,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,13348,B,,Rattus norvegicus,10116.0,,,
1533,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,13630,F,,,,,,
1534,Autocuration,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10862,B,,,,,,
1535,Autocuration,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",12058,B,,,,,,
1536,Autocuration,51,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,4639,B,,,,,,
1537,Expert,51,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,15453,B,,,,,,
1538,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,4820,B,,,,,,
1539,Autocuration,51,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1089,B,,,,,,
1540,Autocuration,51,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,386,B,,,,,,Brain membranes
1541,Autocuration,51,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,6011,B,,,,,,
1542,Autocuration,51,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,5014,B,,,,,,
1543,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,4402,B,,,,,,
1544,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,17066,B,,,,,,
1545,Autocuration,51,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,17515,B,,,,,,
1546,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,2474,B,,,,,,
1547,Autocuration,51,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,4775,B,,,,,,
1548,Expert,51,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,14294,B,,Homo sapiens,9606.0,,,
1549,Expert,51,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,14294,B,,Homo sapiens,9606.0,,,
1550,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12249,B,,,,,CHO,
1551,Expert,51,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,11376,B,,,,,,
1552,Autocuration,51,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,2474,B,In vivo,,,,,
1553,Autocuration,51,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,13311,B,,,,,,
1554,Autocuration,51,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,4373,B,,,,,,
1555,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1633,B,,,,,,
1556,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,11866,B,,,,,,
1557,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,4373,B,,,,,,
1558,Autocuration,51,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,4687,B,,,,,,
1559,Autocuration,11863,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,16946,B,,,,,,
1560,Autocuration,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,13291,B,,,,,,
1561,Autocuration,11863,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,14159,B,,,,,,
1562,Autocuration,11863,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,10812,B,,,,,,
1563,Expert,11863,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,3032,B,,Mus musculus,10090.0,,CHO,
1564,Autocuration,11863,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,16655,B,,,,,,
1565,Autocuration,11863,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,14532,B,,,,,,
1566,Autocuration,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor,13944,B,,,,,,
1567,Autocuration,11863,,,Binding affinity against serotonergic 5-HT1a receptor,13033,B,,,,,,
1568,Autocuration,11863,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,10321,B,,,,,,
1569,Expert,11863,,,Binding affinity for 5-hydroxytryptamine 1A receptor,2968,B,,Mus musculus,10090.0,,,
1570,Autocuration,11863,,,Binding affinity at 5-hydroxytryptamine 1A receptor,13964,B,,,,,,
1571,Autocuration,11863,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",15527,B,,,,,,
1572,Autocuration,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12248,B,,,,,CHO,
1573,Autocuration,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,12249,B,,,,,CHO,
1574,Autocuration,11863,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,15120,B,,,,,,
1575,Autocuration,11863,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,13313,B,,,,,,
1576,Autocuration,11863,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,2613,B,,,,,,
1577,Autocuration,11863,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,16700,B,,,,,,
1578,Autocuration,11863,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,2201,B,,,,,,
1579,Expert,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor,1274,B,,Mus musculus,10090.0,,,
1580,Autocuration,11863,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1317,B,,,,,,
1581,Autocuration,11863,,,Tested against 5-hydroxytryptamine 1A receptor,12146,B,,,,,,
1582,Autocuration,11863,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,14059,B,,,,,,
1583,Expert,106,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,14025,B,,Oryctolagus cuniculus,9986.0,,,
1584,Autocuration,106,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,14025,B,,Oryctolagus cuniculus,9986.0,,,
1585,Intermediate,105571,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,14447,B,,Gorilla gorilla,9593.0,,HEK293,
1586,Autocuration,106,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,3025,F,In vivo,Cavia porcellus,10141.0,,,
1587,Autocuration,106,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,3025,F,In vivo,Cavia porcellus,10141.0,,,
1588,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,15329,F,,Cavia porcellus,10141.0,,,
1589,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,15329,F,,Cavia porcellus,10141.0,,,
1590,Autocuration,106,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,15847,F,,Cavia porcellus,10141.0,,,
1591,Autocuration,106,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,15847,F,,Cavia porcellus,10141.0,,,
1592,Autocuration,106,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,14165,F,,,,,,
1593,Autocuration,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),14214,F,,,,,,
1594,Autocuration,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),14214,F,,,,,,
1595,Expert,106,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,14214,F,,Homo sapiens,9606.0,,,
1596,Expert,106,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,13729,F,,Homo sapiens,9606.0,,CHO-K1,
1597,Autocuration,106,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,3025,F,,,,,CHO,
1598,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,2391,B,,,,,,
1599,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,2391,F,,,,,,
1600,Expert,106,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",14956,F,,,,,CHO,
1601,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,2598,F,,,,,CHO,
1602,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,2598,F,,,,,CHO,
1603,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,2598,F,,,,,CHO,
1604,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,2598,F,,,,,CHO,
1605,Expert,106,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",14956,F,,,,,,
1606,Autocuration,106,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",14956,F,,,,,,
1607,Expert,106,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,14214,B,,Homo sapiens,9606.0,,,
1608,Expert,106,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,3463,B,,,,,CHO,
1609,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,15331,B,,,,,,
1610,Expert,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor,16146,B,,Homo sapiens,9606.0,,,
1611,Expert,106,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,14159,B,,Homo sapiens,9606.0,,CHO,
1612,Expert,106,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,14158,B,,,,,CHO,
1613,Autocuration,106,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,14159,B,,,,,,
1614,Expert,106,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,15250,B,,,,,CHO,
1615,Expert,106,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,15250,B,,,,,CHO,
1616,Expert,106,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,15331,B,,,,,CHO,
1617,Expert,106,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,15332,B,,,,,CHO,
1618,Expert,106,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,14956,B,,,,,CHO,
1619,Autocuration,106,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),3805,B,,,,,,
1620,Autocuration,106,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,14875,B,,,,,,
1621,Autocuration,105,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,F,,Oryctolagus cuniculus,9986.0,,,
1622,Expert,105,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,F,,Oryctolagus cuniculus,9986.0,,,
1623,Autocuration,105,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),16288,B,,,,,,
1624,Autocuration,105,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),16288,B,,,,,,
1625,Autocuration,105,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,16312,B,,,,,,
1626,Expert,105,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1348,B,,Bos taurus,9913.0,,,
1627,Autocuration,105,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,5834,B,,Bos taurus,9913.0,,,
1628,Autocuration,105,Striatum,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,13366,B,,Bos taurus,9913.0,,,
1629,Expert,105,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1414,B,,Bos taurus,9913.0,,,
1630,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,14998,B,,Bos taurus,9913.0,,,
1631,Autocuration,105,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,11473,B,,Bos taurus,9913.0,,,
1632,Autocuration,105,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,11473,B,,Bos taurus,9913.0,,,
1633,Autocuration,105,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,10639,B,,Bos taurus,9913.0,,,
1634,Autocuration,105,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,10639,B,,Bos taurus,9913.0,,,
1635,Autocuration,105,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1375,B,,Bos taurus,9913.0,,,
1636,Autocuration,105,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1375,B,,Bos taurus,9913.0,,,
1637,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,16532,B,,Bos taurus,9913.0,,,
1638,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,11147,B,,Bos taurus,9913.0,,,
1639,Autocuration,105,Striatum,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,13366,B,,Bos taurus,9913.0,,,
1640,Autocuration,105,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,10444,B,,Bos taurus,9913.0,,,
1641,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,16532,B,,Bos taurus,9913.0,,,
1642,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,16532,B,,Bos taurus,9913.0,,,
1643,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,12827,B,,Bos taurus,9913.0,,,
1644,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,12827,B,,Bos taurus,9913.0,,,
1645,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,F,,Bos taurus,9913.0,,,
1646,Autocuration,105,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,14025,B,,Bos taurus,9913.0,,,
1647,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,F,,Bos taurus,9913.0,,,
1648,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,F,,Bos taurus,9913.0,,,
1649,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,12919,F,,Bos taurus,9913.0,,,
1650,Autocuration,105,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,14447,B,,Gorilla gorilla,9593.0,,HEK293,
1651,Intermediate,105570,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1375,B,,Cavia porcellus,10141.0,,,
1652,Intermediate,105570,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1375,B,,Cavia porcellus,10141.0,,,
1653,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,12409,F,,Cavia porcellus,10141.0,,,
1654,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,F,,Cavia porcellus,10141.0,,,
1655,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,12409,F,,Cavia porcellus,10141.0,,,
1656,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,12409,F,,Cavia porcellus,10141.0,,,
1657,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,12409,F,,Cavia porcellus,10141.0,,,
1658,Intermediate,105570,,,Binding affinity against 5-hydroxytryptamine 1D receptor,11574,B,,Cavia porcellus,10141.0,,,
1659,Intermediate,105570,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1558,B,,Cavia porcellus,10141.0,,,
1660,Intermediate,105570,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,F,,Cavia porcellus,10141.0,,,
1661,Intermediate,105570,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,F,,Cavia porcellus,10141.0,,,
1662,Intermediate,105570,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,12409,F,,Cavia porcellus,10141.0,,,
1663,Intermediate,105570,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,12409,F,,Cavia porcellus,10141.0,,,
1664,Intermediate,105570,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,12253,B,,Cavia porcellus,10141.0,,,
1665,Intermediate,105570,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,12936,B,,Cavia porcellus,10141.0,,,
1666,Autocuration,105,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,13181,B,,Cavia porcellus,10141.0,,,
1667,Intermediate,105570,Striatum,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,12409,B,,Cavia porcellus,10141.0,,,
1668,Intermediate,105570,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,10639,B,,Cavia porcellus,10141.0,,,
1669,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1D receptor,5254,B,,,,,,
1670,Autocuration,106,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,13051,B,,,,,,
1671,Expert,105,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,3463,F,,,,,,
1672,Autocuration,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,15315,F,,,,,,
1673,Autocuration,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,6011,F,,,,,,
1674,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",14159,F,,Homo sapiens,9606.0,,CHO,
1675,Autocuration,105,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",14159,F,,,,,CHO,
1676,Expert,105,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,15250,B,,,,,CHO,
1677,Autocuration,105,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,15250,B,,,,,CHO,
1678,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",15331,F,,,,,CHO,
1679,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",15332,F,,Homo sapiens,9606.0,,CHO,
1680,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",15332,F,,,,,CHO,
1681,Autocuration,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",3294,F,,,,,CHO,
1682,Expert,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",14158,F,,,,,CHO,
1683,Expert,105,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",14956,F,,,,,CHO,
1684,Autocuration,105,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,12469,F,,,,,,
1685,Expert,105,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,3463,F,,,,,CHO,
1686,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",15250,F,,Homo sapiens,9606.0,,CHO,
1687,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",15250,F,,Homo sapiens,9606.0,,CHO,
1688,Expert,105,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",14956,F,,,,,,
1689,Autocuration,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",14159,F,,,,,,
1690,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",14159,F,,Homo sapiens,9606.0,,,
1691,Expert,105,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,14499,F,,Homo sapiens,9606.0,,CHO,
1692,Autocuration,105,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,15315,F,,,,,,
1693,Autocuration,105,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),3294,B,In vitro,,,,,
1694,Expert,105,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,3463,B,,,,,CHO,
1695,Autocuration,105,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,15331,B,,,,,,
1696,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14159,B,,Homo sapiens,9606.0,,CHO,
1697,Expert,105,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,14158,B,,,,,CHO,
1698,Autocuration,105,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,14159,B,,,,,,
1699,Expert,105,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,15250,B,,,,,CHO,
1700,Expert,105,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15250,B,,,,,CHO,
1701,Expert,105,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15331,B,,,,,CHO,
1702,Expert,105,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,15332,B,,Homo sapiens,9606.0,,CHO,
1703,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14499,B,,Homo sapiens,9606.0,,CHO,
1704,Expert,105,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,15332,B,,,,,CHO,
1705,Expert,105,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,14956,B,,,,,CHO,
1706,Autocuration,105,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),3805,B,,,,,,
1707,Expert,105,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,6011,B,,Homo sapiens,9606.0,,CHO,
1708,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,16190,B,,,,,CHO,
1709,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,14165,B,,,,,,
1710,Expert,105,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,4234,B,,Homo sapiens,9606.0,,,
1711,Autocuration,105,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",15527,B,,,,,,
1712,Expert,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,6328,B,,,,,,
1713,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,16209,B,,,,,,
1714,Autocuration,105,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,14770,B,,,,,,
1715,Autocuration,105,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,2598,B,,,,,,
1716,Expert,105,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,6897,B,,,,,,
1717,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,6013,B,,,,,,
1718,Expert,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,5843,B,,,,,,
1719,Expert,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,14454,B,,,,,,
1720,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,14454,B,,,,,,
1721,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,14454,B,,,,,,
1722,Autocuration,105,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,15818,B,,,,,,
1723,Expert,105,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,13729,F,,,,,CHO-K1,
1724,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),6011,B,In vitro,Homo sapiens,9606.0,,,
1725,Expert,105,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,4234,B,,Homo sapiens,9606.0,,,
1726,Expert,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,17085,B,,,,,,
1727,Autocuration,105,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,3025,B,,,,,,
1728,Expert,105,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,15315,B,,,,,,
1729,Expert,105,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,14214,B,,Homo sapiens,9606.0,,,
1730,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,3804,B,,Homo sapiens,9606.0,,,
1731,Autocuration,105,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,16700,B,,,,,,
1732,Expert,105,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,2391,B,,Homo sapiens,9606.0,,,
1733,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,4175,B,,Homo sapiens,9606.0,,,
1734,Autocuration,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,17085,B,,,,,,
1735,Expert,105,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,17085,B,,,,,,
1736,Expert,105,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,15926,B,,Homo sapiens,9606.0,,,
1737,Autocuration,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,16312,B,,,,,CHO-K1,
1738,Autocuration,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,16312,B,,,,,CHO-K1,
1739,Autocuration,104802,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,14956,B,,,,,CHO,
1740,Autocuration,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",3294,F,,,,,,
1741,Autocuration,105,,,Binding activity radioligand.,12861,B,,,,,,
1742,Autocuration,105,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,B,,,,,,
1743,Expert,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,16312,B,,,,,CHO-K1,
1744,Autocuration,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,5104,B,,,,,,
1745,Autocuration,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,5105,B,,,,,,
1746,Autocuration,105,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,14499,B,,,,,,
1747,Expert,105,,,Binding activity against human 5-hydroxytryptamine 1D receptor,15926,B,,Homo sapiens,9606.0,,,
1748,Expert,105,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,4540,B,,Homo sapiens,9606.0,,CHO,
1749,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,15779,B,,,,,CHO,
1750,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
1751,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,6166,B,,,,,,
1752,Autocuration,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
1753,Autocuration,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,15779,B,,,,,CHO,
1754,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,17451,B,,,,,HEK293,
1755,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,17451,B,,,,,HEK293,
1756,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,17451,B,,,,,HEK293,
1757,Autocuration,105,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,4199,B,,,,,CHO,
1758,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,14875,B,,Homo sapiens,9606.0,,,
1759,Autocuration,105,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,15146,B,,,,,CHO,
1760,Autocuration,105,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,5213,B,,,,,,
1761,Autocuration,105,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,14818,B,,,,,CHO,
1762,Autocuration,105,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",4829,B,,,,,CHO,
1763,Expert,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,14454,F,,,,,,
1764,Expert,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,14454,F,,,,,,
1765,Autocuration,108,,,Binding affinity against 5-HT2C receptor,5254,B,,,,,,
1766,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 1D receptor,5254,B,,,,,,
1767,Autocuration,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10639,B,,,,,,
1768,Autocuration,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10639,F,,,,,,
1769,Expert,10577,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",12352,B,,,,,,
1770,Autocuration,10577,,,Binding affinity towards 5-HT1B was determined,9098,B,,,,,,
1771,Expert,10577,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,14430,B,,,,,,
1772,Expert,10577,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",13657,B,,,,,,
1773,Autocuration,10577,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",13657,B,,,,,,
1774,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,B,,,,,,
1775,Expert,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10639,B,,Rattus norvegicus,10116.0,,,
1776,Autocuration,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10025,B,,,,,,
1777,Autocuration,10577,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10025,B,,,,,,
1778,Autocuration,10577,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,14286,B,,,,,,
1779,Autocuration,10577,Striatum,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,3651,B,,,,,,
1780,Expert,10577,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,14178,B,,Rattus norvegicus,10116.0,,,
1781,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10639,B,,,,,,
1782,Autocuration,10577,Striatum,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,13605,B,,,,,,
1783,Autocuration,10577,Striatum,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,5834,B,,,,,,
1784,Autocuration,10577,Striatum,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10922,B,,,,,,
1785,Autocuration,10577,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,14286,B,,,,,,
1786,Autocuration,10577,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,11825,B,,,,,,
1787,Autocuration,10577,Striatum,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,14826,B,,,,,,
1788,Autocuration,10577,Striatum,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,9699,B,,,,,,
1789,Autocuration,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,14423,B,,,,,,
1790,Expert,10577,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10062,B,,,,,,
1791,Autocuration,10577,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10062,B,,,,,,
1792,Expert,10577,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,12280,B,,Rattus norvegicus,10116.0,,,
1793,Autocuration,10577,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,15412,B,,,,,,
1794,Autocuration,10577,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,15412,B,,,,,,
1795,Autocuration,10577,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10062,B,,,,,,
1796,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,11147,B,,,,,,
1797,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,9547,B,,,,,,
1798,Autocuration,10577,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10444,B,,,,,,
1799,Autocuration,10577,Striatum,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,12469,B,,,,,,
1800,Expert,10577,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,9098,B,,,,,,
1801,Autocuration,10577,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,9098,B,,,,,,
1802,Autocuration,10577,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,9699,B,,,,,,
1803,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10394,B,,,,,,
1804,Autocuration,10577,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,12092,B,,,,,,
1805,Autocuration,10577,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,16700,B,,,,,,
1806,Expert,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,403,B,,Rattus norvegicus,10116.0,,,
1807,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,12771,B,,Rattus norvegicus,10116.0,,,
1808,Autocuration,10577,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,11642,B,,,,,,
1809,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,12953,B,,,,,,
1810,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,12953,B,,,,,,
1811,Expert,10577,Striatum,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,12953,B,,,,,,
1812,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,12953,B,,,,,,
1813,Autocuration,10577,Brain,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,B,,,,,,
1814,Autocuration,10577,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,9737,B,,,,,,
1815,Autocuration,10577,Brain,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,B,,,,,,
1816,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,12827,B,,,,,,
1817,Autocuration,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,5033,B,,,,,,
1818,Expert,10577,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,9786,B,,Rattus norvegicus,10116.0,,,
1819,Expert,10577,,,Binding affinity at 5-hydroxytryptamine 1B receptor,13116,B,,,,,,
1820,Autocuration,10577,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,16429,B,,,,,,
1821,Expert,10577,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,12409,B,,Rattus norvegicus,10116.0,,,
1822,Autocuration,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,15194,B,,,,,,
1823,Autocuration,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,15194,B,,,,,,
1824,Autocuration,104686,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,5486,B,,,,,,
1825,Autocuration,106,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,4639,B,,,,,,
1826,Autocuration,106,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,386,B,,,,,,Brain membranes
1827,Autocuration,106,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,2474,B,,,,,,
1828,Autocuration,106,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,6011,B,,,,,,
1829,Autocuration,106,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,5014,B,,,,,,
1830,Autocuration,106,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,17515,B,,,,,,
1831,Autocuration,106,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,4373,B,,,,,,
1832,Expert,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1633,B,,,,,,
1833,Autocuration,106,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1633,B,,,,,,
1834,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,4373,B,,,,,,
1835,Autocuration,106,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,4687,B,,,,,,
1836,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor,11574,B,,,,,,
1837,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,10321,B,,,,,,
1838,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,15527,B,,,,,,
1839,Autocuration,106,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,17200,B,,,,,,
1840,Autocuration,104802,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,14423,B,,,,,,
1841,Autocuration,108,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,5834,B,,Bos taurus,9913.0,,,
1842,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,11473,B,,Sus scrofa,9823.0,,,
1843,Autocuration,108,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,11473,B,,Sus scrofa,9823.0,,,
1844,Autocuration,108,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,10639,B,,Sus scrofa,9823.0,,,
1845,Autocuration,108,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,10639,B,,Sus scrofa,9823.0,,,
1846,Autocuration,108,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,14331,B,,Sus scrofa,9823.0,,,
1847,Autocuration,108,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,10796,B,,Sus scrofa,9823.0,,,
1848,Expert,108,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,9098,B,,Sus scrofa,9823.0,,,
1849,Expert,108,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,14331,B,,Sus scrofa,9823.0,,,
1850,Expert,108,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,11828,B,,Sus scrofa,9823.0,,,
1851,Autocuration,108,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,11866,B,,Sus scrofa,9823.0,,,
1852,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
1853,Autocuration,12689,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,188,B,,Rattus norvegicus,10116.0,,,
1854,Autocuration,12689,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,11825,B,,Rattus norvegicus,10116.0,,,
1855,Autocuration,12689,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,11825,B,,Rattus norvegicus,10116.0,,,
1856,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,11624,B,,Rattus norvegicus,10116.0,,,
1857,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,11139,B,,Rattus norvegicus,10116.0,,,
1858,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,11147,B,,Rattus norvegicus,10116.0,,,
1859,Autocuration,12689,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,10444,B,,Rattus norvegicus,10116.0,,,
1860,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,11624,B,,Rattus norvegicus,10116.0,,,
1861,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,B,,Rattus norvegicus,10116.0,,,
1862,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,B,,Rattus norvegicus,10116.0,,,
1863,Expert,12689,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,B,,Rattus norvegicus,10116.0,,,
1864,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",11662,B,,Rattus norvegicus,10116.0,,,
1865,Autocuration,12689,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,9098,B,,Rattus norvegicus,10116.0,,,
1866,Autocuration,12689,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,10394,B,,Rattus norvegicus,10116.0,,,
1867,Expert,12689,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,11933,B,,,,,,
1868,Autocuration,12689,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12092,B,,Rattus norvegicus,10116.0,,,
1869,Autocuration,12689,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12253,B,,Rattus norvegicus,10116.0,,,
1870,Autocuration,12689,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12253,B,,Rattus norvegicus,10116.0,,HEK293,
1871,Autocuration,108,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1558,B,,,,,,
1872,Autocuration,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,2474,B,,,,,,
1873,Autocuration,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,2474,B,,,,,,
1874,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,11574,B,,,,,,
1875,Autocuration,12689,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1558,B,,,,,,
1876,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,13944,B,,,,,,
1877,Autocuration,12689,,,Binding affinity against serotonergic 5-HT1c receptor,13033,B,,,,,,
1878,Autocuration,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,10321,B,,,,,,
1879,Autocuration,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,11866,B,,,,,,
1880,Autocuration,105,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),14454,B,,Oryctolagus cuniculus,9986.0,,,
1881,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,11574,B,,,,,,
1882,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,11574,B,,,,,,
1883,Autocuration,104686,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,13631,B,,,,,,
1884,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,9630,B,,Rattus norvegicus,10116.0,,,
1885,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,8822,B,,Rattus norvegicus,10116.0,,,
1886,Autocuration,104686,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,9064,B,,Rattus norvegicus,10116.0,,,
1887,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,8868,B,,,,,,
1888,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,9064,B,,,,,,
1889,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,9806,B,,,,,,
1890,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,9098,B,,,,,,
1891,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,8868,B,,,,,,
1892,Autocuration,104686,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,12765,B,,,,,,
1893,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,B,,,,,,
1894,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,B,,,,,,
1895,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,11049,B,,,,,,
1896,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,11049,B,,,,,,
1897,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,B,,,,,,
1898,Autocuration,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,11473,B,,,,,,
1899,Autocuration,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,11473,B,,,,,,
1900,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,3086,B,,,,,,
1901,Autocuration,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,B,,,,,,
1902,Autocuration,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,11049,B,,,,,,
1903,Autocuration,104686,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,10639,B,,,,,,
1904,Autocuration,104686,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,10922,B,,,,,,
1905,Autocuration,104686,Brain,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,9064,B,,Rattus norvegicus,10116.0,,,
1906,Autocuration,104686,Brain,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,10748,B,,,,,,
1907,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,11614,B,,,,,,Membranes
1908,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,11615,B,,,,,,Membranes
1909,Autocuration,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,11615,B,,,,,,
1910,Autocuration,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,11614,B,,,,,,Membranes
1911,Autocuration,104686,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,11702,B,,,,,,
1912,Autocuration,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,B,,,,,,
1913,Autocuration,104686,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,11702,B,,Rattus norvegicus,10116.0,,,
1914,Autocuration,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,B,,,,,,
1915,Autocuration,104686,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,13346,B,,,,,,
1916,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,10025,B,,,,,,
1917,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,10025,B,,,,,,
1918,Autocuration,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",10025,B,,,,,,
1919,Autocuration,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,9036,B,,,,,,
1920,Autocuration,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,9036,B,,,,,,
1921,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,9161,B,,,,,,
1922,Autocuration,104686,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,12304,B,,,,,,
1923,Autocuration,104686,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,13276,B,,,,,,
1924,Autocuration,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,11825,B,,,,,,
1925,Autocuration,104686,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,12443,B,,,,,,
1926,Autocuration,104686,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,13830,B,,,,,,
1927,Autocuration,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,9592,B,,,,,,Membranes
1928,Autocuration,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,9592,B,,,,,,Membranes
1929,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,10881,B,,,,,,
1930,Autocuration,104686,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,13605,B,,,,,,
1931,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,11624,B,,Rattus norvegicus,10116.0,,,
1932,Autocuration,104686,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4101,B,,,,,,
1933,Autocuration,104686,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4101,B,,,,,,
1934,Autocuration,104686,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,15360,B,,,,,,
1935,Autocuration,104686,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,11576,B,,,,,,
1936,Autocuration,104686,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,5834,B,,,,,,
1937,Autocuration,104686,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,B,,Rattus norvegicus,10116.0,,CHO-K1,
1938,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,11965,B,,,,,,Membranes
1939,Autocuration,104686,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),3967,B,,,,,,
1940,Autocuration,104686,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),11130,B,,,,,,Brain membranes
1941,Autocuration,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,B,In vitro,,,,,
1942,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,9443,B,,,,,,
1943,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,9443,B,,,,,,
1944,Autocuration,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,11825,B,,,,,,
1945,Autocuration,104686,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,12120,B,,,,,,Membranes
1946,Autocuration,104686,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,12120,B,,,,,,Membranes
1947,Autocuration,104686,Thoracic aorta,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,11963,F,,,,,,
1948,Autocuration,104686,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,9069,B,,,,,,
1949,Autocuration,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,8868,B,,,,,,
1950,Autocuration,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,17200,B,,,,,,
1951,Autocuration,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,17200,B,,,,,,
1952,Expert,17106,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,13969,B,,,,,,
1953,Expert,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor,13392,B,,,,,,
1954,Autocuration,17106,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1742,B,,,,,,
1955,Autocuration,17106,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1742,B,,,,,,
1956,Autocuration,17106,Striatum,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,14331,B,,,,,,
1957,Autocuration,17106,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,12861,F,,,,,,
1958,Expert,17106,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,12861,B,,,,,,
1959,Autocuration,17106,,,Binding activity radioligand.,12861,B,,,,,,
1960,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,B,,,,,,
1961,Expert,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,B,,,,,,
1962,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,12861,B,,,,,,
1963,Autocuration,17106,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,675,B,,,,,,
1964,Expert,17106,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,12490,B,,,,,,
1965,Expert,17106,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,11828,B,,,,,,
1966,Autocuration,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,11866,B,,,,,,
1967,Autocuration,105,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,773,B,,Sus scrofa,9823.0,,,
1968,Expert,105,,,The compound was tested for intrinsic activity against 5-HT1D receptor,13047,B,,Oryctolagus cuniculus,9986.0,,,
1969,Autocuration,105,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
1970,Expert,105,,,The compound was tested for binding affinity against 5-HT1D receptor,13047,B,,Oryctolagus cuniculus,9986.0,,,
1971,Autocuration,10578,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,188,B,,,,,,
1972,Autocuration,10578,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10639,F,,,,,,
1973,Autocuration,10578,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,12438,F,,,,,,
1974,Autocuration,10578,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,12438,B,,,,,,
1975,Expert,10578,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,15854,B,,,,,,
1976,Autocuration,10578,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10394,B,,,,,,
1977,Autocuration,10578,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,12092,B,,,,,,
1978,Expert,10578,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,3389,B,,,,,,
1979,Autocuration,105,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,6011,B,,,,,,
1980,Autocuration,105,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,4639,B,,,,,,
1981,Autocuration,105,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,2474,B,,,,,,
1982,Autocuration,105,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,5014,B,,,,,,
1983,Autocuration,105,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,17515,B,,,,,,
1984,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,11866,B,,,,,,
1985,Autocuration,105,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,4687,B,,,,,,
1986,Autocuration,105,,,Tested against 5-hydroxytryptamine 1D receptor,12146,B,,,,,,
1987,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,10321,B,,,,,,
1988,Autocuration,105,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,13267,B,,,,,HEK293,
1989,Expert,105,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,1274,B,,Homo sapiens,9606.0,,,
1990,Autocuration,105,,,,15250,B,,,,,,
1991,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
1992,Autocuration,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
1993,Autocuration,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,13706,B,,,,,HEK293,
1994,Autocuration,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,13706,B,,,,,HEK293,
1995,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,13047,B,,,,,,
1996,Autocuration,105,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,13366,B,,,,,,
1997,Expert,105,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,13366,B,,,,,,
1998,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1558,B,,,,,,
1999,Expert,105,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",12902,B,,,,,CHO-K1,
2000,Autocuration,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
2001,Autocuration,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,13706,F,,,,,,
2002,Autocuration,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,F,,,,,,
2003,Autocuration,105,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,F,,,,,,
2004,Autocuration,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,F,,,,,,
2005,Autocuration,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,14251,F,,,,,,
2006,Autocuration,105,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,13313,B,,,,,,
2007,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,13313,B,,,,,,
2008,Autocuration,105,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,13366,B,,,,,,
2009,Expert,105,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,13051,B,,,,,,
2010,Expert,105,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",12903,B,,,,,CHO,
2011,Autocuration,105,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,12469,B,,Homo sapiens,9606.0,,,
2012,Autocuration,17106,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,5619,B,,,,,,
2013,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
2014,Autocuration,105,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,16633,B,,,,,,
2015,Autocuration,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,16633,B,,,,,,
2016,Autocuration,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,16633,B,,,,,,
2017,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,16633,B,,,,,,
2018,Autocuration,105,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,3269,B,,,,,,
2019,Expert,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,12409,B,,,,,,
2020,Autocuration,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,F,,,,,,
2021,Autocuration,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,13706,B,,,,,HEK293,
2022,Autocuration,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,13706,B,,,,,HEK293,
2023,Autocuration,106,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",12903,B,,,,,CHO,
2024,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,13047,B,,,,,,
2025,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,B,,,,,,
2026,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,B,,,,,,
2027,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,13366,B,,,,,,
2028,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,13366,B,,,,,,
2029,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,13366,B,,,,,,
2030,Autocuration,106,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,12469,B,,,,,CHO,
2031,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
2032,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,13706,B,,,,,CHO-K1,
2033,Autocuration,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,13706,F,,,,,,
2034,Expert,106,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",12902,B,,,,,CHO-K1,
2035,Expert,105,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,13051,B,,,,,,
2036,Expert,106,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",12903,B,,,,,CHO,
2037,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1558,F,,,,,CHO-K1,
2038,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1558,F,,,,,CHO-K1,
2039,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1558,F,,,,,CHO-K1,
2040,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1558,F,,,,,CHO-K1,
2041,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1558,B,,,,,,
2042,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
2043,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,13313,B,,,,,,
2044,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,13313,B,,,,,,
2045,Expert,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,12409,B,,,,,,
2046,Autocuration,10618,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,15250,B,,,,,CHO,
2047,Expert,10618,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1348,B,,Homo sapiens,9606.0,,,
2048,Autocuration,10618,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1348,B,,,,,,
2049,Expert,10618,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,4234,B,,Homo sapiens,9606.0,,,
2050,Autocuration,10618,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,16209,B,,,,,,
2051,Autocuration,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10444,B,,,,,,
2052,Autocuration,10618,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,3935,B,,,,,,
2053,Autocuration,10618,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,15818,B,,,,,,
2054,Autocuration,10618,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,17085,B,,,,,,
2055,Expert,10618,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,12936,B,,Homo sapiens,9606.0,,CHO,
2056,Autocuration,10618,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,6166,B,,,,,,
2057,Autocuration,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
2058,Autocuration,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
2059,Autocuration,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,15779,B,,,,,CHO,
2060,Autocuration,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,13181,B,,,,,,
2061,Autocuration,10618,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,4199,B,,,,,CHO,
2062,Autocuration,10618,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,14875,B,,,,,,
2063,Autocuration,10618,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,15146,B,,,,,CHO,
2064,Autocuration,10618,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,5213,B,,,,,,
2065,Autocuration,10618,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,12146,B,,,,,,
2066,Autocuration,10618,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,13267,B,,,,,CHO,
2067,Autocuration,10618,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,14818,B,,,,,CHO,
2068,Autocuration,10618,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",4829,B,,,,,CHO,
2069,Autocuration,10618,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,4373,B,,,,,,
2070,Autocuration,10618,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,4373,B,,,,,,
2071,Autocuration,10618,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,14159,B,,,,,,
2072,Autocuration,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,16633,B,,,,,,
2073,Autocuration,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",17085,F,,,,,,
2074,Expert,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",17085,F,,,,,,
2075,Autocuration,279,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,16209,F,,,,,,
2076,Autocuration,279,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,16209,F,,,,,,
2077,Expert,279,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",17085,F,,,,,,
2078,Autocuration,279,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,14159,B,,,,,,
2079,Autocuration,279,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,15250,B,,,,,CHO,
2080,Autocuration,279,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),3805,B,,,,,,
2081,Autocuration,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,16190,B,,,,,CHO,
2082,Autocuration,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,16190,B,,,,,,
2083,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,16209,B,,,,,,
2084,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,16209,B,,,,,,
2085,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,16209,B,,,,,,
2086,Autocuration,279,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,6866,B,,,,,,
2087,Expert,279,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,17085,B,,,,,,
2088,Autocuration,279,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,16312,B,,,,,,
2089,Autocuration,279,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,6166,B,,,,,,
2090,Autocuration,279,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,15779,B,,,,,CHO,
2091,Autocuration,279,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,4199,B,,,,,CHO,
2092,Autocuration,279,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,14875,B,,,,,,
2093,Autocuration,279,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,15146,B,,,,,CHO,
2094,Autocuration,279,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,5213,B,,,,,,
2095,Autocuration,279,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,14818,B,,,,,CHO,
2096,Autocuration,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",4829,B,,,,,CHO,
2097,Autocuration,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",4829,B,,,,,CHO,
2098,Autocuration,279,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,4373,B,,,,,,
2099,Autocuration,279,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,4373,B,,,,,,
2100,Autocuration,279,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,5014,B,,,,,,
2101,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",11662,B,,,,,,
2102,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",11662,B,,,,,,
2103,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,B,,,,,,
2104,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,14093,B,,,,,,
2105,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",11200,F,In vivo,,,,,
2106,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2107,Intermediate,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,12352,B,,,,,,
2108,Autocuration,22226,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",13657,B,,Bos taurus,9913.0,,,
2109,Autocuration,22226,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,14331,B,,Bos taurus,9913.0,,,
2110,Autocuration,22226,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,14331,B,,Bos taurus,9913.0,,,
2111,Autocuration,22226,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,14331,B,,,,,,
2112,Autocuration,104784,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,12685,B,,Cavia porcellus,10141.0,,,
2113,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,14389,B,,Cavia porcellus,10141.0,,,
2114,Autocuration,104784,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,14386,B,,Cavia porcellus,10141.0,,,
2115,Autocuration,104784,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,5732,B,,,,,,
2116,Autocuration,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,16293,B,,,,,,
2117,Autocuration,104784,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,2078,B,,,,,,
2118,Autocuration,10209,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,5486,B,,,,,,
2119,Autocuration,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,11820,B,In vivo,,,,,
2120,Autocuration,104826,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10297,B,,,,,,
2121,Autocuration,104826,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,13704,B,,,,,,
2122,Autocuration,104826,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,10297,B,,Mus musculus,10090.0,,,
2123,Autocuration,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,11820,B,In vivo,,,,,
2124,Autocuration,104826,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,10297,B,,Mus musculus,10090.0,,,
2125,Autocuration,104826,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,11555,B,,,,,,
2126,Autocuration,104826,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,11555,B,,,,,,
2127,Autocuration,104826,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,11555,B,,,,,,
2128,Autocuration,104826,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10297,B,,Mus musculus,10090.0,,,
2129,Autocuration,104784,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,16688,B,,Sus scrofa,9823.0,,,
2130,Autocuration,104784,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,16688,B,,Sus scrofa,9823.0,,,
2131,Autocuration,22226,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,5333,B,,,,,,
2132,Autocuration,22226,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,4437,B,,,,,,
2133,Autocuration,17005,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,5033,B,,Sus scrofa,9823.0,,,
2134,Autocuration,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,15267,B,,,,,,
2135,Autocuration,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,15267,B,,,,,,
2136,Autocuration,104826,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,11820,B,,,,,,
2137,Autocuration,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,9069,B,,,,,,
2138,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,9162,B,,Rattus norvegicus,10116.0,,,
2139,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,9162,B,,,,,,
2140,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,9162,B,,,,,,
2141,Autocuration,104686,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,10428,F,,,,,,
2142,Autocuration,104686,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,9628,B,,,,,,
2143,Autocuration,104686,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,12704,B,,,,,,
2144,Autocuration,104686,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,15453,B,,Rattus norvegicus,10116.0,,,
2145,Autocuration,104686,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,188,B,,,,,,
2146,Autocuration,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,10349,B,,,,,,
2147,Autocuration,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,10349,B,,,,,,
2148,Autocuration,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,8868,B,,,,,,
2149,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,10025,B,,,,,,
2150,Autocuration,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",10025,B,,,,,,
2151,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,11702,B,,,,,,
2152,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,11702,B,,,,,,
2153,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,11702,B,,,,,,
2154,Autocuration,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,11702,F,,,,,,
2155,Autocuration,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,11702,F,,,,,,
2156,Autocuration,104686,Hippocampus,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,10085,B,,,,,,
2157,Autocuration,104686,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,10085,B,,,,,,
2158,Autocuration,104686,Brain,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,9630,B,,Rattus norvegicus,10116.0,,,
2159,Autocuration,104686,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,11070,B,,,,,,
2160,Autocuration,104686,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,9841,B,,,,,,Membranes
2161,Autocuration,104686,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,9841,B,,,,,,Membranes
2162,Autocuration,104686,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,13291,B,,,,,,
2163,Autocuration,104686,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,10590,F,,,,,,
2164,Autocuration,104686,Brain,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,9064,B,,Rattus norvegicus,10116.0,,,
2165,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,12268,B,,Rattus norvegicus,10116.0,,,Membranes
2166,Autocuration,104686,Brain,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,13508,B,,,,,,
2167,Autocuration,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,11279,F,,,,,,
2168,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2169,Autocuration,104686,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2170,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,11200,F,,,,,,
2171,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,11200,F,,,,,,
2172,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2173,Autocuration,104686,Brain,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,9231,B,,,,,,
2174,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,9737,B,,,,,,
2175,Autocuration,104686,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,9737,B,,,,,,
2176,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,9737,B,,,,,,
2177,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,9737,B,,,,,,
2178,Autocuration,104686,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,11828,B,,Rattus norvegicus,10116.0,,,
2179,Autocuration,104686,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,12253,B,,,,,,
2180,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,12253,B,,,,,,
2181,Autocuration,104686,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",11279,F,,,,,,
2182,Autocuration,104686,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,11866,B,,,,,,
2183,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,14424,B,,Rattus norvegicus,10116.0,,,
2184,Autocuration,104686,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,15180,B,,Rattus norvegicus,10116.0,,,
2185,Autocuration,104686,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,15180,B,,Rattus norvegicus,10116.0,,,
2186,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,9786,B,,Rattus norvegicus,10116.0,,,
2187,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,12132,B,,,,,,
2188,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,5486,B,,,,,,
2189,Autocuration,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,15316,B,,,,,,
2190,Autocuration,104686,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,16429,B,,,,,,
2191,Autocuration,104686,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,14617,B,,,,,,
2192,Autocuration,104686,Brain,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,11351,B,,,,,,
2193,Autocuration,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,11279,F,,,,,,
2194,Autocuration,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2195,Autocuration,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2196,Autocuration,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2197,Autocuration,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2198,Autocuration,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2199,Autocuration,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,9523,B,,,,,,
2200,Autocuration,105075,,,Hill coefficient of compound was determined,9523,B,,,,,,
2201,Autocuration,22226,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,4771,B,,,,,,
2202,Autocuration,104686,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,5033,B,,Rattus norvegicus,10116.0,,,
2203,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,10845,B,,,,,,
2204,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,10845,B,,,,,,
2205,Autocuration,12687,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),16288,B,,,,,,
2206,Autocuration,12687,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),16288,B,,,,,,
2207,Autocuration,12687,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,16190,B,,,,,,
2208,Autocuration,104686,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,12463,B,,Rattus norvegicus,10116.0,,,
2209,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",9699,B,,,,,,
2210,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,9699,B,,,,,,
2211,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,B,,,,,,
2212,Autocuration,104784,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1205,B,,,,,,
2213,Autocuration,22226,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,11376,B,,,,,,
2214,Autocuration,104784,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",11376,B,,,,,,
2215,Autocuration,104784,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,4639,B,,,,,,
2216,Autocuration,104784,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,2222,B,,,,,,
2217,Autocuration,104784,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1558,B,,,,,,
2218,Autocuration,104784,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1089,B,,,,,,
2219,Autocuration,104784,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,386,B,,,,,,Brain membranes
2220,Autocuration,104784,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,2474,B,,,,,,
2221,Autocuration,104784,,,Binding affinity towards 5-HT2 receptor,17066,B,,,,,,
2222,Autocuration,104784,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,959,B,,,,,,
2223,Autocuration,104784,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,6398,B,,,,,,
2224,Autocuration,104686,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,11889,B,,,,,,
2225,Autocuration,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4221,B,,,,,,
2226,Autocuration,104784,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,11026,B,,,,,,
2227,Autocuration,104784,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,11866,B,,,,,,
2228,Autocuration,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4221,B,,,,,,
2229,Autocuration,22226,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,13950,B,,,,,,
2230,Autocuration,104784,,,5-hydroxytryptamine 2 receptor binding affinity,1263,B,,,,,,
2231,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,13291,B,,,,,,
2232,Autocuration,17005,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,10812,B,,,,,,
2233,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,13020,B,,,,,,
2234,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,13021,B,,,,,,
2235,Autocuration,104784,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,13020,B,,,,,,
2236,Autocuration,17005,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,14532,B,,,,,,
2237,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,13944,B,,,,,,
2238,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,14331,B,,,,,,
2239,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,14118,B,,,,,,
2240,Autocuration,17005,,,Binding affinity against serotonergic 5-HT2 receptor,13033,B,,,,,,
2241,Autocuration,17005,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,10321,B,,,,,,
2242,Autocuration,17005,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,12918,B,,,,,,
2243,Autocuration,17005,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,15120,B,,,,,,
2244,Autocuration,17005,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,2613,B,,,,,,
2245,Autocuration,104784,,,Inhibitory activity against cloned human 5-HT2 receptor,13378,B,,Homo sapiens,9606.0,,,
2246,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",2331,B,,Homo sapiens,9606.0,,CHO,
2247,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",2331,B,,Homo sapiens,9606.0,,CHO,
2248,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",2331,B,,Homo sapiens,9606.0,,CHO,
2249,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",2331,B,,Homo sapiens,9606.0,,CHO,
2250,Autocuration,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4170,B,,,,,,
2251,Autocuration,104784,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,15453,B,,,,,,
2252,Autocuration,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1479,B,,,,,,
2253,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,11139,B,,,,,,
2254,Expert,17005,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,13969,B,,,,,,
2255,Expert,17005,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,13392,B,,,,,,
2256,Expert,17005,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,14430,B,,,,,,
2257,Autocuration,107,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,13181,B,,Cavia porcellus,10141.0,,,
2258,Autocuration,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,B,,,,,,
2259,Autocuration,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,B,,,,,,
2260,Autocuration,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,B,,,,,,
2261,Autocuration,107,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,13463,B,,,,,,
2262,Autocuration,107,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,6347,B,,,,,CHO,
2263,Expert,107,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,6857,F,,Homo sapiens,9606.0,,CHO,
2264,Autocuration,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,4176,F,,,,,,
2265,Autocuration,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,4176,F,,,,,,
2266,Autocuration,107,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,4176,F,,,,,,
2267,Autocuration,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",6347,B,,,,,CHO,
2268,Autocuration,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",6347,B,,,,,CHO,
2269,Autocuration,107,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,15331,B,,,,,,
2270,Expert,107,,,Inhibition of human 5-hydroxytryptamine 2A receptor,16146,B,,Homo sapiens,9606.0,,,
2271,Autocuration,107,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,15250,B,,,,,CHO,
2272,Expert,107,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,13631,B,,,,,,
2273,Autocuration,107,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),3805,B,,,,,,
2274,Autocuration,107,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,4011,B,,,,,CHO,
2275,Expert,107,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,4012,B,,,,,CHO,
2276,Expert,107,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,6366,B,,,,,L929,
2277,Expert,107,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,15949,B,,,,,CHO,
2278,Autocuration,107,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,14093,F,,,,,,
2279,Autocuration,107,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,13481,F,,,,,,
2280,Autocuration,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,6347,B,,,,,CHO,
2281,Autocuration,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,6347,B,,,,,CHO,
2282,Autocuration,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,14093,F,,,,,,
2283,Autocuration,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,14093,F,,,,,,
2284,Autocuration,107,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,13481,F,,,,,,
2285,Autocuration,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,14442,B,,,,,,
2286,Autocuration,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,14442,B,,,,,,
2287,Autocuration,107,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,14755,B,,,,,,
2288,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,16441,B,,,,,,
2289,Autocuration,107,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,14744,B,,,,,,
2290,Expert,107,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,16659,B,,,,,CHO,
2291,Autocuration,107,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,3307,B,,,,,,
2292,Expert,107,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,6857,B,,Homo sapiens,9606.0,,,
2293,Expert,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,5635,B,,,,,,
2294,Expert,107,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,4234,B,,Homo sapiens,9606.0,,,
2295,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,15527,B,,,,,,
2296,Expert,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,6588,B,,,,,CHO,
2297,Expert,107,,,Binding affinity towards human 5-HT2A receptor in BEK cells,13631,B,,,,,,
2298,Autocuration,107,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,17723,B,,,,,,
2299,Autocuration,107,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,14770,B,,,,,,
2300,Expert,107,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,16293,B,,Homo sapiens,9606.0,,,
2301,Autocuration,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16209,B,,,,,,
2302,Autocuration,107,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,12469,B,,,,,,
2303,Autocuration,107,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,15363,B,,,,,,
2304,Autocuration,107,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,15363,B,,,,,,
2305,Expert,107,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",16441,B,,,,,,
2306,Autocuration,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,8,B,,,,,,
2307,Autocuration,107,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,4176,B,,,,,HEK293,
2308,Autocuration,107,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,17085,B,,,,,,
2309,Autocuration,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,B,,,,,,
2310,Expert,107,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,17200,B,,Homo sapiens,9606.0,,,
2311,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,4013,B,,Homo sapiens,9606.0,,CHO,
2312,Autocuration,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,5088,B,,,,,,
2313,Expert,107,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,5088,B,,Homo sapiens,9606.0,,,
2314,Autocuration,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,5088,B,,,,,,
2315,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,5088,B,,Homo sapiens,9606.0,,,
2316,Autocuration,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,5088,B,,,,,,
2317,Autocuration,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,5088,B,,,,,,
2318,Autocuration,104686,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,9786,B,,,,,,
2319,Autocuration,104686,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,9205,B,,Rattus norvegicus,10116.0,,,
2320,Autocuration,104686,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,11257,B,,,,,,
2321,Autocuration,104686,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,9362,B,,,,,,
2322,Autocuration,104686,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,9362,B,,,,,,
2323,Autocuration,104686,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,10590,B,,,,,,
2324,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,10468,B,,,,,,
2325,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,13050,B,,,,,,
2326,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,11624,B,,,,,,
2327,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,10468,B,,,,,,
2328,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,10330,B,,,,,,
2329,Autocuration,104686,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,10062,B,,,,,,
2330,Autocuration,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,11642,B,,,,,,
2331,Autocuration,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,10062,B,,,,,,
2332,Autocuration,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,13427,B,In vitro,,,,,
2333,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,12280,B,,Rattus norvegicus,10116.0,,,
2334,Autocuration,104686,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,4101,B,,Rattus norvegicus,10116.0,,,
2335,Autocuration,104686,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,10062,B,,,,,,
2336,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,11147,B,,,,,,
2337,Autocuration,104686,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,B,,Rattus norvegicus,10116.0,,CHO-K1,
2338,Autocuration,104686,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,2395,B,,Rattus norvegicus,10116.0,,CHO-K1,
2339,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,9098,B,,Rattus norvegicus,10116.0,,,
2340,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,9098,B,,,,,,
2341,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,9098,B,,Rattus norvegicus,10116.0,,,
2342,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,9443,B,,,,,,
2343,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,9443,B,,,,,,
2344,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",9699,B,,,,,,
2345,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,9699,B,,,,,,
2346,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,9098,B,,,,,,
2347,Autocuration,104686,,,Affinity for 5-hydroxytryptamine 2 receptor,3070,B,,Rattus norvegicus,10116.0,,,
2348,Autocuration,104686,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,9547,B,,,,,,
2349,Autocuration,104686,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,10444,B,,,,,,
2350,Autocuration,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,14617,B,,,,,,
2351,Autocuration,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,14617,B,,,,,,
2352,Autocuration,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),11130,B,,,,,,
2353,Autocuration,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),11130,B,In vivo,,,,,
2354,Autocuration,104686,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,14542,B,,,,,,
2355,Autocuration,104686,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,2797,B,,,,,,
2356,Autocuration,104686,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,11332,B,,,,,,
2357,Autocuration,104686,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,11332,B,,,,,,
2358,Autocuration,104686,Frontal cortex,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,10752,B,,,,,,
2359,Autocuration,104686,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1185,B,,,,,,
2360,Autocuration,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1185,B,,,,,,
2361,Autocuration,104686,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,11624,B,,Rattus norvegicus,10116.0,,,
2362,Autocuration,104686,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1344,B,,,,,,
2363,Autocuration,104686,Striatum,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,15453,B,,Rattus norvegicus,10116.0,,,
2364,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",11662,B,,,,,,
2365,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",11662,B,,,,,,
2366,Autocuration,104686,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,10796,B,,,,,,
2367,Autocuration,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,9069,B,,,,,,
2368,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,8814,B,,Rattus norvegicus,10116.0,,,
2369,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,8908,B,,Rattus norvegicus,10116.0,,,
2370,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,9098,B,,,,,,
2371,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,9098,B,,,,,,
2372,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,9098,B,,,,,,
2373,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,9098,B,,,,,,
2374,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,9098,B,,,,,,
2375,Autocuration,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,9098,B,,,,,,
2376,Autocuration,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,9098,B,,,,,,
2377,Autocuration,104686,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,9161,B,,,,,,
2378,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,9161,B,,,,,,
2379,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,9161,B,,,,,,
2380,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,9161,B,,,,,,
2381,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,9161,B,,,,,,
2382,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,9161,B,,,,,,
2383,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,9161,B,,,,,,
2384,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,9161,B,,,,,,
2385,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,9161,B,,,,,,
2386,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,9161,B,,,,,,
2387,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,9161,B,,,,,,
2388,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,9161,B,,,,,,
2389,Autocuration,104686,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,12094,B,,,,,,
2390,Autocuration,104686,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,12018,B,,,,,,
2391,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,10394,B,,,,,,
2392,Autocuration,104686,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,15260,B,,,,,,
2393,Autocuration,104686,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,11624,B,,Rattus norvegicus,10116.0,,,
2394,Autocuration,104686,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,13654,B,,,,,,
2395,Autocuration,104686,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,9541,B,,,,,,
2396,Autocuration,104686,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,11933,B,,,,,,
2397,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,15538,B,,,,,,
2398,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,15538,B,,,,,,
2399,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,15538,B,,,,,,
2400,Autocuration,104686,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,8841,B,,,,,,
2401,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1455,B,,,,,,
2402,Autocuration,104686,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1455,B,,,,,,
2403,Autocuration,104686,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,11752,B,,,,,,
2404,Autocuration,104686,Brain,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,11642,B,,,,,,
2405,Autocuration,104686,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,12092,B,,,,,,
2406,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,3967,B,,,,,,
2407,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,12771,B,,Rattus norvegicus,10116.0,,,
2408,Autocuration,104686,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,11642,B,,,,,,
2409,Autocuration,104686,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,11628,B,,,,,,
2410,Autocuration,104686,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,13654,B,,,,,,
2411,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2412,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,11200,F,,,,,,
2413,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",11200,F,In vivo,,,,,
2414,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",11200,F,In vivo,,,,,
2415,Autocuration,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",11200,F,In vivo,,,,,
2416,Autocuration,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",11200,F,In vivo,,,,,
2417,Expert,12687,Brain,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,15436,B,,,,,,
2418,Expert,12687,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,B,,Rattus norvegicus,10116.0,,,
2419,Autocuration,12687,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,14025,B,,,,,,
2420,Autocuration,12687,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,4342,B,,,,,,
2421,Expert,12687,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,13735,B,,Rattus norvegicus,10116.0,,,
2422,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,5816,B,,Rattus norvegicus,10116.0,,,
2423,Expert,12687,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,14287,B,,,,,,
2424,Autocuration,12687,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,15738,B,,,,,,
2425,Expert,12687,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,15738,B,,Rattus norvegicus,10116.0,,,
2426,Autocuration,12687,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,15026,B,,,,,,
2427,Expert,12687,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,16647,B,,,,,,
2428,Autocuration,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,16647,B,,,,,,
2429,Expert,12687,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,13345,B,,Rattus norvegicus,10116.0,,,
2430,Autocuration,12687,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1543,B,,,,,,Membranes
2431,Autocuration,12687,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12444,B,,,,,,
2432,Expert,12687,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,16404,B,,,,,,
2433,Autocuration,12687,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,16404,B,,,,,CHO,
2434,Expert,12687,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,15577,B,,,,,,
2435,Autocuration,12687,,,Serotonergic activity of the compound.,15577,B,,,,,,
2436,Autocuration,12687,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,2495,B,,,,,,
2437,Expert,12687,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,15042,B,,Rattus norvegicus,10116.0,,,
2438,Expert,12687,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,15026,B,,,,,,
2439,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,F,,Rattus norvegicus,10116.0,,,
2440,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,F,,Rattus norvegicus,10116.0,,,
2441,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12919,F,,Rattus norvegicus,10116.0,,,
2442,Autocuration,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,15194,B,,,,,,
2443,Autocuration,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,15194,B,,,,,,
2444,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,4820,B,,,,,,
2445,Autocuration,107,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,6736,B,,,,,,
2446,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,5163,B,,,,,,
2447,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,5163,B,,,,,,
2448,Autocuration,107,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,6011,B,,,,,,
2449,Expert,107,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,14294,B,,Homo sapiens,9606.0,,,
2450,Autocuration,107,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,5014,B,,,,,,
2451,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,17066,B,,,,,,
2452,Autocuration,107,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,17515,B,,,,,,
2453,Expert,107,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,6736,B,,,,,,
2454,Expert,107,,,Affinity for 5-hydroxytryptamine 2A receptor,5163,B,,,,,,
2455,Expert,107,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,16911,B,,,,,NIH3T3,
2456,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,6841,B,,,,,,
2457,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,6119,B,,,,,,
2458,Autocuration,107,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,3962,B,,,,,,
2459,Autocuration,107,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,4373,B,,,,,,
2460,Autocuration,107,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,4373,B,,,,,,
2461,Autocuration,107,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,3962,F,,,,,,
2462,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1633,B,,,,,,
2463,Autocuration,107,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,4373,B,,,,,,
2464,Expert,107,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,6576,B,,,,,,
2465,Autocuration,107,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,4687,B,,,,,,
2466,Autocuration,107,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,16946,B,,,,,,
2467,Autocuration,107,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,14159,B,,,,,,
2468,Expert,107,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,3032,B,,Mus musculus,10090.0,,CHO,
2469,Autocuration,107,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,16655,B,,,,,,
2470,Autocuration,107,,,Binding affinity at 5-hydroxytryptamine 2A receptor,13964,B,,,,,,
2471,Expert,107,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,16989,B,,,,,,
2472,Autocuration,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,16117,B,,,,,,
2473,Autocuration,107,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,16700,B,,,,,,
2474,Autocuration,107,,,Affinity against 5-hydroxytryptamine 2A receptor,3269,B,,,,,,
2475,Expert,107,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,1274,B,,Homo sapiens,9606.0,,,
2476,Autocuration,107,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1317,B,,,,,,
2477,Autocuration,107,,,Tested against 5-hydroxytryptamine 2A receptor,12146,B,,,,,,
2478,Autocuration,105075,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,12652,B,,,,,,
2479,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,12652,B,,,,,,
2480,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,12652,B,,,,,,
2481,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,12652,B,,,,,,
2482,Autocuration,107,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),16647,B,,,,,,
2483,Expert,227,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,15851,B,,Homo sapiens,9606.0,,HEK293,
2484,Expert,227,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,6857,F,,Homo sapiens,9606.0,,CHO,
2485,Autocuration,227,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),3805,B,,,,,,
2486,Expert,227,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
2487,Autocuration,227,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,14093,F,,,,,,
2488,Autocuration,227,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,13481,F,,,,,,
2489,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,14093,F,,,,,,
2490,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,14093,F,,,,,,
2491,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,14093,F,,,,,,
2492,Autocuration,227,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,13481,F,,,,,,
2493,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,14442,B,,,,,,
2494,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,14442,B,,,,,,
2495,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,14442,B,,,,,,
2496,Autocuration,107,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,12369,B,,,,,,
2497,Expert,107,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,12369,B,,,,,,
2498,Expert,107,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,12369,B,,,,,,
2499,Autocuration,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,14447,B,,,,,,
2500,Autocuration,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,14447,B,,,,,,
2501,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,B,,,,,NIH3T3,
2502,Autocuration,107,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,F,,,,,CHO,
2503,Expert,107,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,F,,Homo sapiens,9606.0,,CHO,
2504,Autocuration,104817,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,5635,B,,,,,,
2505,Autocuration,107,,,Binding activity radioligand.,12861,B,,,,,,
2506,Autocuration,107,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,B,,,,,,
2507,Autocuration,107,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,5105,B,,,,,L929,
2508,Expert,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,5104,B,,,,,L929,
2509,Expert,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,5105,B,,,,,L929,
2510,Autocuration,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,5105,B,,,,,L929,
2511,Autocuration,107,,,Binding affinity against 5-HT2A receptor,5254,B,,,,,,
2512,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor,5254,B,,,,,,
2513,Autocuration,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,13267,B,,,,,HEK293,
2514,Autocuration,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,13267,B,,,,,HEK293,
2515,Expert,107,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,14157,B,,Homo sapiens,9606.0,,HEK293,
2516,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,B,,Homo sapiens,9606.0,,HEK293,
2517,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,14068,B,,,,,,
2518,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,B,,Homo sapiens,9606.0,,HEK293,
2519,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,B,,Homo sapiens,9606.0,,HEK293,
2520,Expert,107,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,4540,B,,Homo sapiens,9606.0,,HEK293,
2521,Expert,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,6166,B,,,,,,
2522,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,17296,B,,,,,HEK293,
2523,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,17296,B,,,,,HEK293,
2524,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,17296,B,,,,,HEK293,
2525,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,15779,B,,Homo sapiens,9606.0,,HEK293,
2526,Expert,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,14391,B,,,,,HEK293,
2527,Expert,107,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",15851,B,,,,,HEK293,
2528,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,15851,B,,Homo sapiens,9606.0,,HEK293,
2529,Expert,107,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,3832,B,,,,,HEK293,
2530,Expert,107,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,3833,B,,,,,HEK293,
2531,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,12936,B,,Homo sapiens,9606.0,,HEK293,
2532,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,17451,B,,,,,NIH3T3,
2533,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,B,,,,,NIH3T3,
2534,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,B,,,,,NIH3T3,
2535,Autocuration,107,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,4199,B,,,,,HEK293,
2536,Autocuration,107,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1883,B,,,,,CHO-K1,
2537,Expert,107,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1883,B,,,,,CHO-K1,
2538,Expert,107,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,14875,B,,Homo sapiens,9606.0,,,
2539,Autocuration,107,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,15146,B,,,,,HEK293,
2540,Autocuration,107,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,5213,B,,,,,HEK293,
2541,Expert,107,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,16404,B,,Homo sapiens,9606.0,,CHO,
2542,Autocuration,107,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,14818,B,,,,,HEK293,
2543,Autocuration,107,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",4829,B,,,,,HEK293,
2544,Autocuration,10620,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,12652,F,,,,,NIH3T3,
2545,Expert,107,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,4682,B,,,,,NIH3T3,
2546,Autocuration,10620,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,12652,F,,,,,,
2547,Autocuration,10621,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,4921,B,,,,,,
2548,Autocuration,10621,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,4921,B,,,,,,
2549,Autocuration,107,,,Binding affinity against rabbit aorta 5-HT2A receptor,16312,B,,Oryctolagus cuniculus,9986.0,,,
2550,Expert,107,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,14998,B,,Oryctolagus cuniculus,9986.0,,,
2551,Expert,107,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,14025,B,,Oryctolagus cuniculus,9986.0,,,
2552,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
2553,Expert,107,,,The compound was tested for binding affinity against 5-HT2A receptor,13047,B,,Oryctolagus cuniculus,9986.0,,,
2554,Autocuration,10576,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1883,B,,,,,CHO-K1,
2555,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,13463,B,,,,,,
2556,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,13463,B,,,,,,
2557,Autocuration,12687,Stomach,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,13463,B,,,,,,
2558,Expert,12687,Stomach,,Binding affinity for 5-HT 2A in rat stomach fundus,13463,B,,Rattus norvegicus,10116.0,,,
2559,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,13463,B,,,,,,
2560,Expert,12687,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,16326,B,,,,,NIH3T3,
2561,Autocuration,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,14093,F,,,,,,
2562,Autocuration,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,14093,F,,,,,,
2563,Autocuration,12687,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,15740,B,,,,,,
2564,Autocuration,12687,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,16633,B,,,,,,
2565,Expert,12687,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,17200,F,,Rattus norvegicus,10116.0,,,
2566,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,B,,,,,,
2567,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,B,,,,,,
2568,Autocuration,12687,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,17133,B,,,,,,
2569,Autocuration,12687,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,F,,,,,,
2570,Autocuration,12687,,,Efficacy at 5-hydroxytryptamine 2A receptor,15363,F,,,,,,
2571,Autocuration,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),17200,B,,,,,,
2572,Expert,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),17200,B,,Rattus norvegicus,10116.0,,,
2573,Expert,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),17200,B,,Rattus norvegicus,10116.0,,,
2574,Expert,12687,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,F,,Rattus norvegicus,10116.0,,,
2575,Autocuration,12687,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,17200,F,,,,,,
2576,Autocuration,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,17211,B,,,,,,
2577,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,17331,B,,,,,,
2578,Expert,12687,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,13565,B,,,,,,
2579,Expert,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,13730,B,,,,,,
2580,Expert,12687,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12416,B,,,,,,
2581,Autocuration,12687,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,15295,B,,,,,,
2582,Autocuration,12687,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1742,B,,,,,,
2583,Autocuration,12687,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,15295,B,,,,,,
2584,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,14970,B,,,,,,
2585,Expert,12687,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,16693,B,,,,,,
2586,Expert,12687,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,14776,B,,Rattus norvegicus,10116.0,,,
2587,Autocuration,12687,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,14286,B,,,,,,
2588,Expert,12687,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,17200,B,,Rattus norvegicus,10116.0,,,
2589,Expert,12687,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),15306,B,,,,,,
2590,Expert,12687,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,14178,B,,Rattus norvegicus,10116.0,,,
2591,Expert,12687,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,14229,B,,Rattus norvegicus,10116.0,,,
2592,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12884,B,,,,,,
2593,Expert,12687,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",13149,B,,,,,,
2594,Expert,12687,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,15295,B,,Rattus norvegicus,10116.0,,,
2595,Autocuration,12687,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,15740,B,,,,,,
2596,Autocuration,12687,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",15185,B,,,,,,
2597,Autocuration,12687,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",15185,B,,,,,,
2598,Expert,12687,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,17529,B,,,,,,
2599,Autocuration,12687,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,14826,B,,,,,,
2600,Expert,12687,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,17211,B,,,,,,
2601,Autocuration,12687,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,14826,B,,,,,,
2602,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,14093,B,,,,,,
2603,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,14093,B,,,,,,
2604,Expert,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,13246,B,,,,,NIH3T3,
2605,Expert,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,13246,B,,,,,,
2606,Expert,12687,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,B,,Rattus norvegicus,10116.0,,,
2607,Expert,12687,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,15436,B,,Rattus norvegicus,10116.0,,,
2608,Autocuration,12687,Brain,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,14442,B,,,,,,
2609,Expert,12687,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12457,B,,,,,,
2610,Expert,12687,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12457,B,,,,,NIH3T3,
2611,Autocuration,12687,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",14755,F,,,,,,
2612,Autocuration,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,4707,B,,,,,,
2613,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor,13297,B,,,,,,
2614,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,17331,B,,,,,,
2615,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,4664,B,,,,,,
2616,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16633,B,,,,,,
2617,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,4664,B,,Rattus norvegicus,10116.0,,NIH3T3,
2618,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,16133,B,,,,,,
2619,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,16133,B,,,,,,
2620,Expert,12687,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,14060,B,,Rattus norvegicus,10116.0,,,
2621,Expert,12687,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,16326,B,,,,,,
2622,Expert,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,16659,B,,,,,CHO,
2623,Autocuration,12687,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,14776,B,,,,,,
2624,Autocuration,12687,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,13481,B,,,,,,
2625,Autocuration,12687,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,17386,B,,,,,,
2626,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A receptor,6611,B,,Rattus norvegicus,10116.0,,,
2627,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,14423,B,,,,,,
2628,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,15412,B,,,,,,
2629,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,15412,B,,,,,,
2630,Autocuration,12687,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,6238,B,,,,,,
2631,Expert,12687,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,6648,B,,,,,,
2632,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,5667,B,,,,,,
2633,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,6611,B,,Rattus norvegicus,10116.0,,,
2634,Autocuration,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,13481,B,,,,,,
2635,Autocuration,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,13481,B,,,,,,
2636,Expert,12687,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,15558,B,,,,,NIH3T3,
2637,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,6013,B,,,,,,
2638,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,16633,B,,,,,,
2639,Autocuration,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,6013,B,,,,,,
2640,Expert,12687,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,6013,B,,Rattus norvegicus,10116.0,,,
2641,Autocuration,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,6013,B,,,,,,
2642,Expert,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,6013,B,,,,,,
2643,Autocuration,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,6013,B,,,,,,
2644,Autocuration,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,6013,B,,,,,,
2645,Autocuration,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,16293,B,,,,,,
2646,Expert,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,17175,B,,,,,NIH3T3,
2647,Expert,12687,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,13278,B,,Rattus norvegicus,10116.0,,,
2648,Autocuration,12687,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,3682,B,,,,,,
2649,Autocuration,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,2014,B,,,,,,
2650,Autocuration,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,2014,B,,,,,,
2651,Autocuration,12687,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,4932,B,,,,,,
2652,Autocuration,12687,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,4932,B,,,,,,
2653,Autocuration,12687,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,3935,B,,,,,,
2654,Expert,12687,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,5432,B,,Rattus norvegicus,10116.0,,,
2655,Autocuration,12687,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,15818,B,,,,,,
2656,Autocuration,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,13672,B,,,,,,
2657,Autocuration,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,13672,B,,,,,,
2658,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,14749,B,,,,,NIH3T3,
2659,Autocuration,12687,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,13462,B,,,,,,
2660,Autocuration,12687,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,15740,B,,,,,,
2661,Expert,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,16647,B,,,,,,
2662,Autocuration,12687,Brain,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,13345,B,,,,,,
2663,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,B,,,,,,
2664,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,B,,,,,,
2665,Expert,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,15535,B,,Rattus norvegicus,10116.0,,,
2666,Expert,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,B,,,,,,
2667,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,B,,,,,,
2668,Autocuration,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,16740,B,,,,,,
2669,Expert,12687,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,4795,B,,Rattus norvegicus,10116.0,,,
2670,Expert,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,8,B,,,,,,
2671,Autocuration,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,8,B,,,,,,
2672,Expert,12687,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,17200,B,,Rattus norvegicus,10116.0,,,
2673,Expert,12687,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,2148,B,,Rattus norvegicus,10116.0,,,
2674,Expert,105102,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",13345,B,,Rattus norvegicus,10116.0,,,
2675,Autocuration,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,5088,B,,,,,,
2676,Autocuration,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,5088,B,,,,,,
2677,Autocuration,12687,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,17133,B,,,,,,
2678,Expert,12687,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,17133,B,,Rattus norvegicus,10116.0,,,
2679,Autocuration,12687,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,16532,B,,,,,,
2680,Autocuration,12687,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,15086,B,,,,,,
2681,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,2309,B,,Rattus norvegicus,10116.0,,,
2682,Expert,12687,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12953,B,,,,,,
2683,Autocuration,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12953,B,,,,,,
2684,Autocuration,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12953,B,,,,,,
2685,Autocuration,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,16659,B,,,,,CHO,
2686,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,16740,B,,,,,,
2687,Autocuration,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,16740,B,,,,,,
2688,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,17133,B,,,,,,
2689,Autocuration,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,17211,B,,,,,,
2690,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,17331,B,,,,,,
2691,Autocuration,12687,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,16633,B,,,,,,
2692,Autocuration,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,16633,B,,,,,,
2693,Autocuration,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,16633,B,,,,,,
2694,Expert,12687,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,15026,B,,,,,,
2695,Expert,12687,,,Ratio of pKi of 5-HT2A to that of D2 receptor,15026,B,,,,,,
2696,Expert,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,16404,B,,,,,,
2697,Expert,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,16404,B,,,,,,
2698,Expert,105075,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,16404,B,,,,,,
2699,Autocuration,12687,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,16404,B,,,,,,
2700,Expert,12687,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,16326,B,,,,,,
2701,Autocuration,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,15847,F,,,,,,
2702,Autocuration,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,15847,F,,,,,,
2703,Autocuration,12687,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,15329,F,,,,,,
2704,Expert,12687,Thoracic aorta,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,16404,F,,,,,,
2705,Expert,12687,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,16404,F,,,,,,
2706,Autocuration,12687,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,16404,F,,,,,,
2707,Autocuration,12687,,,Binding activity radioligand.,12861,B,,,,,,
2708,Expert,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,B,,,,,,
2709,Autocuration,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12861,B,,,,,,
2710,Expert,12687,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12490,B,,,,,,
2711,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12827,B,,,,,N1E-115,
2712,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12827,B,,,,,N1E-115,
2713,Autocuration,12687,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12918,B,,,,,,
2714,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12919,F,,Rattus norvegicus,10116.0,,,
2715,Autocuration,108,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,17723,B,,,,,,
2716,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,6013,B,,,,,,
2717,Autocuration,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,16293,B,,,,,,
2718,Expert,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,3857,B,,,,,,
2719,Expert,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,3857,B,,,,,,
2720,Expert,108,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,3857,B,,,,,,
2721,Autocuration,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,15363,B,,,,,,
2722,Autocuration,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,15363,B,,,,,,
2723,Expert,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,16441,B,,,,,,
2724,Expert,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,16441,B,,,,,,
2725,Autocuration,108,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,4176,B,,,,,HEK293,
2726,Autocuration,108,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,17085,B,,,,,,
2727,Expert,108,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,17200,B,,Homo sapiens,9606.0,,,
2728,Expert,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,5088,B,,,,,,
2729,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,5088,B,,,,,,
2730,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,5088,B,,,,,,
2731,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,5088,B,,,,,,
2732,Autocuration,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,16659,B,,,,,CHO,
2733,Autocuration,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,16659,B,,,,,CHO,
2734,Autocuration,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,17451,B,,,,,NIH3T3,
2735,Expert,108,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,F,,Homo sapiens,9606.0,,CHO,
2736,Expert,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,3857,B,,,,,,
2737,Autocuration,108,,,Binding activity radioligand.,12861,B,,,,,,
2738,Autocuration,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,12861,B,,,,,,
2739,Expert,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,5104,B,,,,,CHO,
2740,Expert,108,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,5105,B,,,,,CHO,
2741,Autocuration,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,5105,B,,,,,CHO,
2742,Autocuration,108,,,Binding affinity against 5-HT2C receptor,5254,B,,,,,,
2743,Autocuration,108,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,13267,B,,,,,HEK293,
2744,Expert,108,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,14157,B,,Homo sapiens,9606.0,,HEK293,
2745,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,12936,B,,Homo sapiens,9606.0,,HEK293,
2746,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,14068,B,,,,,,
2747,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,12936,B,,Homo sapiens,9606.0,,HEK293,
2748,Expert,108,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,4540,B,,Homo sapiens,9606.0,,HEK293,
2749,Expert,108,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,4540,B,,Homo sapiens,9606.0,,HEK293,
2750,Autocuration,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,6166,B,,,,,,
2751,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,17296,B,,,,,HEK293,
2752,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,17296,B,,,,,HEK293,
2753,Autocuration,108,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,B,,,,,HEK293,
2754,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,B,,,,,HEK293,
2755,Expert,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,14391,B,,,,,HEK293,
2756,Autocuration,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",15779,B,,,,,HEK293,
2757,Expert,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",15851,B,,,,,HEK293,
2758,Expert,108,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,15851,B,,Homo sapiens,9606.0,,HEK293,
2759,Autocuration,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",15779,B,,,,,HEK293,
2760,Expert,108,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,3832,B,,,,,HEK293,
2761,Expert,108,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,3833,B,,,,,HEK293,
2762,Autocuration,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,17451,B,,,,,NIH3T3,
2763,Autocuration,108,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,4199,B,,,,,HEK293,
2764,Expert,108,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1883,B,,,,,CHO-K1,
2765,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor,4321,B,,Homo sapiens,9606.0,,,
2766,Autocuration,108,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,14875,B,,,,,,
2767,Autocuration,108,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,15146,B,,,,,HEK293,
2768,Autocuration,108,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,5213,B,,,,,HEK293,
2769,Autocuration,108,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,16404,B,,,,,HeLa,
2770,Autocuration,108,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,13267,F,,,,,,
2771,Autocuration,108,Hippocampus,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,13267,F,,,,,,
2772,Autocuration,108,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,14818,B,,,,,HEK293,
2773,Autocuration,108,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",4829,B,,,,,HEK293,
2774,Autocuration,11864,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,13463,B,,,,,,
2775,Autocuration,11864,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,13463,B,,,,,,
2776,Autocuration,11864,Stomach,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,13463,B,,,,,,
2777,Autocuration,11864,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,12652,F,,,,,A9,
2778,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,4682,B,,,,,NIH3T3,
2779,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,4682,B,,,,,NIH3T3,
2780,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,4682,B,,,,,NIH3T3,
2781,Autocuration,11864,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,12652,F,,,,,,
2782,Autocuration,12689,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,13463,B,,Mus musculus,10090.0,,,
2783,Expert,12689,Stomach,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,13463,B,,Rattus norvegicus,10116.0,,,
2784,Expert,108,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,13969,B,,,,,,
2785,Expert,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor,13392,B,,Sus scrofa,9823.0,,,
2786,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,13392,B,,,,,,
2787,Expert,108,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,14430,B,,,,,,
2788,Autocuration,108,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1742,B,,,,,,
2789,Autocuration,108,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,14286,B,,,,,,
2790,Autocuration,108,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,5619,B,,,,,,
2791,Autocuration,108,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,15086,B,,,,,,
2792,Autocuration,108,,,Binding activity radioligand.,12861,B,,,,,,
2793,Expert,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,B,,,,,,
2794,Autocuration,108,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12861,B,,,,,,
2795,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,12827,B,,,,,,
2796,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,12827,B,,,,,,
2797,Expert,108,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,12919,F,,Sus scrofa,9823.0,,,
2798,Expert,108,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,12919,F,,Sus scrofa,9823.0,,,
2799,Autocuration,108,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,16429,B,,Sus scrofa,9823.0,,,
2800,Autocuration,108,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,773,B,,Sus scrofa,9823.0,,,
2801,Autocuration,108,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,5033,B,,Sus scrofa,9823.0,,,
2802,Autocuration,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12861,B,,,,,,
2803,Autocuration,12689,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,14093,F,,,,,,
2804,Expert,12689,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,14970,B,,,,,,
2805,Autocuration,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,14970,B,,,,,,
2806,Autocuration,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,14970,B,,,,,,
2807,Expert,12689,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,14178,B,,Rattus norvegicus,10116.0,,,
2808,Expert,12689,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,14178,B,,Rattus norvegicus,10116.0,,,
2809,Expert,12689,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,14229,B,,Rattus norvegicus,10116.0,,,Brain membranes
2810,Autocuration,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,16532,B,,,,,,
2811,Autocuration,12689,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,14826,B,,,,,,
2812,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,17211,B,,,,,,
2813,Expert,12689,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,17211,B,In vitro,,,,,
2814,Expert,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,13246,B,,,,,NIH3T3,
2815,Expert,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,13246,B,,,,,,
2816,Expert,12689,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12457,B,,,,,,
2817,Expert,12689,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12457,B,,,,,NIH3T3,
2818,Autocuration,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,4707,B,,,,,,
2819,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor,13297,B,,,,,,
2820,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,16633,B,,,,,,
2821,Expert,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,16133,B,,,,,,
2822,Expert,12689,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,16326,B,,,,,,
2823,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,14423,B,,,,,,
2824,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,15412,B,,,,,,
2825,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,15412,B,,,,,,
2826,Expert,12689,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,15558,B,,,,,A9,
2827,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,16633,B,,,,,,
2828,Expert,12689,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,6013,B,,,,,,
2829,Expert,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,17175,B,In vitro,,,,,
2830,Autocuration,12689,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12469,B,,,,,,
2831,Autocuration,12689,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,3682,B,,,,,,
2832,Autocuration,12689,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,4932,B,,,,,,
2833,Autocuration,12689,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,4932,B,,,,,,
2834,Autocuration,12689,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,3935,B,,,,,,
2835,Autocuration,12689,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,15818,B,,,,,,
2836,Autocuration,12689,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,15818,B,,,,,,
2837,Expert,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,14749,B,,,,,,
2838,Autocuration,12689,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,15740,B,,,,,,
2839,Expert,12689,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,17133,B,,Rattus norvegicus,10116.0,,,
2840,Autocuration,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,16532,B,,,,,,
2841,Autocuration,12689,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12369,B,,,,,,
2842,Expert,12689,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12369,B,,,,,,
2843,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,2309,B,,Rattus norvegicus,10116.0,,,
2844,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12953,B,,,,,,
2845,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12953,B,,,,,,
2846,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12953,B,,,,,,
2847,Expert,12689,,,Binding affinity for 5-hydroxytryptamine 2C receptor,12953,B,,,,,,
2848,Autocuration,12689,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,17133,B,,,,,,
2849,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,17211,B,,,,,,
2850,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,17211,B,,,,,,
2851,Autocuration,12689,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,14025,B,,,,,,
2852,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,14998,B,,,,,,
2853,Autocuration,12689,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,4342,B,,,,,,
2854,Expert,12689,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,13735,B,,Rattus norvegicus,10116.0,,,
2855,Autocuration,12689,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,13181,B,,,,,,
2856,Autocuration,12689,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1883,B,,,,,CHO-K1,
2857,Autocuration,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,15194,B,,,,,,
2858,Autocuration,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,15194,B,,,,,,
2859,Autocuration,12689,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,14579,F,,,,,,
2860,Autocuration,108,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,4639,B,,,,,,
2861,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,4820,B,,,,,,
2862,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,14442,B,,,,,,
2863,Autocuration,227,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,14755,B,,,,,,
2864,Autocuration,227,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,14744,B,,,,,,
2865,Expert,227,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,6857,B,,Homo sapiens,9606.0,,,
2866,Autocuration,227,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,16209,B,,,,,,
2867,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,15363,B,,,,,,
2868,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,15363,B,,,,,,
2869,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,15363,B,,,,,,
2870,Autocuration,227,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,17085,B,,,,,,
2871,Expert,227,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,17200,B,,Homo sapiens,9606.0,,,
2872,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,15851,B,,Homo sapiens,9606.0,,HEK293,
2873,Expert,227,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,15851,B,,Homo sapiens,9606.0,,HEK293,
2874,Expert,227,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,F,,Homo sapiens,9606.0,,CHO,
2875,Expert,227,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,6857,F,,Homo sapiens,9606.0,,CHO,
2876,Autocuration,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",15779,B,,,,,HEK293,
2877,Expert,227,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,15851,B,,,,,HEK293,
2878,Autocuration,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",15779,B,,,,,HEK293,
2879,Expert,227,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,14157,B,,Homo sapiens,9606.0,,HEK293,
2880,Expert,227,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,4540,B,,Homo sapiens,9606.0,,HEK293,
2881,Autocuration,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,6166,B,,,,,,
2882,Autocuration,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,15779,B,,,,,HEK293,
2883,Expert,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,14391,B,,,,,HEK293,
2884,Expert,227,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,3832,B,,,,,HEK293,
2885,Expert,227,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,3833,B,,,,,HEK293,
2886,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,15851,B,,Homo sapiens,9606.0,,HEK293,
2887,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,15851,B,,Homo sapiens,9606.0,,HEK293,
2888,Autocuration,227,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,4199,B,,,,,HEK293,
2889,Expert,227,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1883,B,,,,,CHO-K1,
2890,Expert,227,,,Binding affinity against 5-hydroxytryptamine 2B receptor,4321,B,,,,,,
2891,Autocuration,227,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,15146,B,,,,,HEK293,
2892,Autocuration,227,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,5213,B,,,,,HEK293,
2893,Autocuration,227,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,14818,B,,,,,HEK293,
2894,Autocuration,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",4829,B,,,,,HEK293,
2895,Autocuration,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",4829,B,,,,,HEK293,
2896,Autocuration,227,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,14025,B,,Oryctolagus cuniculus,9986.0,,,
2897,Expert,12688,Stomach,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,13463,B,,,,,,
2898,Expert,12688,Stomach,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,7259,B,,,,,,
2899,Autocuration,12688,Stomach,,Affinity against serotonergic receptor in the isolated rat stomach fundus,7259,B,,,,,,
2900,Expert,12688,Stomach,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,7185,F,,Rattus norvegicus,10116.0,,,
2901,Expert,12688,,,Antagonistic against 5-hydroxytryptamine 2B receptor,7185,F,,Rattus norvegicus,10116.0,,,
2902,Autocuration,12688,Stomach,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,13267,F,,,,,,
2903,Expert,12688,Stomach,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,13735,B,,Rattus norvegicus,10116.0,,,
2904,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,15738,F,,,,,,
2905,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,15738,F,,,,,,
2906,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,15738,F,,,,,,
2907,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,B,,Rattus norvegicus,10116.0,,,
2908,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,B,,Rattus norvegicus,10116.0,,,
2909,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,B,,Rattus norvegicus,10116.0,,,
2910,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12936,B,,Rattus norvegicus,10116.0,,,
2911,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,F,,,,,,
2912,Expert,12688,Stomach,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,F,,,,,,
2913,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,16404,F,,,,,,
2914,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,16404,F,,,,,,
2915,Expert,12688,Stomach,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,16404,F,,Rattus norvegicus,10116.0,,,
2916,Autocuration,12688,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,16404,F,,,,,,
2917,Autocuration,12688,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,7483,B,,,,,,
2918,Expert,12688,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,7483,B,,,,,,
2919,Autocuration,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,7483,B,,,,,,
2920,Autocuration,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,7483,B,,,,,,
2922,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,16404,F,,Rattus norvegicus,10116.0,,,
2923,Autocuration,227,,,Binding affinity against 5-hydroxytryptamine 1A receptor,6347,B,,,,,,
2924,Autocuration,227,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,4373,B,,,,,,
2925,Autocuration,227,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,4373,B,,,,,,
2926,Autocuration,227,,,Evaluated for the binding affinity to 5-HT 2B receptor,4687,B,,,,,,
2927,Autocuration,227,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,16946,B,,,,,,
2928,Autocuration,227,,,Binding affinities against 5-hydroxytryptamine 2B receptor,16633,B,,,,,,
2929,Autocuration,227,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,16633,B,,,,,,
2930,Autocuration,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,16633,B,,,,,,
2931,Expert,108,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,15026,B,,,,,,
2932,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,15738,B,,Bos taurus,9913.0,,,
2933,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,15738,B,,Bos taurus,9913.0,,,
2934,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,15738,B,,Bos taurus,9913.0,,,
2935,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,15738,B,,Bos taurus,9913.0,,,
2936,Expert,108,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,16404,B,,Bos taurus,9913.0,,,
2937,Expert,108,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,15026,B,,Bos taurus,9913.0,,,
2938,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,15738,B,,Bos taurus,9913.0,,,
2939,Autocuration,108,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,16312,B,,Cavia porcellus,10141.0,,,
2940,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,5486,B,,Cavia porcellus,10141.0,,,
2941,Autocuration,51,,,Binding affinity against 5-HT1A receptor,5254,B,,,,,,
2942,Expert,108,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,3857,F,,,,,CHO,
2943,Expert,108,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,6857,F,,Homo sapiens,9606.0,,CHO,
2944,Autocuration,108,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,4176,F,,,,,,
2945,Autocuration,108,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,6347,B,,,,,CHO,
2946,Autocuration,108,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",6347,B,,,,,CHO,
2947,Expert,108,,,Inhibition of human 5-hydroxytryptamine 2C receptor,16146,B,,Homo sapiens,9606.0,,,
2948,Autocuration,108,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),3805,B,,,,,,
2949,Autocuration,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,3857,B,,,,,,
2950,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,5635,B,,,,,,
2951,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,5635,B,,,,,,
2952,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,5635,B,,,,,,
2953,Expert,108,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,4012,B,,,,,CHO,
2954,Expert,108,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,6366,B,,,,,CHO,
2955,Expert,108,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,15949,B,,,,,CHO,
2956,Autocuration,108,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,17211,B,,,,,CHO,
2957,Expert,108,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
2958,Autocuration,108,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,14093,F,,,,,,
2959,Autocuration,108,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,13481,F,,,,,,
2960,Expert,108,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,6347,B,,Rattus norvegicus,10116.0,,CHO,
2961,Autocuration,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,14093,F,,,,,,
2962,Autocuration,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,14093,F,,,,,,
2963,Autocuration,108,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,13481,F,,,,,,
2964,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,14442,B,,,,,,
2965,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,14442,B,,,,,,
2966,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,14442,B,,,,,,
2967,Autocuration,108,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,14755,B,,,,,,
2968,Autocuration,108,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,14744,B,,,,,,
2969,Expert,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,16659,B,,,,,CHO,
2970,Expert,108,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,6857,B,,Homo sapiens,9606.0,,,
2971,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,5635,B,,,,,,
2972,Expert,108,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,4234,B,,Homo sapiens,9606.0,,,
2973,Autocuration,108,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,16209,B,,,,,,
2974,Autocuration,104698,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,5778,B,,Rattus norvegicus,10116.0,,,Membranes
2975,Autocuration,104698,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,5094,B,,,,,,
2976,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,809,B,,Rattus norvegicus,10116.0,,,
2977,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1578,B,,,,,,
2978,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,809,B,,,,,,
2979,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,12469,B,,,,,,
2980,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,14290,B,,,,,,
2981,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,14290,B,,,,,,
2982,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,10609,B,,,,,,
2983,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,10609,B,,,,,,
2984,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,10609,B,,,,,,
2985,Autocuration,104698,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",15253,B,,,,,,
2986,Autocuration,104698,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",15253,B,,,,,,
2987,Autocuration,104698,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,11683,B,,,,,,Membranes
2988,Autocuration,104698,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,12092,B,,,,,,
2989,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1946,B,,,,,,
2990,Autocuration,104698,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,11623,B,,,,,,
2991,Autocuration,104698,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,11623,B,,,,,,
2992,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,14788,B,,,,,,
2993,Autocuration,104698,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,5432,B,,Rattus norvegicus,10116.0,,,
2994,Autocuration,104698,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,14826,B,,,,,,
2995,Autocuration,104698,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,2222,B,,,,,,
2996,Autocuration,104698,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,11963,B,,,,,,
2997,Autocuration,104698,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,14145,B,,,,,,
2998,Autocuration,104698,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,17819,B,,,,,,
2999,Autocuration,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,10394,B,,,,,,
3000,Autocuration,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,10394,B,,,,,,
3001,Autocuration,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,15034,B,,,,,,
3002,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,691,B,,,,,,
3003,Autocuration,104698,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,12092,B,,,,,,Membranes
3004,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,11752,B,,Rattus norvegicus,10116.0,,,
3005,Autocuration,104698,Brain,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,11752,B,,,,,,
3006,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,301,B,,,,,,
3007,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,16532,B,,,,,,
3008,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,16532,B,,,,,,
3009,Autocuration,104698,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,12092,B,,,,,,
3010,Autocuration,104698,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,11684,B,,,,,,
3011,Autocuration,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,11684,B,,,,,,
3012,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,12953,B,,,,,,
3013,Autocuration,104698,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,12953,B,,,,,,
3014,Autocuration,104698,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,12953,B,,,,,,
3015,Autocuration,104698,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,12861,B,,,,,,
3016,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3017,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,11454,F,In vivo,,,,,
3018,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3019,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3020,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3021,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,11454,F,In vivo,,,,,
3022,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3023,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3024,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3025,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3026,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,11454,F,In vivo,,,,,
3027,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3028,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3029,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3030,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3031,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,11454,F,In vivo,,,,,
3032,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,11454,F,In vivo,,,,,
3033,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,11454,F,In vivo,,,,,
3034,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,10609,F,,,,,,
3035,Autocuration,104698,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,12861,B,,,,,,
3036,Autocuration,104698,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,12861,B,,Rattus norvegicus,10116.0,,,
3037,Autocuration,104698,,,Binding activity radioligand.,12861,B,,,,,,
3038,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,10728,B,,,,,,Brain membranes
3039,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,10728,B,,,,,,Brain membranes
3040,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,5163,B,,,,,,
3041,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,5163,B,,,,,,
3042,Autocuration,108,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,6011,B,,,,,,
3043,Autocuration,108,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,5014,B,,,,,,
3044,Autocuration,108,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,5635,B,,,,,,
3045,Expert,108,,,Affinity for 5-hydroxytryptamine 2C receptor,5163,B,,,,,,
3046,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,6841,B,,,,,,
3047,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,6119,B,,,,,,
3048,Autocuration,108,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,4373,B,,,,,,
3049,Autocuration,108,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1633,B,,,,,,
3050,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1633,B,,,,,,
3051,Autocuration,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,4373,B,,,,,,
3052,Expert,108,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,6576,B,,,,,,
3053,Autocuration,108,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,4687,B,,,,,,
3054,Autocuration,108,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,12146,B,,,,,,
3055,Autocuration,108,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,12146,B,,,,,,
3056,Autocuration,108,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,16946,B,,,,,,
3057,Autocuration,108,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,14159,B,,,,,,
3058,Autocuration,108,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,16700,B,,,,,,
3059,Autocuration,108,,,Affinity against 5-hydroxytryptamine 2C receptor,3269,B,,,,,,
3060,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor,1274,B,,Homo sapiens,9606.0,,,
3061,Autocuration,108,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1317,B,,,,,,
3062,Autocuration,144,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,5834,B,,Bos taurus,9913.0,,,
3063,Autocuration,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,11147,B,,Bos taurus,9913.0,,,
3064,Expert,104714,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,14145,F,,Cavia porcellus,10141.0,,,
3065,Autocuration,104714,Ileum,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10561,B,,Cavia porcellus,10141.0,,,
3066,Autocuration,104714,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,15847,F,,Cavia porcellus,10141.0,,,
3067,Autocuration,104714,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,15847,F,,Cavia porcellus,10141.0,,,
3068,Autocuration,104714,Ileum,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10561,B,,Cavia porcellus,10141.0,,,
3069,Autocuration,104714,Ileum,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,11454,B,,Cavia porcellus,10141.0,,,
3070,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,4639,F,,Cavia porcellus,10141.0,,,
3071,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,4639,F,,Cavia porcellus,10141.0,,,
3072,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,4639,F,,Cavia porcellus,10141.0,,,
3073,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,4639,F,,Cavia porcellus,10141.0,,,
3074,Autocuration,104714,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,4639,F,,Cavia porcellus,10141.0,,,
3075,Autocuration,104714,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,4639,F,,Cavia porcellus,10141.0,,,
3076,Autocuration,104714,Ileum,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",15253,F,,Cavia porcellus,10141.0,,,
3077,Autocuration,104714,Ileum,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",15253,F,,Cavia porcellus,10141.0,,,
3078,Autocuration,104714,Ileum,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,11963,F,,Cavia porcellus,10141.0,,,
3079,Autocuration,104714,Ileum,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1946,B,,Cavia porcellus,10141.0,,,
3080,Autocuration,104714,Ileum,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1946,B,,Cavia porcellus,10141.0,,,
3081,Autocuration,104714,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,12045,B,,Cavia porcellus,10141.0,,,
3082,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,B,,Cavia porcellus,10141.0,,,
3083,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,F,,Cavia porcellus,10141.0,,,
3084,Autocuration,104714,Ileum,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),273,F,,Cavia porcellus,10141.0,,,
3085,Autocuration,104714,Ileum,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,188,F,,Cavia porcellus,10141.0,,,
3086,Autocuration,104714,Ileum,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,12919,F,,Cavia porcellus,10141.0,,,
3087,Autocuration,104714,Ileum,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,12918,F,,Cavia porcellus,10141.0,,,
3088,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,B,,Cavia porcellus,10141.0,,,
3089,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,F,,Cavia porcellus,10141.0,,,
3090,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1559,B,,Cavia porcellus,10141.0,,,
3091,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1559,B,,Cavia porcellus,10141.0,,,
3092,Autocuration,104714,Ileum,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1559,B,,Cavia porcellus,10141.0,,,
3093,Autocuration,104714,Ileum,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,14424,B,,Cavia porcellus,10141.0,,,
3094,Autocuration,22226,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,13181,B,,Cavia porcellus,10141.0,,,
3095,Autocuration,51,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,5486,B,,,,,,
3096,Expert,104714,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
3097,Autocuration,104714,,,Binding affinity towards 5-HT3 receptor,6013,B,,,,,,
3098,Autocuration,104714,,,Binding activity radioligand.,12861,B,,,,,,
3099,Autocuration,104714,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,12861,B,,,,,,
3100,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,5104,B,,,,,,
3101,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,5105,B,,,,,,
3102,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,5104,B,,,,,,
3103,Autocuration,22226,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,3935,B,,,,,,
3104,Expert,105030,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,13657,B,,,,,NG108-15,
3105,Autocuration,105030,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",10369,B,In vivo,,,,,
3106,Autocuration,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),10369,B,,,,,,
3107,Autocuration,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,12918,B,,,,,,
3108,Autocuration,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,12918,B,,,,,,
3109,Autocuration,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),10369,B,,,,,,
3110,Autocuration,105030,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,773,B,,,,,,
3111,Autocuration,105030,,,5-hydroxytryptamine 3 receptor agonism in mouse,12918,F,,,,,,
3112,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,10561,B,,,,,,
3113,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,12827,B,,,,,,
3114,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,12827,B,,,,,,
3115,Autocuration,105030,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,12918,B,,,,,,
3116,Autocuration,105030,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,273,B,,,,,,
3117,Autocuration,105030,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,273,B,,,,,,
3118,Autocuration,105030,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,10561,B,,,,,,
3119,Autocuration,105030,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,5033,B,In vitro,,,,,
3120,Autocuration,105030,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,16429,B,,,,,N1E-115,
3121,Autocuration,11765,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,10322,B,,,,,,
3122,Autocuration,11765,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,14331,B,,,,,,
3123,Autocuration,10630,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,13462,B,,Mus musculus,10090.0,,,
3124,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,12861,B,,,,,,
3125,Autocuration,144,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,15086,B,,Sus scrofa,9823.0,,,
3126,Autocuration,144,,,Binding activity radioligand.,12861,B,,Sus scrofa,9823.0,,,
3127,Autocuration,104714,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,10561,B,,Oryctolagus cuniculus,9986.0,,,
3128,Autocuration,104714,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,10561,B,,Oryctolagus cuniculus,9986.0,,,
3129,Autocuration,104714,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,10561,B,,Oryctolagus cuniculus,9986.0,,,
3130,Autocuration,104714,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,10561,B,,Oryctolagus cuniculus,9986.0,,,
3131,Autocuration,104714,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,F,,Oryctolagus cuniculus,9986.0,,,
3132,Autocuration,104714,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,F,,Oryctolagus cuniculus,9986.0,,,
3133,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),273,F,,Oryctolagus cuniculus,9986.0,,,
3134,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,F,,Oryctolagus cuniculus,9986.0,,,
3135,Autocuration,104714,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,F,,Oryctolagus cuniculus,9986.0,,,
3136,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),273,F,,Oryctolagus cuniculus,9986.0,,,
3137,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),273,F,,Oryctolagus cuniculus,9986.0,,,
3138,Autocuration,104714,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,13047,B,,Oryctolagus cuniculus,9986.0,,CHO,
3139,Autocuration,104698,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1650,B,,Rattus norvegicus,10116.0,,,
3140,Autocuration,12020,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),16288,B,,,,,,
3141,Autocuration,12020,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),16288,B,,,,,,
3142,Autocuration,104698,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,10254,B,,Rattus norvegicus,10116.0,,,
3143,Autocuration,104698,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",14532,B,,,,,,
3144,Autocuration,104698,Heart,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",13392,F,In vivo,,,,,
3145,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",13392,F,,,,,,
3146,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",13392,F,,,,,,
3147,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",13392,F,,,,,,
3148,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",13392,F,,,,,,
3149,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",13392,F,,,,,,
3150,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",13392,F,,,,,,
3151,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",13392,F,,,,,,
3152,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",13392,F,,,,,,
3153,Autocuration,104698,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1089,F,In vivo,Rattus norvegicus,10116.0,,,
3154,Autocuration,104698,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1089,F,In vivo,,,,,
3155,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,Rattus norvegicus,10116.0,,,
3156,Autocuration,104698,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,11454,F,,Rattus norvegicus,10116.0,,,
3157,Autocuration,104698,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,12205,F,In vivo,Rattus norvegicus,10116.0,,,
3158,Autocuration,104698,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1089,F,,Rattus norvegicus,10116.0,,,
3159,Autocuration,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,5094,B,,,,,,
3160,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,2622,B,,Rattus norvegicus,10116.0,,,
3161,Autocuration,104698,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,245,B,,,,,,
3162,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,14788,B,,,,,,
3163,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,14788,B,,,,,,
3164,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,3020,B,,,,,,
3165,Autocuration,104698,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1742,B,,,,,,
3166,Autocuration,104698,Brain,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,17394,B,,,,,,
3167,Autocuration,104698,Brain,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,17394,B,,,,,,
3168,Autocuration,104698,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,17394,B,,,,,,
3169,Autocuration,104698,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,14286,B,,,,,,
3170,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,14178,B,,,,,,
3171,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,14178,B,,Rattus norvegicus,10116.0,,,
3172,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,14178,B,,Rattus norvegicus,10116.0,,,
3173,Autocuration,104698,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,14178,B,,Rattus norvegicus,10116.0,,,
3174,Autocuration,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,15034,B,,,,,,
3175,Autocuration,104698,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1089,B,,,,,,Membranes
3176,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1089,B,,Rattus norvegicus,10116.0,,,
3177,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,16532,B,,,,,,
3178,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,12801,B,,Rattus norvegicus,10116.0,,,
3179,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),15194,B,,,,,NG108-15,
3180,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,15194,B,,,,,NG108-15,
3181,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,15194,B,,,,,,
3182,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,15194,B,,,,,,
3183,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,15194,B,,,,,,
3184,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,15194,B,,,,,,
3185,Autocuration,104698,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,10610,F,,,,,,
3186,Autocuration,104698,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,10355,F,,Rattus norvegicus,10116.0,,,
3187,Autocuration,104698,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",691,F,,,,,,
3188,Autocuration,104698,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,10611,F,,,,,,
3189,Autocuration,104698,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,12801,F,In vivo,,,,,
3190,Autocuration,104698,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,10609,F,,,,,,
3191,Autocuration,104698,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3192,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3193,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),11454,F,In vivo,,,,,
3194,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,Rattus norvegicus,10116.0,,,
3195,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3196,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,11454,F,In vivo,,,,,
3197,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3198,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3199,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3200,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3201,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3202,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3203,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3204,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3205,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3206,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3207,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3208,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,11454,F,In vivo,,,,,
3209,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,11454,F,In vivo,,,,,
3210,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,11454,F,In vivo,,,,,
3211,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,11454,F,In vivo,,,,,
3212,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,11454,F,In vivo,,,,,
3213,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3214,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3215,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3216,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3217,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3218,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3219,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,11454,F,In vivo,,,,,
3220,Autocuration,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",670,F,,,,,,
3221,Autocuration,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",670,F,,,,,,
3222,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,10321,F,In vivo,,,,,
3223,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,10321,F,In vivo,,,,,
3224,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,10321,F,In vivo,,,,,
3225,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,10321,F,In vivo,,,,,
3226,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,10321,F,In vivo,,,,,
3227,Autocuration,104698,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),10322,F,In vivo,,,,,
3228,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,15412,F,,,,,,
3229,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,15412,F,,,,,,
3230,Autocuration,104698,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,15412,B,,Rattus norvegicus,10116.0,,,
3231,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,15412,F,,,,,,
3232,Intermediate,104698,Hippocampus,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,15412,B,,,,,,
3233,Autocuration,104698,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,15412,B,,Rattus norvegicus,10116.0,,,
3234,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,17394,B,,Rattus norvegicus,10116.0,,,
3235,Autocuration,104698,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,12457,B,,,,,,
3236,Autocuration,104698,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,12457,B,,,,,,
3237,Autocuration,104698,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,12205,B,,,,,,
3238,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,14532,B,,,,,,
3239,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1122,B,,,,,,
3240,Autocuration,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,5094,B,,,,,,
3241,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,809,F,,Cavia porcellus,10141.0,,,
3242,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,809,F,,Cavia porcellus,10141.0,,,
3243,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",14290,F,,Cavia porcellus,10141.0,,,
3244,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",14290,F,,Cavia porcellus,10141.0,,,
3245,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",14290,F,,Cavia porcellus,10141.0,,,
3246,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",14290,F,,Cavia porcellus,10141.0,,,
3247,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",14290,F,,Cavia porcellus,10141.0,,,
3248,Intermediate,20033,Ileum,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,13961,F,,Cavia porcellus,10141.0,,,
3249,Intermediate,20033,Ileum,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,13961,F,,Cavia porcellus,10141.0,,,
3250,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,809,F,,Cavia porcellus,10141.0,,,
3251,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,809,F,,Cavia porcellus,10141.0,,,
3252,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,809,F,,Cavia porcellus,10141.0,,,
3253,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",14290,F,,Cavia porcellus,10141.0,,,
3254,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",14290,F,,Cavia porcellus,10141.0,,,
3255,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",14290,F,,Cavia porcellus,10141.0,,,
3256,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,14290,F,,Cavia porcellus,10141.0,,,
3257,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",14290,F,,Cavia porcellus,10141.0,,,
3258,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",14290,F,,Cavia porcellus,10141.0,,,
3259,Intermediate,20033,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,15034,B,,Cavia porcellus,10141.0,,,
3260,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,B,,Cavia porcellus,10141.0,,,
3261,Intermediate,20033,Striatum,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,B,,Cavia porcellus,10141.0,,,
3262,Intermediate,20033,Striatum,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,5399,B,,Cavia porcellus,10141.0,,,
3263,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,17394,B,,Cavia porcellus,10141.0,,,
3264,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,17394,B,,Cavia porcellus,10141.0,,,
3265,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,17394,B,,Cavia porcellus,10141.0,,,
3266,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,13961,F,,Cavia porcellus,10141.0,,,
3267,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,13961,F,,Cavia porcellus,10141.0,,,
3268,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,13961,F,,Cavia porcellus,10141.0,,,
3269,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,16946,B,,Cavia porcellus,10141.0,,,
3270,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,16946,B,,Cavia porcellus,10141.0,,,
3271,Intermediate,20033,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,15034,F,,Cavia porcellus,10141.0,,,
3272,Intermediate,20033,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,15034,F,,Cavia porcellus,10141.0,,,
3273,Intermediate,20033,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,12918,F,,Cavia porcellus,10141.0,,,
3274,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,16946,B,,Cavia porcellus,10141.0,,,
3275,Intermediate,20033,Striatum,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,17394,B,,Cavia porcellus,10141.0,,,
3276,Intermediate,20033,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,15034,B,,Cavia porcellus,10141.0,,,
3277,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,B,,Cavia porcellus,10141.0,,,
3278,Intermediate,20033,Striatum,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,5094,B,,Cavia porcellus,10141.0,,,
3279,Intermediate,20033,Ileum,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,17358,B,,Cavia porcellus,10141.0,,,
3280,Expert,20033,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,12953,B,,Cavia porcellus,10141.0,,,
3281,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,12953,B,,Cavia porcellus,10141.0,,,
3282,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,12953,B,,Cavia porcellus,10141.0,,,
3283,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,12953,B,,Cavia porcellus,10141.0,,,
3284,Intermediate,20033,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,273,F,,Cavia porcellus,10141.0,,,
3285,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,12918,F,,Cavia porcellus,10141.0,,,
3286,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,12919,F,,Cavia porcellus,10141.0,,,
3287,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,273,F,,Cavia porcellus,10141.0,,,
3288,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,273,F,,Cavia porcellus,10141.0,,,
3289,Intermediate,20033,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,13181,B,,Cavia porcellus,10141.0,,,
3290,Autocuration,168,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,13181,B,,Cavia porcellus,10141.0,,,
3291,Intermediate,20033,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,15034,F,,Cavia porcellus,10141.0,,,
3292,Intermediate,20033,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,5033,B,,Cavia porcellus,10141.0,,,
3293,Intermediate,20033,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1980,B,,Cavia porcellus,10141.0,,,
3294,Autocuration,168,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,13181,B,,Cavia porcellus,10141.0,,HEK293,
3295,Intermediate,20033,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,14287,B,,Cavia porcellus,10141.0,,,
3296,Intermediate,20033,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1317,B,,Cavia porcellus,10141.0,,,
3297,Intermediate,20033,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,15316,B,,Cavia porcellus,10141.0,,,
3298,Intermediate,20033,Striatum,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,16429,B,,Cavia porcellus,10141.0,,,
3299,Intermediate,20033,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,14818,B,,Cavia porcellus,10141.0,,,
3300,Intermediate,20033,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,15194,B,,Cavia porcellus,10141.0,,,
3301,Intermediate,20033,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,15194,B,,Cavia porcellus,10141.0,,,
3302,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,13961,F,,Cavia porcellus,10141.0,,,
3303,Autocuration,108,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,5486,B,,,,,,
3304,Autocuration,168,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,16209,B,,,,,,
3305,Autocuration,168,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,17085,B,,,,,,
3306,Autocuration,168,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,4199,B,,,,,HeLa,
3307,Autocuration,168,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,15146,B,,,,,,
3308,Autocuration,168,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,5213,B,,,,,,
3309,Autocuration,168,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",4829,B,,,,,HeLa,
3310,Autocuration,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,17358,B,,,,,,
3311,Autocuration,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,17358,B,,,,,,
3312,Autocuration,10622,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,16946,B,,,,,,
3313,Autocuration,10622,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,17358,B,,,,,,
3314,Autocuration,11249,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,268,F,,,,,,
3315,Autocuration,11249,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,268,F,,,,,,
3316,Autocuration,11249,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,15086,B,,,,,,
3317,Autocuration,11249,Hippocampus,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,14875,B,,,,,,
3318,Autocuration,168,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,13267,B,,Sus scrofa,9823.0,,,
3319,Autocuration,168,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,13047,B,,Oryctolagus cuniculus,9986.0,,,
3320,Expert,10623,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1650,B,,Rattus norvegicus,10116.0,,,
3321,Autocuration,10623,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,567,F,,,,,,
3322,Autocuration,10623,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,17358,B,,,,,,
3323,Autocuration,10623,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,188,B,,,,,,
3324,Autocuration,10623,,,lntrinsic activity relative to 5-HT receptor,670,F,,,,,,
3325,Autocuration,10623,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,204,F,,,,,,
3326,Expert,10623,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1946,F,,,,,,
3327,Autocuration,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,6398,F,,,,,,
3328,Autocuration,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,6398,F,,,,,,
3329,Autocuration,10623,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,17358,F,,,,,,
3330,Autocuration,10623,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,6398,F,,,,,,
3331,Expert,10623,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,11752,B,,,,,,
3332,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,809,F,,,,,,
3333,Expert,10623,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,14178,B,,Rattus norvegicus,10116.0,,,
3334,Autocuration,10623,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,567,B,,,,,,
3335,Autocuration,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1946,B,,,,,,
3336,Autocuration,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1946,B,,,,,,
3337,Expert,10623,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,13961,B,,Rattus norvegicus,10116.0,,,
3338,Autocuration,10623,Striatum,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,6238,B,,,,,,
3339,Autocuration,10623,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,14290,B,,,,,,
3340,Expert,10623,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,14290,B,,,,,,
3341,Expert,10623,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,809,B,,Rattus norvegicus,10116.0,,,
3342,Autocuration,10623,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1578,B,,,,,,
3343,Expert,10623,Striatum,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,16709,B,,,,,,
3344,Expert,10623,Striatum,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1946,B,,,,,,
3345,Expert,10623,Striatum,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,15253,B,,,,,,
3346,Expert,10623,Striatum,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,4535,B,,,,,,
3347,Expert,10623,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,13961,B,,,,,,
3348,Autocuration,10623,Brain,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,17358,F,,,,,,
3349,Autocuration,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,15847,F,,,,,,
3350,Autocuration,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,15847,F,,,,,,
3351,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,670,F,,,,,,
3352,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,670,F,,,,,,
3353,Autocuration,10623,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1317,F,,,,,,
3354,Expert,10623,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,12936,B,,Rattus norvegicus,10116.0,,,
3355,Expert,10623,Striatum,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,4535,B,,,,,,
3356,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,14424,F,,Rattus norvegicus,10116.0,,,
3357,Expert,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,14424,F,,,,,,
3358,Expert,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,14424,F,,,,,,
3359,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,14424,F,,Rattus norvegicus,10116.0,,,
3360,Autocuration,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,14424,F,,,,,,
3361,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,14424,F,,,,,,
3362,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),14424,F,,,,,,
3363,Autocuration,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,14424,F,,,,,,
3364,Autocuration,168,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1980,F,,Rattus norvegicus,10116.0,,,
3365,Autocuration,168,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,4639,F,,,,,,
3366,Autocuration,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,17358,B,,,,,,
3367,Autocuration,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,17358,B,,,,,,
3368,Autocuration,168,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,17358,B,,,,,,
3369,Autocuration,168,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1558,B,,,,,,
3370,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,F,,,,,,
3371,Autocuration,168,,,In vitro binding affinity towards 5-HT4 receptor was determined,16117,B,,,,,,
3372,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,F,,,,,,
3373,Autocuration,168,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,17358,F,,,,,,
3374,Autocuration,168,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,17358,B,,,,,,
3375,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,17358,B,,,,,,
3376,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,17358,B,,,,,,
3377,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,17358,B,,,,,,
3378,Expert,168,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,1274,B,,,,,,
3379,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,10728,B,,,,,,Brain membranes
3380,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,11695,B,,,,,,Brain membranes
3381,Autocuration,104698,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,11695,B,,,,,,Brain membranes
3382,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,12490,B,,,,,,
3383,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,11828,B,,Rattus norvegicus,10116.0,,,
3384,Autocuration,104698,Hippocampus,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,12253,B,,,,,,
3385,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,10561,B,,,,,,
3386,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,10561,B,,,,,,
3387,Autocuration,104698,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,14432,F,,,,,,
3388,Autocuration,104698,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,12936,B,,Rattus norvegicus,10116.0,,,
3389,Autocuration,104698,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,1274,B,,Rattus norvegicus,10116.0,,,
3390,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1980,B,,,,,,
3391,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,670,B,,,,,,
3392,Autocuration,104698,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,968,B,,Rattus norvegicus,10116.0,,,
3393,Autocuration,104698,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,14287,B,,,,,,
3394,Autocuration,104698,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,567,B,,,,,,
3395,Autocuration,104698,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,13267,B,,,,,,
3396,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,14826,B,,,,,,
3397,Autocuration,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,15194,B,,,,,,
3398,Autocuration,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,15194,B,,,,,,
3399,Autocuration,104698,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,10394,B,,Rattus norvegicus,10116.0,,,
3400,Expert,10576,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",13657,B,,,,,,
3401,Autocuration,12020,Brain,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1879,F,,,,,,
3402,Autocuration,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1879,F,,,,,,
3403,Autocuration,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1879,F,,,,,,
3404,Autocuration,12020,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,204,F,In vivo,,,,,
3405,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1879,B,,,,,,
3406,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1879,B,,,,,,
3407,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1879,B,,,,,,
3408,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1879,B,,,,,,
3409,Autocuration,104698,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",10641,B,,,,,,
3410,Autocuration,12020,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,773,B,,,,,,
3411,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,11952,B,,,,,,
3412,Autocuration,12020,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,14145,F,,Rattus norvegicus,10116.0,,,
3413,Expert,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,17066,B,,,,,,
3414,Autocuration,104714,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,6398,B,,,,,,
3415,Autocuration,22226,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,10321,B,,,,,,
3416,Autocuration,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,511,F,,,,,,
3417,Autocuration,104714,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,4639,B,,,,,,
3418,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4639,B,,,,,,
3419,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,4639,F,,Cavia porcellus,10141.0,,,
3420,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4639,F,,Cavia porcellus,10141.0,,,
3421,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,4639,F,,Cavia porcellus,10141.0,,,
3422,Autocuration,104714,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1558,B,,,,,,
3423,Autocuration,104714,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,268,F,,,,,,
3424,Autocuration,104714,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,2474,B,,,,,,
3425,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,5067,F,,,,,,
3426,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,5067,F,,,,,,
3427,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,5067,F,,,,,,
3428,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,5067,B,,,,,,
3429,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,5067,F,,,,,,
3430,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,5067,F,,,,,,
3431,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,5067,F,,,,,,
3432,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,5067,B,,,,,,
3433,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,5067,B,,,,,,
3434,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,5067,F,,,,,,
3435,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,5067,B,,,,,,
3436,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,5067,B,,,,,,
3437,Autocuration,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,14331,B,,,,,,
3438,Autocuration,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,5067,B,,,,,,
3439,Autocuration,104714,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,6179,B,,,,,NG108-15,
3440,Autocuration,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,4265,B,,,,,,
3441,Autocuration,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,4265,B,,,,,NG108-15,
3442,Autocuration,104714,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,17358,B,,,,,,
3443,Autocuration,104714,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,17358,B,,,,,,
3444,Autocuration,104714,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,13628,B,In vitro,,,,,
3445,Autocuration,104714,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,4612,B,,,,,,
3446,Autocuration,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,17358,F,,,,,,
3447,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,4639,F,,Cavia porcellus,10141.0,,,
3448,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,4639,F,,Cavia porcellus,10141.0,,,
3449,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,4639,F,,Cavia porcellus,10141.0,,,
3450,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4639,F,,Cavia porcellus,10141.0,,,
3451,Autocuration,104714,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,511,B,,,,,,
3452,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1479,B,,,,,,
3453,Autocuration,104714,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1317,B,,,,,,
3454,Autocuration,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,12146,B,,,,,,
3455,Autocuration,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,12146,B,,,,,,
3456,Autocuration,104714,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,13969,B,,,,,,
3457,Expert,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor,13392,B,,,,,,
3458,Autocuration,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,13392,B,,,,,,
3459,Autocuration,144,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,14159,B,,,,,,
3460,Autocuration,144,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1558,B,,,,,,
3461,Autocuration,144,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,16655,B,,,,,,
3462,Autocuration,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,13020,B,,,,,,
3463,Autocuration,104714,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,13021,B,,,,,,
3464,Autocuration,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,13020,B,,,,,,
3465,Autocuration,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,10321,B,,,,,,
3466,Autocuration,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,15818,B,,,,,,
3467,Autocuration,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,15818,B,,,,,,
3468,Autocuration,144,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,17358,B,,,,,,
3469,Autocuration,144,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,2222,B,,,,,,
3470,Autocuration,144,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,10322,B,,,,,,
3471,Autocuration,144,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,16117,B,,,,,,
3472,Autocuration,144,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,17200,B,,,,,,
3473,Autocuration,144,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,17358,F,,,,,,
3474,Autocuration,144,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,16700,B,,,,,,
3475,Autocuration,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1980,B,,,,,,
3476,Autocuration,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1980,B,,,,,,
3477,Autocuration,104714,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,12409,B,,,,,,
3478,Autocuration,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,4365,B,,,,,,
3479,Autocuration,144,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,4365,F,,,,,,
3480,Autocuration,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,4365,B,,,,,,
3481,Expert,12020,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,6769,F,,Rattus norvegicus,10116.0,,Oocytes,
3482,Expert,12020,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,6769,F,,Rattus norvegicus,10116.0,,Oocytes,
3483,Expert,12020,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,6769,F,,Rattus norvegicus,10116.0,,Oocytes,
3484,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,809,F,,Cavia porcellus,10141.0,,,
3485,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,809,F,,Cavia porcellus,10141.0,,,
3486,Intermediate,20033,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,14290,F,,Cavia porcellus,10141.0,,,
3487,Intermediate,20033,Ileum,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,17358,B,,Cavia porcellus,10141.0,,,
3488,Intermediate,20033,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,17358,B,,Cavia porcellus,10141.0,,,
3489,Intermediate,20033,Ileum,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,17358,B,,Cavia porcellus,10141.0,,,
3490,Autocuration,10209,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,17386,B,,,,,,
3491,Autocuration,10209,,,Affinity against 5-hydroxytryptamine 7 receptor,3269,B,,,,,,
3492,Autocuration,104841,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,7721,B,,Cavia porcellus,10141.0,,,
3493,Autocuration,104841,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,7721,B,,Cavia porcellus,10141.0,,,
3494,Autocuration,104841,Ileum,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,9117,B,,Cavia porcellus,10141.0,,,
3495,Autocuration,104841,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",7721,B,,Cavia porcellus,10141.0,,,
3496,Autocuration,104841,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",7721,B,,Cavia porcellus,10141.0,,,
3497,Autocuration,104841,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,15796,F,,Cavia porcellus,10141.0,,,
3498,Autocuration,104841,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,15796,F,,Cavia porcellus,10141.0,,,
3499,Expert,168,Cardiac atrium,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,15650,B,,Homo sapiens,9606.0,,,
3500,Expert,168,Cardiac atrium,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,15650,B,,Homo sapiens,9606.0,,,
3501,Autocuration,104841,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",6866,F,,Homo sapiens,9606.0,,,
3502,Expert,168,Cardiac atrium,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",15650,F,,Homo sapiens,9606.0,,,
3503,Autocuration,22226,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,10063,B,,Mus musculus,10090.0,,,
3504,Autocuration,22226,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,12665,B,,Mus musculus,10090.0,,,
3505,Autocuration,104705,,,5-hydroxytryptamine receptor binding affinity was determined in rats,7504,B,,,,,,
3506,Autocuration,104705,,,Binding affinity at rat 5-hydroxytryptamine receptor.,7504,B,,,,,,
3507,Autocuration,104705,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,7038,B,,,,,,
3508,Autocuration,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,7626,B,,,,,,
3509,Autocuration,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,7626,B,,,,,,
3510,Autocuration,104705,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,7185,F,,,,,,
3511,Autocuration,104705,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,7185,F,,,,,,
3512,Autocuration,104705,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,7185,F,,,,,,
3513,Autocuration,104705,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,6960,B,,,,,,
3514,Autocuration,104705,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",6960,B,,,,,,
3515,Autocuration,10576,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,12416,B,,,,,,
3516,Expert,12198,,,Binding affinity for rat 5-hydroxytryptamine transporter.,15753,B,,,,,,
3517,Autocuration,104705,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,8062,B,,,,,,
3518,Autocuration,104705,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,9036,B,,Rattus norvegicus,10116.0,,,
3519,Autocuration,104705,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,15067,B,,Rattus norvegicus,10116.0,,,
3520,Expert,12198,Brain,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,15753,F,,Rattus norvegicus,10116.0,,,
3521,Expert,12198,Cerebellum,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,15753,F,,Rattus norvegicus,10116.0,,,
3522,Autocuration,104705,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,15295,B,,Rattus norvegicus,10116.0,,,
3523,Autocuration,104705,,,Percent binding affinity against 5-hydroxytryptamine receptor,6347,B,,Rattus norvegicus,10116.0,,,
3524,Autocuration,22226,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,6763,B,,,,,,
3525,Autocuration,104705,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,12092,B,,Rattus norvegicus,10116.0,,,
3526,Autocuration,104705,,,Affinity against 5-hydroxytryptamine receptor was determined,1579,B,,Rattus norvegicus,10116.0,,,
3527,Autocuration,104705,Stomach,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1579,B,,Rattus norvegicus,10116.0,,,
3528,Expert,121,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,5963,B,In vitro,Homo sapiens,9606.0,,,
3529,Expert,121,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,5963,B,In vitro,Homo sapiens,9606.0,,,
3530,Autocuration,18065,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,5030,B,,,,,,
3531,Expert,121,,,Inhibition of 5-hydroxytryptamine reuptake,15796,B,,,,,,
3532,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",15413,F,,,,,,
3533,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",15413,F,,,,,,
3534,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",15413,F,,,,,,
3535,Autocuration,18065,,,Tested for 5-hydroxytryptamine receptor uptake,12409,F,,,,,,
3536,Expert,51,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,16909,B,,Homo sapiens,9606.0,,CHO,
3537,Expert,51,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,16909,F,,Homo sapiens,9606.0,,,
3538,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,15629,B,,Homo sapiens,9606.0,,,
3539,Autocuration,10576,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,15629,B,,,,,,
3540,Expert,10576,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,15629,B,,,,,,
3541,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10034,F,,,,,,
3542,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10034,F,,,,,,
3543,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10034,F,,,,,,
3544,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10034,F,,,,,,
3545,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10034,F,,,,,,
3546,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10034,F,,,,,,
3547,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10034,F,,,,,,
3548,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10034,F,,,,,,
3549,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10034,F,,,,,,
3550,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10034,F,,,,,,
3551,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10034,F,,,,,,
3552,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10034,F,,,,,,
3553,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10034,F,,,,,,
3554,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10034,F,,,,,,
3555,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10034,F,,,,,,
3556,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10034,F,,,,,,
3557,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10034,F,,,,,,
3558,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10034,F,,,,,,
3559,Expert,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,1274,B,,,,,,
3560,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,17358,F,,,,,,
3561,Autocuration,168,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,14532,B,,,,,,
3562,Expert,168,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,16989,B,,,,,,
3563,Autocuration,168,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,17200,B,,,,,,
3564,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,15779,B,,,,,,
3565,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,15779,B,,,,,,
3566,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,15779,B,,,,,,
3567,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,15650,B,,,,,COS-7,
3568,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,15650,B,,,,,COS-7,
3569,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,15650,B,,,,,COS-7,
3570,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,15650,B,,,,,COS-7,
3571,Autocuration,168,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,17046,B,,,,,C6,
3572,Expert,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,17046,B,,,,,C6,
3573,Expert,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,15650,B,,,,,C6,
3574,Expert,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,17046,B,,,,,C6,
3575,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,17066,B,,,,,,
3576,Autocuration,105,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,17200,B,,,,,,
3577,Expert,10624,,,Binding affinity against 5-hydroxytryptamine 5A receptor,16146,B,,Homo sapiens,9606.0,,,
3578,Autocuration,10624,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,15250,B,,,,,CHO,
3579,Expert,10624,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
3580,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,17066,B,,Homo sapiens,9606.0,,,
3581,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,17066,B,,Homo sapiens,9606.0,,,
3582,Expert,10624,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,4234,B,,Homo sapiens,9606.0,,,
3583,Autocuration,10624,,,Binding affinity towards 5-HT5A receptor,6013,B,,,,,,
3584,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,17175,B,,,,,,
3585,Autocuration,10624,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,15818,B,,,,,,
3586,Autocuration,10624,,,Binding affinity towards cloned human 5-HT5A receptor was determined,6166,B,,,,,,
3587,Autocuration,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,B,,,,,HEK293,
3588,Autocuration,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,15779,B,,,,,HEK293,
3589,Autocuration,10624,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),5213,B,,,,,HEK293,
3590,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,17066,B,,Mus musculus,10090.0,,,
3591,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,17066,B,,Mus musculus,10090.0,,,
3592,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,17066,B,,Mus musculus,10090.0,,,
3593,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,17066,B,,Mus musculus,10090.0,,,
3594,Expert,10625,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,17066,B,,Mus musculus,10090.0,,,
3595,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,17175,B,,,,,,
3596,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,16190,B,,,,,HEK293,
3597,Autocuration,10626,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,16190,B,,,,,HEK293,
3598,Expert,10624,,,Binding affinity towards 5-HT5a receptor,4820,B,,,,,,
3599,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,17066,B,,Homo sapiens,9606.0,,,
3600,Expert,10624,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,17066,B,,,,,,
3601,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,17175,B,,,,,,
3602,Autocuration,10624,,,Binding affinities against 5-hydroxytryptamine 5A receptor,16633,B,,,,,,
3603,Autocuration,10624,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,16633,B,,,,,,
3604,Autocuration,10624,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,16700,B,,,,,,
3605,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,4639,F,,Cavia porcellus,10141.0,,,
3606,Autocuration,104714,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,5486,B,,,,,,
3607,Expert,10627,,,Inhibition of human 5-hydroxytryptamine 6 receptor,16146,B,,Homo sapiens,9606.0,,,
3608,Expert,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,17273,B,,Homo sapiens,9606.0,,,
3609,Autocuration,10627,,,Inhibition against human 5-hydroxytryptamine 6 receptor,17687,B,,,,,,
3610,Expert,10627,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
3611,Expert,10627,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,16190,B,,,,,HeLa,
3612,Expert,10627,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,17066,B,,Homo sapiens,9606.0,,,
3613,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,17066,B,,Homo sapiens,9606.0,,,
3614,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,17066,B,,Homo sapiens,9606.0,,,
3615,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,17066,B,,Homo sapiens,9606.0,,,
3616,Expert,10627,,,Binding affinity against 5-hydroxytryptamine 6 receptor,3555,B,,Homo sapiens,9606.0,,,
3617,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,5808,B,,,,,,
3618,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,6013,B,,,,,,
3619,Expert,10627,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",15818,B,,,,,HEK293,
3620,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,16209,B,,,,,,
3621,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,3935,B,,,,,HEK293,
3622,Autocuration,10627,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,15818,B,,,,,,
3623,Expert,10627,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,3805,B,,Homo sapiens,9606.0,,HEK293,
3624,Expert,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,16441,B,,,,,,
3625,Expert,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,16441,B,,,,,,
3626,Expert,10627,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,6786,B,,,,,COS-7,
3627,Expert,10627,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,4234,B,,Homo sapiens,9606.0,,,
3628,Autocuration,10627,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,17085,B,,,,,,
3629,Autocuration,10627,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,17200,B,,,,,,
3630,Autocuration,10627,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,17451,B,,,,,HEK293,
3631,Autocuration,10627,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,3935,F,,,,,,
3632,Autocuration,10627,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,5033,B,,,,,,
3633,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,4540,B,,,,,,
3634,Expert,10627,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,4540,B,,Homo sapiens,9606.0,,HeLa,
3635,Expert,10627,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,4540,B,,Homo sapiens,9606.0,,HeLa,
3636,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,17296,B,,,,,HeLa,
3637,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,17296,B,,,,,HeLa,
3638,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,17296,B,,,,,HeLa,
3639,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,15779,B,,,,,CHO,
3640,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,15779,B,,,,,HEK293,
3641,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,15779,B,,,,,HEK293,
3642,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,15779,B,,,,,HEK293,
3643,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,15779,B,,,,,HeLa,
3644,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,6166,B,,,,,,
3645,Autocuration,10627,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,17451,B,,,,,HeLa,
3646,Autocuration,10627,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,15316,B,,,,,,
3647,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,4199,B,,,,,,
3648,Expert,10627,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,15146,B,,,,,HeLa,
3649,Autocuration,10627,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),5213,B,,,,,,
3650,Autocuration,10627,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,16429,B,,,,,,
3651,Autocuration,10627,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,14818,B,,,,,HeLa,
3652,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",4829,B,,,,,HeLa,
3653,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",4829,B,,,,,HeLa,
3654,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",4829,B,,,,,HeLa,
3655,Autocuration,10628,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,15250,B,,,,,CHO,
3656,Autocuration,10628,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,14423,B,,,,,,
3657,Autocuration,10628,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,15086,B,,,,,,
3658,Autocuration,10628,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,4342,B,,,,,,
3659,Autocuration,10627,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,16190,B,,Homo sapiens,9606.0,,HeLa,
3660,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,4820,B,,,,,,
3661,Autocuration,10627,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,4639,B,,,,,,
3662,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,17066,F,,Homo sapiens,9606.0,,,
3663,Autocuration,10627,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,6011,B,,,,,,
3664,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,17066,B,,,,,,
3665,Autocuration,10627,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,17515,B,,,,,,
3666,Autocuration,10627,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,5014,B,,,,,,
3667,Autocuration,10627,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,4373,B,,,,,,
3668,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,17066,F,,,,,,
3669,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,17066,F,,,,,,
3670,Autocuration,10627,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,4373,B,,,,,,
3671,Autocuration,10627,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,4687,B,,,,,,
3672,Autocuration,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,16946,B,,,,,,
3673,Autocuration,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,16946,B,,,,,,
3674,Autocuration,10627,,,Binding affinities against 5-hydroxytryptamine 6 receptor,16633,B,,,,,,
3675,Autocuration,10627,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,16633,B,,,,,,
3676,Expert,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,17066,B,,Homo sapiens,9606.0,,,
3677,Autocuration,10627,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,16700,B,,,,,,
3678,Autocuration,10627,,,Affinity against 5-hydroxytryptamine 6 receptor,3269,B,,,,,,
3679,Autocuration,10627,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],5486,B,,,,,,
3680,Expert,10209,,,Inhibition of human 5-hydroxytryptamine 7 receptor,16146,B,,Homo sapiens,9606.0,,,
3681,Autocuration,10209,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,5014,B,,,,,HEK293,
3682,Autocuration,10209,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,15463,B,,,,,,
3683,Autocuration,10209,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),3805,B,,,,,,
3684,Expert,10209,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,5014,B,,,,,HEK293,
3685,Expert,10209,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,6491,B,,Homo sapiens,9606.0,,,
3686,Autocuration,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,16190,B,,,,,CHO,
3687,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,17066,B,,Homo sapiens,9606.0,,,
3688,Expert,10209,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,17066,B,,Homo sapiens,9606.0,,,
3689,Expert,10209,,,Binding affinity against 5-hydroxytryptamine 7 receptor,3555,B,,Homo sapiens,9606.0,,,
3690,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,6588,B,,,,,CHO,
3691,Autocuration,10209,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,15463,B,,,,,,
3692,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,6013,B,,,,,,
3693,Autocuration,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,16209,B,,,,,,
3694,Autocuration,10209,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,3935,B,,,,,,
3695,Autocuration,10209,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,15818,B,,,,,,
3696,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,5014,B,,,,,HEK293,
3697,Expert,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,16441,B,,,,,,
3698,Expert,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,16441,B,,,,,,
3699,Expert,10209,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,4234,B,,Homo sapiens,9606.0,,,
3700,Autocuration,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,17085,B,,,,,,
3701,Autocuration,10209,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,17200,B,,,,,,
3702,Autocuration,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,17451,B,,,,,CHO,
3703,Autocuration,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,17085,B,,,,,,
3704,Autocuration,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,5104,B,,,,,,
3705,Autocuration,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,5104,B,,,,,,
3706,Expert,10209,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,5033,B,,Homo sapiens,9606.0,,COS-7,
3707,Autocuration,10209,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,5486,B,,,,,COS-7,
3708,Expert,10209,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,4540,B,,Homo sapiens,9606.0,,HEK293,
3709,Expert,10209,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,6166,B,,,,,,
3710,Expert,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,17342,B,,,,,HEK293,
3711,Expert,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,17342,B,,,,,,
3712,Autocuration,10209,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,17296,B,,,,,,
3713,Expert,10209,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,16429,B,,,,,,
3714,Autocuration,10209,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,15779,B,,,,,HEK293,
3715,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,B,,,,,HEK293,
3716,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,B,,,,,HEK293,
3717,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,15779,B,,,,,HEK293,
3718,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,15779,B,,,,,HEK293,
3719,Autocuration,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,17451,B,,,,,CHO,
3720,Autocuration,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),4199,B,,,,,HEK293,
3721,Expert,10209,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,4199,B,,,,,HEK293,
3722,Autocuration,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),4199,B,,,,,HEK293,
3723,Intermediate,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,3680,B,,,,,HEK293,
3724,Intermediate,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,3680,B,,,,,,
3725,Autocuration,10209,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,15316,B,,,,,COS-7,
3726,Autocuration,10209,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,15146,B,,,,,HEK293,
3727,Expert,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,5213,B,,,,,HEK293,
3728,Autocuration,10209,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),5213,B,,,,,HEK293,
3729,Expert,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,14818,B,,Homo sapiens,9606.0,,HEK293,
3730,Autocuration,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,14818,B,,,,,HEK293,
3731,Autocuration,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,14818,B,,,,,HEK293,
3732,Autocuration,10209,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",4829,B,,,,,HEK293,
3733,Autocuration,10209,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,17200,B,,Homo sapiens,9606.0,,,
3734,Expert,10022,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,17066,B,,Mus musculus,10090.0,,,
3735,Autocuration,10209,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,14025,B,,Oryctolagus cuniculus,9986.0,,,
3736,Autocuration,11923,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,15250,B,,,,,CHO,
3737,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,16372,B,,,,,CHO,
3738,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,16372,B,,,,,CHO,
3739,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,16372,B,,,,,CHO,
3740,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,16372,B,,,,,CHO,
3741,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,16372,B,,,,,CHO,
3742,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,16372,B,,,,,CHO,
3743,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,16372,B,,,,,CHO,
3744,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,16372,B,,,,,CHO,
3745,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,16372,B,,,,,CHO,
3746,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,16372,B,,,,,CHO,
3747,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,16372,B,,,,,CHO,
3748,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,16372,B,,,,,CHO,
3749,Expert,11923,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,17066,B,,,,,,
3750,Expert,11923,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,17066,B,,Rattus norvegicus,10116.0,,,
3751,Expert,11923,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,17386,B,,,,,,
3752,Autocuration,11923,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,14423,B,,,,,,
3753,Expert,11923,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,15874,B,,Rattus norvegicus,10116.0,,,
3754,Expert,11923,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,15874,B,,Rattus norvegicus,10116.0,,,
3755,Expert,11923,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,16372,B,,Rattus norvegicus,10116.0,,CHO,
3756,Autocuration,11923,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,4622,B,,,,,,
3757,Autocuration,11923,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,15086,B,,,,,,
3758,Autocuration,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",16372,B,,,,,CHO,
3759,Autocuration,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",16372,B,,,,,CHO,
3760,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,16372,B,,,,,CHO,
3761,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,16372,B,,,,,CHO,
3762,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,17386,F,,,,,,
3763,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,17386,F,,,,,,
3764,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,17386,F,,,,,,
3765,Expert,11923,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,5831,B,,Rattus norvegicus,10116.0,,,Membranes
3766,Autocuration,11923,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,4342,B,,,,,,
3767,Expert,11923,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,17319,B,,,,,,
3768,Expert,11923,Hypothalamus,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,17342,B,,,,,,
3769,Autocuration,11923,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,17342,B,,,,,,
3770,Expert,11923,Hypothalamus,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,3680,B,,,,,,
3771,Expert,11923,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,3680,B,,,,,,
3772,Expert,11923,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,17319,F,,Rattus norvegicus,10116.0,,HEK293,
3773,Expert,11923,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,17319,F,,Rattus norvegicus,10116.0,,HEK293,
3774,Autocuration,11923,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,17319,F,,Rattus norvegicus,10116.0,,HEK293,
3775,Expert,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,4820,B,,,,,,
3776,Autocuration,10209,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,4639,B,,,,,,
3777,Autocuration,10209,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,6011,B,,,,,,
3778,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,17066,B,,Homo sapiens,9606.0,,,
3779,Expert,10209,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,17066,B,,,,,,
3780,Autocuration,10209,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,17515,B,,,,,,
3781,Autocuration,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,4373,B,,,,,,
3782,Expert,10209,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,17066,F,,,,,,
3783,Autocuration,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,4373,B,,,,,,
3784,Autocuration,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,4373,B,,,,,,
3785,Autocuration,10209,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,4687,B,,,,,,
3786,Expert,10209,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,17342,B,,,,,,
3787,Autocuration,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,16946,B,,,,,,
3788,Autocuration,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,16946,B,,,,,,
3789,Autocuration,10209,,,Binding affinities against 5-hydroxytryptamine 7 receptor,16633,B,,,,,,
3790,Autocuration,10209,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,16633,B,,,,,,
3791,Expert,10209,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,17066,B,,,,,,
3792,Autocuration,10209,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,16700,B,,,,,,
3793,Autocuration,10209,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,17386,B,,,,,,
3794,Autocuration,55,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,14080,F,,,,,,
3795,Expert,55,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,14080,F,,Homo sapiens,9606.0,,,
3796,Autocuration,55,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,409,B,,,,,,
3797,Autocuration,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme,409,B,,,,,,
3798,Autocuration,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,409,B,,,,,,
3799,Expert,55,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,11090,B,,,,,,
3800,Expert,55,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,11090,B,,,,,,
3801,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,948,B,,,,,,
3802,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),948,B,,,,,,
3803,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,13622,F,,,,,,
3804,Autocuration,55,Blood,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,13622,F,,,,,,
3805,Autocuration,55,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,9637,B,,,,,,
3806,Autocuration,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),11320,B,,,,,,
3807,Expert,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,11320,B,,,,,,
3808,Autocuration,55,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,6838,B,,,,,,
3809,Expert,55,Blood,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),17667,B,,Homo sapiens,9606.0,,,
3810,Autocuration,55,,,In vitro potency against human 5-Lipoxygenase,12703,B,,,,,,
3811,Expert,55,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,14312,F,,Homo sapiens,9606.0,,,
3812,Autocuration,55,Blood,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,14312,F,,,,,,
3813,Autocuration,55,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,5364,F,,,,,,
3814,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,951,B,,,,,,
3815,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,951,B,,,,,,
3816,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,951,B,,,,,,
3817,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,951,B,,,,,,
3818,Autocuration,55,,,Inhibition of human 5-lipoxygenase in human cells,12365,B,,,,,,
3819,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase,10603,B,,,,,,
3820,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,10501,B,,,,,,
3821,Expert,55,Blood,,Inhibition of 5-lipoxygenase from human whole blood,12281,B,,,,,,
3822,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,2567,B,,,,,,
3823,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,2567,B,,,,,,
3824,Expert,55,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,10193,B,,,,,,
3825,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,B,,,,,,
3826,Expert,55,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,13623,B,,,,,,
3827,Autocuration,55,,,Tested against 5-lipoxygenase,12780,B,,,,,,
3828,Autocuration,55,,,Tested for activity against 5-Lipoxygenase (5-LO),12780,B,,,,,,
3829,Autocuration,55,,,Tested for activity against 5-lipoxygenase,12780,B,,,,,,
3830,Autocuration,55,,,Tested for inhibition of 5-HPETE production by human 5-LO,11966,B,,,,,,
3831,Autocuration,55,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,5364,F,,,,,,
3832,Expert,55,,,Inhibition of Human 5-lipoxygenase,13165,B,,,,,,
3833,Autocuration,55,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,5364,B,,,,,,
3834,Autocuration,55,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
3835,Autocuration,55,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
3836,Autocuration,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,14863,B,,,,,,
3837,Autocuration,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,14863,B,,,,,,
3838,Autocuration,55,Blood,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),11087,B,,,,,,
3839,Autocuration,55,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,455,B,,,,,,
3840,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,B,,,,,,
3841,Expert,55,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,10319,B,,,,,,
3842,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,B,,,,,,
3843,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,951,B,,,,,,
3844,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,951,B,,,,,,
3845,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,951,B,,,,,,
3846,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,951,B,,,,,,
3847,Expert,55,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,9859,B,,,,,,
3848,Expert,55,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,9859,B,,,,,,
3849,Autocuration,55,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,9859,B,,,,,,
3850,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,2567,B,,,,,,
3851,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,10193,B,,,,,,
3852,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,10193,B,,,,,,
3853,Autocuration,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,949,B,,,,,,
3854,Autocuration,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,949,B,,,,,,
3855,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,10603,B,,,,,,
3856,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,10603,B,,,,,,
3857,Autocuration,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,10603,F,,,,,,
3858,Expert,55,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,10603,B,,,,,,
3859,Expert,55,,,Inhibition of lipoxygenase at the concentration of 1 uM,10603,B,,,,,,
3860,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,10193,B,,,,,,
3861,Expert,55,,,Inhibition of 5-Lipoxygenase (5-LOX),14580,B,,Homo sapiens,9606.0,,,
3862,Expert,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,11090,B,,,,,,
3863,Expert,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,11090,B,,,,,,
3864,Autocuration,17087,,,Inhibitory activity against lipoxygenase-2 in mice,6339,B,,,,,,
3865,Expert,17087,,,Inhibitory activity against murine lipoxygenase-2.,6339,B,,,,,,
3866,Expert,17087,,,Inhibition of 5-lipoxygenase from mouse macrophage,12281,B,,Mus musculus,10090.0,,,
3867,Autocuration,17087,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,11311,B,,,,,,
3868,Autocuration,55,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,11089,B,,Sus scrofa,9823.0,,,
3869,Autocuration,55,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,10091,B,,Sus scrofa,9823.0,,,
3870,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,14352,B,,Oryctolagus cuniculus,9986.0,,,
3871,Expert,12166,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,13329,B,,Rattus norvegicus,10116.0,,,
3872,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",13329,B,,,,,,
3873,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",13329,B,,,,,,
3874,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",13329,B,,,,,,
3875,Expert,12166,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),13329,B,,,,,,
3876,Expert,12166,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",13329,B,,,,,,
3877,Autocuration,12166,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,13329,B,,,,,,
3878,Autocuration,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),11311,B,,,,,,
3879,Autocuration,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,11311,B,,,,,,
3880,Autocuration,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",105,B,,,,,RBL-1,
3881,Autocuration,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",105,B,,,,,RBL-1,
3882,Autocuration,12166,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),9138,B,,,,,,
3883,Autocuration,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",9138,B,,,,,,
3884,Autocuration,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",9138,B,,,,,,
3885,Autocuration,12166,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,14427,B,,,,,,
3886,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",13329,B,,,,,,
3887,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",13329,B,,,,,,
3888,Expert,12166,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,14427,B,,Rattus norvegicus,10116.0,,RBL-2H3,
3889,Autocuration,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,14427,B,,,,,,
3890,Autocuration,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,14427,B,,,,,,
3891,Expert,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,10293,B,,,,,RBL-1,
3892,Expert,12166,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,338,B,,Rattus norvegicus,10116.0,,RBL-1,
3893,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),303,B,,,,,,
3894,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,303,B,,,,,RBL-1,
3895,Expert,12166,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,9247,B,,,,,RBL-1,
3896,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,9247,B,,,,,RBL-1,
3897,Autocuration,12166,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,137,B,,,,,RBL-1,
3898,Expert,12166,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,11481,B,,,,,,
3899,Expert,12166,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",11481,B,,,,,,
3900,Expert,12166,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,9029,B,,,,,,
3901,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1701,B,,,,,,
3902,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1701,B,,,,,,
3903,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1701,B,,,,,,
3904,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1701,B,,,,,,
3905,Expert,12166,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,13358,F,,,,,RBL-1,
3906,Expert,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1175,B,,,,,RBL-1,
3907,Expert,12166,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,8797,B,,,,,RBL-1,
3908,Autocuration,12166,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,8797,B,,,,,,
3909,Expert,12166,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,577,B,,Rattus norvegicus,10116.0,,,
3910,Expert,12166,,,In vitro inhibitory activity against RBL-1 5-LO,9295,B,,,,,RBL-1,
3911,Autocuration,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),9295,B,,,,,RBL-1,
3912,Autocuration,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),9295,B,,,,,RBL-1,
3913,Autocuration,12166,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,9295,B,,,,,,
3914,Autocuration,12166,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,9295,B,,,,,,
3915,Autocuration,12166,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,216,B,,,,,,
3916,Autocuration,12166,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,11090,B,,,,,RBL-1,
3917,Autocuration,12166,Blood,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,11090,B,,,,,,
3918,Expert,12166,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,10091,B,,,,,,
3919,Autocuration,12166,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,10274,F,,,,,,
3920,Autocuration,12166,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,13622,F,,,,,,
3921,Expert,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12118,B,,,,,RBL-1,
3922,Expert,12166,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12576,B,,,,,,
3923,Expert,12166,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,9546,B,,,,,RBL-1,
3924,Autocuration,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,9521,B,,,,,RBL-1,
3925,Expert,12166,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,10626,B,,,,,RBL-1,
3926,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase,9225,B,,,,,RBL-1,
3927,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,9225,B,,,,,RBL-1,
3928,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,9225,B,,,,,RBL-1,
3929,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,9225,B,,,,,RBL-1,
3930,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,9225,B,,,,,RBL-1,
3931,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,9225,B,,,,,RBL-1,
3932,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,9225,B,,,,,RBL-1,
3933,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,9225,B,,,,,RBL-1,
3934,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,9225,B,,,,,RBL-1,
3935,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,9225,B,,,,,RBL-1,
3936,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,9225,B,,,,,RBL-1,
3937,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,9225,B,,,,,RBL-1,
3938,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,9225,B,,,,,RBL-1,
3939,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,9225,B,,,,,RBL-1,
3940,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,9225,B,,,,,RBL-1,
3941,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,9225,B,,,,,RBL-1,
3942,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,9225,B,,,,,RBL-1,
3943,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,9225,B,,,,,RBL-1,
3944,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,9225,B,,,,,RBL-1,
3945,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,9225,B,,,,,RBL-1,
3946,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,9225,B,,,,,RBL-1,
3947,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,9225,B,,,,,RBL-1,
3948,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,9225,B,,,,,RBL-1,
3949,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,9225,B,,,,,RBL-1,
3950,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,9401,B,,,,,,
3951,Autocuration,12166,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,10325,B,,,,,,
3952,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1556,F,,,,,RBL-2H3,
3953,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1556,F,,,,,RBL-2H3,
3954,Expert,12166,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,961,B,,Rattus norvegicus,10116.0,,RBL-1,
3955,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,6838,B,,,,,,
3956,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),10325,B,,,,,,
3957,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,9209,B,,Rattus norvegicus,10116.0,,RBL-1,
3958,Expert,12166,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,11520,B,,,,,RBL-1,
3959,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined,137,B,,,,,,
3960,Autocuration,12166,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,4717,B,,,,,RBL-1,
3961,Expert,12166,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,10636,B,,,,,RBL-1,
3962,Expert,12166,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,14312,F,,Rattus norvegicus,10116.0,,,
3963,Autocuration,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1203,B,,,,,RBL-1,
3964,Autocuration,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1203,B,,,,,,
3965,Expert,12166,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,13622,B,,,,,RBL-1,
3966,Autocuration,12166,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,9793,B,,,,,,
3967,Expert,12166,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1143,B,,Rattus norvegicus,10116.0,,RBL-1,
3968,Expert,12166,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,11854,B,,Rattus norvegicus,10116.0,,RBL-1,
3969,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,B,,,,,RBL-1,
3970,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),3595,B,,,,,RBL-1,
3971,Expert,12166,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,10501,B,,Rattus norvegicus,10116.0,,RBL-1,
3972,Expert,12166,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,B,,,,,RBL-1,
3973,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10034,F,,,,,,
3974,Autocuration,10825,Limbic system,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10034,F,,,,,,
3975,Autocuration,10825,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,10034,F,,,,,,
3976,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,B,,,,,,
3977,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10046,B,,,,,,
3978,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10046,B,,,,,,
3979,Autocuration,55,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,12079,F,,Canis lupus familiaris,9615.0,,,
3980,Autocuration,55,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,12079,F,,,,,,
3981,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
3982,Expert,17140,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,12338,B,,,,,,
3983,Expert,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,12143,B,,,,,,
3984,Autocuration,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),12143,B,,,,,,
3985,Expert,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,12143,B,,,,,,
3986,Autocuration,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,12143,B,,,,,,
3987,Expert,17140,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,12365,B,,,,,,
3988,Expert,17140,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,13500,B,,,,,,
3989,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3990,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3991,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3992,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3993,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3994,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3995,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3996,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3997,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3998,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
3999,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4000,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4001,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4002,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4003,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4004,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4005,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4006,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4007,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4008,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4009,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4010,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4011,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4012,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4013,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4014,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4015,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4016,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4017,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4018,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4019,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4020,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4021,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4022,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4023,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4024,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4025,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4026,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4027,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4028,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4029,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4030,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4031,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4032,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4033,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4034,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",12832,F,In vivo,Canis lupus familiaris,9615.0,,,
4035,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,3595,B,,Canis lupus familiaris,9615.0,,,
4036,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,3595,B,,Canis lupus familiaris,9615.0,,,
4037,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,3595,B,,Canis lupus familiaris,9615.0,,,
4038,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,3595,B,,Canis lupus familiaris,9615.0,,,
4039,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,3595,B,,Canis lupus familiaris,9615.0,,,
4040,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,3595,B,,Canis lupus familiaris,9615.0,,,
4041,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,3595,B,,Canis lupus familiaris,9615.0,,,
4042,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,3595,B,,Canis lupus familiaris,9615.0,,,
4043,Autocuration,55,,,Ability to inhibit 5-lipoxygenase in guinea pig,9203,B,,Cavia porcellus,10141.0,,,
4044,Expert,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),82,B,,Cavia porcellus,10141.0,,,
4045,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,11090,B,,Cavia porcellus,10141.0,,,
4046,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",12832,B,,Cavia porcellus,10141.0,,,
4047,Autocuration,55,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1065,B,,Cavia porcellus,10141.0,,,
4048,Autocuration,55,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1065,B,,Cavia porcellus,10141.0,,,
4049,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,12832,B,,Cavia porcellus,10141.0,,,
4050,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,12832,B,,Cavia porcellus,10141.0,,,
4051,Autocuration,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,12832,B,,Cavia porcellus,10141.0,,,
4052,Autocuration,55,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10504,B,,Cavia porcellus,10141.0,,,
4053,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase,7788,B,,Cavia porcellus,10141.0,,,
4054,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,10001,B,,Cavia porcellus,10141.0,,,
4055,Autocuration,55,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,10193,B,,Cavia porcellus,10141.0,,,
4056,Autocuration,55,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,13243,B,,Cavia porcellus,10141.0,,,
4057,Autocuration,55,,,Inhibitory activity uM,13243,B,,Cavia porcellus,10141.0,,,
4058,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,969,B,,Cavia porcellus,10141.0,,,
4059,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at 10 uM,10001,B,,Cavia porcellus,10141.0,,,
4060,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,7788,B,,Cavia porcellus,10141.0,,,
4061,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,10001,B,,Cavia porcellus,10141.0,,,
4062,Autocuration,55,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10193,B,,Cavia porcellus,10141.0,,,
4063,Autocuration,55,,,Inhibitory activity uM,13243,B,,Cavia porcellus,10141.0,,,
4064,Autocuration,55,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,13243,B,,Cavia porcellus,10141.0,,,
4065,Expert,55,,,Inhibitory activity uM,13243,B,,Cavia porcellus,10141.0,,,
4066,Autocuration,55,,,Inhibitory activity uM,13243,F,,Cavia porcellus,10141.0,,,
4067,Autocuration,55,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10504,B,,Cavia porcellus,10141.0,,,
4068,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,7788,B,,Cavia porcellus,10141.0,,,
4069,Expert,55,Ileum,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,10546,F,,Cavia porcellus,10141.0,,,
4070,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,B,,,,,,
4071,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),13183,B,,,,,,
4072,Autocuration,55,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),2578,B,,,,,,
4073,Expert,55,,,In vitro inhibition of human 5-Lipoxygenase.,12780,B,,,,,,
4074,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4075,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4076,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4077,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4078,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4079,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4080,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4081,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4082,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4083,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4084,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4085,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4086,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4087,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4088,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4089,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4090,Autocuration,22226,Liver,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4091,Autocuration,22226,Liver,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4092,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4093,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4094,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4095,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4096,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4097,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4098,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4099,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4100,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4101,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4102,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4103,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4104,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4105,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4106,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4107,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4108,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4109,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4110,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4111,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4112,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4113,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4114,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4115,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4116,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4117,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4118,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4119,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4120,Autocuration,22226,Liver,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4121,Autocuration,22226,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4122,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4123,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4124,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4125,Autocuration,22226,Liver,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4126,Autocuration,22226,Liver,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4127,Intermediate,80433,,,In vitro inhibition of 7226/S myeloma cancer cell line,10797,F,,Homo sapiens,9606.0,,RPMI-8226,
4128,Intermediate,80698,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),6881,F,,Homo sapiens,9606.0,,BEL-7404 tumor cell line,
4129,Intermediate,80640,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,3838,F,,Homo sapiens,9606.0,,786-0,
4130,Intermediate,80640,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,3838,F,,Homo sapiens,9606.0,,786-0,
4131,Expert,81264,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,12981,F,,Cricetulus griseus,10029.0,,V79,
4132,Expert,81264,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,12981,F,,Cricetulus griseus,10029.0,,V79,
4133,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4134,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4135,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4136,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4137,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4138,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,7653,F,,Rattus norvegicus,10116.0,,7800C1 cell line,
4139,Intermediate,80640,,,In vitro antitumor activity against renal 786-0 tumor cell lines,17229,F,,Homo sapiens,9606.0,,786-0,
4140,Intermediate,80640,,,Cytotoxic activity against 786-0 Renal cancer cell line,12858,F,,Homo sapiens,9606.0,,786-0,
4141,Intermediate,80640,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,16325,F,,Homo sapiens,9606.0,,786-0,
4142,Intermediate,80640,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,16325,F,,Homo sapiens,9606.0,,786-0,
4143,Intermediate,80640,,,In vitro antitumor activity against human renal 786-0 cell line,5858,F,,Homo sapiens,9606.0,,786-0,
4144,Intermediate,80640,,,Inhibition of Renal cancer in 786-0 cancer cell lines,16325,F,,Homo sapiens,9606.0,,786-0,
4145,Intermediate,80640,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,14696,F,,Homo sapiens,9606.0,,786-0,
4146,Intermediate,80640,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,3786,F,,Homo sapiens,9606.0,,786-0,
4147,Intermediate,80640,,,inhibition of the growth of renal cancer(786-0) cell line,14696,F,,Homo sapiens,9606.0,,786-0,
4148,Intermediate,80640,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,786-0,
4149,Intermediate,80640,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,15354,F,,Homo sapiens,9606.0,,786-0,
4150,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,14255,F,,Homo sapiens,9606.0,,786-0,
4151,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,14255,F,,Homo sapiens,9606.0,,786-0,
4152,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,14255,F,,Homo sapiens,9606.0,,786-0,
4153,Intermediate,80640,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,14696,F,,Homo sapiens,9606.0,,786-0,
4154,Intermediate,80640,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,12016,F,,Homo sapiens,9606.0,,786-0,
4155,Intermediate,80640,,,Compound was tested for growth inhibitory activity against 786-0 cell line,2597,F,,Homo sapiens,9606.0,,786-0,
4156,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12526,B,,,,,RBL-1,
4157,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12526,B,,,,,RBL-1,
4158,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,14799,B,,,,,,
4159,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),3595,B,,,,,RBL-1,
4160,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),3595,B,,,,,RBL-1,
4161,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12767,B,,,,,,
4162,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,10997,B,,,,,,
4163,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,11388,B,,,,,RBL-1,
4164,Autocuration,12166,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,167,B,,,,,,
4165,Autocuration,12166,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",167,B,,,,,,
4166,Expert,12166,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,13744,B,,,,,,
4167,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1630,B,,,,,,
4168,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1630,B,,,,,,
4169,Expert,12166,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",969,B,,Rattus norvegicus,10116.0,,,
4170,Autocuration,12166,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,13621,B,,,,,RBL-1,
4171,Autocuration,12166,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,10089,B,,,,,,
4172,Expert,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,10193,B,,,,,,
4173,Autocuration,12166,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,11966,B,,,,,,
4174,Autocuration,12166,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12251,B,,,,,,
4175,Autocuration,12166,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),211,B,,,,,RBL-1,
4176,Expert,12166,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12251,F,,,,,,
4177,Autocuration,12166,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12495,B,,,,,RBL-1,
4178,Autocuration,12166,,,Tested for its inhibitory activity against 5-lipoxygenase,414,B,,,,,,
4179,Autocuration,12166,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,414,B,,,,,,
4180,Expert,12166,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",10325,B,,,,,,
4181,Expert,12166,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,11966,B,,,,,,
4182,Expert,12166,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,B,,,,,RBL-1,
4183,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,165,B,,,,,RBL-1,
4184,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,B,,,,,RBL-1,
4185,Expert,12166,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,165,B,,,,,RBL-1,
4186,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,11311,B,,,,,,
4187,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,11311,B,,,,,RBL-1,
4188,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,11311,B,,,,,RBL-1,
4189,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
4190,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),11311,B,,,,,,
4191,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),11311,B,In vivo,,,,,
4192,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,11311,F,,,,,RBL-2H3,
4193,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,11311,F,,,,,RBL-2H3,
4194,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],11311,B,,,,,,
4195,Autocuration,12166,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,11732,B,,,,,,
4196,Expert,12166,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,11732,B,,,,,,
4197,Expert,12166,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,11087,B,,,,,,
4198,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,11087,B,,,,,,
4199,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,11087,B,,,,,RBL-1,
4200,Expert,12166,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,11087,B,,Rattus norvegicus,10116.0,,,
4201,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,496,B,,,,,RBL-1,
4202,Expert,12166,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,13986,F,,,,,RBL-1,
4203,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-lipoxygenase,11520,B,,,,,,
4204,Autocuration,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,10293,B,,,,,RBL-1,
4205,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,303,B,,,,,RBL-1,
4206,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,303,B,,,,,RBL-1,
4207,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,9247,B,,,,,RBL-1,
4208,Expert,12166,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,9247,B,,Rattus norvegicus,10116.0,,RBL-1,
4209,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,9247,B,,,,,RBL-1,
4210,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,9247,B,,,,,RBL-1,
4211,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,9247,B,,,,,RBL-1,
4212,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,9247,B,,,,,RBL-1,
4213,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,9247,B,,,,,RBL-1,
4214,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,9247,B,,,,,RBL-1,
4215,Expert,12166,,,Inhibitory activity against 5-lipoxygenase at 10 uM,11481,B,,Rattus norvegicus,10116.0,,,
4216,Autocuration,12166,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,105,B,,,,,,
4217,Expert,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,9029,B,,,,,,
4218,Expert,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1175,B,,,,,RBL-1,
4219,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12118,B,,,,,RBL-1,
4220,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12118,B,,,,,RBL-1,
4221,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12118,B,,,,,RBL-1,
4222,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,9225,B,,,,,RBL-1,
4223,Autocuration,12166,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,9401,B,,,,,,
4224,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,137,B,,,,,,
4225,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,137,B,,,,,,
4226,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,4717,B,,,,,RBL-1,
4227,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,3595,B,,,,,RBL-1,
4228,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,10501,B,,,,,RBL-1,
4229,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,10501,B,,,,,RBL-1,
4230,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,10501,B,,,,,RBL-1,
4231,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,B,,,,,RBL-1,
4232,Expert,12166,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,14799,B,,Rattus norvegicus,10116.0,,RBL-1,
4233,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,14799,B,,,,,,
4234,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,3595,B,,,,,RBL-1,
4235,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,3595,B,,,,,RBL-1,
4236,Autocuration,12166,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,B,,,,,RBL-1,
4237,Autocuration,12166,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12526,B,,,,,RBL-1,
4238,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,10193,B,,,,,,
4239,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,10193,B,,,,,,
4240,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,10193,B,,,,,,
4241,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,10193,B,,,,,,
4242,Expert,12166,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),9138,B,,,,,,
4243,Autocuration,12166,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,9138,B,,,,,,
4244,Autocuration,12166,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,11966,B,,,,,,
4245,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,165,B,,,,,RBL-1,
4246,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,165,B,,,,,RBL-1,
4247,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,11311,B,,,,,RBL-2H3,
4248,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,11311,B,,,,,RBL-2H3,
4249,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,11311,F,,,,,RBL-2H3,
4250,Autocuration,12166,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,11311,F,,,,,,
4251,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase,11311,B,,,,,,
4252,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,11311,F,,,,,RBL-2H3,
4253,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,11087,B,,,,,,
4254,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,11087,B,,,,,,
4255,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,11087,B,,,,,,
4256,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,11087,B,,,,,,
4257,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,11087,B,,,,,,
4258,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,496,B,,,,,RBL-1,
4259,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,496,B,,,,,RBL-1,
4260,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,13986,F,,,,,RBL-1,
4261,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,13986,F,,,,,RBL-1,
4262,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,13986,F,,,,,RBL-1,
4263,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,13986,F,,,,,RBL-1,
4264,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,13986,F,,,,,RBL-1,
4265,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,13986,F,,,,,RBL-1,
4266,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,13986,F,,,,,RBL-1,
4267,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,13986,F,,,,,RBL-1,
4268,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,13986,F,,,,,RBL-1,
4269,Expert,12166,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,13986,F,,Rattus norvegicus,10116.0,,,
4270,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,10193,B,,,,,,
4271,Autocuration,12166,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,9295,B,,,,,,
4272,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,4717,B,,,,,RBL-1,
4273,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,4717,B,,,,,RBL-1,
4274,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,11854,B,,,,,RBL-1,
4275,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,11854,B,,,,,RBL-1,
4276,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,11854,B,,,,,RBL-1,
4277,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,10193,B,,,,,,
4278,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,9295,B,,,,,RBL-1,
4279,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,9295,B,,,,,RBL-1,
4280,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,9295,B,,,,,RBL-1,
4281,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,9295,B,,,,,RBL-1,
4282,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,165,B,,,,,RBL-1,
4283,Autocuration,12166,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,11311,B,,,,,,
4284,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10489,B,,Homo sapiens,9606.0,,RBL-1,
4285,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10489,B,,Rattus norvegicus,10116.0,,RBL-1,
4286,Expert,12166,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),10489,B,,Rattus norvegicus,10116.0,,RBL-1,
4287,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,14799,B,,Rattus norvegicus,10116.0,,,
4288,Autocuration,12054,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),9295,B,,Glycine max,3847.0,,,
4289,Autocuration,22226,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",16811,B,,,,,,
4290,Expert,55,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,168,B,,,,,,
4291,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,6309,B,,,,,,
4292,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,6309,B,,,,,,
4293,Autocuration,55,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,3092,B,,,,,RBL-1,
4294,Expert,55,,,Inhibitory activity against 5-lipoxygenase.,168,B,,,,,,
4295,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,168,B,,,,,,
4296,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,168,B,,,,,,
4297,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,168,B,,,,,,
4298,Expert,55,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,12338,F,,,,,,
4299,Autocuration,55,,,Tested for the inhibitory activity against 5-lipoxygenase,4501,B,,,,,,
4300,Autocuration,55,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,1132,B,,,,,,
4301,Autocuration,55,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,2117,B,,,,,,
4302,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,168,B,,,,,,
4303,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,168,B,,,,,,
4304,Autocuration,12166,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,13575,B,,,,,RBL-1,
4305,Autocuration,12166,,,,11089,B,,,,,,
4306,Autocuration,10102,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),216,B,,,,,,
4307,Autocuration,10102,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,13165,B,,,,,,
4308,Autocuration,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,3278,B,,,,,,
4309,Expert,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,3278,B,,,,,,
4310,Autocuration,10102,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,11966,B,,,,,,
4311,Autocuration,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",175,B,,,,,,
4312,Autocuration,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",175,B,,,,,,
4313,Autocuration,10102,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,13449,B,,,,,,
4314,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,12014,B,,,,,,
4315,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),12014,B,,,,,,
4316,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),12014,B,,,,,,
4317,Intermediate,100284,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,99,B,,,,,,
4318,Autocuration,22226,,,The dark toxicity against 543 human galactophore carcinoma cells,4349,F,,Homo sapiens,9606.0,,,
4319,Expert,80623,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,4071,F,,Homo sapiens,9606.0,,Panel (56 tumour cell lines),
4320,Expert,80008,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,17589,F,,Homo sapiens,9606.0,,5637,
4321,Intermediate,80008,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,15002,F,,Homo sapiens,9606.0,,5637,
4322,Intermediate,80008,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",13958,F,,Homo sapiens,9606.0,,5637,
4323,Expert,80008,,,Growth inhibition against human 5637 cell lines,17589,F,,Homo sapiens,9606.0,,5637,
4324,Expert,80008,,,Antitumor activity against human bladder carcinoma 5637 cells.,16748,F,,Homo sapiens,9606.0,,5637,
4325,Intermediate,80008,,,Antitumor activity against human bladder carcinoma 5637 cells,16747,F,,Homo sapiens,9606.0,,5637,
4326,Intermediate,80008,,,Antitumor activity against human bladder carcinoma 5637 cells,16747,F,,Homo sapiens,9606.0,,5637,
4327,Expert,10443,,,In vitro inhibition of bovine trypsin(Trp).,15285,B,,Bos taurus,9913.0,,,
4328,Expert,240,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,3726,B,,Cercopithecidae,9527.0,,CV-1,
4329,Autocuration,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,5033,B,,,,,,
4330,Autocuration,104698,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,11756,F,,,,,,
4331,Autocuration,22226,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,11953,F,In vivo,,,,,
4332,Intermediate,20033,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,5033,B,,Cavia porcellus,10141.0,,,
4333,Expert,17045,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,11347,A,,Rattus norvegicus,10116.0,,,Microsomes
4334,Expert,17045,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,11347,A,,Rattus norvegicus,10116.0,,,Microsomes
4335,Intermediate,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1229,F,,,,,,
4336,Intermediate,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1229,F,,,,,,
4337,Expert,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,17588,B,,Trypanosoma brucei,5691.0,,,
4338,Autocuration,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,17588,B,,Trypanosoma brucei,5691.0,,,
4339,Expert,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,17588,B,,Ovis aries,9940.0,,,
4340,Autocuration,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,17588,B,,Ovis aries,9940.0,,,
4341,Autocuration,11938,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,16485,B,,,,,,
4342,Intermediate,22226,,,Average inhibitory concentration against 60 human cell lines was reported,4337,F,,Homo sapiens,9606.0,,,
4343,Expert,22226,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,4112,F,,Homo sapiens,9606.0,,,
4344,Intermediate,80315,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,16160,F,,Homo sapiens,9606.0,,Panel NCI-60 (60 carcinoma cell lines),
4345,Intermediate,80315,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,16160,F,,Homo sapiens,9606.0,,Panel NCI-60 (60 carcinoma cell lines),
4346,Expert,80315,,,In vitro mean growth inhibitory activity against 60-cell panel,17376,F,,,,,Panel NCI-60 (60 carcinoma cell lines),
4347,Expert,80315,,,In vitro mean growth lethal concentration against 60-cell panel,17376,F,,,,,Panel NCI-60 (60 carcinoma cell lines),
4348,Expert,80315,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,17376,F,,,,,Panel NCI-60 (60 carcinoma cell lines),
4349,Expert,80315,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,17376,F,,,,,Panel NCI-60 (60 carcinoma cell lines),
4350,Autocuration,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,3241,F,,,,,,
4351,Autocuration,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,3241,F,,,,,,
4352,Expert,275,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,3725,B,,,,,,
4353,Expert,50425,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,10805,F,,Plasmodium falciparum,5833.0,,,
4354,Expert,50425,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,10805,F,,Plasmodium falciparum,5833.0,,,
4355,Expert,50425,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,10805,F,,Plasmodium falciparum,5833.0,,,
4356,Expert,50425,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,10805,F,,Plasmodium falciparum,5833.0,,,
4357,Intermediate,50425,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,10805,F,,Plasmodium falciparum,5833.0,,,
4358,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4359,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4360,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4361,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4362,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4363,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,6C3HED,
4364,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4365,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4366,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),10685,F,In vivo,Mus musculus,10090.0,,,
4367,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4368,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4369,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4370,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4371,Autocuration,22224,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",10685,F,In vivo,Mus musculus,10090.0,,,
4372,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),10685,F,In vivo,Mus musculus,10090.0,,,
4373,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),10685,F,In vivo,Mus musculus,10090.0,,,
4374,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,10685,F,In vivo,Mus musculus,10090.0,,,
4375,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,,
4376,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,,
4377,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,,
4378,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10144,F,,Mus musculus,10090.0,,,
4379,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,10685,F,,Mus musculus,10090.0,,,
4380,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,10685,F,,Mus musculus,10090.0,,,
4381,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,10685,F,,Mus musculus,10090.0,,,
4382,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,10685,F,,Mus musculus,10090.0,,,
4383,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,10685,A,,Mus musculus,10090.0,,,
4384,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,10685,A,,Mus musculus,10090.0,,,
4385,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,10685,A,,Mus musculus,10090.0,,,
4386,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,10685,A,,Mus musculus,10090.0,,,
4387,Intermediate,80628,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",8831,F,,Mus musculus,10090.0,,6C3HED,
4388,Autocuration,22224,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,11704,F,In vivo,,,,,
4389,Intermediate,50594,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,11704,A,,Mus musculus,10090.0,,,
4390,Intermediate,80628,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,10685,F,In vivo,Mus musculus,10090.0,,6C3HED,
4391,Intermediate,80628,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,10685,F,In vivo,Mus musculus,10090.0,,6C3HED,
4392,Expert,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),11368,F,,Mus musculus,10090.0,,6C3HED,
4393,Intermediate,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),11368,F,,Mus musculus,10090.0,,6C3HED,
4394,Expert,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),11368,F,,Mus musculus,10090.0,,6C3HED,
4395,Autocuration,22226,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",17763,B,,Staphylococcus aureus,1280.0,,,
4396,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4397,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4398,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4399,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4400,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4401,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4402,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4403,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4404,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4405,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4406,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4407,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,7411,B,,Rattus norvegicus,10116.0,,,Microsomes
4408,Autocuration,22224,Plasma,,The apparent total plasma clearance in monkey,347,A,In vivo,Cercopithecidae,9527.0,,,
4409,Autocuration,22224,,,Compound was evaluated for Hepatic clearance in monkey,3341,A,In vivo,Cercopithecidae,9527.0,,,
4410,Autocuration,22224,,,Lower clearance in monkey (i.v.) at 0.5 mpk,17853,A,In vivo,Cercopithecidae,9527.0,,,
4411,Autocuration,22224,,,Plasma clearance in rhesus monkey,4514,A,In vivo,Cercopithecidae,9527.0,,,
4412,Autocuration,22224,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,6062,A,In vivo,Cercopithecidae,9527.0,,,
4413,Autocuration,22224,,,Plasma clearance of compound was determined in monkey,6821,A,In vivo,Cercopithecidae,9527.0,,,
4414,Autocuration,22224,,,Plasma clearance was calculated in rhesus monkey,6057,A,In vivo,Cercopithecidae,9527.0,,,
4415,Autocuration,22224,,,Plasma clearance in rhesus monkey,5145,A,In vivo,Cercopithecidae,9527.0,,,
4416,Autocuration,22224,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Cercopithecidae,9527.0,,,
4417,Autocuration,22224,,,Plasma clearance was evaluated in rhesus,5472,A,In vivo,Cercopithecidae,9527.0,,,
4418,Autocuration,22224,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,4257,A,In vivo,Cercopithecidae,9527.0,,,
4419,Autocuration,22224,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Cercopithecidae,9527.0,,,
4420,Autocuration,22224,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
4421,Autocuration,22224,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
4422,Autocuration,22224,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,17509,A,In vivo,Cercopithecidae,9527.0,,,
4423,Autocuration,22224,,,Cmax in monkey after administration of 1 mg/kg iv,6535,A,In vivo,Cercopithecidae,9527.0,,,
4424,Autocuration,22224,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,5668,A,In vivo,Cercopithecidae,9527.0,,,
4425,Autocuration,22224,,,Cmax in cynomolgus monkey by iv administration,5922,A,In vivo,Cercopithecidae,9527.0,,,
4426,Autocuration,22224,,,Cmax in cynomolgus monkey by po administration,5922,A,In vivo,Cercopithecidae,9527.0,,,
4427,Autocuration,22224,,,Cmax value evaluated in monkey,6078,A,In vivo,Cercopithecidae,9527.0,,,
4428,Autocuration,22224,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
4429,Autocuration,22224,Plasma,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,3249,A,In vivo,Cercopithecidae,9527.0,,,
4430,Autocuration,22224,Plasma,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,3249,A,In vivo,Cercopithecidae,9527.0,,,
4431,Autocuration,22224,Plasma,,Maximal plasma concentration in squirrel monkeys,5553,A,In vivo,Cercopithecidae,9527.0,,,
4432,Autocuration,22224,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,A,In vivo,Cercopithecidae,9527.0,,,
4433,Autocuration,22224,Plasma,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,6227,A,In vivo,Cercopithecidae,9527.0,,,
4434,Autocuration,22224,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4435,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4436,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4437,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4438,Autocuration,22224,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
4439,Autocuration,22224,Plasma,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,6221,A,In vivo,Cercopithecidae,9527.0,,,
4440,Autocuration,22224,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,167,A,,Cercopithecidae,9527.0,,,
4441,Autocuration,22224,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,167,A,,Cercopithecidae,9527.0,,,
4442,Autocuration,22224,,,Absolute bioavailability was evaluated in monkey,4257,A,In vivo,monkey,9443.0,,,
4443,Autocuration,22224,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,6221,A,In vivo,monkey,9443.0,,,
4444,Autocuration,22224,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,17667,A,In vivo,monkey,9443.0,,,
4445,Autocuration,22224,,,Bioavailability of compound was determined in rhesus monkey,17267,A,In vivo,Macaca mulatta,9544.0,,,
4446,Autocuration,22224,,,Bioavailability determined after oral administration in marmoset,4256,A,In vivo,marmosets,38020.0,,,
4447,Autocuration,22224,,,Oral bioavailability in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
4448,Autocuration,22224,,,Bioavailability in monkey (p.o.) at 2.0 mpk,17853,A,In vivo,monkey,9443.0,,,
4449,Autocuration,22224,,,Bioavailability was evaluated after oral administration in monkey,16365,A,In vivo,monkey,9443.0,,,
4450,Autocuration,22224,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,A,In vivo,Macaca fascicularis,9541.0,,,
4451,Autocuration,22224,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,A,In vivo,Macaca mulatta,9544.0,,,
4452,Autocuration,22224,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,A,In vivo,Macaca mulatta,9544.0,,,
4453,Autocuration,22224,,,Bioavailability of the compound was determined in monkey,17592,A,In vivo,monkey,9443.0,,,
4454,Autocuration,22224,,,Bioavailability in squirrel monkey (dose 5 mg/kg),1399,A,In vivo,Saimiri sciureus,9521.0,,,
4455,Autocuration,22224,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,A,In vivo,monkey,9443.0,,,
4456,Autocuration,22224,,,Oral bioavailability in monkey,3341,A,In vivo,monkey,9443.0,,,
4457,Autocuration,22224,,,Compound was tested for bioavailability in squirrel monkey,64,A,In vivo,Saimiri sciureus,9521.0,,,
4458,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,5005,A,In vivo,Macaca mulatta,9544.0,,,
4459,Autocuration,22224,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),5005,A,In vivo,Macaca mulatta,9544.0,,,
4460,Autocuration,22224,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,5237,A,In vivo,Macaca fascicularis,9541.0,,,
4461,Autocuration,22224,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,5237,A,In vivo,Macaca fascicularis,9541.0,,,
4462,Autocuration,22224,,,Oral bioavailability in monkey (dose 5 mg/kg),5302,A,In vivo,monkey,9443.0,,,
4463,Autocuration,22224,,,Oral bioavailability of compound at 5 mg/kg in monkey,17667,A,In vivo,monkey,9443.0,,,
4464,Intermediate,50588,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,6161,A,In vivo,Canis lupus familiaris,9615.0,,,
4465,Intermediate,50588,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,6161,A,In vivo,Canis lupus familiaris,9615.0,,,
4466,Intermediate,50588,Plasma,,Plasma half life determined,3854,A,,Canis lupus familiaris,9615.0,,,
4467,Intermediate,50588,Plasma,,Plasma half life in dog,993,A,,Canis lupus familiaris,9615.0,,,
4468,Intermediate,50588,Plasma,,Plasma half-life in Beagle dogs,4514,A,,Canis lupus familiaris,9615.0,,,
4469,Intermediate,50588,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
4470,Intermediate,50588,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
4471,Intermediate,50588,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
4472,Intermediate,50588,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
4473,Intermediate,50588,,,Tested for the half life period in dog,5313,A,,Canis lupus familiaris,9615.0,,,
4474,Intermediate,50588,,,Tested for the half life period in dog at dosage of 10 mpk,5313,A,In vivo,Canis lupus familiaris,9615.0,,,
4475,Intermediate,50588,,,The compound was tested for half life in dog,3880,A,,Canis lupus familiaris,9615.0,,,
4476,Intermediate,50588,Plasma,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",3639,A,,Canis lupus familiaris,9615.0,,,
4477,Intermediate,50588,,,The half life was determined,3880,A,,Canis lupus familiaris,9615.0,,,
4478,Intermediate,50588,Plasma,,The plasma half-life in dogs,3918,A,,Canis lupus familiaris,9615.0,,,
4479,Intermediate,50588,Plasma,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,16452,A,,Canis lupus familiaris,9615.0,,,
4480,Intermediate,50588,,,Half life in dog,17796,A,,Canis lupus familiaris,9615.0,,,
4481,Intermediate,50588,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,5983,A,In vivo,Canis lupus familiaris,9615.0,,,
4482,Intermediate,50588,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
4483,Intermediate,50588,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Canis lupus familiaris,9615.0,,,
4484,Expert,50506,,,Cmax in ferrets after 30 mg/kg oral dose,6113,A,In vivo,Mustela putorius furo,9669.0,,,
4485,Expert,50506,,,Emesis in ferrets at 30 mg/kg oral dose,6113,F,In vivo,Mustela putorius furo,9669.0,,,
4486,Autocuration,22224,,,Bioavailability in cynomolgus monkey,17796,A,In vivo,Macaca fascicularis,9541.0,,,
4487,Intermediate,100710,,,Volume of distribution in cynomolgus,17796,A,In vivo,Macaca fascicularis,9541.0,,,
4488,Autocuration,22224,Plasma,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,5308,A,,Cavia porcellus,10141.0,,,
4489,Autocuration,22224,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,4877,A,,Cavia porcellus,10141.0,,,
4490,Autocuration,22224,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",4876,A,,Cavia porcellus,10141.0,,,
4491,Autocuration,22224,Plasma,,AUC in guinea pig after 3mg/kg oral dose,4878,A,In vivo,Cavia porcellus,10141.0,,,
4492,Autocuration,22224,,,Bioavailability in guinea pig was tested,5308,A,In vivo,Cavia porcellus,10141.0,,,
4493,Autocuration,22224,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,4877,A,In vivo,Cavia porcellus,10141.0,,,
4494,Autocuration,22224,,,Tested for the oral bioavailability of the compound,4876,A,In vivo,Cavia porcellus,10141.0,,,
4495,Autocuration,22224,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,4876,A,In vivo,Cavia porcellus,10141.0,,,
4496,Autocuration,22224,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,5308,A,In vivo,Cavia porcellus,10141.0,,,
4497,Autocuration,22224,Lung,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,4877,A,In vivo,Cavia porcellus,10141.0,,,
4498,Autocuration,22224,,,Cmax in guinea pig after 3mg/kg oral dose,4878,A,In vivo,Cavia porcellus,10141.0,,,
4499,Autocuration,22224,Blood,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4500,Autocuration,22224,Brain,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4501,Autocuration,22224,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4502,Autocuration,22224,Intestine,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4503,Autocuration,22224,Kidney,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4504,Autocuration,22224,Liver,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4505,Autocuration,22224,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4506,Autocuration,22224,Spleen,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,5689,A,,Cavia porcellus,10141.0,,,
4507,Autocuration,22224,,,Elimination T1/2 in Guinea pig (PO dose),14465,A,In vivo,Cavia porcellus,10141.0,,,
4508,Autocuration,22224,,,Partition coefficient was measured as -log (counts per min ),5689,A,,Cavia porcellus,10141.0,,,
4509,Autocuration,22224,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,611,A,In vivo,Cavia porcellus,10141.0,,,
4510,Autocuration,22224,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,611,A,In vivo,Cavia porcellus,10141.0,,,
4511,Autocuration,22224,,,Elimination T1/2 in Guinea pig (PO dose),14465,A,In vivo,Cavia porcellus,10141.0,,,
4512,Autocuration,22224,,,"Tested for the half life period of the compound, intravenously",4876,A,In vivo,Cavia porcellus,10141.0,,,
4513,Autocuration,22224,,,Half-life was measured,5689,A,,Cavia porcellus,10141.0,,,
4514,Autocuration,22224,,,The time required for onset of inotropy after addition of a single dose of delta F75,7515,A,,Cavia porcellus,10141.0,,,
4515,Autocuration,22224,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,17667,A,In vivo,Cavia porcellus,10141.0,,,
4516,Autocuration,22224,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,17667,A,In vivo,Cavia porcellus,10141.0,,,
4517,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4518,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4519,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4520,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4521,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4522,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,10107,A,In vivo,Mus musculus,10090.0,,,
4523,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4524,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
4525,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4526,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4527,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4528,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4529,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4530,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4531,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4532,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4533,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4534,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4535,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4536,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4537,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4538,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4539,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4540,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4541,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4542,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4543,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4544,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4545,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4546,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4547,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4548,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4549,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4550,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4551,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4552,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4553,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4554,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4555,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4556,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4557,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,3655,A,In vivo,Mus musculus,10090.0,,,
4558,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,16597,A,In vivo,Mus musculus,10090.0,,,
4559,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,16597,F,In vivo,Mus musculus,10090.0,,,
4560,Intermediate,50594,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4561,Intermediate,50594,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4562,Intermediate,50594,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
4563,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4564,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,3830,F,,Homo sapiens,9606.0,,A2780,
4565,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,3829,F,,Homo sapiens,9606.0,,A2780,
4566,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,2040,F,,Homo sapiens,9606.0,,A2780,
4567,Intermediate,81034,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4568,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4569,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4570,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4571,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4572,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4573,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell line,2859,F,,Homo sapiens,9606.0,,A2780,
4574,Intermediate,81034,,,In vitro inhibitory activity against human tumor cell line A2780,5618,F,,Homo sapiens,9606.0,,A2780,
4575,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4576,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4577,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4578,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4579,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,2113,F,,Homo sapiens,9606.0,,A2780,
4580,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,2113,F,,Homo sapiens,9606.0,,A2780,
4581,Intermediate,81034,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,16745,F,,Homo sapiens,9606.0,,A2780,
4582,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,F,,Homo sapiens,9606.0,,A2780,
4583,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,15684,F,,Homo sapiens,9606.0,,A2780,
4584,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,15684,F,,Homo sapiens,9606.0,,A2780,
4585,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,2040,F,,Homo sapiens,9606.0,,A2780,
4586,Intermediate,81034,,,Relative resistance factor in A2780 cisplatin-resistant line,2040,F,,Homo sapiens,9606.0,,A2780,
4587,Intermediate,81034,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,16165,F,,Homo sapiens,9606.0,,A2780,
4588,Intermediate,81034,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,16165,F,,Homo sapiens,9606.0,,A2780,
4589,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,F,,Homo sapiens,9606.0,,A2780,
4590,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,16597,F,,Homo sapiens,9606.0,,A2780,
4591,Intermediate,81034,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,3992,F,,Homo sapiens,9606.0,,A2780,
4592,Intermediate,81034,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,10553,F,,Homo sapiens,9606.0,,A2780,
4593,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,15608,F,,Homo sapiens,9606.0,,A2780,
4594,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,15608,F,,Homo sapiens,9606.0,,A2780,
4595,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,15608,F,,Homo sapiens,9606.0,,A2780,
4596,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,15608,F,,Homo sapiens,9606.0,,A2780,
4597,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,15608,F,,Homo sapiens,9606.0,,A2780,
4598,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,15608,F,,Homo sapiens,9606.0,,A2780,
4599,Intermediate,81034,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,15569,F,,Homo sapiens,9606.0,,A2780,
4600,Intermediate,81034,,,Antiproliferative effect of compound on A2780/DX cell line,17420,F,,Homo sapiens,9606.0,,A2780,
4601,Intermediate,81034,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,17420,F,,Homo sapiens,9606.0,,A2780,
4602,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),15099,F,,Homo sapiens,9606.0,,A2780,
4603,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),15099,F,,Homo sapiens,9606.0,,A2780,
4604,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,17672,F,,Homo sapiens,9606.0,,A2780,
4605,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,17672,F,,Homo sapiens,9606.0,,A2780,
4606,Intermediate,81034,,,In vitro cytotoxicity against A2780ADR cell line,17270,F,,Homo sapiens,9606.0,,A2780,
4607,Intermediate,81034,,,In vitro cytotoxicity against A2780CIS cell line,17270,F,,Homo sapiens,9606.0,,A2780,
4608,Intermediate,81034,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,5574,F,,Homo sapiens,9606.0,,A2780,
4609,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,2113,F,,Homo sapiens,9606.0,,A2780,
4610,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4611,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4612,Autocuration,22224,,,Oral bioavailability of compound in rhesus macaques,17839,A,In vivo,Macaca mulatta,9544.0,,,
4613,Autocuration,22224,,,Oral bioavailability in monkey,6821,A,In vivo,monkey,9443.0,,,
4614,Autocuration,22224,,,Oral bioavailability evaluated in monkey,6078,A,In vivo,monkey,9443.0,,,
4615,Autocuration,22224,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),6535,A,In vivo,monkey,9443.0,,,
4616,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,4449,A,In vivo,Macaca mulatta,9544.0,,,
4617,Autocuration,22224,,,Oral bioavailability was calculated in rhesus monkey,6057,A,In vivo,Macaca mulatta,9544.0,,,
4618,Autocuration,22224,,,Oral bioavailability in cynomolgus monkey,5922,A,In vivo,Macaca fascicularis,9541.0,,,
4619,Autocuration,22224,,,Oral bioavailability in monkey,5940,A,In vivo,monkey,9443.0,,,
4620,Autocuration,22224,,,Oral bioavailability in monkey,6265,A,In vivo,monkey,9443.0,,,
4621,Autocuration,22224,,,Oral bioavailability in monkey (dose 1 mg/kg),6265,A,In vivo,monkey,9443.0,,,
4622,Autocuration,22224,,,Oral bioavailability in monkey (dose 5 mg/kg),6265,A,In vivo,monkey,9443.0,,,
4623,Autocuration,22224,,,Oral bioavailability in monkey,5940,A,In vivo,monkey,9443.0,,,
4624,Autocuration,22224,,,Oral bioavailability in monkey,5940,A,In vivo,monkey,9443.0,,,
4625,Autocuration,22224,,,Oral bioavailability in rhesus monkey,4514,A,In vivo,Macaca mulatta,9544.0,,,
4626,Autocuration,22224,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,5546,A,In vivo,Macaca mulatta,9544.0,,,
4627,Autocuration,22224,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,5553,A,In vivo,Saimiri sciureus,9521.0,,,
4628,Autocuration,22224,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,monkey,9443.0,,,
4629,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,5472,A,In vivo,Macaca mulatta,9544.0,,,
4630,Autocuration,22224,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),5668,A,In vivo,Macaca mulatta,9544.0,,,
4631,Autocuration,22224,,,Oral bioavailability in monkey at 10 mg/kg of the compound,5711,A,In vivo,monkey,9443.0,,,
4632,Autocuration,22224,,,Bioavailability in Rhesus monkey,5145,A,In vivo,Macaca mulatta,9544.0,,,
4633,Autocuration,22224,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4634,Autocuration,22224,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4635,Autocuration,22224,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,3249,A,In vivo,Cercopithecidae,9527.0,,,
4636,Autocuration,22224,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,3249,A,In vivo,Cercopithecidae,9527.0,,,
4637,Autocuration,22224,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
4638,Autocuration,22224,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4639,Autocuration,22224,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4640,Autocuration,22224,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4641,Autocuration,22224,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4642,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),14294,A,,Cercopithecidae,9527.0,,,Microsomes
4643,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),14294,A,,Cercopithecidae,9527.0,,,Microsomes
4644,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),14294,A,,Cercopithecidae,9527.0,,,Microsomes
4645,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),14294,A,,Cercopithecidae,9527.0,,,Microsomes
4646,Autocuration,22224,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,In vivo,Cercopithecidae,9527.0,,,
4647,Autocuration,22224,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,In vivo,Cercopithecidae,9527.0,,,
4648,Autocuration,22224,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,11271,A,,Cercopithecidae,9527.0,,,
4649,Autocuration,22224,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4650,Autocuration,22224,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4651,Autocuration,22224,,,Elimination Half-life of compound was determined in monkey,6821,A,,Cercopithecidae,9527.0,,,
4652,Autocuration,22224,,,Half life of compound was determined in rhesus monkey,17267,A,,Cercopithecidae,9527.0,,,
4653,Autocuration,22224,Plasma,,Half life in monkey plasma,5819,A,,Cercopithecidae,9527.0,,,
4654,Autocuration,22224,Plasma,,Half life in monkey plasma; Not detected,5819,A,,Cercopithecidae,9527.0,,,
4655,Autocuration,22224,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,A,In vivo,Cercopithecidae,9527.0,,,
4656,Autocuration,22224,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,17509,A,In vivo,Cercopithecidae,9527.0,,,
4657,Autocuration,22224,,,Terminal half life of the compound.,1399,A,,Cercopithecidae,9527.0,,,
4658,Autocuration,22224,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,A,In vivo,Cercopithecidae,9527.0,,,
4659,Autocuration,22224,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4660,Autocuration,22224,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,A,,Cercopithecidae,9527.0,,,
4661,Autocuration,22224,Urine,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4662,Autocuration,22224,Urine,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
4663,Autocuration,22224,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,4257,A,In vivo,Cercopithecidae,9527.0,,,
4664,Autocuration,22224,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,6221,A,In vivo,Cercopithecidae,9527.0,,,
4665,Autocuration,22224,,,Volume of distribution was evaluated in rhesus,5472,A,In vivo,Cercopithecidae,9527.0,,,
4666,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4667,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4668,Autocuration,22224,,,Bioavailability in hamster was determined,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4669,Autocuration,22224,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4670,Autocuration,22224,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,4727,A,In vivo,Cricetulus griseus,10029.0,,,
4671,Autocuration,22224,Blood,,Half life of compound was determined in hamster blood,4727,A,,Cricetulus griseus,10029.0,,,
4672,Autocuration,22224,,,Michaelis-Menten constant of the compound.,1452,A,,Sus scrofa,9823.0,,,
4673,Autocuration,22224,,,Vmax value was measured at 0 uM concentration of silyl ether.,1452,A,,Sus scrofa,9823.0,,,
4674,Autocuration,22224,,,Vmax value was measured at 10 uM concentration of silyl ether.,1452,A,,Sus scrofa,9823.0,,,
4675,Autocuration,22224,,,Vmax value was measured at 5 uM concentration of silyl ether.,1452,A,,Sus scrofa,9823.0,,,
4676,Expert,235,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,11706,B,,Homo sapiens,9606.0,,,
4677,Autocuration,22224,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1916,A,,Homo sapiens,9606.0,,,
4678,Autocuration,22224,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),17791,A,,Homo sapiens,9606.0,,,
4679,Autocuration,22224,,,Active metabolite of ifosfamide determined in humans; A-Active,7766,A,,Homo sapiens,9606.0,,,
4680,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,6567,A,,Homo sapiens,9606.0,,,
4681,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,6567,A,,Homo sapiens,9606.0,,,
4682,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,6567,A,,Homo sapiens,9606.0,,,
4683,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,6567,A,,Homo sapiens,9606.0,,,
4684,Autocuration,22224,,,Compound was evaluated for oral bioavailability in human,17791,A,,Homo sapiens,9606.0,,,
4685,Autocuration,22224,Urine,,Metabolite of ifosfamide determined in urine; NF-Not found,7766,A,,Homo sapiens,9606.0,,,
4686,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),6852,A,,Homo sapiens,9606.0,,,
4687,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,6852,A,,Homo sapiens,9606.0,,,
4688,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,6852,A,,Homo sapiens,9606.0,,,
4689,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,6852,A,,Homo sapiens,9606.0,,,
4690,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,6852,A,,Homo sapiens,9606.0,,,
4691,Autocuration,22224,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),6852,A,,Homo sapiens,9606.0,,,
4692,Autocuration,22224,,,Percent of compound in healthy individuals (Group D),6852,A,,Homo sapiens,9606.0,,,
4693,Autocuration,22224,Liver,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,4397,A,,Homo sapiens,9606.0,,,Microsomes
4694,Autocuration,22224,,,Binding towards human plasma protein at 10 uM,17409,A,,Homo sapiens,9606.0,,,
4695,Autocuration,22224,,,Binding towards human plasma protein at 100 uM,17409,A,,Homo sapiens,9606.0,,,
4696,Autocuration,22224,,,Human plasma protein binding activity was determined,17176,A,,Homo sapiens,9606.0,,,
4697,Autocuration,22224,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),15444,A,,Homo sapiens,9606.0,,,
4698,Autocuration,22224,,,Percent binding of compound towards human plasma protein was determined,17267,A,,Homo sapiens,9606.0,,,
4699,Autocuration,22224,Liver,,Plasma clearance in human liver microsomes,5944,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4700,Autocuration,22224,Liver,,In vitro intrinsic clearance in human liver microsome,5668,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4701,Autocuration,22224,Liver,,In vitro intrinsic clearance in human liver microsome,5669,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4702,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined,5041,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4703,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined; High,5041,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4704,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,5041,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4705,Autocuration,22224,Liver,,Pharmacokinetic property (clearance) in human liver microsome,5676,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4706,Autocuration,22224,Liver,,Plasma clearance in human liver microsomes,5944,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4707,Autocuration,22224,Liver,,In vitro clearance in human liver microsomes,17538,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4708,Autocuration,22224,Liver,,Intrinsic clearance in human liver microsomes was determined,6331,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4709,Autocuration,22224,Liver,,Intrinsic clearance in human liver microsomes was determined,5948,A,In vitro,Homo sapiens,9606.0,,,Microsomes
4710,Autocuration,22224,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,5965,A,In vivo,Homo sapiens,9606.0,,,
4711,Autocuration,22224,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1916,A,In vivo,Homo sapiens,9606.0,,,
4712,Autocuration,22224,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,5965,A,,Homo sapiens,9606.0,,,
4713,Autocuration,22224,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,1299,A,,Homo sapiens,9606.0,,,
4714,Autocuration,22224,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,1299,A,,Homo sapiens,9606.0,,,
4715,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4716,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4717,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4718,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4719,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4720,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4721,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4722,Intermediate,50594,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4723,Intermediate,50594,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),14294,A,,Mus musculus,10090.0,,,
4724,Intermediate,50594,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),14294,A,,Mus musculus,10090.0,,,
4725,Intermediate,50594,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),14294,A,,Mus musculus,10090.0,,,
4726,Intermediate,50594,Liver,,In vitro metabolic potential in mouse liver microsomes,6251,A,,Mus musculus,10090.0,,,
4727,Intermediate,50594,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,17582,A,,Mus musculus,10090.0,,,
4728,Intermediate,50594,Adrenal gland,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),17811,A,,Mus musculus,10090.0,,,
4729,Intermediate,50594,Brain,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,17811,A,,Mus musculus,10090.0,,,
4730,Intermediate,50594,Brain,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,17811,A,,Mus musculus,10090.0,,,
4731,Intermediate,50594,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),17811,A,,Mus musculus,10090.0,,,
4732,Intermediate,50594,Kidney,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),17811,A,,Mus musculus,10090.0,,,
4733,Intermediate,50594,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),17811,A,,Mus musculus,10090.0,,,
4734,Intermediate,50594,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,5288,A,,Mus musculus,10090.0,,,
4735,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,2717,A,,Mus musculus,10090.0,,,
4736,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,2717,A,,Mus musculus,10090.0,,,
4737,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,2717,A,,Mus musculus,10090.0,,,
4738,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 24 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4739,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 40 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4740,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 5 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4741,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 18 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4742,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 23 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4743,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 25 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4744,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 26 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4745,Intermediate,50594,,,Half life after intravenous administration in mice at 23 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4746,Intermediate,50594,,,Half life after intravenous administration in mice at 24 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
4747,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,16597,A,In vivo,Mus musculus,10090.0,,,
4748,Intermediate,50594,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,2675,A,In vivo,Mus musculus,10090.0,,,
4749,Intermediate,50594,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,2675,A,In vivo,Mus musculus,10090.0,,,
4750,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),16597,A,In vivo,Mus musculus,10090.0,,,
4751,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",4890,A,In vivo,Mus musculus,10090.0,,,
4752,Intermediate,50594,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,429,A,In vivo,Mus musculus,10090.0,,,
4753,Intermediate,50594,Blood,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,17837,A,In vivo,Mus musculus,10090.0,,,
4754,Intermediate,50594,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4755,Intermediate,50594,,,Half life at a dose of 10 mg/kg peroral administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4756,Intermediate,50594,,,Half life in ob/ob mice,6619,A,,Mus musculus,10090.0,,,
4757,Intermediate,50594,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,4066,A,In vivo,Mus musculus,10090.0,,,
4758,Intermediate,50594,,,Half-life was measured in mouse,4239,A,,Mus musculus,10090.0,,,
4759,Intermediate,50594,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
4760,Intermediate,50594,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,8999,A,,Mus musculus,10090.0,,,
4761,Intermediate,50594,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,8999,A,,Mus musculus,10090.0,,,
4762,Intermediate,50594,Brain,,T2 in brain of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
4763,Intermediate,50594,Kidney,,T2 in kidney of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
4764,Intermediate,50594,Liver,,T2 in liver of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
4765,Intermediate,50594,Lung,,T2 in lungs of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
4766,Intermediate,50594,Spleen,,T2 in spleen of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
4767,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,16597,A,In vivo,Mus musculus,10090.0,,,
4768,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",4890,A,In vivo,Mus musculus,10090.0,,,
4769,Intermediate,50594,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,429,A,In vivo,Mus musculus,10090.0,,,
4770,Intermediate,50594,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,429,A,In vivo,Mus musculus,10090.0,,,
4771,Intermediate,50594,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
4772,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4773,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4774,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4775,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4776,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4777,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",16913,F,,Homo sapiens,9606.0,,A2780,
4778,Intermediate,81034,,,In vitro cytotoxicity against A2780TAX cell line,17270,F,,Homo sapiens,9606.0,,A2780,
4779,Intermediate,80017,,,In vitro inhibitory activity against human tumor cell line A2780cis,5618,F,,Homo sapiens,9606.0,,A2780cisR,
4780,Expert,81034,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,17777,F,,Homo sapiens,9606.0,,A2780,
4781,Intermediate,80017,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,16112,F,,Homo sapiens,9606.0,,A2780cisR,
4782,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),15748,F,,Homo sapiens,9606.0,,A2780cisR,
4783,Intermediate,81034,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,6633,F,,Homo sapiens,9606.0,,A2780,
4784,Intermediate,81034,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,16930,F,,Homo sapiens,9606.0,,A2780,
4785,Intermediate,81034,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,17496,F,,Homo sapiens,9606.0,,A2780,
4786,Expert,81034,,,In vitro antitumor activity against A2780cisR cell line.,12989,F,,Homo sapiens,9606.0,,A2780,
4787,Intermediate,81034,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),4840,F,,Homo sapiens,9606.0,,A2780,
4788,Expert,81034,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,12989,F,,Homo sapiens,9606.0,,A2780,
4789,Intermediate,80017,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,16745,F,,Homo sapiens,9606.0,,A2780cisR,
4790,Expert,81034,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A2780,
4791,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,16547,B,,Rattus norvegicus,10116.0,,,
4792,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),16547,F,,,,,,
4793,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),16547,F,,Rattus norvegicus,10116.0,,,
4794,Expert,278,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,15856,F,,Homo sapiens,9606.0,,HEK293,
4795,Expert,278,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,15856,F,,Homo sapiens,9606.0,,HEK293,
4796,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,16547,B,,Mus musculus,10090.0,,,
4797,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),16547,F,,,,,,
4798,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),16547,F,,Mus musculus,10090.0,,,
4799,Expert,280,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,17402,B,,,,,,
4800,Autocuration,22226,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),11746,F,,Homo sapiens,9606.0,,T-cells,
4801,Autocuration,22226,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,11746,F,,Homo sapiens,9606.0,,T-cells,
4802,Intermediate,80018,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,5455,F,,Homo sapiens,9606.0,,A-375,
4803,Intermediate,80018,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,2068,F,,Homo sapiens,9606.0,,A-375,
4804,Intermediate,80018,,,In vitro antitumor activity against A375cell line extracted form melanoma,2683,F,,Homo sapiens,9606.0,,A-375,
4805,Expert,80018,,,Inhibition of cell growth in (A375) melan cell line,15313,F,,Homo sapiens,9606.0,,A-375,
4806,Intermediate,80018,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,13739,F,,Homo sapiens,9606.0,,A-375,
4807,Intermediate,80018,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,13739,F,,Homo sapiens,9606.0,,A-375,
4808,Intermediate,80018,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,14750,F,,Homo sapiens,9606.0,,A-375,
4809,Intermediate,80019,,,Antiproliferative activity measured against A427 human lung carcinoma,14777,F,,Homo sapiens,9606.0,,A-427,
4810,Intermediate,80019,,,Antiproliferative activity measured against A427 human lung carcinoma,14777,F,,Homo sapiens,9606.0,,A-427,
4811,Intermediate,80019,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,17672,F,,Homo sapiens,9606.0,,A-427,
4812,Intermediate,80019,,,Inhibition of large cell lung carcinoma (A427),14368,F,,Homo sapiens,9606.0,,A-427,
4813,Intermediate,80019,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,14368,F,,Homo sapiens,9606.0,,A-427,
4814,Intermediate,80019,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,13866,F,,Homo sapiens,9606.0,,A-427,
4815,Intermediate,80019,,,Inhibitory concentration in human lung carcinoma A427 cell line,2545,F,,Homo sapiens,9606.0,,A-427,
4816,Intermediate,80019,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,2545,F,,Homo sapiens,9606.0,,A-427,
4817,Autocuration,22224,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,6062,A,In vivo,Cercopithecidae,9527.0,,,
4818,Autocuration,22224,,,Tested for volume of distribution upon iv administration to african green monkey,4578,A,In vivo,Cercopithecidae,9527.0,,,
4819,Autocuration,22224,,,Volume of distribution in monkey,17592,A,In vivo,Cercopithecidae,9527.0,,,
4820,Autocuration,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,A,In vivo,Macaca mulatta,9544.0,,,
4821,Autocuration,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,5005,A,In vivo,Macaca mulatta,9544.0,,,
4822,Autocuration,22224,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,5922,A,In vivo,Cercopithecidae,9527.0,,,
4823,Autocuration,22224,,,The distribution volume after intravenous administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
4824,Autocuration,22224,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4825,Autocuration,22224,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
4826,Autocuration,22224,,,Volume displacement was calculated in rhesus monkey,6057,A,In vivo,Cercopithecidae,9527.0,,,
4827,Autocuration,22224,,,Volume of distribution in steady state was determined in rhesus monkey,5145,A,In vivo,Cercopithecidae,9527.0,,,
4828,Autocuration,22224,,,Volume of distribution of compound was determined in monkey,6821,A,In vivo,Cercopithecidae,9527.0,,,
4829,Autocuration,22224,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
4830,Autocuration,22224,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
4831,Autocuration,22224,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Cercopithecidae,9527.0,,,
4832,Autocuration,22224,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
4833,Autocuration,22224,,,Volume distribution in monkey after administration of 1 mg/kg iv,6535,A,In vivo,Cercopithecidae,9527.0,,,
4834,Autocuration,22224,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4835,Autocuration,22224,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,6062,A,In vivo,Cercopithecidae,9527.0,,,
4836,Autocuration,22224,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,In vivo,Cercopithecidae,9527.0,,,
4837,Autocuration,22224,,,Oral systemic bioavailability upon iv administration to african green monkey,4578,A,In vivo,Cercopithecidae,9527.0,,,
4838,Autocuration,22224,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4839,Autocuration,22224,,,Baboon plasma free fraction. ,11271,A,,Cercopithecidae,9527.0,,,
4840,Autocuration,22224,,,Area under the curve was calculated in rhesus monkey after iv administration,6057,A,,Cercopithecidae,9527.0,,,
4841,Autocuration,22224,,,Area under the curve was calculated in rhesus monkey after peroral administration,6057,A,,Cercopithecidae,9527.0,,,
4842,Autocuration,22224,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,17853,A,,Cercopithecidae,9527.0,,,
4843,Autocuration,22224,,,Half life period in monkey after 5 mg/kg dose,5302,A,In vivo,Cercopithecidae,9527.0,,,
4844,Autocuration,22224,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,4257,A,In vivo,Cercopithecidae,9527.0,,,
4845,Autocuration,22224,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,4257,A,In vivo,Cercopithecidae,9527.0,,,
4846,Autocuration,22224,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,13501,A,In vivo,Cercopithecidae,9527.0,,,
4847,Autocuration,22224,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,5394,A,In vivo,Cercopithecidae,9527.0,,,
4848,Autocuration,22224,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
4849,Autocuration,22224,,,Compound was evaluated for terminal half life in monkey,3341,A,,Cercopithecidae,9527.0,,,
4850,Autocuration,22224,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,3045,A,In vivo,Cercopithecidae,9527.0,,,
4851,Autocuration,22224,Plasma,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,A,In vivo,Macaca mulatta,9544.0,,,
4852,Autocuration,22224,,,Half life of compound was determined in squirrel monkey,4847,A,,Cercopithecidae,9527.0,,,
4853,Autocuration,22224,,,Half life after iv administration in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
4854,Autocuration,22224,Plasma,,Half life in monkey plasma after administration of 1 mg/kg iv,6535,A,In vivo,Cercopithecidae,9527.0,,,
4855,Autocuration,22224,,,Half life was calculated in rhesus monkey,6057,A,,Cercopithecidae,9527.0,,,
4856,Autocuration,22224,,,Half life in monkey,17592,A,,Cercopithecidae,9527.0,,,
4857,Autocuration,22224,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Cercopithecidae,9527.0,,,
4858,Autocuration,22224,,,Half life was evaluated in rhesus,5472,A,,Cercopithecidae,9527.0,,,
4859,Autocuration,22224,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,6221,A,In vivo,Cercopithecidae,9527.0,,,
4860,Autocuration,22224,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,5668,A,In vivo,Cercopithecidae,9527.0,,,
4861,Autocuration,22224,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),4809,A,In vivo,Cercopithecidae,9527.0,,,
4862,Autocuration,22224,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Cercopithecidae,9527.0,,,
4863,Autocuration,22224,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,5553,A,In vivo,Cercopithecidae,9527.0,,,
4864,Autocuration,22224,,,Half-life was calculated in monkey,6078,A,,Cercopithecidae,9527.0,,,
4865,Autocuration,22224,,,Half-life in Squirrel monkey,5147,A,,Cercopithecidae,9527.0,,,
4866,Autocuration,22224,,,Half-life in rhesus monkey,5145,A,,Cercopithecidae,9527.0,,,
4867,Autocuration,22224,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,6062,A,In vivo,Cercopithecidae,9527.0,,,
4868,Autocuration,22224,,,Half-life period after intravenous administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
4869,Autocuration,22224,,,Half-life period after oral administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
4870,Autocuration,22224,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,5355,A,In vivo,Cercopithecidae,9527.0,,,
4871,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4872,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4873,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4874,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,7766,A,,Homo sapiens,9606.0,,,
4875,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,7766,A,,Homo sapiens,9606.0,,,
4876,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,7766,A,,Homo sapiens,9606.0,,,
4877,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,7766,A,,Homo sapiens,9606.0,,,
4878,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,7766,A,,Homo sapiens,9606.0,,,
4879,Autocuration,22224,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1916,A,In vivo,Homo sapiens,9606.0,,,
4880,Autocuration,22224,,,Oral bioavailability in human,16643,A,In vivo,Homo sapiens,9606.0,,,
4881,Autocuration,22224,,,Compound was tested for human plasma protein binding,17248,A,,Homo sapiens,9606.0,,,
4882,Autocuration,22224,,,Compound was tested for human plasma protein binding; Not determined,17248,A,,Homo sapiens,9606.0,,,
4883,Autocuration,22224,,,Protein binding activity of compound in human plasma; % Free,6241,A,,Homo sapiens,9606.0,,,
4884,Autocuration,22224,,,Unbound fraction (plasma),17716,A,,Homo sapiens,9606.0,,,
4885,Autocuration,22224,Plasma,,Half life for the hydrolysis of compound in human blood serum,17605,A,,Homo sapiens,9606.0,,,
4886,Autocuration,22224,Plasma,,Half life period in human plasma using phosphate buffer (0.08 M),17625,A,,Homo sapiens,9606.0,,,
4887,Autocuration,22224,Plasma,,Half life period in human plasma using phosphate buffer (0.1 M),17625,A,,Homo sapiens,9606.0,,,
4888,Autocuration,22224,Plasma,,Half-life in human plasma was determined,17747,A,,Homo sapiens,9606.0,,,
4889,Autocuration,22224,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,15613,A,,Homo sapiens,9606.0,,,
4890,Autocuration,22224,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),354,A,,Homo sapiens,9606.0,,,
4891,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",3741,A,,Homo sapiens,9606.0,,,
4892,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",3741,A,,Homo sapiens,9606.0,,,
4893,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",3741,A,,Homo sapiens,9606.0,,,
4894,Autocuration,22224,,,Partition coefficient (logP),17599,A,,Homo sapiens,9606.0,,,
4895,Autocuration,22224,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,5486,A,,Homo sapiens,9606.0,,,
4896,Autocuration,22224,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,5600,A,,Homo sapiens,9606.0,,,Microsomes
4897,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),14294,A,,Homo sapiens,9606.0,,,
4898,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),14294,A,,Homo sapiens,9606.0,,,
4899,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),14294,A,,Homo sapiens,9606.0,,,
4900,Autocuration,22224,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),14294,A,,Homo sapiens,9606.0,,,Microsomes
4901,Autocuration,22224,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),14294,A,,Homo sapiens,9606.0,,,Microsomes
4902,Autocuration,22224,,,Metabolism of compound in human microsomes; Trace,14294,A,,Homo sapiens,9606.0,,,Microsomes
4903,Autocuration,22224,Liver,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,6260,A,,Homo sapiens,9606.0,,,Microsomes
4904,Autocuration,22224,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,6187,A,,Homo sapiens,9606.0,,,Microsomes
4905,Autocuration,22224,Liver,,In vitro metabolic potential in human liver microsomes,6251,A,,Homo sapiens,9606.0,,,Microsomes
4906,Autocuration,22224,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,3246,A,,Homo sapiens,9606.0,,,
4907,Autocuration,22224,,,Tested for human plasma protein binding of the compound; Not tested,17313,A,,Homo sapiens,9606.0,,,
4908,Autocuration,22224,,,Compound was tested for percent protein binding (PB) in human,6227,A,,Homo sapiens,9606.0,,,
4909,Autocuration,22224,Plasma,,Protein binding in human plasma,5530,A,,Homo sapiens,9606.0,,,
4910,Autocuration,22224,,,Permeability coefficient (B to A) in Caco-2 cell,6108,A,,Homo sapiens,9606.0,,,
4911,Autocuration,22224,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,6108,A,,Homo sapiens,9606.0,,,
4912,Autocuration,22224,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),2774,A,,Homo sapiens,9606.0,,,
4913,Autocuration,22224,,,In vitro rate of absorption observed as Caco-2 permeability in humans,16643,A,,Homo sapiens,9606.0,,,
4914,Autocuration,22224,,,Cellular permeability of compound was determined in Caco-2 cells; High,17582,A,,Homo sapiens,9606.0,,Caco-2,
4915,Autocuration,22224,,,Permeability in Caco-2 cells of compound,6838,A,,Homo sapiens,9606.0,,Caco-2,
4916,Autocuration,22224,,,Permeability coefficient (A to B) in Caco-2 cell,6108,A,,Homo sapiens,9606.0,,,
4917,Autocuration,22224,,,Permeability coefficient (B to A) in Caco-2 cell,6108,A,,Homo sapiens,9606.0,,,
4918,Autocuration,22224,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),6108,A,,Homo sapiens,9606.0,,,
4919,Autocuration,22224,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,2146,A,,Homo sapiens,9606.0,,,
4920,Autocuration,22224,,,Compound was tested for protein binding in human plasma,4514,A,,Homo sapiens,9606.0,,,
4921,Autocuration,22224,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,6108,A,,Homo sapiens,9606.0,,,
4922,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,7766,A,,Homo sapiens,9606.0,,,
4923,Intermediate,50594,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
4924,Intermediate,50594,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,A,In vivo,Mus musculus,10090.0,,,
4925,Intermediate,50594,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,3802,A,In vivo,Mus musculus,10090.0,,,
4926,Intermediate,50594,Plasma,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
4927,Intermediate,50594,Plasma,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
4928,Intermediate,50594,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,17764,F,In vivo,Mus musculus,10090.0,,,
4929,Intermediate,50594,,,Tmax after oral administration at 30 mg/kg in ICR mouse,5781,A,In vivo,Mus musculus,10090.0,,,
4930,Intermediate,50594,,,Tmax after peroral administration in mice at 2.4 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
4931,Intermediate,50594,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,4066,A,In vivo,Mus musculus,10090.0,,,
4932,Intermediate,50594,Brain,,Tmax in brain of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
4933,Intermediate,50594,Kidney,,Tmax in kidney of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
4934,Intermediate,50594,Liver,,Tmax in liver of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
4935,Intermediate,50594,Lung,,Tmax in lungs of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
4936,Intermediate,50594,,,Tmax in mice at 18 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
4937,Intermediate,50594,,,Tmax in mice at 23 uM/kg i.v. administration,17764,F,In vivo,Mus musculus,10090.0,,,
4938,Intermediate,50594,,,Tmax in mice at 25 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
4939,Intermediate,50594,,,Tmax in mice at 26 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
4940,Intermediate,50594,Spleen,,Tmax in spleen of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
4941,Intermediate,50594,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4942,Intermediate,50594,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4943,Intermediate,50594,,,Tmax value in IRC mice,5951,A,,Mus musculus,10090.0,,,
4944,Intermediate,50594,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,A,In vivo,Mus musculus,10090.0,,,
4945,Intermediate,50594,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,A,In vivo,Mus musculus,10090.0,,,
4946,Intermediate,50594,Urine,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),429,A,,Mus musculus,10090.0,,,
4947,Intermediate,50594,Urine,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),429,A,,Mus musculus,10090.0,,,
4948,Intermediate,50594,Urine,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),4066,A,,Mus musculus,10090.0,,,
4949,Intermediate,50594,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,A,,Mus musculus,10090.0,,,
4950,Intermediate,50594,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,A,,Mus musculus,10090.0,,,
4951,Intermediate,50594,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,6062,A,In vivo,Mus musculus,10090.0,,,
4952,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
4953,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
4954,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,A,In vivo,Mus musculus,10090.0,,,
4955,Intermediate,50594,,,Vd in mice,5980,A,In vivo,Mus musculus,10090.0,,,
4956,Intermediate,50594,,,Volume of distribution in mouse,17592,A,In vivo,Mus musculus,10090.0,,,
4957,Intermediate,50594,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
4958,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4959,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4960,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
4961,Intermediate,50594,,,Pharmacokinetic property (vdss) was measured in mouse,4239,A,In vivo,Mus musculus,10090.0,,,
4962,Intermediate,50594,,,Value distribution upon iv administration in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
4963,Intermediate,50594,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,17734,A,In vivo,Mus musculus,10090.0,,,
4964,Intermediate,50594,,,Volume of distribution was evaluated in mice after intravenous administration,2675,A,In vivo,Mus musculus,10090.0,,,
4965,Intermediate,50594,,,Volume of distribution was evaluated in mice after oral administration,2675,A,In vivo,Mus musculus,10090.0,,,
4966,Intermediate,50594,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,17837,A,In vivo,Mus musculus,10090.0,,,
4967,Intermediate,50594,,,Steady state volume of distribution was determined in mice,5727,A,In vivo,Mus musculus,10090.0,,,
4968,Intermediate,50594,,,Volume distribution (steady state) of compound was determined in mouse,17852,A,In vivo,Mus musculus,10090.0,,,
4969,Intermediate,50594,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
4970,Intermediate,50594,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
4971,Intermediate,50594,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,6062,A,In vivo,Mus musculus,10090.0,,,
4972,Intermediate,50594,Kidney,,Biodistribution of compound (oxidized form) in in kidney tissue,16438,A,In vivo,Mus musculus,10090.0,,,
4973,Intermediate,50594,Blood,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,A,In vivo,Mus musculus,10090.0,,,
4974,Intermediate,50594,Blood,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
4975,Intermediate,50594,Blood,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
4976,Intermediate,80019,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A-427,
4977,Expert,80852,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A-431,
4978,Expert,80852,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,16062,F,,Homo sapiens,9606.0,,A-431,
4979,Expert,80852,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,16062,F,,Homo sapiens,9606.0,,A-431,
4980,Expert,80852,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,16958,F,,Homo sapiens,9606.0,,A-431,
4981,Expert,80852,,,Inhibition of A431 human carcinoma cell proliferation,6700,F,,Homo sapiens,9606.0,,A-431,
4982,Expert,80852,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,17226,F,,Homo sapiens,9606.0,,A-431,
4983,Intermediate,80852,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,6828,F,,Homo sapiens,9606.0,,A-431,
4984,Intermediate,80852,,,In vitro cytotoxicity against epidermoid carcinoma cell line,12314,F,,Homo sapiens,9606.0,,A-431,
4985,Expert,9,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",13412,F,,Homo sapiens,9606.0,,A-431,
4986,Intermediate,80852,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,13299,F,,Homo sapiens,9606.0,,A-431,
4987,Intermediate,80852,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,17420,F,,Homo sapiens,9606.0,,A-431,
4988,Intermediate,80852,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,13678,F,,Homo sapiens,9606.0,,A-431,
4989,Expert,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,14171,F,,,,,A-431,
4990,Expert,80852,,,Tested for antiproliferative activity against human A431 cells,6333,F,,Homo sapiens,9606.0,,A-431,
4991,Expert,9,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,2356,F,,Homo sapiens,9606.0,,A-431,
4992,Expert,80852,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,15578,F,,Homo sapiens,9606.0,,A-431,
4993,Expert,80852,,,Inhibition of A431 cell proliferation,5126,F,,Homo sapiens,9606.0,,A-431,
4994,Expert,80852,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,6844,F,,Homo sapiens,9606.0,,A-431,
4995,Expert,80852,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),6844,F,,Homo sapiens,9606.0,,A-431,
4996,Intermediate,80852,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,4925,F,,Homo sapiens,9606.0,,A-431,
4997,Intermediate,80852,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,4925,F,,Homo sapiens,9606.0,,A-431,
4998,Intermediate,80852,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,13978,F,,Homo sapiens,9606.0,,A-431,
4999,Intermediate,80852,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,16786,F,,Homo sapiens,9606.0,,A-431,
5000,Expert,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,13412,F,,,,,A-431,
5001,Intermediate,80852,,,In vivo antiproliferative activity against A431 cell line,17824,F,,Homo sapiens,9606.0,,A-431,
5002,Expert,9,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,12751,F,,Homo sapiens,9606.0,,A-431,
5003,Expert,80852,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,12380,F,,Homo sapiens,9606.0,,A-431,
5004,Expert,9,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,4959,F,,Homo sapiens,9606.0,,A-431,
5005,Intermediate,80852,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),6333,F,,Homo sapiens,9606.0,,A-431,
5006,Intermediate,80852,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),6333,F,,Homo sapiens,9606.0,,A-431,
5007,Intermediate,80852,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),6333,F,,Homo sapiens,9606.0,,A-431,
5008,Expert,9,,,Inhibition of EGFR overexpressing A431 cell proliferation,5296,F,,Homo sapiens,9606.0,,,
5009,Expert,80852,,,Inhibition of A431 cell proliferation,12624,F,,Homo sapiens,9606.0,,A-431,
5010,Expert,9,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,14926,F,,Homo sapiens,9606.0,,A-431,
5011,Expert,9,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",14926,F,,Homo sapiens,9606.0,,A-431,
5012,Expert,9,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),14926,F,,,,,A-431,
5013,Intermediate,80852,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,15144,F,,Homo sapiens,9606.0,,A-431,
5014,Intermediate,80852,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,15144,F,,Homo sapiens,9606.0,,A-431,
5015,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,5245,F,,Homo sapiens,9606.0,,A-431,
5016,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,5245,F,,Homo sapiens,9606.0,,A-431,
5017,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,5245,F,,Homo sapiens,9606.0,,A-431,
5018,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,5245,F,,Homo sapiens,9606.0,,A-431,
5019,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,5245,F,,Homo sapiens,9606.0,,A-431,
5020,Autocuration,22224,,,Half-life period in cynomolgus monkey,5922,A,,Cercopithecidae,9527.0,,,
5021,Autocuration,22224,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1116,A,In vitro,Cercopithecidae,9527.0,,,
5022,Autocuration,22224,,,Longer half-life in monkey (i.v.) at 0.5 mpk,17853,A,In vivo,Cercopithecidae,9527.0,,,
5023,Autocuration,22224,Plasma,,Plasma half life in monkey,993,A,,Cercopithecidae,9527.0,,,
5024,Autocuration,22224,Plasma,,Plasma half-life in rhesus monkey,4514,A,,Cercopithecidae,9527.0,,,
5025,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
5026,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),5334,A,In vivo,Cercopithecidae,9527.0,,,
5027,Autocuration,22224,,,Tested for half life upon iv administration to african green monkey,4578,A,In vivo,Cercopithecidae,9527.0,,,
5028,Autocuration,22224,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
5029,Autocuration,22224,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
5030,Autocuration,22224,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
5031,Autocuration,22224,,,The time for peak concentration value after oral administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
5032,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5033,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5034,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5035,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5036,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5037,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5038,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5039,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5040,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5041,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5042,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5043,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5044,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5045,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5046,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5047,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,11271,A,,Cercopithecidae,9527.0,,,
5048,Intermediate,50597,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),5809,A,In vivo,Rattus norvegicus,10116.0,,,
5049,Intermediate,50597,Plasma,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,A,In vivo,Rattus norvegicus,10116.0,,,
5050,Intermediate,50597,Plasma,,AUC value in rat after IV administration at a dose of 10 mg/kg,3546,A,,Rattus norvegicus,10116.0,,,
5051,Intermediate,50597,Plasma,,AUC value in rat after oral administration at a dose of 10 mg/kg,3546,A,,Rattus norvegicus,10116.0,,,
5052,Intermediate,50597,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,3546,A,In vivo,Rattus norvegicus,10116.0,,,
5053,Intermediate,50597,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,3546,A,In vivo,Rattus norvegicus,10116.0,,,
5054,Intermediate,50597,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,3546,A,In vivo,Rattus norvegicus,10116.0,,,
5055,Intermediate,50597,,,Vc value in rat after IV administration at a dose of 10 mg/kg,3546,A,,Rattus norvegicus,10116.0,,,
5056,Intermediate,50597,,,Half life period in rat after IV administration at a dose of 10 mg/kg,3546,A,In vivo,Rattus norvegicus,10116.0,,,
5057,Autocuration,22224,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,10625,A,,Papio hamadryas,9557.0,,,
5058,Autocuration,22224,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),10625,A,,Papio hamadryas,9557.0,,,
5059,Autocuration,22224,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),10625,A,,Papio hamadryas,9557.0,,,
5060,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,10625,A,,Papio hamadryas,9557.0,,,
5061,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,10625,A,,Papio hamadryas,9557.0,,,
5062,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,10625,A,,Papio hamadryas,9557.0,,,
5063,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,10625,A,,Papio hamadryas,9557.0,,,
5064,Autocuration,22224,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,10625,A,,Papio hamadryas,9557.0,,,
5065,Autocuration,22224,,,Area under curve after 1 mpk peroral administration to beagles,3510,A,,beagle,9615.0,,,
5066,Autocuration,22224,,,Area under curve after 2 mpk peroral administration to beagles,3510,A,,beagle,9615.0,,,
5067,Autocuration,22224,,,Cmax value after 1 mpk peroral administration to beagles,3510,A,In vivo,beagle,9615.0,,,
5068,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,7766,A,,Homo sapiens,9606.0,,,
5069,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,7766,A,,Homo sapiens,9606.0,,,
5070,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,7766,A,,Homo sapiens,9606.0,,,
5071,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,7766,A,,Homo sapiens,9606.0,,,
5072,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,7766,A,,Homo sapiens,9606.0,,,
5073,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,7766,A,,Homo sapiens,9606.0,,,
5074,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,7766,A,,Homo sapiens,9606.0,,,
5075,Autocuration,22224,Liver,,Metabolic stability observed at 30 min after administration in human liver microsomes,16643,A,,Homo sapiens,9606.0,,,Microsomes
5076,Autocuration,22224,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,6852,A,,Homo sapiens,9606.0,,,
5077,Autocuration,22224,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,6852,A,,Homo sapiens,9606.0,,,
5078,Autocuration,22224,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,6852,A,,Homo sapiens,9606.0,,,
5079,Autocuration,22224,Liver,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",6567,A,,Homo sapiens,9606.0,,,Microsomes
5080,Autocuration,22224,,,Metabolic stability (% remaining at 30 mins) in human S9.,6570,A,,Homo sapiens,9606.0,,,
5081,Autocuration,22224,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,6570,A,,Homo sapiens,9606.0,,,
5082,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes,5237,A,,Homo sapiens,9606.0,,,Microsomes
5083,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,5237,A,,Homo sapiens,9606.0,,,Microsomes
5084,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,5237,A,,Homo sapiens,9606.0,,,Microsomes
5085,Autocuration,22224,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,5202,A,,Homo sapiens,9606.0,,,
5086,Autocuration,22224,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,5481,A,,Homo sapiens,9606.0,,,
5087,Autocuration,22224,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,5481,A,,Homo sapiens,9606.0,,,
5088,Autocuration,22224,,,The percent remaining in human plasma after 30 min was determined,3956,A,,Homo sapiens,9606.0,,,
5089,Autocuration,22224,Plasma,,Conversion rate of the prodrug in human plasma,5074,A,,Homo sapiens,9606.0,,,
5090,Autocuration,22224,Plasma,,Conversion rate of the prodrug in human plasma; ND means no data,5074,A,,Homo sapiens,9606.0,,,
5091,Autocuration,22224,Blood,,Half life of compound was determined in human blood,4727,A,,Homo sapiens,9606.0,,,
5092,Autocuration,22224,,,Half life of compound was determined in man with once daily dosing,5965,A,,Homo sapiens,9606.0,,,
5093,Autocuration,22224,,,Half life in human microsomes,5732,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5094,Autocuration,22224,Plasma,,Half life in human plasma,5819,A,,Homo sapiens,9606.0,,,
5095,Autocuration,22224,Plasma,,Half life in human plasma; Not detected,5819,A,,Homo sapiens,9606.0,,,
5096,Autocuration,22224,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1916,A,In vivo,Homo sapiens,9606.0,,,
5097,Autocuration,22224,Liver,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,6597,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5098,Autocuration,22224,Plasma,,Half-life in human plasma,5229,A,,Homo sapiens,9606.0,,,
5099,Autocuration,22224,Plasma,,Half-life of the parent prodrug in plasma,5229,A,,Homo sapiens,9606.0,,,
5100,Autocuration,22224,Plasma,,In vitro half life in human plasma was determined,2192,A,In vitro,Homo sapiens,9606.0,,,
5101,Autocuration,22224,Liver,,The compound was tested In Vitro for half life in human liver microsomes.,3032,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5102,Autocuration,22224,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1916,A,In vivo,Homo sapiens,9606.0,,,
5103,Autocuration,22224,,,Observed volume of distribution,17716,A,In vivo,Homo sapiens,9606.0,,,
5104,Autocuration,22224,,,Oral bioavailability in human,15778,A,In vivo,Homo sapiens,9606.0,,,
5105,Autocuration,22224,,,Tested for human plasma protein binding of the compound,17313,A,,Homo sapiens,9606.0,,,
5106,Autocuration,22224,,,"First order rate constant, k was determined in human plasma",4231,A,,Homo sapiens,9606.0,,,
5107,Autocuration,22224,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,4755,A,,Homo sapiens,9606.0,,,
5108,Autocuration,22224,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,4755,A,,Homo sapiens,9606.0,,,
5109,Autocuration,22224,Liver,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,16907,A,,Homo sapiens,9606.0,,,Microsomes
5110,Autocuration,22224,,,The compound was tested for the plasma binding in human,10839,A,,Homo sapiens,9606.0,,,
5111,Autocuration,22224,,,Plasma protein binding (human),10839,A,,Homo sapiens,9606.0,,,
5112,Autocuration,22224,Liver,,Compound was evaluated for half-life in human liver microsomes,3199,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5113,Autocuration,22224,Blood,,Half life measured in vitro for its stability in human blood,1345,A,In vitro,Homo sapiens,9606.0,,,
5114,Autocuration,22224,Serum,,Half life in human serum,4297,A,,Homo sapiens,9606.0,,,
5115,Autocuration,22224,Serum,,Half life in human serum; ND=not determined,4297,A,,Homo sapiens,9606.0,,,
5116,Autocuration,22224,,,Half life were determined in CEM-SS cell extract in decomposition step 1,4297,A,,Homo sapiens,9606.0,,,
5117,Autocuration,22224,,,Half life were determined in CEM-SS cell extract in decomposition step 2,4297,A,,Homo sapiens,9606.0,,,
5118,Autocuration,22224,Plasma,,Half life of the in human plasma,4231,A,,Homo sapiens,9606.0,,,
5119,Autocuration,22224,,,Half life period in human hepatic S9 fraction was determined,5633,A,In vitro,Homo sapiens,9606.0,,,S9
5120,Autocuration,22224,Liver,,Half life period in human liver microsome was determined,5633,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5121,Autocuration,22224,,,Half life period was determined; 6-7,17791,A,,Homo sapiens,9606.0,,,
5122,Autocuration,22224,,,Half life period was evaluated in human,17791,A,,Homo sapiens,9606.0,,,
5123,Autocuration,22224,Plasma,,Half life time in human plasma,3160,A,,Homo sapiens,9606.0,,,
5124,Intermediate,50594,Brain,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5125,Intermediate,50594,Heart,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5126,Intermediate,50594,Heart,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5127,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5128,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5129,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5130,Intermediate,50594,Liver,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5131,Intermediate,50594,Liver,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,A,In vivo,Mus musculus,10090.0,,,
5132,Intermediate,50594,Liver,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5133,Intermediate,50594,Spleen,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,16438,A,In vivo,Mus musculus,10090.0,,,
5134,Intermediate,50594,Spleen,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5135,Intermediate,50594,Spleen,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5136,Intermediate,50594,Brain,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5137,Intermediate,50594,Blood,,Biodistribution of compound (oxidized form) in blood tissue,16438,A,In vivo,Mus musculus,10090.0,,,
5138,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5139,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5140,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5141,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5142,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5143,Intermediate,50594,Brain,,Biodistribution of compound (oxidized form) in brain tissue of mice,16438,A,In vivo,Mus musculus,10090.0,,,
5144,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5145,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5146,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5147,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5148,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5149,Intermediate,50594,Heart,,Biodistribution of compound (oxidized form) in heart tissue of mice,16438,A,In vivo,Mus musculus,10090.0,,,
5150,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5151,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5152,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5153,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5154,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5155,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5156,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5157,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5158,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5159,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
5160,Intermediate,50594,Liver,,Biodistribution of compound (oxidized form) in liver tissue,16438,A,In vivo,Mus musculus,10090.0,,,
5161,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
5162,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
5163,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,5245,F,,Homo sapiens,9606.0,,A-431,
5164,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,5245,F,,Homo sapiens,9606.0,,A-431,
5165,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",16289,F,,,,,A-431,
5166,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",16289,F,,,,,A-431,
5167,Expert,9,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,16093,F,,Homo sapiens,9606.0,,A-431,
5168,Intermediate,80852,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",16825,F,,Homo sapiens,9606.0,,A-431,
5169,Intermediate,80852,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,4848,F,,Homo sapiens,9606.0,,A-431,
5170,Expert,9,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,14827,F,,Homo sapiens,9606.0,,A-431,
5171,Expert,9,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,14827,F,,Homo sapiens,9606.0,,A-431,
5172,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",16289,F,,,,,A-431,
5173,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",16289,F,,,,,A-431,
5174,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",16289,F,,,,,A-431,
5175,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",16289,F,,,,,A-431,
5176,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",16289,F,,,,,A-431,
5177,Expert,9,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",16289,F,,Homo sapiens,9606.0,,A-431,
5178,Expert,9,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,16289,F,,,,,A-431,
5179,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",16289,F,,,,,A-431,
5180,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",16289,F,,,,,A-431,
5181,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",16289,F,,,,,A-431,
5182,Expert,80852,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,F,,Mus musculus,10090.0,,A-431,
5183,Expert,80852,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,F,,Mus musculus,10090.0,,A-431,
5184,Expert,80852,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,F,,Mus musculus,10090.0,,A-431,
5185,Expert,80852,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",14555,F,,Mus musculus,10090.0,,A-431,
5186,Expert,80852,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1937,F,,Homo sapiens,9606.0,,A-431,
5187,Intermediate,80852,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,13739,F,,Homo sapiens,9606.0,,A-431,
5188,Intermediate,80852,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,3558,F,,Homo sapiens,9606.0,,A-431,
5189,Intermediate,80852,,,Dose giving a 50% decrease in the living cell number (A437 cells),3558,F,,Homo sapiens,9606.0,,A-431,
5190,Expert,80682,,,In vitro inhibitory concentration against proliferation of A459 cell line.,17686,F,,Homo sapiens,9606.0,,A549,
5191,Intermediate,80682,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,5305,F,,Homo sapiens,9606.0,,A549,
5192,Intermediate,80682,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,3614,F,,Homo sapiens,9606.0,,A549,
5193,Intermediate,80021,,,In vitro antitumor activity against renal A498 tumor cell lines,17229,F,,Homo sapiens,9606.0,,A498,
5194,Intermediate,80021,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",15935,F,,Homo sapiens,9606.0,,A498,
5195,Intermediate,80021,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",15935,F,,Homo sapiens,9606.0,,A498,
5196,Intermediate,80021,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,15560,F,,Homo sapiens,9606.0,,A498,
5197,Intermediate,80021,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,13891,F,,Homo sapiens,9606.0,,A498,
5198,Intermediate,80021,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,13891,F,,Homo sapiens,9606.0,,A498,
5199,Intermediate,80021,,,Cytotoxicity on kidney carcinoma (A-498) cell line,13788,F,,Homo sapiens,9606.0,,A498,
5200,Intermediate,80021,,,Compound was evaluated against Human cell line renal A498,15403,F,,Homo sapiens,9606.0,,A498,
5201,Intermediate,80021,,,Compound was tested for inhibition of A498 human renal cancer cell line,1009,F,,Homo sapiens,9606.0,,A498,
5202,Intermediate,80021,,,Growth inhibitory activity against A498 human cancer cell line,1043,F,,Homo sapiens,9606.0,,A498,
5203,Intermediate,80021,,,In vitro antitumor activity against human renal A498 cell line,5858,F,,Homo sapiens,9606.0,,A498,
5204,Intermediate,80021,,,In vitro cytotoxic activity against renal (A498) cell line,5958,F,,Homo sapiens,9606.0,,A498,
5205,Intermediate,80021,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,5506,F,,Homo sapiens,9606.0,,A498,
5206,Intermediate,80021,,,Tested for cytostatic activity against renal A498 cell line,12781,F,,Homo sapiens,9606.0,,A498,
5207,Intermediate,80021,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,14399,F,,Homo sapiens,9606.0,,A498,
5208,Expert,80021,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,5958,F,,Homo sapiens,9606.0,,A498,
5209,Autocuration,22224,,,Cmax value after 2 mpk peroral administration to beagles,3510,A,In vivo,beagle,9615.0,,,
5210,Autocuration,22224,,,Bioavailability,3510,A,In vivo,Canis lupus familiaris,9615.0,beagle,,
5211,Autocuration,22224,,,Bioavailability after 1 mpk peroral administration to beagles,3510,A,In vivo,Canis lupus familiaris,9615.0,beagle,,
5212,Autocuration,22224,,,Bioavailability after 2 mpk peroral administration to beagles,3510,A,In vivo,Canis lupus familiaris,9615.0,beagle,,
5213,Autocuration,22224,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,3085,A,,Bos taurus,9913.0,,,
5214,Autocuration,22224,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,3085,A,,Bos taurus,9913.0,,,
5215,Autocuration,22224,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,3085,A,,Bos taurus,9913.0,,,
5216,Autocuration,22224,,,Solubility against bovine alpha-chymotrypsin,9372,A,,Bos taurus,9913.0,,,
5217,Autocuration,22224,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,3085,A,,Bos taurus,9913.0,,,
5218,Autocuration,22224,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,3085,A,,Bos taurus,9913.0,,,
5219,Autocuration,22224,Spleen,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1469,A,,Bos taurus,9913.0,,,
5220,Autocuration,22224,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,4297,A,,Bos taurus,9913.0,,,
5221,Autocuration,22224,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,4297,A,,Bos taurus,9913.0,,,
5222,Autocuration,22224,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,17585,A,,Bos taurus,9913.0,,,
5223,Autocuration,22224,Spleen,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1336,A,,Bos taurus,9913.0,,,
5224,Autocuration,22224,,,Half life in presence of 2 mg/mL BSA at pH 8.8,3085,A,,Bos taurus,9913.0,,,
5225,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,2857,A,,Bos taurus,9913.0,,,
5226,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,2857,A,,Bos taurus,9913.0,,,
5227,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,2857,A,,Bos taurus,9913.0,,,
5228,Autocuration,22224,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1540,A,,Bos taurus,9913.0,,,
5229,Intermediate,50588,Plasma,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,6316,A,,Canis lupus familiaris,9615.0,,,
5230,Intermediate,50588,Plasma,,AUC after administration at 100 mg/kg/day in dogs,17594,A,,Canis lupus familiaris,9615.0,,,
5231,Intermediate,50588,Plasma,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,4953,A,,Canis lupus familiaris,9615.0,,,
5232,Intermediate,50588,Plasma,,AUC value after 15 mg/kg iv dose in Dogs,16907,A,,Canis lupus familiaris,9615.0,,,
5233,Intermediate,50588,Plasma,,AUC value after 30 mg/kg po dose in Dogs,16907,A,,Canis lupus familiaris,9615.0,,,
5234,Intermediate,50588,Plasma,,AUC value after administration of 4 mg/Kg oral dose in dog,2959,A,,Canis lupus familiaris,9615.0,,,
5235,Intermediate,50588,Plasma,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,17594,A,,Canis lupus familiaris,9615.0,,,
5236,Intermediate,50588,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,5356,A,,Canis lupus familiaris,9615.0,,,
5237,Intermediate,50588,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,16807,A,,Canis lupus familiaris,9615.0,,,
5238,Intermediate,50588,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,4527,A,,Canis lupus familiaris,9615.0,,,
5239,Intermediate,50588,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,4527,A,,Canis lupus familiaris,9615.0,,,
5240,Intermediate,50588,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,15660,A,,Canis lupus familiaris,9615.0,,,
5241,Intermediate,50588,,,Area under curve determined in dogs after oral administration of 10 mg/kg,15660,A,,Canis lupus familiaris,9615.0,,,
5242,Intermediate,50588,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,A,,Canis lupus familiaris,9615.0,,,
5243,Expert,50588,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,A,,Canis lupus familiaris,9615.0,,,
5244,Expert,50588,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,3598,A,,Canis lupus familiaris,9615.0,,,
5245,Intermediate,50588,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),5944,A,,Canis lupus familiaris,9615.0,,,
5246,Intermediate,50588,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,5944,A,,Canis lupus familiaris,9615.0,,,
5247,Intermediate,50588,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),5944,A,,Canis lupus familiaris,9615.0,,,
5248,Intermediate,50588,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,5944,A,,Canis lupus familiaris,9615.0,,,
5249,Intermediate,50588,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,4186,A,,Canis lupus familiaris,9615.0,,,
5250,Intermediate,50588,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,A,,Canis lupus familiaris,9615.0,,,
5251,Intermediate,50588,,,Area under curve was determine after peroral administration at 10 mpk in dog,5668,A,,Canis lupus familiaris,9615.0,,,
5252,Intermediate,50588,,,Area under curve was determine after peroral administration at 5 mpk in dog,5668,A,,Canis lupus familiaris,9615.0,,,
5253,Intermediate,50588,,,Area under curve was determined,5006,A,,Canis lupus familiaris,9615.0,,,
5254,Intermediate,50588,,,Area under curve in dogs,5006,A,,Canis lupus familiaris,9615.0,,,
5255,Intermediate,50588,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,3771,A,,Canis lupus familiaris,9615.0,,,
5256,Intermediate,50588,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),3771,A,,Canis lupus familiaris,9615.0,,,
5257,Intermediate,50588,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,3771,A,,Canis lupus familiaris,9615.0,,,
5258,Intermediate,50588,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,A,,Canis lupus familiaris,9615.0,,,
5259,Intermediate,50588,,,Area under curve value in dog at a dose of 5 mg/kg,5302,A,,Canis lupus familiaris,9615.0,,,
5260,Intermediate,50588,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,5600,A,,Canis lupus familiaris,9615.0,,,
5261,Intermediate,50588,,,Area under curve was determined after 0.3 mg/kg po administration in dog,5600,A,,Canis lupus familiaris,9615.0,,,
5262,Intermediate,50588,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,17764,A,,Canis lupus familiaris,9615.0,,,
5263,Intermediate,50588,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,4368,A,,Canis lupus familiaris,9615.0,,,
5264,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,5318,A,,Homo sapiens,9606.0,,,
5265,Autocuration,22224,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,5318,A,,Homo sapiens,9606.0,,,
5266,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,5318,A,,Homo sapiens,9606.0,,,
5267,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,5318,A,,Homo sapiens,9606.0,,,
5268,Autocuration,22224,Blood,,Time taken to reduce 50% of the concentration of compound in blood plasma,14518,A,,Homo sapiens,9606.0,,,
5269,Autocuration,22224,Plasma,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",2209,A,,Homo sapiens,9606.0,,,
5270,Autocuration,22224,Plasma,,Half life in human plasma,6787,A,,Homo sapiens,9606.0,,,
5271,Autocuration,22224,Plasma,,Half life in human plasma was reported,4898,A,,Homo sapiens,9606.0,,,
5272,Autocuration,22224,Serum,,Half life in human serum,6072,A,,Homo sapiens,9606.0,,,
5273,Autocuration,22224,Plasma,,Half life upon exposure to human plasma,16907,A,,Homo sapiens,9606.0,,,
5274,Autocuration,22224,,,t1/2 in human microsomes,5656,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5275,Autocuration,22224,Plasma,,Half life period in 80% human plasma at 37 degree Centigrade,4755,A,,Homo sapiens,9606.0,,,
5276,Autocuration,22224,Zone of skin,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),17503,A,,Homo sapiens,9606.0,,,
5277,Autocuration,22224,Plasma,,Half-life measured in in vitro Cathepsin B assay in human plasma,12357,A,In vitro,Homo sapiens,9606.0,,,
5278,Autocuration,22224,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,3076,A,,Homo sapiens,9606.0,,,
5279,Autocuration,22224,Liver,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,6410,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5280,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",3741,A,,Homo sapiens,9606.0,,,
5281,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",3741,A,,Homo sapiens,9606.0,,,
5282,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",3741,A,,Homo sapiens,9606.0,,,
5283,Autocuration,22224,,,Half-life in the CEM cell extracts,1540,A,,Homo sapiens,9606.0,,,
5284,Autocuration,22224,Plasma,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,2905,A,,Homo sapiens,9606.0,,,
5285,Autocuration,22224,Plasma,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,2905,A,,Homo sapiens,9606.0,,,
5286,Autocuration,22224,,,Half-life was determined,5523,A,,Homo sapiens,9606.0,,,
5287,Autocuration,22224,Blood,,Half-life (human blood stability),1499,A,,Homo sapiens,9606.0,,,
5288,Autocuration,22224,Blood,,Half-life (human blood stability); no data,1499,A,,Homo sapiens,9606.0,,,
5289,Autocuration,22224,Plasma,,Half-life in human plasma,17065,A,,Homo sapiens,9606.0,,,
5290,Autocuration,22224,,,CYP3A4 metabolism half-life (t1/2),6861,A,,Homo sapiens,9606.0,,,
5291,Autocuration,22224,Blood,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1499,A,,Homo sapiens,9606.0,,,
5292,Autocuration,22224,Plasma,,In vitro half life in human plasma,530,A,In vitro,Homo sapiens,9606.0,,,
5293,Autocuration,22224,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1116,A,In vitro,Homo sapiens,9606.0,,,
5294,Autocuration,22224,Plasma,,In vitro hydrolysis in human plasma,6695,A,In vitro,Homo sapiens,9606.0,,,
5295,Autocuration,22224,Plasma,,In vitro hydrolysis in human plasma; no data,6695,A,In vitro,Homo sapiens,9606.0,,,
5296,Autocuration,22224,Liver,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,10,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5297,Autocuration,22224,Plasma,,Plasma half life in human,993,A,,Homo sapiens,9606.0,,,
5298,Autocuration,22224,Plasma,,Stability after incubation with human plasma (at 37 degree C),15429,A,,Homo sapiens,9606.0,,,
5299,Autocuration,22224,Plasma,,T1/2 was evaluated in human plasma,1675,A,,Homo sapiens,9606.0,,,
5300,Autocuration,22224,Plasma,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",2209,A,,Homo sapiens,9606.0,,,
5301,Autocuration,22224,Plasma,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",2209,A,,Homo sapiens,9606.0,,,
5302,Autocuration,22224,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,5318,A,,Homo sapiens,9606.0,,,
5303,Autocuration,22224,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,2412,A,In vitro,Homo sapiens,9606.0,,,
5304,Autocuration,22224,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,2412,A,In vitro,Homo sapiens,9606.0,,,
5305,Autocuration,22224,Plasma,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,2906,A,,Homo sapiens,9606.0,,,
5306,Autocuration,22224,Plasma,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,2906,A,,Homo sapiens,9606.0,,,
5307,Autocuration,22224,,,Time taken for 50% to be consumed by serum PON1 was determined,5495,A,,Homo sapiens,9606.0,,,
5308,Autocuration,22224,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,5495,A,,Homo sapiens,9606.0,,,
5309,Autocuration,22224,Liver,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,4397,A,,Homo sapiens,9606.0,,,Microsomes
5310,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5311,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5312,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5313,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5314,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5315,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,A,,Mus sp.,10095.0,,,
5316,Intermediate,80640,,,Compound tested for growth inhibition of renal cancer cell line 786-0,6058,F,,Homo sapiens,9606.0,,786-0,
5317,Intermediate,80640,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,17708,F,,Homo sapiens,9606.0,,786-0,
5318,Expert,80640,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,14017,F,,Homo sapiens,9606.0,,786-0,
5319,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",16818,F,,Homo sapiens,9606.0,,786-0,
5320,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",16818,F,,Homo sapiens,9606.0,,786-0,
5321,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",16818,F,,Homo sapiens,9606.0,,786-0,
5322,Intermediate,80640,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,11970,F,,Homo sapiens,9606.0,,786-0,
5323,Intermediate,80640,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,12400,F,,Homo sapiens,9606.0,,786-0,
5324,Expert,80640,,,Cytotoxic effect on renal cancer line 786-0,12888,F,,Homo sapiens,9606.0,,786-0,
5325,Intermediate,80640,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,15300,F,,Homo sapiens,9606.0,,786-0,
5326,Intermediate,80640,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,786-0,
5327,Intermediate,80640,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",15895,F,,Homo sapiens,9606.0,,786-0,
5328,Intermediate,80640,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,17376,F,,Homo sapiens,9606.0,,786-0,
5329,Intermediate,80640,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,14882,F,,Homo sapiens,9606.0,,786-0,
5330,Intermediate,80640,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),14882,F,,Homo sapiens,9606.0,,786-0,
5331,Intermediate,80640,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,15176,F,,Homo sapiens,9606.0,,786-0,
5332,Intermediate,80640,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,12696,F,,Homo sapiens,9606.0,,786-0,
5333,Intermediate,80640,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),2496,F,,Homo sapiens,9606.0,,786-0,
5334,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,11831,F,,Homo sapiens,9606.0,,791T cell line,
5335,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),11831,F,,Homo sapiens,9606.0,,791T cell line,
5336,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,11831,F,,Homo sapiens,9606.0,,791T cell line,
5337,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),11831,F,,Homo sapiens,9606.0,,791T cell line,
5338,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),11831,F,,Homo sapiens,9606.0,,791T cell line,
5339,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,11831,F,,Homo sapiens,9606.0,,791T cell line,
5340,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),11831,F,,Homo sapiens,9606.0,,791T cell line,
5341,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),11831,F,,Homo sapiens,9606.0,,791T cell line,
5342,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),11831,F,,Homo sapiens,9606.0,,791T cell line,
5343,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,11831,F,,Homo sapiens,9606.0,,791T cell line,
5344,Intermediate,80640,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,12782,F,,Homo sapiens,9606.0,,786-0,
5345,Intermediate,22226,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1229,F,,,,,,
5346,Expert,80433,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,15313,F,,Homo sapiens,9606.0,,RPMI-8226,
5347,Expert,80433,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,15313,F,,Homo sapiens,9606.0,,RPMI-8226,
5348,Intermediate,80433,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,11544,F,,Homo sapiens,9606.0,,RPMI-8226,
5349,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5350,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5351,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5352,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5353,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5354,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5355,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5356,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5357,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5358,Intermediate,80021,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,A498,
5359,Intermediate,80021,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,15354,F,,Homo sapiens,9606.0,,A498,
5360,Intermediate,80021,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),17445,F,,Homo sapiens,9606.0,,A498,
5361,Intermediate,80021,,,In vitro inhibitory concentration against renal cancer cell line A498,4337,F,,Homo sapiens,9606.0,,A498,
5362,Intermediate,80021,,,Cytotoxicity against A 498 tumor cell line,15277,F,,Homo sapiens,9606.0,,A498,
5363,Intermediate,80021,,,In vitro antitumor activity against A498 human cancer cell line,4812,F,,Homo sapiens,9606.0,,A498,
5364,Intermediate,80021,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),4812,F,,Homo sapiens,9606.0,,A498,
5365,Intermediate,80021,,,Inhibitory dose required against A498 human tumor cell lines,4995,F,,Homo sapiens,9606.0,,A498,
5366,Intermediate,80021,,,Anticancer activity against one renal cancer (A498 cell line),5847,F,,Homo sapiens,9606.0,,A498,
5367,Intermediate,80021,,,In vitro cytotoxicity against melanoma A498 cell line,6557,F,,Homo sapiens,9606.0,,A498,
5368,Intermediate,80021,,,Compound was tested for growth inhibitory activity against A498 cell line,2597,F,,Homo sapiens,9606.0,,A498,
5369,Intermediate,80021,,,Compound tested for growth inhibition of renal cancer cell line A498,6058,F,,Homo sapiens,9606.0,,A498,
5370,Intermediate,80021,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,17708,F,,Homo sapiens,9606.0,,A498,
5371,Intermediate,80021,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,15176,F,,Homo sapiens,9606.0,,A498,
5372,Intermediate,80021,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,15300,F,,Homo sapiens,9606.0,,A498,
5373,Intermediate,80021,,,Tested for cytotoxicity against A498 cell lines in renal cancer,11970,F,,Homo sapiens,9606.0,,A498,
5374,Intermediate,80021,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,12400,F,,Homo sapiens,9606.0,,A498,
5375,Expert,80021,,,Cytotoxic effect on renal cancer lines A498,12888,F,,Homo sapiens,9606.0,,A498,
5376,Intermediate,80021,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,3030,F,,Homo sapiens,9606.0,,A498,
5377,Intermediate,80021,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,A498,
5378,Intermediate,80021,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,17376,F,,Homo sapiens,9606.0,,A498,
5379,Intermediate,80021,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,16558,F,,Homo sapiens,9606.0,,A498,
5380,Intermediate,80021,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,5194,F,,Homo sapiens,9606.0,,A498,
5381,Intermediate,80021,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A498,
5382,Expert,80682,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,16880,F,,Homo sapiens,9606.0,,A549,
5383,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line,10196,F,,Homo sapiens,9606.0,,A549,
5384,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,10196,F,,Homo sapiens,9606.0,,A549,
5385,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,10196,F,,Homo sapiens,9606.0,,A549,
5386,Intermediate,80682,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",12083,F,,Homo sapiens,9606.0,,A549,
5387,Expert,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,16464,F,,Homo sapiens,9606.0,,A549,
5388,Intermediate,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A549,
5389,Expert,80682,,,In vitro cytotoxic activity against human lung A549 cell line,16470,F,,Homo sapiens,9606.0,,A549,
5390,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),16470,F,,Homo sapiens,9606.0,,A549,
5391,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line),16470,F,,Homo sapiens,9606.0,,A549,
5392,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,16470,F,,Homo sapiens,9606.0,,A549,
5393,Expert,80682,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,16582,F,,Homo sapiens,9606.0,,A549,
5394,Intermediate,80682,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",15935,F,,Homo sapiens,9606.0,,A549,
5395,Intermediate,80682,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",15935,F,,Homo sapiens,9606.0,,A549,
5396,Expert,80682,,,Inhibition of A549 human lung carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A549,
5397,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line,17376,F,,Homo sapiens,9606.0,,A549,
5398,Intermediate,80682,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,16496,F,,Homo sapiens,9606.0,,A549,
5399,Intermediate,80682,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,16152,F,,Homo sapiens,9606.0,,A549,
5400,Intermediate,80682,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,16152,F,,Homo sapiens,9606.0,,A549,
5401,Intermediate,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A549,
5402,Intermediate,80682,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,2288,F,,Homo sapiens,9606.0,,A549,
5403,Intermediate,80682,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,17350,F,,Homo sapiens,9606.0,,A549,
5404,Expert,80682,,,Inhibition of A549 cancer cell proliferation,4090,F,,Homo sapiens,9606.0,,A549,
5405,Expert,80682,,,Inhibition of A549 cancer cell proliferation (Not tested),4090,F,,Homo sapiens,9606.0,,A549,
5406,Intermediate,80682,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,17350,F,,Homo sapiens,9606.0,,A549,
5407,Intermediate,80682,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,4197,F,,Homo sapiens,9606.0,,A549,
5408,Intermediate,80682,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,17072,F,,Homo sapiens,9606.0,,A549,
5409,Intermediate,80682,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,17072,F,,Homo sapiens,9606.0,,A549,
5410,Intermediate,80682,,,Cytotoxicity against Renal cell lines A549 was determined,5194,F,,Homo sapiens,9606.0,,A549,
5411,Intermediate,50588,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,4257,A,,Canis lupus familiaris,9615.0,,,
5412,Intermediate,50588,,,Area under curve was determined in dog after oral administration at 1 mg/kg,6123,A,,Canis lupus familiaris,9615.0,,,
5413,Intermediate,50588,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,A,,Canis lupus familiaris,9615.0,,,
5414,Intermediate,50588,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,A,,Canis lupus familiaris,9615.0,,,
5415,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),8833,A,,Canis lupus familiaris,9615.0,,,
5416,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),8833,A,,Canis lupus familiaris,9615.0,,,
5417,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),8833,A,,Canis lupus familiaris,9615.0,,,
5418,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),8833,A,,Canis lupus familiaris,9615.0,,,
5419,Intermediate,50588,Plasma,,Area under plasma concentration time curve in dog upon oral administration,17657,A,,Canis lupus familiaris,9615.0,,,
5420,Intermediate,50588,Plasma,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,17650,A,,Canis lupus familiaris,9615.0,,,
5421,Intermediate,50588,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1977,A,,Canis lupus familiaris,9615.0,,,
5422,Intermediate,50588,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1977,A,,Canis lupus familiaris,9615.0,,,
5423,Intermediate,50588,,,Area under the curve for the compound was obtained when tested in dog,3132,A,,Canis lupus familiaris,9615.0,,,
5424,Intermediate,50588,,,Area under the curve at a dose of 1 mg/kg,5473,A,,Canis lupus familiaris,9615.0,,,
5425,Intermediate,50588,,,Area under the curve at a dose of 1 mg/kg (oral),5474,A,,Canis lupus familiaris,9615.0,,,
5426,Intermediate,50588,,,Area under the curve at i.v. dose of 0.2 mg/kg,5474,A,,Canis lupus familiaris,9615.0,,,
5427,Intermediate,50588,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,6062,A,,Canis lupus familiaris,9615.0,,,
5428,Intermediate,50588,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,4709,A,,Canis lupus familiaris,9615.0,,,
5429,Intermediate,50588,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,2652,A,,Canis lupus familiaris,9615.0,,,
5430,Intermediate,50588,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,2652,A,,Canis lupus familiaris,9615.0,,,
5431,Intermediate,50588,,,Compound was evaluated for area under the curve in dog blood.,2877,A,,Canis lupus familiaris,9615.0,,,
5432,Intermediate,50588,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,5444,A,,Canis lupus familiaris,9615.0,,,
5433,Intermediate,50588,Plasma,,AUC in dog after oral dose (1 mg/kg),5130,A,,Canis lupus familiaris,9615.0,,,
5434,Intermediate,50588,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,6265,A,,Canis lupus familiaris,9615.0,,,
5435,Intermediate,50588,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",4657,A,,Canis lupus familiaris,9615.0,,,
5436,Intermediate,50588,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,16367,A,,Canis lupus familiaris,9615.0,,,
5437,Intermediate,50588,,,Pharmacokinetic parameter AUC after oral administration to dogs,16367,A,,Canis lupus familiaris,9615.0,,,
5438,Intermediate,50588,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,9579,A,,Canis lupus familiaris,9615.0,,,
5439,Intermediate,50588,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,9579,A,,Canis lupus familiaris,9615.0,,,
5440,Intermediate,50588,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,5983,A,,Canis lupus familiaris,9615.0,,,
5441,Intermediate,50588,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,6241,A,,Canis lupus familiaris,9615.0,,,
5442,Intermediate,50588,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",5313,A,,Canis lupus familiaris,9615.0,,,
5443,Intermediate,50588,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",5313,A,,Canis lupus familiaris,9615.0,,,
5444,Intermediate,50588,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,A,,Canis lupus familiaris,9615.0,,,
5445,Intermediate,50588,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,A,,Canis lupus familiaris,9615.0,,,
5446,Intermediate,50588,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),6641,A,,Canis lupus familiaris,9615.0,,,
5447,Intermediate,50588,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),6642,A,,Canis lupus familiaris,9615.0,,,
5448,Intermediate,50588,,,Compound was evaluated for oral bioavailability in dog; 90-100,17791,A,,Canis lupus familiaris,9615.0,,,
5449,Intermediate,50588,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,17655,A,,Canis lupus familiaris,9615.0,,,
5450,Intermediate,50588,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,17655,A,,Canis lupus familiaris,9615.0,,,
5451,Intermediate,50588,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,6596,A,,Canis lupus familiaris,9615.0,,,
5452,Intermediate,50588,,,Oral bioavailability in dog,3880,A,,Canis lupus familiaris,9615.0,,,
5453,Intermediate,50588,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,16367,A,,Canis lupus familiaris,9615.0,,,
5454,Intermediate,50588,Plasma,,Plasma protein binding towards dog plasma at 10 uM,17409,A,,Canis lupus familiaris,9615.0,,,
5455,Intermediate,50588,Plasma,,Plasma protein binding towards dog plasma at 100 uM,17409,A,,Canis lupus familiaris,9615.0,,,
5456,Intermediate,50588,,,Bioavailability in dog (dose 4 mg/kg p.o.),2959,A,In vivo,Canis lupus familiaris,9615.0,,,
5457,Intermediate,50588,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,13501,A,In vivo,Canis lupus familiaris,9615.0,,,
5458,Intermediate,50588,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,4527,A,In vivo,Canis lupus familiaris,9615.0,,,
5459,Intermediate,50588,,,Bioavailability in dogs,15145,A,In vivo,Canis lupus familiaris,9615.0,,,
5460,Intermediate,50588,,,Bioavailability,4219,A,In vivo,Canis lupus familiaris,9615.0,,,
5461,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),17538,A,In vivo,Canis lupus familiaris,9615.0,,,
5462,Intermediate,50588,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,17538,A,In vivo,Canis lupus familiaris,9615.0,,,
5463,Intermediate,50588,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),1466,A,In vivo,Canis lupus familiaris,9615.0,,,
5464,Intermediate,50588,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,17650,A,In vivo,Canis lupus familiaris,9615.0,,,
5465,Intermediate,50588,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,3132,A,In vivo,Canis lupus familiaris,9615.0,,,
5466,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5467,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5468,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,A,,Mus sp.,10095.0,,,
5469,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5470,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5471,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5472,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5473,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,A,,Mus sp.,10095.0,,,
5474,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5475,Autocuration,22224,Spleen,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5476,Autocuration,22224,Spleen,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5477,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,2413,A,,Mus sp.,10095.0,,,
5478,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,A,,Mus sp.,10095.0,,,
5479,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5480,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,2413,A,,Mus sp.,10095.0,,,
5481,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,2413,A,,Mus sp.,10095.0,,,
5482,Autocuration,22224,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5483,Autocuration,22224,Cerebellum,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5484,Autocuration,22224,Frontal cortex,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5485,Autocuration,22224,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5486,Autocuration,22224,Striatum,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5487,Autocuration,22224,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5488,Autocuration,22224,Cerebellum,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5489,Autocuration,22224,Frontal cortex,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5490,Autocuration,22224,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5491,Autocuration,22224,Striatum,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),17827,A,,Cercopithecidae,9527.0,,,
5492,Autocuration,22224,,,Compound was evaluated for oral bioavailability in rats,17791,A,,Cercopithecidae,9527.0,,,
5493,Autocuration,22224,Plasma,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,17667,A,In vivo,Cercopithecidae,9527.0,,,
5494,Autocuration,22224,,,Half life period was evaluated in monkey,17791,A,,Cercopithecidae,9527.0,,,
5495,Autocuration,22224,,,Half-life in rhesus monkeys by intravenous administration of dose,110,A,In vivo,Cercopithecidae,9527.0,,,
5496,Intermediate,50594,Plasma,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,5781,A,,Mus musculus,10090.0,,,
5497,Intermediate,50594,Plasma,,AUC after intraperitoneal administration of 100 mg/kg in mice,17734,A,,Mus musculus,10090.0,,,
5498,Intermediate,50594,Plasma,,AUC value was determined after oral administration,17718,A,,Mus musculus,10090.0,,,
5499,Intermediate,50594,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,4573,A,,Mus musculus,10090.0,,,
5500,Intermediate,50594,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,A,,Mus musculus,10090.0,,,
5501,Intermediate,50594,,,Area under curve by ioral administration in mouse,2862,A,,Mus musculus,10090.0,,,
5502,Intermediate,50594,,,Area under curve by iv administration in mouse,2862,A,,Mus musculus,10090.0,,,
5503,Intermediate,50594,,,Area under curve at 0-8 hr in IRC mice after peroral administration,5951,A,,Mus musculus,10090.0,,,
5504,Intermediate,50594,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,17729,A,,Mus musculus,10090.0,,,
5505,Intermediate,50594,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,17728,A,,Mus musculus,10090.0,,,
5506,Intermediate,50594,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,17728,A,,Mus musculus,10090.0,,,
5507,Intermediate,50594,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,17729,A,,Mus musculus,10090.0,,,
5508,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5509,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5510,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5511,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5512,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5513,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5514,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5515,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5516,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5517,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5518,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5519,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5520,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5521,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5522,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5523,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5524,Expert,80433,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,9424,F,,Homo sapiens,9606.0,,RPMI-8226,
5525,Intermediate,80433,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,11544,F,,Homo sapiens,9606.0,,RPMI-8226,
5526,Intermediate,80433,,,Cytotoxicity of compound against 8226/DOX1V cells,17378,F,,Homo sapiens,9606.0,,RPMI-8226,
5527,Intermediate,80433,,,Cytotoxicity of compound against 8226/S cells,17378,F,,Homo sapiens,9606.0,,RPMI-8226,
5528,Intermediate,80433,,,Inhibitory concentration against 8226 myeloma cancer cell line,17079,F,,Homo sapiens,9606.0,,RPMI-8226,
5529,Intermediate,80433,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,17079,F,,Homo sapiens,9606.0,,RPMI-8226,
5530,Intermediate,80647,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,13466,F,,Homo sapiens,9606.0,,833K,
5531,Intermediate,80647,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',13466,F,,Homo sapiens,9606.0,,833K,
5532,Expert,80647,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,2392,F,,Homo sapiens,9606.0,,833K,
5533,Intermediate,80647,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,2392,F,,Homo sapiens,9606.0,,833K,
5534,Autocuration,22226,,,Inhibitory activity against caspase-1,6608,B,,,,,,
5535,Autocuration,45,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,10199,B,,Enterococcus faecalis,1351.0,,,
5536,Intermediate,80648,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,17749,F,,Homo sapiens,9606.0,,8701-BC,
5537,Intermediate,80648,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,17749,F,,Homo sapiens,9606.0,,8701-BC,
5538,Intermediate,22226,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1229,F,,,,,,
5539,Intermediate,22226,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1229,F,,,,,,
5540,Intermediate,22226,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1229,F,,,,,,
5541,Autocuration,22226,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,6390,B,,,,,,
5542,Autocuration,22226,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,16219,F,,Streptococcus pyogenes,1314.0,,,
5543,Autocuration,22226,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,16219,F,,Streptococcus pyogenes,1314.0,,,
5544,Autocuration,11922,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,17043,B,,,,,,
5545,Intermediate,81115,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,6929,F,,Homo sapiens,9606.0,,KB ,
5546,Intermediate,81115,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,6929,A,,Homo sapiens,9606.0,,KB ,
5547,Autocuration,22226,,,In vitro cytotoxicity of compound was tested against 9KB cells.,7083,F,,Homo sapiens,9606.0,,,
5548,Intermediate,80653,,,Cytotoxic concentration against 9L cells was determined on day 3,12446,F,,Rattus norvegicus,10116.0,,9L,
5549,Expert,80653,,,Tested in vitro for anticancer activity against 9L cells,15345,F,,Rattus norvegicus,10116.0,,9L,
5550,Expert,80653,,,Tested in vitro for anticancer activity against 9L cells; Not determined,15345,F,,Rattus norvegicus,10116.0,,9L,
5551,Intermediate,80682,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,6301,F,,Homo sapiens,9606.0,,A549,
5552,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,4833,F,,Homo sapiens,9606.0,,A549,
5553,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,4833,F,,Homo sapiens,9606.0,,A549,
5554,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,4833,F,,Homo sapiens,9606.0,,A549,
5555,Expert,80682,,,Cytotoxicity against human lung carcinoma A549 cell line,13330,F,,Homo sapiens,9606.0,,A549,
5556,Expert,25,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,17517,F,,Homo sapiens,9606.0,,A549,
5557,Expert,25,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",17517,F,,Homo sapiens,9606.0,,A549,
5558,Intermediate,80682,,,"In vitro growth inhibition of A549, lung carcinoma",14425,F,,Homo sapiens,9606.0,,A549,
5559,Intermediate,80682,,,"In vitro growth inhibition of A549, lung carcinoma.",14425,F,,Homo sapiens,9606.0,,A549,
5560,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,5228,F,,Homo sapiens,9606.0,,A549,
5561,Intermediate,80682,,,Cytotoxic activity against human lung cancer A549 cell line was determined,5351,F,,Homo sapiens,9606.0,,A549,
5562,Expert,80682,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,12198,F,,Homo sapiens,9606.0,,A549,
5563,Intermediate,80682,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,13891,F,,Homo sapiens,9606.0,,A549,
5564,Expert,80682,,,Cytotoxicity in A549 (human carcinoma) cell line.,5677,F,,Homo sapiens,9606.0,,A549,
5565,Intermediate,80682,,,Cytotoxicity on lung carcinoma (A-549) cell line,13788,F,,Homo sapiens,9606.0,,A549,
5566,Expert,80682,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,13384,F,,Homo sapiens,9606.0,,A549,
5567,Intermediate,80682,,,Effective dose of compound against replication of A549 cell line was evaluated,6726,F,,Homo sapiens,9606.0,,A549,
5568,Expert,80682,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,3455,F,,Homo sapiens,9606.0,,A549,
5569,Intermediate,80682,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),5726,F,,Homo sapiens,9606.0,,A549,
5570,Intermediate,80682,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,5726,F,,Homo sapiens,9606.0,,A549,
5571,Intermediate,80682,,,The compound was evaluated for antiproliferative activity against A549 cell line,3936,F,,Homo sapiens,9606.0,,A549,
5572,Intermediate,80682,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,14991,F,,Homo sapiens,9606.0,,A549,
5573,Intermediate,80682,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,5243,F,,Homo sapiens,9606.0,,A549,
5574,Intermediate,80682,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,12858,F,,Homo sapiens,9606.0,,A549,
5575,Intermediate,80682,,,Growth inhibition against A549 cell line was evaluated,6776,F,,Homo sapiens,9606.0,,A549,
5576,Intermediate,80682,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,16558,F,,Homo sapiens,9606.0,,A549,
5577,Expert,80682,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,4583,F,,Homo sapiens,9606.0,,A549,
5578,Intermediate,80682,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,13514,F,,Homo sapiens,9606.0,,A549,
5579,Expert,80682,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,15166,F,,Homo sapiens,9606.0,,A549,
5580,Intermediate,80682,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,13873,F,,Homo sapiens,9606.0,,A549,
5581,Expert,80682,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,6447,F,,Homo sapiens,9606.0,,A549,
5582,Intermediate,80682,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,2068,F,,Homo sapiens,9606.0,,A549,
5583,Expert,80682,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1863,F,,Homo sapiens,9606.0,,A549,
5584,Intermediate,80682,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,13873,F,,Homo sapiens,9606.0,,A549,
5585,Intermediate,80682,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,13873,F,,Homo sapiens,9606.0,,A549,
5586,Expert,80682,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,13873,F,,Homo sapiens,9606.0,,A549,
5587,Intermediate,80682,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),579,F,,Homo sapiens,9606.0,,A549,
5588,Intermediate,80682,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,579,F,,Homo sapiens,9606.0,,A549,
5589,Intermediate,80682,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,4584,F,,Homo sapiens,9606.0,,A549,
5590,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,5421,F,,Homo sapiens,9606.0,,A549,
5591,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,5421,F,,Homo sapiens,9606.0,,A549,
5592,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,5421,F,,Homo sapiens,9606.0,,A549,
5593,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,5421,F,,Homo sapiens,9606.0,,A549,
5594,Intermediate,80682,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,14188,F,,Homo sapiens,9606.0,,A549,
5595,Intermediate,80682,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,14188,F,,Homo sapiens,9606.0,,A549,
5596,Intermediate,80682,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,15354,F,,Homo sapiens,9606.0,,A549,
5597,Expert,80682,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,14253,F,,Homo sapiens,9606.0,,A549,
5598,Intermediate,80682,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,13873,F,,Homo sapiens,9606.0,,A549,
5599,Intermediate,50588,,,Oral bioavailability in dog (conscious),3043,A,In vivo,Canis lupus familiaris,9615.0,,,
5600,Intermediate,50588,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,3045,A,In vivo,Canis lupus familiaris,9615.0,,,
5601,Intermediate,50588,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,3022,A,In vivo,Canis lupus familiaris,9615.0,,,
5602,Intermediate,50588,,,Oral bioavailability in dog,4453,A,In vivo,Canis lupus familiaris,9615.0,,,
5603,Intermediate,50588,,,Oral bioavailability in dog,1696,A,In vivo,Canis lupus familiaris,9615.0,,,
5604,Intermediate,50588,,,Oral bioavailability in dog,5045,A,In vivo,Canis lupus familiaris,9615.0,,,
5605,Intermediate,50588,,,Oral bioavailability in dog (fasted),5356,A,In vivo,Canis lupus familiaris,9615.0,,,
5606,Intermediate,50588,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
5607,Intermediate,50588,,,Oral bioavailability in dog,6448,A,In vivo,Canis lupus familiaris,9615.0,,,
5608,Intermediate,50588,,,Oral bioavailability in dog,1475,A,In vivo,Canis lupus familiaris,9615.0,,,
5609,Intermediate,50588,,,Percent bioavailability in dog,3788,A,In vivo,Canis lupus familiaris,9615.0,,,
5610,Intermediate,50588,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,3639,A,In vivo,Canis lupus familiaris,9615.0,,,
5611,Intermediate,50588,,,Oral bioavailability in dog,13397,A,In vivo,Canis lupus familiaris,9615.0,,,
5612,Intermediate,50588,,,The compound was evaluated for bioavailability in dogs; 34-44,2137,A,In vivo,Canis lupus familiaris,9615.0,,,
5613,Intermediate,50588,,,Bioavailability in dog (dose 4 mg/kg p.o.),2959,A,In vivo,Canis lupus familiaris,9615.0,,,
5614,Intermediate,50588,,,Oral bioavailability in dog,6448,A,In vivo,Canis lupus familiaris,9615.0,,,
5615,Intermediate,50588,,,8 hour trough Blood level in dog was measured after administration of compound,6084,A,,Canis lupus familiaris,9615.0,,,
5616,Intermediate,50588,Plasma,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,3639,A,In vivo,Canis lupus familiaris,9615.0,,,
5617,Intermediate,50588,,,C24 after oral administration at 5 mg/kg,6316,A,,Canis lupus familiaris,9615.0,,,
5618,Intermediate,50588,,,Clearance after oral and iv dosing in dogs,5238,A,,Canis lupus familiaris,9615.0,,,
5619,Intermediate,50588,Plasma,,Clearance of the drug was measured in the plasma of dog,17796,A,,Canis lupus familiaris,9615.0,,,
5620,Intermediate,50588,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,2652,A,,Canis lupus familiaris,9615.0,,,
5621,Intermediate,50588,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,A,In vivo,Canis lupus familiaris,9615.0,,,
5622,Intermediate,50588,,,Clearance of compound was determined in dogs,6621,A,In vivo,Canis lupus familiaris,9615.0,,,
5623,Intermediate,50588,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,6505,A,In vivo,Canis lupus familiaris,9615.0,,,
5624,Intermediate,50588,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,A,In vivo,Canis lupus familiaris,9615.0,,,
5625,Intermediate,50588,,,Plasma clearance in dog was determined,17267,A,In vivo,Canis lupus familiaris,9615.0,,,
5626,Intermediate,50588,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
5627,Intermediate,50588,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
5628,Intermediate,50588,,,Plasma clearance in dog after administration of 1 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
5629,Intermediate,50588,,,Plasma clearance in dogs,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
5630,Intermediate,50588,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,5542,A,In vivo,Canis lupus familiaris,9615.0,,,
5631,Intermediate,50588,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
5632,Intermediate,50588,,,Plasma clearance after 15 mg/kg iv dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
5633,Intermediate,50588,,,Plasma clearance after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
5634,Intermediate,50588,,,Plasma administration to dogs,16367,A,In vivo,Canis lupus familiaris,9615.0,,,
5635,Intermediate,50588,,,Plasma clearance was determined,5505,A,In vivo,Canis lupus familiaris,9615.0,,,
5636,Intermediate,50588,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,6215,A,In vivo,Canis lupus familiaris,9615.0,,,
5637,Intermediate,50588,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
5638,Intermediate,102164,Liver,,Intrinsic clearance in human liver microsomes,5007,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5639,Intermediate,102164,Liver,,Intrinsic clearance in human liver microsomes,5007,A,In vitro,Homo sapiens,9606.0,,,Microsomes
5640,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
5641,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
5642,Intermediate,50588,,,Clearance in dog (dose 1 mg/kg i.v.),16452,A,In vivo,Canis lupus familiaris,9615.0,,,
5643,Intermediate,50588,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,6221,A,In vivo,Canis lupus familiaris,9615.0,,,
5644,Intermediate,50588,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,A,In vivo,Canis lupus familiaris,9615.0,,,
5645,Intermediate,50588,,,Plasma clearance after peroral administration at 10 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5646,Intermediate,50588,,,Plasma clearance after peroral administration at 5 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5647,Intermediate,50588,,,Plasma clearance after peroral administration at 5 mg/kg in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5648,Intermediate,50588,,,Plasma clearance was measured in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
5649,Intermediate,50588,,,Plasma clearance was measured in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
5650,Intermediate,50588,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,5983,A,In vivo,Canis lupus familiaris,9615.0,,,
5651,Intermediate,50588,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,5600,A,In vivo,Canis lupus familiaris,9615.0,,,
5652,Intermediate,50588,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
5653,Intermediate,50588,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
5654,Intermediate,50588,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
5655,Intermediate,50588,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
5656,Intermediate,50588,,,Clearance by intravenous administration of 1.2 mg/kg in dog,4368,A,In vivo,Canis lupus familiaris,9615.0,,,
5657,Intermediate,50588,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,4305,A,In vivo,Canis lupus familiaris,9615.0,,,
5658,Intermediate,50588,Plasma,,Clearance value was evaluated in dog plasma,1918,A,In vivo,Canis lupus familiaris,9615.0,,,
5659,Intermediate,50588,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,6005,A,In vivo,Canis lupus familiaris,9615.0,,,
5660,Intermediate,50588,Plasma,,Compound was tested for plasma clearance in dog,4839,A,In vivo,Canis lupus familiaris,9615.0,,,
5661,Intermediate,50588,,,Pharmacokinetic property (Plasma clearance) was measured in dog,4239,A,In vivo,Canis lupus familiaris,9615.0,,,
5662,Intermediate,50594,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,17729,A,,Mus musculus,10090.0,,,
5663,Intermediate,50594,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,17728,A,,Mus musculus,10090.0,,,
5664,Intermediate,50594,,,Area under curve value in mouse at a dose of 10 mg/kg,5302,A,,Mus musculus,10090.0,,,
5665,Intermediate,50594,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,A,,Mus musculus,10090.0,,,
5666,Intermediate,50594,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,A,,Mus musculus,10090.0,,,
5667,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,17764,F,,Mus musculus,10090.0,,,
5668,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,17764,F,,Mus musculus,10090.0,,,
5669,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,17764,F,,Mus musculus,10090.0,,,
5670,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,17764,F,,Mus musculus,10090.0,,,
5671,Intermediate,50594,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,17764,A,,Mus musculus,10090.0,,,
5672,Intermediate,50594,,,Area under curve was determined for the compound at 24 mg/Kg,17753,A,,Mus musculus,10090.0,,,
5673,Intermediate,50594,,,Area under curve was determined for the compound at 40 mg/Kg,17753,A,,Mus musculus,10090.0,,,
5674,Intermediate,50594,,,Area under curve was determined for the compound at 5 mg/Kg,17753,A,,Mus musculus,10090.0,,,
5675,Intermediate,50594,,,Area under the curve for the compound is obtained at dose 25 mg/kg,3132,A,,Mus musculus,10090.0,,,
5676,Intermediate,50594,,,Area under the curve for the compound was obtained when tested in mouse,3132,A,,Mus musculus,10090.0,,,
5677,Intermediate,50594,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,17837,A,,Mus musculus,10090.0,,,
5678,Intermediate,50594,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,17837,A,,Mus musculus,10090.0,,,
5679,Intermediate,50594,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,6062,A,,Mus musculus,10090.0,,,
5680,Intermediate,50594,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,4066,A,,Mus musculus,10090.0,,,
5681,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),16597,A,,Mus musculus,10090.0,,,
5682,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,14239,A,,Mus musculus,10090.0,,,
5683,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,14239,A,,Mus musculus,10090.0,,,
5684,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",4890,A,,Mus musculus,10090.0,,,
5685,Intermediate,50594,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),429,A,,Mus musculus,10090.0,,,
5686,Intermediate,50594,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),429,A,,Mus musculus,10090.0,,,
5687,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,5969,A,,Mus musculus,10090.0,,,
5688,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,5969,A,,Mus musculus,10090.0,,,
5689,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,A,,Mus musculus,10090.0,,,
5690,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,6091,A,,Mus musculus,10090.0,,,
5691,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,6091,A,,Mus musculus,10090.0,,,
5692,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,6091,A,,Mus musculus,10090.0,,,
5693,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,6091,A,,Mus musculus,10090.0,,,
5694,Intermediate,50594,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,6178,A,,Mus musculus,10090.0,,,
5695,Intermediate,50594,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,6178,A,,Mus musculus,10090.0,,,
5696,Intermediate,50594,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",6619,A,,Mus musculus,10090.0,,,
5697,Intermediate,50594,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",6619,A,,Mus musculus,10090.0,,,
5698,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",3760,A,,Mus musculus,10090.0,,,
5699,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",3760,A,,Mus musculus,10090.0,,,
5700,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",3760,A,,Mus musculus,10090.0,,,
5701,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",3760,A,,Mus musculus,10090.0,,,
5702,Intermediate,50594,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,3192,A,,Mus musculus,10090.0,,,
5703,Intermediate,50594,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,3192,A,,Mus musculus,10090.0,,,
5704,Intermediate,50594,,,Area under the curve was evaluated in mice after intravenous administration,2675,A,,Mus musculus,10090.0,,,
5705,Intermediate,50594,,,Area under the curve was evaluated in mice after oral administration,2675,A,,Mus musculus,10090.0,,,
5706,Intermediate,50594,Plasma,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,16597,A,,Mus musculus,10090.0,,,
5707,Intermediate,50594,Plasma,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,16597,A,,Mus musculus,10090.0,,,
5708,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),16597,A,,Mus musculus,10090.0,,,
5709,Intermediate,50594,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,17734,A,,Mus musculus,10090.0,,,
5710,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5711,Intermediate,80653,,,The compound was tested in vitro for anticancer activity against 9L cells,15345,F,,,,,9L,
5712,Autocuration,22226,,,Anti proliferation activity determined; Weak effect,2181,F,,Rattus norvegicus,10116.0,,,
5713,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,2181,F,,Rattus norvegicus,10116.0,,,
5714,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,2181,F,,Rattus norvegicus,10116.0,,,
5715,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,2181,F,,Rattus norvegicus,10116.0,,,
5716,Autocuration,22226,,,The cytotoxic activity was in vitro tested by 9PS assay method,10486,F,,Mus musculus,10090.0,,,
5717,Autocuration,22226,,,The cytotoxic activity was in vitro tested by 9PS assay method.,10486,F,,Mus musculus,10090.0,,,
5718,Autocuration,22224,,,Partition coefficient (logD6.5),15508,A,,,,,,
5719,Expert,81034,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,5242,F,,Homo sapiens,9606.0,,A2780,
5720,Intermediate,80018,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),16167,F,,Homo sapiens,9606.0,,A-375,
5721,Expert,80852,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,4782,F,,Homo sapiens,9606.0,,A-431,
5722,Expert,9,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,16093,F,,Homo sapiens,9606.0,,A-431,
5723,Intermediate,80021,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,2596,F,,Homo sapiens,9606.0,,A498,
5724,Intermediate,80021,,,in vitro cytotoxicity against A 498 cancer cell line,2596,F,,Homo sapiens,9606.0,,A498,
5725,Intermediate,80021,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,3239,F,,Homo sapiens,9606.0,,A498,
5726,Intermediate,80021,,,Cytotoxic activity against A 498 renal cancer cell lines.,1847,F,,Homo sapiens,9606.0,,A498,
5727,Intermediate,80021,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,10553,F,,Homo sapiens,9606.0,,A498,
5728,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,16219,F,,Staphylococcus aureus,1280.0,,,
5729,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,16219,F,,Staphylococcus aureus,1280.0,,,
5730,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,16219,F,,Staphylococcus aureus,1280.0,,,
5731,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,16219,F,,Staphylococcus aureus,1280.0,,,
5732,Intermediate,80682,,,Inhibitory concentration required against A 549 lung cancer cell line,4782,F,,Homo sapiens,9606.0,,A549,
5733,Intermediate,80682,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,11805,F,,Homo sapiens,9606.0,,A549,
5734,Intermediate,80682,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,11805,F,,Homo sapiens,9606.0,,A549,
5735,Intermediate,80682,,,In vitro cytotoxicity against lung cancer A 549 cell lines,2007,F,,Homo sapiens,9606.0,,A549,
5736,Intermediate,80682,,,Compound was tested for its cytotoxicity against A 549 cell line,4594,F,,Homo sapiens,9606.0,,A549,
5737,Expert,80682,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",6018,F,,Homo sapiens,9606.0,,A549,
5738,Intermediate,80682,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",6018,F,,Homo sapiens,9606.0,,A549,
5739,Expert,80682,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,3599,F,,Homo sapiens,9606.0,,A549,
5740,Intermediate,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,2551,F,,Homo sapiens,9606.0,,A549,
5741,Expert,80682,,,In vitro inhibition of A549 (human lung cancer) cell growth.,16132,F,,Homo sapiens,9606.0,,A549,
5742,Intermediate,80682,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,16132,F,,Homo sapiens,9606.0,,A549,
5743,Expert,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,2551,F,,Homo sapiens,9606.0,,A549,
5744,Expert,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),2551,F,,Homo sapiens,9606.0,,A549,
5745,Autocuration,22226,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,11913,F,,,,,,
5746,Autocuration,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,12621,F,In vivo,,,,,
5747,Autocuration,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,12621,F,In vivo,,,,,
5748,Autocuration,104694,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,12621,F,In vivo,,,,,
5749,Autocuration,104694,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,12621,F,In vivo,,,,,
5750,Autocuration,104694,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,12621,F,In vivo,,,,,
5751,Expert,80021,,,Inhibition of A-498 human Renal cell proliferation,3600,F,,Homo sapiens,9606.0,,A498,
5752,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1796,F,,Rattus norvegicus,10116.0,,,
5753,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1796,F,,Rattus norvegicus,10116.0,,,
5754,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1796,F,,Rattus norvegicus,10116.0,,,
5755,Expert,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,16464,F,,Homo sapiens,9606.0,,A 172,
5756,Intermediate,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A 172,
5757,Intermediate,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A 172,
5758,Expert,80682,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,13617,F,,Homo sapiens,9606.0,,A549,
5759,Intermediate,80682,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,4584,F,,Homo sapiens,9606.0,,A549,
5760,Expert,80682,,,Cytotoxic activity evaluated against A549 tumor cells,13799,F,,Homo sapiens,9606.0,,A549,
5761,Intermediate,80682,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,16726,F,,Homo sapiens,9606.0,,A549,
5762,Intermediate,80682,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,16109,F,,Homo sapiens,9606.0,,A549,
5763,Intermediate,80682,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,16109,F,,Homo sapiens,9606.0,,A549,
5764,Intermediate,80682,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,15474,F,,Homo sapiens,9606.0,,A549,
5765,Intermediate,80682,,,Cytotoxicity of compound against A549 cell line,6851,F,,Homo sapiens,9606.0,,A549,
5766,Expert,80682,,,Cytotoxicity against human lung cell carcinoma A549 cell line,17534,F,,Homo sapiens,9606.0,,A549,
5767,Intermediate,80682,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,2621,F,,Homo sapiens,9606.0,,A549,
5768,Intermediate,80682,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,830,F,,Homo sapiens,9606.0,,A549,
5769,Intermediate,80682,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,14255,F,,Homo sapiens,9606.0,,A549,
5770,Intermediate,80682,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,14255,F,,Homo sapiens,9606.0,,A549,
5771,Intermediate,80682,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1590,F,,Homo sapiens,9606.0,,A549,
5772,Expert,80682,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,6146,F,,Homo sapiens,9606.0,,A549,
5773,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,17427,F,,Homo sapiens,9606.0,,A549,
5774,Intermediate,80682,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,5280,F,,Homo sapiens,9606.0,,A549,
5775,Intermediate,80682,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,16786,F,,Homo sapiens,9606.0,,A549,
5776,Intermediate,80682,,,In vitro cytotoxicity against A549 (human lung cancer),5895,F,,Homo sapiens,9606.0,,A549,
5777,Expert,80682,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,14297,F,,Homo sapiens,9606.0,,A549,
5778,Intermediate,80682,,,In vivo antiproliferative activity against A549 cell line,17824,F,,Homo sapiens,9606.0,,A549,
5779,Intermediate,80682,,,Inhibition of non-small-cell lung adenocarcinoma (A549),14368,F,,Homo sapiens,9606.0,,A549,
5780,Intermediate,80682,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,14368,F,,Homo sapiens,9606.0,,A549,
5781,Intermediate,80682,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,14254,F,,Homo sapiens,9606.0,,A549,
5782,Intermediate,80682,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),15897,F,,Homo sapiens,9606.0,,A549,
5783,Intermediate,80682,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,13866,F,,Homo sapiens,9606.0,,A549,
5784,Intermediate,80682,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,13370,F,,Homo sapiens,9606.0,,A549,
5785,Intermediate,80682,,,Inhibitory activity against A549 lung cancer cell line,4862,F,,Homo sapiens,9606.0,,A549,
5786,Intermediate,80682,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,4862,F,,Homo sapiens,9606.0,,A549,
5787,Intermediate,80682,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,4862,F,,Homo sapiens,9606.0,,A549,
5788,Intermediate,80682,,,Inhibitory concentration against A549 (lung cancer) cell line,15970,F,,Homo sapiens,9606.0,,A549,
5789,Expert,80682,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,17713,F,,Homo sapiens,9606.0,,A549,
5790,Intermediate,80682,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,4833,F,,Homo sapiens,9606.0,,A549,
5791,Expert,80682,,,Activity against A549 cancer cell line.,13736,F,,Homo sapiens,9606.0,,A549,
5792,Intermediate,80682,,,The compound was evaluated for cytotoxicity against A549 cell line,4312,F,,Homo sapiens,9606.0,,A549,
5793,Intermediate,80682,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,5421,F,,Homo sapiens,9606.0,,A549,
5794,Intermediate,80682,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,5421,F,,Homo sapiens,9606.0,,A549,
5795,Intermediate,80682,,,Growth inhibitory activity was measured for human A549 tumor cell line.,14717,F,,Homo sapiens,9606.0,,A549,
5796,Intermediate,80682,,,Inhibitory activity against A549 lung cancer cell line,4634,F,,Homo sapiens,9606.0,,A549,
5797,Intermediate,80682,,,Inhibitory activity against A549 cell line; inactive,1149,F,,Homo sapiens,9606.0,,A549,
5798,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,5421,F,,Homo sapiens,9606.0,,A549,
5799,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,5421,F,,Homo sapiens,9606.0,,A549,
5800,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,5421,F,,Homo sapiens,9606.0,,A549,
5801,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),3320,F,,Homo sapiens,9606.0,,A549,
5802,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),3320,F,,Homo sapiens,9606.0,,A549,
5803,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),3320,F,,Homo sapiens,9606.0,,A549,
5804,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),3320,F,,Homo sapiens,9606.0,,A549,
5805,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),3320,F,,Homo sapiens,9606.0,,A549,
5806,Intermediate,80682,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,5726,F,,Homo sapiens,9606.0,,A549,
5807,Intermediate,50588,,,Plasma clearance (in vivo) in mongrel dogs was determined,17800,A,In vivo,Canis lupus familiaris,9615.0,,,
5808,Intermediate,50588,,,Plasma clearance was measured in dog,5985,A,In vivo,Canis lupus familiaris,9615.0,,,
5809,Intermediate,50588,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,5530,A,In vivo,Canis lupus familiaris,9615.0,,,
5810,Intermediate,50588,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,5530,A,In vivo,Canis lupus familiaris,9615.0,,,
5811,Intermediate,50588,Plasma,,Tested for plasma clearance in dog,4839,A,In vivo,Canis lupus familiaris,9615.0,,,
5812,Intermediate,50588,,,The compound was tested for clearance in dog plasma.,3639,A,In vivo,Canis lupus familiaris,9615.0,,,
5813,Intermediate,50588,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",4838,A,In vivo,Canis lupus familiaris,9615.0,,,
5814,Intermediate,50588,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,4137,A,In vivo,Canis lupus familiaris,9615.0,,,
5815,Intermediate,50588,Plasma,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),5017,A,In vivo,Canis lupus familiaris,9615.0,,,
5816,Intermediate,50588,Liver,,In vitro clearance in dog liver microsomes,17538,A,In vitro,Canis lupus familiaris,9615.0,,,Microsomes
5817,Intermediate,50588,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,6161,A,In vivo,Canis lupus familiaris,9615.0,,,
5818,Intermediate,50588,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,6161,A,In vivo,Canis lupus familiaris,9615.0,,,
5819,Intermediate,50588,,,Plasma clearance in dog,1696,A,In vivo,Canis lupus familiaris,9615.0,,,
5820,Intermediate,50588,,,Clearance rate in dog,6762,A,In vivo,Canis lupus familiaris,9615.0,,,
5821,Intermediate,50588,Plasma,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,5932,A,In vivo,Canis lupus familiaris,9615.0,,,
5822,Intermediate,50588,,,Clearance in dogs,6305,A,In vivo,Canis lupus familiaris,9615.0,,,
5823,Intermediate,50588,,,Plasma clearance in dogs,4942,A,In vivo,Canis lupus familiaris,9615.0,,,
5824,Intermediate,50588,,,Plasma clearance was determined,4219,A,In vivo,Canis lupus familiaris,9615.0,,,
5825,Intermediate,50588,,,Lower clearance in dog (i.v.) at 0.5 mpk,17853,A,In vivo,Canis lupus familiaris,9615.0,,,
5826,Intermediate,50588,,,Plasma clearance in Beagle dogs,4514,A,In vivo,Canis lupus familiaris,9615.0,,,
5827,Intermediate,50588,,,Plasma clearance (Clp) in dog,6448,A,In vivo,Canis lupus familiaris,9615.0,,,
5828,Intermediate,50588,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
5829,Intermediate,50588,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
5830,Intermediate,50588,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,6062,A,In vivo,Canis lupus familiaris,9615.0,,,
5831,Intermediate,50588,,,Plasma clearance of compound was determined in dog,6821,A,In vivo,Canis lupus familiaris,9615.0,,,
5832,Intermediate,50588,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,4709,A,In vivo,Canis lupus familiaris,9615.0,,,
5833,Intermediate,50588,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
5834,Intermediate,50588,,,Plasma clearance in dog was determined,5374,A,In vivo,Canis lupus familiaris,9615.0,,,
5835,Intermediate,50588,,,Plasma clearance was calculated in dog,6057,A,In vivo,Canis lupus familiaris,9615.0,,,
5836,Intermediate,50588,,,Plasma clearance at the dose of 2 mg/kg in dog,4727,A,In vivo,Canis lupus familiaris,9615.0,,,
5837,Intermediate,50588,,,Plasma clearance in dog,5145,A,In vivo,Canis lupus familiaris,9615.0,,,
5838,Intermediate,50588,,,Plasma clearance in dog,17657,A,In vivo,Canis lupus familiaris,9615.0,,,
5839,Intermediate,50588,,,Plasma clearance in dog; Unable to calculate,17657,A,In vivo,Canis lupus familiaris,9615.0,,,
5840,Intermediate,50588,,,Plasma clearance in rhesus monkey,5145,A,In vivo,Canis lupus familiaris,9615.0,,,
5841,Intermediate,50588,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
5842,Intermediate,50588,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Canis lupus familiaris,9615.0,,,
5843,Intermediate,50588,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
5844,Intermediate,50588,,,Plasma clearance was evaluated in dog,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
5845,Intermediate,50588,,,Plasma clearance was evaluated in dog; Not tested,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
5846,Intermediate,50588,,,Plasma clearance was evaluated in rhesus,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
5847,Intermediate,50588,,,Plasma clearance was evaluated in rhesus; Not tested,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
5848,Intermediate,50588,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,4257,A,In vivo,Canis lupus familiaris,9615.0,,,
5849,Intermediate,50588,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Canis lupus familiaris,9615.0,,,
5850,Intermediate,50588,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Canis lupus familiaris,9615.0,,,
5851,Intermediate,50588,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
5852,Intermediate,50588,,,Clearance value at a dose of 0.2 mg/kg i.v.,5474,A,In vivo,Canis lupus familiaris,9615.0,,,
5853,Intermediate,50588,Plasma,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,6316,A,In vivo,Canis lupus familiaris,9615.0,,,
5854,Intermediate,50588,,,Cmax after oral dose of compound at 3 mg/kg in dogs,17594,A,In vivo,Canis lupus familiaris,9615.0,,,
5855,Intermediate,50588,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,17594,A,In vivo,Canis lupus familiaris,9615.0,,,
5856,Intermediate,50588,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,A,In vivo,Canis lupus familiaris,9615.0,,,
5857,Intermediate,50588,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
5858,Intermediate,50588,,,Cmax in dog after administration of 1 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
5859,Intermediate,50588,Plasma,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
5860,Intermediate,50588,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,6505,A,In vivo,Canis lupus familiaris,9615.0,,,
5861,Intermediate,50588,,,Cmax was determine after peroral administration at 10 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5862,Intermediate,50588,,,Cmax was determine after peroral administration at 5 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5863,Intermediate,50588,,,Cmax was determine after peroral administration at 5 mg/kg in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
5864,Intermediate,50588,,,Cmax after 0.3 mg/kg po administration in dog,5600,A,In vivo,Canis lupus familiaris,9615.0,,,
5865,Intermediate,50588,,,Cmax after peroral administration in dogs at 2.4 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
5866,Intermediate,50588,,,Cmax in dog after oral administration at 1 mg/kg,6123,A,In vivo,Canis lupus familiaris,9615.0,,,
5867,Intermediate,50588,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,6123,A,In vivo,Canis lupus familiaris,9615.0,,,
5868,Intermediate,50588,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,6757,A,In vivo,Canis lupus familiaris,9615.0,,,
5869,Intermediate,50588,,,Cmax value after 15 mg/kg iv dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
5870,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5871,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5872,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5873,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5874,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5875,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5876,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5877,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5878,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5879,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5880,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5881,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5882,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5883,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5884,Intermediate,50594,Intestine,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5885,Intermediate,50594,Intestine,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5886,Intermediate,50594,Intestine,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5887,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5888,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5889,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5890,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5891,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5892,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5893,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5894,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5895,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5896,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5897,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5898,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5899,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5900,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5901,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5902,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5903,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5904,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5905,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5906,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
5907,Expert,80012,,,Cytotoxicity against A-172 human tumor cell lines,2036,F,,Homo sapiens,9606.0,,A 172,
5908,Intermediate,80012,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,2357,F,,Homo sapiens,9606.0,,A 172,
5909,Intermediate,80014,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1457,F,,Homo sapiens,9606.0,,A204,
5910,Intermediate,81034,,,Tested for antiproliferative activity against A-2780 tumoral cell line,4379,F,,Homo sapiens,9606.0,,A2780,
5911,Intermediate,80018,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1093,F,,Homo sapiens,9606.0,,A-375,
5912,Intermediate,80018,,,Tested in vitro against A-375 cell line human melanoma,12152,F,,Homo sapiens,9606.0,,A-375,
5913,Expert,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,16464,F,,Homo sapiens,9606.0,,A-427,
5914,Intermediate,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A-427,
5915,Expert,80019,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,16582,F,,Homo sapiens,9606.0,,A-427,
5916,Intermediate,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,16464,F,,Homo sapiens,9606.0,,A-427,
5917,Intermediate,80019,,,Antitumor activity on A-427 lung carcinoma cell lines,10413,F,,Homo sapiens,9606.0,,A-427,
5918,Intermediate,80019,,,Cytotoxic activity against human A-427 lung tumor cell line,6418,F,,Homo sapiens,9606.0,,A-427,
5919,Expert,80019,,,In vitro antitumor effects against human A-427 cell lines.,17134,F,,Homo sapiens,9606.0,,A-427,
5920,Expert,80019,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,16132,F,,Homo sapiens,9606.0,,A-427,
5921,Intermediate,80019,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,16132,F,,Homo sapiens,9606.0,,A-427,
5922,Intermediate,80019,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,16780,F,,Homo sapiens,9606.0,,A-427,
5923,Expert,80852,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,4085,F,,Homo sapiens,9606.0,,A-431,
5924,Intermediate,80021,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1276,F,,Homo sapiens,9606.0,,A498,
5925,Expert,80021,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,3498,F,,Homo sapiens,9606.0,,A498,
5926,Intermediate,80021,,,Cytotoxicity against human kidney carcinoma A-498cell lines,1169,F,,Homo sapiens,9606.0,,A498,
5927,Intermediate,80021,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,4450,F,,Homo sapiens,9606.0,,A498,
5928,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,3311,F,,Homo sapiens,9606.0,,A498,
5929,Intermediate,80021,,,Antitumor cytotoxic activity against A-498 cell line was determined,4461,F,,Homo sapiens,9606.0,,A498,
5930,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,3311,F,,Homo sapiens,9606.0,,A498,
5931,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,3311,F,,Homo sapiens,9606.0,,A498,
5932,Intermediate,80021,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1457,F,,Homo sapiens,9606.0,,A498,
5933,Intermediate,80021,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,3664,F,,Homo sapiens,9606.0,,A498,
5934,Intermediate,80021,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",15895,F,,Homo sapiens,9606.0,,A498,
5935,Intermediate,80682,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,11843,F,,Homo sapiens,9606.0,,A549,
5936,Intermediate,80682,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,11843,F,,Homo sapiens,9606.0,,A549,
5937,Intermediate,80682,,,In vitro antiproliferative activity against human A-549 NSCL cell line,17705,F,,Homo sapiens,9606.0,,A549,
5938,Intermediate,80682,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,17705,F,,Homo sapiens,9606.0,,A549,
5939,Intermediate,80682,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,4369,F,,Homo sapiens,9606.0,,A549,
5940,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,4369,F,,Homo sapiens,9606.0,,A549,
5941,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,4369,F,,Homo sapiens,9606.0,,A549,
5942,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,4369,F,,Homo sapiens,9606.0,,A549,
5943,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,4369,F,,Homo sapiens,9606.0,,A549,
5944,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,4369,F,,Homo sapiens,9606.0,,A549,
5945,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,4369,F,,Homo sapiens,9606.0,,A549,
5946,Expert,80682,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,4787,F,,Homo sapiens,9606.0,,A549,
5947,Intermediate,80682,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,4787,F,,Homo sapiens,9606.0,,A549,
5948,Intermediate,80682,,,Cytotoxic activity against A-549 cell line,6513,F,,Homo sapiens,9606.0,,A549,
5949,Intermediate,80682,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,6690,F,,Homo sapiens,9606.0,,A549,
5950,Intermediate,80682,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,6690,F,,Homo sapiens,9606.0,,A549,
5951,Expert,80682,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",12263,F,,Homo sapiens,9606.0,,A549,
5952,Intermediate,80682,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1054,F,,Homo sapiens,9606.0,,A549,
5953,Intermediate,80682,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1359,F,,Homo sapiens,9606.0,,A549,
5954,Intermediate,80682,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,3547,F,,Homo sapiens,9606.0,,A549,
5955,Expert,80682,,,Cytotoxic activity towards A-549 cells,5771,F,,Homo sapiens,9606.0,,A549,
5956,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.",14425,F,,Homo sapiens,9606.0,,A549,
5957,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma",14425,F,,Homo sapiens,9606.0,,A549,
5958,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.",14425,F,,Homo sapiens,9606.0,,A549,
5959,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",14425,F,,Homo sapiens,9606.0,,A549,
5960,Intermediate,80682,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,5280,F,,Homo sapiens,9606.0,,A549,
5961,Intermediate,80682,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,15176,F,,Homo sapiens,9606.0,,A549,
5962,Intermediate,80682,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,15300,F,,Homo sapiens,9606.0,,A549,
5963,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,F,,Homo sapiens,9606.0,,A549,
5964,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,F,,Homo sapiens,9606.0,,A549,
5965,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,F,,Homo sapiens,9606.0,,A549,
5966,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,F,,Homo sapiens,9606.0,,A549,
5967,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",17824,F,,Homo sapiens,9606.0,,A549,
5968,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",17824,F,,Homo sapiens,9606.0,,A549,
5969,Intermediate,80682,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),17528,F,,Homo sapiens,9606.0,,A549,
5970,Expert,80682,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,6870,F,,Homo sapiens,9606.0,,A549,
5971,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,6870,F,,Homo sapiens,9606.0,,A549,
5972,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,6870,F,,Homo sapiens,9606.0,,A549,
5973,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,6870,F,,Homo sapiens,9606.0,,A549,
5974,Intermediate,80682,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,16726,F,,Homo sapiens,9606.0,,A549,
5975,Intermediate,80682,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",6170,F,,Homo sapiens,9606.0,,A549,
5976,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,6583,F,,Homo sapiens,9606.0,,A549,
5977,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,6583,F,,Homo sapiens,9606.0,,A549,
5978,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,6583,F,,Homo sapiens,9606.0,,A549,
5979,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,6583,F,,Homo sapiens,9606.0,,A549,
5980,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,6583,F,,Homo sapiens,9606.0,,A549,
5981,Intermediate,80682,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,17321,F,,Homo sapiens,9606.0,,A549,
5982,Expert,80682,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,17528,F,,Homo sapiens,9606.0,,A549,
5983,Expert,80682,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,12888,F,,Homo sapiens,9606.0,,A549,
5984,Intermediate,80682,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,4312,F,,Homo sapiens,9606.0,,A549,
5985,Intermediate,80682,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,4312,F,,Homo sapiens,9606.0,,A549,
5986,Intermediate,80682,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,4312,F,,Homo sapiens,9606.0,,A549,
5987,Intermediate,80682,,,In vitro antiproliferative activity against A549 cell line,17737,F,,Mus musculus,10090.0,,A549,
5988,Intermediate,80682,,,Synergism with indomethacin in A549 cells,6630,F,,,,,A549,
5989,Intermediate,80682,,,Synergism with tolmetin in A549 cells,6630,F,,,,,A549,
5990,Intermediate,80682,,,Synergism with sulindac in A549 cells,6630,F,,,,,A549,
5991,Intermediate,80682,,,Antagonism of indomethacin in A549 cells,6630,F,,,,,A549,
5992,Intermediate,80682,,,Antagonism of sulindac in A549 cells,6630,F,,,,,A549,
5993,Intermediate,80682,,,Antagonism of tolmetin in A549 cells,6630,F,,,,,A549,
5994,Intermediate,80682,,,Synergism with indomethacin in A549 cells,6630,F,,,,,A549,
5995,Intermediate,80682,,,Synergism with sulindac in A549 cells,6630,F,,,,,A549,
5996,Intermediate,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,6630,F,,,,,A549,
5997,Intermediate,50588,,,Cmax value after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
5998,Intermediate,50588,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),5944,A,In vivo,Canis lupus familiaris,9615.0,,,
5999,Intermediate,50588,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,5944,A,In vivo,Canis lupus familiaris,9615.0,,,
6000,Intermediate,50588,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),5944,A,In vivo,Canis lupus familiaris,9615.0,,,
6001,Intermediate,50588,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,5944,A,In vivo,Canis lupus familiaris,9615.0,,,
6002,Intermediate,50588,,,Cmax value after administration of 4 mg/Kg oral dose in dog,2959,A,In vivo,Canis lupus familiaris,9615.0,,,
6003,Intermediate,50588,,,Cmax value in dog,6241,A,In vivo,Canis lupus familiaris,9615.0,,,
6004,Intermediate,50588,,,Cmax value in dogs after oral administration at 1 mg/kg,6241,A,In vivo,Canis lupus familiaris,9615.0,,,
6005,Intermediate,50588,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,2652,A,In vivo,Canis lupus familiaris,9615.0,,,
6006,Intermediate,50588,Plasma,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1806,A,In vivo,Canis lupus familiaris,9615.0,,,
6007,Intermediate,50588,Plasma,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1806,A,In vivo,Canis lupus familiaris,9615.0,,,
6008,Intermediate,50588,,,Concentration maxima after oral dosing in dogs,1021,A,In vivo,Canis lupus familiaris,9615.0,,,
6009,Intermediate,50588,,,Concentration maxima after oral dosing in dogs; not available,1021,A,In vivo,Canis lupus familiaris,9615.0,,,
6010,Intermediate,50588,,,Concentration maxima after oral dosing in dogs; not available,1021,A,In vivo,Canis lupus familiaris,9615.0,,,
6011,Intermediate,50588,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
6012,Intermediate,50588,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
6013,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
6014,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
6015,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
6016,Intermediate,50588,Plasma,,Cmax in dog plasma after oral dose (1 mg/kg),5130,A,In vivo,Canis lupus familiaris,9615.0,,,
6017,Intermediate,50588,Plasma,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,3249,A,In vivo,Canis lupus familiaris,9615.0,,,
6018,Intermediate,50588,Plasma,,Maximal plasma concentration at a dose of 1 mg/kg,5473,A,In vivo,Canis lupus familiaris,9615.0,,,
6019,Intermediate,50588,Plasma,,Maximal plasma concentration at a dose of 1 mg/kg (oral),5474,A,In vivo,Canis lupus familiaris,9615.0,,,
6020,Intermediate,50588,Plasma,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,4657,A,In vivo,Canis lupus familiaris,9615.0,,,
6021,Intermediate,50588,,,Maximum concentration of compound in dog was evaluated.,3031,A,In vivo,Canis lupus familiaris,9615.0,,,
6022,Intermediate,50588,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,4527,A,In vivo,Canis lupus familiaris,9615.0,,,
6023,Intermediate,50588,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,4186,A,In vivo,Canis lupus familiaris,9615.0,,,
6024,Intermediate,50588,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,A,In vivo,Canis lupus familiaris,9615.0,,,
6025,Intermediate,50588,Plasma,,Maximum concentration obtained in dog plasma was determined,3132,A,In vivo,Canis lupus familiaris,9615.0,,,
6026,Intermediate,50588,,,Maximum concentration was determined,5006,A,In vivo,Canis lupus familiaris,9615.0,,,
6027,Intermediate,50588,,,Maximum concentration at the dose of 2 mg/kg in dog,4727,A,In vivo,Canis lupus familiaris,9615.0,,,
6028,Intermediate,50588,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,A,In vivo,Canis lupus familiaris,9615.0,,,
6029,Intermediate,50588,Plasma,,Maximum concentration was evaluated in dog plasma,1918,A,In vivo,Canis lupus familiaris,9615.0,,,
6030,Intermediate,50588,,,Maximum concentration was evaluated after 75 min after administration in dog,3045,A,In vivo,Canis lupus familiaris,9615.0,,,
6031,Intermediate,50588,Plasma,,Maximum plasma concentration determined in dog after oral administration of 17b,9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6032,Intermediate,50588,Plasma,,Maximum plasma concentration determined in dog after oral administration of 2b,9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6033,Intermediate,50588,Plasma,,Maximum plasma concentration in dog,933,A,In vivo,Canis lupus familiaris,9615.0,,,
6034,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6035,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6036,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6037,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6038,Intermediate,50588,Plasma,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
6039,Intermediate,50588,Plasma,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,16367,A,In vivo,Canis lupus familiaris,9615.0,,,
6040,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
6041,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
6042,Intermediate,50588,Plasma,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
6043,Intermediate,50588,Plasma,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,17650,A,In vivo,Canis lupus familiaris,9615.0,,,
6044,Intermediate,50588,Plasma,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,6679,A,In vivo,Canis lupus familiaris,9615.0,,,
6045,Intermediate,50588,Plasma,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,5356,A,In vivo,Canis lupus familiaris,9615.0,,,
6046,Intermediate,50588,Plasma,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,5356,A,In vivo,Canis lupus familiaris,9615.0,,,
6047,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6048,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6049,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6050,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6051,Expert,50588,Plasma,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Canis lupus familiaris,9615.0,,,
6052,Intermediate,50588,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,4368,A,In vivo,Canis lupus familiaris,9615.0,,,
6053,Intermediate,50588,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,6265,A,In vivo,Canis lupus familiaris,9615.0,,,
6054,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
6055,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,7767,A,In vivo,Mus musculus,10090.0,,,
6056,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,7767,A,In vivo,Mus musculus,10090.0,,,
6057,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,7767,A,In vivo,Mus musculus,10090.0,,,
6058,Intermediate,50594,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,17811,A,,Mus musculus,10090.0,,,
6059,Intermediate,50594,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,17811,A,,Mus musculus,10090.0,,,
6060,Intermediate,50594,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6061,Intermediate,50594,Blood,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6062,Intermediate,50594,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6063,Intermediate,50594,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6064,Intermediate,50594,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6065,Intermediate,50594,Blood,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6066,Intermediate,50594,Blood,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6067,Intermediate,50594,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6068,Intermediate,50594,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,17827,A,,Mus musculus,10090.0,,,
6069,Intermediate,50594,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,A,,Mus musculus,10090.0,,,
6070,Intermediate,50594,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,A,,Mus musculus,10090.0,,,
6071,Intermediate,50594,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",17827,A,,Mus musculus,10090.0,,,
6072,Intermediate,50594,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,17257,A,,Mus musculus,10090.0,,,
6073,Intermediate,50594,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,17257,A,,Mus musculus,10090.0,,,
6074,Intermediate,50594,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,17257,A,,Mus musculus,10090.0,,,
6075,Intermediate,50594,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,17257,A,,Mus musculus,10090.0,,,
6076,Intermediate,50594,,,Time at maximum activity in mice (Radiolabeled compound),17827,A,,Mus musculus,10090.0,,,
6077,Intermediate,50594,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,3760,A,,Mus musculus,10090.0,,,
6078,Intermediate,50594,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,3760,A,,Mus musculus,10090.0,,,
6079,Intermediate,50594,,,Binding towards mouse plasma protein at 10 uM,17409,A,,Mus musculus,10090.0,,,
6080,Intermediate,50594,,,Binding towards mouse plasma protein at 100 uM,17409,A,,Mus musculus,10090.0,,,
6081,Intermediate,50594,,,Bioavailability was evaluated in mice after intravenous administration,2675,A,In vivo,Mus musculus,10090.0,,,
6082,Intermediate,50594,,,Bioavailability was evaluated in mice after oral administration,2675,A,In vivo,Mus musculus,10090.0,,,
6083,Intermediate,50594,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,3132,A,In vivo,Mus musculus,10090.0,,,
6084,Intermediate,50594,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,3132,A,In vivo,Mus musculus,10090.0,,,
6085,Intermediate,50594,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
6086,Intermediate,50594,,,Oral bioavailability in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
6087,Intermediate,50594,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
6088,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6089,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6090,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6091,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6092,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6093,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6094,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6095,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6096,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6097,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6098,Intermediate,80682,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1276,F,,Homo sapiens,9606.0,,A549,
6099,Expert,80682,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,3498,F,,Homo sapiens,9606.0,,A549,
6100,Intermediate,80682,,,Cytotoxicity against human lung carcinoma A-549 cell lines,1169,F,,Homo sapiens,9606.0,,A549,
6101,Intermediate,80682,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,4450,F,,Homo sapiens,9606.0,,A549,
6102,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,358,F,,Homo sapiens,9606.0,,A549,
6103,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,358,F,,Homo sapiens,9606.0,,A549,
6104,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,358,F,,Homo sapiens,9606.0,,A549,
6105,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,358,F,,Homo sapiens,9606.0,,A549,
6106,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,358,F,,Homo sapiens,9606.0,,A549,
6107,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,358,F,,Homo sapiens,9606.0,,A549,
6108,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,358,F,,Homo sapiens,9606.0,,A549,
6109,Intermediate,80682,,,In vitro cytotoxicity against A-549 human lung cancer cells,15167,F,,Homo sapiens,9606.0,,A549,
6110,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,4139,F,,Homo sapiens,9606.0,,A549,
6111,Intermediate,80682,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,833,F,,Homo sapiens,9606.0,,A549,
6112,Expert,80682,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,15718,F,,Homo sapiens,9606.0,,A549,
6113,Intermediate,80682,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,12373,F,,Homo sapiens,9606.0,,A549,
6114,Intermediate,80682,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,637,F,,Homo sapiens,9606.0,,A549,
6115,Expert,80682,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,14867,F,,Homo sapiens,9606.0,,A549,
6116,Intermediate,80682,,,Antitumor cytotoxic activity against A-549 cell line was determined,4461,F,,Homo sapiens,9606.0,,A549,
6117,Intermediate,80682,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",5406,F,,Homo sapiens,9606.0,,A549,
6118,Intermediate,80682,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,4457,F,,Homo sapiens,9606.0,,A549,
6119,Expert,80682,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1386,F,,Homo sapiens,9606.0,,A549,
6120,Intermediate,80682,,,Antitumoral activity was assayed against A-549 cell line,3265,F,,Homo sapiens,9606.0,,A549,
6121,Intermediate,80682,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,2359,F,,Homo sapiens,9606.0,,A549,
6122,Intermediate,80682,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,4457,F,,Homo sapiens,9606.0,,A549,
6123,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,12454,F,,Homo sapiens,9606.0,,A549,
6124,Intermediate,80682,,,Compound was tested for inhibition of cell growth of A-549 cells,1481,F,,Homo sapiens,9606.0,,A549,
6125,Intermediate,80682,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1750,F,,Homo sapiens,9606.0,,A549,
6126,Intermediate,80682,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,5065,F,,Homo sapiens,9606.0,,A549,
6127,Expert,80682,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,808,F,,Homo sapiens,9606.0,,A549,
6128,Expert,80682,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,16364,F,,Homo sapiens,9606.0,,A549,
6129,Intermediate,80682,,,Cytotoxic activity against A-549 cell lines.,1847,F,,Homo sapiens,9606.0,,A549,
6130,Expert,80682,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1747,F,,Homo sapiens,9606.0,,A549,
6131,Intermediate,80682,,,Cytotoxicity against human A549 non small cell lung cell lines,1003,F,,Homo sapiens,9606.0,,A549,
6132,Expert,80682,,,Inhibition of cell growth in (A-549) lung cell line,15313,F,,Homo sapiens,9606.0,,A549,
6133,Intermediate,80682,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,3122,F,,Homo sapiens,9606.0,,A549,
6134,Intermediate,80682,,,In vitro antitumor activity against A-549 tumor cells.,16049,F,,Homo sapiens,9606.0,,A549,
6135,Expert,80682,,,In vitro antitumor effects against human A-549 cell lines.,17134,F,,Homo sapiens,9606.0,,A549,
6136,Intermediate,80682,,,In vitro cytotoxic activity of compound against A-549 cell line,6406,F,,Homo sapiens,9606.0,,A549,
6137,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,627,F,,Homo sapiens,9606.0,,A549,
6138,Intermediate,80682,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,12307,F,,Homo sapiens,9606.0,,A549,
6139,Intermediate,80682,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,17861,F,,Homo sapiens,9606.0,,A549,
6140,Expert,80682,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,6682,F,,Homo sapiens,9606.0,,A549,
6141,Intermediate,80682,,,Inhibitory concentration of compound against A-549 cell line,6663,F,,Homo sapiens,9606.0,,A549,
6142,Intermediate,80682,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,2454,F,,Homo sapiens,9606.0,,A549,
6143,Intermediate,80682,,,cytotoxic activity against leukemia (A-549) cancer cell line,14709,F,,Homo sapiens,9606.0,,A549,
6144,Expert,80682,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,15718,F,,Homo sapiens,9606.0,,A549,
6145,Intermediate,80682,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,15718,F,,Homo sapiens,9606.0,,A549,
6146,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),17130,F,,Homo sapiens,9606.0,,A549,
6147,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),17130,F,,Homo sapiens,9606.0,,A549,
6148,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),17130,F,,Homo sapiens,9606.0,,A549,
6149,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),17130,F,,Homo sapiens,9606.0,,A549,
6150,Intermediate,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,6630,F,,,,,A549,
6151,Intermediate,80682,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,16726,F,,Homo sapiens,9606.0,,A549,
6152,Intermediate,80682,,,Cytotoxicity against A549 cells; No cytotoxicity,17846,F,,Homo sapiens,9606.0,,A549,
6153,Expert,80682,,,Cytotoxicity against human lung carcinoma (A549) cell lines,3415,F,,Homo sapiens,9606.0,,A549,
6154,Expert,80682,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,3415,F,,Homo sapiens,9606.0,,A549,
6155,Intermediate,80682,,,In vitro anticancer activity against human lung (A549) cell line,5609,F,,Homo sapiens,9606.0,,A549,
6156,Intermediate,80682,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6157,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6158,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6159,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6160,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6161,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6162,Expert,80682,,,Inhibition of A549 human lung tumor cell proliferation,16295,F,,Homo sapiens,9606.0,,A549,
6163,Intermediate,80682,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",16825,F,,Homo sapiens,9606.0,,A549,
6164,Expert,80682,,,In vitro cytotoxicity against human tumor cell line A549,3439,F,,Homo sapiens,9606.0,,A549,
6165,Intermediate,80682,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,10870,F,,Homo sapiens,9606.0,,A549,
6166,Intermediate,80682,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,4845,F,,Homo sapiens,9606.0,,A549,
6167,Intermediate,80682,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,5822,F,,Homo sapiens,9606.0,,A549,
6168,Intermediate,80682,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,5822,F,,Homo sapiens,9606.0,,A549,
6169,Intermediate,80682,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,5822,F,,Homo sapiens,9606.0,,A549,
6170,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6171,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6172,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6173,Intermediate,80682,,,In vitro anticancer activity against human lung (A549) cell line,5609,F,,Homo sapiens,9606.0,,A549,
6174,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,4644,F,,Homo sapiens,9606.0,,A549,
6175,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,4644,F,,Homo sapiens,9606.0,,A549,
6176,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,4644,F,,Homo sapiens,9606.0,,A549,
6177,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,4644,F,,Homo sapiens,9606.0,,A549,
6178,Intermediate,80682,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,5822,F,,Homo sapiens,9606.0,,A549,
6179,Expert,80682,,,Percentage inhibition of human lung carcinoma (A549) cell lines,3415,F,,Homo sapiens,9606.0,,A549,
6180,Intermediate,80682,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,16726,F,,Homo sapiens,9606.0,,A549,
6181,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",17206,F,,Homo sapiens,9606.0,,A549,
6182,Intermediate,80682,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,17206,F,,Homo sapiens,9606.0,,A549,
6183,Intermediate,80682,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,17206,F,,Homo sapiens,9606.0,,A549,
6184,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",17206,F,,Homo sapiens,9606.0,,A549,
6185,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",17206,F,,Homo sapiens,9606.0,,A549,
6186,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",17206,F,,Homo sapiens,9606.0,,A549,
6187,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",17206,F,,Homo sapiens,9606.0,,A549,
6188,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",17206,F,,Homo sapiens,9606.0,,A549,
6189,Intermediate,80682,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6190,Intermediate,80682,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6191,Intermediate,80682,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,16726,F,,Homo sapiens,9606.0,,A549,
6192,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6193,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6194,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6195,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6196,Intermediate,50588,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6197,Intermediate,50588,,,Pharmacokinetic activity (Cmax) in dog,6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6198,Intermediate,50588,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
6199,Intermediate,50588,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,5983,A,In vivo,Canis lupus familiaris,9615.0,,,
6200,Intermediate,50588,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,6251,A,In vivo,Canis lupus familiaris,9615.0,,,
6201,Intermediate,50588,Plasma,,Cmax in dog plasma after 30mg/kg oral dose,5932,A,In vivo,Canis lupus familiaris,9615.0,,,
6202,Intermediate,50588,Blood,,Tested for the peak blood level in dog,4273,A,In vivo,Canis lupus familiaris,9615.0,,,
6203,Intermediate,50588,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",5313,A,In vivo,Canis lupus familiaris,9615.0,,,
6204,Intermediate,50588,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",5313,A,In vivo,Canis lupus familiaris,9615.0,,,
6205,Intermediate,50588,Blood,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,6221,A,In vivo,Canis lupus familiaris,9615.0,,,
6206,Intermediate,50588,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,4709,A,,Canis lupus familiaris,9615.0,,,
6207,Intermediate,50588,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,167,A,,Canis lupus familiaris,9615.0,,,
6208,Intermediate,50588,Plasma,,Final plasma concentration in dogs after oral administration at 1 mg/kg,6241,A,,Canis lupus familiaris,9615.0,,,
6209,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,344,A,,Canis lupus familiaris,9615.0,,,
6210,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,344,A,,Canis lupus familiaris,9615.0,,,
6211,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,344,A,,Canis lupus familiaris,9615.0,,,
6212,Intermediate,50588,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,2189,A,,Canis lupus familiaris,9615.0,,,
6213,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,2189,A,,Canis lupus familiaris,9615.0,,,
6214,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,2189,A,,Canis lupus familiaris,9615.0,,,
6215,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,2189,A,,Canis lupus familiaris,9615.0,,,
6216,Intermediate,50588,,,Absolute bioavailability was evaluated in dog,4257,A,In vivo,Canis lupus familiaris,9615.0,,,
6217,Intermediate,50588,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,6221,A,In vivo,Canis lupus familiaris,9615.0,,,
6218,Intermediate,50588,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,6215,A,In vivo,Canis lupus familiaris,9615.0,,,
6219,Intermediate,50588,,,Bioavailability in dog,17267,A,In vivo,Canis lupus familiaris,9615.0,,,
6220,Intermediate,50588,,,Bioavailability in dog,6621,A,In vivo,Canis lupus familiaris,9615.0,,,
6221,Intermediate,50588,,,Bioavailability after intravenous administration in dogs,3854,A,In vivo,Canis lupus familiaris,9615.0,,,
6222,Intermediate,50588,,,Bioavailability after peroral administration in dogs,3854,A,In vivo,Canis lupus familiaris,9615.0,,,
6223,Intermediate,50588,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),5007,A,In vivo,Canis lupus familiaris,9615.0,,,
6224,Intermediate,50588,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,4333,A,In vivo,Canis lupus familiaris,9615.0,,,
6225,Intermediate,50588,Plasma,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,4333,A,In vivo,Canis lupus familiaris,9615.0,,,
6226,Intermediate,50588,,,Bioavailability,5006,A,In vivo,Canis lupus familiaris,9615.0,,,
6227,Intermediate,50588,,,Bioavailability,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
6228,Intermediate,50588,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,4368,A,In vivo,Canis lupus familiaris,9615.0,,,
6229,Intermediate,50588,,,Bioavailability in dog,3771,A,In vivo,Canis lupus familiaris,9615.0,,,
6230,Intermediate,50588,,,Bioavailability in dog,4953,A,In vivo,Canis lupus familiaris,9615.0,,,
6231,Intermediate,50588,,,Bioavailability in dog,5064,A,In vivo,Canis lupus familiaris,9615.0,,,
6232,Intermediate,50588,,,Bioavailability in dog,17657,A,In vivo,Canis lupus familiaris,9615.0,,,
6233,Intermediate,50588,,,Bioavailability in dog,17796,A,In vivo,Canis lupus familiaris,9615.0,,,
6234,Intermediate,50588,,,Bioavailability in dog (p.o.) at 2.0 mpk,17853,A,In vivo,Canis lupus familiaris,9615.0,,,
6235,Intermediate,50588,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),4521,A,In vivo,Canis lupus familiaris,9615.0,,,
6236,Intermediate,50588,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
6237,Intermediate,50588,,,Bioavailability in dog,5006,A,In vivo,Canis lupus familiaris,9615.0,,,
6238,Intermediate,50588,,,Bioavailability was evaluated after oral administration in dog,16365,A,In vivo,Canis lupus familiaris,9615.0,,,
6239,Intermediate,50588,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,A,In vivo,Canis lupus familiaris,9615.0,,,
6240,Intermediate,50588,,,Bioavailability was evaluated in dog,1918,A,In vivo,Canis lupus familiaris,9615.0,,,
6241,Intermediate,50588,,,Bioavailability in dog,4239,A,In vivo,Canis lupus familiaris,9615.0,,,
6242,Intermediate,50588,,,Bioavailability in dog,6505,A,In vivo,Canis lupus familiaris,9615.0,,,
6243,Intermediate,50588,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
6244,Intermediate,50588,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
6245,Intermediate,50588,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
6246,Intermediate,50588,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
6247,Intermediate,50588,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,6005,A,In vivo,Canis lupus familiaris,9615.0,,,
6248,Intermediate,50588,,,Bioavailability of compound in dog was determined after peroral administration,17804,A,In vivo,Canis lupus familiaris,9615.0,,,
6249,Intermediate,50588,,,Oral bioavailability in dog,3184,A,In vivo,Canis lupus familiaris,9615.0,,,
6250,Intermediate,50588,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1806,A,In vivo,Canis lupus familiaris,9615.0,,,
6251,Intermediate,50588,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1806,A,In vivo,Canis lupus familiaris,9615.0,,,
6252,Intermediate,50588,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1806,A,In vivo,Canis lupus familiaris,9615.0,,,
6253,Intermediate,50588,,,Bioavailability in dog,4839,A,In vivo,Canis lupus familiaris,9615.0,,,
6254,Intermediate,50588,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),5017,A,In vivo,Canis lupus familiaris,9615.0,,,
6255,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6256,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6257,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6258,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6259,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6260,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6261,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6262,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6263,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6264,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6265,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6266,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6267,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6268,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6269,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6270,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6271,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6272,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6273,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6274,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,846,A,In vivo,Mus musculus,10090.0,,,
6275,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6276,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6277,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6278,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6279,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6280,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6281,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6282,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6283,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6284,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6285,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6286,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6287,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6288,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6289,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6290,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6291,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6292,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6293,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,17130,F,,Homo sapiens,9606.0,,A549,
6294,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,17130,F,,Homo sapiens,9606.0,,A549,
6295,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),17130,F,,Homo sapiens,9606.0,,A549,
6296,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),17130,F,,Homo sapiens,9606.0,,A549,
6297,Expert,80682,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,3263,F,,Homo sapiens,9606.0,,A549,
6298,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,6663,F,,Homo sapiens,9606.0,,A549,
6299,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,6663,F,,Homo sapiens,9606.0,,A549,
6300,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,6663,F,,Homo sapiens,9606.0,,A549,
6301,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,6663,F,,Homo sapiens,9606.0,,A549,
6302,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,6663,F,,Homo sapiens,9606.0,,A549,
6303,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,6663,F,,Homo sapiens,9606.0,,A549,
6304,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,6663,F,,Homo sapiens,9606.0,,A549,
6305,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,6663,F,,Homo sapiens,9606.0,,A549,
6306,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,6663,F,,Homo sapiens,9606.0,,A549,
6307,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,6663,F,,Homo sapiens,9606.0,,A549,
6308,Intermediate,80682,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,3983,F,,Homo sapiens,9606.0,,A549,
6309,Expert,80682,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,11141,F,,Homo sapiens,9606.0,,A549,
6310,Intermediate,80682,,,Cytotoxic activity of compound against A-549 tumor cell line.,5076,F,,Homo sapiens,9606.0,,A549,
6311,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,3311,F,,Homo sapiens,9606.0,,A549,
6312,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,3311,F,,Homo sapiens,9606.0,,A549,
6313,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,3311,F,,Homo sapiens,9606.0,,A549,
6314,Intermediate,80682,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,5076,F,,Homo sapiens,9606.0,,A549,
6315,Intermediate,80682,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),4150,F,,Homo sapiens,9606.0,,A549,
6316,Expert,80682,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,2150,F,,Homo sapiens,9606.0,,A549,
6317,Intermediate,80682,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,4644,F,,Homo sapiens,9606.0,,A549,
6318,Intermediate,80682,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,263,F,,Homo sapiens,9606.0,,A549,
6319,Intermediate,80682,,,Cytotoxic concentration against A-549 tumor cells.,11333,F,,Homo sapiens,9606.0,,A549,
6320,Intermediate,80682,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,11333,F,,Homo sapiens,9606.0,,A549,
6321,Intermediate,80682,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",15895,F,,Homo sapiens,9606.0,,A549,
6322,Expert,50191,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,16677,F,,Acinetobacter baumannii,470.0,,,
6323,Intermediate,50192,,,Activity against Acinetobacter calcoaceticus (AC54),10624,F,,Acinetobacter calcoaceticus,471.0,,,
6324,Expert,50274,,,In vitro antifungal activity against Aspergillus flavus CM74,16717,F,,Aspergillus flavus,5059.0,,,
6325,Expert,50274,,,In vitro antifungal activity against Aspergillus flavus CM74,16717,F,,Aspergillus flavus,5059.0,,,
6326,Intermediate,50416,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,5513,F,,Aspergillus fumigatus,746128.0,,,
6327,Intermediate,50416,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),15962,F,,Aspergillus fumigatus,746128.0,,,
6328,Intermediate,50416,,,Antimicrobial activity against Aspergillus fumigatus (MIC),15962,F,,Aspergillus fumigatus,746128.0,,,
6329,Intermediate,50416,,,Antimicrobial activity against Aspergillus fumigatus (MIC),15962,F,,Aspergillus fumigatus,746128.0,,,
6330,Intermediate,50416,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),15962,F,,Aspergillus fumigatus,746128.0,,,
6331,Expert,50416,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,16717,F,,Aspergillus fumigatus,746128.0,,,
6332,Expert,50416,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,16717,F,,Aspergillus fumigatus,746128.0,,,
6333,Intermediate,50296,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,8117,F,,Actinomyces naeslundii,1655.0,,,
6334,Intermediate,50366,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,8117,F,,Actinomyces viscosus,1656.0,,,
6335,Intermediate,50535,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),15472,F,,Acanthocheilonema viteae,6277.0,,,
6336,Intermediate,50535,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),15472,F,,Acanthocheilonema viteae,6277.0,,,
6337,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,16443,F,,Aggregatibacter actinomycetemcomitans,714.0,,,
6338,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,16443,F,,Aggregatibacter actinomycetemcomitans,714.0,,,
6339,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,16443,F,,Aggregatibacter actinomycetemcomitans,714.0,,,
6340,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6341,Intermediate,80682,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6342,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6343,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6344,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,16381,F,,Homo sapiens,9606.0,,A549,
6345,Intermediate,80682,,,GI values against A549 cells (lung cancer),16381,F,,Homo sapiens,9606.0,,A549,
6346,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,17206,F,,Homo sapiens,9606.0,,A549,
6347,Intermediate,80682,,,Inhibitory activity against A549 human adenocarcinoma,16325,F,,Homo sapiens,9606.0,,A549,
6348,Intermediate,80682,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,10708,F,,Homo sapiens,9606.0,,A549,
6349,Intermediate,80682,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,10708,F,,Homo sapiens,9606.0,,A549,
6350,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line,17376,F,,Homo sapiens,9606.0,,A549,
6351,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,17376,F,,Homo sapiens,9606.0,,A549,
6352,Intermediate,80682,,,Cytotoxicity against human A549 lung cells,17488,F,,Homo sapiens,9606.0,,A549,
6353,Intermediate,80682,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,17404,F,,Homo sapiens,9606.0,,A549,
6354,Expert,80682,,,Growth inhibition of A549 (human lung carcinoma) cell line.,10958,F,,Homo sapiens,9606.0,,A549,
6355,Expert,80682,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,17099,F,,Homo sapiens,9606.0,,A549,
6356,Intermediate,80682,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,17099,F,,Homo sapiens,9606.0,,A549,
6357,Intermediate,80682,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,4096,F,,Homo sapiens,9606.0,,A549,
6358,Expert,80682,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,4096,F,,Homo sapiens,9606.0,,A549,
6359,Intermediate,80682,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,4096,F,,Homo sapiens,9606.0,,A549,
6360,Intermediate,80682,,,In vitro inhibitory activity against A549 tumor cell culture,2525,F,,Homo sapiens,9606.0,,A549,
6361,Intermediate,80682,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,2525,F,,Homo sapiens,9606.0,,A549,
6362,Intermediate,80682,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),5302,F,,Homo sapiens,9606.0,,A549,
6363,Intermediate,80682,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,16325,F,,Homo sapiens,9606.0,,A549,
6364,Intermediate,80682,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,16939,F,,Homo sapiens,9606.0,,A549,
6365,Intermediate,80682,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,17229,F,,Homo sapiens,9606.0,,A549,
6366,Intermediate,80682,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,17380,F,,Homo sapiens,9606.0,,A549,
6367,Intermediate,80682,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,17380,F,,Homo sapiens,9606.0,,A549,
6368,Intermediate,80682,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1903,F,,Homo sapiens,9606.0,,A549,
6369,Intermediate,80682,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,3838,F,,Homo sapiens,9606.0,,A549,
6370,Intermediate,80682,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,14696,F,,Homo sapiens,9606.0,,A549,
6371,Intermediate,80682,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,3838,F,,Homo sapiens,9606.0,,A549,
6372,Intermediate,80682,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1522,F,,Homo sapiens,9606.0,,A549,
6373,Intermediate,80682,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,12400,F,,Homo sapiens,9606.0,,A549,
6374,Intermediate,80682,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,14696,F,,Homo sapiens,9606.0,,A549,
6375,Intermediate,80682,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,A549,
6376,Intermediate,80682,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,14696,F,,Homo sapiens,9606.0,,A549,
6377,Intermediate,80682,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1888,F,,Homo sapiens,9606.0,,A549,
6378,Intermediate,80682,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,12016,F,,Homo sapiens,9606.0,,A549,
6379,Intermediate,80682,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,6058,F,,Homo sapiens,9606.0,,A549,
6380,Intermediate,80682,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,17708,F,,Homo sapiens,9606.0,,A549,
6381,Intermediate,80682,,,Antitumor activity against A549/ATCC cell line,12301,F,,Homo sapiens,9606.0,,A549,
6382,Intermediate,80682,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,11970,F,,Homo sapiens,9606.0,,A549,
6383,Expert,80682,,,In vitro cytotoxicity against A549/ATCC cell line.,11818,F,,Homo sapiens,9606.0,,A549,
6384,Intermediate,80682,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,12400,F,,Homo sapiens,9606.0,,A549,
6385,Intermediate,80682,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,3381,F,,Homo sapiens,9606.0,,A549,
6386,Intermediate,80682,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,17376,F,,Homo sapiens,9606.0,,A549,
6387,Intermediate,80682,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A549,
6388,Autocuration,22226,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,2964,F,,Homo sapiens,9606.0,,,
6389,Intermediate,22224,,,Compound was tested for oral bioavailability in dogs,5005,A,In vivo,Canis lupus familiaris,9615.0,,,
6390,Intermediate,50588,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,6229,A,In vivo,Canis lupus familiaris,9615.0,,,
6391,Intermediate,50588,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,6229,A,In vivo,Canis lupus familiaris,9615.0,,,
6392,Intermediate,50588,,,Oral bioavailability in dog,5374,A,In vivo,Canis lupus familiaris,9615.0,,,
6393,Intermediate,50588,,,Compound was tested for the oral bioavailability in dog; No availability,5374,A,In vivo,Canis lupus familiaris,9615.0,,,
6394,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),6265,A,In vivo,Canis lupus familiaris,9615.0,,,
6395,Intermediate,50588,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,5654,A,In vivo,Canis lupus familiaris,9615.0,,,
6396,Intermediate,50588,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,5654,A,In vivo,Canis lupus familiaris,9615.0,,,
6397,Intermediate,50588,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),16456,A,In vivo,Canis lupus familiaris,9615.0,,,
6398,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),5302,A,In vivo,Canis lupus familiaris,9615.0,,,
6399,Intermediate,50588,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),3624,A,In vivo,Canis lupus familiaris,9615.0,,,
6400,Intermediate,50588,,,Oral bioavailability of active FTIs in dogs,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
6401,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),5802,A,In vivo,Canis lupus familiaris,9615.0,,,
6402,Expert,50588,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Canis lupus familiaris,9615.0,,,
6403,Intermediate,50588,,,Oral bioavailability in dog,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6404,Intermediate,50588,,,Oral bioavailability in dog,6762,A,In vivo,Canis lupus familiaris,9615.0,,,
6405,Intermediate,50588,,,Oral bioavailability in dog,6821,A,In vivo,Canis lupus familiaris,9615.0,,,
6406,Intermediate,50588,,,Oral bioavailability of compound was determined in dog; Not tested,6821,A,In vivo,Canis lupus familiaris,9615.0,,,
6407,Intermediate,50588,,,Oral bioavailability in dog,5210,A,In vivo,Canis lupus familiaris,9615.0,,,
6408,Intermediate,50588,,,Oral bioavailability (10 mg/kg) was determined in dog,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6409,Intermediate,50588,,,Oral bioavailability,761,A,In vivo,Canis lupus familiaris,9615.0,,,
6410,Intermediate,50588,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),761,A,In vivo,Canis lupus familiaris,9615.0,,,
6411,Intermediate,50588,,,Oral bioavailability administered in solution in rats,761,A,In vivo,Canis lupus familiaris,9615.0,,,
6412,Intermediate,50588,,,Oral bioavailability after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6413,Intermediate,50588,,,Oral bioavailability at a dose of 1 mg/kg in dogs,5474,A,In vivo,Canis lupus familiaris,9615.0,,,
6414,Intermediate,50588,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),6535,A,In vivo,Canis lupus familiaris,9615.0,,,
6415,Intermediate,50588,,,Oral bioavailability in Dog; ND = not determined,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
6416,Intermediate,50588,,,Oral bioavailability in dog,3352,A,In vivo,Canis lupus familiaris,9615.0,,,
6417,Intermediate,50588,,,Oral bioavailability in dog,6168,A,In vivo,Canis lupus familiaris,9615.0,,,
6418,Intermediate,50588,,,Oral bioavailability in dog,5988,A,In vivo,Canis lupus familiaris,9615.0,,,
6419,Intermediate,50588,,,Oral bioavailability in dog,4942,A,In vivo,Canis lupus familiaris,9615.0,,,
6420,Intermediate,50588,,,Oral bioavailability in dogs; No data,4942,A,In vivo,Canis lupus familiaris,9615.0,,,
6421,Intermediate,50588,,,Oral bioavailability measured in dogs,14541,A,In vivo,Canis lupus familiaris,9615.0,,,
6422,Intermediate,50588,,,Oral bioavailability in dog,4449,A,In vivo,Canis lupus familiaris,9615.0,,,
6423,Intermediate,50588,,,Oral bioavailability was calculated in dog,6057,A,In vivo,Canis lupus familiaris,9615.0,,,
6424,Intermediate,50588,,,Oral bioavailability after 0.3 mg/kg po administration in dog,5600,A,In vivo,Canis lupus familiaris,9615.0,,,
6425,Intermediate,50588,,,Oral bioavailability in dog (i.v. dosing),5542,A,In vivo,Canis lupus familiaris,9615.0,,,
6426,Intermediate,50588,,,Oral bioavailability in dog,5542,A,In vivo,Canis lupus familiaris,9615.0,,,
6427,Intermediate,50588,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,5546,A,In vivo,Canis lupus familiaris,9615.0,,,
6428,Intermediate,50588,,,Oral bioavailability in Beagle dogs,4514,A,In vivo,Canis lupus familiaris,9615.0,,,
6429,Intermediate,50588,,,Oral bioavailability in dog,3624,A,In vivo,Canis lupus familiaris,9615.0,,,
6430,Intermediate,50588,,,Oral bioavailability in dog,3854,A,In vivo,Canis lupus familiaris,9615.0,,,
6431,Intermediate,50588,,,Oral bioavailability in dog,5836,A,In vivo,Canis lupus familiaris,9615.0,,,
6432,Intermediate,50588,,,Oral bioavailability in dog,5940,A,In vivo,Canis lupus familiaris,9615.0,,,
6433,Intermediate,50588,,,Oral bioavailability in dog,6168,A,In vivo,Canis lupus familiaris,9615.0,,,
6434,Intermediate,50588,,,Oral bioavailability in dog,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
6435,Intermediate,50588,,,Oral bioavailability in dog,6251,A,In vivo,Canis lupus familiaris,9615.0,,,
6436,Intermediate,50588,,,Oral bioavailability in dog,6448,A,In vivo,Canis lupus familiaris,9615.0,,,
6437,Intermediate,50588,,,Oral bioavailability in dog,6647,A,In vivo,Canis lupus familiaris,9615.0,,,
6438,Intermediate,50588,,,Oral bioavailability in dog,5940,A,In vivo,Canis lupus familiaris,9615.0,,,
6439,Intermediate,50588,,,Oral bioavailability in dog,933,A,In vivo,Canis lupus familiaris,9615.0,,,
6440,Intermediate,50588,,,Oral bioavailability in dog,5210,A,In vivo,Canis lupus familiaris,9615.0,,,
6441,Intermediate,50588,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
6442,Intermediate,50588,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),6641,A,In vivo,Canis lupus familiaris,9615.0,,,
6443,Intermediate,50588,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
6444,Intermediate,50588,,,Oral bioavailability in dog,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
6445,Intermediate,50588,,,Oral bioavailability in dog,5985,A,In vivo,Canis lupus familiaris,9615.0,,,
6446,Intermediate,50588,,,Oral bioavailability in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
6447,Intermediate,50588,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),5530,A,In vivo,Canis lupus familiaris,9615.0,,,
6448,Intermediate,50588,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),5530,A,In vivo,Canis lupus familiaris,9615.0,,,
6449,Intermediate,50588,,,Oral bioavailability (F) in dogs,6305,A,In vivo,Canis lupus familiaris,9615.0,,,
6450,Intermediate,50588,,,Oral bioavailability in dog,5210,A,In vivo,Canis lupus familiaris,9615.0,,,
6451,Intermediate,50588,,,Bioavailability in dog,5238,A,In vivo,Canis lupus familiaris,9615.0,,,
6452,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),5668,A,In vivo,Canis lupus familiaris,9615.0,,,
6453,Intermediate,50588,,,Oral bioavailability after peroral administration at 5 mpk in Dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
6454,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),5668,A,In vivo,Canis lupus familiaris,9615.0,,,
6455,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6456,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6457,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6458,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6459,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6460,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6461,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6462,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6463,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6464,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6465,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6466,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6467,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6468,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6469,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6470,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6471,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6472,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6473,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6474,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6475,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6476,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6477,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6478,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6479,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6480,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6481,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6482,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6483,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6484,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6485,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6486,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6487,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6488,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6489,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6490,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6491,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6492,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6493,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6494,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6495,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6496,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6497,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6498,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6499,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6500,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,F,,aeinetobacter anitrotap,107673.0,,,
6501,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,F,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,
6502,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,F,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,
6503,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,12269,F,,aeinetobacter anitrotap,107673.0,,,
6504,Intermediate,50192,,,Activity against Acinetobacter calcoaceticus (AC54),10624,F,,Acinetobacter calcoaceticus,471.0,,,
6505,Intermediate,50714,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,17216,F,,Anolis carolinensis,28377.0,,,
6506,Intermediate,50714,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,17216,F,,Anolis carolinensis,28377.0,,,
6507,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,9560,F,,Actinomyces naeslundii,1655.0,,,
6508,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,9560,F,,Actinomyces naeslundii,1655.0,,,
6509,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,9560,F,,Actinomyces naeslundii,1655.0,,,
6510,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,9560,F,,Actinomyces naeslundii,1655.0,,,
6511,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii 631,9560,F,,Actinomyces naeslundii,1655.0,,,
6512,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii N/9,9560,F,,Actinomyces naeslundii,1655.0,,,
6513,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii B74,9560,F,,Actinomyces naeslundii,1655.0,,,
6514,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii N/3,9560,F,,Actinomyces naeslundii,1655.0,,,
6515,Intermediate,50056,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,114,F,,Artemia salina,85549.0,,,
6516,Intermediate,50056,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",114,F,,Artemia salina,85549.0,,,
6517,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,10841,F,,Ascaris suum,6253.0,,,
6518,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,10841,F,,Ascaris suum,6253.0,,,
6519,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,10841,F,,Ascaris suum,6253.0,,,
6520,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,10841,F,,Ascaris suum,6253.0,,,
6521,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,10841,F,,Ascaris suum,6253.0,,,
6522,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,10841,F,,Ascaris suum,6253.0,,,
6523,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,10841,F,,Ascaris suum,6253.0,,,
6524,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,10841,F,,Ascaris suum,6253.0,,,
6525,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,10841,F,,Ascaris suum,6253.0,,,
6526,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,10841,F,,Ascaris suum,6253.0,,,
6527,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,10841,F,,Ascaris suum,6253.0,,,
6528,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,10841,F,,Ascaris suum,6253.0,,,
6529,Intermediate,50366,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,8117,F,,Actinomyces viscosus,1656.0,,,
6530,Intermediate,50366,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,8117,F,,Actinomyces viscosus,1656.0,,,
6531,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,9560,F,,Actinomyces viscosus,1656.0,,,
6532,Expert,50366,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,9560,F,,Actinomyces viscosus,1656.0,,,
6533,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,9560,F,,Actinomyces viscosus,1656.0,,,
6534,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,9560,F,,Actinomyces viscosus,1656.0,,,
6535,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus 8A06,9560,F,,Actinomyces viscosus,1656.0,,,
6536,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus M-100,9560,F,,Actinomyces viscosus,1656.0,,,
6537,Expert,50366,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,9560,F,,Actinomyces viscosus,1656.0,,,
6538,Intermediate,50366,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",9560,F,,Actinomyces viscosus,1656.0,,,
6539,Intermediate,50366,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",9560,F,,Actinomyces viscosus,1656.0,,,
6540,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus 626,9560,F,,Actinomyces viscosus,1656.0,,,
6541,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus T14V,9560,F,,Actinomyces viscosus,1656.0,,,
6542,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6543,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6544,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6545,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6546,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6547,Intermediate,80023,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A673,
6548,Intermediate,80661,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A704,
6549,Autocuration,22226,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,416,F,,Rattus norvegicus,10116.0,,,
6550,Intermediate,80024,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,14354,F,,Mus musculus,10090.0,,A9,
6551,Intermediate,80024,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,14354,F,,Mus musculus,10090.0,,A9,
6552,Intermediate,80024,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,5116,F,,Homo sapiens,9606.0,,A9,
6553,Intermediate,80024,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,5116,F,,Homo sapiens,9606.0,,A9,
6554,Expert,81037,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,15694,F,,Homo sapiens,9606.0,,Human ovarian carcinoma cell line,
6555,Expert,80024,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",13038,F,,Mus musculus,10090.0,,A9,
6556,Expert,80024,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,13038,F,,Mus musculus,10090.0,,A9,
6557,Expert,80024,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,10923,F,,Mus musculus,10090.0,,A9,
6558,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,10923,F,,Mus musculus,10090.0,,A9,
6559,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,10923,F,,Mus musculus,10090.0,,A9,
6560,Expert,10649,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10923,F,,,,,,
6561,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,10923,F,,Mus musculus,10090.0,,A9,
6562,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,10923,F,,Mus musculus,10090.0,,A9,
6563,Intermediate,80663,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,8158,F,,Cricetulus griseus,10029.0,,AA6,
6564,Autocuration,22226,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,15494,F,,Homo sapiens,9606.0,,,
6565,Autocuration,22226,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",15494,F,,Homo sapiens,9606.0,,,
6566,Intermediate,80662,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),12348,F,,Homo sapiens,9606.0,,AA5,
6567,Intermediate,80662,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),12348,F,,Homo sapiens,9606.0,,AA5,
6568,Intermediate,80662,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,2726,F,,Homo sapiens,9606.0,,AA5,
6569,Intermediate,80566,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,2726,F,,Homo sapiens,9606.0,,U-937,
6570,Intermediate,80578,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,10747,F,,Cricetulus griseus,10029.0,,UV4,
6571,Expert,80089,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",11005,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6572,Intermediate,80089,,,Average intracellular compound concentration when the hypoxic SER=1.6,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6573,Intermediate,80089,,,Average intracellular compound concentration when the hypoxic SER=1.6.,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6574,Intermediate,80089,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6575,Intermediate,80089,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6576,Intermediate,80089,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6577,Intermediate,80089,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",13436,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6578,Intermediate,80089,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",13435,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6579,Intermediate,80089,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,13302,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6580,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6581,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,12687,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6582,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,12687,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6583,Expert,80089,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,12878,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6584,Intermediate,80089,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,12878,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6585,Expert,80089,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,14367,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6586,Intermediate,80089,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,14367,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6587,Expert,80089,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,12398,F,,hampster,36483.0,,CHO-AA8,
6588,Expert,80089,,,Aerobic growth inhibition in Chinese hamster cell line AA8,12878,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6589,Expert,80089,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,13820,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6590,Expert,80089,,,Inhibition of growth under aerobic conditions in AA8 cells,13436,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6591,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6592,Intermediate,50588,,,Oral bioavailability in dog at 10 mg/kg of the compound,5711,A,In vivo,Canis lupus familiaris,9615.0,,,
6593,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),4353,A,In vivo,Canis lupus familiaris,9615.0,,,
6594,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),4353,A,In vivo,Canis lupus familiaris,9615.0,,,
6595,Intermediate,50588,,,Oral bioavailability in dog (mongrel),17800,A,In vivo,Canis lupus familiaris,9615.0,,,
6596,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),3994,A,In vivo,Canis lupus familiaris,9615.0,,,
6597,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),3994,F,In vivo,Canis lupus familiaris,9615.0,,,
6598,Intermediate,50588,,,Bioavailability in dog,5145,A,In vivo,Canis lupus familiaris,9615.0,,,
6599,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),16452,A,In vivo,Canis lupus familiaris,9615.0,,,
6600,Intermediate,50588,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),16452,A,In vivo,Canis lupus familiaris,9615.0,,,
6601,Intermediate,50588,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,5983,A,In vivo,Canis lupus familiaris,9615.0,,,
6602,Intermediate,50588,,,Bioavailability in dog,4273,A,In vivo,Canis lupus familiaris,9615.0,,,
6603,Intermediate,50588,,,Bioavailability in dog (dose 3-10 mg/kg),12500,A,In vivo,Canis lupus familiaris,9615.0,,,
6604,Intermediate,50588,Plasma,,The compound was tested for bioavailability of compound in plasma of dog; Complete,12500,A,In vivo,Canis lupus familiaris,9615.0,,,
6605,Intermediate,50588,,,Oral bioavailability in dog,3639,A,In vivo,Canis lupus familiaris,9615.0,,,
6606,Intermediate,50588,,,Oral bioavailability in dog,3880,A,In vivo,Canis lupus familiaris,9615.0,,,
6607,Intermediate,50588,,,Bioavailability in dog,4838,A,In vivo,Canis lupus familiaris,9615.0,,,
6608,Intermediate,50588,,,oral bioavailability was measured in dogs,15600,A,In vivo,Canis lupus familiaris,9615.0,,,
6609,Intermediate,50588,,,Compound was tested for plasma protein binding in dog; Not determined,17248,A,,Canis lupus familiaris,9615.0,,,
6610,Intermediate,50588,,,Compound was tested for plasma protein binding of dog,17248,A,,Canis lupus familiaris,9615.0,,,
6611,Intermediate,50588,,,Compound was tested for plasma protein binding of dog; Not determined,17248,A,,Canis lupus familiaris,9615.0,,,
6612,Intermediate,50588,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,17443,A,,Canis lupus familiaris,9615.0,,,
6613,Intermediate,50588,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,4186,A,In vivo,Canis lupus familiaris,9615.0,,,
6614,Intermediate,50588,,,Half life was determined,3749,A,,Canis lupus familiaris,9615.0,,,
6615,Intermediate,50588,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,3249,A,In vivo,Canis lupus familiaris,9615.0,,,
6616,Intermediate,50588,,,Half life was evaluated in dog,3022,A,,Canis lupus familiaris,9615.0,,,
6617,Intermediate,50588,,,Half life was determined,3749,A,,Canis lupus familiaris,9615.0,,,
6618,Intermediate,50588,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6619,Intermediate,50588,Heart,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6620,Intermediate,50588,Kidney,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6621,Intermediate,50588,Liver,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6622,Intermediate,50588,Lung,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6623,Intermediate,50588,Spleen,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),2517,A,In vivo,Canis lupus familiaris,9615.0,,,
6624,Intermediate,50588,,,LogP in dog,3639,A,,Canis lupus familiaris,9615.0,,,
6625,Intermediate,50588,,,Partition coefficient (logP),6227,A,,Canis lupus familiaris,9615.0,,,
6626,Intermediate,50588,,,Partition coefficient in dog,6227,A,,Canis lupus familiaris,9615.0,,,
6627,Intermediate,50588,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
6628,Intermediate,50588,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
6629,Intermediate,50588,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,5600,A,,Canis lupus familiaris,9615.0,,,
6630,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),14294,A,,Canis lupus familiaris,9615.0,,,
6631,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),14294,A,,Canis lupus familiaris,9615.0,,,
6632,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes; Trace,14294,A,,Canis lupus familiaris,9615.0,,,
6633,Intermediate,50588,Liver,,In vitro metabolic potential in dog liver microsomes,6251,A,,Canis lupus familiaris,9615.0,,,
6634,Intermediate,50588,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,3748,A,In vivo,Canis lupus familiaris,9615.0,,,
6635,Intermediate,50588,,,Oral bioavailability in dog,2713,A,In vivo,Canis lupus familiaris,9615.0,,,
6636,Intermediate,50588,,,Oral bioavailability in dog,6512,A,In vivo,Canis lupus familiaris,9615.0,,,
6637,Intermediate,50588,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Canis lupus familiaris,9615.0,,,
6638,Intermediate,50588,,,The compound was tested for bioavailability in dogs,3749,A,In vivo,Canis lupus familiaris,9615.0,,,
6639,Intermediate,50588,,,The compound was tested for oral bioavailability in dogs,3749,A,In vivo,Canis lupus familiaris,9615.0,,,
6640,Intermediate,50588,,,Oral bioavailability in dog,6742,A,In vivo,Canis lupus familiaris,9615.0,,,
6641,Intermediate,50588,,,Compound was tested for percent protein binding (PB) in dog,6227,A,,Canis lupus familiaris,9615.0,,,
6642,Intermediate,50588,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,6874,A,,Canis lupus familiaris,9615.0,,,
6643,Intermediate,50588,Plasma,,Compound was evaluated for plasma clearance.,2877,A,In vivo,Canis lupus familiaris,9615.0,,,
6644,Intermediate,50588,Plasma,,The compound was tested for plasma clearance in dog,12500,A,In vivo,Canis lupus familiaris,9615.0,,,
6645,Intermediate,50588,Plasma,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,12500,A,In vivo,Canis lupus familiaris,9615.0,,,
6646,Intermediate,50588,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,4709,A,,Canis lupus familiaris,9615.0,,,
6647,Intermediate,50588,Liver,,In vitro relative rate of metabolism was determined in dog liver microsomes,5542,A,,Canis lupus familiaris,9615.0,,,
6648,Intermediate,50588,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,17594,A,In vivo,Canis lupus familiaris,9615.0,,,
6649,Intermediate,50588,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,2652,A,In vivo,Canis lupus familiaris,9615.0,,,
6650,Intermediate,50588,,,Half life after intravenous administration in dogs at 1.2 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
6651,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6652,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6653,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6654,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6655,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6656,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6657,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6658,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,6599,A,,Mus musculus,10090.0,,CCRF S-180,
6659,Intermediate,50594,Brain,,C2 in brain of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
6660,Intermediate,50594,Kidney,,C2 in kidney of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
6661,Intermediate,50594,Liver,,C2 in liver of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
6662,Intermediate,50594,Lung,,C2 in lungs of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
6663,Intermediate,50594,Spleen,,C2 in spleen of mice at the oral dose of 50 mg/kg,17641,A,,Mus musculus,10090.0,,,
6664,Intermediate,50594,,,Plasma clearance in mouse,17852,A,In vivo,Mus musculus,10090.0,,,
6665,Intermediate,50594,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
6666,Intermediate,50594,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,17837,A,In vivo,Mus musculus,10090.0,,,
6667,Intermediate,50594,,,Clearance was evaluated in mice after intravenous administration,2675,A,In vivo,Mus musculus,10090.0,,,
6668,Intermediate,50594,,,Clearance was evaluated in mice after oral administration,2675,A,In vivo,Mus musculus,10090.0,,,
6669,Intermediate,50594,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,4239,A,In vivo,Mus musculus,10090.0,,,
6670,Intermediate,50594,,,Plasma clearance of compound was determined at 40 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
6671,Intermediate,50594,,,Plasma clearance of at 24 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
6672,Intermediate,50594,,,Plasma clearance at 24 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
6673,Intermediate,50594,,,Plasma clearance at 5 mg/Kg,17753,A,In vivo,Mus musculus,10090.0,,,
6674,Intermediate,50594,,,Plasma clearance in mice,5727,A,In vivo,Mus musculus,10090.0,,,
6675,Intermediate,50594,,,Plasma clearance value upon iv administration in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
6676,Intermediate,50594,Plasma,,Total plasma clearance in mice,5980,A,In vivo,Mus musculus,10090.0,,,
6677,Intermediate,50594,,,Clearance in mouse,17592,A,In vivo,Mus musculus,10090.0,,,
6678,Intermediate,50594,,,Clearance value was determined,17718,A,In vivo,Mus musculus,10090.0,,,
6679,Intermediate,50594,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
6680,Intermediate,22229,,,Calculated partition coefficient (clogP),17384,P,,,,,,
6681,Intermediate,50594,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,6062,A,In vivo,Mus musculus,10090.0,,,
6682,Intermediate,50594,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,17734,A,In vivo,Mus musculus,10090.0,,,
6683,Intermediate,50594,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
6684,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
6685,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
6686,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,5969,A,In vivo,Mus musculus,10090.0,,,
6687,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,16597,A,In vivo,Mus musculus,10090.0,,,
6688,Intermediate,50594,,,Cmax after oral administration at 30 mg/kg in ICR mouse,5781,A,In vivo,Mus musculus,10090.0,,,
6689,Intermediate,50594,,,Cmax after peroral administration in mice at 2.4 uM/kg,17764,A,In vivo,Mus musculus,10090.0,,,
6690,Intermediate,50594,Brain,,Cmax in brain of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
6691,Intermediate,50594,Kidney,,Cmax in kidney of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
6692,Intermediate,50594,Liver,,Cmax in liver of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
6693,Intermediate,50594,Lung,,Cmax in lungs of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
6694,Intermediate,50594,,,Cmax in mice at 18 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
6695,Intermediate,50594,,,Cmax in mice at 23 uM/kg i.v. administration,17764,F,In vivo,Mus musculus,10090.0,,,
6696,Intermediate,50594,,,Cmax in mice at 24 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
6697,Intermediate,50594,,,Cmax in mice at 25 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
6698,Intermediate,50594,,,Cmax in mice at 26 uM/kg i.p. administration,17764,F,In vivo,Mus musculus,10090.0,,,
6699,Intermediate,50594,Spleen,,Cmax in spleen of mice at the oral dose of 50 mg/kg,17641,A,In vivo,Mus musculus,10090.0,,,
6700,Intermediate,50594,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
6701,Intermediate,50594,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,16597,A,In vivo,Mus musculus,10090.0,,,
6702,Intermediate,50594,,,Cmax value was determined,5727,A,In vivo,Mus musculus,10090.0,,,
6703,Intermediate,50594,,,Cmax value in IRC mice,5951,A,In vivo,Mus musculus,10090.0,,,
6704,Intermediate,50594,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,5506,A,In vivo,Mus musculus,10090.0,,,
6705,Intermediate,50594,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,5506,A,In vivo,Mus musculus,10090.0,,,
6706,Intermediate,50594,Plasma,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,14239,A,In vivo,Mus musculus,10090.0,,,
6707,Intermediate,50594,Plasma,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",4890,A,In vivo,Mus musculus,10090.0,,,
6708,Intermediate,50594,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,429,A,In vivo,Mus musculus,10090.0,,,
6709,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6710,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6711,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,10986,F,,Acanthocheilonema viteae,6277.0,,,
6712,Intermediate,80018,,,Inhibitory activity against human tumor cell line A0375 melanoma.,13227,F,,Homo sapiens,9606.0,,A-375,
6713,Expert,12512,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,4481,B,,Rattus norvegicus,10116.0,,,Brain membranes
6714,Expert,114,,,Forskolin-induced cAMP production at human A1 adenosine receptor,16931,F,,Homo sapiens,9606.0,,,
6715,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6716,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,3850,F,,,,,CHO,
6717,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,3850,F,,,,,CHO,
6718,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,3850,F,,,,,CHO,
6719,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,3850,F,,,,,CHO,
6720,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,3850,F,,,,,CHO,
6721,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6722,Expert,114,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,3850,F,,Homo sapiens,9606.0,,CHO,
6723,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,3850,F,,,,,CHO,
6724,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6725,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,3850,F,,,,,CHO,
6726,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6727,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,3850,F,,,,,CHO,
6728,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,3850,F,,,,,CHO,
6729,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,3850,F,,,,,CHO,
6730,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6731,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,3850,F,,,,,CHO,
6732,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,3850,F,,,,,CHO,
6733,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,3850,F,,,,,CHO,
6734,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,3850,F,,,,,CHO,
6735,Intermediate,80013,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,12680,F,,Oryctolagus cuniculus,9986.0,,A10,
6736,Autocuration,22226,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1313,F,,Rattus norvegicus,10116.0,,A10,
6737,Autocuration,22226,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1313,F,,Rattus norvegicus,10116.0,,A10,
6738,Intermediate,80013,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,17567,F,,Rattus norvegicus,10116.0,,A10,
6739,Intermediate,80013,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,17567,F,,Rattus norvegicus,10116.0,,A10,
6740,Intermediate,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,11819,F,,Rattus norvegicus,10116.0,,A10,
6741,Intermediate,80089,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,13436,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6742,Intermediate,80089,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6743,Intermediate,80089,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,12651,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6744,Intermediate,80089,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,13300,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6745,Intermediate,80089,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,15296,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6746,Intermediate,80089,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",15328,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6747,Intermediate,80089,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),13302,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6748,Expert,80089,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",14367,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6749,Expert,80089,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,17002,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6750,Intermediate,80089,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,13436,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6751,Intermediate,80089,,,Inhibitory activity against aerobic growth of AA8 cells.,13435,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6752,Intermediate,80089,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6753,Expert,80089,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6754,Intermediate,80089,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10503,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6755,Expert,80089,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,15090,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6756,Expert,80089,,,Cytotoxicity against AA8 cell line,10368,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6757,Intermediate,80089,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),12651,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6758,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6759,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6760,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),12687,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6761,Intermediate,80089,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1890,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6762,Intermediate,80089,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10747,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6763,Intermediate,80089,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10747,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6764,Autocuration,22224,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),11616,F,,Cricetulus griseus,10029.0,,,
6765,Expert,80089,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,11616,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6766,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6767,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6768,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6769,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6770,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6771,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6772,Autocuration,22224,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,3471,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6773,Expert,80089,,,Concentration required to reduce AA8 cell survival by 10%,11616,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6774,Autocuration,22224,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",2656,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6775,Autocuration,22224,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6776,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6777,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6778,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6779,Autocuration,22224,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,16156,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6780,Autocuration,22224,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,2656,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6781,Autocuration,22224,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",11005,F,,Cricetulus griseus,10029.0,,,
6782,Autocuration,22224,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,11942,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6783,Autocuration,22224,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,2128,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6784,Intermediate,50588,,,Half life period after 15 mg/kg iv dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6785,Intermediate,50588,,,Half life period after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6786,Intermediate,50588,,,Half life was measured after oral 2b administration (tested in 6 dogs),9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6787,Intermediate,50588,,,Half life was measured in dog after oral 17b administration,9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6788,Intermediate,50588,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6789,Intermediate,50588,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,9579,A,In vivo,Canis lupus familiaris,9615.0,,,
6790,Intermediate,50588,,,Tmax value after 15 mg/kg iv dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6791,Intermediate,50588,,,Tmax value after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6792,Intermediate,50588,,,Compound was evaluated for its half life when administered intravenously in dog,3184,A,In vivo,Canis lupus familiaris,9615.0,,,
6793,Intermediate,50588,Plasma,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),5017,A,In vivo,Canis lupus familiaris,9615.0,,,
6794,Intermediate,50588,,,Elimination Half-life of compound was determined in dog,6821,A,,Canis lupus familiaris,9615.0,,,
6795,Intermediate,50588,,,Half life of compound in dog following oral administration,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
6796,Intermediate,50588,,,Half life of compound was determined in dog,17267,A,,Canis lupus familiaris,9615.0,,,
6797,Intermediate,50588,Blood,,Half life of compound was determined in dog blood,4727,A,,Canis lupus familiaris,9615.0,,,
6798,Intermediate,50588,,,Half life after oral and iv dosing in dogs,5238,A,In vivo,Canis lupus familiaris,9615.0,,,
6799,Intermediate,50588,,,Half life in dogs in hours,4942,A,,Canis lupus familiaris,9615.0,,,
6800,Intermediate,50588,,,Half life on i.v. administration of 2 mg/kg was measured in dog,6505,A,In vivo,Canis lupus familiaris,9615.0,,,
6801,Intermediate,50588,,,t1/2 in dog after oral dose (1 mg/kg),5130,A,In vivo,Canis lupus familiaris,9615.0,,,
6802,Intermediate,50588,,,Half life was evaluated in dog,1475,A,,Canis lupus familiaris,9615.0,,,
6803,Intermediate,50588,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,17804,A,In vivo,Canis lupus familiaris,9615.0,,,
6804,Intermediate,50588,,,Half life period of compound was determined after peroral administration at 2 mg/kg,17804,A,In vivo,Canis lupus familiaris,9615.0,,,
6805,Intermediate,50588,,,Half life period (10 mg/kg) was determined in dog,6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6806,Intermediate,50588,,,Half life period (10 mg/kg) was determined in dog,6084,A,In vivo,Canis lupus familiaris,9615.0,,,
6807,Intermediate,50588,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,5542,A,In vivo,Canis lupus familiaris,9615.0,,,
6808,Intermediate,50588,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,5542,A,In vivo,Canis lupus familiaris,9615.0,,,
6809,Intermediate,50588,,,Half life period in dog,6084,A,,Canis lupus familiaris,9615.0,,,
6810,Intermediate,50588,,,Half life period in dogs after oral administration at 1 mg/kg,6241,A,In vivo,Canis lupus familiaris,9615.0,,,
6811,Intermediate,50588,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,A,In vivo,Canis lupus familiaris,9615.0,,,
6812,Intermediate,50588,,,Half-life of compound was determined in dogs,6621,A,,Canis lupus familiaris,9615.0,,,
6813,Intermediate,50588,Plasma,,Half-life in dog plasma,1696,A,,Canis lupus familiaris,9615.0,,,
6814,Intermediate,50588,,,Half-life in mongrel dogs was determined,17800,A,,Canis lupus familiaris,9615.0,,,
6815,Intermediate,50588,,,Half-life in dog upon oral administration,17657,A,In vivo,Canis lupus familiaris,9615.0,,,
6816,Intermediate,50588,,,Half-life in dog upon oral administration; Unable to calculate,17657,A,In vivo,Canis lupus familiaris,9615.0,,,
6817,Intermediate,50588,,,Half-life was measured in dog,4239,A,,Canis lupus familiaris,9615.0,,,
6818,Intermediate,50588,,,Half-life was measured in dog,5985,A,,Canis lupus familiaris,9615.0,,,
6819,Intermediate,50588,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,9932,A,,Canis lupus familiaris,9615.0,,,
6820,Intermediate,50588,,,Oral half life was determined,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
6821,Intermediate,50588,Plasma,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
6822,Intermediate,50588,Plasma,,Plasma half life was evaluated,1475,A,,Canis lupus familiaris,9615.0,,,
6823,Intermediate,50588,Plasma,,Plasma half life was evaluated in Dog,1475,A,,Canis lupus familiaris,9615.0,,,
6824,Intermediate,50588,Plasma,,Plasma half life was evaluated in dog,1475,A,,Canis lupus familiaris,9615.0,,,
6825,Intermediate,50588,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,6316,A,In vivo,Canis lupus familiaris,9615.0,,,
6826,Intermediate,50588,,,Tested for the half life value in dog,4883,A,,Canis lupus familiaris,9615.0,,,
6827,Intermediate,50588,,,Maximum time at the dose of 2 mg/kg in dog,4727,A,In vivo,Canis lupus familiaris,9615.0,,,
6828,Intermediate,50588,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1916,A,In vivo,Canis lupus familiaris,9615.0,,,
6829,Intermediate,50588,Blood,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
6830,Intermediate,50588,Blood,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
6831,Intermediate,50588,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,6265,A,In vivo,Canis lupus familiaris,9615.0,,,
6832,Intermediate,50588,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
6833,Intermediate,50588,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,5983,A,In vivo,Canis lupus familiaris,9615.0,,,
6834,Intermediate,50588,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",5313,A,,Canis lupus familiaris,9615.0,,,
6835,Intermediate,50588,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",5313,A,In vivo,Canis lupus familiaris,9615.0,,,
6836,Intermediate,50588,Plasma,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,17650,A,In vivo,Canis lupus familiaris,9615.0,,,
6837,Intermediate,50588,Plasma,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
6838,Intermediate,50588,Plasma,,Time taken for maximum plasma concentration in dog,933,A,,Canis lupus familiaris,9615.0,,,
6839,Intermediate,50588,,,Time to reach Cmax after oral administration to dogs,16367,A,In vivo,Canis lupus familiaris,9615.0,,,
6840,Intermediate,50588,Plasma,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
6841,Intermediate,50588,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,6316,A,In vivo,Canis lupus familiaris,9615.0,,,
6842,Intermediate,50588,,,Tmax after peroral administration (1 mg/kg) was determined in dog,6215,A,In vivo,Canis lupus familiaris,9615.0,,,
6843,Expert,50588,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Canis lupus familiaris,9615.0,,,
6844,Intermediate,50588,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,4527,A,In vivo,Canis lupus familiaris,9615.0,,,
6845,Intermediate,50588,,,Tmax after peroral administration in dogs at 2.4 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
6846,Intermediate,50594,,,In vivo Cmax in mice at dose of 100 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
6847,Intermediate,50594,,,In vivo Cmax in mice at dose of 50 mg/kg,5969,A,In vivo,Mus musculus,10090.0,,,
6848,Intermediate,50594,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,4573,A,In vivo,Mus musculus,10090.0,,,
6849,Intermediate,50594,Plasma,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,A,In vivo,Mus musculus,10090.0,,,
6850,Intermediate,50594,Plasma,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,17734,A,In vivo,Mus musculus,10090.0,,,
6851,Intermediate,50594,Plasma,,Maximum concentration obtained in mouse plasma was determined,3132,A,In vivo,Mus musculus,10090.0,,,
6852,Intermediate,50594,Plasma,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,3132,A,In vivo,Mus musculus,10090.0,,,
6853,Intermediate,50594,Plasma,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
6854,Intermediate,50594,Plasma,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,17729,A,In vivo,Mus musculus,10090.0,,,
6855,Intermediate,50594,Plasma,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,17729,A,In vivo,Mus musculus,10090.0,,,
6856,Intermediate,50594,Plasma,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,17729,A,In vivo,Mus musculus,10090.0,,,
6857,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,17728,A,In vivo,Mus musculus,10090.0,,,
6858,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,17728,A,In vivo,Mus musculus,10090.0,,,
6859,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,17728,A,In vivo,Mus musculus,10090.0,,,
6860,Intermediate,50594,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,4066,A,In vivo,Mus musculus,10090.0,,,
6861,Intermediate,50594,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,6178,A,In vivo,Mus musculus,10090.0,,,
6862,Intermediate,50594,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,6178,A,In vivo,Mus musculus,10090.0,,,
6863,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,3760,A,In vivo,Mus musculus,10090.0,,,
6864,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,3760,A,In vivo,Mus musculus,10090.0,,,
6865,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,3760,A,In vivo,Mus musculus,10090.0,,,
6866,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,3760,A,In vivo,Mus musculus,10090.0,,,
6868,Intermediate,50594,,,Cmax in male mice after 2 mg/kg oral dose,5961,A,In vivo,Mus musculus,10090.0,,,
6869,Intermediate,50594,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,6137,A,In vivo,Mus musculus,10090.0,,,
6870,Intermediate,50594,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,3802,A,In vivo,Mus musculus,10090.0,,,
6871,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,3535,A,,Mus musculus,10090.0,,,
6872,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,3535,A,,Mus musculus,10090.0,,,
6873,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,3535,A,,Mus musculus,10090.0,,,
6874,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,3535,A,,Mus musculus,10090.0,,,
6875,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,3535,A,,Mus musculus,10090.0,,,
6876,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,3535,A,,Mus musculus,10090.0,,,
6877,Intermediate,50594,Plasma,,Maximum concentration in plasma upon oral administration in mouse,2862,A,,Mus musculus,10090.0,,,
6878,Intermediate,50594,Plasma,,Maximum plasma concentration was evaluated in mice after oral administration,2675,A,,Mus musculus,10090.0,,,
6879,Intermediate,50594,Plasma,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,2675,A,In vivo,Mus musculus,10090.0,,,
6880,Intermediate,50594,,,Dose at which the compound induced fecal excretion in mice,5399,A,,Mus musculus,10090.0,,,
6893,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,11819,F,,Rattus norvegicus,10116.0,,A10,
6894,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,11819,F,,Rattus norvegicus,10116.0,,A10,
6895,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,11819,F,,Rattus norvegicus,10116.0,,A10,
6896,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,11819,F,,Rattus norvegicus,10116.0,,A10,
6897,Intermediate,80013,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),16361,F,,Rattus norvegicus,10116.0,,A10,
6898,Intermediate,80655,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,2288,F,,Homo sapiens,9606.0,,A121,
6899,Intermediate,80655,,,Anticancer activity against human ovarian carcinoma A121 cells,10404,F,,Homo sapiens,9606.0,,A121,
6900,Intermediate,80655,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,14790,F,,Homo sapiens,9606.0,,A121,
6901,Intermediate,80655,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,14790,F,,Homo sapiens,9606.0,,A121,
6902,Expert,80655,,,Growth inhibition of human ovarian carcinoma (A121) cell line,14253,F,,Homo sapiens,9606.0,,A121,
6903,Expert,80655,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,13617,F,,Homo sapiens,9606.0,,A121,
6904,Intermediate,80655,,,Cytotoxicity against human A121 ovarian cells,1003,F,,Homo sapiens,9606.0,,A121,
6905,Intermediate,80655,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,830,F,,Homo sapiens,9606.0,,A121,
6906,Intermediate,80655,,,In vitro cytotoxicity against human ovarian carcinoma A21,12307,F,,Homo sapiens,9606.0,,A121,
6907,Intermediate,80655,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,14254,F,,Homo sapiens,9606.0,,A121,
6908,Intermediate,80655,,,Inhibitory activity of compound against human A121 ovarian cell line.,13370,F,,Homo sapiens,9606.0,,A121,
6909,Intermediate,80655,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,14790,F,,Homo sapiens,9606.0,,A121,
6910,Intermediate,80655,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,3614,F,,Homo sapiens,9606.0,,A121,
6911,Intermediate,80012,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,2664,F,,Homo sapiens,9606.0,,A 172,
6912,Expert,80012,,,In vitro cytotoxicity against A172 human tumor cell lines.,2037,F,,Homo sapiens,9606.0,,A 172,
6913,Intermediate,80012,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,14539,F,,Homo sapiens,9606.0,,A 172,
6914,Intermediate,80012,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,2836,F,,Homo sapiens,9606.0,,A 172,
6915,Intermediate,80012,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,10708,F,,Homo sapiens,9606.0,,A 172,
6916,Autocuration,104729,,,Association constant against A2 adenosine receptor,8975,B,,Canis lupus familiaris,9615.0,,,
6917,Intermediate,80656,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,7645,F,,fish,,,A2,
6918,Autocuration,104713,,,Ratio of Ki for adenosine A2 and A1 receptor binding,11377,B,,Rattus norvegicus,10116.0,,,
6919,Expert,80014,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,13528,F,,Homo sapiens,9606.0,,A204,
6920,Expert,80014,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,10160,F,,Homo sapiens,9606.0,,A204,
6921,Intermediate,80015,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,15144,F,,Homo sapiens,9606.0,,A2058,
6922,Intermediate,80657,,,Growth inhibition against Human squamous cell line(A 253),13160,F,,Homo sapiens,9606.0,,A253 cell line,
6923,Intermediate,80657,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,12898,F,,Homo sapiens,9606.0,,A253 cell line,
6924,Intermediate,80657,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,13069,F,,Homo sapiens,9606.0,,A253 cell line,
6925,Intermediate,80657,,,Growth inhibition of A253 cell lines.,15984,F,,Homo sapiens,9606.0,,A253 cell line,
6926,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),15564,F,,Homo sapiens,9606.0,,A253 cell line,
6927,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,15564,F,,Homo sapiens,9606.0,,A253 cell line,
6928,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,15564,F,,Homo sapiens,9606.0,,A253 cell line,
6929,Intermediate,81034,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,4720,F,,Homo sapiens,9606.0,,A2780,
6930,Intermediate,81034,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,16112,F,,Homo sapiens,9606.0,,A2780,
6931,Expert,81034,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,16597,F,,Homo sapiens,9606.0,,A2780,
6932,Intermediate,81034,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),16378,F,,Homo sapiens,9606.0,,A2780,
6933,Expert,81034,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,16085,F,,Homo sapiens,9606.0,,A2780,
6934,Intermediate,81034,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,16317,F,,Homo sapiens,9606.0,,A2780,
6935,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),15748,F,,Homo sapiens,9606.0,,A2780,
6936,Expert,81034,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A2780,
6937,Expert,81034,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A2780,
6938,Expert,81034,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,16597,F,,Homo sapiens,9606.0,,A2780,
6939,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,15608,F,,Homo sapiens,9606.0,,A2780,
6940,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,15608,F,,Homo sapiens,9606.0,,A2780,
6941,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,15608,F,,Homo sapiens,9606.0,,A2780,
6942,Autocuration,22224,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,15296,F,,Cricetulus griseus,10029.0,,,
6943,Autocuration,22224,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,10251,A,,Cricetulus griseus,10029.0,,CHO-AA8,
6944,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,10251,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6945,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,10251,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6946,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),10251,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6947,Autocuration,22224,,,Growth inhibition against CHO-derived cell line AA8,11858,F,,Cricetulus griseus,10029.0,,,
6948,Autocuration,22224,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],11858,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6949,Expert,80089,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,11616,F,,hampster,36483.0,,CHO-AA8,
6950,Expert,80089,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,11616,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6951,Autocuration,22224,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6952,Autocuration,22224,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,11396,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6953,Autocuration,22224,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,10518,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6954,Expert,80089,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,11616,F,,Cricetulus griseus,10029.0,,CHO-AA8,
6955,Autocuration,12675,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,14837,F,,,,,,
6956,Autocuration,12675,,,Number of binding sites (n) of isolated serum protein AAG,14837,F,,,,,,
6957,Intermediate,22222,,,Association constant for binding to AATT duplex,16037,B,,,,,,
6958,Expert,100090,,,Inhibition of ABAE human fibroblast cell proliferation,16597,F,,Homo sapiens,9606.0,,ABAE,
6959,Intermediate,80668,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",8831,F,,Mus musculus,10090.0,,AC755,
6960,Expert,102444,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,13419,F,,Oryctolagus cuniculus,9986.0,,,
6961,Expert,102444,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,13419,F,In vivo,Oryctolagus cuniculus,9986.0,,,
6962,Autocuration,69,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,15778,B,,,,,,
6963,Autocuration,69,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,15778,B,,,,,,
6964,Intermediate,80669,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,12988,F,,Homo sapiens,9606.0,,ACH-2 cell line,
6965,Intermediate,80669,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),12988,F,,Homo sapiens,9606.0,,ACH-2 cell line,
6966,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,12988,F,,Human immunodeficiency virus 1,11676.0,,T cell line,
6967,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),12988,F,,Human immunodeficiency virus 1,11676.0,,T cell line,
6968,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),12988,F,,Human immunodeficiency virus 1,11676.0,,T cell line,
6969,Intermediate,80025,,,Inhibition of growth of renal cancer ACHN cell line,11843,F,,Homo sapiens,9606.0,,ACHN,
6970,Intermediate,80025,,,Inhibition of growth of ACHN renal cancer cell line,16939,F,,Homo sapiens,9606.0,,ACHN,
6971,Intermediate,80025,,,Inhibitory concentration required against ACHN renal cancer cell line,4782,F,,Homo sapiens,9606.0,,ACHN,
6972,Expert,80025,,,Concentration required to inhibit growth of human renal (ACHN) cell line,6310,F,,Homo sapiens,9606.0,,ACHN,
6973,Intermediate,80025,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,6310,F,,Homo sapiens,9606.0,,ACHN,
6974,Intermediate,80025,,,Cytotoxic activity against ACHN Renal cancer cell line,12858,F,,Homo sapiens,9606.0,,ACHN,
6975,Intermediate,80025,,,Cytotoxicity evaluation against ACHN renal cancer cells,17380,F,,Homo sapiens,9606.0,,ACHN,
6976,Intermediate,80025,,,In vitro antitumor activity against human renal ACHN cell line,5858,F,,Homo sapiens,9606.0,,ACHN,
6977,Intermediate,80025,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,3838,F,,Homo sapiens,9606.0,,ACHN,
6978,Intermediate,80025,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,3838,F,,Homo sapiens,9606.0,,ACHN,
6979,Intermediate,80025,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",5406,F,,Homo sapiens,9606.0,,ACHN,
6980,Intermediate,80025,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,4071,F,,Homo sapiens,9606.0,,ACHN,
6981,Expert,80025,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,4071,F,,Homo sapiens,9606.0,,ACHN,
6982,Intermediate,80025,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,4071,F,,Homo sapiens,9606.0,,ACHN,
6983,Intermediate,80025,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,15002,F,,Homo sapiens,9606.0,,ACHN,
6984,Intermediate,80025,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,ACHN,
6985,Intermediate,80025,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",13958,F,,Homo sapiens,9606.0,,ACHN,
6986,Intermediate,80025,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1665,F,,Homo sapiens,9606.0,,ACHN,
6987,Intermediate,80025,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,15354,F,,Homo sapiens,9606.0,,ACHN,
6988,Intermediate,80025,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,15354,F,,Homo sapiens,9606.0,,ACHN,
6989,Intermediate,80025,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,13978,F,,Homo sapiens,9606.0,,ACHN,
6990,Intermediate,80025,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,6798,F,,Homo sapiens,9606.0,,ACHN,
6991,Intermediate,50588,,,Tmax value after administration of 4 mg/Kg oral dose in dog,2959,A,In vivo,Canis lupus familiaris,9615.0,,,
6992,Intermediate,50588,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",9932,A,,Canis lupus familiaris,9615.0,,,
6993,Intermediate,50588,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,A,,Canis lupus familiaris,9615.0,,,
6994,Intermediate,50588,,,Volume distribution after 15 mg/kg iv dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6995,Intermediate,50588,,,Volume distribution after 30 mg/kg po dose in Dogs,16907,A,In vivo,Canis lupus familiaris,9615.0,,,
6996,Intermediate,50588,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,4257,A,In vivo,Canis lupus familiaris,9615.0,,,
6997,Intermediate,50588,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,4305,A,In vivo,Canis lupus familiaris,9615.0,,,
6998,Intermediate,50588,,,Volume of distribution was evaluated in dog,5472,A,In vivo,Canis lupus familiaris,9615.0,,,
6999,Intermediate,50588,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,6062,A,In vivo,Canis lupus familiaris,9615.0,,,
7000,Expert,50588,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,3598,A,,Canis lupus familiaris,9615.0,,,
7001,Intermediate,50588,,,The compound was tested for volume of distribution in dog,12500,A,In vivo,Canis lupus familiaris,9615.0,,,
7002,Intermediate,50588,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,12500,A,In vivo,Canis lupus familiaris,9615.0,,,
7003,Intermediate,50588,,,Vd (1 mg/kg) was determined in dog (in vivo),6227,A,In vivo,Canis lupus familiaris,9615.0,,,
7004,Intermediate,50588,,,Vd in dog,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
7005,Intermediate,50588,,,Volume distribution was determined,4219,A,In vivo,Canis lupus familiaris,9615.0,,,
7006,Intermediate,50588,,,Volume of distribution in dog,1696,A,In vivo,Canis lupus familiaris,9615.0,,,
7007,Intermediate,50588,,,Volume of distribution by as 4 fold increase by iv administration in dogs,5542,A,In vivo,Canis lupus familiaris,9615.0,,,
7008,Intermediate,50588,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,5199,A,In vivo,Canis lupus familiaris,9615.0,,,
7009,Intermediate,50588,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
7010,Intermediate,50588,,,Volume distribution at the dose of 2 mg/kg in dog,4727,A,In vivo,Canis lupus familiaris,9615.0,,,
7011,Intermediate,50588,,,Steady state volume of distribution was determined,16367,A,In vivo,Canis lupus familiaris,9615.0,,,
7012,Intermediate,50588,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,2652,A,In vivo,Canis lupus familiaris,9615.0,,,
7013,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7014,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7015,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7016,Intermediate,50588,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
7017,Intermediate,50588,,,Pharmacokinetic property (vdss) was measured in dog,4239,A,In vivo,Canis lupus familiaris,9615.0,,,
7018,Intermediate,50588,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,4709,A,In vivo,Canis lupus familiaris,9615.0,,,
7019,Intermediate,50588,,,Vdss was determined after iv 0.1 mg/kg administration in dog,5600,A,In vivo,Canis lupus familiaris,9615.0,,,
7020,Intermediate,50588,,,Volume displacement was calculated in dog,6057,A,In vivo,Canis lupus familiaris,9615.0,,,
7021,Intermediate,50588,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,A,In vivo,Canis lupus familiaris,9615.0,,,
7022,Intermediate,50588,,,Volume distribution constant was determined,5505,A,In vivo,Canis lupus familiaris,9615.0,,,
7023,Intermediate,50588,,,Volume distribution at a dose of 1 uM/kg in dog was determined,4527,A,In vivo,Canis lupus familiaris,9615.0,,,
7024,Intermediate,50588,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
7025,Intermediate,50588,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
7026,Intermediate,50588,,,Volume distribution (Vdss) was measured in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
7027,Intermediate,50588,,,Volume distribution (Vdss) was measured in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
7028,Intermediate,50588,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Canis lupus familiaris,9615.0,,,
7029,Intermediate,50588,,,Volume of distribution in steady state was determined in dog,5145,A,In vivo,Canis lupus familiaris,9615.0,,,
7030,Intermediate,50588,,,Volume of distribution of compound was determined in dog,6821,A,In vivo,Canis lupus familiaris,9615.0,,,
7031,Intermediate,50588,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,4137,A,In vivo,Canis lupus familiaris,9615.0,,,
7032,Intermediate,50588,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),5334,A,In vivo,Canis lupus familiaris,9615.0,,,
7033,Intermediate,50588,,,Volume of distribution (Vdss) was measured in dog,15660,A,In vivo,Canis lupus familiaris,9615.0,,,
7034,Intermediate,50588,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
7035,Intermediate,50588,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Canis lupus familiaris,9615.0,,,
7036,Intermediate,50588,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
7037,Intermediate,50588,,,Maximum rate of depolarization of the upstroke of the action potential,11659,A,,Canis lupus familiaris,9615.0,,,
7038,Intermediate,50588,,,Steady state volume distribution in dog,6448,A,In vivo,Canis lupus familiaris,9615.0,,,
7039,Intermediate,50588,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,5474,A,In vivo,Canis lupus familiaris,9615.0,,,
7040,Intermediate,50588,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1466,A,In vivo,Canis lupus familiaris,9615.0,,,
7041,Intermediate,50588,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
7042,Intermediate,50588,,,Volume distribution in dog after administration of 1 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
7043,Intermediate,50588,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,17764,A,In vivo,Canis lupus familiaris,9615.0,,,
7044,Intermediate,50588,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,6215,A,In vivo,Canis lupus familiaris,9615.0,,,
7045,Intermediate,50588,,,Vss on i.v. administration of 2 mg/kg was measured in dog,6505,A,In vivo,Canis lupus familiaris,9615.0,,,
7046,Intermediate,50588,,,Vss was determined,3639,A,,Canis lupus familiaris,9615.0,,,
7047,Intermediate,50588,,,Vss in dog,3639,A,,Canis lupus familiaris,9615.0,,,
7048,Intermediate,50588,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,6062,A,In vivo,Canis lupus familiaris,9615.0,,,
7049,Intermediate,50588,,,Volume distribution in dogs,4942,A,In vivo,Canis lupus familiaris,9615.0,,,
7050,Intermediate,50588,,,Volume of distribution in dog,17796,A,In vivo,Canis lupus familiaris,9615.0,,,
7051,Intermediate,50588,,,Tested for the oral bioavailability in dog,4883,A,In vivo,Canis lupus familiaris,9615.0,,,
7060,Intermediate,50594,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,17837,A,In vivo,Mus musculus,10090.0,,,
7061,Intermediate,50594,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,17729,A,In vivo,Mus musculus,10090.0,,,
7062,Intermediate,50594,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,17729,A,In vivo,Mus musculus,10090.0,,,
7063,Intermediate,50594,,,Bioavailability was measured in mouse,4239,A,In vivo,Mus musculus,10090.0,,,
7064,Intermediate,50594,,,Bioavailability in mouse,17592,A,In vivo,Mus musculus,10090.0,,,
7065,Intermediate,50594,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
7066,Intermediate,50594,,,Bioavailability in mouse,2801,A,In vivo,Mus musculus,10090.0,,,
7067,Intermediate,50594,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,2801,A,In vivo,Mus musculus,10090.0,,,
7068,Intermediate,50594,,,Oral bioavailability in mouse,17718,A,In vivo,Mus musculus,10090.0,,,
7069,Intermediate,50594,,,Oral availability at 50 mg/kg po in male mice,5727,A,In vivo,Mus musculus,10090.0,,,
7070,Intermediate,50594,,,Oral bioavailability in mouse (dose 10 mg/kg),5302,A,In vivo,Mus musculus,10090.0,,,
7071,Expert,50594,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Mus musculus,10090.0,,,
7072,Intermediate,50594,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",5961,A,In vivo,Mus musculus,10090.0,,,
7074,Intermediate,50594,,,Oral bioavailability in mouse,6091,A,In vivo,Mus musculus,10090.0,,,
7075,Intermediate,50594,,,Oral bioavailability in vivo in mice;ND=Not determined,6091,A,In vivo,Mus musculus,10090.0,,,
7076,Intermediate,50594,,,Oral bioavailability in mouse at 10 mg/kg of the compound,5711,A,In vivo,Mus musculus,10090.0,,,
7077,Intermediate,50594,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),17728,A,In vivo,Mus musculus,10090.0,,,
7078,Intermediate,50594,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),17728,A,In vivo,Mus musculus,10090.0,,,
7079,Intermediate,50594,,,Tested for bioavailability of the compound,3802,A,In vivo,Mus musculus,10090.0,,,
7080,Intermediate,50594,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,3802,A,In vivo,Mus musculus,10090.0,,,
7081,Intermediate,50594,Plasma,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,14029,A,,Mus musculus,10090.0,,,
7082,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by human plasma. ,14029,A,,Mus musculus,10090.0,,,
7083,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,14029,A,,Mus musculus,10090.0,,,
7084,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,14029,A,,Mus musculus,10090.0,,,
7085,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,14029,A,,Mus musculus,10090.0,,,
7086,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,17753,F,,Mus musculus,10090.0,,,
7087,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,17753,A,,Mus musculus,10090.0,,,
7088,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,17753,A,,Mus musculus,10090.0,,,
7089,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7090,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7091,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7092,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7093,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7094,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7095,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7096,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7097,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7098,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,15608,F,,Homo sapiens,9606.0,,A2780,
7099,Expert,81034,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,3290,F,,Homo sapiens,9606.0,,A2780,
7100,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell line,2859,F,,Homo sapiens,9606.0,,A2780,
7101,Expert,81034,,,Inhibition of A2780 cell clonogenic assay,15688,F,,Homo sapiens,9606.0,,A2780,
7102,Expert,81034,,,Cytotoxic effect on ovarian cancer cell line (A2780),5642,F,,Homo sapiens,9606.0,,A2780,
7103,Intermediate,81034,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,6633,F,,Homo sapiens,9606.0,,A2780,
7104,Intermediate,81034,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",3906,F,,Homo sapiens,9606.0,,A2780,
7105,Expert,81034,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,6788,F,,Homo sapiens,9606.0,,A2780,
7106,Expert,81034,,,Antiproliferative activity against human A2780 cells,17582,F,,Homo sapiens,9606.0,,A2780,
7107,Expert,81034,,,Inhibition of human A2780 cell proliferation,17764,F,,Homo sapiens,9606.0,,A2780,
7108,Expert,81034,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,17764,F,,Homo sapiens,9606.0,,A2780,
7109,Expert,81034,,,Inhibition of human A2780 cell proliferation (No data),17764,F,,Homo sapiens,9606.0,,A2780,
7110,Intermediate,81034,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,2815,F,,Homo sapiens,9606.0,,A2780,
7111,Intermediate,81034,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,16930,F,,Homo sapiens,9606.0,,A2780,
7112,Expert,81034,,,Growth inhibition against A2780 wild-type ovarian cell lines,17777,F,,Homo sapiens,9606.0,,A2780,
7113,Intermediate,81034,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,17777,F,,Homo sapiens,9606.0,,A2780,
7114,Autocuration,104766,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,16936,F,,Homo sapiens,9606.0,,,
7115,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,13759,F,,Homo sapiens,9606.0,,A2780,
7116,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,13759,F,,Homo sapiens,9606.0,,A2780,
7117,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,13759,F,,Homo sapiens,9606.0,,A2780,
7118,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,13759,F,,Homo sapiens,9606.0,,A2780,
7119,Intermediate,81034,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,15292,F,,Homo sapiens,9606.0,,A2780,
7120,Intermediate,81034,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,15292,F,,Homo sapiens,9606.0,,A2780,
7121,Expert,81034,,,In vitro inhibition of human ovarian cell line A2780,15069,F,,Homo sapiens,9606.0,,A2780,
7122,Expert,81034,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",15069,F,,Homo sapiens,9606.0,,A2780,
7123,Intermediate,81034,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),14073,F,,Homo sapiens,9606.0,,A2780,
7124,Expert,81034,,,Concentration required to inhibit A2780-cell growth by 50%,14553,F,,Homo sapiens,9606.0,,A2780,
7125,Expert,81034,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,13040,F,,Homo sapiens,9606.0,,A2780,
7126,Expert,81034,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,6891,F,,Homo sapiens,9606.0,,A2780,
7127,Intermediate,81034,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,15569,F,,Homo sapiens,9606.0,,A2780,
7128,Expert,81034,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,14190,F,,Homo sapiens,9606.0,,A2780,
7129,Expert,81034,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,15014,F,,Homo sapiens,9606.0,,A2780,
7130,Intermediate,81034,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,15014,F,,Homo sapiens,9606.0,,A2780,
7131,Intermediate,81034,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,17496,F,,Homo sapiens,9606.0,,A2780,
7132,Intermediate,81034,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",13617,F,,Homo sapiens,9606.0,,A2780,
7133,Intermediate,81034,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",13617,F,,Homo sapiens,9606.0,,A2780,
7134,Intermediate,81034,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",13617,F,,Homo sapiens,9606.0,,A2780,
7135,Intermediate,81034,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",13617,F,,Homo sapiens,9606.0,,A2780,
7136,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,17672,F,,Homo sapiens,9606.0,,A2780,
7137,Intermediate,81034,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,4544,F,,Homo sapiens,9606.0,,A2780,
7138,Intermediate,81034,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,4544,F,,Homo sapiens,9606.0,,A2780,
7139,Intermediate,81034,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",16317,F,,Homo sapiens,9606.0,,A2780,
7140,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,15099,F,,Homo sapiens,9606.0,,A2780,
7141,Intermediate,81034,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,13978,F,,Homo sapiens,9606.0,,A2780,
7142,Expert,81034,,,In vitro antitumor activity against A2780 cell line.,12989,F,,Homo sapiens,9606.0,,A2780,
7143,Intermediate,81034,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,5574,F,,Homo sapiens,9606.0,,A2780,
7144,Expert,81034,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,13528,F,,Homo sapiens,9606.0,,A2780,
7145,Intermediate,80025,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,12782,F,,Homo sapiens,9606.0,,ACHN,
7146,Intermediate,80025,,,The IC50 value was measured on ACHN cell line in renal tumor type.,14255,F,,Homo sapiens,9606.0,,ACHN,
7147,Intermediate,80025,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,16364,F,,Homo sapiens,9606.0,,ACHN,
7148,Expert,80025,,,In vitro lethal concentration against most sensitive ACHN cell line,17376,F,,Homo sapiens,9606.0,,ACHN,
7149,Intermediate,80025,,,Tested for cytotoxic activity against renal cancer ACHN cell line,12016,F,,Homo sapiens,9606.0,,ACHN,
7150,Intermediate,80025,,,Compound tested for growth inhibition of renal cancer cell line ACHN,6058,F,,Homo sapiens,9606.0,,ACHN,
7151,Intermediate,80025,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,17708,F,,Homo sapiens,9606.0,,ACHN,
7152,Intermediate,80025,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,15176,F,,Homo sapiens,9606.0,,ACHN,
7153,Intermediate,80025,,,In vitro anticancer activity against ACHN renal cancer cell line,2806,F,,Homo sapiens,9606.0,,ACHN,
7154,Intermediate,80025,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,15300,F,,Homo sapiens,9606.0,,ACHN,
7155,Intermediate,80025,,,Percent selectivity was evaluated in renal ACHN cell lines,16364,F,,Homo sapiens,9606.0,,ACHN,
7156,Intermediate,80025,,,In vitro inhibitory activity against renal ACHN cancer cell line,13859,F,,Homo sapiens,9606.0,,ACHN,
7157,Intermediate,80025,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,11970,F,,Homo sapiens,9606.0,,ACHN,
7158,Intermediate,80025,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,2450,F,,Homo sapiens,9606.0,,ACHN,
7159,Intermediate,80025,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,12696,F,,Homo sapiens,9606.0,,ACHN,
7160,Intermediate,80025,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,12400,F,,Homo sapiens,9606.0,,ACHN,
7161,Expert,80025,,,Cytotoxic effect on renal cancer line ACHN,12888,F,,Homo sapiens,9606.0,,ACHN,
7162,Intermediate,80025,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,3156,F,,Homo sapiens,9606.0,,ACHN,
7163,Intermediate,80025,,,In vitro inhibition of Renal Cancer ACHN cell lines,3381,F,,Homo sapiens,9606.0,,ACHN,
7164,Intermediate,80025,,,Antitumor activity against human renal adenocarcinoma ACHN cells,16747,F,,Homo sapiens,9606.0,,ACHN,
7165,Expert,80025,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,16748,F,,Homo sapiens,9606.0,,ACHN,
7166,Intermediate,80025,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,12062,F,,Homo sapiens,9606.0,,ACHN,
7167,Intermediate,80025,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),14769,F,,Homo sapiens,9606.0,,ACHN,
7168,Intermediate,80025,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",15895,F,,Homo sapiens,9606.0,,ACHN,
7169,Intermediate,80025,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,17376,F,,Homo sapiens,9606.0,,ACHN,
7170,Intermediate,80025,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,14882,F,,Homo sapiens,9606.0,,ACHN,
7171,Intermediate,80025,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,14882,F,,Homo sapiens,9606.0,,ACHN,
7172,Intermediate,80025,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,15661,F,,Homo sapiens,9606.0,,ACHN,
7173,Autocuration,22224,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,9680,A,,,,,,
7174,Autocuration,10647,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,14579,F,,,,,,
7175,Expert,50529,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,17290,F,,Cytomegalovirus,10358.0,,HEL,
7176,Intermediate,50529,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,17290,F,,Cytomegalovirus,10358.0,,,
7177,Autocuration,12159,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),15891,B,,,,,,
7178,Autocuration,12159,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),15890,B,,,,,,
7179,Intermediate,80670,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,3801,F,,Bos taurus,9913.0,,ADDP cell line,
7180,Intermediate,80671,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,9222,F,,Mus musculus,10090.0,,ADJ/PC6,
7181,Intermediate,80671,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,9222,F,,Mus musculus,10090.0,,ADJ/PC6,
7182,Intermediate,80671,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",7257,F,,Mus musculus,10090.0,,ADJ/PC6,
7183,Intermediate,80671,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,7257,F,,Mus musculus,10090.0,,ADJ/PC6,
7184,Intermediate,80671,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,7257,A,,Mus musculus,10090.0,,ADJ/PC6,
7185,Intermediate,80671,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,8084,F,,Mus musculus,10090.0,,ADJ/PC6,
7186,Autocuration,22224,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,14943,F,,Mus musculus,10090.0,,,
7187,Autocuration,22224,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,14943,F,,Mus musculus,10090.0,,,
7188,Autocuration,22224,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,14943,F,,Mus musculus,10090.0,,,
7189,Autocuration,22224,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),10524,A,In vivo,Bacillus subtilis,1423.0,,,
7190,Intermediate,50588,Plasma,,AUC value in dog after IV administration at a dose of 5 mg/kg,3546,A,,Canis lupus familiaris,9615.0,,,
7191,Intermediate,50588,Plasma,,AUC value in dog after oral administration at a dose of 5 mg/kg,3546,A,,Canis lupus familiaris,9615.0,,,
7192,Intermediate,50588,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,3546,A,In vivo,Canis lupus familiaris,9615.0,,,
7193,Intermediate,50588,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,3546,A,In vivo,Canis lupus familiaris,9615.0,,,
7194,Intermediate,50588,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,3546,A,In vivo,Canis lupus familiaris,9615.0,,,
7195,Intermediate,50588,,,Compound was evaluated for its clearance when administered intravenously in dog,3184,A,In vivo,Canis lupus familiaris,9615.0,,,
7196,Intermediate,50588,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Canis lupus familiaris,9615.0,,,
7197,Intermediate,50588,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
7198,Intermediate,22229,,,Calculated partition coefficient (clogP),4219,P,,,,,,
7199,Intermediate,50588,,,Half life in dog,3748,A,,Canis lupus familiaris,9615.0,,,
7200,Intermediate,50588,,,Time taken for EC90 was determined when tested in dog,3132,A,,Canis lupus familiaris,9615.0,,,
7201,Intermediate,50588,,,Half life (iv) was determined,4219,A,,Canis lupus familiaris,9615.0,,,
7202,Intermediate,50588,Liver,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,16907,A,,Canis lupus familiaris,9615.0,,,
7203,Intermediate,50588,,,Area under the curve was calculated in dog after iv administration,6057,A,,Canis lupus familiaris,9615.0,,,
7204,Intermediate,50588,,,Area under the curve was calculated in dog after peroral administration,6057,A,,Canis lupus familiaris,9615.0,,,
7205,Intermediate,50588,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,17853,A,,Canis lupus familiaris,9615.0,,,
7206,Intermediate,50588,,,pKa was evaluated in dog,3639,A,,Canis lupus familiaris,9615.0,,,
7207,Intermediate,50588,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,14541,A,,Canis lupus familiaris,9615.0,,,
7208,Intermediate,50588,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Canis lupus familiaris,9615.0,,,
7209,Intermediate,50588,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Canis lupus familiaris,9615.0,,,
7210,Intermediate,50588,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,2652,A,In vivo,Canis lupus familiaris,9615.0,,,
7211,Intermediate,50588,,,Compound was evaluated for the half-life (t 1/2) in hours,3624,A,,Canis lupus familiaris,9615.0,,,
7212,Intermediate,50588,Blood,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
7213,Intermediate,50588,Blood,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1337,A,In vivo,Canis lupus familiaris,9615.0,,,
7214,Intermediate,50588,,,Half life after intravenous administration of 1 mg/kg in dog,4709,A,In vivo,Canis lupus familiaris,9615.0,,,
7215,Intermediate,50588,,,Half life was measured in dog,15660,A,,Canis lupus familiaris,9615.0,,,
7216,Intermediate,50588,,,Half life period in dog after 5 mg/kg dose,5302,A,In vivo,Canis lupus familiaris,9615.0,,,
7217,Intermediate,50588,,,Half life period was evaluated in dog; 4-4.8,17791,A,,Canis lupus familiaris,9615.0,,,
7218,Intermediate,50588,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,6348,A,In vivo,Canis lupus familiaris,9615.0,,,
7219,Intermediate,50588,,,Half-life was determined in dog after a3 mg/kg of iv dose,4257,A,In vivo,Canis lupus familiaris,9615.0,,,
7220,Intermediate,50588,,,Half-life was determined,3771,A,,Canis lupus familiaris,9615.0,,,
7221,Intermediate,50588,,,Half life in dogs,6305,A,,Canis lupus familiaris,9615.0,,,
7222,Intermediate,50588,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,13501,A,In vivo,Canis lupus familiaris,9615.0,,,
7223,Intermediate,50588,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,17594,A,In vivo,Canis lupus familiaris,9615.0,,,
7224,Intermediate,50588,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,3045,A,In vivo,Canis lupus familiaris,9615.0,,,
7225,Intermediate,50588,,,Compound was evaluated for the half life period after oral administration in conscious dog.,3043,A,In vivo,Canis lupus familiaris,9615.0,,,
7226,Intermediate,50588,,,Compound was tested for half life in dog,4839,A,,Canis lupus familiaris,9615.0,,,
7227,Intermediate,50588,,,Compound was tested for its half life in dog,4839,A,,Canis lupus familiaris,9615.0,,,
7228,Intermediate,50588,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,5802,A,In vivo,Canis lupus familiaris,9615.0,,,
7229,Intermediate,50588,,,Half life of compound in dog was determined,17839,A,,Canis lupus familiaris,9615.0,,,
7230,Intermediate,50588,,,Half life (iv) was determined,4219,A,In vivo,Canis lupus familiaris,9615.0,,,
7231,Intermediate,50588,Blood,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),13966,A,,Canis lupus familiaris,9615.0,,,
7232,Intermediate,50588,Plasma,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,3994,A,In vivo,Canis lupus familiaris,9615.0,,,
7233,Intermediate,50588,Plasma,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,3994,F,In vivo,Canis lupus familiaris,9615.0,,,
7234,Intermediate,50588,,,Half life in dog,4453,A,,Canis lupus familiaris,9615.0,,,
7235,Intermediate,50588,Plasma,,Half life in dog plasma,6535,A,,Canis lupus familiaris,9615.0,,,
7236,Intermediate,50588,Plasma,,Half life in dog plasma after administration of 0.25 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
7237,Intermediate,50588,Plasma,,Half life in dog plasma after administration of 1 mg/kg iv,6535,A,In vivo,Canis lupus familiaris,9615.0,,,
7238,Intermediate,50588,Plasma,,Half life in dog plasma was determined at dose 10 mg/kg,3132,A,In vivo,Canis lupus familiaris,9615.0,,,
7239,Intermediate,50588,,,Half life in dog was determined,5374,A,,Canis lupus familiaris,9615.0,,,
7240,Intermediate,50588,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),5007,A,In vivo,Canis lupus familiaris,9615.0,,,
7241,Intermediate,50588,Plasma,,Half life upon exposure to human plasma,16907,A,,Canis lupus familiaris,9615.0,,,
7242,Intermediate,50588,,,Half life was calculated in dog,6057,A,,Canis lupus familiaris,9615.0,,,
7243,Intermediate,50588,,,Half life was determined,5006,A,,Canis lupus familiaris,9615.0,,,
7244,Intermediate,50588,,,Half life was determined,5473,A,,Canis lupus familiaris,9615.0,,,
7245,Intermediate,50588,,,Half life by intravenous administration of 1.2 mg/kg in dog,4368,A,In vivo,Canis lupus familiaris,9615.0,,,
7246,Intermediate,50588,,,Half life in dog,6448,A,,Canis lupus familiaris,9615.0,,,
7247,Intermediate,50588,,,Half life in dog after intra venous administration of the compound,4353,A,,Canis lupus familiaris,9615.0,,,
7248,Intermediate,50588,,,Half life in dog after intra venous administration of the compound; ND means Not determined,4353,A,,Canis lupus familiaris,9615.0,,,
7249,Intermediate,50588,,,Half life in dog after po administration of the compound,4353,A,In vivo,Canis lupus familiaris,9615.0,,,
7250,Intermediate,50588,,,Half life in dog after po administration of the compound; ND means Not determined,4353,A,In vivo,Canis lupus familiaris,9615.0,,,
7251,Intermediate,50588,,,Half life in dog at the single oral dose of 1 mg/kg,6265,A,In vivo,Canis lupus familiaris,9615.0,,,
7252,Intermediate,50588,,,Half life in dogs,5006,A,,Canis lupus familiaris,9615.0,,,
7253,Intermediate,50588,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,5356,A,In vivo,Canis lupus familiaris,9615.0,,,
7254,Intermediate,50588,,,Half life in rat,405,A,,Canis lupus familiaris,9615.0,,,
7255,Intermediate,50588,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
7256,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7257,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7258,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7259,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7260,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7261,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7262,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7263,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7264,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7265,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7266,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7267,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7268,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7269,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7270,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7271,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7272,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7273,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7274,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7275,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7276,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7277,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7278,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7279,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7280,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7281,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7282,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7283,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7284,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7285,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7286,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7287,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7288,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7289,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7290,Intermediate,81034,,,In vitro cytotoxicity against A2780 (human ovarian cancer),5895,F,,Homo sapiens,9606.0,,A2780,
7291,Intermediate,81034,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,6338,F,,Homo sapiens,9606.0,,A2780,
7292,Intermediate,81034,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,15163,F,,Homo sapiens,9606.0,,A2780,
7293,Intermediate,81034,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,15163,F,,Homo sapiens,9606.0,,A2780,
7294,Expert,81034,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,15000,F,,Homo sapiens,9606.0,,A2780,
7295,Expert,81034,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,15000,F,,Homo sapiens,9606.0,,A2780,
7296,Expert,81034,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,14729,F,,Homo sapiens,9606.0,,A2780,
7297,Intermediate,81034,,,In vitro cytotoxicity against A2780 cell line,17270,F,,Homo sapiens,9606.0,,A2780,
7298,Intermediate,81034,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,5685,F,,Homo sapiens,9606.0,,A2780,
7299,Intermediate,81034,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,3563,F,,Homo sapiens,9606.0,,A2780,
7300,Intermediate,81034,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,17753,F,,Homo sapiens,9606.0,,A2780,
7301,Intermediate,81034,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",16317,F,,Homo sapiens,9606.0,,A2780,
7302,Intermediate,81034,,,Inhibition of tubulin polymerization in analogy of ca.,16936,F,,Homo sapiens,9606.0,,A2780,
7303,Intermediate,81034,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,3801,F,,Homo sapiens,9606.0,,A2780,
7304,Expert,81034,,,Cytotoxic effect in ovarian cancer cell line (A2780),6181,F,,Homo sapiens,9606.0,,A2780,
7305,Intermediate,81034,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,5318,F,,Homo sapiens,9606.0,,A2780,
7306,Intermediate,81034,,,Tested for the cytotoxicity in A2780 ovarian cell line,4840,F,,Homo sapiens,9606.0,,A2780,
7307,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),15748,F,,Homo sapiens,9606.0,,A2780,
7308,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,15748,F,,Homo sapiens,9606.0,,A2780,
7309,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,15748,F,,,,,A2780cisR,
7310,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),15748,F,,,,,A2780cisR,
7311,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,15748,F,,,,,A2780cisR,
7312,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),15748,F,,,,,A2780cisR,
7313,Intermediate,81034,,,In vivo log of cells killed after administration of compound in A2780 cell line,17753,F,,Homo sapiens,9606.0,,A2780,
7314,Intermediate,81034,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,17753,F,In vivo,Homo sapiens,9606.0,,A2780,
7315,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,16936,F,,Homo sapiens,9606.0,,A2780,
7316,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,16936,F,,Homo sapiens,9606.0,,A2780,
7317,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,16936,F,,Homo sapiens,9606.0,,A2780,
7318,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,16936,F,,Homo sapiens,9606.0,,A2780,
7319,Intermediate,81034,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),17528,F,,Homo sapiens,9606.0,,A2780,
7320,Intermediate,81034,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,6633,F,,Homo sapiens,9606.0,,A2780,
7321,Expert,81034,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,15000,F,,Homo sapiens,9606.0,,A2780,
7322,Expert,81034,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,17528,F,,Homo sapiens,9606.0,,A2780,
7323,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,16936,F,,Homo sapiens,9606.0,,A2780,
7324,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,16936,F,,Homo sapiens,9606.0,,A2780,
7325,Intermediate,81034,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,16936,F,,Homo sapiens,9606.0,,A2780,
7326,Intermediate,81034,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",16936,F,,Homo sapiens,9606.0,,A2780,
7327,Intermediate,81034,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),16936,F,,Homo sapiens,9606.0,,A2780,
7328,Expert,81034,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",16936,F,,Homo sapiens,9606.0,,A2780,
7329,Intermediate,81034,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,F,,Homo sapiens,9606.0,,A2780,
7330,Intermediate,81034,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,F,,Homo sapiens,9606.0,,A2780,
7331,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),16936,F,,Homo sapiens,9606.0,,A2780,
7332,Intermediate,81034,,,In vitro antiproliferative activity against A2780 cell line,17737,F,,Mus musculus,10090.0,,A2780,
7333,Expert,81034,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,17764,F,,Mus musculus,10090.0,,A2780,
7334,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,3830,F,,Homo sapiens,9606.0,,A2780,
7335,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,3829,F,,Homo sapiens,9606.0,,A2780,
7336,Intermediate,50588,,,Vc value in dog after IV administration at a dose of 5 mg/kg,3546,A,,Canis lupus familiaris,9615.0,,,
7337,Intermediate,50588,,,Half life period in dog after IV administration at a dose of 5 mg/kg,3546,A,In vivo,Canis lupus familiaris,9615.0,,,
7338,Autocuration,22224,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,5668,A,,Cercopithecidae,9527.0,,,
7339,Autocuration,22224,Plasma,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
7340,Autocuration,22224,Plasma,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,,Cercopithecidae,9527.0,,,
7341,Autocuration,22224,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
7342,Autocuration,22224,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
7343,Autocuration,22224,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
7344,Autocuration,22224,,,Oral Bioavailability in rat,4256,A,In vivo,Rattus norvegicus,10116.0,,,
7345,Autocuration,22224,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1916,A,,Cercopithecidae,9527.0,,,
7346,Autocuration,22224,,,Area under curve value in monkey at a dose of 5 mg/kg,5302,A,,Cercopithecidae,9527.0,,,
7347,Autocuration,22224,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,4257,A,,Cercopithecidae,9527.0,,,
7348,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,5355,A,,Cercopithecidae,9527.0,,,
7349,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,5355,A,,Cercopithecidae,9527.0,,,
7350,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,5355,A,,Cercopithecidae,9527.0,,,
7351,Autocuration,22224,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,6078,A,,Cercopithecidae,9527.0,,,
7352,Autocuration,22224,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,6078,A,,Cercopithecidae,9527.0,,,
7353,Autocuration,22224,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,6062,A,,Cercopithecidae,9527.0,,,
7354,Autocuration,22224,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,A,,Cercopithecidae,9527.0,,,
7355,Autocuration,22224,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,A,,Cercopithecidae,9527.0,,,
7356,Autocuration,22224,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,5394,A,,Cercopithecidae,9527.0,,,
7357,Autocuration,22224,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,4397,A,,Cercopithecidae,9527.0,,,
7358,Autocuration,22224,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,17509,A,,Cercopithecidae,9527.0,,,
7359,Autocuration,22224,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,17509,A,,Cercopithecidae,9527.0,,,
7360,Autocuration,22224,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),6641,A,In vivo,Cercopithecidae,9527.0,,,
7361,Autocuration,22224,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),5355,A,,Cercopithecidae,9527.0,,,
7362,Autocuration,22224,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,In vivo,Cercopithecidae,9527.0,,,
7363,Autocuration,22224,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,3443,A,In vivo,Cercopithecidae,9527.0,,,
7364,Autocuration,22224,,,Binding towards monkey plasma protein at 10 uM,17409,A,,Cercopithecidae,9527.0,,,
7365,Autocuration,22224,,,Binding towards monkey plasma protein at 100 uM,17409,A,,Cercopithecidae,9527.0,,,
7366,Autocuration,22224,,,Apparent bioavailability in squirrel monkey was determined,1052,A,In vivo,Cercopithecidae,9527.0,,,
7367,Autocuration,22224,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,13501,A,In vivo,Cercopithecidae,9527.0,,,
7368,Autocuration,22224,,,Bioavailability in monkey (dose 2 mg/kg),17509,A,In vivo,monkey,9443.0,,,
7369,Autocuration,22224,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,5394,A,In vivo,Cercopithecidae,9527.0,,,
7370,Autocuration,22224,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
7371,Autocuration,22224,,,Bioavailability in monkey (i.d. dosing),11219,A,In vivo,monkey,9443.0,,,
7372,Autocuration,22224,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,3045,A,In vivo,Cercopithecidae,9527.0,,,
7373,Autocuration,22224,,,Clearance of the drug was measured in cynomolgus,17796,A,,Cercopithecidae,9527.0,,,
7374,Autocuration,22224,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1399,A,In vivo,Cercopithecidae,9527.0,,,
7375,Autocuration,22224,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,2661,A,In vivo,Cercopithecidae,9527.0,,,
7376,Autocuration,22224,Plasma,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,A,In vivo,Macaca mulatta,9544.0,,,
7377,Autocuration,22224,,,Plasma clearance in rhesus monkey was determined,17267,A,In vivo,Cercopithecidae,9527.0,,,
7378,Autocuration,22224,,,Plasma clearance in monkey after administration of 1 mg/kg iv,6535,A,In vivo,Cercopithecidae,9527.0,,,
7379,Autocuration,22224,,,Plasma clearance in cynomolgus monkey,5922,A,In vivo,Cercopithecidae,9527.0,,,
7380,Autocuration,22224,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,6221,A,In vivo,Cercopithecidae,9527.0,,,
7381,Autocuration,22224,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,5668,A,In vivo,Cercopithecidae,9527.0,,,
7382,Autocuration,22224,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,5355,A,In vivo,Cercopithecidae,9527.0,,,
7383,Autocuration,22224,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
7384,Autocuration,22224,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,5355,A,In vivo,Cercopithecidae,9527.0,,,
7385,Autocuration,22224,,,Tested for Clearance upon iv administration to african green monkey,4578,A,In vivo,Cercopithecidae,9527.0,,,
7386,Autocuration,22224,,,Clearance in monkey,17592,A,In vivo,Cercopithecidae,9527.0,,,
7387,Intermediate,50588,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6641,A,In vivo,Canis lupus familiaris,9615.0,,,
7388,Intermediate,50588,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),6642,A,In vivo,Canis lupus familiaris,9615.0,,,
7389,Intermediate,50588,,,Half life was evaluated after intravenous administration to dogs,16367,A,In vivo,Canis lupus familiaris,9615.0,,,
7390,Intermediate,50588,,,Half life was evaluated in dog,5472,A,,Canis lupus familiaris,9615.0,,,
7391,Intermediate,50588,,,Half life was evaluated in dog,5474,A,,Canis lupus familiaris,9615.0,,,
7392,Intermediate,50588,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,5654,A,In vivo,Canis lupus familiaris,9615.0,,,
7393,Intermediate,50588,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),6227,A,In vivo,Canis lupus familiaris,9615.0,,,
7394,Intermediate,50588,,,Half life period after intravenous administration in dog,6227,A,In vivo,Canis lupus familiaris,9615.0,,,
7395,Intermediate,50588,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,6221,A,In vivo,Canis lupus familiaris,9615.0,,,
7396,Intermediate,50588,,,Half life period at a dose of 1 uM/kg in dog was determined,4527,A,,Canis lupus familiaris,9615.0,,,
7397,Intermediate,50588,,,Half life period was determine after peroral administration at 10 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
7398,Intermediate,50588,,,Half life period was determine after peroral administration at 5 mpk in dog,5668,A,In vivo,Canis lupus familiaris,9615.0,,,
7399,Intermediate,50588,,,Half life period was determined,3854,A,,Canis lupus familiaris,9615.0,,,
7400,Intermediate,50588,,,Half life period was determined,5505,A,,Canis lupus familiaris,9615.0,,,
7401,Intermediate,50588,,,Half life period by iv administration in dog at a dose of 6 mg/kg,6251,A,In vivo,Canis lupus familiaris,9615.0,,,
7402,Intermediate,50588,,,Half life period was evaluated in dog,1918,A,,Canis lupus familiaris,9615.0,,,
7403,Intermediate,50588,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Canis lupus familiaris,9615.0,,,
7404,Intermediate,50588,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),4809,A,In vivo,Canis lupus familiaris,9615.0,,,
7405,Intermediate,50588,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,6215,A,In vivo,Canis lupus familiaris,9615.0,,,
7406,Intermediate,50588,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,4527,A,In vivo,Canis lupus familiaris,9615.0,,,
7407,Intermediate,50588,,,Half-life after oral dose of compound at 3 mg/kg in dogs,17594,A,In vivo,Canis lupus familiaris,9615.0,,,
7408,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
7409,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
7410,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
7411,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,17839,A,In vivo,Canis lupus familiaris,9615.0,,,
7412,Intermediate,50588,Plasma,,Half-life of compound in plasma of dog was determined,5210,A,,Canis lupus familiaris,9615.0,,,
7413,Intermediate,50588,,,Half-life of compound was determined in dogs,5210,A,,Canis lupus familiaris,9615.0,,,
7414,Intermediate,50588,,,Half-life after administration of 4 mg/Kg oral dose in dog,2959,A,In vivo,Canis lupus familiaris,9615.0,,,
7415,Intermediate,50588,,,Half-life after intravenous administration of 1 mg/kg/h in dog,4137,A,In vivo,Canis lupus familiaris,9615.0,,,
7416,Intermediate,50588,,,Half-life in Dog,5064,A,,Canis lupus familiaris,9615.0,,,
7417,Intermediate,50588,,,Half-life in Dog,5147,A,,Canis lupus familiaris,9615.0,,,
7418,Intermediate,50588,,,Half-life in dog,5145,A,,Canis lupus familiaris,9615.0,,,
7419,Intermediate,50588,,,Half-life in dog after oral administration at 1 mg/kg,6123,A,In vivo,Canis lupus familiaris,9615.0,,,
7420,Intermediate,50588,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,6123,A,In vivo,Canis lupus familiaris,9615.0,,,
7421,Intermediate,50588,,,Half-life in dogs,4333,A,,Canis lupus familiaris,9615.0,,,
7422,Intermediate,50588,,,Half-life in dogs; ND indicates not determined,4333,A,,Canis lupus familiaris,9615.0,,,
7423,Intermediate,50588,Plasma,,Half-life in plasma of dog,12500,A,,Canis lupus familiaris,9615.0,,,
7424,Intermediate,50588,Plasma,,Half-life in plasma of dog at dose of 3-10 mgkg,12500,A,,Canis lupus familiaris,9615.0,,,
7425,Intermediate,50588,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,6005,A,In vivo,Canis lupus familiaris,9615.0,,,
7426,Intermediate,50588,,,Half-life was measured in dog after an iv dose of 1 mg/kg,6062,A,In vivo,Canis lupus familiaris,9615.0,,,
7427,Intermediate,50588,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,17650,A,In vivo,Canis lupus familiaris,9615.0,,,
7428,Intermediate,50588,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,5530,A,In vivo,Canis lupus familiaris,9615.0,,,
7429,Intermediate,50588,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,5530,A,In vivo,Canis lupus familiaris,9615.0,,,
7430,Intermediate,50588,,,Half-life of the compound after 0.3 mg/kg po administration in dog,5600,A,In vivo,Canis lupus familiaris,9615.0,,,
7431,Intermediate,50588,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
7432,Intermediate,50588,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
7433,Intermediate,50588,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,6039,A,In vivo,Canis lupus familiaris,9615.0,,,
7434,Intermediate,50588,,,t1/2 in dog,6227,A,,Canis lupus familiaris,9615.0,,,
7435,Intermediate,50588,,,Half-life period measured in dogs,14541,A,,Canis lupus familiaris,9615.0,,,
7436,Intermediate,50588,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
7437,Intermediate,50588,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,4521,A,In vivo,Canis lupus familiaris,9615.0,,,
7438,Intermediate,50588,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Canis lupus familiaris,9615.0,,,
7439,Intermediate,50588,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1116,A,In vitro,Canis lupus familiaris,9615.0,,,
7440,Intermediate,50588,,,In vivo half life period was calculated at 1 mg/kg in dog,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
7441,Intermediate,50588,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,5444,A,In vivo,Canis lupus familiaris,9615.0,,,
7442,Intermediate,50588,,,Longer half-life in dog (i.v.) at 0.5 mpk,17853,A,In vivo,Canis lupus familiaris,9615.0,,,
7443,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),4353,A,In vivo,Canis lupus familiaris,9615.0,,,
7444,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7445,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7446,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),16452,A,In vivo,Canis lupus familiaris,9615.0,,,
7447,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7448,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7449,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7450,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7451,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7452,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7453,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7454,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7455,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7456,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7457,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7458,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7459,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7460,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7461,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7462,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7463,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7464,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7465,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7466,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7467,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7468,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7469,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7470,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7471,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7472,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7473,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7474,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7475,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7476,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7477,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7478,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7479,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7480,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10107,A,In vivo,Mus musculus,10090.0,,,
7481,Intermediate,50597,,,Oral bioavailability in rat,4689,A,In vivo,Rattus norvegicus,10116.0,,,
7482,Intermediate,50597,,,Tested for the bioavailability in rat,4950,A,In vivo,Rattus norvegicus,10116.0,,,
7483,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),5328,A,In vivo,Rattus norvegicus,10116.0,,,
7484,Intermediate,50597,,,Bioavailability in rat,406,A,In vivo,Rattus norvegicus,10116.0,,,
7485,Intermediate,50597,,,Bioavailability in rat,12500,A,In vivo,Rattus norvegicus,10116.0,,,
7486,Intermediate,50597,,,Bioavailability in rat (dose 3-10 mg/kg),12500,A,In vivo,Rattus norvegicus,10116.0,,,
7487,Intermediate,50597,,,Bioavailability in rat,5247,A,In vivo,Rattus norvegicus,10116.0,,,
7488,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
7489,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
7490,Intermediate,50597,,,Half life after oral administration was determined in rats at 6 mg/kg,6647,A,In vivo,Rattus norvegicus,10116.0,,,
7491,Intermediate,50597,,,Half life was determined,6484,A,,Rattus norvegicus,10116.0,,,
7492,Intermediate,50597,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,3249,A,In vivo,Rattus norvegicus,10116.0,,,
7493,Intermediate,50597,Plasma,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,6281,A,In vivo,Rattus norvegicus,10116.0,,,
7494,Intermediate,50597,,,Half life in rats,3307,A,,Rattus norvegicus,10116.0,,,
7495,Intermediate,50597,Blood,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,12058,A,In vivo,Rattus norvegicus,10116.0,,,
7496,Intermediate,50597,,,Hill coefficient of the compound,8833,A,,Rattus norvegicus,10116.0,,,
7497,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,3193,A,,Rattus norvegicus,10116.0,,,
7498,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,3193,A,,Rattus norvegicus,10116.0,,,
7499,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,3193,A,,Rattus norvegicus,10116.0,,,
7500,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,3193,A,,Rattus norvegicus,10116.0,,,
7501,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,3193,A,,Rattus norvegicus,10116.0,,,
7502,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,3193,A,,Rattus norvegicus,10116.0,,,
7503,Intermediate,50597,Blood,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",3193,A,,Rattus norvegicus,10116.0,,,
7504,Intermediate,50597,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,5960,A,,Rattus norvegicus,10116.0,,,
7505,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7506,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7507,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7508,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7509,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7510,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7511,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7512,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7513,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7514,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,13950,A,In vivo,Rattus norvegicus,10116.0,,,
7515,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7516,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7517,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7518,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7519,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7520,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7521,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7522,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7523,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7524,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7525,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7526,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7527,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7528,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7529,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7530,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7531,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7532,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7533,Intermediate,50597,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,6351,A,,Rattus norvegicus,10116.0,,,
7534,Intermediate,50597,,,Compound was tested for solubility in water,1465,A,,Rattus norvegicus,10116.0,,,
7535,Intermediate,22229,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),5182,P,,,,,,
7536,Intermediate,50597,,,Solubility was determined,17847,A,,Rattus norvegicus,10116.0,,,
7537,Intermediate,50597,,,solubility in water (ug/mL) at 37 degree C.,15339,A,,Rattus norvegicus,10116.0,,,
7538,Intermediate,50597,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,5202,A,,Rattus norvegicus,10116.0,,,
7539,Intermediate,50597,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1088,A,,Rattus norvegicus,10116.0,,,
7540,Intermediate,50597,,,Half life in rats,3169,A,,Rattus norvegicus,10116.0,,,
7541,Intermediate,50597,,,Half life in Dawley rat,5353,A,,Rattus norvegicus,10116.0,,,
7542,Intermediate,50597,,,Half life period after 3 mg/kg iv administration,2864,A,In vivo,Rattus norvegicus,10116.0,,,
7543,Intermediate,50597,,,Half life period after 3 mg/kg iv administration in rat,2864,A,In vivo,Rattus norvegicus,10116.0,,,
7544,Intermediate,50597,,,Half life period after 3 mg/kg iv administration in the rat,2864,A,In vivo,Rattus norvegicus,10116.0,,,
7545,Intermediate,50597,,,Half life period in female Sprague-Dawley rats,6362,A,,Rattus norvegicus,10116.0,,,
7546,Intermediate,50597,,,Half life period in rat,6249,A,,Rattus norvegicus,10116.0,,,
7547,Intermediate,50597,,,Half-life in rats was determined,3169,A,,Rattus norvegicus,10116.0,,,
7548,Intermediate,50597,,,Half-life in rats with metabolic oxidation,3169,A,,Rattus norvegicus,10116.0,,,
7549,Intermediate,50597,,,Half-life in rats,3169,A,,Rattus norvegicus,10116.0,,,
7550,Intermediate,50597,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7551,Intermediate,50597,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7552,Intermediate,50597,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7553,Intermediate,50597,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7554,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat,2879,A,,Rattus norvegicus,10116.0,,,
7555,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat; 22-25,2879,A,,Rattus norvegicus,10116.0,,,
7556,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat; 9-16,2879,A,,Rattus norvegicus,10116.0,,,
7557,Intermediate,50597,,,Compound was evaluated for its half life when administered intravenously in rat,3184,A,In vivo,Rattus norvegicus,10116.0,,,
7558,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,4891,A,In vivo,Rattus norvegicus,10116.0,,,
7559,Intermediate,50597,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,429,A,In vivo,Rattus norvegicus,10116.0,,,
7560,Intermediate,50597,,,Half life (T1/2) after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
7561,Intermediate,50597,,,Half life of compound after iv administration of 20 mg/kg dose in rat,4413,A,In vivo,Rattus norvegicus,10116.0,,,
7562,Expert,50597,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Rattus norvegicus,10116.0,,,
7563,Intermediate,50597,,,Half life of compound was determined in rat,17267,A,,Rattus norvegicus,10116.0,,,
7564,Intermediate,50597,Blood,,Half life of compound was determined in rat blood,4727,A,,Rattus norvegicus,10116.0,,,
7565,Intermediate,50597,,,Half life at 1 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
7566,Intermediate,50597,,,Half life at 10 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
7567,Intermediate,50597,,,Half life in rats,401,A,,Rattus norvegicus,10116.0,,,
7568,Intermediate,50597,,,Half life in rats in hours,4942,A,,Rattus norvegicus,10116.0,,,
7569,Intermediate,50597,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,17735,A,In vivo,Rattus norvegicus,10116.0,,,
7570,Intermediate,50597,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,6056,A,In vivo,Rattus norvegicus,10116.0,,,
7571,Intermediate,50597,,,Half life was determined,5213,A,,Rattus norvegicus,10116.0,,,
7572,Intermediate,50597,,,Half life after i.v. administration,6616,A,In vivo,Rattus norvegicus,10116.0,,,
7573,Intermediate,50597,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,5937,A,In vivo,Rattus norvegicus,10116.0,,,
7574,Intermediate,50597,Plasma,,Half life in rat plasma,5819,A,,Rattus norvegicus,10116.0,,,
7575,Intermediate,50597,Plasma,,Half life in rat plasma; Not detected,5819,A,,Rattus norvegicus,10116.0,,,
7576,Intermediate,50597,,,Half life in rats,6803,A,,Rattus norvegicus,10116.0,,,
7577,Intermediate,50597,,,Half life period of compound was determined after peroral administration,17804,A,In vivo,Rattus norvegicus,10116.0,,,
7578,Intermediate,50597,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,17804,A,In vivo,Rattus norvegicus,10116.0,,,
7579,Intermediate,50597,,,Half life period in rat,5948,A,,Rattus norvegicus,10116.0,,,
7580,Intermediate,50597,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
7581,Intermediate,50597,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
7582,Intermediate,50597,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1916,A,In vivo,Rattus norvegicus,10116.0,,,
7583,Intermediate,50597,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
7584,Intermediate,50597,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
7585,Intermediate,50597,,,Half life time in rat the dose of 2 mg/kg,4727,A,In vivo,Rattus norvegicus,10116.0,,,
7586,Intermediate,50597,,,Half-life 24 hr after 10 mg/kg iv administration in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
7587,Intermediate,50597,,,Half-life 24 hr after 2 mg/kg iv administration in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
7588,Intermediate,50597,,,Half-life consistent with the observed metabolic steady state in rats,6597,A,,Rattus norvegicus,10116.0,,,
7589,Intermediate,50597,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,17735,A,In vivo,Rattus norvegicus,10116.0,,,
7590,Intermediate,50597,,,Half-life for oxidative metabolic stability was determined using male human,6597,A,,Rattus norvegicus,10116.0,,,
7591,Intermediate,50597,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",17670,A,In vivo,Rattus norvegicus,10116.0,,,
7592,Intermediate,50597,Plasma,,Half-life in rat plasma,1696,A,,Rattus norvegicus,10116.0,,,
7593,Intermediate,50597,Plasma,,Half-life in rat plasma was determined,1742,A,,Rattus norvegicus,10116.0,,,
7594,Intermediate,50597,,,Half-life in rats was determined,17800,A,,Rattus norvegicus,10116.0,,,
7595,Autocuration,22224,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,12923,A,,,,,,
7596,Autocuration,22224,,,Area under curve after oral dose of 0.1 mg//kg,11954,A,,,,,,
7597,Autocuration,22224,,,Area under curve after oral dose of 0.3 mg/kg,11954,A,,,,,,
7598,Autocuration,22224,,,Area under curve after oral dose of 1 mg/kg,11954,A,,,,,,
7599,Autocuration,22224,,,Area under curve after oral dose of 10 mg/kg,11954,A,,,,,,
7600,Autocuration,22224,,,Area under curve after oral dose of 23.4 mg/kg,11954,A,,,,,,
7601,Autocuration,22224,,,Area under curve after oral dose of 3 mg/kg,11954,A,,,,,,
7602,Autocuration,22224,,,Area under curve after oral dose of 3.87 mg/kg,11954,A,,,,,,
7603,Autocuration,22224,,,Area under curve was determined,5237,A,,,,,,
7604,Autocuration,22224,,,Area under curve at a dose of 10 mg/kg,4026,A,,,,,,
7605,Intermediate,50597,,,Area under curve was determined; ND=No data,5237,A,,Rattus norvegicus,10116.0,,,
7606,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7607,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7608,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7609,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7610,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7611,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,14793,A,,Rattus norvegicus,10116.0,,,
7612,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7613,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,14793,A,,Rattus norvegicus,10116.0,,,
7614,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7615,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7616,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7617,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7618,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7619,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7620,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,14793,A,,Rattus norvegicus,10116.0,,,
7621,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,14793,A,,Rattus norvegicus,10116.0,,,
7622,Intermediate,50594,Plasma,,AUC in mice,11637,A,,Mus musculus,10090.0,,,
7623,Autocuration,22224,,,Area under curve was measured from the graph obtained from concentration Vs time,11149,A,,,,,,
7624,Autocuration,22224,,,Area under curve value of compound per hour after oral administration,10016,A,,,,,,
7625,Intermediate,50597,,,Area under curve was determined after oral administration in rats,17796,A,,Rattus norvegicus,10116.0,,,
7626,Intermediate,50597,,,Area under curve was determined after oral administration in rats; No data,17796,A,,Rattus norvegicus,10116.0,,,
7627,Intermediate,50597,,,Area under curve was determined after oral administration in rats;No data,17796,A,,Rattus norvegicus,10116.0,,,
7628,Intermediate,50588,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,12923,A,,Canis lupus familiaris,9615.0,,,
7629,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7630,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,15372,A,,Rattus norvegicus,10116.0,,,
7631,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7632,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7633,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7634,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7635,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
7636,Intermediate,50588,,,Area under curve was determined in Dogs after peroral administration,14169,A,,Canis lupus familiaris,9615.0,,,
7637,Intermediate,50597,,,Area under curve was determined in Rats after peroral administration,14169,A,,Rattus norvegicus,10116.0,,,
7638,Intermediate,50597,,,Area under curve was determined in carotid blood of rat when administered intradermally,14258,A,,Rattus norvegicus,10116.0,,,
7639,Intermediate,50597,,,Area under curve was determined in portal blood of rat when administered intradermally,14258,A,,Rattus norvegicus,10116.0,,,
7640,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,15011,A,,Mus musculus,10090.0,,,
7641,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,15011,A,,Mus musculus,10090.0,,,
7642,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),15011,A,,Mus musculus,10090.0,,,
7643,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,15011,A,,Mus musculus,10090.0,,,
7644,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),15011,A,,Mus musculus,10090.0,,,
7645,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,15011,A,,Mus musculus,10090.0,,,
7646,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),15011,A,,Mus musculus,10090.0,,,
7647,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
7648,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7649,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7650,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7651,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7652,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7653,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7654,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7655,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7656,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7657,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7658,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7659,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7660,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7661,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7662,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7663,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7664,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7665,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7666,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7667,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7668,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7669,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7670,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7671,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7672,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7673,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7674,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7675,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7676,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7677,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,10130,A,,Rattus norvegicus,10116.0,,,
7678,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,6295,A,,Rattus norvegicus,10116.0,,,
7679,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,6296,A,,Rattus norvegicus,10116.0,,,
7680,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,6296,A,,Rattus norvegicus,10116.0,,,
7681,Intermediate,50597,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,6295,A,,Rattus norvegicus,10116.0,,,
7682,Intermediate,50597,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,6296,A,,Rattus norvegicus,10116.0,,,
7683,Intermediate,50597,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7684,Intermediate,50597,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7685,Intermediate,50597,,,C24h in rat p.o. at 20 mg/kg concentration,17686,A,,Rattus norvegicus,10116.0,,,
7686,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7687,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7688,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7689,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7690,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7691,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7692,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7693,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7694,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7695,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7696,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7697,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7698,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7699,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7700,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7701,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7702,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7703,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7704,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7705,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7706,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7707,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7708,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7709,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7710,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7711,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7712,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7713,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7714,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7715,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7716,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7717,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7718,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7719,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7720,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7721,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7722,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7723,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7724,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7725,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7726,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7727,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7728,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7729,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7730,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7731,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7732,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7733,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7734,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7735,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7736,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7737,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7738,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7739,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7740,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7741,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7742,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7743,Intermediate,50597,Plasma,,Half-life from rat plasma at a single oral dose of 25 mg/kg,17752,A,In vivo,Rattus norvegicus,10116.0,,,
7744,Intermediate,50597,,,Half-life in male rat,5610,A,,Rattus norvegicus,10116.0,,,
7745,Intermediate,50597,,,Half-life in rat after peroral administration at 10 mg/kg concentration,5939,A,In vivo,Rattus norvegicus,10116.0,,,
7746,Intermediate,50597,,,Half-life in rat after peroral administration at 5 mg/kg concentration,5939,A,In vivo,Rattus norvegicus,10116.0,,,
7747,Intermediate,50597,,,Half-life in rat at a dose of 3 mg/kg,17771,A,In vivo,Rattus norvegicus,10116.0,,,
7748,Intermediate,50597,,,Half-life was evaluated in rats,1974,A,,Rattus norvegicus,10116.0,,,
7749,Intermediate,50597,,,Half-life was measured in rat,4239,A,,Rattus norvegicus,10116.0,,,
7750,Intermediate,50597,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,6681,A,In vivo,Rattus norvegicus,10116.0,,,
7751,Intermediate,50597,,,Half-life period in rats after intravenous administration at 5 mg/kg,17752,A,In vivo,Rattus norvegicus,10116.0,,,
7752,Intermediate,50597,,,Half-life period in rat at 10 mg/kg,6046,A,In vivo,Rattus norvegicus,10116.0,,,
7753,Intermediate,50597,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
7754,Intermediate,50597,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
7755,Intermediate,50597,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
7756,Intermediate,50597,,,Half-life time in rat the dose of 2 mg/kg,4727,A,In vivo,Rattus norvegicus,10116.0,,,
7757,Intermediate,50597,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1088,A,In vivo,Rattus norvegicus,10116.0,,,
7758,Intermediate,50597,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,5610,A,In vivo,Rattus norvegicus,10116.0,,,
7759,Intermediate,50597,Plasma,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",3032,A,In vivo,Rattus norvegicus,10116.0,,,
7760,Intermediate,50597,,,Oral half life was determined,5199,A,In vivo,Rattus norvegicus,10116.0,,,
7761,Intermediate,50597,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",14941,A,In vivo,Rattus norvegicus,10116.0,,,
7762,Intermediate,50597,,,Pharmacokinetic property (t1/2) in rat,4408,A,In vivo,Rattus norvegicus,10116.0,,,
7763,Intermediate,50597,Plasma,,Plasma elimination half-life was determined,2552,A,,Rattus norvegicus,10116.0,,,
7764,Intermediate,50597,Plasma,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,5199,A,In vivo,Rattus norvegicus,10116.0,,,
7765,Intermediate,50597,Plasma,,Plasma half life was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
7766,Intermediate,50597,Plasma,,Plasma half-life was determined,1465,A,,Rattus norvegicus,10116.0,,,
7767,Intermediate,50597,Plasma,,Plasma half-life following oral administration in Fisher rats,1446,A,In vivo,Rattus norvegicus,10116.0,,,
7768,Intermediate,50597,Plasma,,Plasma half-life in rat,6824,A,,Rattus norvegicus,10116.0,,,
7769,Intermediate,50597,Plasma,,Plasmatic Half-life after intravenous administration to rat,17533,A,In vivo,Rattus norvegicus,10116.0,,,
7770,Intermediate,50597,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,5979,A,In vivo,Rattus norvegicus,10116.0,,,
7771,Intermediate,50597,,,Terminal half life after intravenous administration (1 mg/kg) in rat,4689,A,In vivo,Rattus norvegicus,10116.0,,,
7772,Intermediate,50597,,,Terminal half life in Rat at a oral dose of 5 mg/kg,4689,A,In vivo,Rattus norvegicus,10116.0,,,
7773,Intermediate,50597,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,2463,A,In vivo,Rattus norvegicus,10116.0,,,
7774,Intermediate,50597,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,4883,A,In vivo,Rattus norvegicus,10116.0,,,
7775,Intermediate,50597,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,4883,A,In vivo,Rattus norvegicus,10116.0,,,
7776,Intermediate,50597,Plasma,,plasma half life was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
7777,Expert,50597,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Rattus norvegicus,10116.0,,,
7778,Intermediate,50597,,,Half life of compound determined in rat,4576,A,,Rattus norvegicus,10116.0,,,
7779,Intermediate,50597,,,Mean residence time determined in rat,4576,A,,Rattus norvegicus,10116.0,,,
7780,Intermediate,50597,,,Plasma half life determined in rat,4576,A,,Rattus norvegicus,10116.0,,,
7781,Intermediate,50597,Brain,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,4910,A,In vivo,Rattus norvegicus,10116.0,,,
7782,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter maximum time period,4891,A,In vivo,Rattus norvegicus,10116.0,,,
7783,Intermediate,50597,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,429,A,In vivo,Rattus norvegicus,10116.0,,,
7784,Intermediate,50597,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
7785,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
7786,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
7787,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
7788,Intermediate,50597,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
7789,Intermediate,50597,,,Maximum time (Tmax) required to reach Cmax in rats,4026,A,,Rattus norvegicus,10116.0,,,
7790,Intermediate,50597,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
7791,Intermediate,50597,,,Maximum time of clearance of compound in rats after peroral administration,6571,A,In vivo,Rattus norvegicus,10116.0,,,
7792,Intermediate,50597,,,Maximum time at the dose of 2 mg/kg in rat,4727,A,,Rattus norvegicus,10116.0,,,
7793,Intermediate,50597,Plasma,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,17651,A,In vivo,Rattus norvegicus,10116.0,,,
7794,Intermediate,50597,Plasma,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,17651,A,In vivo,Rattus norvegicus,10116.0,,,
7795,Intermediate,50597,,,Tmax in Guinea pig (PO dose),14465,A,In vivo,Rattus norvegicus,10116.0,,,
7796,Intermediate,50597,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",14941,A,In vivo,Rattus norvegicus,10116.0,,,
7797,Intermediate,50597,,,Pharmacokinetic parameter (Tmax) in rat,5960,A,In vivo,Rattus norvegicus,10116.0,,,
7798,Intermediate,50597,,,Pharmacokinetic parameter (Tmax) was estimated,5022,A,In vivo,Rattus norvegicus,10116.0,,,
7799,Intermediate,50597,,,Pharmacokinetic property (Tmax) in rat,4408,A,In vivo,Rattus norvegicus,10116.0,,,
7800,Intermediate,50597,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,5983,A,In vivo,Rattus norvegicus,10116.0,,,
7801,Intermediate,50597,,,T max in Rat at a oral dose of 5 mg/kg,4689,A,In vivo,Rattus norvegicus,10116.0,,,
7802,Intermediate,50597,,,T max was determined at 10 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
7803,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),15011,A,,Mus musculus,10090.0,,,
7804,Intermediate,50588,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,14180,A,,Canis lupus familiaris,9615.0,,,
7805,Intermediate,50597,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,14180,A,,Rattus norvegicus,10116.0,,,
7806,Intermediate,50588,,,Area under curve was measured after i.v. administration into Beagle dog.,14599,A,,Canis lupus familiaris,9615.0,,,
7807,Intermediate,50588,,,Area under curve was measured after iv administration into Beagle dog,14599,A,,Canis lupus familiaris,9615.0,,,
7808,Intermediate,50588,,,Area under curve was measured after po administration into Beagle dog,14599,A,,Canis lupus familiaris,9615.0,,,
7809,Intermediate,50588,,,Area under curve was measured after po administration into Beagle dog.,14599,A,,Canis lupus familiaris,9615.0,,,
7810,Autocuration,22224,,,Area under curve was measured at peroral dose of 3 mg/kg,15675,A,,,,,,
7811,Autocuration,22224,,,Area under curve was measured by using concentration Vs time,12706,A,,,,,,
7812,Autocuration,22224,,,Area under curve was measured by using concentration Vs time; not tested,12706,A,,,,,,
7813,Intermediate,50594,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),9750,A,,Mus musculus,10090.0,,,
7814,Intermediate,50594,,,Area under curve(AUC) was measured in mice after oral administration.,9750,A,,Mus musculus,10090.0,,,
7815,Autocuration,22224,,,Area under curve(AUC) value of the compound,14691,A,,,,,,
7816,Autocuration,22224,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,14691,A,,,,,,
7817,Intermediate,50588,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,14691,A,,Canis lupus familiaris,9615.0,,,
7818,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood,2939,A,,,,,,
7819,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,2939,A,,,,,,
7820,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood; No data,2939,A,,,,,,
7821,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood,2939,A,,,,,,
7822,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,2939,A,,,,,,
7823,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood; No data,2939,A,,,,,,
7824,Intermediate,50797,Plasma,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",9552,A,,Macaca mulatta,9544.0,,,
7825,Intermediate,50797,Plasma,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",9552,A,,Macaca mulatta,9544.0,,,
7826,Intermediate,50797,Plasma,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,9552,A,,Macaca mulatta,9544.0,,,
7827,Intermediate,50588,Plasma,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",9552,A,,Canis lupus familiaris,9615.0,,,
7828,Intermediate,50588,Plasma,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",9552,A,,Canis lupus familiaris,9615.0,,,
7829,Autocuration,22224,Plasma,,Area under plasma concentration vs time curve observed in rats for 0-3 h,9552,A,,,,,,
7830,Intermediate,50597,Plasma,,Area under plasma time curve determined in male rat,11911,A,,Rattus norvegicus,10116.0,,,
7831,Autocuration,22224,,,Area under the MAP curve measured over 5 min.,16618,A,,,,,,
7832,Intermediate,50594,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,14387,A,,Mus musculus,10090.0,,,
7833,Intermediate,50594,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,14387,A,,Mus musculus,10090.0,,,
7834,Intermediate,50588,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,12836,A,,Canis lupus familiaris,9615.0,,,
7835,Intermediate,100712,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,12836,A,,Cricetinae,10026.0,,,
7836,Intermediate,50597,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,12836,A,,Rattus norvegicus,10116.0,,,
7837,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,14339,A,,Canis lupus familiaris,9615.0,,,
7838,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,14339,A,,Canis lupus familiaris,9615.0,,,
7839,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,14339,A,,Canis lupus familiaris,9615.0,,,
7840,Intermediate,50588,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),10524,A,,Canis lupus familiaris,9615.0,,,
7841,Intermediate,50588,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),9994,A,,Canis lupus familiaris,9615.0,,,
7842,Intermediate,50588,,,Serum AUC in marmosets (IV dose),11325,A,,Canis lupus familiaris,9615.0,,,
7843,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,12536,A,,,,,,
7844,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,12536,A,,,,,,
7845,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,12536,A,,,,,,
7846,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,12536,A,,,,,,
7847,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,12536,A,,,,,,
7848,Intermediate,50597,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,15556,A,,Rattus norvegicus,10116.0,,,
7849,Autocuration,22224,,,Area under the curve for the compound was calculated.,2809,A,,,,,,
7850,Autocuration,22224,,,Area under the curve in concentration/ time,9511,A,,,,,,
7851,Intermediate,50597,,,Area under the curve administered intraintestinal in rats.,12818,A,,Rattus norvegicus,10116.0,,,
7852,Intermediate,50597,,,Area under the curve administered intravenously in rats.,12818,A,,Rattus norvegicus,10116.0,,,
7853,Autocuration,22224,,,Area under the curve during intravenous administration,15118,A,,,,,,
7854,Autocuration,22224,,,Area under the curve during intravenous administration; Not determined,15118,A,,,,,,
7855,Autocuration,22224,,,Area under the curve during systemic administration,15118,A,,,,,,
7856,Autocuration,22224,,,Area under the curve during systemic administration; Not determined,15118,A,,,,,,
7857,Autocuration,22224,,,Area under the curve was calculated for the compound.,2632,A,,,,,,
7858,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,14346,A,,Canis lupus familiaris,9615.0,,,
7859,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,14346,A,,Canis lupus familiaris,9615.0,,,
7860,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
7861,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
7862,Intermediate,50597,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,11149,A,,Rattus norvegicus,10116.0,,,
7863,Intermediate,50597,Plasma,,Clearance of the drug was measured in the plasma of rat; No data,17796,A,,Rattus norvegicus,10116.0,,,
7864,Intermediate,50597,Plasma,,The pharmacokinetic parameter plasma clearance in vivo in rats,5247,A,,Rattus norvegicus,10116.0,,,
7865,Intermediate,50597,,,Plasma clearance at the dose of 2 mg/kg in rat,4727,A,,Rattus norvegicus,10116.0,,,
7866,Intermediate,50597,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
7867,Intermediate,50597,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
7868,Intermediate,50597,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
7869,Intermediate,50597,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,17065,A,In vivo,Rattus norvegicus,10116.0,,,
7870,Intermediate,50597,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,17671,A,In vivo,Rattus norvegicus,10116.0,,,
7871,Intermediate,50597,,,Clearance rate in rat,6672,A,In vivo,Rattus norvegicus,10116.0,,,
7872,Intermediate,50597,,,Clearance rate in rat,6673,A,In vivo,Rattus norvegicus,10116.0,,,
7873,Intermediate,50597,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
7874,Intermediate,50597,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
7875,Intermediate,50597,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
7876,Intermediate,50597,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
7877,Intermediate,50597,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,4413,A,In vivo,Rattus norvegicus,10116.0,,,
7878,Intermediate,50597,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
7879,Intermediate,50597,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
7880,Intermediate,22224,Plasma,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,A,In vivo,Macaca mulatta,9544.0,,,
7881,Intermediate,22224,Plasma,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,5005,A,In vivo,Rattus norvegicus,10116.0,,,
7882,Intermediate,50597,,,Mean (%CV) PK parameters for CL(mL/min/kg).,15765,A,In vivo,Rattus norvegicus,10116.0,,,
7883,Intermediate,50597,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,3747,A,In vivo,Rattus norvegicus,10116.0,,,
7884,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,16366,A,In vivo,Rattus norvegicus,10116.0,,,
7885,Intermediate,50597,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,4199,A,In vivo,Rattus norvegicus,10116.0,,,
7886,Intermediate,50597,,,Plasma clearance in rat was determined,17267,A,In vivo,Rattus norvegicus,10116.0,,,
7887,Intermediate,50597,,,Plasma clearance in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
7888,Intermediate,50597,,,Plasma clearance in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
7889,Intermediate,50597,,,Plasma clearance was determined,5041,A,In vivo,Rattus norvegicus,10116.0,,,
7890,Intermediate,50597,,,Plasma clearance in rat,5960,A,In vivo,Rattus norvegicus,10116.0,,,
7891,Intermediate,50597,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,5937,A,In vivo,Rattus norvegicus,10116.0,,,
7892,Intermediate,50597,,,Plasma clearance in rat by iv administration,5871,A,In vivo,Rattus norvegicus,10116.0,,,
7893,Intermediate,50597,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,5874,A,In vivo,Rattus norvegicus,10116.0,,,
7894,Intermediate,50597,,,Plasma clearance in rat p.o.,6504,A,In vivo,Rattus norvegicus,10116.0,,,
7895,Intermediate,50597,,,Plasma clearance in rats,6803,A,In vivo,Rattus norvegicus,10116.0,,,
7896,Intermediate,50597,,,Plasma clearance was determined; ND denotes no data,5041,A,In vivo,Rattus norvegicus,10116.0,,,
7897,Intermediate,50597,,,Plasma clearance was determined; ND denotes not determined,5041,A,In vivo,Rattus norvegicus,10116.0,,,
7898,Intermediate,50597,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
7899,Intermediate,50597,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,5199,A,In vivo,Rattus norvegicus,10116.0,,,
7900,Intermediate,50597,,,Plasma administration to rats,16367,A,In vivo,Rattus norvegicus,10116.0,,,
7901,Intermediate,50597,,,Plasma clearance of the compound in female Sprague-Dawley rats,6362,A,In vivo,Rattus norvegicus,10116.0,,,
7902,Intermediate,50597,,,Plasma clearance was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
7903,Intermediate,50597,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,6215,A,In vivo,Rattus norvegicus,10116.0,,,
7904,Intermediate,50597,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
7905,Intermediate,50597,Plasma,,plasma clearance was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
7906,Intermediate,50597,,,In vivo CL/F determined,4723,A,In vivo,Rattus norvegicus,10116.0,,,
7907,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
7908,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
7909,Intermediate,50597,,,Compound was tested for the lower blood clearance in rat,5213,A,In vivo,Rattus norvegicus,10116.0,,,
7910,Intermediate,50597,,,Evaluated for the low clearance in rat (in vivo),4687,A,In vivo,Rattus norvegicus,10116.0,,,
7911,Intermediate,50597,,,Pharmacokinetic property (CLb)of the compound was determined in rat,3371,A,In vivo,Rattus norvegicus,10116.0,,,
7912,Intermediate,50597,,,Rapid clearance after intravenous administration in rat was determined,4690,A,In vivo,Rattus norvegicus,10116.0,,,
7913,Intermediate,50597,,,Clearance measured in rat,5702,A,In vivo,Rattus norvegicus,10116.0,,,
7914,Intermediate,50597,Plasma,,Compound was evaluated for plasma clearance in rat,740,A,In vivo,Rattus norvegicus,10116.0,,,
7915,Intermediate,50597,Plasma,,Low plasma clearance was calculated in rat,4853,A,In vivo,Rattus norvegicus,10116.0,,,
7916,Intermediate,50597,,,Pharmacokinetic property (Clp) in rat,5789,A,In vivo,Rattus norvegicus,10116.0,,,
7917,Intermediate,50597,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
7918,Intermediate,50597,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
7919,Intermediate,50597,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
7920,Intermediate,50597,,,Plasma clearance after IV dosing at 1 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
7921,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7922,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7923,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7924,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7925,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7926,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7927,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7928,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7929,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7930,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7931,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7932,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7933,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7934,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7935,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7936,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7937,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7938,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7939,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7940,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7941,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7942,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7943,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7944,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7945,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7946,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7947,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7948,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7949,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7950,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7951,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7952,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7953,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7954,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7955,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7956,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7957,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7958,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7959,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7960,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7961,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7962,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7963,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7964,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7965,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7966,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7967,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7968,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7969,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7970,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7971,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7972,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7973,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7974,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7975,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7976,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7977,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
7978,Intermediate,50597,,,T max was determined at 3 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
7979,Intermediate,50597,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
7980,Intermediate,50597,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
7981,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
7982,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
7983,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
7984,Intermediate,50597,Plasma,,Time for maximum plasma concentration determined in rat,4576,A,,Rattus norvegicus,10116.0,,,
7985,Intermediate,50597,Plasma,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,6681,A,In vivo,Rattus norvegicus,10116.0,,,
7986,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
7987,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
7988,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
7989,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
7990,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
7991,Intermediate,50597,Plasma,,Time of maximum plasma concentration in rat,6824,A,,Rattus norvegicus,10116.0,,,
7992,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",6685,A,,Rattus norvegicus,10116.0,,,
7993,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",6685,A,,Rattus norvegicus,10116.0,,,
7994,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",6685,A,,Rattus norvegicus,10116.0,,,
7995,Intermediate,50597,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
7996,Intermediate,50597,Plasma,,Time required to reach maximum concentration in rat plasma,1742,A,,Rattus norvegicus,10116.0,,,
7997,Intermediate,50597,Plasma,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,2774,A,In vivo,Rattus norvegicus,10116.0,,,
7998,Intermediate,50597,Plasma,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,5199,A,In vivo,Rattus norvegicus,10116.0,,,
7999,Intermediate,50597,Plasma,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,12873,A,In vivo,Rattus norvegicus,10116.0,,,
8000,Intermediate,50597,Plasma,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,12873,A,In vivo,Rattus norvegicus,10116.0,,,
8001,Intermediate,50597,Plasma,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
8002,Intermediate,50597,,,Time to reach Cmax after oral administration to rats,16367,A,In vivo,Rattus norvegicus,10116.0,,,
8003,Intermediate,50597,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,16366,A,In vivo,Rattus norvegicus,10116.0,,,
8004,Intermediate,50597,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,216,A,,Rattus norvegicus,10116.0,,,
8005,Intermediate,50597,Plasma,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,6410,A,In vivo,Rattus norvegicus,10116.0,,,
8006,Intermediate,50597,Plasma,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
8007,Intermediate,50597,,,Tmax after peroral administration (10 mg/kg) was determined in rat,6215,A,In vivo,Rattus norvegicus,10116.0,,,
8008,Expert,50597,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Rattus norvegicus,10116.0,,,
8009,Intermediate,50597,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
8010,Intermediate,50597,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",17670,A,In vivo,Rattus norvegicus,10116.0,,,
8011,Intermediate,50597,,,Tmax was determined,1465,A,,Rattus norvegicus,10116.0,,,
8012,Intermediate,50597,,,Tmax was determined,2552,A,,Rattus norvegicus,10116.0,,,
8013,Intermediate,50597,,,Tmax after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
8014,Intermediate,50597,,,Tmax after peroral administration in rats at 2.4 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
8015,Intermediate,50597,,,Tmax in male rat,5610,A,,Rattus norvegicus,10116.0,,,
8016,Intermediate,50597,,,Tmax in rat at 10 mg/kg,6046,A,In vivo,Rattus norvegicus,10116.0,,,
8017,Intermediate,50597,,,Tmax in rat by po administration at a dose of 40 mg/kg,5874,A,In vivo,Rattus norvegicus,10116.0,,,
8018,Intermediate,50597,,,Tmax in rats,17596,A,,Rattus norvegicus,10116.0,,,
8019,Intermediate,50597,,,Tmax was measured in rats after peroral administration at 5 mg/kg,17804,A,In vivo,Rattus norvegicus,10116.0,,,
8020,Intermediate,50597,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1908,A,In vivo,Rattus norvegicus,10116.0,,,
8021,Intermediate,50597,,,Tmax value after administration of 20 mg/Kg oral dose in rat,2959,A,In vivo,Rattus norvegicus,10116.0,,,
8022,Intermediate,50597,,,Tmax value at a dose of 10 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8023,Intermediate,50597,,,Tmax value at a dose of 100 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8024,Intermediate,50597,,,Tmax value at a dose of 50 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8025,Intermediate,50597,Plasma,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
8026,Intermediate,50597,,,time required to reach maximum concentration (Cmax) after oral administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
8027,Intermediate,50597,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),429,A,,Rattus norvegicus,10116.0,,,
8028,Intermediate,50597,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),429,A,,Rattus norvegicus,10116.0,,,
8029,Intermediate,50597,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,5546,A,,Rattus norvegicus,10116.0,,,
8030,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,3173,A,,Rattus norvegicus,10116.0,,,
8031,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,3173,A,,Rattus norvegicus,10116.0,,,
8032,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,3173,A,,Rattus norvegicus,10116.0,,,
8033,Intermediate,50597,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,4257,A,In vivo,Rattus norvegicus,10116.0,,,
8034,Intermediate,50597,,,Compound distribution in rat tissues was determined,6011,A,In vivo,Rattus norvegicus,10116.0,,,
8035,Intermediate,50597,,,Volume of distribution was evaluated in rat,5472,A,In vivo,Rattus norvegicus,10116.0,,,
8036,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8037,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8038,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,14346,A,,Canis lupus familiaris,9615.0,,,
8039,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8040,Autocuration,22224,,,Area under the curve was determined after oral administration (300 uM/Kg),15469,A,,,,,,
8041,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8042,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8043,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8044,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8045,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,14346,A,,Rattus norvegicus,10116.0,,,
8046,Intermediate,50597,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,15372,A,,Rattus norvegicus,10116.0,,,
8047,Intermediate,50588,Plasma,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,12935,A,,Canis lupus familiaris,9615.0,,,
8048,Intermediate,50588,Plasma,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,12935,A,,Canis lupus familiaris,9615.0,,,
8049,Autocuration,22224,,,Plasma drug AUC in rat (PO dose),14813,A,,,,,,
8050,Intermediate,50594,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,15792,A,,Mus musculus,10090.0,,,
8051,Autocuration,22224,,,Area under was determined at a dose of 30 mg/kg,3579,A,,,,,,
8052,Intermediate,50506,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,12487,A,,Mustela putorius furo,9669.0,,,
8053,Intermediate,50597,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,12487,A,,Rattus norvegicus,10116.0,,,
8054,Intermediate,50597,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,12487,A,,Rattus norvegicus,10116.0,,,
8055,Intermediate,50506,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,12487,A,,Mustela putorius furo,9669.0,,,
8056,Intermediate,50588,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,12487,A,,Canis lupus familiaris,9615.0,,,
8057,Intermediate,50588,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,12487,A,,Canis lupus familiaris,9615.0,,,
8058,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8059,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8060,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8061,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8062,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8063,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8064,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8065,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",12902,A,,Rattus norvegicus,10116.0,,,
8066,Intermediate,50594,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
8067,Intermediate,50594,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),12745,A,,Mus musculus,10090.0,,,
8068,Intermediate,50594,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
8069,Intermediate,50594,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),12745,A,,Mus musculus,10090.0,,,
8070,Intermediate,50594,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
8071,Intermediate,50594,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),12745,A,,Mus musculus,10090.0,,,
8072,Intermediate,50594,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
8073,Intermediate,50594,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),12745,A,,Mus musculus,10090.0,,,
8074,Autocuration,22224,Plasma,,AUC in mice after oral dose (50 mg/kg),13298,A,,,,,,
8075,Intermediate,50594,Serum,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,12226,A,,Mus musculus,10090.0,,,
8076,Autocuration,22224,Plasma,,AUC (0-4 hr) ug/ml/h,12634,A,,,,,,
8077,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,14810,A,,Rattus norvegicus,10116.0,,,
8078,Autocuration,22224,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,13889,A,,,,,,
8079,Intermediate,50594,,,Compound was evaluated for Area under curve in mice,10018,A,,Mus musculus,10090.0,,,
8080,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,8758,A,,Rattus norvegicus,10116.0,,,
8081,Autocuration,22224,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,8758,F,,,,,,
8082,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,8758,A,,Rattus norvegicus,10116.0,,,
8083,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,2249,A,,,,,,
8084,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,2249,A,,,,,,
8085,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,2249,A,,,,,,
8086,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,2249,A,,,,,,
8087,Intermediate,50594,,,Compound was evaluated for area under curve when administered through oral route in mouse,15115,A,,Mus musculus,10090.0,,,
8088,Intermediate,50597,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8089,Intermediate,50597,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8090,Intermediate,50597,,,Plasma clearance in rat,6249,A,In vivo,Rattus norvegicus,10116.0,,,
8091,Intermediate,50597,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,2463,A,In vivo,Rattus norvegicus,10116.0,,,
8092,Intermediate,50597,,,Plasma clearance rate in Sprague-Dawley rats,4969,A,In vivo,Rattus norvegicus,10116.0,,,
8093,Intermediate,50597,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,F,In vivo,Rattus norvegicus,10116.0,,,
8094,Intermediate,50597,,,Pharmacokinetic property (total body clearance) in rat,3457,A,In vivo,Rattus norvegicus,10116.0,,,
8095,Intermediate,50597,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,5983,A,In vivo,Rattus norvegicus,10116.0,,,
8096,Intermediate,50597,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,6295,A,,Rattus norvegicus,10116.0,,,
8097,Intermediate,50597,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,6296,A,,Rattus norvegicus,10116.0,,,
8098,Intermediate,50597,,,Cl in rat i.v. at 2 mg/kg concentration,17686,A,In vivo,Rattus norvegicus,10116.0,,,
8099,Intermediate,50597,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
8100,Intermediate,50597,,,Clearance was determined,5503,A,In vivo,Rattus norvegicus,10116.0,,,
8101,Intermediate,50597,,,Clearance by intravenous administration of 3.4 mg/kg in rat,4368,A,In vivo,Rattus norvegicus,10116.0,,,
8102,Intermediate,50597,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,6005,A,In vivo,Rattus norvegicus,10116.0,,,
8103,Intermediate,50597,,,Clearance rate after i.v. administration in rats,5031,A,In vivo,Rattus norvegicus,10116.0,,,
8104,Intermediate,50597,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
8105,Intermediate,50597,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,5182,A,In vivo,Rattus norvegicus,10116.0,,,
8106,Intermediate,50597,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,5979,A,In vivo,Rattus norvegicus,10116.0,,,
8107,Intermediate,50597,,,Clearance (Cl) after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
8108,Intermediate,50597,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,17804,A,In vivo,Rattus norvegicus,10116.0,,,
8109,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat,4839,A,In vivo,Rattus norvegicus,10116.0,,,
8110,Intermediate,50597,,,In vitro microsome metabolism clearance in rat was determined,5041,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
8111,Intermediate,50597,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,5041,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
8112,Intermediate,50597,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8113,Intermediate,50597,Plasma,,In vivo plasma clearance was determined,5496,A,In vivo,Rattus norvegicus,10116.0,,,
8114,Intermediate,50597,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,5739,A,In vivo,Rattus norvegicus,10116.0,,,
8115,Intermediate,50597,Liver,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,5676,A,In vivo,Rattus norvegicus,10116.0,,Hepatocyte,
8116,Intermediate,50597,,,Pharmacokinetic property (Plasma clearance) was measured in rat,4239,A,In vivo,Rattus norvegicus,10116.0,,,
8117,Intermediate,50597,,,Pharmacokinetic property (clearance) in rat i.v.,5676,A,In vivo,Rattus norvegicus,10116.0,,,
8118,Intermediate,50597,,,"Plasma Clearance was evaluated in rats, iv",1918,A,In vivo,Rattus norvegicus,10116.0,,,
8119,Intermediate,50597,,,Plasma clearance (in vivo) in rats was determined,17800,A,In vivo,Rattus norvegicus,10116.0,,,
8120,Intermediate,50597,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,6056,A,In vivo,Rattus norvegicus,10116.0,,,
8121,Intermediate,50597,,,Plasma clearance was determined,5496,A,In vivo,Rattus norvegicus,10116.0,,,
8122,Intermediate,50597,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,5939,A,In vivo,Rattus norvegicus,10116.0,,,
8123,Intermediate,50597,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,5939,A,In vivo,Rattus norvegicus,10116.0,,,
8124,Intermediate,50597,,,Plasma clearance in rats,17752,A,In vivo,Rattus norvegicus,10116.0,,,
8125,Intermediate,50597,,,Plasma clearance rate determined in rat,4576,A,In vivo,Rattus norvegicus,10116.0,,,
8126,Intermediate,50597,,,Plasma clearance was determined in rat,6011,A,In vivo,Rattus norvegicus,10116.0,,,
8127,Intermediate,50597,,,Plasma clearance was determined,5510,A,In vivo,Rattus norvegicus,10116.0,,,
8128,Intermediate,50597,,,Plasma clearance value in rat,5948,A,In vivo,Rattus norvegicus,10116.0,,,
8129,Intermediate,50597,Liver,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,6125,A,Ex vivo,Rattus norvegicus,10116.0,,,
8130,Intermediate,50597,,,Clearance in rat,4839,A,In vivo,Rattus norvegicus,10116.0,,,
8131,Intermediate,50597,,,Total body clearance in rat i.v. at 2 mg/kg concentration,17686,A,In vivo,Rattus norvegicus,10116.0,,,
8132,Intermediate,50597,,,Clearance of compound in rats after intravenous administration,6571,A,In vivo,Rattus norvegicus,10116.0,,,
8133,Intermediate,50597,,,Clearance after iv administration to rats,3364,A,In vivo,Rattus norvegicus,10116.0,,,
8134,Intermediate,50597,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8135,Intermediate,50597,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8136,Intermediate,50597,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8137,Intermediate,50597,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8138,Intermediate,50597,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8139,Intermediate,50597,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8140,Intermediate,50597,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8141,Intermediate,50597,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",17670,A,In vivo,Rattus norvegicus,10116.0,,,
8142,Intermediate,50597,,,Clearance in rat,5970,A,In vivo,Rattus norvegicus,10116.0,,,
8143,Intermediate,50597,,,Clearance in rat after oral administration at 10 mg/kg,6495,A,In vivo,Rattus norvegicus,10116.0,,,
8144,Intermediate,50597,,,Clearance in rat.,4590,A,In vivo,Rattus norvegicus,10116.0,,,
8145,Intermediate,50597,,,Clearance rate following an oral dose of 20 mg/kg in rats,6193,A,In vivo,Rattus norvegicus,10116.0,,,
8146,Intermediate,50597,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,2832,A,In vivo,Rattus norvegicus,10116.0,,,
8147,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1052,A,In vivo,Rattus norvegicus,10116.0,,,
8148,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8149,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8150,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8151,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8152,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8153,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8154,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8155,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8156,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8157,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8158,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8159,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8160,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8161,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8162,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8163,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8164,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8165,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8166,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8167,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8168,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8169,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8170,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8171,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8172,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8173,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),9866,A,In vivo,Rattus norvegicus,10116.0,,,
8174,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8175,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8176,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8177,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8178,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8179,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8180,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8181,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8182,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8183,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8184,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8185,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,9866,A,In vivo,Rattus norvegicus,10116.0,,,
8186,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8187,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8188,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8189,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8190,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8191,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8192,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8193,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8194,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8195,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8196,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8197,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8198,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8199,Intermediate,50597,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,6062,A,In vivo,Rattus norvegicus,10116.0,,,
8200,Expert,50597,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,,Rattus norvegicus,10116.0,,,
8201,Intermediate,50597,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,1908,A,In vivo,Rattus norvegicus,10116.0,,,
8202,Intermediate,50597,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,17596,A,In vivo,Rattus norvegicus,10116.0,,,
8203,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,4891,A,In vivo,Rattus norvegicus,10116.0,,,
8204,Intermediate,50597,,,Compound was evaluated for volume of distribution in rat,740,A,In vivo,Rattus norvegicus,10116.0,,,
8205,Intermediate,50597,,,Steady state volume distribution was determined; steady state(ss),16366,A,In vivo,Rattus norvegicus,10116.0,,,
8206,Intermediate,50597,,,Steady state volume of distribution after iv administration to rats,3364,A,In vivo,Rattus norvegicus,10116.0,,,
8207,Intermediate,50597,,,Steady state volume of distribution dosing at 3 mg/kg iv,2552,A,In vivo,Rattus norvegicus,10116.0,,,
8208,Intermediate,50597,,,The compound was evaluated for volume of distribution in rat,406,A,In vivo,Rattus norvegicus,10116.0,,,
8209,Intermediate,50597,,,The compound was tested for volume of distribution in rat,12500,A,In vivo,Rattus norvegicus,10116.0,,,
8210,Intermediate,50597,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,12500,A,In vivo,Rattus norvegicus,10116.0,,,
8211,Intermediate,50597,,,Volume distribution (VD) after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
8212,Intermediate,50597,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,17671,A,In vivo,Rattus norvegicus,10116.0,,,
8213,Intermediate,50597,,,Volume distribution in rat,1094,A,In vivo,Rattus norvegicus,10116.0,,,
8214,Intermediate,50597,,,Volume distribution in rat,5833,A,In vivo,Rattus norvegicus,10116.0,,,
8215,Intermediate,50597,,,Volume distribution in rat after peroral administration at 10 mg/kg,5939,A,In vivo,Rattus norvegicus,10116.0,,,
8216,Intermediate,50597,,,Volume distribution in rat after peroral administration at 5 mg/kg,5939,A,In vivo,Rattus norvegicus,10116.0,,,
8217,Intermediate,50597,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,6005,A,In vivo,Rattus norvegicus,10116.0,,,
8218,Intermediate,50597,,,Volume of distribution in rat.,1696,A,In vivo,Rattus norvegicus,10116.0,,,
8219,Intermediate,50597,,,Volume of distribution in rat,6672,A,In vivo,Rattus norvegicus,10116.0,,,
8220,Intermediate,50597,,,Volume of distribution in rat,6673,A,In vivo,Rattus norvegicus,10116.0,,,
8221,Intermediate,50597,,,Volume of distribution in rat by iv administration,5871,A,In vivo,Rattus norvegicus,10116.0,,,
8222,Intermediate,50597,,,Volume of distribution in rats,6803,A,In vivo,Rattus norvegicus,10116.0,,,
8223,Intermediate,50597,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,5199,A,In vivo,Rattus norvegicus,10116.0,,,
8224,Intermediate,50597,,,Volume distribution at the dose of 2 mg/kg in rat,4727,A,,Rattus norvegicus,10116.0,,,
8225,Intermediate,50597,,,Steady state volume of distribution was determined,16367,A,In vivo,Rattus norvegicus,10116.0,,,
8226,Intermediate,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,5005,A,In vivo,Macaca mulatta,9544.0,,,
8227,Intermediate,22224,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,5005,A,In vivo,Rattus norvegicus,10116.0,,,
8228,Intermediate,22224,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,5005,A,In vivo,Rattus norvegicus,10116.0,,,
8229,Intermediate,50597,,,Mean (%CV) PK parameters for Vdss(mL/kg).,15765,A,In vivo,Rattus norvegicus,10116.0,,,
8230,Intermediate,50597,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
8231,Intermediate,50597,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
8232,Intermediate,50597,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8233,Intermediate,50597,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8234,Intermediate,50597,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,5739,A,In vivo,Rattus norvegicus,10116.0,,,
8235,Intermediate,50597,,,Pharmacokinetic property (Vdss) in rat,5789,A,In vivo,Rattus norvegicus,10116.0,,,
8236,Intermediate,50597,,,Pharmacokinetic property (vdss) was measured in rat,4239,A,In vivo,Rattus norvegicus,10116.0,,,
8237,Intermediate,50597,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,4709,A,In vivo,Rattus norvegicus,10116.0,,,
8238,Intermediate,50597,,,Volume of distribution in rat,6642,A,In vivo,Rattus norvegicus,10116.0,,,
8239,Intermediate,50597,,,The pharmacokinetic parameter volume of distribution in vivo in rats,5247,A,In vivo,Rattus norvegicus,10116.0,,,
8240,Intermediate,50597,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,F,In vivo,Rattus norvegicus,10116.0,,,
8241,Intermediate,50597,,,Vdss in rat i.v. at 2 mg/kg concentration,17686,A,In vivo,Rattus norvegicus,10116.0,,,
8242,Intermediate,50597,,,Volume distribution after intravenous administration (1 mg/kg) in rat,4689,A,In vivo,Rattus norvegicus,10116.0,,,
8243,Intermediate,50597,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
8244,Intermediate,50597,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
8245,Intermediate,50597,,,Volume distribution at a dose of 10 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
8246,Intermediate,50597,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,4521,A,In vivo,Rattus norvegicus,10116.0,,,
8247,Intermediate,50597,,,Volume distribution was calculated in rat,6057,A,In vivo,Rattus norvegicus,10116.0,,,
8248,Intermediate,50597,,,Volume distribution was determined,5510,A,In vivo,Rattus norvegicus,10116.0,,,
8249,Intermediate,50597,,,Volume of distribution after intravenous administration was evaluated in rat,2938,A,In vivo,Rattus norvegicus,10116.0,,,
8250,Intermediate,50597,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Rattus norvegicus,10116.0,,,
8251,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8252,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8253,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8254,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,5145,A,In vivo,Rattus norvegicus,10116.0,,,
8255,Intermediate,50597,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,6467,A,In vivo,Rattus norvegicus,10116.0,,,
8256,Intermediate,50597,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,6467,A,In vivo,Rattus norvegicus,10116.0,,,
8257,Intermediate,50594,,,Compound was evaluated for area under curve when administered through oral route to mouse,15115,A,,Mus musculus,10090.0,,,
8258,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,8758,A,,Rattus norvegicus,10116.0,,,
8259,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,8758,A,,Rattus norvegicus,10116.0,,,
8260,Autocuration,22224,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,8267,F,In vivo,,,,,
8261,Intermediate,50588,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,8267,A,,Canis lupus familiaris,9615.0,,,
8262,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,14239,A,,Mus musculus,10090.0,,,
8263,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,14239,A,,Mus musculus,10090.0,,,
8264,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,10754,A,,Mus musculus,10090.0,,,
8265,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,10754,A,,Mus musculus,10090.0,,,
8266,Intermediate,50588,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,10754,A,,Canis lupus familiaris,9615.0,,,
8267,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,14681,A,,Rattus norvegicus,10116.0,,,
8268,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,14681,A,,Rattus norvegicus,10116.0,,,
8269,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,14681,A,,Rattus norvegicus,10116.0,,,
8270,Autocuration,22224,,,Concentration of compound in Central nervous system,13118,A,,,,,,
8271,Autocuration,22224,,,Concentration of compound in Central nervous system; Not detectable,13118,A,,,,,,
8272,Intermediate,50594,,,"Concentration of diester in the blood, following oral administration in mice",13318,A,,Mus musculus,10090.0,,,
8273,Intermediate,50594,,,"Concentration of monoester in the blood, following oral administration in mice",13318,A,,Mus musculus,10090.0,,,
8274,Intermediate,50594,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,13318,A,,Mus musculus,10090.0,,,
8275,Autocuration,22224,,,Evaluated for Pharmacokinetic property: Area under the curve,15692,A,,,,,,
8276,Intermediate,50594,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,14839,A,,Mus musculus,10090.0,,,
8277,Intermediate,100710,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,14839,A,,Macaca fascicularis,9541.0,,,
8278,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,14839,A,,Macaca fascicularis,9541.0,,,
8279,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,14839,A,,Macaca fascicularis,9541.0,,,
8280,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,14839,A,,Macaca fascicularis,9541.0,,,
8281,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,14839,A,,Macaca fascicularis,9541.0,,,
8282,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8283,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8284,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8285,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8286,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8287,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8288,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",14839,A,,Macaca fascicularis,9541.0,,,
8289,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8290,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8291,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8292,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8293,Intermediate,50594,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8294,Intermediate,50594,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,14839,A,,Mus musculus,10090.0,,,
8295,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",14839,A,,Mus musculus,10090.0,,,
8296,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",14839,A,,Mus musculus,10090.0,,,
8297,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",14839,A,,Mus musculus,10090.0,,,
8298,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",14839,A,,Mus musculus,10090.0,,,
8299,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",14839,A,,Mus musculus,10090.0,,,
8300,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",14839,A,,Mus musculus,10090.0,,,
8301,Intermediate,50597,Plasma,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,5408,A,In vivo,Rattus norvegicus,10116.0,,,
8302,Intermediate,50597,,,High i.v. clearance in Dawley rats,6827,A,In vivo,Rattus norvegicus,10116.0,,,
8303,Intermediate,50597,Liver,,In vitro clearance in rat liver microsomes,17538,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
8304,Intermediate,50597,Liver,,Intrinsic clearance in rat liver microsomes was determined,6331,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
8305,Intermediate,50597,Liver,,Intrinsic clearance in rat hepatocytes was determined,5948,A,In vitro,Rattus norvegicus,10116.0,,Hepatocyte,
8306,Intermediate,50597,,,Plasma Clearance was determined,4026,A,In vivo,Rattus norvegicus,10116.0,,,
8307,Intermediate,50597,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,6647,A,In vivo,Rattus norvegicus,10116.0,,,
8308,Intermediate,50597,,,Plasma clearance in rat.,1696,A,In vivo,Rattus norvegicus,10116.0,,,
8309,Intermediate,50597,,,Plasma clearance in rats,6597,A,In vivo,Rattus norvegicus,10116.0,,,
8310,Intermediate,50597,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,347,A,In vivo,Rattus norvegicus,10116.0,,,
8311,Intermediate,50597,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,16423,A,In vivo,Rattus norvegicus,10116.0,,,
8312,Intermediate,50597,,,Plasma clearance was measured in rat,2879,A,In vivo,Rattus norvegicus,10116.0,,,
8313,Intermediate,50597,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,4883,A,In vivo,Rattus norvegicus,10116.0,,,
8314,Intermediate,50597,Plasma,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",5328,A,In vivo,Rattus norvegicus,10116.0,,,
8315,Intermediate,50597,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,5160,A,In vivo,Rattus norvegicus,10116.0,,,
8316,Intermediate,50597,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
8317,Intermediate,50597,,,Total clearance at 1 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
8318,Intermediate,50597,,,Total clearance at 10 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
8319,Intermediate,50597,,,Clearance in rat,6596,A,In vivo,Rattus norvegicus,10116.0,,,
8320,Intermediate,50597,,,Plasma clearance rate determined in rats,4796,A,In vivo,Rattus norvegicus,10116.0,,,
8321,Intermediate,50597,,,Clearance of compound in rat was evaluated,6850,A,In vivo,Rattus norvegicus,10116.0,,,
8322,Intermediate,50597,Plasma,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,5932,A,In vivo,Rattus norvegicus,10116.0,,,
8323,Intermediate,50597,,,Pharmacokinetic property (blood clearance) in rat,3371,A,In vivo,Rattus norvegicus,10116.0,,,
8324,Intermediate,50597,,,Plasma clearance in rat,2083,A,In vivo,Rattus norvegicus,10116.0,,,
8325,Intermediate,50597,,,Plasma clearance in rats,4942,A,In vivo,Rattus norvegicus,10116.0,,,
8326,Intermediate,50597,Liver,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,6838,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
8327,Intermediate,50597,,,Clearance in Dawley rat,5353,A,In vivo,Rattus norvegicus,10116.0,,,
8328,Intermediate,50597,,,Clearance rat,6641,A,In vivo,Rattus norvegicus,10116.0,,,
8329,Intermediate,50597,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),6641,A,In vivo,Rattus norvegicus,10116.0,,,
8330,Intermediate,50597,,,Clearance rat; Not determined,6641,A,In vivo,Rattus norvegicus,10116.0,,,
8331,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8332,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8333,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8334,Intermediate,50597,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,6211,A,In vivo,Rattus norvegicus,10116.0,,,
8335,Intermediate,50597,Plasma,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",12873,A,In vivo,Rattus norvegicus,10116.0,,,
8336,Intermediate,50597,,,Clearance of compound in rat after 1 mg/kg i.v. administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
8337,Intermediate,50597,,,Compound was evaluated for Hepatic clearance in rat,3341,A,In vivo,Rattus norvegicus,10116.0,,,
8338,Intermediate,50597,,,In vivo clearance after 5 mg/kg dose,4891,A,In vivo,Rattus norvegicus,10116.0,,,
8339,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rats,1094,A,In vivo,Rattus norvegicus,10116.0,,,
8340,Intermediate,50597,,,Hepatic clearance after intravenous administration was evaluated in rat,2938,A,In vivo,Rattus norvegicus,10116.0,,,
8341,Intermediate,50597,,,Lower clearance in rat (i.v.) at 0.5 mpk,17853,A,In vivo,Rattus norvegicus,10116.0,,,
8342,Intermediate,50597,Plasma,,Pharmacokinetic parameter expressed as plasma clearance in rat,6049,A,In vivo,Rattus norvegicus,10116.0,,,
8343,Intermediate,50597,,,Pharmacokinetic property (Clp) in rat,5789,A,In vivo,Rattus norvegicus,10116.0,,,
8344,Intermediate,50597,,,Plasma clearance in Sprague-Dawley rats,4514,A,In vivo,Rattus norvegicus,10116.0,,,
8345,Intermediate,50597,,,Plasma clearance (Clp) in rat,6448,A,In vivo,Rattus norvegicus,10116.0,,,
8346,Intermediate,50597,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,6062,A,In vivo,Rattus norvegicus,10116.0,,,
8347,Intermediate,50597,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,5710,A,In vivo,Rattus norvegicus,10116.0,,,
8348,Intermediate,50597,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,4709,A,In vivo,Rattus norvegicus,10116.0,,,
8349,Intermediate,50597,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,4521,A,In vivo,Rattus norvegicus,10116.0,,,
8350,Intermediate,50597,,,Plasma clearance in rat was determined,1742,A,In vivo,Rattus norvegicus,10116.0,,,
8351,Intermediate,50597,,,Plasma clearance measured in rat,6057,A,In vivo,Rattus norvegicus,10116.0,,,
8352,Intermediate,50597,,,Plasma clearance was calculated in rat,6057,A,In vivo,Rattus norvegicus,10116.0,,,
8353,Intermediate,50597,,,Plasma clearance in rat,5145,A,In vivo,Rattus norvegicus,10116.0,,,
8354,Intermediate,50597,,,Plasma clearance in rat,5833,A,In vivo,Rattus norvegicus,10116.0,,,
8355,Intermediate,50597,,,Plasma clearance in rat,6453,A,In vivo,Rattus norvegicus,10116.0,,,
8356,Intermediate,50597,,,Plasma clearance in rat,6640,A,In vivo,Rattus norvegicus,10116.0,,,
8357,Intermediate,50597,,,Plasma clearance in rats,6305,A,In vivo,Rattus norvegicus,10116.0,,,
8358,Intermediate,50597,,,Plasma clearance in rat,6642,A,In vivo,Rattus norvegicus,10116.0,,,
8359,Intermediate,50597,,,Plasma clearance was evaluated in rat,5472,A,In vivo,Rattus norvegicus,10116.0,,,
8360,Intermediate,50597,,,Plasma clearance was evaluated in rat; Not tested,5472,A,In vivo,Rattus norvegicus,10116.0,,,
8361,Intermediate,50597,,,Plasma clearance rate was determined for the compound in rat,5144,A,In vivo,Rattus norvegicus,10116.0,,,
8362,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8363,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8364,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8365,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8366,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8367,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8368,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8369,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8370,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8371,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8372,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8373,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8374,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8375,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8376,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8377,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8378,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8379,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8380,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8381,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8382,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8383,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8384,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8385,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8386,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8387,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8388,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8389,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8390,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8391,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8392,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8393,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8394,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8395,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8396,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8397,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8398,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8399,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8400,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8401,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,13950,A,In vivo,Rattus norvegicus,10116.0,,,
8402,Intermediate,50597,Cerebellum,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8403,Intermediate,50597,Cerebellum,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8404,Intermediate,50597,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8405,Intermediate,50597,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
8406,Intermediate,50597,,,Volume of distribution of compound in rats after intravenous administration,6571,A,In vivo,Rattus norvegicus,10116.0,,,
8407,Intermediate,50597,,,Volume of distribution in rat,6453,A,In vivo,Rattus norvegicus,10116.0,,,
8408,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8409,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8410,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
8411,Intermediate,50597,,,Volume of distribution was determined in Dawley rat,5353,A,In vivo,Rattus norvegicus,10116.0,,,
8412,Intermediate,50597,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8413,Intermediate,50597,,,Volume of distribution was reported in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8414,Intermediate,50597,,,Volumes of distribution in rat after peroral administration,6641,A,In vivo,Rattus norvegicus,10116.0,,,
8415,Intermediate,50597,,,Volumes of distribution in rat after po administration,6641,A,In vivo,Rattus norvegicus,10116.0,,,
8416,Intermediate,50597,,,Volumes of distribution in rat after po administration; Not determined,6641,A,In vivo,Rattus norvegicus,10116.0,,,
8417,Intermediate,50597,,,Pharmacokinetic property (Volume) in rat i.v.,5676,A,In vivo,Rattus norvegicus,10116.0,,,
8418,Intermediate,50597,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,6410,A,In vivo,Rattus norvegicus,10116.0,,,
8419,Intermediate,50597,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",17670,A,In vivo,Rattus norvegicus,10116.0,,,
8420,Intermediate,50597,,,Volume distribution in rat after oral administration at 10 mg/kg,6495,A,In vivo,Rattus norvegicus,10116.0,,,
8421,Intermediate,50597,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,5408,A,In vivo,Rattus norvegicus,10116.0,,,
8422,Intermediate,50597,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,4883,A,In vivo,Rattus norvegicus,10116.0,,,
8423,Intermediate,50597,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,6647,A,In vivo,Rattus norvegicus,10116.0,,,
8424,Intermediate,50597,,,Volume of distribution in rats,6495,A,In vivo,Rattus norvegicus,10116.0,,,
8425,Intermediate,50597,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
8426,Intermediate,50597,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
8427,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8428,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8429,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8430,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8431,Intermediate,50597,,,Pharmacokinetic parameter (Vss) in rat,5960,A,In vivo,Rattus norvegicus,10116.0,,,
8432,Intermediate,50597,,,Pharmacokinetic property (Volume) in rat i.v.,5676,A,In vivo,Rattus norvegicus,10116.0,,,
8433,Intermediate,50597,,,Pharmacokinetic property (Vss) in rat,5948,A,,Rattus norvegicus,10116.0,,,
8434,Intermediate,50597,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,5979,A,In vivo,Rattus norvegicus,10116.0,,,
8435,Intermediate,50597,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8436,Intermediate,50597,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8437,Intermediate,50597,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8438,Intermediate,50597,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8439,Intermediate,50597,,,Steady state volume distribution in rat,6448,A,In vivo,Rattus norvegicus,10116.0,,,
8440,Intermediate,50597,Plasma,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",12873,A,In vivo,Rattus norvegicus,10116.0,,,
8441,Intermediate,50597,,,Steady state volume of distribution determined in rat,4576,A,In vivo,Rattus norvegicus,10116.0,,,
8442,Intermediate,50597,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
8443,Intermediate,50597,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
8444,Intermediate,50597,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,5182,A,,Rattus norvegicus,10116.0,,,
8445,Intermediate,50597,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,5182,A,,Rattus norvegicus,10116.0,,,
8446,Intermediate,50597,,,Volume distribution in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
8447,Intermediate,50597,,,Volume distribution in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
8448,Intermediate,50597,,,Volume in steady state distribution value was determined,5041,A,In vivo,Rattus norvegicus,10116.0,,,
8449,Intermediate,50597,,,Volume in steady state distribution value was determined; ND denotes no data,5041,A,In vivo,Rattus norvegicus,10116.0,,,
8450,Intermediate,50597,,,Volume in steady state distribution value was determined; ND denotes not determined,5041,A,In vivo,Rattus norvegicus,10116.0,,,
8451,Intermediate,50597,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,17065,A,In vivo,Rattus norvegicus,10116.0,,,
8452,Intermediate,50597,,,Volume of distribution at steady state was evaluated in rats,6597,A,In vivo,Rattus norvegicus,10116.0,,,
8453,Intermediate,50597,,,Volume of distribution at steady state was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
8454,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,6485,A,In vivo,Rattus norvegicus,10116.0,,,
8455,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,17655,A,In vivo,Rattus norvegicus,10116.0,,,
8456,Intermediate,50597,,,Volume of distribution after i.v. administration,6616,A,In vivo,Rattus norvegicus,10116.0,,,
8457,Intermediate,50597,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
8458,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
8459,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
8460,Intermediate,50594,Spleen,,Biodistribution of compound (oxidized form) in spleen tissue,16438,A,In vivo,Mus musculus,10090.0,,,
8461,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
8462,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
8463,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8464,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",16438,A,In vivo,Mus musculus,10090.0,,,
8465,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",16438,A,In vivo,Mus musculus,10090.0,,,
8466,Intermediate,50594,Blood,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,16438,A,In vivo,Mus musculus,10090.0,,,
8467,Intermediate,50594,Blood,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8468,Intermediate,50594,Brain,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,16438,A,In vivo,Mus musculus,10090.0,,,
8469,Intermediate,50594,Brain,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8470,Intermediate,50594,Brain,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8471,Intermediate,50594,Heart,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,16438,A,In vivo,Mus musculus,10090.0,,,
8472,Intermediate,50594,Heart,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8473,Intermediate,50594,Heart,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8474,Intermediate,50594,Kidney,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,16438,A,In vivo,Mus musculus,10090.0,,,
8475,Intermediate,50594,Kidney,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8476,Intermediate,50594,Kidney,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8477,Intermediate,50594,Liver,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,16438,A,In vivo,Mus musculus,10090.0,,,
8478,Intermediate,50594,Liver,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8479,Intermediate,50594,Spleen,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,16438,A,In vivo,Mus musculus,10090.0,,,
8480,Intermediate,50594,Spleen,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8481,Intermediate,50594,Spleen,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",16438,A,In vivo,Mus musculus,10090.0,,,
8482,Intermediate,50594,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,12467,A,,Mus musculus,10090.0,,,
8483,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8484,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8485,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8486,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8487,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8488,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8489,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8490,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8491,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8492,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8493,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8494,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8495,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8496,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8497,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8498,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8499,Intermediate,50597,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,5089,A,In vivo,Rattus norvegicus,10116.0,,,
8500,Intermediate,50597,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,5089,A,In vivo,Rattus norvegicus,10116.0,,,
8501,Intermediate,50597,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,4257,A,In vivo,Rattus norvegicus,10116.0,,,
8502,Intermediate,50597,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Rattus norvegicus,10116.0,,,
8503,Intermediate,50597,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Rattus norvegicus,10116.0,,,
8504,Intermediate,50597,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,6141,A,In vivo,Rattus norvegicus,10116.0,,,
8505,Intermediate,50597,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8506,Intermediate,50597,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8507,Intermediate,50597,,,Plasma clearance was reported in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
8508,Intermediate,50597,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,4689,A,In vivo,Rattus norvegicus,10116.0,,,
8509,Intermediate,50597,,,Plasma clearance of compound in rats was evaluated,6848,A,In vivo,Rattus norvegicus,10116.0,,,
8510,Intermediate,50597,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,6848,A,In vivo,Rattus norvegicus,10116.0,,,
8511,Intermediate,50597,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,6467,A,In vivo,Rattus norvegicus,10116.0,,,
8512,Intermediate,50597,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,6467,A,In vivo,Rattus norvegicus,10116.0,,,
8513,Intermediate,50597,,,Plasma clearance rate in Sprague-Dawley rats,4956,A,In vivo,Rattus norvegicus,10116.0,,,
8514,Intermediate,50597,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),5529,A,In vivo,Rattus norvegicus,10116.0,,,
8515,Intermediate,50597,Plasma,,The compound was evaluated for plasma clearance in rat,406,A,In vivo,Rattus norvegicus,10116.0,,,
8516,Intermediate,50597,Plasma,,Total plasma clearance in rat,17655,A,In vivo,Rattus norvegicus,10116.0,,,
8517,Intermediate,50597,Blood,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,3293,A,In vivo,Rattus norvegicus,10116.0,,,
8518,Intermediate,50597,Blood,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,4075,A,In vivo,Rattus norvegicus,10116.0,,,
8519,Intermediate,50597,,,C max was determined at 10 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
8520,Intermediate,50597,,,C max was determined at 3 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
8521,Intermediate,50597,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,17594,A,In vivo,Rattus norvegicus,10116.0,,,
8522,Intermediate,50597,,,Cmax after single intravenous bolus of 1 mg/kg in rats,17594,A,In vivo,Rattus norvegicus,10116.0,,,
8523,Intermediate,50597,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,4762,A,In vivo,Rattus norvegicus,10116.0,,,
8524,Intermediate,50597,,,Cmax 24 hr after 10 mg/kg oral administration in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
8525,Intermediate,50597,,,Cmax 24 hr after 2 mg/kg oral administration in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
8526,Intermediate,50597,Plasma,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
8527,Intermediate,50597,,,Cmax in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
8528,Intermediate,50597,,,Cmax in rat after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
8529,Intermediate,50597,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,3169,A,In vivo,Rattus norvegicus,10116.0,,,
8530,Intermediate,50597,Plasma,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,6515,A,In vivo,Rattus norvegicus,10116.0,,,
8531,Intermediate,50597,Blood,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,11149,A,In vivo,Rattus norvegicus,10116.0,,,
8532,Intermediate,50597,Blood,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,11149,A,In vivo,Rattus norvegicus,10116.0,,,
8533,Intermediate,50597,,,Cmax after 10 mg/kg oral administration in rat,17858,A,In vivo,Rattus norvegicus,10116.0,,,
8534,Intermediate,50597,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8535,Intermediate,50597,,,Cmax after IV dosing at 1 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8536,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats,4426,A,In vivo,Rattus norvegicus,10116.0,,,
8537,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats; Not performed.,4426,A,In vivo,Rattus norvegicus,10116.0,,,
8538,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,4426,A,In vivo,Rattus norvegicus,10116.0,,,
8539,Intermediate,50597,,,Cmax after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
8540,Intermediate,50597,,,Cmax after oral administration at a dose of 2 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8541,Intermediate,50597,,,Cmax after oral administration at a dose of 4 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
8542,Intermediate,50597,,,Cmax in rats after 20 mg/kg oral dose,6113,A,In vivo,Rattus norvegicus,10116.0,,,
8543,Intermediate,50597,,,Cmax after peroral administration in rats at 2.4 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
8544,Intermediate,50597,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,4756,A,In vivo,Rattus norvegicus,10116.0,,,
8545,Intermediate,50597,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,4756,A,In vivo,Rattus norvegicus,10116.0,,,
8546,Intermediate,50597,,,Cmax by administering at 20 mg/kg p.o. in rats,6402,A,In vivo,Rattus norvegicus,10116.0,,,
8547,Intermediate,50597,,,Cmax in male rat,5610,A,In vivo,Rattus norvegicus,10116.0,,,
8548,Intermediate,50597,,,Cmax in rat,5207,A,In vivo,Rattus norvegicus,10116.0,,,
8549,Intermediate,50597,,,Cmax in rat,6011,A,In vivo,Rattus norvegicus,10116.0,,,
8550,Intermediate,50597,,,Cmax in rat,6504,A,In vivo,Rattus norvegicus,10116.0,,,
8551,Intermediate,50597,,,Cmax in rat at 10 mg/kg,6046,A,In vivo,Rattus norvegicus,10116.0,,,
8552,Intermediate,50597,,,Cmax in rat at the dose of 1 mg/kg i.v.,6504,A,In vivo,Rattus norvegicus,10116.0,,,
8553,Intermediate,50597,,,Cmax in rat by po administration at a dose of 40 mg/kg,5874,A,In vivo,Rattus norvegicus,10116.0,,,
8554,Intermediate,50597,,,Cmax in rat p.o. at 20 mg/kg concentration,17686,A,In vivo,Rattus norvegicus,10116.0,,,
8555,Intermediate,50597,,,Cmax in rats,5836,A,In vivo,Rattus norvegicus,10116.0,,,
8556,Intermediate,50597,,,Cmax in rats,17596,A,In vivo,Rattus norvegicus,10116.0,,,
8557,Intermediate,50597,,,Cmax was evaluated after 20 uM/kg of peroral administration,16423,A,In vivo,Rattus norvegicus,10116.0,,,
8558,Intermediate,50597,,,Cmax was measured in rats after peroral administration at 3 mg/kg,17804,A,In vivo,Rattus norvegicus,10116.0,,,
8559,Intermediate,50597,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1908,A,In vivo,Rattus norvegicus,10116.0,,,
8560,Intermediate,50597,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8561,Intermediate,50597,Frontal cortex,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8562,Intermediate,50597,Frontal cortex,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8563,Intermediate,50597,Hippocampus,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8564,Intermediate,50597,Hippocampus,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8565,Intermediate,50597,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8566,Intermediate,50597,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8567,Intermediate,50597,Midbrain,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8568,Intermediate,50597,Midbrain,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8569,Intermediate,50597,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8570,Intermediate,50597,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8571,Intermediate,50597,Striatum,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8572,Intermediate,50597,Striatum,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,13950,A,,Rattus norvegicus,10116.0,,,
8573,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8574,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8575,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8576,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8577,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8578,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8579,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8580,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8581,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8582,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8583,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8584,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8585,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8586,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8587,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8588,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8589,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
8590,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
8591,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
8592,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8593,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8594,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8595,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8596,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8597,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8598,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8599,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8600,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8601,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8602,Intermediate,50597,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
8603,Intermediate,50597,,,Volume of steady state distribution after i.v. administration in rats,5031,A,In vivo,Rattus norvegicus,10116.0,,,
8604,Intermediate,50597,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,6215,A,In vivo,Rattus norvegicus,10116.0,,,
8605,Intermediate,50597,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,17671,A,In vivo,Rattus norvegicus,10116.0,,,
8606,Intermediate,50597,,,Vss was determined,17752,A,In vivo,Rattus norvegicus,10116.0,,,
8607,Intermediate,50597,,,Vss in rat,6596,A,In vivo,Rattus norvegicus,10116.0,,,
8608,Intermediate,50597,,,Vss was evaluated after 10 uM/kg of intra arterial administration,16423,A,In vivo,Rattus norvegicus,10116.0,,,
8609,Intermediate,50597,,,volume of distribution at steady state was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
8610,Intermediate,50597,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,6062,A,In vivo,Rattus norvegicus,10116.0,,,
8611,Intermediate,50597,,,Pharmacokinetic (PK) parameter Vz in rat,5874,A,In vivo,Rattus norvegicus,10116.0,,,
8612,Intermediate,50597,,,Volume distribution in rats,4942,A,In vivo,Rattus norvegicus,10116.0,,,
8613,Intermediate,50597,,,Volume of distribution in rat; No data,17796,A,In vivo,Rattus norvegicus,10116.0,,,
8614,Intermediate,50597,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
8615,Intermediate,50597,Ileum,,% absorption predicted from in vitro rat ileum transport studies,15765,A,,Rattus norvegicus,10116.0,,,
8616,Intermediate,50597,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8617,Intermediate,50597,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8618,Intermediate,50597,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8619,Intermediate,50597,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),13569,A,In vivo,Rattus norvegicus,10116.0,,,
8620,Intermediate,50597,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8621,Intermediate,50597,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8622,Intermediate,50597,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8623,Intermediate,50597,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,13569,A,In vivo,Rattus norvegicus,10116.0,,,
8624,Intermediate,50597,,,Oral bioavailability in rat,4576,A,In vivo,Rattus norvegicus,10116.0,,,
8625,Intermediate,50597,Plasma,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,750,A,In vivo,Rattus norvegicus,10116.0,,,
8626,Intermediate,50597,,,Oral bioavailability in rat,750,A,In vivo,Rattus norvegicus,10116.0,,,
8627,Intermediate,50597,,,Oral bioavailability in rat,4590,A,In vivo,Rattus norvegicus,10116.0,,,
8628,Intermediate,50597,,,Oral bioavailability in rat,1716,A,In vivo,Rattus norvegicus,10116.0,,,
8629,Intermediate,50597,,,Bioavailability in rat,1974,A,In vivo,Rattus norvegicus,10116.0,,,
8630,Intermediate,50597,,,Oral bioavailability in rat (dose 30 mg/kg),4502,A,In vivo,Rattus norvegicus,10116.0,,,
8631,Intermediate,50597,,,Pharmacokinetic property (cLogP) in rat,3371,A,,Rattus norvegicus,10116.0,,,
8632,Intermediate,50597,Blood,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,9099,F,,Rattus norvegicus,10116.0,,,
8633,Intermediate,50597,Blood,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,9099,F,,Rattus norvegicus,10116.0,,,
8634,Intermediate,50597,,,Clearance in rat.,4590,A,In vivo,Rattus norvegicus,10116.0,,,
8635,Intermediate,50597,,,Compound was evaluated for its clearance when administered intravenously in rat,3184,A,In vivo,Rattus norvegicus,10116.0,,,
8636,Intermediate,50597,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Rattus norvegicus,10116.0,,,
8637,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat,4199,A,,Rattus norvegicus,10116.0,,,
8638,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,4199,A,,Rattus norvegicus,10116.0,,,
8639,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,4199,A,,Rattus norvegicus,10116.0,,,
8640,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
8641,Intermediate,50597,,,Percent dose excreted in 0-48 hours administered ip to male rat,7449,F,,Rattus norvegicus,10116.0,,,
8642,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8643,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8644,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,,Rattus norvegicus,10116.0,,,
8645,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8646,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8647,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8648,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8649,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,,Rattus norvegicus,10116.0,,,
8650,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8651,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8652,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8653,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8654,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8655,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8656,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8657,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8658,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8659,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8660,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8661,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8662,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8663,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8664,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8665,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8666,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8667,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8668,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8669,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8670,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8671,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8672,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8673,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8674,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8675,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8676,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8677,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8678,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8679,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8680,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8681,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8682,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8683,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8684,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8685,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8686,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8687,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8688,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8689,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8690,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8691,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),17208,A,In vivo,Mus musculus,10090.0,,,
8692,Intermediate,50594,,,Time taken for EC90 was determined when tested in mouse,3132,A,,Mus musculus,10090.0,,,
8693,Intermediate,50594,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,3132,A,,Mus musculus,10090.0,,,
8694,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),16597,A,In vivo,Mus musculus,10090.0,,,
8695,Intermediate,50594,,,Half life in mice,5727,A,,Mus musculus,10090.0,,,
8696,Intermediate,50594,,,Half life period in mouse after 10 mg/Kg dose,5302,A,In vivo,Mus musculus,10090.0,,,
8697,Intermediate,50594,,,Half life period in mouse after 10 mg/kg dose,5302,A,In vivo,Mus musculus,10090.0,,,
8698,Intermediate,50594,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,6348,A,In vivo,Mus musculus,10090.0,,,
8699,Intermediate,50597,,,Cmax value at 5 mg/kg po was determined in rat,5964,A,In vivo,Rattus norvegicus,10116.0,,,
8700,Intermediate,50597,,,Cmax value evaluated in rat,6078,A,In vivo,Rattus norvegicus,10116.0,,,
8701,Intermediate,50597,Brain,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,5206,A,In vivo,Rattus norvegicus,10116.0,,,
8702,Intermediate,50597,,,Cmax value after administration of 20 mg/Kg oral dose in rat,2959,A,In vivo,Rattus norvegicus,10116.0,,,
8703,Intermediate,50597,,,Cmax value at 1 mg/kg po in rat,5964,A,In vivo,Rattus norvegicus,10116.0,,,
8704,Intermediate,50597,,,Cmax value at 5 mg/kg po in rat,5964,A,In vivo,Rattus norvegicus,10116.0,,,
8705,Intermediate,50597,,,Cmax value at a dose of 10 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8706,Intermediate,50597,,,Cmax value at a dose of 100 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8707,Intermediate,50597,,,Cmax value at a dose of 50 mg/kg in male SD rats,6757,A,In vivo,Rattus norvegicus,10116.0,,,
8708,Intermediate,50597,,,Cmax value in rats at 10 mg/kg,17617,A,In vivo,Rattus norvegicus,10116.0,,,
8709,Intermediate,50597,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,1445,A,In vivo,Rattus norvegicus,10116.0,,,
8710,Intermediate,50597,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,6082,A,In vivo,Rattus norvegicus,10116.0,,,
8711,Intermediate,50597,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1446,A,In vivo,Rattus norvegicus,10116.0,,,
8712,Intermediate,50597,Plasma,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,5407,A,In vivo,Rattus norvegicus,10116.0,,,
8713,Intermediate,50597,Plasma,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,2690,A,In vivo,Rattus norvegicus,10116.0,,,
8714,Intermediate,50597,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
8715,Intermediate,50597,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
8716,Intermediate,50597,Plasma,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,4891,A,In vivo,Rattus norvegicus,10116.0,,,
8717,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,2807,A,In vivo,Rattus norvegicus,10116.0,,,
8718,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,2807,A,In vivo,Rattus norvegicus,10116.0,,,
8719,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,2807,A,In vivo,Rattus norvegicus,10116.0,,,
8720,Intermediate,50597,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,3634,A,In vivo,Rattus norvegicus,10116.0,,,
8721,Intermediate,50597,Plasma,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1881,A,In vivo,Rattus norvegicus,10116.0,,,
8722,Intermediate,50597,Plasma,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1881,A,In vivo,Rattus norvegicus,10116.0,,,
8723,Intermediate,50597,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,429,A,In vivo,Rattus norvegicus,10116.0,,,
8724,Intermediate,50597,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8725,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8726,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8727,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
8728,Intermediate,50597,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,17582,A,In vivo,Rattus norvegicus,10116.0,,,
8729,Intermediate,50597,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,17582,A,In vivo,Rattus norvegicus,10116.0,,,
8730,Intermediate,50597,Plasma,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",3032,A,In vivo,Rattus norvegicus,10116.0,,,
8731,Intermediate,50597,Plasma,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,6295,A,In vivo,Rattus norvegicus,10116.0,,,
8732,Intermediate,50597,,,Maximal concentration in rat was determined,6619,A,In vivo,Rattus norvegicus,10116.0,,,
8733,Intermediate,50597,,,Maximal concentration after i.v. administration,6616,A,In vivo,Rattus norvegicus,10116.0,,,
8734,Intermediate,50597,Plasma,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,3249,A,In vivo,Rattus norvegicus,10116.0,,,
8735,Intermediate,50597,Plasma,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,17791,A,In vivo,Rattus norvegicus,10116.0,,,
8736,Intermediate,50597,Plasma,,Cmax in rat plasma after oral dose (50 mg/Kg),17791,A,In vivo,Rattus norvegicus,10116.0,,,
8737,Intermediate,50597,Plasma,,Maximal plasma concentration was determined.,1360,A,In vivo,Rattus norvegicus,10116.0,,,
8738,Intermediate,50597,Plasma,,Maximal plasma drug concentration was determined,2552,A,In vivo,Rattus norvegicus,10116.0,,,
8739,Intermediate,50597,,,Maximal concentration in rats after peroral administration,6571,A,In vivo,Rattus norvegicus,10116.0,,,
8740,Intermediate,50597,,,Maximum concentration in rat after 2 mg/kg peroral administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
8741,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,6567,A,In vivo,Rattus norvegicus,10116.0,,,
8742,Intermediate,50597,,,Maximum concentration of compound in rat was evaluated.,3031,A,In vivo,Rattus norvegicus,10116.0,,,
8743,Intermediate,50597,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,3436,A,In vivo,Rattus norvegicus,10116.0,,,
8744,Intermediate,50597,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,3436,A,In vivo,Rattus norvegicus,10116.0,,,
8745,Intermediate,50597,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,2083,A,In vivo,Rattus norvegicus,10116.0,,,
8746,Intermediate,50597,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,3436,A,In vivo,Rattus norvegicus,10116.0,,,
8747,Intermediate,50597,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
8748,Intermediate,50597,,,Maximum concentration was evaluated in rats,1974,A,In vivo,Rattus norvegicus,10116.0,,,
8749,Intermediate,50597,Cerebrospinal fluid,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,3307,A,In vivo,Rattus norvegicus,10116.0,,,
8750,Intermediate,50597,Plasma,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,3307,A,In vivo,Rattus norvegicus,10116.0,,,
8751,Intermediate,50597,Plasma,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1916,A,In vivo,Rattus norvegicus,10116.0,,,
8752,Intermediate,50597,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1500,A,In vivo,Rattus norvegicus,10116.0,,,
8753,Intermediate,50597,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1500,A,In vivo,Rattus norvegicus,10116.0,,,
8754,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
8755,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8756,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8757,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8758,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8759,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8760,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8761,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8762,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8763,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8764,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8765,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8766,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8767,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
8768,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
8769,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
8770,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8771,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8772,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8773,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8774,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8775,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8776,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8777,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8778,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8779,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8780,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8781,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8782,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8783,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8784,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8785,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8786,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8787,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8788,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8789,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8790,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8791,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8792,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
8793,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
8794,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
8795,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8796,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8797,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8798,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8799,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8800,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8801,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,,Rattus norvegicus,10116.0,,,
8802,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8803,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8804,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8805,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8806,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8807,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8808,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8809,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,,Rattus norvegicus,10116.0,,,
8810,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8811,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,,Rattus norvegicus,10116.0,,,
8812,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8813,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8814,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8815,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8816,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8817,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8818,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8819,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8820,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8821,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8822,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8823,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8824,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8825,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8826,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8827,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8828,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8829,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8830,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8831,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8832,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8833,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8834,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8835,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8836,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8837,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8838,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8839,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8840,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8841,Intermediate,50594,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,4573,A,In vivo,Mus musculus,10090.0,,,
8842,Intermediate,50594,Plasma,,Half life in mouse plasma was determined at dose 25 mg/kg,3132,A,In vivo,Mus musculus,10090.0,,,
8843,Intermediate,50594,,,Half life was determined,17718,A,,Mus musculus,10090.0,,,
8844,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8845,Intermediate,50594,,,Half-life in male mice after 1 mg/kg intravenous dose,5961,A,In vivo,Mus musculus,10090.0,,,
8847,Intermediate,50594,Plasma,,Half life in mice plasma,17731,A,,Mus musculus,10090.0,,,
8848,Intermediate,50594,,,Half life in mouse,17592,A,,Mus musculus,10090.0,,,
8849,Intermediate,50594,Plasma,,Half life in mouse plasma at dose 25 mg/kg,3132,A,In vivo,Mus musculus,10090.0,,,
8850,Intermediate,50594,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,17729,A,In vivo,Mus musculus,10090.0,,,
8851,Intermediate,50594,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,17729,A,In vivo,Mus musculus,10090.0,,,
8852,Intermediate,50594,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,17729,A,In vivo,Mus musculus,10090.0,,,
8853,Intermediate,50594,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),3277,A,In vivo,Mus musculus,10090.0,,,
8854,Intermediate,50594,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",3760,A,In vivo,Mus musculus,10090.0,,,
8855,Intermediate,50594,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",3760,A,In vivo,Mus musculus,10090.0,,,
8856,Intermediate,50594,,,Half-life by iv administration in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
8857,Intermediate,50594,,,Half-life by oral administration in mouse,2862,A,In vivo,Mus musculus,10090.0,,,
8858,Intermediate,50594,,,Half-life in mice,5980,A,,Mus musculus,10090.0,,,
8859,Intermediate,50594,Brain,,Half-life using mouse brain homogenate,6159,A,,Mus musculus,10090.0,,,
8860,Intermediate,50594,,,Half-life was measured in mice,6254,A,,Mus musculus,10090.0,,,
8861,Intermediate,50594,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,6062,A,In vivo,Mus musculus,10090.0,,,
8862,Intermediate,50594,Blood,,Half-life period was determined in mouse blood,1574,A,,Mus musculus,10090.0,,,
8863,Intermediate,50594,Brain,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",56,A,,Mus musculus,10090.0,,,
8864,Intermediate,50594,Plasma,,Plasma half life in mouse,993,A,,Mus musculus,10090.0,,,
8865,Intermediate,50594,,,Stability of the peptide in the presence of mouse serum,6652,A,,Mus musculus,10090.0,,,
8866,Intermediate,50594,,,Terminal half life of compound was determined in mouse,17852,A,,Mus musculus,10090.0,,,
8867,Intermediate,50594,,,Terminal half life was evaluated in mice after intravenous administration,2675,A,In vivo,Mus musculus,10090.0,,,
8868,Intermediate,50594,,,Terminal half life was evaluated in mice after oral administration,2675,A,In vivo,Mus musculus,10090.0,,,
8869,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,499,A,,Mus musculus,10090.0,,,
8870,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,499,A,,Mus musculus,10090.0,,,
8871,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,499,A,,Mus musculus,10090.0,,,
8872,Intermediate,50594,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,14239,A,In vivo,Mus musculus,10090.0,,,
8873,Intermediate,50594,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",5506,A,In vivo,Mus musculus,10090.0,,,
8874,Intermediate,50594,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",5506,A,In vivo,Mus musculus,10090.0,,,
8875,Intermediate,50594,,,Half life after intraperitoneal administration of 100 mg/kg in mice,17734,A,,Mus musculus,10090.0,,,
8876,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8877,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8878,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8879,Intermediate,50594,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8880,Intermediate,50594,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,17728,A,In vivo,Mus musculus,10090.0,,,
8881,Autocuration,22224,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),14294,A,,Sus scrofa,9823.0,,,Microsomes
8882,Autocuration,22224,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),14294,A,,Sus scrofa,9823.0,,,Microsomes
8883,Autocuration,22224,,,Stability to porcine renal DHP-I,6056,A,,Sus scrofa,9823.0,,,
8884,Autocuration,22224,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,1317,A,In vivo,Sus scrofa,9823.0,,,
8885,Autocuration,22224,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,1317,A,In vivo,Sus scrofa,9823.0,,,
8886,Autocuration,22224,,,Half-life of the parent prodrug in porcine esterase solution,5229,A,,Sus scrofa,9823.0,,,
8887,Autocuration,22224,,,"First order rate constant, k was determined in in pig liver Esterase",4231,A,,Sus scrofa,9823.0,,,
8888,Autocuration,22224,Liver,,Half life of the in pig liver Esterase,4231,A,,Sus scrofa,9823.0,,,
8889,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,5318,A,,Sus scrofa,9823.0,,,
8890,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,5318,A,,Sus scrofa,9823.0,,,
8891,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,5318,A,,Sus scrofa,9823.0,,,
8892,Autocuration,22224,Liver,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,3305,A,,Sus scrofa,9823.0,,,
8893,Autocuration,22224,Liver,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,3305,A,,Sus scrofa,9823.0,,,
8894,Autocuration,22224,Liver,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,2842,A,,Sus scrofa,9823.0,,,
8895,Autocuration,22224,Liver,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,2842,A,,Sus scrofa,9823.0,,,
8896,Autocuration,22224,Liver,,Half-life in vitro in pig liver,889,A,In vitro,Sus scrofa,9823.0,,,
8897,Autocuration,22224,Liver,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,1904,A,,Sus scrofa,9823.0,,,
8898,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
8899,Intermediate,50597,Plasma,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,2774,A,In vivo,Rattus norvegicus,10116.0,,,
8900,Intermediate,50597,Plasma,,Maximum concentration in rat plasma was determined,1742,A,In vivo,Rattus norvegicus,10116.0,,,
8901,Intermediate,50597,,,Maximum concentration in rats,3169,A,In vivo,Rattus norvegicus,10116.0,,,
8902,Intermediate,50597,,,Maximum concentration in rats at 1-2 hours,3169,A,In vivo,Rattus norvegicus,10116.0,,,
8903,Intermediate,50597,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,2081,A,In vivo,Rattus norvegicus,10116.0,,,
8904,Intermediate,50597,Brain,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,3307,A,In vivo,Rattus norvegicus,10116.0,,,
8905,Intermediate,50597,,,Maximum concentration at the dose of 2 mg/kg in rat,4727,A,In vivo,Rattus norvegicus,10116.0,,,
8906,Intermediate,50597,,,Maximum concentration was evaluated in rats,6597,A,In vivo,Rattus norvegicus,10116.0,,,
8907,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
8908,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
8909,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
8910,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
8911,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
8912,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,2591,A,In vivo,Rattus norvegicus,10116.0,,,
8913,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,2591,A,In vivo,Rattus norvegicus,10116.0,,,
8914,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,2591,A,In vivo,Rattus norvegicus,10116.0,,,
8915,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8916,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8917,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8918,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8919,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8920,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8921,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
8922,Intermediate,50597,,,Cmax in rat (PO dose),14465,A,In vivo,Rattus norvegicus,10116.0,,,
8923,Intermediate,50597,Plasma,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
8924,Intermediate,50597,Plasma,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
8925,Intermediate,50597,Plasma,,Maximum plasma concentration determined in rat,4576,A,In vivo,Rattus norvegicus,10116.0,,,
8926,Intermediate,50597,Plasma,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,12873,A,In vivo,Rattus norvegicus,10116.0,,,
8927,Intermediate,50597,Plasma,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,12873,A,In vivo,Rattus norvegicus,10116.0,,,
8928,Intermediate,50597,Plasma,,Maximum plasma concentration in rat,6824,A,In vivo,Rattus norvegicus,10116.0,,,
8929,Intermediate,50597,Plasma,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,17065,A,In vivo,Rattus norvegicus,10116.0,,,
8930,Intermediate,50597,Plasma,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,2932,A,In vivo,Rattus norvegicus,10116.0,,,
8931,Intermediate,50597,Plasma,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,2932,A,In vivo,Rattus norvegicus,10116.0,,,
8932,Intermediate,50597,Plasma,,Maximum plasma concentration of compound was measured in rat,2879,A,In vivo,Rattus norvegicus,10116.0,,,
8933,Intermediate,50597,Plasma,,Maximum plasma concentration after 20 mg/kg oral administration in rat,2864,A,In vivo,Rattus norvegicus,10116.0,,,
8934,Intermediate,50597,Plasma,,Maximum plasma concentration after oral administration to rats,16367,A,In vivo,Rattus norvegicus,10116.0,,,
8935,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
8936,Intermediate,50597,Plasma,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",17717,A,In vivo,Rattus norvegicus,10116.0,,,
8937,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
8938,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,17717,A,In vivo,Rattus norvegicus,10116.0,,,
8939,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,17720,F,In vivo,Rattus norvegicus,10116.0,,,
8940,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,F,In vivo,Rattus norvegicus,10116.0,,,
8941,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,17720,F,In vivo,Rattus norvegicus,10116.0,,,
8942,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats,4516,A,In vivo,Rattus norvegicus,10116.0,,,
8943,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats after 6 hours,4516,A,In vivo,Rattus norvegicus,10116.0,,,
8944,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,4516,A,In vivo,Rattus norvegicus,10116.0,,,
8945,Intermediate,50597,Plasma,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,5199,A,In vivo,Rattus norvegicus,10116.0,,,
8946,Intermediate,50597,Plasma,,Maximum plasma concentration in rat after po administration,17538,A,In vivo,Rattus norvegicus,10116.0,,,
8947,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8948,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
8949,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8950,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8951,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8952,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8953,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8954,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8955,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8956,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8957,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8958,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8959,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8960,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8961,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
8962,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
8963,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
8964,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8965,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8966,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8967,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8968,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
8969,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
8970,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8971,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8972,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8973,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8974,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8975,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8976,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8977,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8978,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
8979,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
8980,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
8981,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
8982,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8983,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8984,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8985,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8986,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
8987,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
8988,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
8989,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
8990,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
8991,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
8992,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
8993,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
8994,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8995,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8996,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8997,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8998,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
8999,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9000,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9001,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9002,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9003,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9004,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9005,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9006,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9007,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9008,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9009,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9010,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9011,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9012,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9013,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9014,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),11977,A,In vivo,Rattus norvegicus,10116.0,,,
9015,Intermediate,50597,,,Half life in rats,3748,A,,Rattus norvegicus,10116.0,,,
9016,Intermediate,50597,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,15765,A,,Rattus norvegicus,10116.0,,,
9017,Intermediate,50597,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),4871,A,,Rattus norvegicus,10116.0,,,
9018,Intermediate,50597,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,4871,A,,Rattus norvegicus,10116.0,,,
9019,Intermediate,50597,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),4872,A,,Rattus norvegicus,10116.0,,,
9020,Intermediate,50597,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,4872,A,,Rattus norvegicus,10116.0,,,
9021,Intermediate,50597,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),5413,A,,Rattus norvegicus,10116.0,,,
9022,Intermediate,50597,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,5413,A,,Rattus norvegicus,10116.0,,,
9023,Intermediate,50597,Blood,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,15272,A,In vivo,Rattus norvegicus,10116.0,,,
9024,Intermediate,50597,Liver,,Stability (%) in rat liver microsomes,4689,A,,Rattus norvegicus,10116.0,,,
9025,Intermediate,50597,,,Area under curve was calculated after intravenous administration,6057,A,,Rattus norvegicus,10116.0,,,
9026,Intermediate,50597,,,Area under the curve was calculated after iv administration in rat,6057,A,,Rattus norvegicus,10116.0,,,
9027,Intermediate,50597,,,Area under the curve was calculated in rat after peroral administration,6057,A,,Rattus norvegicus,10116.0,,,
9028,Intermediate,50597,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,6211,A,,Rattus norvegicus,10116.0,,,
9029,Intermediate,50597,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,5710,A,,Rattus norvegicus,10116.0,,,
9030,Intermediate,50597,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,5710,A,,Rattus norvegicus,10116.0,,,
9031,Intermediate,50597,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,17853,A,,Rattus norvegicus,10116.0,,,
9032,Intermediate,50597,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,17853,A,,Rattus norvegicus,10116.0,,,
9033,Intermediate,50597,,,p value of the compound,15765,A,,Rattus norvegicus,10116.0,,,
9034,Intermediate,50597,,,p value of the compound,15765,F,,Rattus norvegicus,10116.0,,,
9035,Intermediate,50597,,,p value of the compound,15765,A,,Rattus norvegicus,10116.0,,,
9036,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9037,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9038,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9039,Autocuration,22224,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),7991,F,,Oryctolagus cuniculus,9986.0,,,
9040,Autocuration,22224,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),429,A,,Oryctolagus cuniculus,9986.0,,,
9041,Autocuration,22224,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),429,A,,Oryctolagus cuniculus,9986.0,,,
9042,Autocuration,22224,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,6253,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9043,Autocuration,22224,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,6253,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9044,Autocuration,22224,,,Clearance rate in rabbits,3615,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9045,Autocuration,22224,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,4059,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9046,Autocuration,22224,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9047,Autocuration,22224,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9048,Autocuration,22224,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9049,Autocuration,22224,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,429,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9050,Autocuration,22224,Plasma,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,4059,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9051,Autocuration,22224,Liver,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,9659,A,,Oryctolagus cuniculus,9986.0,,,Microsomes
9052,Autocuration,22224,Liver,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,9659,A,,Oryctolagus cuniculus,9986.0,,,Microsomes
9053,Autocuration,22224,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,3639,A,,Oryctolagus cuniculus,9986.0,,,
9054,Autocuration,22224,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,3639,A,,Oryctolagus cuniculus,9986.0,,,
9055,Autocuration,22224,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,3639,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9056,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9057,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9058,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9059,Autocuration,22224,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),14294,A,,Oryctolagus cuniculus,9986.0,,,Microsomes
9060,Autocuration,22224,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),14294,A,,Oryctolagus cuniculus,9986.0,,,Microsomes
9061,Autocuration,22224,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,429,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9062,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9063,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9064,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,5124,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9065,Autocuration,22224,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,429,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9066,Autocuration,22224,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),429,A,,Oryctolagus cuniculus,9986.0,,,
9067,Autocuration,22224,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),429,A,,Oryctolagus cuniculus,9986.0,,,
9068,Autocuration,22224,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,4059,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9069,Autocuration,22224,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,4137,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9070,Autocuration,22224,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,11672,A,In vitro,Oryctolagus cuniculus,9986.0,,,
9071,Autocuration,22224,,,Time within which only 10% of the drug was degraded,12886,A,,Oryctolagus cuniculus,9986.0,,,
9072,Autocuration,22224,Liver,,Half life period in rabbit liver homogenate,3853,A,,Oryctolagus cuniculus,9986.0,,,
9073,Autocuration,22224,,,Half life value in rabbits,3615,A,,Oryctolagus cuniculus,9986.0,,,
9074,Autocuration,22224,Blood,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,6253,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9075,Autocuration,22224,Blood,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,6253,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9076,Autocuration,22224,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,6077,A,In vivo,Oryctolagus cuniculus,9986.0,,,
9077,Intermediate,50597,Plasma,,AUC 0-8 hr value in rats at 10 mg/kg,17617,A,,Rattus norvegicus,10116.0,,,
9078,Intermediate,50597,Plasma,,AUC after administration at 2000 mg/kg/day in rats,17594,A,,Rattus norvegicus,10116.0,,,
9079,Intermediate,50597,Plasma,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,6149,A,,Rattus norvegicus,10116.0,,,
9080,Intermediate,50597,Plasma,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,17260,A,,Rattus norvegicus,10116.0,,,
9081,Intermediate,50597,Plasma,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,17260,A,,Rattus norvegicus,10116.0,,,
9082,Intermediate,50597,Plasma,,AUC in rat after oral administration at 10.5 mg/kg dose,6644,A,,Rattus norvegicus,10116.0,,,
9083,Intermediate,50597,Plasma,,AUC in rat after oral administration at 11.2 mg/kg dose,6644,A,,Rattus norvegicus,10116.0,,,
9084,Intermediate,50597,Plasma,,AUC in rat after oral administration at 9.7 mg/kg dose,6644,A,,Rattus norvegicus,10116.0,,,
9085,Intermediate,50597,Brain,,AUC in rat brain after oral administration at 10 mg/kg,6495,A,,Rattus norvegicus,10116.0,,,
9086,Intermediate,50597,Plasma,,AUC in rat p.o.,6504,A,,Rattus norvegicus,10116.0,,,
9087,Intermediate,50597,Plasma,,AUC in rat p.o. at 20 mg/kg concentration,17686,A,,Rattus norvegicus,10116.0,,,
9088,Intermediate,50597,Plasma,,AUC in rat plasma after oral administration at 10 mg/kg,6495,A,,Rattus norvegicus,10116.0,,,
9089,Intermediate,50597,Plasma,,AUC in rats,216,A,,Rattus norvegicus,10116.0,,,
9090,Intermediate,50597,Plasma,,AUC value after IV dose at a dose of 5 mg/kg in rats.,1908,A,,Rattus norvegicus,10116.0,,,
9091,Intermediate,50597,Plasma,,AUC value after oral dose at a dose of 10 mg/kg in rats.,1908,A,,Rattus norvegicus,10116.0,,,
9092,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
9093,Intermediate,50597,Plasma,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,216,A,In vivo,Rattus norvegicus,10116.0,,,
9094,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rat,6049,A,In vivo,Rattus norvegicus,10116.0,,,
9095,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,2463,A,In vivo,Rattus norvegicus,10116.0,,,
9096,Intermediate,50597,Plasma,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,6679,A,In vivo,Rattus norvegicus,10116.0,,,
9097,Intermediate,50597,Plasma,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,6681,A,In vivo,Rattus norvegicus,10116.0,,,
9098,Intermediate,50597,Plasma,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
9099,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
9100,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
9101,Intermediate,50597,Plasma,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,16366,A,In vivo,Rattus norvegicus,10116.0,,,
9102,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,6227,A,In vivo,Rattus norvegicus,10116.0,,,
9103,Expert,50597,Plasma,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Rattus norvegicus,10116.0,,,
9104,Intermediate,50597,Plasma,,Maximum plasma drug concentration was determined,1465,A,In vivo,Rattus norvegicus,10116.0,,,
9105,Intermediate,50597,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,4368,A,In vivo,Rattus norvegicus,10116.0,,,
9106,Intermediate,50597,Plasma,,Mean peak plasma concentration was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
9107,Intermediate,50597,Plasma,,Mean peak plasma concentration was observed after oral administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
9108,Intermediate,50597,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,5355,A,In vivo,Rattus norvegicus,10116.0,,,
9109,Intermediate,50597,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,5355,A,In vivo,Rattus norvegicus,10116.0,,,
9110,Intermediate,50597,Plasma,,Peak oral plasma concentration was determined in rats by oral administration,1567,A,In vivo,Rattus norvegicus,10116.0,,,
9111,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) was determined,4026,A,In vivo,Rattus norvegicus,10116.0,,,
9112,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,6193,A,In vivo,Rattus norvegicus,10116.0,,,
9113,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) in rats,4026,A,In vivo,Rattus norvegicus,10116.0,,,
9114,Intermediate,50597,Plasma,,Peak plasma concentration at 1 mg/kg peroral administration,6485,A,In vivo,Rattus norvegicus,10116.0,,,
9115,Intermediate,50597,Plasma,,Peak plasma concentration in rat,17655,A,In vivo,Rattus norvegicus,10116.0,,,
9116,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",14941,A,In vivo,Rattus norvegicus,10116.0,,,
9117,Intermediate,50597,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,5394,A,In vivo,Rattus norvegicus,10116.0,,,
9118,Intermediate,50597,,,Pharmacokinetic property (Cmax) in rat,4408,A,In vivo,Rattus norvegicus,10116.0,,,
9119,Intermediate,50597,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,5983,A,In vivo,Rattus norvegicus,10116.0,,,
9120,Intermediate,50597,,,Cmax in rat after 3mg/kg oral dose,4878,A,In vivo,Rattus norvegicus,10116.0,,,
9121,Intermediate,50597,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,5862,A,In vivo,Rattus norvegicus,10116.0,Sprague-Dawley,,
9122,Intermediate,50597,,,Cmax in rats after 20 mg/kg oral dose,4517,A,In vivo,Rattus norvegicus,10116.0,,,
9123,Intermediate,50597,Plasma,,Cmax in rat plasma after 30mg/kg oral dose,5932,A,In vivo,Rattus norvegicus,10116.0,,,
9124,Intermediate,50597,Plasma,,Plasma concentration after oral administration of 100 mg/kg to rats,5436,A,In vivo,Rattus norvegicus,10116.0,,,
9125,Intermediate,50597,Brain,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,4910,A,In vivo,Rattus norvegicus,10116.0,,,
9126,Intermediate,50597,,,Tested for the Cmax in rat at 10 mg/kg per orally,4950,A,In vivo,Rattus norvegicus,10116.0,,,
9127,Intermediate,50597,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
9128,Intermediate,50597,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
9129,Intermediate,50597,,,Bioavailability as oral Cmax in rats at 30 mins,3360,A,In vivo,Rattus norvegicus,10116.0,,,
9130,Intermediate,50597,,,Bioavailability as oral Cmax in rats at 6hr,3360,A,In vivo,Rattus norvegicus,10116.0,,,
9131,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,15022,A,In vivo,Rattus norvegicus,10116.0,,,
9132,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,15022,A,In vivo,Rattus norvegicus,10116.0,,,
9133,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,15022,A,In vivo,Rattus norvegicus,10116.0,,,
9134,Intermediate,50597,Plasma,,The maximum plasma levels for the compounds were determined by LC-MS.,5160,A,In vivo,Rattus norvegicus,10116.0,,,
9135,Intermediate,50597,Plasma,,mean peak plasma concentration was observed after intravenous administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
9136,Intermediate,50597,Plasma,,mean peak plasma concentration was observed after oral administration in rat,15662,A,In vivo,Rattus norvegicus,10116.0,,,
9137,Intermediate,50597,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,4709,A,,Rattus norvegicus,10116.0,,,
9138,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,3535,A,,Rattus norvegicus,10116.0,,,
9139,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,3535,A,,Rattus norvegicus,10116.0,,,
9140,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,3535,A,,Rattus norvegicus,10116.0,,,
9141,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,3535,A,,Rattus norvegicus,10116.0,,,
9142,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,3535,A,,Rattus norvegicus,10116.0,,,
9143,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,3535,A,,Rattus norvegicus,10116.0,,,
9144,Intermediate,22224,Plasma,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,5005,A,In vivo,Rattus norvegicus,10116.0,,,
9145,Intermediate,50597,Hypothalamus,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",6326,A,,Rattus norvegicus,10116.0,,,
9146,Intermediate,50597,Hypothalamus,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",6326,A,,Rattus norvegicus,10116.0,,,
9147,Intermediate,50597,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",6326,A,,Rattus norvegicus,10116.0,,,
9148,Intermediate,50597,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",6326,A,,Rattus norvegicus,10116.0,,,
9149,Intermediate,50597,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9150,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9151,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9152,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9153,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9154,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9155,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9156,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9157,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9158,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9159,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9160,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9161,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9162,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9163,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9164,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9165,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9166,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9167,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9168,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9169,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9170,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9171,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9172,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9173,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9174,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9175,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9176,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9177,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9178,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9179,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9180,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9181,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9182,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9183,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9184,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9185,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9186,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9187,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9188,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9189,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9190,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9191,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9192,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9193,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9194,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9195,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9196,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9197,Intermediate,50597,Stomach,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9198,Intermediate,50597,Stomach,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),6175,A,,Rattus norvegicus,10116.0,,,
9199,Intermediate,50597,,,The compound was tested for the plasma binding in rat,10839,A,,Rattus norvegicus,10116.0,,,
9200,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",16459,A,,Rattus norvegicus,10116.0,,,
9201,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",16459,A,,Rattus norvegicus,10116.0,,,
9202,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",16459,A,,Rattus norvegicus,10116.0,,,
9203,Intermediate,50597,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),16459,A,,Rattus norvegicus,10116.0,,,
9204,Intermediate,50597,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),16459,A,,Rattus norvegicus,10116.0,,,
9205,Intermediate,50597,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),16459,A,,Rattus norvegicus,10116.0,,,
9206,Intermediate,50597,,,Plasma level at 2 hr after administration of the compound,3278,A,,Rattus norvegicus,10116.0,,,
9207,Intermediate,50597,,,plasma level at 2 hr after administration of the compound,3278,A,,Rattus norvegicus,10116.0,,,
9208,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 1 min,4684,A,,Rattus norvegicus,10116.0,,,
9209,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 10 min,4684,A,,Rattus norvegicus,10116.0,,,
9210,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 10 mins,4684,A,,Rattus norvegicus,10116.0,,,
9211,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 2 hr,4684,A,,Rattus norvegicus,10116.0,,,
9212,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 3 min,4684,A,,Rattus norvegicus,10116.0,,,
9213,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 3 mins,4684,A,,Rattus norvegicus,10116.0,,,
9214,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 5 min,4684,A,,Rattus norvegicus,10116.0,,,
9215,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 5 mins,4684,A,,Rattus norvegicus,10116.0,,,
9216,Intermediate,50597,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Rattus norvegicus,10116.0,,,
9217,Intermediate,50597,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Rattus norvegicus,10116.0,,,
9218,Intermediate,50597,Plasma,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,723,A,,Rattus norvegicus,10116.0,,,
9219,Intermediate,50597,Plasma,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,723,A,,Rattus norvegicus,10116.0,,,
9220,Intermediate,50597,,,Half life tested in mature male rat at a dose of 30 mg/kg,5160,A,In vivo,Rattus norvegicus,10116.0,,,
9221,Intermediate,50597,,,Half life after intravenous administration of 1 mg/kg in rat,4709,A,In vivo,Rattus norvegicus,10116.0,,,
9222,Intermediate,50597,,,Half life period after administration (30 mg/kg) in rat,5633,A,In vivo,Rattus norvegicus,10116.0,,,
9223,Intermediate,50597,,,Half life period in rat after 5 mg/Kg dose,5302,A,In vivo,Rattus norvegicus,10116.0,,,
9224,Intermediate,50597,,,Half life period in rat after 5 mg/kg dose,5302,A,In vivo,Rattus norvegicus,10116.0,,,
9225,Intermediate,50597,,,Half life period was determined,17791,A,,Rattus norvegicus,10116.0,,,
9226,Intermediate,50597,,,Half life period was evaluated in rat,17791,A,,Rattus norvegicus,10116.0,,,
9227,Intermediate,50597,,,Half life period was evaluated in rat; 0.5-1.0,17791,A,,Rattus norvegicus,10116.0,,,
9228,Intermediate,50597,,,Half life period was evaluated in rat; 5.9-7.5,17791,A,,Rattus norvegicus,10116.0,,,
9229,Intermediate,50597,Plasma,,Half-life in rat plasma,14512,A,,Rattus norvegicus,10116.0,,,
9230,Intermediate,50597,,,Half-life time in rat was determined,6230,A,,Rattus norvegicus,10116.0,,,
9231,Intermediate,50597,,,Terminal half-life after iv administration to rats,3364,A,In vivo,Rattus norvegicus,10116.0,,,
9232,Intermediate,50597,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,6874,A,In vivo,Rattus norvegicus,10116.0,,,
9233,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,857,A,,Rattus norvegicus,10116.0,,,
9234,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),858,A,In vivo,Rattus norvegicus,10116.0,,,
9235,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),858,A,In vivo,Rattus norvegicus,10116.0,,,
9236,Intermediate,50597,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,5355,A,In vivo,Rattus norvegicus,10116.0,,,
9237,Intermediate,50597,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,5355,A,In vivo,Rattus norvegicus,10116.0,,,
9238,Intermediate,50597,,,Half life in rats,6305,A,,Rattus norvegicus,10116.0,,,
9239,Intermediate,50597,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,13501,A,In vivo,Rattus norvegicus,10116.0,,,
9240,Intermediate,50597,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,17594,A,In vivo,Rattus norvegicus,10116.0,,,
9241,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,A,In vivo,Rattus norvegicus,10116.0,,,
9242,Intermediate,50597,Plasma,,Biological half-life was measured in plasma of rats,2932,A,,Rattus norvegicus,10116.0,,,
9243,Intermediate,50597,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,17065,A,In vivo,Rattus norvegicus,10116.0,,,
9244,Intermediate,50597,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,15765,A,In vivo,Rattus norvegicus,10116.0,,,
9245,Intermediate,50597,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,2713,A,In vivo,Rattus norvegicus,10116.0,,,
9246,Intermediate,50597,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
9247,Intermediate,50597,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
9248,Intermediate,50597,Plasma,,Compound was evaluated for plasma half life in rat,740,A,,Rattus norvegicus,10116.0,,,
9249,Intermediate,50597,Plasma,,AUC value at a dose of 5 mg/kg (p.o.) in rats,6597,A,,Rattus norvegicus,10116.0,,,
9250,Intermediate,50597,Plasma,,AUC value after administration of 20 mg/Kg oral dose in rat,2959,A,,Rattus norvegicus,10116.0,,,
9251,Intermediate,50597,Plasma,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,17594,A,,Rattus norvegicus,10116.0,,,
9252,Intermediate,50597,Plasma,,AUC0-96 after administration at 50 mg/kg,17596,A,,Rattus norvegicus,10116.0,,,
9253,Intermediate,50597,Plasma,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,17594,A,,Rattus norvegicus,10116.0,,,
9254,Intermediate,50597,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",3293,A,,Rattus norvegicus,10116.0,,,
9255,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,6757,A,,Rattus norvegicus,10116.0,,,
9256,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,6757,A,,Rattus norvegicus,10116.0,,,
9257,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,6757,A,,Rattus norvegicus,10116.0,,,
9258,Intermediate,50597,Kidney,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,5979,A,,Rattus norvegicus,10116.0,,,
9259,Intermediate,50597,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,5979,A,,Rattus norvegicus,10116.0,,,
9260,Intermediate,50597,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,5979,A,,Rattus norvegicus,10116.0,,,
9261,Intermediate,50597,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,4026,A,,Rattus norvegicus,10116.0,,,
9262,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,5355,A,,Rattus norvegicus,10116.0,,,
9263,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,5355,A,,Rattus norvegicus,10116.0,,,
9264,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,5355,A,,Rattus norvegicus,10116.0,,,
9265,Intermediate,50597,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,5633,A,,Rattus norvegicus,10116.0,,,
9266,Intermediate,50597,,,Area under curve (Pharmacokinetic property) was determined,1716,A,,Rattus norvegicus,10116.0,,,
9267,Intermediate,50597,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,1716,A,,Rattus norvegicus,10116.0,,,
9268,Intermediate,50597,,,Area under curve after intravenous administration (1 mg/kg) in rat,4689,A,,Rattus norvegicus,10116.0,,,
9269,Intermediate,50597,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,4527,A,,Rattus norvegicus,10116.0,,,
9270,Intermediate,50597,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,4527,A,,Rattus norvegicus,10116.0,,,
9271,Intermediate,50597,,,Area under curve in male SD rats was observed after oral administration in rat,15662,A,,Rattus norvegicus,10116.0,,,
9272,Intermediate,50597,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,4413,A,,Rattus norvegicus,10116.0,,,
9273,Expert,50597,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,,Rattus norvegicus,10116.0,,,
9274,Expert,50597,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,3598,A,,Rattus norvegicus,10116.0,,,
9275,Intermediate,50597,,,Area under curve at 5 mg/kg po was determined in rat,5964,A,,Rattus norvegicus,10116.0,,,
9276,Intermediate,50597,,,Area under curve in Rat at a oral dose of 5 mg/kg,4689,A,,Rattus norvegicus,10116.0,,,
9277,Intermediate,50597,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,4186,A,,Rattus norvegicus,10116.0,,,
9278,Intermediate,50597,,,Area under curve was determined,5510,A,,Rattus norvegicus,10116.0,,,
9279,Intermediate,50597,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,17858,A,,Rattus norvegicus,10116.0,,,
9280,Intermediate,50597,,,Area under curve after intravenous administration at 3 mg/kg,17804,A,,Rattus norvegicus,10116.0,,,
9281,Intermediate,50597,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,6106,A,,Rattus norvegicus,10116.0,,,
9282,Intermediate,50597,,,Area under curve at 4 hr in rat,5964,A,,Rattus norvegicus,10116.0,,,
9283,Intermediate,50597,,,Area under curve at a dose of 30 mg/kg,4026,A,,Rattus norvegicus,10116.0,,,
9284,Intermediate,50597,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,4756,A,,Rattus norvegicus,10116.0,,,
9285,Intermediate,50597,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,4756,A,,Rattus norvegicus,10116.0,,,
9286,Intermediate,50597,,,Area under curve for a 2-mpk po dose in SD rats,5862,A,,Rattus norvegicus,10116.0,,,
9287,Intermediate,50597,,,Area under curve in SD rats,5862,A,,Rattus norvegicus,10116.0,,,
9288,Intermediate,50597,,,Area under curve in rat after oral administration at 13 mg/kg dose,6644,A,,Rattus norvegicus,10116.0,,,
9289,Intermediate,50597,,,Area under curve in rat by po administration at 0-24 hr,5871,A,,Rattus norvegicus,10116.0,,,
9290,Intermediate,50597,Plasma,,Area under curve in rat plasma,5919,A,,Rattus norvegicus,10116.0,,,
9291,Intermediate,50597,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,5939,A,,Rattus norvegicus,10116.0,,,
9292,Intermediate,50597,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,5939,A,,Rattus norvegicus,10116.0,,,
9293,Intermediate,50597,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,10,A,,Rattus norvegicus,10116.0,,,
9294,Intermediate,50597,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,11149,A,,Rattus norvegicus,10116.0,,,
9295,Intermediate,50597,,,Area under curve value in rat at a dose of 5 mg/kg,5302,A,,Rattus norvegicus,10116.0,,,
9296,Intermediate,50597,,,Area under curve was determined after oral administration in rats,17796,A,,Rattus norvegicus,10116.0,,,
9297,Intermediate,50597,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,4890,A,,Rattus norvegicus,10116.0,,,
9298,Intermediate,50597,,,Area under curve was determined after peroral administration in rat,6011,A,,Rattus norvegicus,10116.0,,,
9299,Intermediate,50597,,,Area under curve was determined at a dose 30 mpk administered orally.,5375,A,,Rattus norvegicus,10116.0,,,
9300,Intermediate,50597,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,17764,A,,Rattus norvegicus,10116.0,,,
9301,Intermediate,50597,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,4368,A,,Rattus norvegicus,10116.0,,,
9302,Intermediate,50597,,,Area under curve was determined in male rat,5610,A,,Rattus norvegicus,10116.0,,,
9303,Intermediate,50597,,,Area under curve was determined in rat after PO administration,5833,A,,Rattus norvegicus,10116.0,,,
9304,Intermediate,50597,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,4257,A,,Rattus norvegicus,10116.0,,,
9305,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,5937,A,,Rattus norvegicus,10116.0,,,
9306,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,5932,A,,Rattus norvegicus,10116.0,,,
9307,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,5932,A,,Rattus norvegicus,10116.0,,,
9308,Intermediate,50597,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9309,Intermediate,50597,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9310,Intermediate,50597,Plasma,,Peak plasma concentration in rat at a dose of 3 mg/kg,17771,A,,Rattus norvegicus,10116.0,,,
9311,Intermediate,50597,,,Plasma concentration at 2 hr in rats was evaluated.,1628,A,,Rattus norvegicus,10116.0,,,
9312,Intermediate,50597,,,Plasma concentration at 2 hr in rats was evaluated; Not available,1628,A,,Rattus norvegicus,10116.0,,,
9313,Intermediate,50597,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9314,Intermediate,50597,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9315,Intermediate,50597,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9316,Intermediate,50597,Plasma,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9317,Intermediate,50597,Plasma,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9318,Intermediate,50597,Plasma,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9319,Intermediate,50597,Plasma,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9320,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,5510,A,,Rattus norvegicus,10116.0,,,
9321,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,5510,A,,Rattus norvegicus,10116.0,,,
9322,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,5510,A,,Rattus norvegicus,10116.0,,,
9323,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,5510,A,,Rattus norvegicus,10116.0,,,
9324,Intermediate,50597,,,PK study was carried to determine the relative absorption ranking in rat.,16427,A,,Rattus norvegicus,10116.0,,,
9325,Intermediate,50597,Plasma,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,4689,A,In vivo,Rattus norvegicus,10116.0,,,
9326,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9327,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9328,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9329,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9330,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9331,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9332,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9333,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9334,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9335,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9336,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9337,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9338,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9339,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9340,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9341,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9342,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9343,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9344,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9345,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9346,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9347,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9348,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9349,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9350,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9351,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9352,Intermediate,50597,Lung,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9353,Intermediate,50597,Lung,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9354,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9355,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9356,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9357,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9358,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9359,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9360,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9361,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9362,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9363,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9364,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9365,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9366,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9367,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9368,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9369,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9370,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9371,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9372,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9373,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9374,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9375,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9376,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9377,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9378,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9379,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9380,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9381,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9382,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9383,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9384,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9385,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9386,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9387,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9388,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9389,Intermediate,50597,,,Compound was evaluated for terminal half life in rat,3341,A,,Rattus norvegicus,10116.0,,,
9390,Intermediate,50597,Plasma,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,3634,A,In vivo,Rattus norvegicus,10116.0,,,
9391,Intermediate,50597,Plasma,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,3634,A,In vivo,Rattus norvegicus,10116.0,,,
9392,Intermediate,50597,,,Compound was tested for its half life in rat,4839,A,,Rattus norvegicus,10116.0,,,
9393,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,5005,A,In vivo,Macaca mulatta,9544.0,,,
9394,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in Sprague Dawley rats,5005,A,,Rattus norvegicus,10116.0,,,
9395,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,5005,A,,Rattus norvegicus,10116.0,,,
9396,Intermediate,50597,Plasma,,Compound was tested for plasma half-life period in rat,1094,A,,Rattus norvegicus,10116.0,,,
9397,Intermediate,50597,,,Elimination half life after i.v. administration of compound in rats,5031,A,In vivo,Rattus norvegicus,10116.0,,,
9398,Intermediate,50597,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
9399,Intermediate,50597,,,Elimination half-life after IV dosing at 1 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
9400,Intermediate,50597,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
9401,Intermediate,50597,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
9402,Intermediate,50597,Brain,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,5408,A,In vivo,Rattus norvegicus,10116.0,,,
9403,Intermediate,50597,Plasma,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,5408,A,In vivo,Rattus norvegicus,10116.0,,,
9404,Intermediate,50597,Brain,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,5408,A,In vivo,Rattus norvegicus,10116.0,,,
9405,Intermediate,50597,Plasma,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,5408,A,In vivo,Rattus norvegicus,10116.0,,,
9406,Intermediate,50597,,,Evaluated for the half life in rat (in vivo),4687,A,In vivo,Rattus norvegicus,10116.0,,,
9407,Intermediate,50597,,,Hafl life in rat,6640,A,,Rattus norvegicus,10116.0,,,
9408,Intermediate,50597,,,Hafl life rat,6640,A,,Rattus norvegicus,10116.0,,,
9409,Intermediate,50597,,,Hafl life rat,6641,A,,Rattus norvegicus,10116.0,,,
9410,Intermediate,50597,,,Hafl life rat; Not determined,6640,A,,Rattus norvegicus,10116.0,,,
9411,Intermediate,50597,,,Hafl life rat; Not determined,6641,A,,Rattus norvegicus,10116.0,,,
9412,Intermediate,50597,Kidney,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,In vivo,Rattus norvegicus,10116.0,,,
9413,Intermediate,50597,Liver,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,In vivo,Rattus norvegicus,10116.0,,,
9414,Intermediate,50597,Lung,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,In vivo,Rattus norvegicus,10116.0,,,
9415,Intermediate,50597,,,Half life in rat after 1 mg/kg i.v. administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
9416,Intermediate,50597,,,Half life in rat after 2 mg/kg peroral administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
9417,Intermediate,50597,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,In vivo,Rattus norvegicus,10116.0,,,
9418,Intermediate,50597,,,Half life of 10 mg/kg oral dose determined in rats,4722,A,In vivo,Rattus norvegicus,10116.0,,,
9419,Intermediate,50597,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9420,Intermediate,50597,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9421,Intermediate,50597,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9422,Intermediate,50597,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9423,Intermediate,50597,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9424,Intermediate,50597,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9425,Intermediate,50597,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9426,Intermediate,50597,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
9427,Intermediate,50597,,,Half life of compound at 5 mg/kg after po administration was determined in rat,4762,A,In vivo,Rattus norvegicus,10116.0,,,
9428,Intermediate,50597,,,Half life of compound determined after intravenous administration to rat,5327,A,In vivo,Rattus norvegicus,10116.0,,,
9429,Intermediate,50597,,,Half life of compound was determined in rat,4847,A,,Rattus norvegicus,10116.0,,,
9430,Intermediate,50597,Plasma,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,A,In vivo,Rattus norvegicus,10116.0,,,
9431,Intermediate,50597,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
9432,Intermediate,50597,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
9433,Intermediate,22224,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,4256,A,In vivo,Macaca fascicularis,9541.0,,,
9434,Intermediate,22224,,,Half life determined in rat by intravenous administration,4256,A,In vivo,Rattus norvegicus,10116.0,,,
9435,Intermediate,50597,,,Half life determined in rats after iv administration,4722,A,In vivo,Rattus norvegicus,10116.0,,,
9436,Intermediate,50597,Plasma,,Half life in rat plasma after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
9437,Intermediate,50597,Plasma,,Half life in rat plasma after administration of 2 mg/kg iv,6535,A,In vivo,Rattus norvegicus,10116.0,,,
9438,Intermediate,50597,Plasma,,Half life in rat plasma was determined,1435,A,,Rattus norvegicus,10116.0,,,
9439,Intermediate,50597,Plasma,,Half life in rat plasma was determined; NA means not applicable,1435,A,,Rattus norvegicus,10116.0,,,
9440,Intermediate,50597,,,Half life in rat was tested,5206,A,,Rattus norvegicus,10116.0,,,
9441,Intermediate,50597,Plasma,,Half life measured in rat plasma,6080,A,,Rattus norvegicus,10116.0,,,
9442,Intermediate,50597,,,Half life recorded in rats,4449,A,,Rattus norvegicus,10116.0,,,
9443,Intermediate,50597,,,Half life was calculated,6057,A,,Rattus norvegicus,10116.0,,,
9444,Intermediate,50597,,,Half life was calculated in rat,6057,A,,Rattus norvegicus,10116.0,,,
9445,Intermediate,50597,,,Half life was determined,3747,A,,Rattus norvegicus,10116.0,,,
9446,Intermediate,50597,,,Half life after 10 mg/kg oral administration in rat,17858,A,In vivo,Rattus norvegicus,10116.0,,,
9447,Intermediate,50597,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9448,Intermediate,50597,,,Half life after administering orally a dose of 30 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9449,Intermediate,50597,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,5031,A,,Rattus norvegicus,10116.0,,,
9450,Intermediate,50597,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,4722,A,,Rattus norvegicus,10116.0,,,
9451,Intermediate,50597,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,6078,A,,Rattus norvegicus,10116.0,,,
9452,Intermediate,50597,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,6078,A,,Rattus norvegicus,10116.0,,,
9453,Intermediate,50597,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,6078,A,,Rattus norvegicus,10116.0,,,
9454,Intermediate,50597,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,6078,A,,Rattus norvegicus,10116.0,,,
9455,Intermediate,50597,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,17065,A,,Rattus norvegicus,10116.0,,,
9456,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1353,A,,Rattus norvegicus,10116.0,,,
9457,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1353,A,,Rattus norvegicus,10116.0,,,
9458,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1353,A,,Rattus norvegicus,10116.0,,,
9459,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1353,A,,Rattus norvegicus,10116.0,,,
9460,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1353,A,,Rattus norvegicus,10116.0,,,
9461,Intermediate,50597,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,16423,A,,Rattus norvegicus,10116.0,,,
9462,Intermediate,50597,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,16423,A,,Rattus norvegicus,10116.0,,,
9463,Intermediate,50597,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,6062,A,,Rattus norvegicus,10116.0,,,
9464,Intermediate,50597,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,6056,A,,Rattus norvegicus,10116.0,,,
9465,Intermediate,50597,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,5182,A,,Rattus norvegicus,10116.0,,,
9466,Intermediate,50597,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,6410,A,,Rattus norvegicus,10116.0,,,
9467,Intermediate,50597,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,6410,A,,Rattus norvegicus,10116.0,,,
9468,Intermediate,50597,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9469,Intermediate,50597,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9470,Intermediate,50597,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9471,Intermediate,50597,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9472,Intermediate,50597,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9473,Intermediate,50597,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,,Rattus norvegicus,10116.0,,,
9474,Intermediate,50597,Plasma,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,2463,A,,Rattus norvegicus,10116.0,,,
9475,Intermediate,50597,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,4709,A,,Rattus norvegicus,10116.0,,,
9476,Intermediate,50597,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,4075,A,,Rattus norvegicus,10116.0,,,
9477,Intermediate,50597,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,5394,A,,Rattus norvegicus,10116.0,,,
9478,Intermediate,50597,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,2661,A,,Rattus norvegicus,10116.0,,,
9479,Intermediate,50597,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,2661,A,,Rattus norvegicus,10116.0,,,
9480,Intermediate,50597,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,2661,A,,Rattus norvegicus,10116.0,,,
9481,Intermediate,50597,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,2661,A,,Rattus norvegicus,10116.0,,,
9482,Intermediate,50597,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),17791,A,,Rattus norvegicus,10116.0,,,
9483,Intermediate,50597,,,Compound was tested for area under curve in rat,2591,A,,Rattus norvegicus,10116.0,,,
9484,Intermediate,50597,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,6567,A,,Rattus norvegicus,10116.0,,,
9485,Intermediate,50597,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,6211,A,,Rattus norvegicus,10116.0,,,
9486,Intermediate,50597,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),5529,A,,Rattus norvegicus,10116.0,,,
9487,Intermediate,50597,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,5408,A,,Rattus norvegicus,10116.0,,,
9488,Intermediate,50597,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,5408,A,,Rattus norvegicus,10116.0,,,
9489,Intermediate,50597,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,5408,A,,Rattus norvegicus,10116.0,,,
9490,Intermediate,50597,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,5408,A,,Rattus norvegicus,10116.0,,,
9491,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),429,A,,Rattus norvegicus,10116.0,,,
9492,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),429,A,,Rattus norvegicus,10116.0,,,
9493,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),429,A,,Rattus norvegicus,10116.0,,,
9494,Intermediate,50597,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,4796,A,,Rattus norvegicus,10116.0,,,
9495,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,,Rattus norvegicus,10116.0,,,
9496,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,,Rattus norvegicus,10116.0,,,
9497,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,5974,A,,Rattus norvegicus,10116.0,,,
9498,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9499,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9500,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9501,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9502,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9503,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9504,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9505,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9506,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9507,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9508,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9509,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9510,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9511,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9512,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9513,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9514,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9515,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9516,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9517,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9518,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9519,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9520,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9521,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9522,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9523,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9524,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9525,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9526,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9527,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9528,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9529,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9530,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9531,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9532,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9533,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9534,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9535,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9536,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9537,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9538,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9539,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9540,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9541,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9542,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9543,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9544,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9545,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9546,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9547,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9548,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9549,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9550,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9551,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9552,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9553,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9554,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9555,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9556,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9557,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9558,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9559,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9560,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9561,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9562,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9563,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9564,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9565,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9566,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9567,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9568,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9569,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9570,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9571,Intermediate,50597,,,Half life after administering orally a dose of 3 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9572,Intermediate,50597,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9573,Intermediate,50597,,,Half life after administering intravenously a dose of 1 mg/kg,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9574,Intermediate,50597,,,Half life after oral dosing in rats,526,A,In vivo,Rattus norvegicus,10116.0,,,
9575,Intermediate,50597,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
9576,Intermediate,50597,,,Half life by intravenous administration of 3.4 mg/kg in rat,4368,A,In vivo,Rattus norvegicus,10116.0,,,
9577,Intermediate,50597,,,Half life in rat,3371,A,,Rattus norvegicus,10116.0,,,
9578,Intermediate,50597,,,Half life in rat,6448,A,,Rattus norvegicus,10116.0,,,
9579,Intermediate,50597,,,Half life in rat,6453,A,,Rattus norvegicus,10116.0,,,
9580,Intermediate,50597,,,Half life in rat after intravenous administration of the compound,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9581,Intermediate,50597,Plasma,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9582,Intermediate,50597,,,Half life in rat after po administration of the compound,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9583,Intermediate,50597,,,Half life in rat after po administration of the compound; ND means Not determined,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9584,Intermediate,50597,Plasma,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9585,Intermediate,50597,Plasma,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,4353,A,In vivo,Rattus norvegicus,10116.0,,,
9586,Intermediate,50597,,,Half life in rat i.v.,5789,A,In vivo,Rattus norvegicus,10116.0,,,
9587,Intermediate,50597,,,Half life in rat i.v. at 2 mg/kg concentration,17686,A,In vivo,Rattus norvegicus,10116.0,,,
9588,Intermediate,50597,,,Half life in rats,6495,A,,Rattus norvegicus,10116.0,,,
9589,Intermediate,50597,,,Half life in rats after intravenous administration,484,A,In vivo,Rattus norvegicus,10116.0,,,
9590,Intermediate,50597,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,6467,A,In vivo,Rattus norvegicus,10116.0,,,
9591,Expert,50597,,,Half life in rat,6642,A,,Rattus norvegicus,10116.0,,,
9592,Intermediate,50597,,,Half life was evaluated after intravenous administration to rats,16367,A,In vivo,Rattus norvegicus,10116.0,,,
9593,Intermediate,50597,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1369,A,,Rattus norvegicus,10116.0,,,
9594,Intermediate,50597,,,Half life was evaluated in rat,5472,A,,Rattus norvegicus,10116.0,,,
9595,Intermediate,50597,,,Half life was evaluated in rat,6049,A,,Rattus norvegicus,10116.0,,,
9596,Intermediate,50597,,,Half life was evaluated in rat; Not tested,5472,A,,Rattus norvegicus,10116.0,,,
9597,Intermediate,50597,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,16366,A,In vivo,Rattus norvegicus,10116.0,,,
9598,Intermediate,50597,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,11149,A,In vivo,Rattus norvegicus,10116.0,,,
9599,Intermediate,50597,Blood,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,11149,A,In vivo,Rattus norvegicus,10116.0,,,
9600,Intermediate,22224,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,2891,A,In vivo,Primates,9443.0,,,
9601,Intermediate,22224,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,2891,A,In vivo,Primates,9443.0,,,
9602,Intermediate,22224,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,2891,A,In vivo,Rattus norvegicus,10116.0,,,
9603,Intermediate,22224,,,Half life was measured in rat at dose of 30 mg/kg by po administration,2891,A,In vivo,Rattus norvegicus,10116.0,,,
9604,Intermediate,50597,,,Half life (t1/2) was determined,4026,A,,Rattus norvegicus,10116.0,,,
9605,Intermediate,50597,,,Half life period at a dose of 10 uM/kg in rat was determined,4527,A,,Rattus norvegicus,10116.0,,,
9606,Intermediate,50597,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
9607,Intermediate,50597,,,Half life period was determined,5503,A,,Rattus norvegicus,10116.0,,,
9608,Intermediate,50597,,,Half life period after intravenous administration at 20 mpk in rats,4426,A,In vivo,Rattus norvegicus,10116.0,,,
9609,Intermediate,50597,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,4426,A,In vivo,Rattus norvegicus,10116.0,,,
9610,Intermediate,50597,,,Half life period after intravenous administration in rat,6109,A,In vivo,Rattus norvegicus,10116.0,,,
9611,Intermediate,50597,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
9612,Intermediate,50597,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
9613,Intermediate,50597,Plasma,,Half life period in 80% rat plasma at 37 degree Centigrade,4755,A,,Rattus norvegicus,10116.0,,,
9614,Intermediate,50597,,,Half life period in SD rats,5862,A,,Rattus norvegicus,10116.0,,,
9615,Intermediate,50597,Plasma,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1515,A,,Rattus norvegicus,10116.0,,,
9616,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1515,A,,Rattus norvegicus,10116.0,,,
9617,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1515,A,,Rattus norvegicus,10116.0,,,
9618,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1515,A,,Rattus norvegicus,10116.0,,,
9619,Intermediate,50597,,,Half life period in rat,5960,A,,Rattus norvegicus,10116.0,,,
9620,Intermediate,50597,,,Half life period in rat,6103,A,,Rattus norvegicus,10116.0,,,
9621,Intermediate,50597,,,Half life period in rat,6317,A,,Rattus norvegicus,10116.0,,,
9622,Intermediate,50597,,,Half life period in rat after oral administration at 10.5 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
9623,Intermediate,50597,,,Half life period in rat after oral administration at 11.2 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
9624,Intermediate,50597,,,Half life period in rat after oral administration at 13 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
9625,Intermediate,50597,,,Half life period in rat after oral administration at 9.7 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
9626,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,,Rattus norvegicus,10116.0,,,
9627,Intermediate,50597,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,6295,A,,Rattus norvegicus,10116.0,,,
9628,Intermediate,50597,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,6296,A,,Rattus norvegicus,10116.0,,,
9629,Intermediate,50597,,,PK study was carried to determine AUC (area under curve) value in rat,16427,A,,Rattus norvegicus,10116.0,,,
9630,Intermediate,50597,,,Pharmacokinetic parameter AUC after intravenous administration to rats,16367,A,,Rattus norvegicus,10116.0,,,
9631,Intermediate,50597,,,Pharmacokinetic parameter AUC after oral administration to rats,16367,A,,Rattus norvegicus,10116.0,,,
9632,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,16365,A,,Rattus norvegicus,10116.0,,,
9633,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,16365,A,,Rattus norvegicus,10116.0,,,
9634,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,16365,A,,Rattus norvegicus,10116.0,,,
9635,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,16365,A,,Rattus norvegicus,10116.0,,,
9636,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,16365,A,,Rattus norvegicus,10116.0,,,
9637,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,16365,A,,Rattus norvegicus,10116.0,,,
9638,Intermediate,50597,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,5394,A,,Rattus norvegicus,10116.0,,,
9639,Intermediate,50597,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,5394,A,,Rattus norvegicus,10116.0,,,
9640,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,2792,A,,Rattus norvegicus,10116.0,,,
9641,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,2792,A,,Rattus norvegicus,10116.0,,,
9642,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,2792,A,,Rattus norvegicus,10116.0,,,
9643,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,2792,A,,Rattus norvegicus,10116.0,,,
9644,Intermediate,50597,,,Pharmacokinetic parameter area under curve was reported,5334,A,,Rattus norvegicus,10116.0,,,
9645,Intermediate,50597,,,Pharmacokinetic property (AUC) in rat,4408,A,,Rattus norvegicus,10116.0,,,
9646,Intermediate,50597,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,5983,A,,Rattus norvegicus,10116.0,,,
9647,Intermediate,50597,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,4397,A,,Rattus norvegicus,10116.0,,,
9648,Intermediate,50597,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,4397,A,,Rattus norvegicus,10116.0,,,
9649,Intermediate,50597,,,Pharmacokinetic property was determined,5491,A,,Rattus norvegicus,10116.0,,,
9650,Intermediate,50597,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,5491,A,,Rattus norvegicus,10116.0,,,
9651,Intermediate,50597,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,5491,A,,Rattus norvegicus,10116.0,,,
9652,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,4199,A,,Rattus norvegicus,10116.0,,,
9653,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,4199,A,,Rattus norvegicus,10116.0,,,
9654,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,4199,A,,Rattus norvegicus,10116.0,,,
9655,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",5173,A,,Rattus norvegicus,10116.0,,,
9656,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",5173,A,,Rattus norvegicus,10116.0,,,
9657,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",5173,A,,Rattus norvegicus,10116.0,,,
9658,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",5173,A,,Rattus norvegicus,10116.0,,,
9659,Intermediate,50597,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,16366,A,,Rattus norvegicus,10116.0,,,
9660,Intermediate,50597,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,16366,A,,Rattus norvegicus,10116.0,,,
9661,Intermediate,50597,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,5327,A,,Rattus norvegicus,10116.0,,,
9662,Intermediate,50597,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,6681,A,,Rattus norvegicus,10116.0,,,
9663,Intermediate,50597,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),12873,A,,Rattus norvegicus,10116.0,,,
9664,Intermediate,50597,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),12873,A,,Rattus norvegicus,10116.0,,,
9665,Intermediate,50597,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",6685,A,,Rattus norvegicus,10116.0,,,
9666,Intermediate,50597,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",6685,A,,Rattus norvegicus,10116.0,,,
9667,Intermediate,50597,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",6685,A,,Rattus norvegicus,10116.0,,,
9668,Intermediate,50597,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",6619,A,,Rattus norvegicus,10116.0,,,
9669,Intermediate,50597,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",6619,A,,Rattus norvegicus,10116.0,,,
9670,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,10363,A,,Rattus norvegicus,10116.0,,,
9671,Intermediate,50597,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,4796,A,,Rattus norvegicus,10116.0,,,
9672,Intermediate,50597,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9673,Intermediate,50597,Plasma,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
9674,Intermediate,50597,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,4839,A,,Rattus norvegicus,10116.0,,,
9675,Intermediate,50597,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9676,Intermediate,50597,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9677,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9678,Intermediate,50597,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9679,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9680,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",11450,A,,Rattus norvegicus,10116.0,,,
9681,Intermediate,50597,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,8151,A,,Rattus norvegicus,10116.0,,,
9682,Intermediate,50597,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,8151,A,,Rattus norvegicus,10116.0,,,
9683,Intermediate,50597,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,8151,A,,Rattus norvegicus,10116.0,,,
9684,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9685,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9686,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9687,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9688,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9689,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9690,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9691,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9692,Intermediate,50597,Brain,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,8677,A,In vivo,Rattus norvegicus,10116.0,,,
9693,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9694,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9695,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9696,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9697,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9698,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9699,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9700,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9701,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9702,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9703,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9704,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9705,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9706,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9707,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9708,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9709,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9710,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9711,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9712,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9713,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9714,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9715,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9716,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9717,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9718,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9719,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9720,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9721,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9722,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9723,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9724,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,16434,A,,Rattus norvegicus,10116.0,,,
9725,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9726,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9727,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9728,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9729,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9730,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9731,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,16435,A,,Rattus norvegicus,10116.0,,,
9732,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,16435,A,,Rattus norvegicus,10116.0,,,
9733,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,16435,A,,Rattus norvegicus,10116.0,,,
9734,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,16435,A,,Rattus norvegicus,10116.0,,,
9735,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9736,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9737,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9738,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9739,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9740,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9741,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,A,,Rattus norvegicus,10116.0,,,
9742,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9743,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9744,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,16434,A,,Rattus norvegicus,10116.0,,,
9745,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,16434,A,,Rattus norvegicus,10116.0,,,
9746,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,16434,A,,Rattus norvegicus,10116.0,,,
9747,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,16434,A,,Rattus norvegicus,10116.0,,,
9748,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,16434,A,,Rattus norvegicus,10116.0,,,
9749,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,16434,A,,Rattus norvegicus,10116.0,,,
9750,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,16435,F,,Rattus norvegicus,10116.0,,,
9751,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9752,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9753,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,16435,F,,Rattus norvegicus,10116.0,,,
9754,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,16435,A,,Rattus norvegicus,10116.0,,,
9755,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,16435,A,,Rattus norvegicus,10116.0,,,
9756,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9757,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9758,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9759,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9760,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9761,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9762,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9763,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9764,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9765,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9766,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9767,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9768,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9769,Intermediate,50597,,,Half life period in rat by iv administration at a dose of 3 mg/kg,5874,A,In vivo,Rattus norvegicus,10116.0,,,
9770,Intermediate,50597,Plasma,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1515,A,,Rattus norvegicus,10116.0,,,
9771,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1515,A,,Rattus norvegicus,10116.0,,,
9772,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1515,A,,Rattus norvegicus,10116.0,,,
9773,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1515,A,,Rattus norvegicus,10116.0,,,
9774,Intermediate,50597,Plasma,,Half life period was evaluated in rat plasma,5491,A,,Rattus norvegicus,10116.0,,,
9775,Intermediate,50597,Plasma,,Half life period was evaluated in rat plasma; Not tested,5491,A,,Rattus norvegicus,10116.0,,,
9776,Intermediate,50597,,,Half life period was evaluated in rats,1918,A,,Rattus norvegicus,10116.0,,,
9777,Intermediate,50597,,,"Half life period was evaluated in rats, iv",1918,A,In vivo,Rattus norvegicus,10116.0,,,
9778,Intermediate,50597,,,Half life period after intravenous administration at 5 mg/kg in rat,6113,A,In vivo,Rattus norvegicus,10116.0,,,
9779,Intermediate,50597,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,5546,A,In vivo,Rattus norvegicus,10116.0,,,
9780,Intermediate,50597,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,5553,A,In vivo,Rattus norvegicus,10116.0,,,
9781,Intermediate,50597,Plasma,,Half life stability of compound was evaluated in rat plasma,4188,A,,Rattus norvegicus,10116.0,,,
9782,Intermediate,50597,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,6215,A,In vivo,Rattus norvegicus,10116.0,,,
9783,Intermediate,50597,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,6141,A,In vivo,Rattus norvegicus,10116.0,,,
9784,Intermediate,50597,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,5182,A,In vivo,Rattus norvegicus,10116.0,,,
9785,Intermediate,50597,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,5182,A,In vivo,Rattus norvegicus,10116.0,,,
9786,Intermediate,50597,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,5710,A,In vivo,Rattus norvegicus,10116.0,,,
9787,Intermediate,50597,,,Half in rat i.v.,5789,A,In vivo,Rattus norvegicus,10116.0,,,
9788,Intermediate,50597,,,Half period in rat after intravenous administration,6011,A,In vivo,Rattus norvegicus,10116.0,,,
9789,Intermediate,50597,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,17594,A,In vivo,Rattus norvegicus,10116.0,,,
9790,Intermediate,50597,Liver,,Half-life measured in in vitro Cathepsin B assay in rat liver,12357,A,In vitro,Rattus norvegicus,10116.0,,,
9791,Intermediate,50597,,,Half-life of compound was determined in rats,5210,A,,Rattus norvegicus,10116.0,,,
9792,Intermediate,50597,,,Half-life at 10 mg/kg in rat upon intravenous administration,17596,A,In vivo,Rattus norvegicus,10116.0,,,
9793,Intermediate,50597,,,Half-life determined in rat,6672,A,,Rattus norvegicus,10116.0,,,
9794,Intermediate,50597,,,Half-life determined in rat,6673,A,,Rattus norvegicus,10116.0,,,
9795,Intermediate,50597,Brain,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,4910,A,In vivo,Rattus norvegicus,10116.0,,,
9796,Intermediate,50597,Plasma,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",3741,A,,Rattus norvegicus,10116.0,,,
9797,Intermediate,50597,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,17671,A,In vivo,Rattus norvegicus,10116.0,,,
9798,Intermediate,50597,Plasma,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,4910,A,In vivo,Rattus norvegicus,10116.0,,,
9799,Intermediate,50597,Plasma,,Half-life in rat plasma,17537,A,,Rattus norvegicus,10116.0,,,
9800,Intermediate,50597,Plasma,,Half-life in rat plasma was determined,4965,A,,Rattus norvegicus,10116.0,,,
9801,Intermediate,50597,Plasma,,Half-life in rat plasma; Not tested,17537,A,,Rattus norvegicus,10116.0,,,
9802,Intermediate,50597,Serum,,Half-life in rat serum,6124,A,,Rattus norvegicus,10116.0,,,
9803,Intermediate,50597,Serum,,Half-life in rat serum; na is not available,6124,A,,Rattus norvegicus,10116.0,,,
9804,Intermediate,50597,,,Half-life was calculated in rat,6078,A,,Rattus norvegicus,10116.0,,,
9805,Intermediate,50597,Plasma,,Half-life was calculated in rat plasma,17668,A,,Rattus norvegicus,10116.0,,,
9806,Intermediate,50597,,,Half-life was determined,3185,A,,Rattus norvegicus,10116.0,,,
9807,Intermediate,50597,,,Half-life was determined,4883,A,,Rattus norvegicus,10116.0,,,
9808,Intermediate,50597,,,Half-life after administration of 20 mg/Kg oral dose in rat,2959,A,In vivo,Rattus norvegicus,10116.0,,,
9809,Intermediate,50597,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,4029,A,In vivo,Rattus norvegicus,10116.0,,,
9810,Intermediate,50597,,,Half-life after intravenous administration in female rat,4029,A,In vivo,Rattus norvegicus,10116.0,,,
9811,Intermediate,50597,,,Half-life after intravenous administration in male rat,4029,A,In vivo,Rattus norvegicus,10116.0,,,
9812,Intermediate,50597,,,Half-life after intravenous dose in rat,6180,A,In vivo,Rattus norvegicus,10116.0,,,
9813,Intermediate,50597,Liver,,Half-life in a rat liver homogenate preparation,1557,A,,Rattus norvegicus,10116.0,,,
9814,Intermediate,50597,Plasma,,Half-life in plasma of rat,12500,A,,Rattus norvegicus,10116.0,,,
9815,Intermediate,50597,Plasma,,Half-life in plasma of rat at dose of 3-10 mgkg,12500,A,,Rattus norvegicus,10116.0,,,
9816,Intermediate,50597,,,Half-life in rat,5064,A,,Rattus norvegicus,10116.0,,,
9817,Intermediate,50597,,,Half-life in rat,5145,A,,Rattus norvegicus,10116.0,,,
9818,Intermediate,50597,,,Half-life in rat,5147,A,,Rattus norvegicus,10116.0,,,
9819,Intermediate,50597,,,Half-life in rat,5833,A,,Rattus norvegicus,10116.0,,,
9820,Intermediate,50597,,,Half-life in rat,6596,A,,Rattus norvegicus,10116.0,,,
9821,Intermediate,50597,,,Half-life in rat,17655,A,,Rattus norvegicus,10116.0,,,
9822,Intermediate,50597,,,Half-life in rat after oral administration at 10 mg/kg,6495,A,In vivo,Rattus norvegicus,10116.0,,,
9823,Intermediate,50597,,,Half-life in rat after po administration at a dose of 10 mg/kg,17538,A,In vivo,Rattus norvegicus,10116.0,,,
9824,Intermediate,50597,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,17538,A,In vivo,Rattus norvegicus,10116.0,,,
9825,Intermediate,50597,,,Half-life in rat at 3 mg/kg dose administered intravenously,10,A,In vivo,Rattus norvegicus,10116.0,,,
9826,Intermediate,50597,Brain,,Half-life in rat brain homogenate,17669,A,,Rattus norvegicus,10116.0,,,
9827,Intermediate,50597,Plasma,,Half-life in rat plasma,17065,A,,Rattus norvegicus,10116.0,,,
9828,Intermediate,50597,,,Half-life in rats,4333,A,,Rattus norvegicus,10116.0,,,
9829,Intermediate,50597,,,Half-life in Dawley rats,6827,A,,Rattus norvegicus,10116.0,,,
9830,Intermediate,50597,Plasma,,Half-life in vitro in rat plasma,889,A,In vitro,Rattus norvegicus,10116.0,,,
9831,Intermediate,50597,Plasma,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,889,A,In vitro,Rattus norvegicus,10116.0,,,
9832,Intermediate,50597,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",3747,A,,Rattus norvegicus,10116.0,,,
9833,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 100 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
9834,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 300 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
9835,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 30 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
9836,Intermediate,50597,,,Bioavailability as oral AUC in rats,3360,A,In vivo,Rattus norvegicus,10116.0,,,
9837,Intermediate,50597,Plasma,,The plasma concentration versus time curve (AUC) was determined,5334,A,,Rattus norvegicus,10116.0,,,
9838,Intermediate,50597,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9839,Intermediate,50597,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9840,Intermediate,50597,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9841,Intermediate,50597,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,6570,A,,Rattus norvegicus,10116.0,,,
9842,Intermediate,50597,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,6570,A,,Rattus norvegicus,10116.0,,,
9843,Intermediate,50597,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,17411,A,,Rattus norvegicus,10116.0,,,
9844,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",14941,A,,Rattus norvegicus,10116.0,,,
9845,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",14941,A,,Rattus norvegicus,10116.0,,,
9846,Intermediate,50597,Plasma,,AUC in rat after po administration at a dose of 10 mg/kg,17538,A,,Rattus norvegicus,10116.0,,,
9847,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,17752,A,,Rattus norvegicus,10116.0,,,
9848,Intermediate,50597,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,17509,A,,Rattus norvegicus,10116.0,,,
9849,Intermediate,50597,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,17509,A,,Rattus norvegicus,10116.0,,,
9850,Intermediate,50597,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,17509,A,,Rattus norvegicus,10116.0,,,
9851,Intermediate,50597,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,17509,A,,Rattus norvegicus,10116.0,,,
9852,Intermediate,50597,,,Area under curve value 6 hr after po administration in rat,17509,A,,Rattus norvegicus,10116.0,,,
9853,Intermediate,50597,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,,Rattus norvegicus,10116.0,,,
9854,Intermediate,50597,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",17717,A,,Rattus norvegicus,10116.0,,,
9855,Intermediate,50597,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,,Rattus norvegicus,10116.0,,,
9856,Intermediate,50597,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,17717,A,,Rattus norvegicus,10116.0,,,
9857,Intermediate,50597,Plasma,,AUC normalized for dose (AUCN) in rat,6642,A,,Rattus norvegicus,10116.0,,,
9858,Intermediate,50597,,,Area under curve in rat after p.o. administration,6640,A,,Rattus norvegicus,10116.0,,,
9859,Intermediate,50597,,,Area under curve in rat after p.o. administration,6641,A,,Rattus norvegicus,10116.0,,,
9860,Intermediate,50597,,,Area under curve in rat after p.o. administration; Not determined,6641,A,,Rattus norvegicus,10116.0,,,
9861,Intermediate,50597,,,Area under curve in rat after peroral administration,6641,A,,Rattus norvegicus,10116.0,,,
9862,Intermediate,50597,,,Area under curve (carotid artery) value of the compound,3603,A,,Rattus norvegicus,10116.0,,,
9863,Intermediate,50597,,,Bioavailability expressed as the area under curve of rat carotid artery,3550,A,,Rattus norvegicus,10116.0,,,
9864,Intermediate,50597,,,Area under curve in male SD rats was observed after intravenous administration in rat,15662,A,,Rattus norvegicus,10116.0,,,
9865,Intermediate,50597,,,Area under curve of the compound was determined,17720,A,,Rattus norvegicus,10116.0,,,
9866,Intermediate,50597,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,5407,A,,Rattus norvegicus,10116.0,,,
9867,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,17752,A,,Rattus norvegicus,10116.0,,,
9868,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,17752,A,,Rattus norvegicus,10116.0,,,
9869,Intermediate,50597,,,Area under curve (portal vein) value of the compound,3603,A,,Rattus norvegicus,10116.0,,,
9870,Intermediate,50597,,,Bioavailability expressed as the area under curve of rat portal vein,3550,A,,Rattus norvegicus,10116.0,,,
9871,Intermediate,50597,Plasma,,Area Under plasma concentration time curve in rat upon peroral administration,17655,A,,Rattus norvegicus,10116.0,,,
9872,Intermediate,50597,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,17582,A,,Rattus norvegicus,10116.0,,,
9873,Intermediate,50597,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,17582,A,,Rattus norvegicus,10116.0,,,
9874,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats,17791,A,,Rattus norvegicus,10116.0,,,
9875,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats after iv administration,17791,A,,Rattus norvegicus,10116.0,,,
9876,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 30-80,17791,A,,Rattus norvegicus,10116.0,,,
9877,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 50-60,17791,A,,Rattus norvegicus,10116.0,,,
9878,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; no data,17791,A,,Rattus norvegicus,10116.0,,,
9879,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; peptide,17791,A,,Rattus norvegicus,10116.0,,,
9880,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",7768,A,,Rattus norvegicus,10116.0,,,
9881,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",7768,A,,Rattus norvegicus,10116.0,,,
9882,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",7768,A,,Rattus norvegicus,10116.0,,,
9883,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",7768,A,,Rattus norvegicus,10116.0,,,
9884,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9885,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9886,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9887,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9888,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9889,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9890,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9891,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9892,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",8677,A,In vivo,Rattus norvegicus,10116.0,,,
9893,Intermediate,50597,Urine,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,6899,A,,Rattus norvegicus,10116.0,,,
9894,Intermediate,50597,Urine,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,6899,A,,Rattus norvegicus,10116.0,,,
9895,Intermediate,50597,Liver,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,6899,A,,Rattus norvegicus,10116.0,,,
9896,Intermediate,50597,Urine,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,6899,A,,Rattus norvegicus,10116.0,,,
9897,Intermediate,50597,Urine,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,6899,A,,Rattus norvegicus,10116.0,,,
9898,Intermediate,50597,Muscle tissue,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",8677,A,,Rattus norvegicus,10116.0,,,
9899,Intermediate,50597,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,6899,A,,Rattus norvegicus,10116.0,,,
9900,Intermediate,50597,Urine,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,6899,A,,Rattus norvegicus,10116.0,,,
9901,Intermediate,50597,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,2189,A,,Rattus norvegicus,10116.0,,,
9902,Intermediate,50597,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,2189,A,,Rattus norvegicus,10116.0,,,
9903,Intermediate,50597,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,2189,A,,Rattus norvegicus,10116.0,,,
9904,Intermediate,50597,Blood,,Biodistribution of compound in rat blood after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9905,Intermediate,50597,Blood,,Biodistribution of compound in rat blood after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9906,Intermediate,50597,Brain,,Biodistribution of compound in rat brain after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9907,Intermediate,50597,Heart,,Biodistribution of compound in rat heart after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9908,Intermediate,50597,Heart,,Biodistribution of compound in rat heart after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9909,Intermediate,50597,Kidney,,Biodistribution of compound in rat kidney after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9910,Intermediate,50597,Kidney,,Biodistribution of compound in rat kidney after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9911,Intermediate,50597,Liver,,Biodistribution of compound in rat liver after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9912,Intermediate,50597,Liver,,Biodistribution of compound in rat liver after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9913,Intermediate,50597,Lung,,Biodistribution of compound in rat lung after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9914,Intermediate,50597,Lung,,Biodistribution of compound in rat lung after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9915,Intermediate,50597,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9916,Intermediate,50597,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration.,10839,A,In vivo,Rattus norvegicus,10116.0,,,
9917,Intermediate,50597,Heart,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9918,Intermediate,50597,Heart,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9919,Intermediate,50597,Liver,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9920,Intermediate,50597,Liver,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9921,Intermediate,50597,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9922,Intermediate,50597,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9923,Intermediate,50597,Spleen,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9924,Intermediate,50597,Spleen,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9925,Intermediate,50597,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9926,Intermediate,50597,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,4043,A,,Rattus norvegicus,10116.0,,,
9927,Intermediate,50597,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1446,A,,Rattus norvegicus,10116.0,,,
9928,Intermediate,50597,Urine,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,9971,A,,Rattus norvegicus,10116.0,,,
9929,Intermediate,50597,Urine,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,9971,A,,Rattus norvegicus,10116.0,,,
9930,Intermediate,50597,,,% Bioavailability after 1 day of the drug administration in rats,5765,A,In vivo,Rattus norvegicus,10116.0,,,
9931,Intermediate,50597,,,% Bioavailability after 4 day of the drug administration in rats,5765,A,In vivo,Rattus norvegicus,10116.0,,,
9932,Intermediate,50597,,,Absolute bioavailability was evaluated in rat,4257,A,In vivo,Rattus norvegicus,10116.0,,,
9933,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9934,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9935,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9936,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9937,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9938,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9939,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9940,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9941,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9942,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9943,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9944,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9945,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9946,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9947,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9948,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9949,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9950,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9951,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9952,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9953,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9954,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9955,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9956,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9957,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9958,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9959,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9960,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9961,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9962,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9963,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9964,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,13091,A,,Rattus norvegicus,10116.0,,,
9965,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,13091,A,,Rattus norvegicus,10116.0,,,
9966,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9967,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,13091,A,,Rattus norvegicus,10116.0,,,
9968,Intermediate,50597,,,Dissociation constant was determined,11977,A,,Rattus norvegicus,10116.0,,,
9969,Intermediate,50597,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",14941,A,,Rattus norvegicus,10116.0,,,
9970,Intermediate,50597,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9971,Intermediate,50597,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
9972,Intermediate,50597,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,4755,A,,Rattus norvegicus,10116.0,,,
9973,Intermediate,50597,,,LogP value was evaluated in the in situ rat gut perfusion assay,589,A,,Rattus norvegicus,10116.0,,,
9974,Intermediate,50597,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
9975,Intermediate,50597,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,5031,A,In vivo,Rattus norvegicus,10116.0,,,
9976,Intermediate,50597,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
9977,Intermediate,50597,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,A,,Rattus norvegicus,10116.0,,,
9978,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,2862,F,,Rattus norvegicus,10116.0,,,
9979,Intermediate,50597,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,16423,A,,Rattus norvegicus,10116.0,,,
9980,Intermediate,50597,,,Half-life was evaluated after 20 uM/kg of peroral administration,16423,A,In vivo,Rattus norvegicus,10116.0,,,
9981,Intermediate,50597,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,6005,A,In vivo,Rattus norvegicus,10116.0,,,
9982,Intermediate,50597,Plasma,,Half-life was evaluated in plasma of rat,2938,A,,Rattus norvegicus,10116.0,,,
9983,Intermediate,50597,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
9984,Intermediate,50597,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
9985,Intermediate,50597,,,Half-life was measured in rat after an iv dose of 1 mg/kg,6062,A,In vivo,Rattus norvegicus,10116.0,,,
9986,Intermediate,50597,,,Half-life period of compound in rats after peroral administration,6571,A,In vivo,Rattus norvegicus,10116.0,,,
9987,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma.,3136,A,,Rattus norvegicus,10116.0,,,
9988,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma; ND is not determined,3136,A,,Rattus norvegicus,10116.0,,,
9989,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma; not determined,3136,A,,Rattus norvegicus,10116.0,,,
9990,Intermediate,50597,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,4521,A,In vivo,Rattus norvegicus,10116.0,,,
9991,Intermediate,50597,,,Half-life period in rat by iv administration,5871,A,In vivo,Rattus norvegicus,10116.0,,,
9992,Intermediate,50597,,,Half-life period in rats following intravenous administration at 2 mg/kg,6077,A,In vivo,Rattus norvegicus,10116.0,,,
9993,Intermediate,50597,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Rattus norvegicus,10116.0,,,
9994,Intermediate,50597,,,Half-life period was determined for the compound in rat,5144,A,,Rattus norvegicus,10116.0,,,
9995,Intermediate,50597,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",4498,A,In vivo,Rattus norvegicus,10116.0,,,
9996,Intermediate,50597,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",4498,A,In vivo,Rattus norvegicus,10116.0,,,
9997,Intermediate,50597,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1908,A,In vivo,Rattus norvegicus,10116.0,,,
9998,Intermediate,50597,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,6211,A,In vivo,Rattus norvegicus,10116.0,,,
9999,Intermediate,50597,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),5529,A,In vivo,Rattus norvegicus,10116.0,,,
10000,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.,6444,A,In vivo,Rattus norvegicus,10116.0,,,
10001,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
10002,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,6444,A,In vivo,Rattus norvegicus,10116.0,,,
10003,Intermediate,50597,,,Half-life in rat,5207,A,,Rattus norvegicus,10116.0,,,
10004,Intermediate,50597,Plasma,,In vitro half life in rat plasma,530,A,In vitro,Rattus norvegicus,10116.0,,,
10005,Intermediate,50597,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1116,A,In vitro,Rattus norvegicus,10116.0,,,
10006,Intermediate,50597,,,In vitro half life in rat,3219,A,In vitro,Rattus norvegicus,10116.0,,,
10007,Intermediate,50597,,,In vivo half life period after intravenous administration in rat,6109,A,In vivo,Rattus norvegicus,10116.0,,,
10008,Intermediate,50597,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
10009,Intermediate,50597,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
10010,Intermediate,50597,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10011,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10012,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10013,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10014,Intermediate,50597,,,Longer half-life in rat (i.v.) at 0.5 mpk,17853,A,In vivo,Rattus norvegicus,10116.0,,,
10015,Intermediate,50597,,,Longer half-life in rat (p.o.) at 2.0 mpk,17853,A,In vivo,Rattus norvegicus,10116.0,,,
10016,Intermediate,50597,,,Pharmacokinetic property (half life) in rat,3457,A,,Rattus norvegicus,10116.0,,,
10017,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
10018,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
10019,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
10020,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
10021,Intermediate,50597,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,5739,A,In vivo,Rattus norvegicus,10116.0,,,
10022,Intermediate,50597,,,Pharmacokinetic half time was determined intravenously in rats.,15765,A,In vivo,Rattus norvegicus,10116.0,,,
10023,Intermediate,50597,Plasma,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,6567,A,In vivo,Rattus norvegicus,10116.0,,,
10024,Intermediate,50597,Plasma,,Plasma half life of hydrolysis of the compound,2448,A,,Rattus norvegicus,10116.0,,,
10025,Intermediate,50597,Plasma,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,5423,A,In vivo,Rattus norvegicus,10116.0,,,
10026,Intermediate,50597,Plasma,,Plasma half life period was calculated in rat,4853,A,,Rattus norvegicus,10116.0,,,
10027,Intermediate,50597,Plasma,,Plasma half-life in Sprague-Dawley rats,4514,A,,Rattus norvegicus,10116.0,,,
10028,Intermediate,50597,Plasma,,Plasma half-life in Sprague-Dawley rats; Not determined,4514,A,,Rattus norvegicus,10116.0,,,
10029,Intermediate,50597,Plasma,,Plasma half-life in rats,1500,A,,Rattus norvegicus,10116.0,,,
10030,Intermediate,50597,Plasma,,Plasma half-life in rats; <MQL,1500,A,,Rattus norvegicus,10116.0,,,
10031,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was determined,5334,A,,Rattus norvegicus,10116.0,,,
10032,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,5334,A,,Rattus norvegicus,10116.0,,,
10033,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
10034,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,5334,A,In vivo,Rattus norvegicus,10116.0,,,
10035,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,4956,A,,Rattus norvegicus,10116.0,,,
10036,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,4956,A,,Rattus norvegicus,10116.0,,,
10037,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",7768,A,,Rattus norvegicus,10116.0,,,
10038,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",7768,A,,Rattus norvegicus,10116.0,,,
10039,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",7768,A,,Rattus norvegicus,10116.0,,,
10040,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",7768,A,,Rattus norvegicus,10116.0,,,
10041,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",7768,A,,Rattus norvegicus,10116.0,,,
10042,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",7768,A,,Rattus norvegicus,10116.0,,,
10043,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",7768,A,,Rattus norvegicus,10116.0,,,
10044,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",7768,A,,Rattus norvegicus,10116.0,,,
10045,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",7768,A,,Rattus norvegicus,10116.0,,,
10046,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",7768,A,,Rattus norvegicus,10116.0,,,
10047,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",7768,A,,Rattus norvegicus,10116.0,,,
10048,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",7768,A,,Rattus norvegicus,10116.0,,,
10049,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",7768,A,,Rattus norvegicus,10116.0,,,
10050,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",7768,A,,Rattus norvegicus,10116.0,,,
10051,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",7768,A,,Rattus norvegicus,10116.0,,,
10052,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",7768,A,,Rattus norvegicus,10116.0,,,
10053,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",7768,A,,Rattus norvegicus,10116.0,,,
10054,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",7768,A,,Rattus norvegicus,10116.0,,,
10055,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",7768,A,,Rattus norvegicus,10116.0,,,
10056,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",7768,A,,Rattus norvegicus,10116.0,,,
10057,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",7768,A,,Rattus norvegicus,10116.0,,,
10058,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",7768,A,,Rattus norvegicus,10116.0,,,
10059,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",7768,A,,Rattus norvegicus,10116.0,,,
10060,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",7768,A,,Rattus norvegicus,10116.0,,,
10061,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",7768,A,,Rattus norvegicus,10116.0,,,
10062,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",7768,A,,Rattus norvegicus,10116.0,,,
10063,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",7768,A,,Rattus norvegicus,10116.0,,,
10064,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",7768,A,,Rattus norvegicus,10116.0,,,
10065,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",7768,A,,Rattus norvegicus,10116.0,,,
10066,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",7768,A,,Rattus norvegicus,10116.0,,,
10067,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",7768,A,,Rattus norvegicus,10116.0,,,
10068,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",7768,A,,Rattus norvegicus,10116.0,,,
10069,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",7768,A,,Rattus norvegicus,10116.0,,,
10070,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",7768,A,,Rattus norvegicus,10116.0,,,
10071,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",7768,A,,Rattus norvegicus,10116.0,,,
10072,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",7768,A,,Rattus norvegicus,10116.0,,,
10073,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",7768,A,,Rattus norvegicus,10116.0,,,
10074,Intermediate,50597,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",4498,A,In vivo,Rattus norvegicus,10116.0,,,
10075,Intermediate,50597,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",4498,A,In vivo,Rattus norvegicus,10116.0,,,
10076,Intermediate,50597,,,Bioavailability after a dose of 10 mg/kg p.o.,3603,A,In vivo,Rattus norvegicus,10116.0,,,
10077,Intermediate,50597,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,6215,A,In vivo,Rattus norvegicus,10116.0,,,
10078,Intermediate,50597,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,5710,A,In vivo,Rattus norvegicus,10116.0,,,
10079,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),5710,A,In vivo,Rattus norvegicus,10116.0,,,
10080,Intermediate,50597,,,Bioavailability in rat po was determined,5676,A,In vivo,Rattus norvegicus,10116.0,,,
10081,Intermediate,50597,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,17667,A,In vivo,Rattus norvegicus,10116.0,,,
10082,Intermediate,50597,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,17667,A,In vivo,Rattus norvegicus,10116.0,,,
10083,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),6848,A,In vivo,Rattus norvegicus,10116.0,,,
10084,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),6848,A,In vivo,Rattus norvegicus,10116.0,,,
10085,Intermediate,50597,,,Bioavailability in rat,17267,A,In vivo,Rattus norvegicus,10116.0,,,
10086,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (female),6362,A,In vivo,Rattus norvegicus,10116.0,,,
10087,Intermediate,50597,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,17671,A,In vivo,Rattus norvegicus,10116.0,,,
10088,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),17671,A,In vivo,Rattus norvegicus,10116.0,,,
10089,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,4333,A,In vivo,Rattus norvegicus,10116.0,,,
10090,Intermediate,50597,,,Bioavailability in rat at an oral dose of 2 mg/kg,6077,A,In vivo,Rattus norvegicus,10116.0,,,
10091,Intermediate,50597,,,Bioavailability in rat,3278,A,In vivo,Rattus norvegicus,10116.0,,,
10092,Intermediate,50597,,,Bioavailability in rat,5964,A,In vivo,Rattus norvegicus,10116.0,,,
10093,Intermediate,50597,,,Bioavailability in rat,4884,A,In vivo,Rattus norvegicus,10116.0,,,
10094,Intermediate,50597,,,Bioavailability in rat,4905,A,In vivo,Rattus norvegicus,10116.0,,,
10095,Intermediate,50597,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,4884,A,In vivo,Rattus norvegicus,10116.0,,,
10096,Intermediate,50597,,,Bioavailability in rat,6850,A,In vivo,Rattus norvegicus,10116.0,,,
10097,Intermediate,50597,,,Oral bioavailability in rat,2864,A,In vivo,Rattus norvegicus,10116.0,,,
10098,Intermediate,50597,,,Bioavailability was determined in rat,5780,A,In vivo,Rattus norvegicus,10116.0,,,
10099,Intermediate,50597,,,Bioavailability,1465,A,In vivo,Rattus norvegicus,10116.0,,,
10100,Intermediate,50597,,,Bioavailability,5199,A,In vivo,Rattus norvegicus,10116.0,,,
10101,Intermediate,50597,,,Bioavailability in rat after 1 day dosing,5765,A,In vivo,Rattus norvegicus,10116.0,,,
10102,Intermediate,50597,,,Bioavailability in rat after 4 day dosing,5765,A,In vivo,Rattus norvegicus,10116.0,,,
10103,Intermediate,50597,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
10104,Intermediate,50597,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,6518,A,In vivo,Rattus norvegicus,10116.0,,,
10105,Intermediate,50597,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
10106,Intermediate,50597,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,6518,A,In vivo,Rattus norvegicus,10116.0,,,
10107,Intermediate,50597,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,2083,A,In vivo,Rattus norvegicus,10116.0,,,
10108,Intermediate,50597,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,17260,A,In vivo,Rattus norvegicus,10116.0,,,
10109,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),4956,A,In vivo,Rattus norvegicus,10116.0,,,
10110,Intermediate,50597,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,4368,A,In vivo,Rattus norvegicus,10116.0,,,
10111,Intermediate,50597,Plasma,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,17752,A,In vivo,Rattus norvegicus,10116.0,,,
10112,Intermediate,50597,,,Bioavailability in rat (Fisher) (fasted),1446,A,In vivo,Rattus norvegicus,10116.0,,,
10113,Intermediate,22224,,,Bioavailability in monkey after po administration of 10 mg/kg dose,2891,A,In vivo,Primates,9443.0,,,
10114,Intermediate,22224,,,Oral bioavailability in monkey (dose 10 mg/kg),2891,A,In vivo,Primates,9443.0,,,
10115,Intermediate,50597,,,Bioavailability in rat,6672,A,In vivo,Rattus norvegicus,10116.0,,,
10116,Intermediate,50597,,,Bioavailability in rat,6673,A,In vivo,Rattus norvegicus,10116.0,,,
10117,Intermediate,50597,,,Bioavailability in rat,17655,A,In vivo,Rattus norvegicus,10116.0,,,
10118,Intermediate,50597,,,Bioavailability in rat,17796,A,In vivo,Rattus norvegicus,10116.0,,,
10119,Intermediate,50597,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),17853,A,In vivo,Rattus norvegicus,10116.0,,,
10120,Intermediate,50597,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),4521,A,In vivo,Rattus norvegicus,10116.0,,,
10121,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),4940,A,In vivo,Rattus norvegicus,10116.0,,,
10122,Intermediate,22224,,,Bioavailability in rat after po administration of 30 mg/kg dose,2891,A,In vivo,Rattus norvegicus,10116.0,,,
10123,Intermediate,22224,,,Bioavailability in rat after po administration of 30 mg/kg dose,2891,A,In vivo,Rattus norvegicus,10116.0,,,
10124,Intermediate,50597,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,4521,A,In vivo,Rattus norvegicus,10116.0,,,
10125,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg i.v.),17686,A,In vivo,Rattus norvegicus,10116.0,,,
10126,Intermediate,50597,,,Bioavailability in rat,17796,A,In vivo,Rattus norvegicus,10116.0,,,
10127,Intermediate,50597,Plasma,,Bioavailability in rat; Only traces detected in rat plasma,17796,A,In vivo,Rattus norvegicus,10116.0,,,
10128,Intermediate,50597,,,Bioavailability in rat,5064,A,In vivo,Rattus norvegicus,10116.0,,,
10129,Intermediate,50597,,,Bioavailability upon oral administration of compound,5147,A,In vivo,Rattus norvegicus,10116.0,,,
10130,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1916,A,In vivo,Rattus norvegicus,10116.0,,,
10131,Intermediate,50597,,,Bioavailability in rat,6049,A,In vivo,Rattus norvegicus,10116.0,,,
10132,Intermediate,50597,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1445,A,In vivo,Rattus norvegicus,10116.0,,,
10133,Intermediate,50597,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1445,A,In vivo,Rattus norvegicus,10116.0,,,
10134,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,2862,F,,Rattus norvegicus,10116.0,,,
10135,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,2862,F,,Rattus norvegicus,10116.0,,,
10136,Intermediate,50597,,,In vitro and metabolic stability was determined,4194,A,,Rattus norvegicus,10116.0,,,
10137,Intermediate,50597,,,In vitro metabolic stability in rat hepatocytes,4194,A,,Rattus norvegicus,10116.0,,,
10138,Intermediate,50597,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,5486,A,,Rattus norvegicus,10116.0,,,
10139,Intermediate,50597,Liver,,Metabolic rate for compound was observed in rat hepatocytes,17582,A,In vitro,Rattus norvegicus,10116.0,,Hepatocyte,
10140,Intermediate,50597,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,5600,A,,Rattus norvegicus,10116.0,,,
10141,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),14294,A,,Rattus norvegicus,10116.0,,,
10142,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),14294,A,,Rattus norvegicus,10116.0,,,
10143,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes; Trace,14294,A,,Rattus norvegicus,10116.0,,,
10144,Intermediate,50597,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,17847,A,,Rattus norvegicus,10116.0,,,
10145,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10146,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10147,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,11020,A,,Rattus norvegicus,10116.0,,,
10148,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,11020,A,,Rattus norvegicus,10116.0,,,
10149,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,11020,A,,Rattus norvegicus,10116.0,,,
10150,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,11020,A,,Rattus norvegicus,10116.0,,,
10151,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10152,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10153,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10154,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10155,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10156,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10157,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10158,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10159,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,11020,A,,Rattus norvegicus,10116.0,,,
10160,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10161,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10162,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,11020,A,,Rattus norvegicus,10116.0,,,
10163,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,11020,A,,Rattus norvegicus,10116.0,,,
10164,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,11020,A,,Rattus norvegicus,10116.0,,,
10165,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,11020,A,,Rattus norvegicus,10116.0,,,
10166,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,11020,A,,Rattus norvegicus,10116.0,,,
10167,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10168,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10169,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10170,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10171,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10172,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10173,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10174,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,4969,A,,Rattus norvegicus,10116.0,,,
10175,Intermediate,50597,Plasma,,Stability in rat plasma was determined,6737,A,,Rattus norvegicus,10116.0,,,
10176,Intermediate,50597,Plasma,,Stability in rat plasma was determined; ND= no data,6737,A,,Rattus norvegicus,10116.0,,,
10177,Intermediate,50597,Plasma,,Tested for plasma half life period in rat (0-8 hr),5089,A,,Rattus norvegicus,10116.0,,,
10178,Intermediate,50597,Plasma,,Tested for plasma half life period in rat (0-8 hr); Not determined,5089,A,,Rattus norvegicus,10116.0,,,
10179,Intermediate,50597,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
10180,Intermediate,50597,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
10181,Intermediate,50597,,,Tested for the half life in rat,4950,A,,Rattus norvegicus,10116.0,,,
10182,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,2412,A,In vitro,Rattus norvegicus,10116.0,,,
10183,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,2412,A,In vitro,Rattus norvegicus,10116.0,,,
10184,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,2412,A,In vitro,Rattus norvegicus,10116.0,,,
10185,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,2412,A,In vitro,Rattus norvegicus,10116.0,,,
10186,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,2412,A,In vitro,Rattus norvegicus,10116.0,,,
10187,Intermediate,50597,,,The biological half life the compound was measured at the dose of 100 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
10188,Intermediate,50597,,,The biological half life the compound was measured at the dose of 30 umol/kg,15022,A,,Rattus norvegicus,10116.0,,,
10189,Intermediate,50597,Plasma,,The compound was evaluated for plasma half life period in rat,406,A,,Rattus norvegicus,10116.0,,,
10190,Intermediate,50597,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
10191,Intermediate,50597,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
10192,Intermediate,50597,,,The pharmacokinetic parameter half-life period in vivo in rats,5247,A,In vivo,Rattus norvegicus,10116.0,,,
10193,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined",5041,A,In vivo,Rattus norvegicus,10116.0,,,
10194,Intermediate,50597,,,"The pharmacokinetic property, Half-life in rat in vivo",5041,A,In vivo,Rattus norvegicus,10116.0,,,
10195,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",5041,A,In vivo,Rattus norvegicus,10116.0,,,
10196,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",5041,A,In vivo,Rattus norvegicus,10116.0,,,
10197,Intermediate,50597,Plasma,,The plasma half life period in rats,3918,A,,Rattus norvegicus,10116.0,,,
10198,Intermediate,50597,Liver,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,2906,A,,Rattus norvegicus,10116.0,,,
10199,Intermediate,50597,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,6467,A,In vivo,Rattus norvegicus,10116.0,,,
10200,Intermediate,50597,,,t1/2 (apparent elimination)of the compound was determined,5510,A,,Rattus norvegicus,10116.0,,,
10201,Intermediate,50597,,,t1/2 value in rat,3788,A,,Rattus norvegicus,10116.0,,,
10202,Intermediate,50597,,,Half life in rat,17796,A,,Rattus norvegicus,10116.0,,,
10203,Intermediate,50597,Plasma,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",12873,A,In vivo,Rattus norvegicus,10116.0,,,
10204,Intermediate,50597,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,5983,A,In vivo,Rattus norvegicus,10116.0,,,
10205,Intermediate,50597,,,Half-life period in fasted rats,15765,A,,Rattus norvegicus,10116.0,,,
10206,Intermediate,50597,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
10207,Intermediate,50597,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
10208,Intermediate,50597,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,429,A,In vivo,Rattus norvegicus,10116.0,,,
10209,Intermediate,50597,,,Maximum time required to achieve Cmax was determined in rat,17655,A,,Rattus norvegicus,10116.0,,,
10210,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10211,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10212,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10213,Intermediate,50597,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,6570,A,In vivo,Rattus norvegicus,10116.0,,,
10214,Intermediate,50597,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,6570,A,In vivo,Rattus norvegicus,10116.0,,,
10215,Intermediate,50597,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10216,Intermediate,50597,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10217,Intermediate,50597,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10218,Intermediate,50597,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10219,Intermediate,50597,Plasma,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,17720,A,In vivo,Rattus norvegicus,10116.0,,,
10220,Intermediate,50597,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
10221,Intermediate,50597,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,4723,A,In vivo,Rattus norvegicus,10116.0,,,
10222,Intermediate,50597,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,4756,A,In vivo,Rattus norvegicus,10116.0,,,
10223,Intermediate,50597,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,4756,A,In vivo,Rattus norvegicus,10116.0,,,
10224,Intermediate,50597,Plasma,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,17720,A,In vivo,Rattus norvegicus,10116.0,,,
10225,Intermediate,50597,Plasma,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,17720,A,In vivo,Rattus norvegicus,10116.0,,,
10226,Intermediate,50597,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
10227,Intermediate,50597,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,7449,F,,Rattus norvegicus,10116.0,,,
10228,Intermediate,50597,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,7449,F,,Rattus norvegicus,10116.0,,,
10229,Intermediate,50597,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,7449,F,,Rattus norvegicus,10116.0,,,
10230,Intermediate,50597,,,Percent total excretion of N-methoxyacetaminophen glucuronide,7449,F,,Rattus norvegicus,10116.0,,,
10231,Intermediate,50597,,,Percent total excretion of N-methoxyacetaminophen sulfate,7449,F,,Rattus norvegicus,10116.0,,,
10232,Intermediate,50597,,,Percent total excretion of acetaminophen,7449,F,,Rattus norvegicus,10116.0,,,
10233,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",7768,A,,Rattus norvegicus,10116.0,,,
10234,Intermediate,50597,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",17655,A,,Rattus norvegicus,10116.0,,,
10235,Intermediate,50597,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,17735,A,,Rattus norvegicus,10116.0,,,
10236,Intermediate,50597,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,5960,A,,Rattus norvegicus,10116.0,,,
10237,Intermediate,50597,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,17735,A,,Rattus norvegicus,10116.0,,,
10238,Intermediate,50597,,,Compound was tested for antidiuretic activity in rats,7116,A,,Rattus norvegicus,10116.0,,,
10239,Intermediate,50597,Plasma,,AUC in rat after 3mg/kg oral dose,4878,A,In vivo,Rattus norvegicus,10116.0,,,
10240,Intermediate,50597,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,5939,A,,Rattus norvegicus,10116.0,,,
10241,Intermediate,50597,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,5939,A,,Rattus norvegicus,10116.0,,,
10242,Intermediate,50597,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,16367,A,,Rattus norvegicus,10116.0,,,
10243,Intermediate,50597,,,Oral Bioavailability was determined,16366,A,,Rattus norvegicus,10116.0,,,
10244,Intermediate,50597,,,Oral bioavailability in rat,4426,A,,Rattus norvegicus,10116.0,,,
10245,Intermediate,50597,,,Oral bioavailability in rat; Not performed.,4426,A,,Rattus norvegicus,10116.0,,,
10246,Intermediate,50597,,,Bioavailability,5041,A,,Rattus norvegicus,10116.0,,,
10247,Intermediate,50597,,,Bioavailability was determined; ND denotes no data,5041,A,,Rattus norvegicus,10116.0,,,
10248,Intermediate,50597,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1500,A,,Rattus norvegicus,10116.0,,,
10249,Intermediate,50597,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1500,A,,Rattus norvegicus,10116.0,,,
10250,Intermediate,50597,,,Binding towards rat plasma protein at 10 uM,17409,A,,Rattus norvegicus,10116.0,,,
10251,Intermediate,50597,,,Binding towards rat plasma protein at 100 uM,17409,A,,Rattus norvegicus,10116.0,,,
10252,Intermediate,50597,,,Bioavailability in rat (dose 20 mg/kg p.o.),2959,A,In vivo,Rattus norvegicus,10116.0,,,
10253,Intermediate,50597,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,13501,A,In vivo,Rattus norvegicus,10116.0,,,
10254,Intermediate,50597,,,Bioavailability in rat after 5 mg/kg oral gavage,6567,A,In vivo,Rattus norvegicus,10116.0,,,
10255,Intermediate,50597,,,Bioavailability in rat,6571,A,In vivo,Rattus norvegicus,10116.0,,,
10256,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v.),6715,A,In vivo,Rattus norvegicus,10116.0,,,
10257,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg p.o.),6715,A,In vivo,Rattus norvegicus,10116.0,,,
10258,Intermediate,50597,,,Oral bioavailability in rat,2932,A,In vivo,Rattus norvegicus,10116.0,,,
10259,Intermediate,50597,,,Bioavailability of the compound in rats after administration of 30 mg/kg,4171,A,In vivo,Rattus norvegicus,10116.0,,,
10260,Intermediate,50597,,,Bioavailability after administration of 10 mg/kg in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
10261,Intermediate,50597,,,Bioavailability after administration of 2 mg/kg in rats,17509,A,In vivo,Rattus norvegicus,10116.0,,,
10262,Intermediate,50597,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,4527,A,In vivo,Rattus norvegicus,10116.0,,,
10263,Intermediate,50597,,,Bioavailability in dogs was determined; high,4026,A,In vivo,Rattus norvegicus,10116.0,,,
10264,Intermediate,50597,,,Bioavailability in monkey after intravenous administration at 1 mpk,6659,A,In vivo,Rattus norvegicus,10116.0,,,
10265,Intermediate,50597,,,Bioavailability in monkey after peroral administration at 10 mpk,6659,A,In vivo,Rattus norvegicus,10116.0,,,
10266,Intermediate,50597,,,Bioavailability in rat after intravenous administration at 1 mpk,6659,A,In vivo,Rattus norvegicus,10116.0,,,
10267,Intermediate,50597,,,Bioavailability in rat after intravenous administration at 2 mpk,6659,F,In vivo,Rattus norvegicus,10116.0,,,
10268,Intermediate,50597,,,Bioavailability in rat after peroral administration at 30 mpk,6659,A,In vivo,Rattus norvegicus,10116.0,,,
10269,Intermediate,50597,,,Bioavailability in rat after peroral administration at at 100 mpk,6659,F,In vivo,Rattus norvegicus,10116.0,,,
10270,Intermediate,50597,,,Bioavailability in rats was evaluated,6597,A,In vivo,Rattus norvegicus,10116.0,,,
10271,Intermediate,50597,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1202,A,In vivo,Rattus norvegicus,10116.0,,,
10272,Intermediate,50597,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1202,A,In vivo,Rattus norvegicus,10116.0,,,
10273,Intermediate,50597,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1202,A,In vivo,Rattus norvegicus,10116.0,,,
10274,Intermediate,50597,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1202,A,In vivo,Rattus norvegicus,10116.0,,,
10275,Intermediate,50597,,,Bioavailability in rat,5207,A,In vivo,Rattus norvegicus,10116.0,,,
10276,Intermediate,50597,,,Bioavailability in rat,5970,A,In vivo,Rattus norvegicus,10116.0,,,
10277,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),17538,A,In vivo,Rattus norvegicus,10116.0,,,
10278,Intermediate,50597,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,17538,A,In vivo,Rattus norvegicus,10116.0,,,
10279,Intermediate,50597,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1466,A,In vivo,Rattus norvegicus,10116.0,,,
10280,Intermediate,50597,,,Oral bioavailability in rat,2879,A,In vivo,Rattus norvegicus,10116.0,,,
10281,Intermediate,50597,,,Bioavailability was measured in rat after oral administration; 2-4,2879,A,In vivo,Rattus norvegicus,10116.0,,,
10282,Intermediate,50597,,,Bioavailability was measured in rat after oral administration; 3-7,2879,A,In vivo,Rattus norvegicus,10116.0,,,
10283,Intermediate,50597,,,Bioavailability in rat (intraduodenal administration),3777,A,In vivo,Rattus norvegicus,10116.0,,,
10284,Intermediate,50597,,,Bioavailability in rat (intraduodenal administration),3777,A,In vivo,Rattus norvegicus,10116.0,,,
10285,Intermediate,50597,,,Oral bioavailability in rat,3777,A,In vivo,Rattus norvegicus,10116.0,,,
10286,Intermediate,50597,,,Oral bioavailability in rat,3777,A,In vivo,Rattus norvegicus,10116.0,,,
10287,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),5423,A,In vivo,Rattus norvegicus,10116.0,,,
10288,Intermediate,50597,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,16365,A,In vivo,Rattus norvegicus,10116.0,,,
10289,Intermediate,50597,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,16365,A,In vivo,Rattus norvegicus,10116.0,,,
10290,Intermediate,50597,,,Bioavailability was measured in rat,4239,A,In vivo,Rattus norvegicus,10116.0,,,
10291,Intermediate,50597,,,Bioavailability was reported,5438,A,In vivo,Rattus norvegicus,10116.0,,,
10292,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),5334,A,In vivo,Rattus norvegicus,10116.0,,,
10293,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),5334,A,In vivo,Rattus norvegicus,10116.0,,,
10294,Intermediate,50597,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,4199,A,In vivo,Rattus norvegicus,10116.0,,,
10295,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),4199,A,In vivo,Rattus norvegicus,10116.0,,,
10296,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),4199,A,In vivo,Rattus norvegicus,10116.0,,,
10297,Intermediate,50597,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,4890,A,In vivo,Rattus norvegicus,10116.0,,,
10298,Intermediate,50597,,,Bioavailability was determined at 3 mg/kg po dose in rats,2792,A,In vivo,Rattus norvegicus,10116.0,,,
10299,Intermediate,50597,,,Oral bioavailability in rat (dose 2 mg/kg),5529,A,In vivo,Rattus norvegicus,10116.0,,,
10300,Intermediate,50597,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",6685,A,In vivo,Rattus norvegicus,10116.0,,,
10301,Intermediate,50597,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
10302,Intermediate,50597,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",6685,A,In vivo,Rattus norvegicus,10116.0,,,
10303,Intermediate,50597,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,6005,A,In vivo,Rattus norvegicus,10116.0,,,
10304,Intermediate,50597,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,6410,A,In vivo,Rattus norvegicus,10116.0,,,
10305,Intermediate,50597,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
10306,Intermediate,50597,,,Bioavailability in rat,6103,A,In vivo,Rattus norvegicus,10116.0,,,
10307,Intermediate,50597,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,6410,A,In vivo,Rattus norvegicus,10116.0,,,
10308,Intermediate,50597,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,6410,A,In vivo,Rattus norvegicus,10116.0,,,
10309,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley),5353,A,In vivo,Rattus norvegicus,10116.0,,,
10310,Intermediate,50597,,,Bioavailability in rat at the dose of 2 mg/kg,4727,A,In vivo,Rattus norvegicus,10116.0,,,
10311,Intermediate,50597,,,Oral bioavailability in rat,17804,A,In vivo,Rattus norvegicus,10116.0,,,
10312,Intermediate,50597,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),5809,A,In vivo,Rattus norvegicus,10116.0,,,
10313,Intermediate,50597,,,Bioavailability value of compound in rats was determined after peroral administration,17804,A,In vivo,Rattus norvegicus,10116.0,,,
10314,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg),3634,A,In vivo,Rattus norvegicus,10116.0,,,
10315,Intermediate,50597,,,Oral bioavailability in rat,3341,A,In vivo,Rattus norvegicus,10116.0,,,
10316,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg),2690,A,In vivo,Rattus norvegicus,10116.0,,,
10317,Intermediate,50597,,,Oral bioavailability in rat,3184,A,In vivo,Rattus norvegicus,10116.0,,,
10318,Intermediate,50597,,,Oral bioavailability in rat,740,A,In vivo,Rattus norvegicus,10116.0,,,
10319,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,1806,A,In vivo,Rattus norvegicus,10116.0,,,
10320,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,4891,A,In vivo,Rattus norvegicus,10116.0,,,
10321,Intermediate,50597,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),3634,A,In vivo,Rattus norvegicus,10116.0,,,
10322,Intermediate,50597,,,Compound was tested for bioavailability in rats,64,A,In vivo,Rattus norvegicus,10116.0,,,
10323,Intermediate,50597,,,Bioavailability in rat,4839,A,In vivo,Rattus norvegicus,10116.0,,,
10324,Intermediate,50597,,,Oral bioavailability in rat,1094,A,In vivo,Rattus norvegicus,10116.0,,,
10325,Intermediate,22224,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,5005,A,In vivo,Macaca mulatta,9544.0,,,
10326,Intermediate,22224,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),5005,A,In vivo,Rattus norvegicus,10116.0,,,
10327,Intermediate,50597,,,Evaluated for the bioavailability in rat (in vivo),4687,A,In vivo,Rattus norvegicus,10116.0,,,
10328,Intermediate,50597,,,F value of compound in rats was determined after peroral administration,17804,A,In vivo,Rattus norvegicus,10116.0,,,
10329,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10330,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10331,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10332,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,5974,A,In vivo,Rattus norvegicus,10116.0,,,
10333,Intermediate,50597,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1088,A,In vivo,Rattus norvegicus,10116.0,,,
10334,Intermediate,50597,,,Maximum fall in carotid flow in rat,1742,A,In vivo,Rattus norvegicus,10116.0,,,
10335,Intermediate,50597,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,4689,A,In vivo,Rattus norvegicus,10116.0,,,
10336,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg),2463,A,In vivo,Rattus norvegicus,10116.0,,,
10337,Intermediate,50597,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
10338,Intermediate,50597,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,5654,A,In vivo,Rattus norvegicus,10116.0,,,
10339,Intermediate,50597,,,Oral bioavailability in rat (male Wistar),6874,A,In vivo,Rattus norvegicus,10116.0,,,
10340,Intermediate,50597,,,Oral bioavailability after administration (30 mg/kg) in rat; good,5633,A,In vivo,Rattus norvegicus,10116.0,,,
10341,Intermediate,50597,,,Oral bioavailability at the dose of 2 mg/kg in rat,5496,A,In vivo,Rattus norvegicus,10116.0,,,
10342,Intermediate,50597,,,Oral bioavailability determined in rats,2358,A,In vivo,Rattus norvegicus,10116.0,,,
10343,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),16456,A,In vivo,Rattus norvegicus,10116.0,,,
10344,Intermediate,50597,,,Oral bioavailability in rat (dose single 10 mg/kg),5302,A,In vivo,Rattus norvegicus,10116.0,,,
10345,Intermediate,50597,,,Oral bioavailability in rat (dose single 10 mg/kg),5302,A,In vivo,Rattus norvegicus,10116.0,,,
10346,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg,5302,A,In vivo,Rattus norvegicus,10116.0,,,
10347,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10348,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,11020,A,,Rattus norvegicus,10116.0,,,
10349,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10350,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10351,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,11020,A,,Rattus norvegicus,10116.0,,,
10352,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,11020,A,,Rattus norvegicus,10116.0,,,
10353,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,11020,A,,Rattus norvegicus,10116.0,,,
10354,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,11020,A,,Rattus norvegicus,10116.0,,,
10355,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10356,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10357,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10358,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10359,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10360,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10361,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10362,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,11020,A,,Rattus norvegicus,10116.0,,,
10363,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,11020,A,,Rattus norvegicus,10116.0,,,
10364,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",11020,A,,Rattus norvegicus,10116.0,,,
10365,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",11020,A,,Rattus norvegicus,10116.0,,,
10366,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",11020,A,,Rattus norvegicus,10116.0,,,
10367,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",11020,A,,Rattus norvegicus,10116.0,,,
10368,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",11020,A,,Rattus norvegicus,10116.0,,,
10369,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",11020,A,,Rattus norvegicus,10116.0,,,
10370,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",11020,A,,Rattus norvegicus,10116.0,,,
10371,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",11020,A,,Rattus norvegicus,10116.0,,,
10372,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",11020,A,,Rattus norvegicus,10116.0,,,
10373,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",11020,A,,Rattus norvegicus,10116.0,,,
10374,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",11020,A,,Rattus norvegicus,10116.0,,,
10375,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",11020,A,,Rattus norvegicus,10116.0,,,
10376,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10377,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,11020,A,,Rattus norvegicus,10116.0,,,
10378,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,11020,A,,Rattus norvegicus,10116.0,,,
10379,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,11020,A,,Rattus norvegicus,10116.0,,,
10380,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,11020,A,,Rattus norvegicus,10116.0,,,
10381,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,11020,A,,Rattus norvegicus,10116.0,,,
10382,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,11020,A,,Rattus norvegicus,10116.0,,,
10383,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10384,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10385,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10386,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,11020,A,,Rattus norvegicus,10116.0,,,
10387,Intermediate,50597,,,Percent total excretion of acetaminophen cysteine conjugate,7449,F,,Rattus norvegicus,10116.0,,,
10388,Intermediate,50597,,,Percent total excretion of acetaminophen glucuronide,7449,F,,Rattus norvegicus,10116.0,,,
10389,Intermediate,50597,,,Percent total excretion of acetaminophen sulfate,7449,F,,Rattus norvegicus,10116.0,,,
10390,Intermediate,50597,,,Percent total excretion of acetaminophen-mercapturic acid,7449,F,,Rattus norvegicus,10116.0,,,
10391,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,3172,A,,Rattus norvegicus,10116.0,,,
10392,Intermediate,50597,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,16456,A,In vivo,Rattus norvegicus,10116.0,,,
10393,Autocuration,22224,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration,10839,A,In vivo,ratrat,8656.0,,,
10394,Autocuration,22224,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration.,10839,A,In vivo,ratrat,8656.0,,,
10395,Autocuration,22224,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10396,Autocuration,22224,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10397,Autocuration,22224,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10398,Autocuration,22224,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10399,Autocuration,22224,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10400,Autocuration,22224,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10401,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10402,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),5334,A,In vivo,Ovis aries,9940.0,,,
10403,Intermediate,50497,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1735,A,,Serpentes,8570.0,,,
10404,Intermediate,50497,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1469,A,,Serpentes,8570.0,,,
10405,Intermediate,50497,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1336,A,,Serpentes,8570.0,,,
10406,Autocuration,22224,Plasma,,The human biological plasma half life of the compound,12403,A,,Homo sapiens,9606.0,,,
10407,Intermediate,50597,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,8151,A,,Rattus norvegicus,10116.0,,,
10408,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,8004,A,,Rattus norvegicus,10116.0,,,
10409,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10410,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,8004,A,,Rattus norvegicus,10116.0,,,
10411,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10412,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10413,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10414,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,8004,A,,Rattus norvegicus,10116.0,,,
10415,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10416,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,8004,A,,Rattus norvegicus,10116.0,,,
10417,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10418,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10419,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10420,Intermediate,50597,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10421,Intermediate,50597,Blood,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10422,Intermediate,50597,Blood,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,8004,A,,Rattus norvegicus,10116.0,,,
10423,Expert,180,,,Dissociation constant against binding to human cyclophilin A,15917,B,,Homo sapiens,9606.0,,,
10424,Expert,11591,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,12396,B,,Bos taurus,9913.0,,,
10425,Autocuration,22224,,,-Log C was determined by performing the electroshock minimum test,7065,A,,,,,,
10426,Autocuration,22224,,,-Log C was determined by performing the foot shock test,7065,A,,,,,,
10427,Autocuration,22224,,,-Log C was determined by performing the incl screen test,7065,A,,,,,,
10428,Autocuration,22224,,,-Log C was determined by performing the maximum electroshock test,7065,A,,,,,,
10429,Autocuration,22224,,,-Log C was determined by performing the pentylenetetrazole test,7065,A,,,,,,
10430,Autocuration,22224,,,Tested for experimental arotinoid inhibitory dose,12415,A,,,,,,
10431,Autocuration,22224,,,Negative log transformed activity,10256,A,,,,,,
10432,Autocuration,22224,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",7991,A,,,,,,
10433,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,14342,A,,Cavia porcellus,10141.0,,,
10434,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,14342,A,,Cavia porcellus,10141.0,,,
10435,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,14342,A,,Cavia porcellus,10141.0,,,
10436,Intermediate,50512,Ileum,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,14342,A,,Cavia porcellus,10141.0,,,
10437,Autocuration,22229,,,Solubility in water was determined; values expressed as -log,6047,P,,,,,,
10438,Autocuration,22224,,,Ratio of Kcat to that of Km was determined,17269,A,,,,,,
10439,Autocuration,22224,,,Observed first order rate constant,10026,A,,,,,,
10440,Autocuration,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,14583,A,,,,,,
10441,Intermediate,50597,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
10442,Intermediate,50597,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,2661,A,In vivo,Rattus norvegicus,10116.0,,,
10443,Intermediate,50597,,,Oral Bioavailability after administration of 10 mg/kg in male rat,4029,A,In vivo,Rattus norvegicus,10116.0,,,
10444,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),17735,A,In vivo,Rattus norvegicus,10116.0,,,
10445,Intermediate,50597,,,Oral bioavailability in rat,4576,A,In vivo,Rattus norvegicus,10116.0,,,
10446,Intermediate,50597,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,17582,A,In vivo,Rattus norvegicus,10116.0,,,
10447,Intermediate,50597,,,Oral bioavailability at 1 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
10448,Intermediate,50597,,,Oral bioavailability at 10 mg/kg was determined in rat,17651,A,In vivo,Rattus norvegicus,10116.0,,,
10449,Intermediate,50597,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",17670,A,In vivo,Rattus norvegicus,10116.0,,,
10450,Intermediate,50597,,,Oral bioavailability in rat,5045,A,In vivo,Rattus norvegicus,10116.0,,,
10451,Intermediate,50597,,,Oral bioavailability in rat,1696,A,In vivo,Rattus norvegicus,10116.0,,,
10452,Intermediate,50597,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,17764,A,In vivo,Rattus norvegicus,10116.0,,,
10453,Intermediate,50597,,,Oral bioavailability in rat,6448,A,In vivo,Rattus norvegicus,10116.0,,,
10454,Intermediate,50597,,,Oral bioavailability in rat,6596,A,In vivo,Rattus norvegicus,10116.0,,,
10455,Intermediate,50597,,,Oral bioavailability in rat,17547,A,In vivo,Rattus norvegicus,10116.0,,,
10456,Intermediate,50597,,,Oral bioavailability in rat at a dose of 3 mg/kg,17771,A,In vivo,Rattus norvegicus,10116.0,,,
10457,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 10 mg/kg,6495,A,In vivo,Rattus norvegicus,10116.0,,,
10458,Intermediate,50597,,,Oral bioavailability in rat,4558,A,In vivo,Rattus norvegicus,10116.0,,,
10459,Intermediate,50597,,,Oral bioavailability in rat,17596,A,In vivo,Rattus norvegicus,10116.0,,,
10460,Intermediate,50597,,,Oral bioavailability in Dawley rats,6827,A,In vivo,Rattus norvegicus,10116.0,,,
10461,Intermediate,50597,,,Oral bioavailability,4026,A,In vivo,Rattus norvegicus,10116.0,,,
10462,Intermediate,50597,,,Oral bioavailability in rat (dose 30 mg/kg),10,A,In vivo,Rattus norvegicus,10116.0,,,
10463,Intermediate,50597,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10464,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg i.v.),17717,A,In vivo,Rattus norvegicus,10116.0,,,
10465,Intermediate,50597,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10466,Intermediate,50597,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),17717,A,In vivo,Rattus norvegicus,10116.0,,,
10467,Intermediate,50597,,,Percent oral bioavailability determined in rats,4796,A,In vivo,Rattus norvegicus,10116.0,,,
10468,Intermediate,50597,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,4883,A,In vivo,Rattus norvegicus,10116.0,,,
10469,Intermediate,50597,,,The compound was evaluated for bioavailability in rats; 32-51,2137,A,In vivo,Rattus norvegicus,10116.0,,,
10470,Intermediate,50597,,,Bioavailability in rat (dose 20 mg/kg p.o.),2959,A,In vivo,Rattus norvegicus,10116.0,,,
10471,Intermediate,50597,,,Oral bioavailability in rat,1361,A,In vivo,Rattus norvegicus,10116.0,,,
10472,Intermediate,50597,,,Bioavailability percent in rat at the dose of 2 mg/kg,4727,A,In vivo,Rattus norvegicus,10116.0,,,
10473,Intermediate,50597,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,16423,A,In vivo,Rattus norvegicus,10116.0,,,
10474,Intermediate,50597,,,Oral bioavailability in rat,5206,A,In vivo,Rattus norvegicus,10116.0,,,
10475,Intermediate,50597,,,Oral bioavailability in rat,6448,A,In vivo,Rattus norvegicus,10116.0,,,
10476,Intermediate,50597,,,Bioavailability in rats,17723,A,In vivo,Rattus norvegicus,10116.0,,,
10477,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10478,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10479,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10480,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10481,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10482,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10483,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10484,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10485,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10486,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10487,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10488,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10489,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10490,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10491,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10492,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10493,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10494,Intermediate,50597,,,Oral bioavailability in rats was determined; High,5237,A,In vivo,Rattus norvegicus,10116.0,,,
10495,Intermediate,50597,,,Oral bioavailability in the rat was determined,5503,A,In vivo,Rattus norvegicus,10116.0,,,
10496,Intermediate,50597,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,15765,A,In vivo,Rattus norvegicus,10116.0,,,
10497,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),15660,A,In vivo,Rattus norvegicus,10116.0,,,
10498,Intermediate,50597,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10499,Intermediate,50597,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10500,Intermediate,50597,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10501,Intermediate,50597,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,5978,A,In vivo,Rattus norvegicus,10116.0,,,
10502,Intermediate,50597,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,5656,A,In vivo,Rattus norvegicus,10116.0,,,
10503,Expert,50597,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,3598,A,In vivo,Rattus norvegicus,10116.0,,,
10504,Intermediate,50597,,,Oral bioavailability of compound in Sprague Dawley rats,4216,A,In vivo,Rattus norvegicus,10116.0,,,
10505,Intermediate,50597,,,Oral bioavailability of compound in rat,17839,A,In vivo,Rattus norvegicus,10116.0,,,
10506,Intermediate,50597,,,Oral bioavailability in rat (dose 2 mg/kg),6570,A,In vivo,Rattus norvegicus,10116.0,,,
10507,Intermediate,50597,,,Oral bioavailability of compound in rat was determined,5334,A,In vivo,Rattus norvegicus,10116.0,,,
10508,Intermediate,50597,,,Oral bioavailability of compound in rats,6886,A,In vivo,Rattus norvegicus,10116.0,,,
10509,Intermediate,50597,,,Oral bioavailability of compound was determined in rats,5210,A,In vivo,Rattus norvegicus,10116.0,,,
10510,Intermediate,50597,,,Oral bioavailability at a dose of 30 mg/kg in rats,4170,A,In vivo,Rattus norvegicus,10116.0,,,
10511,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),6028,A,In vivo,Rattus norvegicus,10116.0,,,
10512,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),6028,A,In vivo,Rattus norvegicus,10116.0,,,
10513,Intermediate,50597,,,Oral bioavailability evaluated in rat,6078,A,In vivo,Rattus norvegicus,10116.0,,,
10514,Intermediate,50597,,,Oral bioavailability in fasted rat,6168,A,In vivo,Rattus norvegicus,10116.0,,,
10515,Intermediate,50597,,,Oral bioavailability in fed rat,6168,A,In vivo,Rattus norvegicus,10116.0,,,
10516,Intermediate,50597,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),5160,A,In vivo,Rattus norvegicus,10116.0,,,
10517,Intermediate,50597,,,Oral bioavailability in rat,6057,A,In vivo,Rattus norvegicus,10116.0,,,
10518,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),6535,A,In vivo,Rattus norvegicus,10116.0,,,
10519,Intermediate,50597,,,Oral bioavailability in rat after administration of 10 mg/kg po,6535,A,In vivo,Rattus norvegicus,10116.0,,,
10520,Intermediate,50597,,,Oral bioavailability in rat,4194,A,In vivo,Rattus norvegicus,10116.0,,,
10521,Intermediate,50597,,,Oral bioavailability in rat,6230,A,In vivo,Rattus norvegicus,10116.0,,,
10522,Intermediate,50597,,,Oral bioavailability in rat,6619,A,In vivo,Rattus norvegicus,10116.0,,,
10523,Intermediate,50597,,,Oral bioavailability in rat,17607,A,In vivo,Rattus norvegicus,10116.0,,,
10524,Intermediate,50597,,,Oral bioavailability in ratrs,4942,A,In vivo,Rattus norvegicus,10116.0,,,
10525,Intermediate,50597,,,Oral bioavailability in rat,4942,A,In vivo,Rattus norvegicus,10116.0,,,
10526,Intermediate,50597,,,Oral bioavailability in rat,6646,A,In vivo,Rattus norvegicus,10116.0,,,
10527,Intermediate,50597,,,Oral bioavailability in rats was determined; High,5237,A,In vivo,Rattus norvegicus,10116.0,,,
10528,Intermediate,50597,,,Oral bioavailability in rat,6646,A,In vivo,Rattus norvegicus,10116.0,,,
10529,Intermediate,50597,,,Oral bioavailability in rat,4449,A,In vivo,Rattus norvegicus,10116.0,,,
10530,Intermediate,50597,,,Oral bioavailability was calculated in rat,6057,A,In vivo,Rattus norvegicus,10116.0,,,
10531,Intermediate,50597,,,Oral bioavailability,2552,A,In vivo,Rattus norvegicus,10116.0,,,
10532,Intermediate,50597,,,Oral bioavailability,5496,A,In vivo,Rattus norvegicus,10116.0,,,
10533,Intermediate,50597,,,Oral bioavailability,6484,A,In vivo,Rattus norvegicus,10116.0,,,
10534,Intermediate,50597,,,Oral bioavailability,6485,A,In vivo,Rattus norvegicus,10116.0,,,
10535,Intermediate,50597,,,Oral bioavailability after i.v. administration,6616,A,In vivo,Rattus norvegicus,10116.0,,,
10536,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),4969,A,In vivo,Rattus norvegicus,10116.0,,,
10537,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley),5862,A,In vivo,Rattus norvegicus,10116.0,,,
10538,Intermediate,50597,,,Oral bioavailability in Sprague-Dawley rats,4514,A,In vivo,Rattus norvegicus,10116.0,,,
10539,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),4514,A,In vivo,Rattus norvegicus,10116.0,,,
10540,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),4514,A,In vivo,Rattus norvegicus,10116.0,,,
10541,Intermediate,50597,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,5546,A,In vivo,Rattus norvegicus,10116.0,,,
10542,Intermediate,50597,,,Oral bioavailability in fasted rat,6168,A,In vivo,Rattus norvegicus,10116.0,,,
10543,Intermediate,50597,,,Oral bioavailability in fed rat,6168,A,In vivo,Rattus norvegicus,10116.0,,,
10544,Intermediate,50597,,,Oral bioavailability in rat,3624,A,In vivo,Rattus norvegicus,10116.0,,,
10545,Intermediate,50597,,,Oral bioavailability in rat,5213,A,In vivo,Rattus norvegicus,10116.0,,,
10546,Intermediate,50597,,,Oral bioavailability in rat,5496,A,In vivo,Rattus norvegicus,10116.0,,,
10547,Intermediate,50597,,,Oral bioavailability in rat,5553,A,In vivo,Rattus norvegicus,10116.0,,,
10548,Intermediate,50597,,,Oral bioavailability in rat,5833,A,In vivo,Rattus norvegicus,10116.0,,,
10549,Intermediate,50597,,,Oral bioavailability in rat,5836,A,In vivo,Rattus norvegicus,10116.0,,,
10550,Intermediate,50597,,,Oral bioavailability in rat,5865,A,In vivo,Rattus norvegicus,10116.0,,,
10551,Intermediate,50597,,,Oral bioavailability in rat,5960,A,In vivo,Rattus norvegicus,10116.0,,,
10552,Intermediate,50597,,,Oral bioavailability in rat,6249,A,In vivo,Rattus norvegicus,10116.0,,,
10553,Intermediate,50597,,,Oral bioavailability in rat,6448,A,In vivo,Rattus norvegicus,10116.0,,,
10554,Intermediate,50597,,,Oral bioavailability in rat,6453,A,In vivo,Rattus norvegicus,10116.0,,,
10555,Intermediate,50597,,,Oral bioavailability in rat,6640,A,In vivo,Rattus norvegicus,10116.0,,,
10556,Intermediate,50597,,,Oral bioavailability in rat,17607,A,In vivo,Rattus norvegicus,10116.0,,,
10557,Intermediate,50597,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,5939,A,In vivo,Rattus norvegicus,10116.0,,,
10558,Intermediate,50597,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,5939,A,In vivo,Rattus norvegicus,10116.0,,,
10559,Intermediate,50597,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),6281,A,In vivo,Rattus norvegicus,10116.0,,,
10560,Intermediate,50597,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,5874,A,In vivo,Rattus norvegicus,10116.0,,,
10561,Intermediate,50597,,,Oral bioavailability in rat; Not measured,5213,A,In vivo,Rattus norvegicus,10116.0,,,
10562,Intermediate,50597,,,Oral bioavailability in rat,4964,A,In vivo,Rattus norvegicus,10116.0,,,
10563,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,11020,A,,Rattus norvegicus,10116.0,,,
10564,Intermediate,50597,Liver,,In vitro metabolic potential in rat liver microsomes,6251,A,,Rattus norvegicus,10116.0,,,
10565,Intermediate,50597,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1568,A,In vivo,Rattus norvegicus,10116.0,,,
10566,Intermediate,50597,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",3032,A,In vivo,Rattus norvegicus,10116.0,,,
10567,Intermediate,50597,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,3748,A,In vivo,Rattus norvegicus,10116.0,,,
10568,Intermediate,50597,,,Oral bioavailability in rat,401,A,In vivo,Rattus norvegicus,10116.0,,,
10569,Intermediate,50597,,,Oral bioavailability in rat,6512,A,In vivo,Rattus norvegicus,10116.0,,,
10570,Intermediate,50597,,,Oral bioavailability in rats at 10 mg/kg,17617,A,In vivo,Rattus norvegicus,10116.0,,,
10571,Intermediate,50597,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,6679,A,In vivo,Rattus norvegicus,10116.0,,,
10572,Intermediate,50597,,,Oral bioavailability in rat,6742,A,In vivo,Rattus norvegicus,10116.0,,,
10573,Intermediate,50597,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,589,A,,Rattus norvegicus,10116.0,,,
10574,Intermediate,50597,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,589,A,,Rattus norvegicus,10116.0,,,
10575,Intermediate,50597,,,Plasma clearance of the compound,3185,A,In vivo,Rattus norvegicus,10116.0,,,
10576,Intermediate,50597,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,17596,A,In vivo,Rattus norvegicus,10116.0,,,
10577,Intermediate,50597,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,2713,A,In vivo,Rattus norvegicus,10116.0,,,
10578,Intermediate,50597,Plasma,,The compound was tested for plasma clearance in rat,12500,A,In vivo,Rattus norvegicus,10116.0,,,
10579,Intermediate,50597,Plasma,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,12500,A,In vivo,Rattus norvegicus,10116.0,,,
10580,Intermediate,50597,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,2713,A,,Rattus norvegicus,10116.0,,,
10581,Intermediate,50597,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1446,A,,Rattus norvegicus,10116.0,,,
10582,Intermediate,50597,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,6227,A,,Rattus norvegicus,10116.0,,,
10583,Intermediate,50597,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,4709,A,,Rattus norvegicus,10116.0,,,
10584,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",5510,A,,Rattus norvegicus,10116.0,,,
10585,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",5510,A,,Rattus norvegicus,10116.0,,,
10586,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",5510,A,,Rattus norvegicus,10116.0,,,
10587,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",5510,A,,Rattus norvegicus,10116.0,,,
10588,Intermediate,50597,,,Compound was tested for protein binding in rat plasma,4514,A,,Rattus norvegicus,10116.0,,,
10589,Intermediate,50597,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,2713,A,,Rattus norvegicus,10116.0,,,
10590,Intermediate,50597,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,2713,A,,Rattus norvegicus,10116.0,,,
10591,Intermediate,50597,Liver,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,5340,A,,Rattus norvegicus,10116.0,,,
10592,Intermediate,50597,,,Area under curve ratio was determined (po/iv) in rat,12058,A,,Rattus norvegicus,10116.0,,,
10593,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,11195,A,,Rattus norvegicus,10116.0,,,
10594,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,11195,A,,Rattus norvegicus,10116.0,,,
10595,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,11195,A,,Rattus norvegicus,10116.0,,,
10596,Intermediate,50597,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,6495,A,,Rattus norvegicus,10116.0,,,
10597,Intermediate,50597,,,Ratio of AUCbrain to AUCplasma,6078,A,,Rattus norvegicus,10116.0,,,
10598,Intermediate,50597,,,Ratio of brain to plasma,5656,A,,Rattus norvegicus,10116.0,,,
10599,Intermediate,50597,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,4910,A,,Rattus norvegicus,10116.0,,,
10600,Intermediate,50597,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,4910,A,,Rattus norvegicus,10116.0,,,
10601,Intermediate,50597,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,4910,A,,Rattus norvegicus,10116.0,,,
10602,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,10130,A,,Rattus norvegicus,10116.0,,,
10603,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,10130,A,,Rattus norvegicus,10116.0,,,
10604,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,10130,A,,Rattus norvegicus,10116.0,,,
10605,Intermediate,50597,,,Steady state brain :blood ratio was determined,5213,A,,Rattus norvegicus,10116.0,,,
10606,Intermediate,50597,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
10607,Intermediate,50597,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,4910,A,,Rattus norvegicus,10116.0,,,
10608,Intermediate,50597,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,4910,A,,Rattus norvegicus,10116.0,,,
10609,Intermediate,50597,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,4910,A,,Rattus norvegicus,10116.0,,,
10610,Intermediate,50597,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,2083,A,,Rattus norvegicus,10116.0,,,
10611,Intermediate,50597,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,2082,A,,Rattus norvegicus,10116.0,,,
10612,Intermediate,50597,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,2082,A,,Rattus norvegicus,10116.0,,,
10613,Intermediate,50597,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,6351,A,,Rattus norvegicus,10116.0,,,
10614,Autocuration,22224,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",14583,A,,,,,,
10615,Autocuration,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,14583,A,,,,,,
10616,Intermediate,50587,,,In vivo absorption in Caco-2 cell line monolayers was determined,4608,A,,Homo sapiens,9606.0,,Caco-2,
10617,Autocuration,22229,,,Calculated partition coefficient (clogP),13668,P,,,,,,
10618,Intermediate,50597,,,Area under curve was determine after peroral administration at 10 mpk in Rat,5669,A,,Rattus norvegicus,10116.0,,,
10619,Intermediate,50797,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,5669,A,,Macaca mulatta,9544.0,,,
10620,Intermediate,50597,,,Area under curve was determine after peroral administration at 160 mpk in Rat,5669,A,,Rattus norvegicus,10116.0,,,
10621,Intermediate,50597,,,Area under curve was determine after peroral administration at 20 mpk in Rat,5669,A,,Rattus norvegicus,10116.0,,,
10622,Intermediate,50597,,,Area under curve was determine after peroral administration at 50 mpk in Rat,5669,A,,Rattus norvegicus,10116.0,,,
10623,Autocuration,22229,,,Calculated partition coefficient (clogP) (AlogP),6472,P,,,,,,
10624,Autocuration,22224,,,Activated partial thromboplastin time measured,15106,A,,,,,,
10625,Autocuration,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),15207,P,,,,,,
10626,Autocuration,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),15207,P,,,,,,
10627,Intermediate,50588,Plasma,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,13941,A,,Canis lupus familiaris,9615.0,,,
10628,Intermediate,50597,Plasma,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,13941,A,,Rattus norvegicus,10116.0,,,
10629,Intermediate,50597,Plasma,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,13941,A,,Rattus norvegicus,10116.0,,,
10630,Intermediate,50588,Plasma,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,13941,A,,Canis lupus familiaris,9615.0,,,
10631,Intermediate,50512,Plasma,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,15240,A,,Cavia porcellus,10141.0,,,
10632,Autocuration,22224,Brain,,AUC in brain,10655,A,,,,,,
10633,Autocuration,22224,Serum,,AUC in serum,10655,A,,,,,,
10634,Autocuration,22224,Plasma,,AUC was determined,6504,A,,,,,,
10635,Autocuration,22224,Plasma,,AUC of the compound.,10615,A,,,,,,
10636,Autocuration,22224,Plasma,,AUC value (0-4 hr),10353,A,,,,,,
10637,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",14907,A,,,,,,
10638,Autocuration,22224,Plasma,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,14907,A,,,,,,
10639,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",14907,A,,,,,,
10640,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",14907,A,,,,,,
10641,Intermediate,50597,Plasma,,AUC(area under curve) was determined after intravenous administration in rats,16359,A,,Rattus norvegicus,10116.0,,,
10642,Intermediate,50597,Plasma,,AUC(area under curve) was determined after oral administration in rats,16359,A,,Rattus norvegicus,10116.0,,,
10643,Intermediate,50512,Plasma,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,15240,A,,Cavia porcellus,10141.0,,,
10644,Intermediate,50597,Plasma,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,15240,A,,Rattus norvegicus,10116.0,,,
10645,Autocuration,22224,,,Area Under Curve after oral dosing of 100 uM/Kg,15469,A,,,,,,
10646,Autocuration,22224,,,Area Under Curve after oral dosing of 30 uM/Kg,15469,A,,,,,,
10647,Autocuration,22224,,,Area Under Curve was measured by ploting the graph between concentration verses time,13520,A,,,,,,
10648,Intermediate,50588,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,17025,A,,Canis lupus familiaris,9615.0,,,
10649,Autocuration,22224,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,17025,A,,Simiiformes,314293.0,,,
10650,Intermediate,50592,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,17025,A,,Oryctolagus cuniculus,9986.0,,,
10651,Intermediate,50597,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,17025,A,,Rattus norvegicus,10116.0,,,
10652,Intermediate,50597,Blood,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,12032,A,,Rattus norvegicus,10116.0,,,
10653,Autocuration,22224,,,Area under curve (AUC) was determined,10291,A,,,,,,
10654,Autocuration,22224,,,Area under curve (AUC) following ip administration at 1 mg/kg,5767,A,,,,,,
10655,Autocuration,22224,,,Area under curve (AUC) was determined; ND is Not determined,1434,A,,,,,,
10656,Intermediate,50588,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,14925,A,,Canis lupus familiaris,9615.0,,,
10657,Intermediate,50588,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,14925,A,,Canis lupus familiaris,9615.0,,,
10658,Intermediate,50588,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,14925,A,,Canis lupus familiaris,9615.0,,,
10659,Autocuration,22224,,,Area under curve (AUR) was determined,1434,A,,,,,,
10660,Autocuration,22224,,,Area under curve at 1 uM/dg administered intravenously,11883,A,,,,,,
10661,Autocuration,22224,,,Area under curve at 10 uM/dg administered perorally,11883,A,,,,,,
10662,Autocuration,22224,,,Area under curve at 2 uM/dg administered intravenously,11883,A,,,,,,
10663,Autocuration,22224,,,Area under curve at 20 uM/dg administered perorally,11883,A,,,,,,
10664,Intermediate,50588,,,Area under curve at a peroral dose of 3 mg/kg in dog,15233,A,,Canis lupus familiaris,9615.0,,,
10665,Intermediate,50597,,,Area under curve at a peroral dose of 3 mg/kg in rat,15233,A,,Rattus norvegicus,10116.0,,,
10666,Intermediate,50588,,,Area under curve at an iv dose of 1 mg/kg in dog,15233,A,,Canis lupus familiaris,9615.0,,,
10667,Intermediate,50597,,,Area under curve at an iv dose of 1 mg/kg in rat,15233,A,,Rattus norvegicus,10116.0,,,
10668,Autocuration,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,12978,A,,,,,,
10669,Autocuration,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,12978,A,,,,,,
10670,Intermediate,50594,,,Area under curve measured as conc vs time after intravenous administration to mice.,11355,A,,Mus musculus,10090.0,,,
10671,Intermediate,50594,,,Area under curve measured as conc vs time after peroral administration to mice.,11355,A,,Mus musculus,10090.0,,,
10672,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,12923,A,,Canis lupus familiaris,9615.0,,,
10673,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,12923,A,,Canis lupus familiaris,9615.0,,,
10674,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,12923,A,,Canis lupus familiaris,9615.0,,,
10675,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,12923,A,,Canis lupus familiaris,9615.0,,,
10676,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10677,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10678,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10679,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10680,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10681,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10682,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10683,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10684,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10685,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10686,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10687,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10688,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10689,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10690,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10691,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10692,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10693,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10694,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10695,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10696,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10697,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,17738,A,In vivo,Rattus norvegicus,10116.0,,,
10698,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10699,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10700,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10701,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10702,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10703,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10704,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10705,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10706,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10707,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10708,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10709,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10710,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10711,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10712,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10713,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10714,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10715,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10716,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10717,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10718,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10719,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10720,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10721,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10722,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10723,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,11195,A,In vivo,Rattus norvegicus,10116.0,,,
10724,Intermediate,50597,,,Oral bioavailability in rat,6193,A,In vivo,Rattus norvegicus,10116.0,,,
10725,Intermediate,50597,,,Oral bioavailability in rat,6803,A,In vivo,Rattus norvegicus,10116.0,,,
10726,Intermediate,50597,,,Oral bioavailability in rats at 6 mg/kg,6647,A,In vivo,Rattus norvegicus,10116.0,,,
10727,Intermediate,50597,,,Oral bioavailability in rat (dose 6 mg/kg),6647,A,In vivo,Rattus norvegicus,10116.0,,,
10728,Intermediate,50597,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,6647,A,In vivo,Rattus norvegicus,10116.0,,,
10729,Intermediate,50597,,,Oral bioavailability in rat,6640,A,In vivo,Rattus norvegicus,10116.0,,,
10730,Intermediate,50597,,,Oral bioavailability in rat,6641,A,In vivo,Rattus norvegicus,10116.0,,,
10731,Intermediate,50597,,,Oral bioavailability in rat,6641,A,In vivo,Rattus norvegicus,10116.0,,,
10732,Intermediate,50597,,,Bioavailability in rat,6642,A,In vivo,Rattus norvegicus,10116.0,,,
10733,Intermediate,50597,,,Oral bioavailability,5472,A,In vivo,Rattus norvegicus,10116.0,,,
10734,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),6141,A,In vivo,Rattus norvegicus,10116.0,,,
10735,Intermediate,50597,,,Oral bioavailability in rat,4390,A,In vivo,Rattus norvegicus,10116.0,,,
10736,Intermediate,50597,,,Oral bioavailability in rat,5472,A,In vivo,Rattus norvegicus,10116.0,,,
10737,Intermediate,50597,,,Oral bioavailability was evaluated; Not tested,5472,A,In vivo,Rattus norvegicus,10116.0,,,
10738,Intermediate,50597,,,Oral bioavailability,5438,A,In vivo,Rattus norvegicus,10116.0,,,
10739,Intermediate,50597,,,Oral bioavailability in rat by oral dosing,4883,A,In vivo,Rattus norvegicus,10116.0,,,
10740,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1908,A,In vivo,Rattus norvegicus,10116.0,,,
10741,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley),4853,A,In vivo,Rattus norvegicus,10116.0,,,
10742,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),4853,A,In vivo,Rattus norvegicus,10116.0,,,
10743,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),4853,A,In vivo,Rattus norvegicus,10116.0,,,
10744,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),4853,A,In vivo,Rattus norvegicus,10116.0,,,
10745,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),4853,A,In vivo,Rattus norvegicus,10116.0,,,
10746,Intermediate,50597,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,4853,A,In vivo,Rattus norvegicus,10116.0,,,
10747,Intermediate,50597,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,4853,A,In vivo,Rattus norvegicus,10116.0,,,
10748,Intermediate,50597,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,12873,A,In vivo,Rattus norvegicus,10116.0,,,
10749,Intermediate,50597,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,12873,A,In vivo,Rattus norvegicus,10116.0,,,
10750,Intermediate,50597,,,Oral bioavailability in rat,3169,A,In vivo,Rattus norvegicus,10116.0,,,
10751,Intermediate,50597,,,Oral bioavailability in rat,6305,A,In vivo,Rattus norvegicus,10116.0,,,
10752,Intermediate,50597,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,4762,A,In vivo,Rattus norvegicus,10116.0,,,
10753,Intermediate,50597,,,Oral bioavailability in rat,17847,A,In vivo,Rattus norvegicus,10116.0,,,
10754,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),6211,A,In vivo,Rattus norvegicus,10116.0,,,
10755,Intermediate,50597,,,Oral bioavailability in rat,6011,A,In vivo,Rattus norvegicus,10116.0,,,
10756,Intermediate,50597,,,Oral bioavailability in rat,6317,A,In vivo,Rattus norvegicus,10116.0,,,
10757,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
10758,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
10759,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
10760,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,6644,A,In vivo,Rattus norvegicus,10116.0,,,
10761,Intermediate,50597,,,Oral bioavailability (dose 20 mg/kg p.o.),6113,A,In vivo,Rattus norvegicus,10116.0,,,
10762,Intermediate,50597,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,5937,A,In vivo,Rattus norvegicus,10116.0,,,
10763,Intermediate,50597,,,Oral bioavailability in rat at 10 mg/kg of the compound,5711,A,In vivo,Rattus norvegicus,10116.0,,,
10764,Intermediate,50597,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10765,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg i.v.),17717,A,In vivo,Rattus norvegicus,10116.0,,,
10766,Intermediate,50597,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,17717,A,In vivo,Rattus norvegicus,10116.0,,,
10767,Intermediate,50597,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),17717,A,In vivo,Rattus norvegicus,10116.0,,,
10768,Intermediate,50597,,,Percent bioavailability (F) in rats after iv administration,4722,A,In vivo,Rattus norvegicus,10116.0,,,
10769,Intermediate,50597,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,4722,A,In vivo,Rattus norvegicus,10116.0,,,
10770,Intermediate,50597,,,Bioavailability in rat (dose 5 uM/kg p.o.),4353,A,In vivo,Rattus norvegicus,10116.0,,,
10771,Intermediate,50597,,,Oral bioavailability,15662,A,In vivo,Rattus norvegicus,10116.0,,,
10772,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg p.o.),4756,A,In vivo,Rattus norvegicus,10116.0,,,
10773,Intermediate,50597,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,4756,A,In vivo,Rattus norvegicus,10116.0,,,
10774,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg),3436,A,In vivo,Rattus norvegicus,10116.0,,,
10775,Intermediate,50597,,,Oral bioavailability in rat,17800,A,In vivo,Rattus norvegicus,10116.0,,,
10776,Intermediate,50597,,,Percent oral bioavailability evaluated in rat,15762,A,In vivo,Rattus norvegicus,10116.0,,,
10777,Intermediate,50597,,,Oral bioavailability in rat,5089,A,In vivo,Rattus norvegicus,10116.0,,,
10778,Intermediate,50597,,,Percent oral bioavailability in rat; Not determined,5089,A,In vivo,Rattus norvegicus,10116.0,,,
10779,Intermediate,50597,,,Oral bioavailability in rat,3185,A,In vivo,Rattus norvegicus,10116.0,,,
10780,Intermediate,50597,,,Bioavailability in rat,5145,A,In vivo,Rattus norvegicus,10116.0,,,
10781,Intermediate,50597,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),3457,A,In vivo,Rattus norvegicus,10116.0,,,
10782,Intermediate,50597,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),3457,A,In vivo,Rattus norvegicus,10116.0,,,
10783,Intermediate,50597,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,5983,A,In vivo,Rattus norvegicus,10116.0,,,
10784,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),5739,A,In vivo,Rattus norvegicus,10116.0,,,
10785,Intermediate,50597,,,Cmax at a dose of 30 mg/kg in rat,3579,A,In vivo,Rattus norvegicus,10116.0,,,
10786,Autocuration,22224,,,Cmax in monkeys at a dose of 1 mg/kg,17788,A,In vivo,Simiiformes,314293.0,,,
10787,Intermediate,50597,,,Cmax in rat,14956,A,In vivo,Rattus norvegicus,10116.0,,,
10788,Intermediate,50597,,,Cmax in rats at a dose of 1 mg/kg,17788,A,In vivo,Rattus norvegicus,10116.0,,,
10789,Intermediate,50594,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,9750,A,In vivo,Mus musculus,10090.0,,,
10790,Autocuration,22224,,,"Cmax value at a dose of 12.7 uM/kg, po",12767,A,In vivo,,,,,
10791,Autocuration,22224,,,"Cmax value at a dose of 6.3 uM/kg, iv",12767,A,In vivo,,,,,
10792,Autocuration,22224,,,"Cmax value at a dose of 7.1 uM/kg, iv",12767,A,In vivo,,,,,
10793,Autocuration,22224,,,Cmax value of compound was determined after 1 hr,12703,A,In vivo,,,,,
10794,Autocuration,22224,,,Cmax value of the compound,15778,A,In vivo,,,,,
10795,Intermediate,50597,,,Cmax value administered intraintestinal in rats.,12818,A,In vivo,Rattus norvegicus,10116.0,,,
10796,Intermediate,50597,,,Cmax value administered perorally was determined in rat; Not determined,14964,A,In vivo,Rattus norvegicus,10116.0,,,
10797,Autocuration,22224,,,Cmax value at the dose of 2.3 mg/kg,15808,A,In vivo,,,,,
10798,Autocuration,22224,,,Cmax value at the dose of 5 mg/kg,15808,A,In vivo,,,,,
10799,Autocuration,22224,,,Cmax value in the period of 8 hr after dosing. ,15778,A,In vivo,,,,,
10800,Autocuration,22224,,,Cmax value at a oral dose of 20 mg/kg; Not tested,3715,A,In vivo,,,,,
10801,Autocuration,22224,,,Cmax value at a oral dose of 20 mg/kg,3715,A,In vivo,,,,,
10802,Intermediate,50597,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1446,A,In vivo,Rattus norvegicus,10116.0,,,
10803,Intermediate,50512,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,15240,A,In vivo,Cavia porcellus,10141.0,,,
10804,Intermediate,50597,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,15240,A,In vivo,Rattus norvegicus,10116.0,,,
10805,Intermediate,50597,Plasma,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,14810,A,In vivo,Rattus norvegicus,10116.0,,,
10806,Intermediate,50594,Plasma,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,14239,A,In vivo,Mus musculus,10090.0,,,
10807,Intermediate,50588,Liver,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,12555,A,In vivo,Canis lupus familiaris,9615.0,,,
10808,Intermediate,50588,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,10754,A,In vivo,Canis lupus familiaris,9615.0,,,
10809,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,10754,A,In vivo,Mus musculus,10090.0,,,
10810,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,10754,A,In vivo,Mus musculus,10090.0,,,
10811,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,10754,A,In vivo,Mus musculus,10090.0,,,
10812,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,10754,A,In vivo,Mus musculus,10090.0,,,
10813,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,10754,A,In vivo,Mus musculus,10090.0,,,
10814,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,14600,F,In vivo,Canis lupus familiaris,9615.0,,,
10815,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,14600,F,In vivo,Canis lupus familiaris,9615.0,,,
10816,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,14600,F,In vivo,Canis lupus familiaris,9615.0,,,
10817,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs,13543,A,In vivo,Canis lupus familiaris,9615.0,,,
10818,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs,13543,A,In vivo,Canis lupus familiaris,9615.0,,,
10819,Intermediate,50597,Plasma,,Bioavailability as maximal plasma concentration in rats,13543,A,In vivo,Rattus norvegicus,10116.0,,,
10820,Autocuration,22224,Plasma,,Bioavailability as maximal plasma concentration in rats,13543,A,In vivo,Rattus norvegicus,10116.0,,,
10821,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10822,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10823,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10824,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10825,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10826,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,14600,A,In vivo,Canis lupus familiaris,9615.0,,,
10827,Intermediate,50597,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,14681,A,In vivo,Rattus norvegicus,10116.0,,,
10828,Autocuration,22224,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,15905,A,In vivo,,,,,
10829,Autocuration,22224,Plasma,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,15905,A,In vivo,,,,,
10830,Intermediate,50597,Plasma,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",13304,A,In vivo,Rattus norvegicus,10116.0,,,
10831,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,15137,A,In vivo,Rattus norvegicus,10116.0,,,
10832,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,15137,A,In vivo,Rattus norvegicus,10116.0,,,
10833,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,15137,A,In vivo,Rattus norvegicus,10116.0,,,
10834,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,15137,A,In vivo,Rattus norvegicus,10116.0,,,
10835,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,15137,A,In vivo,Rattus norvegicus,10116.0,,,
10836,Intermediate,100710,Plasma,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,14839,A,In vivo,Macaca fascicularis,9541.0,,,
10837,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10838,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10839,Intermediate,100710,Plasma,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,14839,A,In vivo,Macaca fascicularis,9541.0,,,
10840,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,8418,A,,Rattus norvegicus,10116.0,,,
10841,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,8418,A,,Rattus norvegicus,10116.0,,,
10842,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,8418,A,,Rattus norvegicus,10116.0,,,
10843,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,8418,A,,Rattus norvegicus,10116.0,,,
10844,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,8418,A,,Rattus norvegicus,10116.0,,,
10845,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,8418,A,,Rattus norvegicus,10116.0,,,
10846,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,8418,A,,Rattus norvegicus,10116.0,,,
10847,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,8418,A,,Rattus norvegicus,10116.0,,,
10848,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,8418,A,,Rattus norvegicus,10116.0,,,
10849,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,8418,A,,Rattus norvegicus,10116.0,,,
10850,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,8418,A,,Rattus norvegicus,10116.0,,,
10851,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,8418,A,,Rattus norvegicus,10116.0,,,
10852,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,8418,A,,Rattus norvegicus,10116.0,,,
10853,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,8418,A,,Rattus norvegicus,10116.0,,,
10854,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,8418,A,,Rattus norvegicus,10116.0,,,
10855,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,8418,A,,Rattus norvegicus,10116.0,,,
10856,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,8418,A,,Rattus norvegicus,10116.0,,,
10857,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,8418,A,,Rattus norvegicus,10116.0,,,
10858,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,8418,A,,Rattus norvegicus,10116.0,,,
10859,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,8418,A,,Rattus norvegicus,10116.0,,,
10860,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,8418,A,,Rattus norvegicus,10116.0,,,
10861,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,8418,A,,Rattus norvegicus,10116.0,,,
10862,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,8418,A,,Rattus norvegicus,10116.0,,,
10863,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,8418,A,,Rattus norvegicus,10116.0,,,
10864,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,8418,A,,Rattus norvegicus,10116.0,,,
10865,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,8418,A,,Rattus norvegicus,10116.0,,,
10866,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,8418,A,,Rattus norvegicus,10116.0,,,
10867,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,8418,A,,Rattus norvegicus,10116.0,,,
10868,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,8418,A,,Rattus norvegicus,10116.0,,,
10869,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,8418,A,,Rattus norvegicus,10116.0,,,
10870,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,8418,A,,Rattus norvegicus,10116.0,,,
10871,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,8418,A,,Rattus norvegicus,10116.0,,,
10872,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,8418,A,,Rattus norvegicus,10116.0,,,
10873,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,8418,A,,Rattus norvegicus,10116.0,,,
10874,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,8418,A,,Rattus norvegicus,10116.0,,,
10875,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,8418,A,,Rattus norvegicus,10116.0,,,
10876,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,8418,A,,Rattus norvegicus,10116.0,,,
10877,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,8418,A,,Rattus norvegicus,10116.0,,,
10878,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,8418,A,,Rattus norvegicus,10116.0,,,
10879,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,8418,A,,Rattus norvegicus,10116.0,,,
10880,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,8418,A,,Rattus norvegicus,10116.0,,,
10881,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,8418,A,,Rattus norvegicus,10116.0,,,
10882,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,8418,A,,Rattus norvegicus,10116.0,,,
10883,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10884,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
10885,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10886,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10887,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
10888,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10889,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
10890,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10891,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10892,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10893,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
10894,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10895,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
10896,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10897,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10898,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10899,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
10900,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10901,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
10902,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10903,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10904,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10905,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
10906,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10907,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
10908,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10909,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10910,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10911,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
10912,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
10913,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
10914,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10915,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
10916,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10917,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10918,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10919,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10920,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10921,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10922,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10923,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10924,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
10925,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10926,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
10927,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10928,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
10929,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10930,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10931,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10932,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10933,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10934,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10935,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10936,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10937,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10938,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10939,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10940,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10941,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10942,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10943,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10944,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10945,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10946,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10947,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10948,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10949,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10950,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
10951,Intermediate,50588,,,Compound was evaluated for its bioavailability in the dogs,2249,A,In vivo,Canis lupus familiaris,9615.0,,,
10952,Intermediate,50597,,,Compound was evaluated for its bioavailability in the rats,2249,A,In vivo,Rattus norvegicus,10116.0,,,
10953,Autocuration,22224,,,Compound was evaluated for oral bioavailability,17515,A,In vivo,,,,,
10954,Intermediate,50597,,,Compound was evaluated for percentage of Oral bioavailability in rats,14541,A,In vivo,Rattus norvegicus,10116.0,,,
10955,Autocuration,22224,,,Bioavailability in guinea pig,12797,A,In vivo,Cavia porcellus,10141.0,,,
10956,Intermediate,50597,,,Compound was evaluated for the oral bioavailability in rat,12797,A,In vivo,Rattus norvegicus,10116.0,,,
10957,Intermediate,50588,,,Compound was evaluated for the oral bioavailability in dog,12797,A,In vivo,Canis lupus familiaris,9615.0,,,
10958,Intermediate,50597,,,Compound was evaluated for the oral bioavailability in rat,12797,A,In vivo,Rattus norvegicus,10116.0,,,
10959,Autocuration,22224,,,Bioavailability in dog (dosed i.v.),11727,F,In vivo,Canis lupus familiaris,9615.0,,,
10960,Intermediate,50588,,,Compound was tested for in vivo bioavailability in dog,13249,A,In vivo,Canis lupus familiaris,9615.0,,,
10961,Intermediate,100712,,,Compound was tested for in vivo bioavailability in hamsters,13249,A,In vivo,Cricetinae,10026.0,,,
10962,Autocuration,22224,,,Compound was tested for in vivo bioavailability in monkey,13249,A,In vivo,Simiiformes,314293.0,,,
10963,Intermediate,50597,,,Compound was tested for in vivo bioavailability in rat,13249,A,In vivo,Rattus norvegicus,10116.0,,,
10964,Autocuration,22224,,,Oral bioavailability in mouse,9552,A,In vivo,Mus musculus,10090.0,,,
10965,Intermediate,50594,,,Compound was tested for percent of oral bioavailability in mice; 56-74,9552,A,In vivo,Mus musculus,10090.0,,,
10966,Autocuration,22224,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),14839,A,In vivo,Mus musculus,10090.0,,,
10967,Autocuration,22224,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),14839,A,In vivo,Macaca fascicularis,9541.0,,,
10968,Autocuration,22224,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),14839,A,In vivo,Macaca fascicularis,9541.0,,,
10969,Intermediate,50594,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),14839,A,In vivo,Mus musculus,10090.0,,,
10970,Intermediate,50594,,,Oral bioavailability in nude mice,14839,A,In vivo,Mus musculus,10090.0,,,
10971,Autocuration,22224,,,Bioavailability in monkey (i.d. dosing),11219,A,In vivo,Primates,9443.0,,,
10972,Autocuration,22224,,,Bioavailability in rat,9552,A,In vivo,Rattus norvegicus,10116.0,,,
10973,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,11732,A,In vivo,,,,,
10974,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,11732,A,In vivo,,,,,
10975,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",14839,A,In vivo,Macaca fascicularis,9541.0,,,
10976,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",14839,A,In vivo,Macaca fascicularis,9541.0,,,
10977,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",14839,A,In vivo,Macaca fascicularis,9541.0,,,
10978,Intermediate,100710,Plasma,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,14839,A,In vivo,Macaca fascicularis,9541.0,,,
10979,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10980,Intermediate,100710,Plasma,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,14839,A,In vivo,Macaca fascicularis,9541.0,,,
10981,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10982,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10983,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,14839,A,In vivo,Mus musculus,10090.0,,,
10984,Autocuration,22224,Plasma,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,13932,A,In vivo,,,,,
10985,Intermediate,50594,Plasma,,Cmax in mouse plasma,11637,A,In vivo,Mus musculus,10090.0,,,
10986,Autocuration,22224,Plasma,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,11637,A,In vivo,,,,,
10987,Intermediate,50597,Plasma,,Maximal plasma concentration in rat,13960,A,In vivo,Rattus norvegicus,10116.0,,,
10988,Intermediate,50597,Plasma,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,15905,A,In vivo,Rattus norvegicus,10116.0,,,
10989,Intermediate,50597,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10990,Intermediate,50597,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10991,Intermediate,50597,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10992,Intermediate,50597,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10993,Intermediate,50597,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10994,Intermediate,50597,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
10995,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,15011,A,In vivo,Mus musculus,10090.0,,,
10996,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,15011,A,In vivo,Mus musculus,10090.0,,,
10997,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),15011,A,In vivo,Mus musculus,10090.0,,,
10998,Intermediate,50594,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,15011,A,In vivo,Mus musculus,10090.0,,,
10999,Intermediate,50594,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,15011,A,In vivo,Mus musculus,10090.0,,,
11000,Autocuration,22224,,,Maximum Concentration of the compound.,10291,A,In vivo,,,,,
11001,Intermediate,50588,,,Maximum Concentration was measured after iv administration into Beagle dog,14599,A,In vivo,Canis lupus familiaris,9615.0,,,
11002,Intermediate,50588,,,Maximum Concentration was measured after iv administration into Beagle dog.,14599,A,In vivo,Canis lupus familiaris,9615.0,,,
11003,Intermediate,50588,,,Maximum Concentration was measured after po administration into Beagle dog,14599,A,In vivo,Canis lupus familiaris,9615.0,,,
11004,Intermediate,50588,,,Maximum Concentration was measured after po administration into Beagle dog.,14599,A,In vivo,Canis lupus familiaris,9615.0,,,
11005,Autocuration,22224,Blood,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,12767,A,In vivo,,,,,
11006,Autocuration,22224,Blood,,Maximum blood level reached after an iv dose of 12.2 uM/kg,12767,A,In vivo,,,,,
11007,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,12767,A,In vivo,,,,,
11008,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,12767,A,In vivo,,,,,
11009,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose of 5.0 mg/kg,12767,A,In vivo,,,,,
11010,Autocuration,22224,Blood,,Maximum blood level reached at dose of 10.6 uM/kg orally,12767,A,In vivo,,,,,
11011,Intermediate,50512,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,14706,A,In vivo,Cavia porcellus,10141.0,,,
11012,Intermediate,50512,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,14706,A,In vivo,Cavia porcellus,10141.0,,,
11013,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11014,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11015,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11016,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11017,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11018,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11019,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11020,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
11021,Intermediate,50278,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),10524,A,In vivo,Bacillus subtilis,1423.0,,,
11022,Autocuration,22224,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,11871,A,In vivo,Simiiformes,314293.0,,,
11023,Intermediate,50597,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,11871,A,In vivo,Rattus norvegicus,10116.0,,,
11024,Autocuration,22224,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,3437,A,In vivo,,,,,
11025,Intermediate,50594,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,12038,A,In vivo,Mus musculus,10090.0,,,
11026,Intermediate,50597,,,Maximum concentration in male rats after iv administration of 20 mg/kg,12038,A,In vivo,Rattus norvegicus,10116.0,,,
11027,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,8418,A,,Rattus norvegicus,10116.0,,,
11028,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,8418,A,,Rattus norvegicus,10116.0,,,
11029,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,8418,A,,Rattus norvegicus,10116.0,,,
11030,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,8418,A,,Rattus norvegicus,10116.0,,,
11031,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,8418,A,,Rattus norvegicus,10116.0,,,
11032,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,8418,A,,Rattus norvegicus,10116.0,,,
11033,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,8418,A,,Rattus norvegicus,10116.0,,,
11034,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,8418,A,,Rattus norvegicus,10116.0,,,
11035,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,8418,A,,Rattus norvegicus,10116.0,,,
11036,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,8418,A,,Rattus norvegicus,10116.0,,,
11037,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,8418,A,,Rattus norvegicus,10116.0,,,
11038,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,8418,A,,Rattus norvegicus,10116.0,,,
11039,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,8418,A,,Rattus norvegicus,10116.0,,,
11040,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,8418,A,,Rattus norvegicus,10116.0,,,
11041,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,8418,A,,Rattus norvegicus,10116.0,,,
11042,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,8418,A,,Rattus norvegicus,10116.0,,,
11043,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,8418,A,,Rattus norvegicus,10116.0,,,
11044,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,8418,A,,Rattus norvegicus,10116.0,,,
11045,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,8418,A,,Rattus norvegicus,10116.0,,,
11046,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,8418,A,,Rattus norvegicus,10116.0,,,
11047,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,8418,A,,Rattus norvegicus,10116.0,,,
11048,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,8418,A,,Rattus norvegicus,10116.0,,,
11049,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,8418,A,,Rattus norvegicus,10116.0,,,
11050,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,8418,A,,Rattus norvegicus,10116.0,,,
11051,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,8418,A,,Rattus norvegicus,10116.0,,,
11052,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,8418,A,,Rattus norvegicus,10116.0,,,
11053,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,8418,A,,Rattus norvegicus,10116.0,,,
11054,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,8418,A,,Rattus norvegicus,10116.0,,,
11055,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,8418,A,,Rattus norvegicus,10116.0,,,
11056,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,8418,A,,Rattus norvegicus,10116.0,,,
11057,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,8418,A,,Rattus norvegicus,10116.0,,,
11058,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,8418,A,,Rattus norvegicus,10116.0,,,
11059,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,8418,A,,Rattus norvegicus,10116.0,,,
11060,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11061,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11062,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11063,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11064,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11065,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11066,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11067,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11068,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11069,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11070,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11071,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
11072,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11073,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11074,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
11075,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11076,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
11077,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11078,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11079,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11080,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
11081,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11082,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
11083,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11084,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
11085,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11086,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11087,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11088,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
11089,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11090,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11091,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
11092,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11093,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
11094,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11095,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11096,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11097,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
11098,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
11099,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
11100,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11101,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
11102,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11103,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11104,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11105,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11106,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11107,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11108,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11109,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11110,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
11111,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11112,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
11113,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11114,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11115,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,11732,A,In vivo,,,,,
11116,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,11732,A,In vivo,,,,,
11117,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,11732,A,In vivo,,,,,
11118,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,11732,A,In vivo,,,,,
11119,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,11732,A,In vivo,,,,,
11120,Autocuration,22224,,,Oral bioavailability in rat (dose 10 mg/kg),13359,A,In vivo,Rattus norvegicus,10116.0,,,
11121,Autocuration,22224,,,Oral bioavailability in rat (Sprague-Dawley),16618,A,In vivo,Rattus norvegicus,10116.0,,,
11122,Autocuration,22224,,,Oral bioavailability in rat,13960,A,In vivo,Rattus norvegicus,10116.0,,,
11123,Autocuration,22224,,,Oral bioavailability in rats was determined in vivo,13917,A,In vivo,Rattus norvegicus,10116.0,,,
11124,Autocuration,22224,,,Oral bioavailability in dog,14266,A,In vivo,Canis lupus familiaris,9615.0,,,
11125,Autocuration,22224,,,Oral bioavailability of compound in monkey,12359,A,In vivo,Simiiformes,314293.0,,,
11126,Intermediate,50597,,,Oral bioavailability of compound in rat,12359,A,In vivo,Rattus norvegicus,10116.0,,,
11127,Autocuration,22224,,,Bioavailability in rat of PMEA prodrug,12359,A,In vivo,Rattus norvegicus,10116.0,,,
11128,Intermediate,50597,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,12359,A,In vivo,Rattus norvegicus,10116.0,,,
11129,Autocuration,22224,,,Serum conc at 3 hours following 25 mg/kg dose,10791,A,In vivo,Macaca mulatta,9544.0,,,
11130,Autocuration,22224,Urine,,Urine conc 0-5 hours following 25 mg/kg dose,10791,A,In vivo,Macaca mulatta,9544.0,,,
11131,Autocuration,22224,Urine,,Urine conc 0-24 hours following 25 mg/kg dose,10791,A,In vivo,Macaca mulatta,9544.0,,,
11132,Autocuration,22224,,,Oral bioavailability in African green monkeys; 20-25,138,A,In vivo,Chlorocebus aethiops,9534.0,,,
11133,Intermediate,100710,,,Oral bioavailability in cynomolgus monkey.,14521,A,In vivo,Macaca fascicularis,9541.0,,,
11134,Autocuration,22224,,,Oral bioavailability in dog,13953,A,In vivo,Canis lupus familiaris,9615.0,,,
11135,Intermediate,50588,,,Oral bioavailability in dog at 10 mg/kg oral dose,12836,A,In vivo,Canis lupus familiaris,9615.0,,,
11136,Intermediate,100712,,,Oral bioavailability in hamster at 10 mg/kg oral dose,12836,A,In vivo,Cricetinae,10026.0,,,
11137,Intermediate,50597,,,Oral bioavailability in rat at 10 mg/kg oral dose,12836,A,In vivo,Rattus norvegicus,10116.0,,,
11138,Autocuration,22224,,,Oral bioavailability in rat,14521,A,In vivo,Rattus norvegicus,10116.0,,,
11139,Autocuration,22224,,,Oral bioavailability in rat,13953,A,In vivo,Rattus norvegicus,10116.0,,,
11140,Autocuration,22224,,,Oral bioavailability,6799,A,In vivo,Eutheria,9347.0,,,
11141,Autocuration,22224,,,Oral bioavailability was determined; range 49-102%,11311,A,In vivo,,,,,
11142,Intermediate,50588,,,Oral bioavailability was determined in dogs,4013,A,In vivo,Canis lupus familiaris,9615.0,,,
11143,Autocuration,22224,,,Oral bioavailability in rat,4013,A,In vivo,Rattus norvegicus,10116.0,,,
11144,Autocuration,22224,,,Oral bioavailability,17591,A,In vivo,Eutheria,9347.0,,,
11145,Autocuration,22224,,,Oral bioavailability was determined; Not orally available,17591,A,In vivo,,,,,
11146,Intermediate,50594,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),15011,A,In vivo,Mus musculus,10090.0,,,
11147,Autocuration,22224,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),15011,A,In vivo,Mus musculus,10090.0,,,
11148,Autocuration,22224,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,15011,A,In vivo,Mus musculus,10090.0,,,
11149,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,9552,A,In vivo,Macaca mulatta,9544.0,,,
11150,Autocuration,22224,,,Oral bioavailability in dog (female mongrel),9552,A,In vivo,Canis lupus familiaris,9615.0,,,
11151,Autocuration,22224,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,3639,A,In vivo,,,,,
11152,Autocuration,22224,,,Oral bioavailability in dog,13397,A,In vivo,Canis lupus familiaris,9615.0,,,
11153,Autocuration,22224,,,Percentage Bioavailability was evaluated.,3031,A,In vivo,,,,,
11154,Autocuration,22224,,,Bioavailability in rat administered i.d.,12818,A,In vivo,Rattus norvegicus,10116.0,,,
11155,Autocuration,22224,,,Bioavailability,4847,A,In vivo,Eutheria,9347.0,,,
11156,Autocuration,22224,,,Bioavailability in dog (male Beagle) i.v. administration,12421,A,In vivo,Canis lupus familiaris,9615.0,,,
11157,Autocuration,22224,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",11966,A,In vivo,Rattus norvegicus,10116.0,,,
11158,Autocuration,22224,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),11218,A,In vivo,Primates,9443.0,,,
11159,Autocuration,22224,,,Oral bioavailability in rat (Sprague-Dawley) (male),13129,A,In vivo,Rattus norvegicus,10116.0,,,
11160,Intermediate,50597,,,The oral bioavailability was measured on rats after oral administration,12350,A,In vivo,Rattus norvegicus,10116.0,,,
11161,Intermediate,50597,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,2231,A,In vivo,Rattus norvegicus,10116.0,,,
11162,Intermediate,50797,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,2231,A,In vivo,Macaca mulatta,9544.0,,,
11163,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg i.d.),12187,A,In vivo,Rattus norvegicus,10116.0,,,
11164,Autocuration,22224,,,Bioavailability in dog (male Beagle) i.v. administration,12421,A,In vivo,Canis lupus familiaris,9615.0,,,
11165,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11166,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11167,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11168,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11169,Intermediate,50597,Plasma,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,2231,A,In vivo,Rattus norvegicus,10116.0,,,
11170,Intermediate,50797,Plasma,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,2231,A,In vivo,Macaca mulatta,9544.0,,,
11171,Intermediate,50597,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),12178,A,In vivo,Rattus norvegicus,10116.0,,,
11172,Autocuration,22224,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),12178,A,In vivo,,,,,
11173,Autocuration,22224,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),12178,A,In vivo,,,,,
11174,Expert,50597,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,15633,A,In vivo,Rattus norvegicus,10116.0,,,
11175,Intermediate,50597,Plasma,,Maximum concentration of compound in plasma administered orally to rats,14258,A,In vivo,Rattus norvegicus,10116.0,,,
11176,Intermediate,50588,Plasma,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",14224,A,In vivo,Canis lupus familiaris,9615.0,,,
11177,Intermediate,50588,Plasma,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",14224,A,In vivo,Canis lupus familiaris,9615.0,,,
11178,Intermediate,50588,Plasma,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",14224,A,In vivo,Canis lupus familiaris,9615.0,,,
11179,Autocuration,22224,,,Maximum concentration after 10 mg/kg by oral administration,5566,A,In vivo,,,,,
11180,Autocuration,22224,,,Maximum concentration at a dose of 1.5 mg/kg,16935,A,In vivo,,,,,
11181,Autocuration,22224,,,Maximum concentration at a dose of 2.0 mg/kg,16935,A,In vivo,,,,,
11182,Intermediate,50588,Plasma,,Maximum concentration in dog plasma,14224,A,In vivo,Canis lupus familiaris,9615.0,,,
11183,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,12536,A,In vivo,,,,,
11184,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,12536,A,In vivo,,,,,
11185,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,12536,A,In vivo,,,,,
11186,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,12536,A,In vivo,,,,,
11187,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,12536,A,In vivo,,,,,
11188,Intermediate,50588,Plasma,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),9994,A,In vivo,Canis lupus familiaris,9615.0,,,
11189,Autocuration,22224,Plasma,,Maximum concentration in plasma at Tmax,1434,A,In vivo,,,,,
11190,Expert,50588,Plasma,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,12836,A,In vivo,Canis lupus familiaris,9615.0,,,
11191,Intermediate,100712,Plasma,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,12836,A,In vivo,Cricetinae,10026.0,,,
11192,Intermediate,50597,Plasma,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,12836,A,In vivo,Rattus norvegicus,10116.0,,,
11193,Intermediate,50597,Plasma,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,12545,A,In vivo,Rattus norvegicus,10116.0,,,
11194,Intermediate,50592,Plasma,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,13856,A,In vivo,Oryctolagus cuniculus,9986.0,,,
11195,Autocuration,22224,,,Maximum concentration was calculated,3550,A,In vivo,,,,,
11196,Autocuration,22224,,,Maximum concentration was calculated.,2632,A,In vivo,,,,,
11197,Autocuration,22224,,,Maximum concentration at a peroral dose of 10 mg/kg,5566,A,In vivo,,,,,
11198,Autocuration,22224,,,Maximum concentration of the drug at 10 uM/dg administered perorally,11883,A,In vivo,,,,,
11199,Autocuration,22224,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,11883,A,In vivo,,,,,
11200,Intermediate,50588,Plasma,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",14122,A,In vivo,Canis lupus familiaris,9615.0,,,
11201,Intermediate,100712,Plasma,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",14122,A,In vivo,Cricetinae,10026.0,,,
11202,Intermediate,50597,Plasma,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",14122,A,In vivo,Rattus norvegicus,10116.0,,,
11203,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,12542,A,In vivo,Rattus norvegicus,10116.0,,,
11204,Intermediate,50588,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,12542,A,In vivo,Canis lupus familiaris,9615.0,,,
11205,Intermediate,100712,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,12542,A,In vivo,Cricetinae,10026.0,,,
11206,Intermediate,100712,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,12542,A,In vivo,Cricetinae,10026.0,,,
11207,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,12542,A,In vivo,Rattus norvegicus,10116.0,,,
11208,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,14080,A,In vivo,Rattus norvegicus,10116.0,,,
11209,Intermediate,50597,,,Maximum concentration reached following intravenous administration in male rat,11911,A,In vivo,Rattus norvegicus,10116.0,,,
11210,Intermediate,50588,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,13204,A,In vivo,Canis lupus familiaris,9615.0,,,
11211,Intermediate,50597,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,13204,A,In vivo,Rattus norvegicus,10116.0,,,
11212,Intermediate,50588,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,14346,A,In vivo,Canis lupus familiaris,9615.0,,,
11213,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
11214,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
11215,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
11216,Intermediate,50597,,,Maximum drug concentration is determined after oral dosing in rats.,14127,A,In vivo,Rattus norvegicus,10116.0,,,
11217,Intermediate,50588,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,14339,A,In vivo,Canis lupus familiaris,9615.0,,,
11218,Intermediate,50588,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,14339,A,In vivo,Canis lupus familiaris,9615.0,,,
11219,Autocuration,22224,Plasma,,Maximum plasma concentration,13494,A,In vivo,,,,,
11220,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,14925,A,In vivo,Rattus norvegicus,10116.0,,,
11221,Intermediate,50597,Plasma,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,14474,A,In vivo,Rattus norvegicus,10116.0,,,
11222,Intermediate,50588,Plasma,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,14474,A,In vivo,Canis lupus familiaris,9615.0,,,
11223,Autocuration,22224,Plasma,,Maximum plasma concentration following oral administration of 30 umol/kg,13917,A,In vivo,,,,,
11224,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,9796,A,,Rattus norvegicus,10116.0,,,
11225,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11226,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11227,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11228,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11229,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11230,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11231,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11232,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11233,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,9796,A,,Rattus norvegicus,10116.0,,,
11234,Intermediate,50597,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11235,Intermediate,50597,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11236,Intermediate,50597,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11237,Intermediate,50597,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11238,Intermediate,50597,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11239,Intermediate,50597,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11240,Intermediate,50597,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11241,Intermediate,50597,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11242,Intermediate,50597,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11243,Intermediate,50597,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11244,Intermediate,50597,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),8363,A,,Rattus norvegicus,10116.0,,,
11245,Intermediate,50597,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),8363,A,,Rattus norvegicus,10116.0,,,
11246,Intermediate,50597,Blood,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11247,Intermediate,50597,Blood,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11248,Intermediate,50597,Blood,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11249,Intermediate,50597,Blood,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11250,Intermediate,50597,Blood,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11251,Intermediate,50597,Blood,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11252,Intermediate,50597,Blood,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11253,Intermediate,50597,Blood,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11254,Intermediate,50597,Brain,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11255,Intermediate,50597,Brain,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11256,Intermediate,50597,Brain,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11257,Intermediate,50597,Brain,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11258,Intermediate,50597,Brain,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11259,Intermediate,50597,Brain,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11260,Intermediate,50597,Brain,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11261,Intermediate,50597,Brain,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11262,Intermediate,50597,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11263,Intermediate,50597,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11264,Intermediate,50597,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11265,Intermediate,50597,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11266,Intermediate,50597,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11267,Intermediate,50597,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11268,Intermediate,50597,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11269,Intermediate,50597,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11270,Intermediate,50597,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11271,Intermediate,50597,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11272,Intermediate,50597,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11273,Intermediate,50597,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11274,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11275,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
11276,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11277,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11278,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
11279,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
11280,Intermediate,50212,,,Observed diffusion coefficient in organic solvent for Escherichia coli,15599,A,,Escherichia coli,562.0,,,
11281,Intermediate,50597,Blood,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11282,Intermediate,50597,Blood,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11283,Intermediate,50597,Cardiac atrium,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11284,Intermediate,50597,Cardiac atrium,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11285,Intermediate,50597,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11286,Intermediate,50597,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11287,Intermediate,50597,Liver,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11288,Intermediate,50597,Liver,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11289,Intermediate,50597,Cardiac atrium,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11290,Intermediate,50597,Cardiac atrium,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11291,Intermediate,50597,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11292,Intermediate,50597,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11293,Intermediate,50597,Spleen,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",9614,A,,Rattus norvegicus,10116.0,,,
11294,Intermediate,50597,Spleen,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",9614,A,,Rattus norvegicus,10116.0,,,
11295,Intermediate,50597,Blood,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11296,Intermediate,50597,Blood,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11297,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11298,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,9071,A,,Rattus norvegicus,10116.0,,,
11299,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11300,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11301,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11302,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11303,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11304,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11305,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,9071,A,,Rattus norvegicus,10116.0,,,
11306,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11307,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11308,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,9071,A,,Rattus norvegicus,10116.0,,,
11309,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,9071,A,,Rattus norvegicus,10116.0,,,
11310,Autocuration,22224,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",10677,A,,,,,,
11311,Intermediate,50594,Urine,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,9750,A,,Mus musculus,10090.0,,,
11312,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11313,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11314,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11315,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11316,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11317,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11318,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11319,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11320,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11321,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11322,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11323,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11324,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11325,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11326,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11327,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11328,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11329,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11330,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11331,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11332,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11333,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11334,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11335,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11336,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11337,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11338,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11339,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11340,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11341,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11342,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11343,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),13256,A,In vivo,Mus musculus,10090.0,,,
11344,Intermediate,50597,Blood,,Biodistribution in Rat blood after 24 hours of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11345,Intermediate,50597,Blood,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11346,Intermediate,50597,Blood,,Biodistribution in Rat blood after 30 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11347,Intermediate,50597,Blood,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11348,Intermediate,50597,Blood,,Biodistribution in Rat blood after 5 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11349,Intermediate,50597,Blood,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11350,Intermediate,50597,Heart,,Biodistribution in Rat heart after 24 hours of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11351,Intermediate,50597,Heart,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11352,Intermediate,50597,Heart,,Biodistribution in Rat heart after 30 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11353,Intermediate,50597,Heart,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11354,Intermediate,50597,Heart,,Biodistribution in Rat heart after 5 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11355,Intermediate,50597,Heart,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11356,Intermediate,50597,Liver,,Biodistribution in Rat liver after 24 hours of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11357,Intermediate,50597,Liver,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11358,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11359,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11360,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11361,Intermediate,50588,Plasma,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,13249,A,In vivo,Canis lupus familiaris,9615.0,,,
11362,Intermediate,100710,,,Cmax in cynomolgus monkey (PO dose),13622,A,In vivo,Macaca fascicularis,9541.0,,,
11363,Intermediate,50597,,,Cmax in rat (PO dose),13622,A,In vivo,Rattus norvegicus,10116.0,,,
11364,Intermediate,50597,,,Cmax in rat (PO dose),13622,A,In vivo,Rattus norvegicus,10116.0,,,
11365,Intermediate,50597,Plasma,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,13494,A,In vivo,Rattus norvegicus,10116.0,,,
11366,Intermediate,50597,Plasma,,Cmax in rat plasma after oral dose (10 mg/kg),12170,A,In vivo,Rattus norvegicus,10116.0,,,
11367,Autocuration,22224,Plasma,,Cmax in plasma after oral dose (10 mg/kg),12170,A,In vivo,,,,,
11368,Intermediate,50588,Plasma,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,17025,A,In vivo,Canis lupus familiaris,9615.0,,,
11369,Autocuration,22224,Plasma,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,17025,A,In vivo,Simiiformes,314293.0,,,
11370,Intermediate,50592,Plasma,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,17025,A,In vivo,Oryctolagus cuniculus,9986.0,,,
11371,Intermediate,50597,Plasma,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,17025,A,In vivo,Rattus norvegicus,10116.0,,,
11372,Intermediate,50597,Plasma,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,14187,A,In vivo,Rattus norvegicus,10116.0,,,
11373,Intermediate,50594,Plasma,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,14816,A,In vivo,Mus musculus,10090.0,,,
11374,Intermediate,50597,Plasma,,Maximum plasma concentration after oral dosing in rat,17820,A,In vivo,Rattus norvegicus,10116.0,,,
11375,Autocuration,22224,Plasma,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11376,Autocuration,22224,Plasma,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11377,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,14691,A,In vivo,Canis lupus familiaris,9615.0,,,
11378,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,14691,A,In vivo,Canis lupus familiaris,9615.0,,,
11379,Intermediate,50597,Plasma,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,13375,A,In vivo,Rattus norvegicus,10116.0,,,
11380,Autocuration,22224,Plasma,,Maximum plasma concentration was determined,6236,A,In vivo,,,,,
11381,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11382,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11383,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11384,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11385,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11386,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11387,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11388,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,14380,A,In vivo,,,,,
11389,Intermediate,50597,Plasma,,Plasma Cmax in rat (PO dose),13622,A,In vivo,Rattus norvegicus,10116.0,,,
11390,Intermediate,50597,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
11391,Intermediate,50597,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
11392,Intermediate,50597,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
11393,Intermediate,50597,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
11394,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,14925,A,In vivo,Canis lupus familiaris,9615.0,,,
11395,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,14925,A,In vivo,Canis lupus familiaris,9615.0,,,
11396,Autocuration,22224,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,11883,A,In vivo,,,,,
11397,Autocuration,22224,,,Maximum concentration of the drug at 20 uM/dg administered perorally,11883,A,In vivo,,,,,
11398,Autocuration,22224,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,13391,A,In vivo,,,,,
11399,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,13391,A,In vivo,,,,,
11400,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,13391,A,In vivo,,,,,
11401,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,13391,A,In vivo,,,,,
11402,Intermediate,50597,Plasma,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,16360,A,In vivo,Rattus norvegicus,10116.0,,,
11403,Intermediate,50588,Plasma,,Cmax in dog plasma after 1mg/kg oral dose,3673,A,In vivo,Canis lupus familiaris,9615.0,,,
11404,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,14431,A,In vivo,Canis lupus familiaris,9615.0,,,
11405,Intermediate,50597,Plasma,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,14431,A,In vivo,Rattus norvegicus,10116.0,,,
11406,Intermediate,50597,,,Oral maximum concentration in rat,14964,A,In vivo,Rattus norvegicus,10116.0,,,
11407,Intermediate,50597,,,Oral maximum concentration in rat,14964,A,In vivo,Rattus norvegicus,10116.0,,,
11408,Intermediate,50594,Plasma,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,14209,A,In vivo,Mus musculus,10090.0,,,
11409,Intermediate,50594,Blood,,Peak concentration in blood after intravenous administration to mice,11355,A,In vivo,Mus musculus,10090.0,,,
11410,Intermediate,50594,Blood,,Peak concentration in blood after peroral administration to mice,11355,A,In vivo,Mus musculus,10090.0,,,
11411,Intermediate,50597,Plasma,,Peak concentration in rat plasma was determined,11966,A,In vivo,Rattus norvegicus,10116.0,,,
11412,Autocuration,22224,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,8918,A,In vivo,Simiiformes,314293.0,,,
11413,Intermediate,50594,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,8918,A,In vivo,Mus musculus,10090.0,,,
11414,Intermediate,50597,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,8918,A,In vivo,Rattus norvegicus,10116.0,,,
11415,Intermediate,50597,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11416,Intermediate,50597,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11417,Intermediate,50597,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11418,Intermediate,50597,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11419,Intermediate,50597,Intestine,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11420,Intermediate,50597,Intestine,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11421,Intermediate,50597,Intestine,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11422,Intermediate,50597,Intestine,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11423,Intermediate,50597,Intestine,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11424,Intermediate,50597,Intestine,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11425,Intermediate,50597,Intestine,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11426,Intermediate,50597,Intestine,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11427,Intermediate,50597,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11428,Intermediate,50597,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11429,Intermediate,50597,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11430,Intermediate,50597,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11431,Intermediate,50597,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11432,Intermediate,50597,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11433,Intermediate,50597,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11434,Intermediate,50597,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11435,Intermediate,50597,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11436,Intermediate,50597,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11437,Intermediate,50597,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11438,Intermediate,50597,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11439,Intermediate,50597,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11440,Intermediate,50597,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11441,Intermediate,50597,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11442,Intermediate,50597,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11443,Intermediate,50597,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11444,Intermediate,50597,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11445,Intermediate,50597,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11446,Intermediate,50597,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11447,Intermediate,50597,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11448,Intermediate,50597,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11449,Intermediate,50597,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11450,Intermediate,50597,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11451,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11452,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11453,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11454,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11455,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11456,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11457,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11458,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11459,Intermediate,50597,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11460,Intermediate,50597,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11461,Intermediate,50597,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11462,Intermediate,50597,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11463,Intermediate,50597,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11464,Intermediate,50597,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11465,Intermediate,50597,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11466,Intermediate,50597,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11467,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11468,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11469,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11470,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11471,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11472,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11473,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11474,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11475,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11476,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11477,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11478,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11479,Intermediate,50594,Urine,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,14571,A,,Mus musculus,10090.0,,,
11480,Intermediate,50597,Urine,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,14571,A,,Rattus norvegicus,10116.0,,,
11481,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11482,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11483,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11484,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11485,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11486,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11487,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11488,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11489,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11490,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11491,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11492,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11493,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11494,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11495,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11496,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11497,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11498,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,8319,A,,Rattus norvegicus,10116.0,,,
11499,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11500,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,8319,A,,Rattus norvegicus,10116.0,,,
11501,Intermediate,50597,Urine,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11502,Intermediate,50597,Urine,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11503,Intermediate,50597,Urine,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11504,Intermediate,50597,Urine,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,12038,A,,Rattus norvegicus,10116.0,,,
11505,Autocuration,22224,,,% dose converted to 2-amino-5-chlorophenyl sulfate,14314,A,,,,,,
11506,Autocuration,22224,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),14314,A,,,,,,
11507,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",11488,A,,Rattus norvegicus,10116.0,,,
11508,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",11488,A,,Rattus norvegicus,10116.0,,,
11509,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",11488,A,,Rattus norvegicus,10116.0,,,
11510,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",11488,A,,Rattus norvegicus,10116.0,,,
11511,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11512,Intermediate,50597,Liver,,Biodistribution in Rat liver after 5 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11513,Intermediate,50597,Liver,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11514,Intermediate,50597,Lung,,Biodistribution in Rat lung after 24 hours of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11515,Intermediate,50597,Lung,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11516,Intermediate,50597,Lung,,Biodistribution in Rat lung after 30 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11517,Intermediate,50597,Lung,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11518,Intermediate,50597,Lung,,Biodistribution in Rat lung after 5 minutes of iv administration,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11519,Intermediate,50597,Lung,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,8829,A,In vivo,Rattus norvegicus,10116.0,,,
11520,Intermediate,50597,Cerebellum,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",14972,A,In vivo,Rattus norvegicus,10116.0,,,
11521,Intermediate,50597,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",14972,A,In vivo,Rattus norvegicus,10116.0,,,
11522,Intermediate,50597,Thalamus,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",14972,A,In vivo,Rattus norvegicus,10116.0,,,
11523,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11524,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11525,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11526,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,,,,,
11527,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,,,,,
11528,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,,,,,
11529,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11530,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11531,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11532,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11533,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11534,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11535,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11536,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11537,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11538,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11539,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11540,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11541,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11542,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11543,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11544,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11545,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11546,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11547,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11548,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11549,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11550,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11551,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11552,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11553,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11554,Autocuration,22224,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,8918,A,In vivo,Simiiformes,314293.0,,,
11555,Intermediate,50594,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,8918,A,In vivo,Mus musculus,10090.0,,,
11556,Intermediate,50597,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,8918,A,In vivo,Rattus norvegicus,10116.0,,,
11557,Intermediate,50588,Plasma,,Peak plasma concentration was measured in dogs,14470,A,In vivo,Canis lupus familiaris,9615.0,,,
11558,Intermediate,50597,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,In vivo,Rattus norvegicus,10116.0,,,
11559,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
11560,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
11561,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
11562,Intermediate,50597,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,In vivo,Rattus norvegicus,10116.0,,,
11563,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11564,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,13465,A,In vivo,Simiiformes,314293.0,,,
11565,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11566,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11567,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,13465,A,In vivo,Rattus norvegicus,10116.0,,,
11568,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,13465,A,In vivo,Rattus norvegicus,10116.0,,,
11569,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11570,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,13465,A,In vivo,Rattus norvegicus,10116.0,,,
11571,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,13465,A,In vivo,Rattus norvegicus,10116.0,,,
11572,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11573,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,13465,A,In vivo,Canis lupus familiaris,9615.0,,,
11574,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,13465,A,In vivo,Simiiformes,314293.0,,,
11575,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,13465,A,In vivo,Simiiformes,314293.0,,,
11576,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,13465,A,In vivo,Rattus norvegicus,10116.0,,,
11577,Intermediate,100710,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,14731,A,In vivo,Macaca fascicularis,9541.0,,,
11578,Intermediate,50594,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,14731,A,In vivo,Mus musculus,10090.0,,,
11579,Intermediate,50588,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,13376,A,In vivo,Canis lupus familiaris,9615.0,,,
11580,Intermediate,50588,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,13376,A,In vivo,Canis lupus familiaris,9615.0,,,
11581,Intermediate,50597,,,Maximum concentration (Cmax) in rat when administered orally,14443,A,In vivo,Rattus norvegicus,10116.0,,,
11582,Autocuration,22224,Plasma,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,13465,A,In vivo,Simiiformes,314293.0,,,
11583,Autocuration,22224,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",16359,A,In vivo,Rattus norvegicus,10116.0,,,
11584,Autocuration,22224,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",16359,A,In vivo,Rattus norvegicus,10116.0,,,
11585,Autocuration,22224,Plasma,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,15618,A,In vivo,,,,,
11586,Intermediate,50597,,,Pharmacokinetic profile Cmax was evaluated in rats,14554,A,In vivo,Rattus norvegicus,10116.0,,,
11587,Intermediate,50588,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),11537,A,In vivo,Canis lupus familiaris,9615.0,,,
11588,Intermediate,50594,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),11537,A,In vivo,Mus musculus,10090.0,,,
11589,Intermediate,50588,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),11537,A,In vivo,Canis lupus familiaris,9615.0,,,
11590,Intermediate,50594,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),11537,A,In vivo,Mus musculus,10090.0,,,
11591,Autocuration,22224,Plasma,,Cmax in rat plasma,2021,A,In vivo,Rattus norvegicus,10116.0,,,
11592,Intermediate,50588,Plasma,,Cmax in dog plasma after 30mg/kg oral dose,5932,A,In vivo,Canis lupus familiaris,9615.0,,,
11593,Intermediate,50597,Plasma,,Cmax in rat plasma after 30mg/kg oral dose,5932,A,In vivo,Rattus norvegicus,10116.0,,,
11594,Intermediate,50597,Plasma,,Plasma level in rats at 30 mg/kg,17320,A,In vivo,Rattus norvegicus,10116.0,,,
11595,Intermediate,50594,Plasma,,Tested for maximum plasma concentration in mice,15831,A,In vivo,Mus musculus,10090.0,,,
11596,Intermediate,50597,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,In vivo,Rattus norvegicus,10116.0,,,
11597,Intermediate,50597,,,The Cmax values in female wistar rats.,14941,A,In vivo,Rattus norvegicus,10116.0,,,
11598,Intermediate,50588,Plasma,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,15343,A,In vivo,Canis lupus familiaris,9615.0,,,
11599,Intermediate,50597,Plasma,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,15343,A,In vivo,Rattus norvegicus,10116.0,,,
11600,Intermediate,50597,Plasma,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,14856,A,In vivo,Rattus norvegicus,10116.0,,,
11601,Intermediate,50597,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,13129,A,In vivo,Rattus norvegicus,10116.0,,,
11602,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,13098,A,In vivo,Rattus norvegicus,10116.0,,,
11603,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,13098,A,In vivo,Rattus norvegicus,10116.0,,,
11604,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,13098,A,In vivo,Rattus norvegicus,10116.0,,,
11605,Autocuration,22224,Blood,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,15478,A,In vivo,Mus musculus,10090.0,,,
11606,Intermediate,50588,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,15341,A,In vivo,Canis lupus familiaris,9615.0,,,
11607,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
11608,Intermediate,50597,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11609,Intermediate,50597,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11610,Intermediate,50597,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11611,Intermediate,50597,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11612,Intermediate,50597,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11613,Intermediate,50597,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11614,Intermediate,50597,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11615,Intermediate,50597,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11616,Intermediate,50597,Spleen,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11617,Intermediate,50597,Spleen,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11618,Intermediate,50597,Spleen,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11619,Intermediate,50597,Spleen,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11620,Intermediate,50597,Spleen,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11621,Intermediate,50597,Spleen,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11622,Intermediate,50597,Spleen,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11623,Intermediate,50597,Spleen,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11624,Intermediate,50597,Uterus,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11625,Intermediate,50597,Uterus,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11626,Intermediate,50597,Uterus,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11627,Intermediate,50597,Uterus,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11628,Intermediate,50597,Uterus,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11629,Intermediate,50597,Uterus,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11630,Intermediate,50597,Uterus,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11631,Intermediate,50597,Uterus,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",8684,A,,Rattus norvegicus,10116.0,,,
11632,Autocuration,22224,,,Distribution in the blood after 120 min of intravenous administration,8926,A,,,,,,
11633,Autocuration,22224,,,Distribution in the blood after 15 min of intravenous administration,8926,A,,,,,,
11634,Autocuration,22224,,,Distribution in the blood after 30 min of intravenous administration,8926,A,,,,,,
11635,Autocuration,22224,,,Distribution in the blood after 5 min of intravenous administration,8926,A,,,,,,
11636,Autocuration,22224,,,Distribution in the blood after 60 min of intravenous administration,8926,A,,,,,,
11637,Autocuration,22224,,,Distribution in the blood after 90 min of intravenous administration,8926,A,,,,,,
11638,Autocuration,22224,,,Distribution in the bone after 120 min of intravenous administration,8926,A,,,,,,
11639,Autocuration,22224,,,Distribution in the bone after 15 min of intravenous administration,8926,A,,,,,,
11640,Autocuration,22224,,,Distribution in the bone after 30 min of intravenous administration,8926,A,,,,,,
11641,Autocuration,22224,,,Distribution in the bone after 5 min of intravenous administration,8926,A,,,,,,
11642,Autocuration,22224,,,Distribution in the bone after 60 min of intravenous administration,8926,A,,,,,,
11643,Autocuration,22224,,,Distribution in the bone after 90 min of intravenous administration,8926,A,,,,,,
11644,Autocuration,22224,,,Distribution in the heart after 120 min of intravenous administration,8926,A,,,,,,
11645,Autocuration,22224,,,Distribution in the heart after 15 min of intravenous administration,8926,A,,,,,,
11646,Autocuration,22224,,,Distribution in the heart after 30 min of intravenous administration,8926,A,,,,,,
11647,Autocuration,22224,,,Distribution in the heart after 5 min of intravenous administration,8926,A,,,,,,
11648,Autocuration,22224,,,Distribution in the heart after 60 min of intravenous administration,8926,A,,,,,,
11649,Autocuration,22224,,,Distribution in the heart after 90 min of intravenous administration,8926,A,,,,,,
11650,Autocuration,22224,,,Distribution in the kidneys after 120 min of intravenous administration,8926,A,,,,,,
11651,Autocuration,22224,,,Distribution in the kidneys after 15 min of intravenous administration,8926,A,,,,,,
11652,Autocuration,22224,,,Distribution in the kidneys after 30 min of intravenous administration,8926,A,,,,,,
11653,Autocuration,22224,,,Distribution in the kidneys after 5 min of intravenous administration,8926,A,,,,,,
11654,Autocuration,22224,,,Distribution in the kidneys after 60 min of intravenous administration,8926,A,,,,,,
11655,Autocuration,22224,,,Distribution in the kidneys after 90 min of intravenous administration,8926,A,,,,,,
11656,Autocuration,22224,,,Distribution in the liver after 120 min of intravenous administration,8926,A,,,,,,
11657,Autocuration,22224,,,Distribution in the liver after 15 min of intravenous administration,8926,A,,,,,,
11658,Autocuration,22224,,,Distribution in the liver after 30 min of intravenous administration,8926,A,,,,,,
11659,Autocuration,22224,,,Distribution in the liver after 5 min of intravenous administration,8926,A,,,,,,
11660,Autocuration,22224,,,Distribution in the liver after 60 min of intravenous administration,8926,A,,,,,,
11661,Autocuration,22224,,,Distribution in the liver after 90 min of intravenous administration,8926,A,,,,,,
11662,Autocuration,22224,,,Distribution in the lung after 120 min of intravenous administration,8926,A,,,,,,
11663,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",14839,A,,Mus musculus,10090.0,,,
11664,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",14839,A,,Mus musculus,10090.0,,,
11665,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",14839,A,,Mus musculus,10090.0,,,
11666,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",14839,A,,Mus musculus,10090.0,,,
11667,Intermediate,50597,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,12178,A,,Rattus norvegicus,10116.0,,,
11668,Intermediate,50597,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,12178,A,,Rattus norvegicus,10116.0,,,
11669,Autocuration,22224,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,12178,A,,,,,,
11670,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,12186,A,,Macaca fascicularis,9541.0,,,
11671,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,12186,A,,Macaca fascicularis,9541.0,,,
11672,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,12186,A,,Macaca fascicularis,9541.0,,,
11673,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,12186,A,,Macaca fascicularis,9541.0,,,
11674,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,12187,A,,Simiiformes,314293.0,,,
11675,Intermediate,50506,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,12187,A,,Mustela putorius furo,9669.0,,,
11676,Intermediate,50506,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",12187,A,,Mustela putorius furo,9669.0,,,
11677,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,12187,A,,Simiiformes,314293.0,,,
11678,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,12187,A,,Simiiformes,314293.0,,,
11679,Intermediate,50597,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,12187,A,,Rattus norvegicus,10116.0,,,
11680,Intermediate,50597,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",12187,A,,Rattus norvegicus,10116.0,,,
11681,Intermediate,50588,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",14122,A,,Canis lupus familiaris,9615.0,,,
11682,Intermediate,100712,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",14122,A,,Cricetinae,10026.0,,,
11683,Intermediate,50597,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",14122,A,,Rattus norvegicus,10116.0,,,
11684,Autocuration,22224,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,13391,A,,,,,,
11685,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,13391,A,,,,,,
11686,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,13391,A,,,,,,
11687,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,13391,A,,,,,,
11688,Autocuration,22224,,,Oral absorption expressed as Area under curve was determined,16360,A,,,,,,
11689,Intermediate,50588,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,3673,A,,Canis lupus familiaris,9615.0,,,
11690,Intermediate,50588,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",14122,A,,Canis lupus familiaris,9615.0,,,
11691,Intermediate,100712,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",14122,A,,Cricetinae,10026.0,,,
11692,Intermediate,100712,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",14122,A,,Cricetinae,10026.0,,,
11693,Intermediate,50597,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",14122,A,,Rattus norvegicus,10116.0,,,
11694,Autocuration,22224,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,13889,A,,,,,,
11695,Intermediate,50597,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,,Rattus norvegicus,10116.0,,,
11696,Intermediate,50597,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),17279,A,,Rattus norvegicus,10116.0,,,
11697,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,14548,A,,Macaca fascicularis,9541.0,,,
11698,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,14548,A,,Macaca fascicularis,9541.0,,,
11699,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,14548,A,,Macaca fascicularis,9541.0,,,
11700,Intermediate,50588,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,14548,A,,Canis lupus familiaris,9615.0,,,
11701,Intermediate,50588,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,14548,A,,Canis lupus familiaris,9615.0,,,
11702,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,14548,A,,Rattus norvegicus,10116.0,,,
11703,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,14548,A,,Rattus norvegicus,10116.0,,,
11704,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,14548,A,,Rattus norvegicus,10116.0,,,
11705,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11706,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11707,Intermediate,50594,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Mus musculus,10090.0,,,
11708,Intermediate,50597,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11709,Intermediate,50597,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11710,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11711,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11712,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11713,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11714,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11715,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11716,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11717,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11718,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,14608,A,In vivo,Rattus norvegicus,10116.0,,,
11719,Intermediate,50594,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11720,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,15383,A,,Mus musculus,10090.0,,,
11721,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,15383,A,,Mus musculus,10090.0,,,
11722,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11723,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11724,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11725,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11726,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11727,Intermediate,50594,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11728,Intermediate,50594,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11729,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,15383,A,,Mus musculus,10090.0,,,
11730,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11731,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,15383,A,,Mus musculus,10090.0,,,
11732,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,15383,A,,Mus musculus,10090.0,,,
11733,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11734,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11735,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,15383,A,,Mus musculus,10090.0,,,
11736,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11737,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,15383,A,,Mus musculus,10090.0,,,
11738,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,15383,A,,Mus musculus,10090.0,,,
11739,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11740,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11741,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11742,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,15383,A,,Mus musculus,10090.0,,,
11743,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,15383,A,,Mus musculus,10090.0,,,
11744,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11745,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11746,Intermediate,50594,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11747,Intermediate,50594,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11748,Intermediate,50594,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11749,Intermediate,50594,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11750,Intermediate,50594,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11751,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
11752,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
11753,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
11754,Intermediate,50588,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,14906,A,In vivo,Canis lupus familiaris,9615.0,,,
11755,Intermediate,50597,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,14906,A,In vivo,Rattus norvegicus,10116.0,,,
11756,Intermediate,50597,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,14906,A,In vivo,Rattus norvegicus,10116.0,,,
11757,Intermediate,50587,Plasma,,The maximum plasma concentration (100 mg/kg) administered orally in human,14215,A,In vivo,Homo sapiens,9606.0,,,
11758,Autocuration,22224,Plasma,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,14215,A,In vivo,Callithrix,9481.0,,,
11759,Autocuration,22224,Plasma,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,14215,A,In vivo,Simiiformes,314293.0,,,
11760,Intermediate,50588,Plasma,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,14215,A,In vivo,Canis lupus familiaris,9615.0,,,
11761,Intermediate,50587,Plasma,,The maximum plasma concentration (200 mg/kg) administered orally in human,14215,A,In vivo,Homo sapiens,9606.0,,,
11762,Intermediate,50597,Plasma,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,14215,A,In vivo,Rattus norvegicus,10116.0,,,
11763,Autocuration,22224,Plasma,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,14215,A,In vivo,Callithrix,9481.0,,,
11764,Autocuration,22224,Plasma,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,14215,A,In vivo,Simiiformes,314293.0,,,
11765,Autocuration,22224,Plasma,,The maximum plasma concentration (30 mg/kg) administered orally in dog,14215,A,In vivo,Canis lupus familiaris,9615.0,,,
11766,Intermediate,50587,Plasma,,The maximum plasma concentration (400 mg/kg) administered orally in human,14215,A,In vivo,Homo sapiens,9606.0,,,
11767,Intermediate,50597,Plasma,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,14215,A,In vivo,Rattus norvegicus,10116.0,,,
11768,Intermediate,50597,Plasma,,The maximum plasma concentration (50 mg/kg) administered orally in rat,14215,A,In vivo,Rattus norvegicus,10116.0,,,
11769,Intermediate,50587,Plasma,,The maximum plasma concentration (800 mg/kg) administered orally in human,14215,A,In vivo,Homo sapiens,9606.0,,,
11770,Intermediate,50597,Plasma,,The maximum plasma concentration was measured on rats,14067,A,In vivo,Rattus norvegicus,10116.0,,,
11771,Intermediate,50597,Plasma,,The maximum plasma concentration was measured on rats after oral administration,12350,A,In vivo,Rattus norvegicus,10116.0,,,
11772,Intermediate,50597,Plasma,,Plasma drug Cmax in rat (PO dose),14813,A,In vivo,Rattus norvegicus,10116.0,,,
11773,Autocuration,22224,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,12536,A,In vivo,,,,,
11774,Intermediate,50588,Plasma,,maximum Plasma concentration in Dog was determined after Peroral administration,14169,A,In vivo,Canis lupus familiaris,9615.0,,,
11775,Intermediate,50597,Plasma,,maximum Plasma concentration in Rats was determined after Peroral administration,14169,A,In vivo,Rattus norvegicus,10116.0,,,
11776,Intermediate,50588,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,15604,A,In vivo,Canis lupus familiaris,9615.0,,,
11777,Autocuration,22224,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,15604,A,In vivo,Simiiformes,314293.0,,,
11778,Intermediate,50597,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,15604,A,In vivo,Rattus norvegicus,10116.0,,,
11779,Intermediate,50594,,,maximum concentration was measured when administered through oral route in mice,14387,A,In vivo,Mus musculus,10090.0,,,
11780,Intermediate,50594,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,15115,A,,Mus musculus,10090.0,,,
11781,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,15115,A,,Simiiformes,314293.0,,,
11782,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,15115,A,,Simiiformes,314293.0,,,
11783,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,15115,A,,Simiiformes,314293.0,,,
11784,Intermediate,50597,,,Pharmacokinetic parameter was evaluated in rats,16359,A,,Rattus norvegicus,10116.0,,,
11785,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,12829,A,,Mus musculus,10090.0,,,
11786,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,12829,A,,Mus musculus,10090.0,,,
11787,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,12829,A,,Mus musculus,10090.0,,,
11788,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,12829,A,,Mus musculus,10090.0,,,
11789,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,12829,A,,Mus musculus,10090.0,,,
11790,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,15137,A,,Rattus norvegicus,10116.0,,,
11791,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,15137,A,,Rattus norvegicus,10116.0,,,
11792,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,15137,A,,Rattus norvegicus,10116.0,,,
11793,Intermediate,50594,Plasma,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,15137,A,,Mus musculus,10090.0,,,
11794,Intermediate,50594,,,Plasma Concentration after 120 min of oral administration to mice,13509,A,,Mus musculus,10090.0,,,
11795,Intermediate,50594,,,Plasma Concentration after 30 min of oral administration to mice,13509,A,,Mus musculus,10090.0,,,
11796,Intermediate,100710,,,Plasma Concentration after 60 min of oral administration to mice,13509,A,,Macaca fascicularis,9541.0,,,
11797,Intermediate,50594,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,13509,A,,Mus musculus,10090.0,,,
11798,Intermediate,50594,,,Plasma Concentration after 90 min of oral administration to mice,13509,A,,Mus musculus,10090.0,,,
11799,Intermediate,50597,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11800,Intermediate,50597,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11801,Intermediate,50597,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,12064,A,,Rattus norvegicus,10116.0,,,
11802,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11803,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11804,Autocuration,22224,,,Distribution in the lung after 15 min of intravenous administration,8926,A,,,,,,
11805,Autocuration,22224,,,Distribution in the lung after 30 min of intravenous administration,8926,A,,,,,,
11806,Autocuration,22224,,,Distribution in the lung after 5 min of intravenous administration,8926,A,,,,,,
11807,Autocuration,22224,,,Distribution in the lung after 60 min of intravenous administration,8926,A,,,,,,
11808,Autocuration,22224,,,Distribution in the lung after 90 min of intravenous administration,8926,A,,,,,,
11809,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 120 min of intravenous administration,8926,A,,,,,,
11810,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 15 min of intravenous administration,8926,A,,,,,,
11811,Intermediate,50594,Muscle tissue,,Distribution in the muscle after 30 min of intravenous administration,8926,A,,Mus musculus,10090.0,,,
11812,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 5 min of intravenous administration,8926,A,,,,,,
11813,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 60 min of intravenous administration,8926,A,,,,,,
11814,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 90 min of intravenous administration,8926,A,,,,,,
11815,Autocuration,22224,Spleen,,Distribution in the spleen after 120 min of intravenous administration,8926,A,,,,,,
11816,Autocuration,22224,Spleen,,Distribution in the spleen after 15 min of intravenous administration,8926,A,,,,,,
11817,Autocuration,22224,Spleen,,Distribution in the spleen after 30 min of intravenous administration,8926,A,,,,,,
11818,Autocuration,22224,Spleen,,Distribution in the spleen after 5 min of intravenous administration,8926,A,,,,,,
11819,Autocuration,22224,Spleen,,Distribution in the spleen after 60 min of intravenous administration,8926,A,,,,,,
11820,Autocuration,22224,Spleen,,Distribution in the spleen after 90 min of intravenous administration,8926,A,,,,,,
11821,Intermediate,50597,Adrenal cortex,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11822,Intermediate,50597,Blood,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11823,Intermediate,50597,Liver,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11824,Intermediate,50597,Female gonad,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11825,Intermediate,50597,Thyroid gland,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11826,Intermediate,50597,Adrenal cortex,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11827,Intermediate,50597,Blood,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11828,Intermediate,50597,Liver,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11829,Intermediate,50597,Female gonad,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11830,Intermediate,50597,Thyroid gland,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,7570,A,,Rattus norvegicus,10116.0,,,
11831,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",8608,A,,Rattus norvegicus,10116.0,,,
11832,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",8608,A,,Rattus norvegicus,10116.0,,,
11833,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",8608,A,,Rattus norvegicus,10116.0,,,
11834,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",8608,A,,Rattus norvegicus,10116.0,,,
11835,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",8608,A,,Rattus norvegicus,10116.0,,,
11836,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",8608,A,,Rattus norvegicus,10116.0,,,
11837,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",8608,A,,Rattus norvegicus,10116.0,,,
11838,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",8608,A,,Rattus norvegicus,10116.0,,,
11839,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",8608,A,,Rattus norvegicus,10116.0,,,
11840,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",8608,A,,Rattus norvegicus,10116.0,,,
11841,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",8608,A,,Rattus norvegicus,10116.0,,,
11842,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",8608,A,,Rattus norvegicus,10116.0,,,
11843,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",8608,A,,Rattus norvegicus,10116.0,,,
11844,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",8608,A,,Rattus norvegicus,10116.0,,,
11845,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",8608,A,,Rattus norvegicus,10116.0,,,
11846,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",8608,A,,Rattus norvegicus,10116.0,,,
11847,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",8608,A,,Rattus norvegicus,10116.0,,,
11848,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",8608,A,,Rattus norvegicus,10116.0,,,
11849,Intermediate,50594,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,13792,A,,Mus musculus,10090.0,,,
11850,Intermediate,50588,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,13376,A,,Canis lupus familiaris,9615.0,,,
11851,Intermediate,50588,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,13376,A,,Canis lupus familiaris,9615.0,,,
11852,Autocuration,22224,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,14380,A,,,,,,
11853,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,14380,A,,,,,,
11854,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,14380,A,,,,,,
11855,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,14380,A,,,,,,
11856,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,14380,A,,,,,,
11857,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,14380,A,,,,,,
11858,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,14380,A,,,,,,
11859,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,14380,A,,,,,,
11860,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,13701,A,,Mus musculus,10090.0,,,
11861,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11862,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11863,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11864,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11865,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,13701,A,,Mus musculus,10090.0,,,
11866,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11867,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11868,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11869,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11870,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11871,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,13701,A,,Mus musculus,10090.0,,,
11872,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11873,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11874,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11875,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11876,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,13701,A,,Mus musculus,10090.0,,,
11877,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),13701,A,,Mus musculus,10090.0,,,
11878,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11879,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,13701,A,,Mus musculus,10090.0,,,
11880,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11881,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11882,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
11883,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,13701,A,,Mus musculus,10090.0,,,
11884,Intermediate,50597,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,,Rattus norvegicus,10116.0,,,
11885,Intermediate,50594,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,14731,A,,Mus musculus,10090.0,,,
11886,Intermediate,100710,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,14731,A,,Macaca fascicularis,9541.0,,,
11887,Intermediate,100710,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,14731,A,,Macaca fascicularis,9541.0,,,
11888,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,13758,A,,,,,,
11889,Autocuration,22224,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,13758,A,,,,,,
11890,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,13758,A,,,,,,
11891,Autocuration,22224,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,13758,A,,,,,,
11892,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),16359,A,,,,,,
11893,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),16359,A,,,,,,
11894,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11895,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11896,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11897,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,15383,A,,Mus musculus,10090.0,,,
11898,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,15383,A,,Mus musculus,10090.0,,,
11899,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,15383,A,,Mus musculus,10090.0,,,
11900,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,15383,A,,Mus musculus,10090.0,,,
11901,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),14439,A,,Mus musculus,10090.0,,,
11902,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),14439,A,,Mus musculus,10090.0,,,
11903,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),14439,A,,Mus musculus,10090.0,,,
11904,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),14439,A,,Mus musculus,10090.0,,,
11905,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),14439,A,,Mus musculus,10090.0,,,
11906,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),14439,A,,Mus musculus,10090.0,,,
11907,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),14439,A,,Mus musculus,10090.0,,,
11908,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),14439,A,,Mus musculus,10090.0,,,
11909,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),14439,A,,Mus musculus,10090.0,,,
11910,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),14439,A,,Mus musculus,10090.0,,,
11911,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),14439,A,,Mus musculus,10090.0,,,
11912,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),14439,A,,Mus musculus,10090.0,,,
11913,Intermediate,50597,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11914,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11915,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11916,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11917,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11918,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11919,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11920,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11921,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11922,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11923,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11924,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11925,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11926,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11927,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11928,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11929,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11930,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11931,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11932,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11933,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11934,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11935,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11936,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11937,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
11938,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11939,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11940,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11941,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,10677,A,,Rattus norvegicus,10116.0,,,
11942,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,10677,A,,Rattus norvegicus,10116.0,,,
11943,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11944,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11945,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11946,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11947,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11948,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11949,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11950,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11951,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11952,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11953,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11954,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11955,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11956,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11957,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11958,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11959,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11960,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11961,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11962,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11963,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11964,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11965,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11966,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11967,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11968,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11969,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11970,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11971,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11972,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11973,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11974,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11975,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11976,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
11977,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",8608,A,,Rattus norvegicus,10116.0,,,
11978,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",8608,A,,Rattus norvegicus,10116.0,,,
11979,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",8608,A,,Rattus norvegicus,10116.0,,,
11980,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",8608,A,,Rattus norvegicus,10116.0,,,
11981,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",8608,A,,Rattus norvegicus,10116.0,,,
11982,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",8608,A,,Rattus norvegicus,10116.0,,,
11983,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",8608,A,,Rattus norvegicus,10116.0,,,
11984,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",8608,A,,Rattus norvegicus,10116.0,,,
11985,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",8608,A,,Rattus norvegicus,10116.0,,,
11986,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",8608,A,,Rattus norvegicus,10116.0,,,
11987,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",8608,A,,Rattus norvegicus,10116.0,,,
11988,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",8608,A,,Rattus norvegicus,10116.0,,,
11989,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",8608,A,,Rattus norvegicus,10116.0,,,
11990,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",8608,A,,Rattus norvegicus,10116.0,,,
11991,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",8608,A,,Rattus norvegicus,10116.0,,,
11992,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",8608,A,,Rattus norvegicus,10116.0,,,
11993,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",8608,A,,Rattus norvegicus,10116.0,,,
11994,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",8608,A,,Rattus norvegicus,10116.0,,,
11995,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",8608,A,,Rattus norvegicus,10116.0,,,
11996,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",8608,A,,Rattus norvegicus,10116.0,,,
11997,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",8608,A,,Rattus norvegicus,10116.0,,,
11998,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",8608,A,,Rattus norvegicus,10116.0,,,
11999,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",8608,A,,Rattus norvegicus,10116.0,,,
12000,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",8608,A,,Rattus norvegicus,10116.0,,,
12001,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",8608,A,,Rattus norvegicus,10116.0,,,
12002,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",8608,A,,Rattus norvegicus,10116.0,,,
12003,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",8608,A,,Rattus norvegicus,10116.0,,,
12004,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",8608,A,,Rattus norvegicus,10116.0,,,
12005,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",8608,A,,Rattus norvegicus,10116.0,,,
12006,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",8608,A,,Rattus norvegicus,10116.0,,,
12007,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",8608,A,,Rattus norvegicus,10116.0,,,
12008,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",8608,A,,Rattus norvegicus,10116.0,,,
12009,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",8608,A,,Rattus norvegicus,10116.0,,,
12010,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",8608,A,,Rattus norvegicus,10116.0,,,
12011,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",8608,A,,Rattus norvegicus,10116.0,,,
12012,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",8608,A,,Rattus norvegicus,10116.0,,,
12013,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),16359,A,,,,,,
12014,Intermediate,50594,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),13701,A,,Mus musculus,10090.0,,,
12015,Intermediate,50597,,,Pharmacokinetic profile AUC was evaluated in rats,14554,A,,Rattus norvegicus,10116.0,,,
12016,Autocuration,22224,,,Pharmacokinetic property (Area under curve),6241,A,,,,,,
12017,Intermediate,50588,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",11537,A,,Canis lupus familiaris,9615.0,,,
12018,Intermediate,50594,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",11537,A,,Mus musculus,10090.0,,,
12019,Intermediate,50588,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",11537,A,,Canis lupus familiaris,9615.0,,,
12020,Intermediate,50594,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",11537,A,,Mus musculus,10090.0,,,
12021,Autocuration,22224,,,Plasma concentration (AUC) was determined,13118,A,,,,,,
12022,Autocuration,22224,,,Plasma concentration (AUC) was determined; Not detectable,13118,A,,,,,,
12023,Intermediate,50512,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),9562,A,,Cavia porcellus,10141.0,,,
12024,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,10363,A,,Rattus norvegicus,10116.0,,,
12025,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,10363,A,,Rattus norvegicus,10116.0,,,
12026,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,10363,A,,Rattus norvegicus,10116.0,,,
12027,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,10363,A,,Rattus norvegicus,10116.0,,,
12028,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,12504,A,,Rattus norvegicus,10116.0,,,
12029,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,12504,A,,Rattus norvegicus,10116.0,,,
12030,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,12504,A,,Rattus norvegicus,10116.0,,,
12031,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,12504,A,,Rattus norvegicus,10116.0,,,
12032,Intermediate,50588,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,13317,A,,Canis lupus familiaris,9615.0,,,
12033,Intermediate,50597,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
12034,Intermediate,50597,,,The AUC(0-infinity) values in female wistar rats.,14941,A,,Rattus norvegicus,10116.0,,,
12035,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
12036,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",15078,A,,Rattus norvegicus,10116.0,,,
12037,Intermediate,50597,,,The AUC(0-t)values in female wistar rats.,14941,A,,Rattus norvegicus,10116.0,,,
12038,Intermediate,50597,,,The Area under the concentration time curve of compound was measured on rats,14067,A,,Rattus norvegicus,10116.0,,,
12039,Intermediate,50587,,,The area under curve (100 mg/kg) administered orally in humans,14215,A,,Homo sapiens,9606.0,,,
12040,Autocuration,22224,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,14215,A,,Callithrix,9481.0,,,
12041,Autocuration,22224,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,14215,A,,Simiiformes,314293.0,,,
12042,Intermediate,50588,,,The area under curve (15 mg/kg) administered intravenously in dog,14215,A,,Canis lupus familiaris,9615.0,,,
12043,Intermediate,50587,,,The area under curve (200 mg/kg) administered orally in humans,14215,A,,Homo sapiens,9606.0,,,
12044,Intermediate,50597,,,The area under curve (25 mg/kg) administered intravenously in rat,14215,A,,Rattus norvegicus,10116.0,,,
12045,Autocuration,22224,,,The area under curve (25 mg/kg) administered orally in marmoset,14215,A,,Callithrix,9481.0,,,
12046,Autocuration,22224,,,The area under curve (25 mg/kg) administered orally in monkey,14215,A,,Simiiformes,314293.0,,,
12047,Intermediate,50588,,,The area under curve (30 mg/kg) administered orally in dog,14215,A,,Canis lupus familiaris,9615.0,,,
12048,Intermediate,50587,,,The area under curve (400 mg/kg) administered orally in humans,14215,A,,Homo sapiens,9606.0,,,
12049,Intermediate,50597,,,The area under curve (50 mg/kg) administered orally in fasted rat,14215,A,,Rattus norvegicus,10116.0,,,
12050,Intermediate,50597,,,The area under curve (50 mg/kg) administered orally in rat,14215,A,,Rattus norvegicus,10116.0,,,
12051,Intermediate,50587,,,The area under curve (800 mg/kg) administered orally in humans,14215,A,,Homo sapiens,9606.0,,,
12052,Autocuration,22224,,,The compound was evaluated for area under the curve,11324,A,,,,,,
12053,Autocuration,22224,,,The compound was evaluated for area under the curve in marmosets,11324,A,,Callithrix,9481.0,,,
12054,Autocuration,22224,,,The compound was evaluated for area under the curve in marmosets,11324,A,,Callithrix,9481.0,,,
12055,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,13875,A,,Rattus norvegicus,10116.0,,,
12056,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,13875,A,,Rattus norvegicus,10116.0,,,
12057,Autocuration,22224,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),13875,A,,,,,,
12058,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,13875,A,,Rattus norvegicus,10116.0,,,
12059,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,13875,A,,Rattus norvegicus,10116.0,,,
12060,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,13875,A,,Rattus norvegicus,10116.0,,,
12061,Intermediate,50597,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,13807,A,,Rattus norvegicus,10116.0,,,
12062,Intermediate,50597,,,Total drug exposure is determined after oral dosing in rats.,14127,A,,Rattus norvegicus,10116.0,,,
12063,Autocuration,22224,,,Total drug exposure (5 mg/kg) when administered intravenously,15116,A,,,,,,
12064,Autocuration,22224,,,Total drug exposure (5 mg/kg) when administered orally,15116,A,,,,,,
12065,Autocuration,22224,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,15604,A,,Simiiformes,314293.0,,,
12066,Intermediate,50597,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,15604,A,,Rattus norvegicus,10116.0,,,
12067,Intermediate,50588,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,15604,A,,Canis lupus familiaris,9615.0,,,
12068,Intermediate,50588,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,15604,A,,Canis lupus familiaris,9615.0,,,
12069,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12070,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12071,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12072,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12073,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12074,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12075,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12076,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12077,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12078,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12079,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12080,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12081,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12082,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12083,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12084,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12085,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12086,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12087,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12088,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12089,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12090,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12091,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12092,Intermediate,50597,Liver,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12093,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12094,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12095,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12096,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12097,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12098,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12099,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12100,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12101,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12102,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12103,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12104,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12105,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12106,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12107,Intermediate,50597,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12108,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12109,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12110,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12111,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12112,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12113,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12114,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12115,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12116,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12117,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12118,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12119,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12120,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12121,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12122,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12123,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12124,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12125,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12126,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12127,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12128,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12129,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12130,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12131,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12132,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12133,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12134,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,10911,A,In vivo,Rattus norvegicus,10116.0,,,
12135,Autocuration,22224,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,8081,A,,,,,,
12136,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),17248,A,,Macaca fascicularis,9541.0,,,
12137,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,17248,A,,Macaca fascicularis,9541.0,,,
12138,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,17248,A,,Macaca fascicularis,9541.0,,,
12139,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),17248,A,,Canis lupus familiaris,9615.0,,,
12140,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,17248,A,,Canis lupus familiaris,9615.0,,,
12141,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,17248,A,,Canis lupus familiaris,9615.0,,,
12142,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,17248,A,,Canis lupus familiaris,9615.0,,,
12143,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",15592,A,,Canis lupus familiaris,9615.0,,,
12144,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,7040,A,,,,,,
12145,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,7040,A,,,,,,
12146,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,7040,A,,,,,,
12147,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,7040,A,,,,,,
12148,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,7040,A,,,,,,
12149,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,7040,A,,,,,,
12150,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,7040,A,,,,,,
12151,Intermediate,50588,Adrenal medulla,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12152,Intermediate,50588,Adrenal medulla,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12153,Intermediate,50588,Blood,,"Concentration of compound in blood of dog 1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12154,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",8608,A,,Rattus norvegicus,10116.0,,,
12155,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",8608,A,,Rattus norvegicus,10116.0,,,
12156,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",8608,A,,Rattus norvegicus,10116.0,,,
12157,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",8608,A,,Rattus norvegicus,10116.0,,,
12158,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",8608,A,,Rattus norvegicus,10116.0,,,
12159,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",8608,A,,Rattus norvegicus,10116.0,,,
12160,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",8608,A,,Rattus norvegicus,10116.0,,,
12161,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",8608,A,,Rattus norvegicus,10116.0,,,
12162,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",8608,A,,Rattus norvegicus,10116.0,,,
12163,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",8608,A,,Rattus norvegicus,10116.0,,,
12164,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",8608,A,,Rattus norvegicus,10116.0,,,
12165,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",8608,A,,Rattus norvegicus,10116.0,,,
12166,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",8608,A,,Rattus norvegicus,10116.0,,,
12167,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",8608,A,,Rattus norvegicus,10116.0,,,
12168,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",8608,A,,Rattus norvegicus,10116.0,,,
12169,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",8608,A,,Rattus norvegicus,10116.0,,,
12170,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",8608,A,,Rattus norvegicus,10116.0,,,
12171,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",8608,A,,Rattus norvegicus,10116.0,,,
12172,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",8608,A,,Rattus norvegicus,10116.0,,,
12173,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",8608,A,,Rattus norvegicus,10116.0,,,
12174,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",8608,A,,Rattus norvegicus,10116.0,,,
12175,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",8608,A,,Rattus norvegicus,10116.0,,,
12176,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",8608,A,,Rattus norvegicus,10116.0,,,
12177,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",8608,A,,Rattus norvegicus,10116.0,,,
12178,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",8608,A,,Rattus norvegicus,10116.0,,,
12179,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",8608,A,,Rattus norvegicus,10116.0,,,
12180,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",8608,A,,Rattus norvegicus,10116.0,,,
12181,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",8608,A,,Rattus norvegicus,10116.0,,,
12182,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",8608,A,,Rattus norvegicus,10116.0,,,
12183,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",8608,A,,Rattus norvegicus,10116.0,,,
12184,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",8608,A,,Rattus norvegicus,10116.0,,,
12185,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",8608,A,,Rattus norvegicus,10116.0,,,
12186,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",8608,A,,Rattus norvegicus,10116.0,,,
12187,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",8608,A,,Rattus norvegicus,10116.0,,,
12188,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",8608,A,,Rattus norvegicus,10116.0,,,
12189,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",8608,A,,Rattus norvegicus,10116.0,,,
12190,Autocuration,22224,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,15604,A,,Simiiformes,314293.0,,,
12191,Intermediate,50597,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,15604,A,,Rattus norvegicus,10116.0,,,
12192,Autocuration,22224,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1806,A,,,,,,
12193,Autocuration,22224,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1806,A,,,,,,
12194,Intermediate,50588,Plasma,,AUC 0-inf in dog,17237,A,,Canis lupus familiaris,9615.0,,,
12195,Intermediate,50512,Plasma,,AUC 0-inf in guinea pig,17237,A,,Cavia porcellus,10141.0,,,
12196,Intermediate,50588,Plasma,,AUC 0-t in dog,17237,A,,Canis lupus familiaris,9615.0,,,
12197,Intermediate,50512,Plasma,,AUC 0-t in guinea pig,17237,A,,Cavia porcellus,10141.0,,,
12198,Intermediate,50597,,,The compound was tested for brain to plasma partition in rat,15194,A,,Rattus norvegicus,10116.0,,,
12199,Intermediate,50597,,,The compound was tested for brain to plasma partition in rat.,15194,A,,Rattus norvegicus,10116.0,,,
12200,Autocuration,22224,Blood,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,8787,A,,,,,,
12201,Intermediate,50588,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,17025,A,,Canis lupus familiaris,9615.0,,,
12202,Autocuration,22224,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,17025,A,,Simiiformes,314293.0,,,
12203,Intermediate,50592,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,17025,A,,Oryctolagus cuniculus,9986.0,,,
12204,Intermediate,50597,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,17025,A,,Rattus norvegicus,10116.0,,,
12205,Intermediate,50797,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,4236,A,,Macaca mulatta,9544.0,,,
12206,Intermediate,50588,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,15343,A,,Canis lupus familiaris,9615.0,,,
12207,Intermediate,50597,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,15343,A,,Rattus norvegicus,10116.0,,,
12208,Autocuration,22224,,,Area under curve of the compound was determined,17720,A,,,,,,
12209,Autocuration,22224,Plasma,,AUC in monkeys at a dose of 1 mg/kg,17788,A,,Simiiformes,314293.0,,,
12210,Intermediate,50597,Plasma,,AUC in rats at a dose of 1 mg/kg,17788,A,,Rattus norvegicus,10116.0,,,
12211,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 2,8778,A,,,,,,
12212,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 4,8778,A,,,,,,
12213,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 7,8778,A,,,,,,
12214,Intermediate,50597,,,Compound was evaluated for its absorption in the rats,2249,A,,Rattus norvegicus,10116.0,,,
12215,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,8881,A,,Rattus norvegicus,10116.0,,,
12216,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,8881,A,,Rattus norvegicus,10116.0,,,
12217,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,8881,A,,Rattus norvegicus,10116.0,,,
12218,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,8881,A,,Rattus norvegicus,10116.0,,,
12219,Intermediate,50597,,,In vitro percent permeability into rat ileum,15286,A,,Rattus norvegicus,10116.0,,,
12220,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-17,15286,A,,Rattus norvegicus,10116.0,,,
12221,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-18,15286,A,,Rattus norvegicus,10116.0,,,
12222,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-19,15286,A,,Rattus norvegicus,10116.0,,,
12223,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 12-15,15286,A,,Rattus norvegicus,10116.0,,,
12224,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 13-19,15286,A,,Rattus norvegicus,10116.0,,,
12225,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 14-17,15286,A,,Rattus norvegicus,10116.0,,,
12226,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 15-18,15286,A,,Rattus norvegicus,10116.0,,,
12227,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 2-5,15286,A,,Rattus norvegicus,10116.0,,,
12228,Autocuration,22224,Ileum,,In vitro percent permeability into rat ileum; Range is 23-42,15286,A,,,,,,
12229,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 28-36,15286,A,,Rattus norvegicus,10116.0,,,
12230,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 29-35,15286,A,,Rattus norvegicus,10116.0,,,
12231,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 46-66,15286,A,,Rattus norvegicus,10116.0,,,
12232,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 50-68,15286,A,,Rattus norvegicus,10116.0,,,
12233,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 78-81,15286,A,,Rattus norvegicus,10116.0,,,
12234,Intermediate,50597,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,15286,A,,Rattus norvegicus,10116.0,,,
12235,Intermediate,50597,,,In vitro percent permeability into rat ileum; nd indicates not detected,15286,A,,Rattus norvegicus,10116.0,,,
12236,Intermediate,50597,,,In vitro percent permeability into rat ileum; nt indicates not detected,15286,A,,Rattus norvegicus,10116.0,,,
12237,Intermediate,50597,,,In vitro percent permeability into rat ileum; nt indicates not tested,15286,A,,Rattus norvegicus,10116.0,,,
12238,Intermediate,50597,,,Compound was tested for oral absorption in bile-duct cannulated rats,13770,A,,Rattus norvegicus,10116.0,,,
12239,Intermediate,50597,,,Compound was tested for oral absorption in bile-duct cannulated rats.,13770,A,,Rattus norvegicus,10116.0,,,
12240,Intermediate,50587,,,Oral absorption using Caco-2 cell monolayers.,5202,A,,Homo sapiens,9606.0,,,
12241,Intermediate,50587,,,Percent of the drug absorbed after administration to humans was determined,14920,A,,Homo sapiens,9606.0,,,
12242,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12243,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12244,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12245,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12246,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12247,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",13751,A,In vivo,Rattus norvegicus,10116.0,,,
12248,Intermediate,50597,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",15807,A,,Rattus norvegicus,10116.0,,,
12249,Intermediate,50597,Striatum,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",15807,A,,Rattus norvegicus,10116.0,,,
12250,Intermediate,50597,Striatum,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",15807,A,,Rattus norvegicus,10116.0,,,
12251,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,14950,A,,Rattus norvegicus,10116.0,,,
12252,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12253,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12254,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12255,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12256,Intermediate,50597,Kidney,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12257,Intermediate,50597,Kidney,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12258,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12259,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12260,Intermediate,50597,Lung,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12261,Intermediate,50597,Lung,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12262,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12263,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12264,Intermediate,50597,Prostate gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12265,Intermediate,50597,Prostate gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12266,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,14950,A,,Rattus norvegicus,10116.0,,,
12267,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12268,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12269,Intermediate,50597,Spleen,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12270,Intermediate,50597,Spleen,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12271,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12272,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,14950,A,,Rattus norvegicus,10116.0,,,
12273,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12274,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12275,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12276,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12277,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,14950,A,,Rattus norvegicus,10116.0,,,
12278,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12279,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12280,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12281,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12282,Intermediate,50588,Blood,,"Concentration of compound in blood of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12283,Intermediate,50588,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12284,Intermediate,50588,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12285,Intermediate,50588,Liver,,"Concentration of compound in liver of dog 1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12286,Intermediate,50588,Liver,,"Concentration of compound in liver of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12287,Intermediate,50588,Lung,,"Concentration of compound in lung of dog 1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12288,Intermediate,50588,Lung,,"Concentration of compound in lung of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12289,Intermediate,50588,Muscle tissue,,"Concentration of compound in muscle of dog 1, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12290,Intermediate,50588,Muscle tissue,,"Concentration of compound in muscle of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12291,Intermediate,50588,Spleen,,"Concentration of compound in spleen of dog 1,after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12292,Intermediate,50588,Spleen,,"Concentration of compound in spleen of dog 2, after administering intravenously",9614,A,,Canis lupus familiaris,9615.0,,,
12293,Autocuration,22224,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,10353,F,,,,,,
12294,Autocuration,22224,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,10353,F,,,,,,
12295,Autocuration,22224,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,10353,A,,,,,,
12296,Autocuration,22224,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,10353,F,,,,,,
12297,Autocuration,22224,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,10353,F,,,,,,
12298,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,9196,A,,,,,,
12299,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,9196,A,,,,,,
12300,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12301,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12302,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12303,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12304,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12305,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12306,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,9196,A,,,,,,
12307,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,9196,A,,,,,,
12308,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12309,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12310,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12311,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12312,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,9196,A,,,,,,
12313,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,9196,A,,,,,,
12314,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12315,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12316,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,9196,A,,,,,,
12317,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12318,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12319,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,9196,A,,,,,,
12320,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12321,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12322,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12323,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,9196,A,,,,,,
12324,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12325,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,9196,A,,,,,,
12326,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",8608,A,,Rattus norvegicus,10116.0,,,
12327,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",8608,A,,Rattus norvegicus,10116.0,,,
12328,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",8608,A,,Rattus norvegicus,10116.0,,,
12329,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",8608,A,,Rattus norvegicus,10116.0,,,
12330,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",8608,A,,Rattus norvegicus,10116.0,,,
12331,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",8608,A,,Rattus norvegicus,10116.0,,,
12332,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",8608,A,,Rattus norvegicus,10116.0,,,
12333,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",8608,A,,Rattus norvegicus,10116.0,,,
12334,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",8608,A,,Rattus norvegicus,10116.0,,,
12335,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",8608,A,,Rattus norvegicus,10116.0,,,
12336,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",8608,A,,Rattus norvegicus,10116.0,,,
12337,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",8608,A,,Rattus norvegicus,10116.0,,,
12338,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",8608,A,,Rattus norvegicus,10116.0,,,
12339,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",8608,A,,Rattus norvegicus,10116.0,,,
12340,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",8608,A,,Rattus norvegicus,10116.0,,,
12341,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",8608,A,,Rattus norvegicus,10116.0,,,
12342,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",8608,A,,Rattus norvegicus,10116.0,,,
12343,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",8608,A,,Rattus norvegicus,10116.0,,,
12344,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12345,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12346,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12347,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12348,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12349,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12350,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12351,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12352,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12353,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,8085,A,,Rattus norvegicus,10116.0,,,
12354,Autocuration,22224,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,7657,P,,,,,,
12355,Intermediate,50594,,,Partition coefficient (logD7.4),8935,A,,Mus musculus,10090.0,,,
12356,Intermediate,50594,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",13792,A,,Mus musculus,10090.0,,,
12357,Intermediate,50594,Brain,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",13792,A,,Mus musculus,10090.0,,,
12358,Intermediate,50594,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,13792,A,,Mus musculus,10090.0,,,
12359,Intermediate,50594,Brain,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,13792,A,,Mus musculus,10090.0,,,
12360,Intermediate,50594,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",13792,A,,Mus musculus,10090.0,,,
12361,Intermediate,50594,Brain,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",13792,A,,Mus musculus,10090.0,,,
12362,Intermediate,50594,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,13792,A,,Mus musculus,10090.0,,,
12363,Intermediate,50597,Brain,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,13792,A,,Rattus norvegicus,10116.0,,,
12364,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12365,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12366,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12367,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12368,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12369,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12370,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12371,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12372,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12373,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12374,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12375,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12376,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12377,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12378,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12379,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12380,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12381,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12382,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12383,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12384,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,14103,A,,Rattus norvegicus,10116.0,,,
12385,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,14103,A,,Rattus norvegicus,10116.0,,,
12386,Autocuration,22224,,,Amount of acetic acid produced by the compound,12904,A,,,,,,
12387,Autocuration,22224,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,12904,A,,,,,,
12388,Intermediate,50597,,,Log of (Cbrain/Cblood) in rats,9663,A,,Rattus norvegicus,10116.0,,,
12389,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),7652,A,,,,,,
12390,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),7652,A,,,,,,
12391,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),7652,A,,,,,,
12392,Autocuration,22224,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),7652,B,,,,,,
12393,Autocuration,22224,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),7652,A,,,,,,
12394,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),7652,A,,,,,,
12395,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),7652,A,,,,,,
12396,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),7652,A,,,,,,
12397,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),7652,A,,,,,,
12398,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),7652,A,,,,,,
12399,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),7652,A,,,,,,
12400,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),7652,A,,,,,,
12401,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),7652,A,,,,,,
12402,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),7652,A,,,,,,
12403,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),7652,A,,,,,,
12404,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),7652,A,,,,,,
12405,Autocuration,22224,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,8267,F,In vivo,,,,,
12406,Intermediate,50588,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,8267,A,,Canis lupus familiaris,9615.0,,,
12407,Autocuration,22224,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,14479,A,,,,,,
12408,Autocuration,22224,,,Compound was evaluated for total body clearance,17515,A,,,,,,
12409,Autocuration,22224,,,Compound was evaluated for volume of distribution at steady state,17515,A,,,,,,
12410,Autocuration,22224,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,8142,A,,,,,,
12411,Autocuration,22224,,,Percentage of the diamine which is monoprotonated at pH 7.4,14849,A,,,,,,
12412,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,7653,A,,,,,,
12413,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12414,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12415,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12416,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12417,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12418,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12419,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12420,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12421,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12422,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12423,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12424,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,8631,A,,Rattus norvegicus,10116.0,,,
12425,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12426,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12427,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12428,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12429,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12430,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12431,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12432,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12433,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12434,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12435,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12436,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,8631,A,,Rattus norvegicus,10116.0,,,
12437,Autocuration,22224,,,Maximum biodistribution (Bmax) was determined.,10263,A,,,,,,
12438,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,12364,A,,Mus musculus,10090.0,,,
12439,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,12364,A,,Mus musculus,10090.0,,,
12440,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,12364,A,,Mus musculus,10090.0,,,
12441,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,12364,A,,Mus musculus,10090.0,,,
12442,Autocuration,22224,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,14793,A,,,,,,
12443,Autocuration,22224,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,14793,A,,,,,,
12444,Autocuration,22224,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,14793,A,,,,,,
12445,Autocuration,22224,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,14793,A,,,,,,
12446,Autocuration,22224,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,14793,A,,,,,,
12447,Autocuration,22224,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,14793,A,,,,,,
12448,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,14793,A,,,,,,
12449,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,14793,A,,,,,,
12450,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,14793,A,,,,,,
12451,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,14793,A,,,,,,
12452,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12453,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,9196,A,,,,,,
12454,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12455,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12456,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12457,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,8374,A,,Rattus norvegicus,10116.0,,,
12458,Intermediate,50597,Blood,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",8374,A,,Rattus norvegicus,10116.0,,,
12459,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,8374,A,,Rattus norvegicus,10116.0,,,
12460,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12461,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12462,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,8374,A,,Rattus norvegicus,10116.0,,,
12463,Intermediate,50597,Blood,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12464,Intermediate,50597,Blood,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12465,Intermediate,50597,Blood,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12466,Intermediate,50597,Blood,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12467,Intermediate,50597,Blood,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12468,Intermediate,50597,Blood,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12469,Intermediate,50597,Blood,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12470,Intermediate,50597,Blood,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12471,Intermediate,50597,Blood,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12472,Intermediate,50597,Blood,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12473,Intermediate,50597,Blood,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12474,Intermediate,50597,Blood,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12475,Intermediate,50597,Blood,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12476,Intermediate,50597,Blood,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12477,Intermediate,50597,Blood,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12478,Intermediate,50597,Blood,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12479,Intermediate,50597,Blood,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12480,Intermediate,50597,Blood,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12481,Intermediate,50597,Blood,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12482,Intermediate,50597,Blood,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12483,Intermediate,50597,Blood,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12484,Intermediate,50597,Blood,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12485,Intermediate,50597,Blood,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,8374,A,,Rattus norvegicus,10116.0,,,
12486,Intermediate,50597,Blood,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,8374,A,,Rattus norvegicus,10116.0,,,
12487,Intermediate,50597,Blood,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12488,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12489,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12490,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,9196,A,,,,,,
12491,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12492,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,9196,A,,,,,,
12493,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12494,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12495,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12496,Intermediate,50588,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,12023,A,,Canis lupus familiaris,9615.0,,,
12497,Intermediate,50597,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,12023,A,,Rattus norvegicus,10116.0,,,
12498,Intermediate,100710,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,12023,A,,Macaca fascicularis,9541.0,,,
12499,Autocuration,22224,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,10580,P,,,,,,
12500,Autocuration,22224,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,10580,P,,,,,,
12501,Autocuration,22224,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,16032,A,,,,,,
12502,Autocuration,22224,Urine,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,16032,A,,,,,,
12503,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12504,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12505,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12506,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12507,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12508,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12509,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12510,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12511,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12512,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12513,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12514,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12515,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12516,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12517,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12518,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12519,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12520,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12521,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12522,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12523,Intermediate,50597,Heart,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",8594,A,,Rattus norvegicus,10116.0,,,
12524,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12525,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12526,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12527,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12528,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12529,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12530,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12531,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12532,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12533,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12534,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12535,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12536,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12537,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),7653,A,,,,,,
12538,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),7653,A,,,,,,
12539,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,7653,A,,,,,,
12540,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,7653,A,,,,,,
12541,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",9104,A,,Rattus norvegicus,10116.0,,,
12542,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",9104,A,,Rattus norvegicus,10116.0,,,
12543,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",9104,A,,Rattus norvegicus,10116.0,,,
12544,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",9104,A,,Rattus norvegicus,10116.0,,,
12545,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",9104,A,,Rattus norvegicus,10116.0,,,
12546,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",9104,A,,Rattus norvegicus,10116.0,,,
12547,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",9104,A,,Rattus norvegicus,10116.0,,,
12548,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",9104,A,,Rattus norvegicus,10116.0,,,
12549,Intermediate,50597,,,Free level in rat plasma,12902,A,,Rattus norvegicus,10116.0,,,
12550,Autocuration,22224,,,Level reaching in blood plasma of rat or human was determined,6614,A,,,,,,
12551,Intermediate,50597,,,Log (Cbrain/Cblood) in rats,9663,A,,Rattus norvegicus,10116.0,,,
12552,Autocuration,22224,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,17658,A,,,,,,
12553,Autocuration,22224,,,Mean percentage of compound transport through membrane; expressed as membrane transport,17658,A,,,,,,
12554,Autocuration,22224,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,14314,A,,,,,,
12555,Autocuration,22224,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,7385,A,,,,,,
12556,Autocuration,22224,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",7385,A,,,,,,
12557,Autocuration,22224,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,7385,A,,,,,,
12558,Autocuration,22224,,,Net water uptake by a carrier mediated transport (%cm) mechanism,1329,A,,,,,,
12559,Autocuration,22224,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,12187,A,,Simiiformes,314293.0,,,
12560,Intermediate,50506,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,12187,A,,Mustela putorius furo,9669.0,,,
12561,Intermediate,50506,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",12187,A,,Mustela putorius furo,9669.0,,,
12562,Autocuration,22224,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,12187,A,,Simiiformes,314293.0,,,
12563,Autocuration,22224,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",12187,A,,Simiiformes,314293.0,,,
12564,Intermediate,50597,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,12187,A,,Rattus norvegicus,10116.0,,,
12565,Intermediate,50597,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",12187,A,,Rattus norvegicus,10116.0,,,
12566,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",9278,A,,Rattus norvegicus,10116.0,,,
12567,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",9278,A,,Rattus norvegicus,10116.0,,,
12568,Intermediate,100710,Plasma,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",9278,A,,Macaca fascicularis,9541.0,,,
12569,Intermediate,50587,Plasma,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",9278,A,,Homo sapiens,9606.0,,,
12570,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",9278,A,,Rattus norvegicus,10116.0,,,
12571,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",9278,A,,Rattus norvegicus,10116.0,,,
12572,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",9278,A,,Rattus norvegicus,10116.0,,,
12573,Intermediate,100710,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,12186,A,,Macaca fascicularis,9541.0,,,
12574,Intermediate,100710,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,12186,A,,Macaca fascicularis,9541.0,,,
12575,Autocuration,22224,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,12186,A,,,,,,
12576,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),12041,A,,Simiiformes,314293.0,,,
12577,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),12041,A,,Simiiformes,314293.0,,,
12578,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),12041,A,,Simiiformes,314293.0,,,
12579,Intermediate,50587,,,Permeability in Caco-2 assay at 10E-6,6737,A,,Homo sapiens,9606.0,,,
12580,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,13758,A,,,,,,
12581,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,13758,A,,,,,,
12582,Autocuration,22224,,,Plasma protein binding was determined,5676,A,,,,,,
12583,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,14793,A,,,,,,
12584,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,14793,A,,,,,,
12585,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,14793,A,,,,,,
12586,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,14793,A,,,,,,
12587,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,14793,A,,,,,,
12588,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,14793,A,,,,,,
12589,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,14793,A,,,,,,
12590,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,14793,A,,,,,,
12591,Autocuration,22224,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,14793,A,,,,,,
12592,Autocuration,22224,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,14793,A,,,,,,
12593,Autocuration,22224,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,14000,A,,,,,,
12594,Autocuration,22224,,,Partition coefficient (logP),5948,A,,,,,,
12595,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),13824,P,,,,,,
12596,Autocuration,22229,,,Calculated partition coefficient (clogP),10778,P,,,,,,
12597,Intermediate,50588,,,C max in dog,17237,A,In vivo,Canis lupus familiaris,9615.0,,,
12598,Intermediate,50512,,,C max in guinea pig,17237,A,In vivo,Cavia porcellus,10141.0,,,
12599,Autocuration,22224,,,C max value was evaluated,2809,A,In vivo,,,,,
12600,Autocuration,22224,,,Cmax value after oral dose of 0.1 mg//kg,11954,A,In vivo,,,,,
12601,Autocuration,22224,,,Cmax value after oral dose of 0.3 mg/kg,11954,A,In vivo,,,,,
12602,Autocuration,22224,,,Cmax value after oral dose of 1 mg/kg,11954,A,In vivo,,,,,
12603,Autocuration,22224,,,Cmax value after oral dose of 10 mg/kg,11954,A,In vivo,,,,,
12604,Autocuration,22224,,,Cmax value after oral dose of 23.4 mg/kg,11954,A,In vivo,,,,,
12605,Autocuration,22224,,,Cmax value after oral dose of 3 mg/kg,11954,A,In vivo,,,,,
12606,Autocuration,22224,,,Cmax value after oral dose of 3.87 mg/kg,11954,A,In vivo,,,,,
12607,Intermediate,50588,,,Cmax value in female Beagle dogs,12768,A,In vivo,Canis lupus familiaris,9615.0,,,
12608,Intermediate,50597,,,Cmax value in male rats,12768,A,In vivo,Rattus norvegicus,10116.0,,,
12609,Intermediate,50597,Plasma,,Cmax value in rat plasma when administered 20 mg/kg perorally,12780,A,In vivo,Rattus norvegicus,10116.0,,,
12610,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,15592,A,In vivo,Canis lupus familiaris,9615.0,,,
12611,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,15592,A,In vivo,Canis lupus familiaris,9615.0,,,
12612,Intermediate,50588,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,17025,A,,Canis lupus familiaris,9615.0,,,
12613,Autocuration,22224,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,17025,A,,Simiiformes,314293.0,,,
12614,Intermediate,50592,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,17025,A,,Oryctolagus cuniculus,9986.0,,,
12615,Intermediate,50597,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,17025,A,,Rattus norvegicus,10116.0,,,
12616,Intermediate,50797,Plasma,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,4236,A,,Macaca mulatta,9544.0,,,
12617,Intermediate,50597,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,15791,A,,Rattus norvegicus,10116.0,,,
12618,Autocuration,22224,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,11149,A,,,,,,
12619,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",15592,A,,Canis lupus familiaris,9615.0,,,
12620,Intermediate,50677,,,cytotoxicity against HIV protease enzyme.,15778,A,,Human immunodeficiency virus,12721.0,,,
12621,Intermediate,50594,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
12622,Intermediate,50594,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,12745,A,,Mus musculus,10090.0,,,
12623,Intermediate,50588,Plasma,,The plasma clearance in dog.,13941,A,In vivo,Canis lupus familiaris,9615.0,,,
12624,Intermediate,50597,Plasma,,The plasma clearance in rat.,13941,A,In vivo,Rattus norvegicus,10116.0,,,
12625,Intermediate,50597,Plasma,,Clearance from plasma in male Sprague-Dawley rats,16449,A,In vivo,Rattus norvegicus,10116.0,,,
12626,Intermediate,100710,Plasma,,Clearance from plasma in male cynomolgus monkeys,16449,A,In vivo,Macaca fascicularis,9541.0,,,
12627,Intermediate,50588,Plasma,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",14224,A,In vivo,Canis lupus familiaris,9615.0,,,
12628,Intermediate,50588,Plasma,,Clearance of compound in dog plasma,14224,A,In vivo,Canis lupus familiaris,9615.0,,,
12629,Intermediate,50587,Plasma,,Clearance of compound in human plasma,14224,A,In vivo,Homo sapiens,9606.0,,,
12630,Intermediate,50588,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,14317,A,In vivo,Canis lupus familiaris,9615.0,,,
12631,Intermediate,50588,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,14317,A,In vivo,Canis lupus familiaris,9615.0,,,
12632,Intermediate,50588,Plasma,,"Clearance (10 mg/kg, intravenously) in dog plasma",14224,A,In vivo,Canis lupus familiaris,9615.0,,,
12633,Intermediate,50588,,,Clearance value in dog,17237,A,In vivo,Canis lupus familiaris,9615.0,,,
12634,Intermediate,50512,,,Clearance value in guinea pig,17237,A,In vivo,Cavia porcellus,10141.0,,,
12635,Intermediate,50597,,,Clearance values in rats after iv administration.,14187,A,In vivo,Rattus norvegicus,10116.0,,,
12636,Autocuration,22224,Plasma,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,4806,A,In vivo,,,,,
12637,Intermediate,50592,,,In vivo clearance (5 mg/kg) was determined in rabbits,15025,A,In vivo,Oryctolagus cuniculus,9986.0,,,
12638,Intermediate,50597,,,Plasma Clearance rate was determined for the compound in rats,13197,A,In vivo,Rattus norvegicus,10116.0,,,
12639,Autocuration,22224,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,13197,A,In vivo,Saimiri,9520.0,,,
12640,Intermediate,50597,,,Plasma clearance in rat,13960,A,In vivo,Rattus norvegicus,10116.0,,,
12641,Autocuration,22224,,,Plasma clearance of the compound,17820,A,In vivo,,,,,
12642,Intermediate,50512,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,14706,A,In vivo,Cavia porcellus,10141.0,,,
12643,Intermediate,50512,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,14706,A,In vivo,Cavia porcellus,10141.0,,,
12644,Autocuration,22224,,,Plasma clearance was determined,6504,A,In vivo,,,,,
12645,Intermediate,50588,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,14925,A,In vivo,Canis lupus familiaris,9615.0,,,
12646,Intermediate,50597,,,Plasma clearance rate was determined for the compound in rats,13197,A,In vivo,Rattus norvegicus,10116.0,,,
12647,Autocuration,22224,,,Plasma clearance rate was determined for the compound in squirrel monkeys,13197,A,In vivo,Saimiri,9520.0,,,
12648,Autocuration,22224,,,Slow clearance (CL) was determined,3437,A,In vivo,,,,,
12649,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12650,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,9196,A,,,,,,
12651,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,9196,A,,,,,,
12652,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12653,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,9196,A,,,,,,
12654,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12655,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12656,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12657,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,9196,A,,,,,,
12658,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12659,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,9196,A,,,,,,
12660,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,9196,A,,,,,,
12661,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,9196,A,,,,,,
12662,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12663,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12664,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12665,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,9196,A,,,,,,
12666,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,9196,A,,,,,,
12667,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,9196,A,,,,,,
12668,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,9196,A,,,,,,
12669,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,9196,A,,,,,,
12670,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,9196,A,,,,,,
12671,Intermediate,50597,Blood,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12672,Intermediate,50597,Blood,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,8374,A,,Rattus norvegicus,10116.0,,,
12673,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,13477,A,,Rattus norvegicus,10116.0,,,
12674,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,13477,A,,Rattus norvegicus,10116.0,,,
12675,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,13477,A,,Rattus norvegicus,10116.0,,,
12676,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 1 hr,10009,A,,Mus musculus,10090.0,,,
12677,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 24 hr r,10009,A,,Mus musculus,10090.0,,,
12678,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 2 hr,10009,A,,Mus musculus,10090.0,,,
12679,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 3 hr,10009,A,,Mus musculus,10090.0,,,
12680,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 6 hr,10009,A,,Mus musculus,10090.0,,,
12681,Intermediate,50594,,,Distribution of compound in mice liver was measured after 1 hr,10009,A,,Mus musculus,10090.0,,,
12682,Intermediate,50594,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,10009,A,,Mus musculus,10090.0,,,
12683,Intermediate,50594,,,Distribution of compound in mice liver was measured after 2 hr,10009,A,,Mus musculus,10090.0,,,
12684,Intermediate,50594,,,Distribution of compound in mice liver was measured after 3 hr,10009,A,,Mus musculus,10090.0,,,
12685,Intermediate,50594,,,Distribution of compound in mice liver was measured after 6 hr,10009,A,,Mus musculus,10090.0,,,
12686,Intermediate,50588,Adrenal medulla,,Distribution in dog adrenal medulla 30 min after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12687,Intermediate,50588,Adrenal medulla,,Distribution in dog adrenal medulla 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12688,Intermediate,50588,,,Distribution in female dog Ovary 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12689,Intermediate,50588,,,Distribution in female dog Ovary 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12690,Intermediate,50588,,,Distribution in female dog adipose 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12691,Intermediate,50588,,,Distribution in female dog adipose 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12692,Intermediate,50588,Adrenal cortex,,Distribution in female dog adrenal cortex 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12693,Intermediate,50588,Adrenal cortex,,Distribution in female dog adrenal cortex 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12694,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12695,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12696,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12697,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12698,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12699,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12700,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12701,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12702,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12703,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12704,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12705,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12706,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12707,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12708,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12709,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12710,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12711,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12712,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12713,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12714,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12715,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12716,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12717,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12718,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12719,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12720,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12721,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12722,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12723,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12724,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12725,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12726,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12727,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12728,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12729,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12730,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12731,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,8594,A,,Rattus norvegicus,10116.0,,,
12732,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12733,Autocuration,22224,,,Rate of acetate production by the compound was determined,12904,A,,,,,,
12734,Autocuration,22224,,,Rate of acetate production by the compound was determined; Not determined,12904,A,,,,,,
12735,Autocuration,22224,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,3730,A,,,,,,
12736,Autocuration,22224,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,3627,A,,,,,,
12737,Intermediate,50592,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,13799,A,,Oryctolagus cuniculus,9986.0,,,
12738,Intermediate,50592,Plasma,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,13799,A,,Oryctolagus cuniculus,9986.0,,,
12739,Intermediate,50594,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,13799,A,,Mus musculus,10090.0,,,
12740,Intermediate,50597,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,13799,A,,Rattus norvegicus,10116.0,,,
12741,Intermediate,50597,Plasma,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,13799,A,,Rattus norvegicus,10116.0,,,
12742,Intermediate,50597,Plasma,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,13799,A,,Rattus norvegicus,10116.0,,,
12743,Autocuration,22229,,,Solubility after at a pH 1.2,6629,P,,,,,,
12744,Autocuration,22229,,,Solubility after at pH 1.2,6629,P,,,,,,
12745,Autocuration,22229,,,Solubility after injection of water,6629,P,,,,,,
12746,Autocuration,22224,,,Statistical significance of IC 50 values; Expressed as R value,14000,A,,,,,,
12747,Autocuration,22224,,,Systemic availability with respect to methyldopa was determined,8267,A,,,,,,
12748,Intermediate,50597,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,13799,A,,Rattus norvegicus,10116.0,,,
12749,Intermediate,50597,Plasma,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,13799,A,,Rattus norvegicus,10116.0,,,
12750,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12751,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12752,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",7132,A,,Oryctolagus cuniculus,9986.0,,,
12753,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",7132,A,,Oryctolagus cuniculus,9986.0,,,
12754,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",7132,A,,Oryctolagus cuniculus,9986.0,,,
12755,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",7132,A,,Oryctolagus cuniculus,9986.0,,,
12756,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
12757,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
12758,Intermediate,50592,Kidney,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12759,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12760,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",7132,A,,Oryctolagus cuniculus,9986.0,,,
12761,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12762,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",7132,A,,Oryctolagus cuniculus,9986.0,,,
12763,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",7132,A,,Oryctolagus cuniculus,9986.0,,,
12764,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",7132,A,,Oryctolagus cuniculus,9986.0,,,
12765,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",7132,A,,Oryctolagus cuniculus,9986.0,,,
12766,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",7132,A,,Oryctolagus cuniculus,9986.0,,,
12767,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
12768,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
12769,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",7132,A,,Oryctolagus cuniculus,9986.0,,,
12770,Intermediate,50592,Kidney,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12771,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12772,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",7132,A,,Oryctolagus cuniculus,9986.0,,,
12773,Intermediate,50592,Feces,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,7132,A,,Oryctolagus cuniculus,9986.0,,,
12774,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,7132,A,,Oryctolagus cuniculus,9986.0,,,
12775,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,7132,A,,Oryctolagus cuniculus,9986.0,,,
12776,Intermediate,50588,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,13317,A,In vivo,Canis lupus familiaris,9615.0,,,
12777,Intermediate,50588,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,15341,A,In vivo,Canis lupus familiaris,9615.0,,,
12778,Intermediate,50597,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
12779,Intermediate,50597,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
12780,Intermediate,50597,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,15341,A,In vivo,Rattus norvegicus,10116.0,,,
12781,Intermediate,50597,esophageal tunica muscularis mucosae,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,12801,A,In vitro,Rattus norvegicus,10116.0,,,
12782,Intermediate,50597,esophageal tunica muscularis mucosae,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,12801,A,In vitro,Rattus norvegicus,10116.0,,,
12783,Intermediate,50597,Plasma,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,14856,A,In vivo,Rattus norvegicus,10116.0,,,
12784,Intermediate,50597,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
12785,Intermediate,50597,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
12786,Intermediate,50597,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
12787,Intermediate,50597,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,14062,A,In vivo,Rattus norvegicus,10116.0,,,
12788,Intermediate,50588,Plasma,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,14346,A,In vivo,Canis lupus familiaris,9615.0,,,
12789,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
12790,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
12791,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
12792,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
12793,Intermediate,50588,Plasma,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,14346,A,In vivo,Canis lupus familiaris,9615.0,,,
12794,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,14346,A,In vivo,Rattus norvegicus,10116.0,,,
12795,Intermediate,50587,Plasma,,plasma clearance in human,15711,A,In vivo,Homo sapiens,9606.0,,,
12796,Intermediate,50597,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
12797,Intermediate,50597,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
12798,Intermediate,50597,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,14886,A,In vivo,Rattus norvegicus,10116.0,,,
12799,Autocuration,22229,,,1-Octanol/water partition coefficient measured at 7.4,4115,P,,,,,,
12800,Autocuration,22229,,,Calculated partition coefficient (clogP),13733,P,,,,,,
12801,Autocuration,22224,,,Partition coefficient (logP),12102,A,,,,,,
12802,Autocuration,22229,,,Calculated partition coefficient (clogP),12676,P,,,,,,
12803,Autocuration,22229,,,Calculated partition coefficient (clogP),13733,P,,,,,,
12804,Autocuration,22229,,,Calculated partition coefficient (clogP),13740,P,,,,,,
12805,Autocuration,22229,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),12766,P,,,,,,
12806,Autocuration,22229,,,Calculated partition coefficient (clogP),2764,P,,,,,,
12807,Autocuration,22229,,,Calculated partition coefficient (clogP),12355,P,,,,,,
12808,Autocuration,22229,,,Calculated partition coefficient of the compound,11314,P,,,,,,
12809,Autocuration,22224,,,Partition coefficient (logP),12706,A,,,,,,
12810,Autocuration,22229,,,Calculated partition coefficient (clogP),12645,P,,,,,,
12811,Autocuration,22229,,,Calculated partition coefficient (clogP),13668,P,,,,,,
12812,Autocuration,22229,,,Calculated partition coefficient (clogP),12819,P,,,,,,
12813,Autocuration,22229,,,Calculated partition coefficient (clogP),13668,P,,,,,,
12814,Autocuration,22229,,,Calculated partition coefficient (clogP),13017,P,,,,,,
12815,Autocuration,22224,,,Partition coefficient of the compound,2448,A,,,,,,
12816,Autocuration,22224,,,Partition coefficient of the compound,11526,A,,,,,,
12817,Autocuration,22224,,,Partition coefficient of compound was determined,12426,A,,,,,,
12818,Autocuration,22224,,,Partition coefficient was determined,2448,A,,,,,,
12819,Autocuration,22229,,,Calculated partition coefficient (clogP),12001,P,,,,,,
12820,Autocuration,22229,,,partition coefficient of compound was determined,12426,P,,,,,,
12821,Intermediate,50588,,,The total body administered intravenously in dog,13204,A,In vivo,Canis lupus familiaris,9615.0,,,
12822,Intermediate,50597,,,The total body administered intravenously in rats,13204,A,In vivo,Rattus norvegicus,10116.0,,,
12823,Intermediate,50594,,,Time taken for the administration to female NIH mice weighing 25-30 g.,13889,A,,Mus musculus,10090.0,,,
12824,Autocuration,22224,,,Time taken for the administration,13889,A,,,,,,
12825,Intermediate,50588,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,17025,A,In vivo,Canis lupus familiaris,9615.0,,,
12826,Autocuration,22224,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,17025,A,In vivo,Simiiformes,314293.0,,,
12827,Intermediate,50592,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,17025,A,In vivo,Oryctolagus cuniculus,9986.0,,,
12828,Intermediate,50597,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,17025,A,In vivo,Rattus norvegicus,10116.0,,,
12829,Autocuration,22224,,,Plasma clearance for the compound was determined.,15067,A,,,,,,
12830,Autocuration,22224,,,CLog P value of the compound,3091,P,,,,,,
12831,Autocuration,22229,,,Calculated partition coefficient (clogP),15592,P,,,,,,
12832,Autocuration,22229,,,Calculated partition coefficient (clogP),14738,P,,,,,,
12833,Autocuration,22224,,,ClogP value of the compound; nd ='no data',14738,P,,,,,,
12834,Autocuration,22224,,,ClogP value of the compound; nd ='not determined',14738,P,,,,,,
12835,Autocuration,22224,,,CLog P was determined,6076,P,,,,,,
12836,Autocuration,22229,,,Calculated partition coefficient (clogP),17840,P,,,,,,
12837,Autocuration,22224,,,CLogP was calculated,13589,A,,,,,,
12838,Autocuration,22224,,,CLogP value was determined,17655,A,,,,,,
12839,Autocuration,22224,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,5867,A,,,,,,
12840,Autocuration,22229,,,Calculated partition coefficient (clogP),5867,P,,,,,,
12841,Autocuration,22229,,,Calculated partition coefficient (clogP),10783,P,,,,,,
12842,Autocuration,22229,,,Calculated partition coefficient (clogP),14849,P,,,,,,
12843,Intermediate,50588,Adrenal medulla,,Distribution in female dog adrenal medulla 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12844,Intermediate,50588,Adrenal medulla,,Distribution in female dog adrenal medulla 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12845,Intermediate,50588,,,Distribution in female dog bile 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12846,Intermediate,50588,,,Distribution in female dog bile 72 hr after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12847,Intermediate,50588,,,Distribution in female dog blood 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12848,Intermediate,50588,,,Distribution in female dog blood 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12849,Intermediate,50588,,,Distribution in female dog heart 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12850,Intermediate,50588,,,Distribution in female dog heart 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12851,Intermediate,50588,,,Distribution in female dog kidney 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12852,Intermediate,50588,,,Distribution in female dog kidney 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12853,Intermediate,50588,Intestine,,Distribution in female dog large intestine 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12854,Intermediate,50588,Intestine,,Distribution in female dog large intestine 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12855,Intermediate,50588,,,Distribution in female dog liver 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12856,Intermediate,50588,,,Distribution in female dog liver 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12857,Intermediate,50588,,,Distribution in female dog lung 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12858,Intermediate,50588,,,Distribution in female dog lung 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12859,Intermediate,50588,Muscle tissue,,Distribution in female dog muscle 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12860,Intermediate,50588,Muscle tissue,,Distribution in female dog muscle 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12861,Intermediate,50588,,,Distribution in female dog pancreas 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12862,Intermediate,50588,,,Distribution in female dog pancreas 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12863,Intermediate,50588,Intestine,,Distribution in female dog small intestine 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12864,Intermediate,50588,Intestine,,Distribution in female dog small intestine 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12865,Intermediate,50588,Spleen,,Distribution in female dog spleen 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12866,Intermediate,50588,Spleen,,Distribution in female dog spleen 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12867,Intermediate,50588,Stomach,,Distribution in female dog stomach 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12868,Intermediate,50588,Stomach,,Distribution in female dog stomach 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12869,Intermediate,50588,Thyroid gland,,Distribution in female dog thyroid 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12870,Intermediate,50588,Thyroid gland,,Distribution in female dog thyroid 72 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12871,Intermediate,50588,Urine,,Distribution in female dog urine 24 hours after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12872,Intermediate,50588,Urine,,Distribution in female dog urine 72 hr after administration.,8170,A,,Canis lupus familiaris,9615.0,,,
12873,Autocuration,22224,Plasma,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,14283,A,,,,,,
12874,Autocuration,22224,,,Plasma concentration at 7 hr after intravenous dosing,5623,A,,,,,,
12875,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12876,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12877,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12878,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12879,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12880,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12881,Intermediate,50597,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,13477,A,,Rattus norvegicus,10116.0,,,
12882,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,13477,A,,Rattus norvegicus,10116.0,,,
12883,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,13477,A,,Rattus norvegicus,10116.0,,,
12884,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,13477,A,,Rattus norvegicus,10116.0,,,
12885,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,13477,A,,Rattus norvegicus,10116.0,,,
12886,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,13477,A,,Rattus norvegicus,10116.0,,,
12887,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,13477,A,,Rattus norvegicus,10116.0,,,
12888,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,13477,A,,Rattus norvegicus,10116.0,,,
12889,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,13477,A,,Rattus norvegicus,10116.0,,,
12890,Autocuration,22224,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,12553,A,,,,,,
12891,Autocuration,22224,Plasma,,The concentration in plasmat; Not determined,14548,A,,,,,,
12892,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in blood,14393,A,,Rattus norvegicus,10116.0,,,
12893,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,14393,A,,Rattus norvegicus,10116.0,,,
12894,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in heart,14393,A,,Rattus norvegicus,10116.0,,,
12895,Intermediate,50597,Liver,,Tissue level at 10 mg/kg/po in wistar rats in liver,14393,A,,Rattus norvegicus,10116.0,,,
12896,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,14393,A,,Rattus norvegicus,10116.0,,,
12897,Intermediate,50597,Muscle tissue,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,14393,A,,Rattus norvegicus,10116.0,,,
12898,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,14393,A,,Rattus norvegicus,10116.0,,,
12899,Autocuration,22224,,,Water solubility at 37 degree C.,1629,A,,,,,,
12900,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,8194,P,,,,,,
12901,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,8194,P,,,,,,
12902,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12903,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12904,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12905,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12906,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12907,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12908,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12909,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12910,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12911,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12912,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12913,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12914,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12915,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12916,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12917,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12918,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12919,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12920,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12921,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12922,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12923,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12924,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12925,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12926,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12927,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12928,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12929,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12930,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12931,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12932,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12933,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12934,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12935,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12936,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,8594,A,,Rattus norvegicus,10116.0,,,
12937,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,8151,A,,,,,,
12938,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,8151,A,,,,,,
12939,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,7132,A,,Oryctolagus cuniculus,9986.0,,,
12940,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,7132,A,,Oryctolagus cuniculus,9986.0,,,
12941,Autocuration,22224,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),5797,A,,,,,,
12942,Autocuration,22224,,,Alkylating activity was determined,7849,A,,,,,,
12943,Autocuration,22224,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),14220,A,,,,,,Microsomes
12944,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",8650,A,,Oryctolagus cuniculus,9986.0,,,
12945,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",8650,A,,Oryctolagus cuniculus,9986.0,,,
12946,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",8650,A,,Oryctolagus cuniculus,9986.0,,,
12947,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",8650,A,,Oryctolagus cuniculus,9986.0,,,
12948,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",8650,A,,Oryctolagus cuniculus,9986.0,,,
12949,Intermediate,50597,,,Compound was tested for antidiuretic activity in rats,7116,A,,Rattus norvegicus,10116.0,,,
12950,Autocuration,22224,,,Compound was tested for inactivation kinetic values,14131,A,,,,,,
12951,Autocuration,22224,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,7415,A,In vivo,,,,,
12952,Autocuration,22224,,,Dissociation rate calculated from the first-order equation using the t1/2 value,13178,A,,,,,,
12953,Autocuration,22229,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,8815,P,,,,,,
12954,Autocuration,22229,,,Aqueous solubility was measured,1450,P,,,,,,
12955,Autocuration,22229,,,Aqueous solubility was measured at a pH 4,1450,P,,,,,,
12956,Autocuration,22229,,,Aqueous solubility (pH 7),1450,P,,,,,,
12957,Autocuration,22229,,,Aqueous solubility was measured at a pH 9,1450,P,,,,,,
12958,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",12711,A,,,,,,
12959,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",12711,A,,,,,,
12960,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",12711,A,,,,,,
12961,Autocuration,22229,,,Aqueous solubility of the compound,15032,P,,,,,,
12962,Autocuration,22229,,,Aqueous solubility at 37 degree Celsius at pH 7.38,9964,P,,,,,,
12963,Autocuration,22229,,,Aqueous solubility in pH 7.4 phosphate buffer,14962,P,,,,,,
12964,Intermediate,50588,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,12487,A,,Canis lupus familiaris,9615.0,,,
12965,Intermediate,50588,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,12487,A,,Canis lupus familiaris,9615.0,,,
12966,Intermediate,50587,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,10026,A,,Homo sapiens,9606.0,,,
12967,Intermediate,50587,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,10026,A,,Homo sapiens,9606.0,,,
12968,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,10026,A,,Homo sapiens,9606.0,,,
12969,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,10026,A,,Homo sapiens,9606.0,,,
12970,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,10026,A,,Homo sapiens,9606.0,,,
12971,Autocuration,22224,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,10026,A,,,,,,
12972,Intermediate,50597,,,Compound was evaluated for the average bile flow rat in rats,7415,A,,Rattus norvegicus,10116.0,,,
12973,Intermediate,50592,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",17025,A,,Oryctolagus cuniculus,9986.0,,,
12974,Intermediate,50592,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",17025,A,,Oryctolagus cuniculus,9986.0,,,
12975,Autocuration,22224,,,Average half life period was determined,10184,A,,,,,,
12976,Autocuration,22224,,,Average half life period was determined,10184,A,,,,,,
12977,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12978,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12979,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12980,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12981,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12982,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12983,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12984,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12985,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
12986,Autocuration,22229,,,Calculated partition coefficient (clogP),6030,P,,,,,,
12987,Autocuration,22229,,,Calculated partition coefficient (clogP),6147,P,,,,,,
12988,Autocuration,22229,,,Calculated partition coefficient (clogP) (MacLogP),14556,P,,,,,,
12989,Autocuration,22224,,,Hydrophilicity was determined,768,A,,,,,,
12990,Autocuration,22229,,,Calculated partition coefficient (clogP),14452,P,,,,,,
12991,Autocuration,22224,,,Increased absorption was determined,5237,A,,,,,,
12992,Autocuration,22224,,,Lipophilicity value was evaluated,14378,P,,,,,,
12993,Autocuration,22224,,,Log P value of the compound.,14418,P,,,,,,
12994,Autocuration,22224,,,Partition coefficient of compound was determined,5249,A,,,,,,
12995,Autocuration,22229,,,Calculated partition coefficient (clogP),14621,P,,,,,,
12996,Autocuration,22229,,,Calculated partition coefficient (clogP),12542,P,,,,,,
12997,Autocuration,22224,,,Partition coefficient was measured by medchem software; Not calculated,12542,A,,,,,,
12998,Autocuration,22224,,,Partition coefficient was measured by octanol-water using standard shake-flask method,12542,P,,,,,,
12999,Autocuration,22229,,,Calculated partition coefficient (clogP),15462,P,,,,,,
13000,Autocuration,22224,,,Partition coefficient (logP),14884,A,,,,,,
13001,Autocuration,22229,,,Calculated partition coefficient (clogP),16526,P,,,,,,
13002,Autocuration,22229,,,The Octanol/Water partition coefficient CLogP,13693,P,,,,,,
13003,Autocuration,22224,,,The pharmacokinetic parameter C Log p was reported,13693,A,,,,,,
13004,Autocuration,22229,,,Calculated partition coefficient (clogP),13779,P,,,,,,
13005,Autocuration,22229,,,Calculated partition coefficient (clogP),14772,P,,,,,,
13006,Autocuration,22229,,,Calculated partition coefficient (clogP),14393,P,,,,,,
13007,Intermediate,50597,Plasma,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
13008,Intermediate,50597,Plasma,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
13009,Intermediate,50588,Plasma,,Compound was administered intravenously in dog to evaluate plasma clearance values,13744,A,In vivo,Canis lupus familiaris,9615.0,,,
13010,Autocuration,22224,Plasma,,Compound was administered intravenously in monkey to evaluate plasma clearance values,13744,A,In vivo,Simiiformes,314293.0,,,
13011,Intermediate,50594,Plasma,,Compound was administered intravenously in mouse to evaluate plasma clearance values,13744,A,In vivo,Mus musculus,10090.0,,,
13012,Intermediate,50588,Plasma,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,13207,A,In vivo,Canis lupus familiaris,9615.0,,,
13013,Intermediate,50797,Liver,,Intrinsic clearance in Rhesus liver microsome,5669,A,In vitro,Macaca mulatta,9544.0,,,Microsomes
13014,Intermediate,50588,Liver,,Intrinsic clearance in dog liver microsome,5669,A,In vitro,Canis lupus familiaris,9615.0,,,Microsomes
13015,Intermediate,50597,Liver,,Intrinsic clearance in rat liver microsome,5669,A,In vitro,Rattus norvegicus,10116.0,,,Microsomes
13016,Intermediate,50797,Plasma,,Low plasma clearance was calculated in rhesus monkey,4853,A,In vivo,Macaca mulatta,9544.0,,,
13017,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,16452,A,In vivo,Canis lupus familiaris,9615.0,,,
13018,Autocuration,22224,,,Plasma clearance after intravenous dose of 0.3 mg/kg,11954,A,In vivo,,,,,
13019,Autocuration,22224,,,Plasma clearance after intravenous dose of 1 mg/kg,11954,A,In vivo,,,,,
13020,Autocuration,22224,,,Plasma clearance after intravenous dose of 3 mg/kg,11954,A,In vivo,,,,,
13021,Autocuration,22224,,,Plasma clearance after intravenous dose of 3.87 mg/kg,11954,A,In vivo,,,,,
13022,Intermediate,50597,,,Plasma clearance after peroral administration at 10 mpk in Rat,5669,A,In vivo,Rattus norvegicus,10116.0,,,
13023,Intermediate,50797,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,5669,A,In vivo,Macaca mulatta,9544.0,,,
13024,Intermediate,50588,,,Plasma clearance after peroral administration at 10 mpk in dog,5669,A,In vivo,Canis lupus familiaris,9615.0,,,
13025,Intermediate,50597,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,13662,A,In vivo,Rattus norvegicus,10116.0,,,
13026,Autocuration,22224,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),8272,A,,,,,,
13027,Autocuration,22224,,,Critical Micellar concentration was determined,13410,A,,,,,,
13028,Autocuration,22224,,,Critical Micellar concentration of the compound. was determined,13410,A,,,,,,
13029,Autocuration,22224,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,12628,A,,,,,,
13030,Autocuration,22224,,,Critical micellar concentration was measured in water by the dye solubilization method,9675,A,,,,,,
13031,Autocuration,22224,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,12628,B,,,,,,
13032,Autocuration,22224,,,CMR value (relative to BAY K 8644),12766,A,,,,,,
13033,Autocuration,22224,,,Carbamoylating activity was determined,7849,A,,,,,,
13034,Autocuration,22224,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,12187,A,,Simiiformes,314293.0,,,
13035,Autocuration,22224,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,2040,A,,,,,,
13036,Autocuration,22224,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,2040,A,,,,,,
13037,Intermediate,50588,Plasma,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,14180,A,In vivo,Canis lupus familiaris,9615.0,,,
13038,Intermediate,50597,Plasma,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,14180,A,In vivo,Rattus norvegicus,10116.0,,,
13039,Intermediate,50588,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",14474,A,In vivo,Canis lupus familiaris,9615.0,,,
13040,Intermediate,50597,,,"Clearance rate at 5.5 mg/kg, iv, in rat",14474,A,In vivo,Rattus norvegicus,10116.0,,,
13041,Intermediate,100710,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,14548,A,In vivo,Macaca fascicularis,9541.0,,,
13042,Intermediate,100710,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,14548,A,In vivo,Macaca fascicularis,9541.0,,,
13043,Intermediate,50588,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,14548,A,In vivo,Canis lupus familiaris,9615.0,,,
13044,Intermediate,50597,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,14548,A,In vivo,Rattus norvegicus,10116.0,,,
13045,Intermediate,50597,Liver,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,6125,A,Ex vivo,Rattus norvegicus,10116.0,,,
13046,Autocuration,22224,,,Tested for the total clearance of the compound,6874,A,In vivo,,,,,
13047,Intermediate,50588,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,15343,A,In vivo,Canis lupus familiaris,9615.0,,,
13048,Autocuration,22224,,,Total body clearance was determined,6236,A,In vivo,,,,,
13049,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13050,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13051,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,8194,P,,,,,,
13052,Autocuration,22229,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,8194,P,,,,,,
13053,Autocuration,22229,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,8194,P,,,,,,
13054,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,8194,P,,,,,,
13055,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,8194,P,,,,,,
13056,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,8194,P,,,,,,
13057,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13058,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,13273,A,,Pneumocystis carinii,4754.0,,,
13059,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,13273,A,,Pneumocystis carinii,4754.0,,,
13060,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,13273,A,,Pneumocystis carinii,4754.0,,,
13061,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,13273,A,,Pneumocystis carinii,4754.0,,,
13062,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,13273,A,,Pneumocystis carinii,4754.0,,,
13063,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13064,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13065,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13066,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13067,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13068,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),13273,A,,Pneumocystis carinii,4754.0,,,
13069,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,13118,A,,,,,,
13070,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,13118,A,,,,,,
13071,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,13118,A,,,,,,
13072,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,13118,A,,,,,,
13073,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,13118,A,,,,,,
13074,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,13118,A,,,,,,
13075,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",10633,A,,Rattus norvegicus,10116.0,,,
13076,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",10633,A,,Rattus norvegicus,10116.0,,,
13077,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",10633,A,,Rattus norvegicus,10116.0,,,
13078,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",10633,A,,Rattus norvegicus,10116.0,,,
13079,Autocuration,22224,,,Cp max following ip administration at 1 mg/kg,5767,A,,,,,,
13080,Autocuration,22224,Plasma,,Maximum concentration in plasma was reported at 0.5 hour,3302,A,In vivo,,,,,
13081,Autocuration,22224,Plasma,,Maximum concentration in plasma was reported at 2 hour,3302,A,In vivo,,,,,
13082,Intermediate,50594,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,12467,A,,Mus musculus,10090.0,,,
13083,Autocuration,22229,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),11778,P,,,,,,
13084,Autocuration,22224,,,Steady state concentration was evaluated,4321,A,,,,,,
13085,Autocuration,22224,,,Partition coefficient (logP),14884,A,,,,,,
13086,Autocuration,22224,,,Partition coefficient (logD7.4),15234,A,,,,,,
13087,Intermediate,50597,Liver,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13088,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13089,Intermediate,50597,Cerebellum,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13090,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13091,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13092,Intermediate,50597,Heart,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13093,Intermediate,50597,Intestine,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13094,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,8151,A,,,,,,
13095,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,8151,A,,,,,,
13096,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,8151,A,,,,,,
13097,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,8151,A,,,,,,
13098,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,8151,A,,,,,,
13099,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,8151,A,,Rattus norvegicus,10116.0,,,
13100,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,8151,A,,Rattus norvegicus,10116.0,,,
13101,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,8151,A,,Rattus norvegicus,10116.0,,,
13102,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,8151,A,,Rattus norvegicus,10116.0,,,
13103,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,8151,A,,Rattus norvegicus,10116.0,,,
13104,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,8151,A,,Rattus norvegicus,10116.0,,,
13105,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,6996,A,,Canis lupus familiaris,9615.0,,,
13106,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,6996,A,,Canis lupus familiaris,9615.0,,,
13107,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,6996,A,,Canis lupus familiaris,9615.0,,,
13108,Expert,50588,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,6996,F,,Canis lupus familiaris,9615.0,,,
13109,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,6996,A,,Canis lupus familiaris,9615.0,,,
13110,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,6996,A,,Canis lupus familiaris,9615.0,,,
13111,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,6996,A,,Canis lupus familiaris,9615.0,,,
13112,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,6996,A,,Canis lupus familiaris,9615.0,,,
13113,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,6996,A,,Canis lupus familiaris,9615.0,,,
13114,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,6996,A,,Canis lupus familiaris,9615.0,,,
13115,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,6996,A,,Canis lupus familiaris,9615.0,,,
13116,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,6996,A,,Canis lupus familiaris,9615.0,,,
13117,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,6996,A,,Canis lupus familiaris,9615.0,,,
13118,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,6996,A,,Canis lupus familiaris,9615.0,,,
13119,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,6996,A,,Canis lupus familiaris,9615.0,,,
13120,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,6996,A,,Canis lupus familiaris,9615.0,,,
13121,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,6996,A,,Canis lupus familiaris,9615.0,,,
13122,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,6996,A,,Canis lupus familiaris,9615.0,,,
13123,Autocuration,22224,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",6996,B,,,,,,
13124,Intermediate,50588,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,6996,A,,Canis lupus familiaris,9615.0,,,
13125,Expert,50597,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",6996,F,,Rattus norvegicus,10116.0,,,
13126,Autocuration,22224,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,6996,B,,,,,,
13127,Expert,50597,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,6996,A,,Rattus norvegicus,10116.0,,,
13128,Intermediate,50597,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,6996,A,,Rattus norvegicus,10116.0,,,
13129,Autocuration,22224,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,7114,A,,,,,,
13130,Intermediate,50597,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,7114,A,,Rattus norvegicus,10116.0,,,
13131,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,8613,A,,Human herpesvirus 1,10298.0,,,
13132,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,8613,A,,Human herpesvirus 1,10298.0,,,
13133,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,8613,A,,Human herpesvirus 1,10298.0,,,
13134,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,8613,A,,Human herpesvirus 1,10298.0,,,
13135,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,8613,A,,Human herpesvirus 1,10298.0,,,
13136,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,8613,A,,Human herpesvirus 1,10298.0,,,
13137,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,8613,A,,Human herpesvirus 1,10298.0,,,
13138,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,8613,A,,Human herpesvirus 1,10298.0,,,
13139,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,8613,A,,Human herpesvirus 1,10298.0,,,
13140,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,8613,A,,Human herpesvirus 1,10298.0,,,
13141,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,8613,A,,Human herpesvirus 1,10298.0,,,
13142,Intermediate,50594,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,8613,A,,Mus musculus,10090.0,,,
13143,Intermediate,50506,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",11219,A,,Mustela putorius furo,9669.0,,,
13144,Intermediate,50506,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",11219,A,,Mustela putorius furo,9669.0,,,
13145,Intermediate,50506,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",11219,A,,Mustela putorius furo,9669.0,,,
13146,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,11219,A,,Mustela putorius furo,9669.0,,,
13147,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,11219,A,,Mustela putorius furo,9669.0,,,
13148,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,11219,A,,Mustela putorius furo,9669.0,,,
13149,Intermediate,50506,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,11219,A,,Mustela putorius furo,9669.0,,,
13150,Autocuration,22224,,,Pharmacokinetic parameter :drug bound to plasma was reported,14837,A,,,,,,
13151,Autocuration,22224,,,compound was evaluated for drug bound in plasma,14837,A,,,,,,
13152,Intermediate,50597,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,15343,A,,Rattus norvegicus,10116.0,,,
13153,Autocuration,22224,,,Bioavailability,13761,A,,Eutheria,9347.0,,,
13154,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,14810,A,,Rattus norvegicus,10116.0,,,
13155,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,14810,A,,Rattus norvegicus,10116.0,,,
13156,Intermediate,50588,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,13249,A,,Canis lupus familiaris,9615.0,,,
13157,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13158,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13159,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13160,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13161,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13162,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,9267,A,,Rattus norvegicus,10116.0,,,
13163,Intermediate,50587,Serum,,In vitro protein binding in human serum at 5 ug/ml,15549,A,,Homo sapiens,9606.0,,,
13164,Autocuration,22224,,,Serum protein binding ability was measured,10929,A,,,,,,
13165,Autocuration,22224,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),15444,A,,,,,,
13166,Autocuration,22224,,,Oral bioavailability in dog,12860,A,In vivo,Canis lupus familiaris,9615.0,,,
13167,Intermediate,50597,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,12170,A,In vivo,Rattus norvegicus,10116.0,,,
13168,Autocuration,22224,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,15173,A,In vivo,,,,,
13169,Autocuration,22224,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,15173,A,In vivo,,,,,
13170,Autocuration,22224,,,Oral bioavailability (dose 15 mg/kg i.v.),15173,A,In vivo,Eutheria,9347.0,,,
13171,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,15173,A,In vivo,,,,,
13172,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,15173,A,In vivo,,,,,
13173,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,15173,A,In vivo,,,,,
13174,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,15173,A,In vivo,,,,,
13175,Intermediate,50588,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,11767,A,In vivo,Canis lupus familiaris,9615.0,,,
13176,Autocuration,22224,,,Bioavailability in ferret,11219,A,In vivo,Mustela putorius furo,9669.0,,,
13177,Intermediate,100710,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,12186,A,In vivo,Macaca fascicularis,9541.0,,,
13178,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13179,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13180,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13181,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13182,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13183,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,11510,A,,Rattus norvegicus,10116.0,,,
13184,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13185,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13186,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13187,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13188,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13189,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13190,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13191,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13192,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13193,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13194,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13195,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13196,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13197,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13198,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13199,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13200,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13201,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13202,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13203,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13204,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13205,Autocuration,22224,,,Total body clearance was measured at given dose,7199,A,,,,,,
13206,Autocuration,22224,,,Total body clearance was measured at given dose.,7199,A,,,,,,
13207,Intermediate,50597,,,Metabolic clearance from the body in rat,7095,A,,Rattus norvegicus,10116.0,,,
13208,Autocuration,22224,,,Renal clearance from the body,7095,A,In vivo,,,,,
13209,Intermediate,50597,,,Renal clearance from the body in rat,7095,A,In vivo,Rattus norvegicus,10116.0,,,
13210,Intermediate,50597,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,12528,A,In vivo,Rattus norvegicus,10116.0,,,
13211,Intermediate,50588,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,12528,A,In vivo,Canis lupus familiaris,9615.0,,,
13212,Intermediate,50597,,,Total clearance from the body in rat,7095,A,,Rattus norvegicus,10116.0,,,
13213,Intermediate,50597,Plasma,,Clearance into cortex from rat plasma or PBS,14223,A,In vivo,Rattus norvegicus,10116.0,,,
13214,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,13569,A,In vivo,,,,,
13215,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,13569,A,In vivo,,,,,
13216,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,13569,A,In vivo,,,,,
13217,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,13569,A,In vivo,,,,,
13218,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,13569,A,In vivo,,,,,
13219,Autocuration,22224,,,Clearance was determined,13979,A,In vivo,,,,,
13220,Intermediate,50594,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,14315,A,In vivo,Mus musculus,10090.0,,,
13221,Intermediate,50592,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,14315,A,In vivo,Oryctolagus cuniculus,9986.0,,,
13222,Intermediate,50597,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,14315,A,In vivo,Rattus norvegicus,10116.0,,,
13223,Intermediate,50597,,,Clearance in rat after iv dose (100 ug/kg),12174,A,In vivo,Rattus norvegicus,10116.0,,,
13224,Autocuration,22224,,,Clearance in guinea pig,12797,A,In vivo,Cavia porcellus,10141.0,,,
13225,Intermediate,50597,,,Compound was evaluated for clearance in rat,12797,A,In vivo,Rattus norvegicus,10116.0,,,
13226,Intermediate,50588,,,Compound was evaluated for the clearance in dog,12797,A,In vivo,Canis lupus familiaris,9615.0,,,
13227,Intermediate,50597,,,Compound was evaluated for the clearance in rat,12797,A,In vivo,Rattus norvegicus,10116.0,,,
13228,Intermediate,50597,,,Compound was tested in vivo for clearance after iv administration in the rat,11500,A,In vivo,Rattus norvegicus,10116.0,,,
13229,Autocuration,22224,,,IV clearance determined at an iv dose of 14 mg/kg,15173,A,In vivo,,,,,
13230,Autocuration,22224,,,IV clearance determined at an iv dose of 15.2 mg/kg,15173,A,In vivo,,,,,
13231,Autocuration,22224,,,IV clearance determined at an iv dose of 15 mg/kg,15173,A,In vivo,,,,,
13232,Autocuration,22224,,,IV clearance determined at an peroral dose of 30 mg/kg.,15173,A,In vivo,,,,,
13233,Autocuration,22224,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,15173,A,In vivo,,,,,
13234,Autocuration,22224,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,15173,A,In vivo,,,,,
13235,Intermediate,50597,Kidney,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13236,Intermediate,50597,Liver,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13237,Intermediate,50597,Lung,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13238,Intermediate,50597,Muscle tissue,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13239,Intermediate,50597,Plasma,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13240,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13241,Intermediate,50597,Spleen,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13242,Intermediate,50597,Trachea,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13243,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13244,Intermediate,50597,Cerebellum,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13245,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13246,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13247,Intermediate,50597,Heart,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13248,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13249,Intermediate,50597,Kidney,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13250,Intermediate,50597,Liver,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13251,Intermediate,50597,Lung,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13252,Intermediate,50597,Muscle tissue,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13253,Intermediate,50597,Plasma,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13254,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13255,Intermediate,50597,Spleen,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13256,Intermediate,50597,Trachea,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13257,Intermediate,50597,Bone,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13258,Intermediate,50597,Cerebellum,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13259,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13260,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13261,Intermediate,50597,Heart,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13262,Intermediate,50597,Intestine,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13263,Intermediate,50597,Kidney,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13264,Intermediate,50597,Liver,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13265,Intermediate,50597,Lung,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13266,Intermediate,50597,Muscle tissue,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13267,Intermediate,50597,Plasma,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13268,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13269,Intermediate,50597,Spleen,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13270,Intermediate,50597,Trachea,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13271,Intermediate,50597,Bone,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13272,Intermediate,50597,Cerebellum,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13273,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13274,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13275,Intermediate,50597,Heart,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13276,Intermediate,50597,Intestine,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13277,Intermediate,50597,Kidney,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13278,Intermediate,50597,Lung,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13279,Intermediate,50597,Muscle tissue,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13280,Intermediate,50597,Plasma,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13281,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13282,Intermediate,50597,Spleen,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13283,Intermediate,50597,Trachea,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,14198,A,In vivo,Rattus norvegicus,10116.0,,,
13284,Intermediate,50212,,,Normal diffusion coefficient in water for Escherichia coli,15599,A,,Escherichia coli,562.0,,,
13285,Autocuration,22224,,,Average max percent decrease in RVR (renal vascular resistance) was determined,8204,A,,,,,,
13286,Autocuration,22224,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,8204,A,,,,,,
13287,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,6154,A,,,,,,
13288,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,6154,A,,,,,,
13289,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,6154,A,,,,,,
13290,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,6154,A,,,,,,
13291,Autocuration,22224,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,7114,A,,,,,,
13292,Intermediate,50597,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,7114,A,,Rattus norvegicus,10116.0,,,
13293,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13294,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13295,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13296,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13297,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13298,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13299,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13300,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13301,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13302,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13303,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13304,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13305,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13306,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13307,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13308,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13309,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13310,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13311,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13312,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13313,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13314,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13315,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13316,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13317,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13318,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13319,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13320,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13321,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13322,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13323,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13324,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13325,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13326,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13327,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13328,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13329,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13330,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13331,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13332,Autocuration,22224,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,12170,A,In vivo,Rattus norvegicus,10116.0,,,
13333,Autocuration,22224,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,12170,A,In vivo,Rattus norvegicus,10116.0,,,
13334,Autocuration,22224,,,Bioavailability (dose 20 mg/kg),4985,A,In vivo,Eutheria,9347.0,,,
13335,Autocuration,22224,,,Bioavailability in dog,15145,A,In vivo,Canis lupus familiaris,9615.0,,,
13336,Autocuration,22224,,,Bioavailability in rat (Sprague-Dawley) (male),14080,A,In vivo,Rattus norvegicus,10116.0,,,
13337,Autocuration,22224,,,Bioavailability in monkey (dose 10 mg/kg i.d.),11219,A,In vivo,Primates,9443.0,,,
13338,Autocuration,22224,,,Bioavailability in rat,15145,A,In vivo,Rattus norvegicus,10116.0,,,
13339,Autocuration,22224,,,Bioavailability in rat,15145,A,In vivo,Rattus norvegicus,10116.0,,,
13340,Autocuration,22224,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),1202,A,In vivo,Canis lupus familiaris,9615.0,,,
13341,Autocuration,22224,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,1202,A,In vivo,Canis lupus familiaris,9615.0,,,
13342,Intermediate,50505,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,1202,A,In vivo,Pan troglodytes,9598.0,,,
13343,Autocuration,22224,,,Bioavailability,4026,A,In vivo,Eutheria,9347.0,,,
13344,Autocuration,22224,,,Bioavailability in squirrel monkey,1492,A,In vivo,Saimiri,9520.0,,,
13345,Intermediate,50588,,,Bioavailability was evaluated in dog,12793,A,In vivo,Canis lupus familiaris,9615.0,,,
13346,Intermediate,100712,,,Bioavailability was evaluated in hamster,12793,A,In vivo,Cricetinae,10026.0,,,
13347,Autocuration,22224,,,Bioavailability in rat,12793,A,In vivo,Rattus norvegicus,10116.0,,,
13348,Intermediate,50597,Plasma,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,14793,A,In vivo,Rattus norvegicus,10116.0,,,
13349,Intermediate,50597,Plasma,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,14793,A,In vivo,Rattus norvegicus,10116.0,,,
13350,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg p.o.),14793,A,In vivo,Rattus norvegicus,10116.0,,,
13351,Intermediate,100710,,,Bioavailability was measured in cynomolgus monkeys.,14731,A,In vivo,Macaca fascicularis,9541.0,,,
13352,Intermediate,50594,,,Bioavailability was measured in nude mice.,14731,A,In vivo,Mus musculus,10090.0,,,
13353,Autocuration,22224,,,Bioavailability in ferret (dose 10 mg/kg i.d.),12187,A,In vivo,Mustela putorius furo,9669.0,,,
13354,Autocuration,22224,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),12187,A,In vivo,Simiiformes,314293.0,,,
13355,Autocuration,22224,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",12187,A,In vivo,Simiiformes,314293.0,,,
13356,Autocuration,22224,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),12187,A,In vivo,Simiiformes,314293.0,,,
13357,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg i.d.),12187,A,In vivo,Rattus norvegicus,10116.0,,,
13358,Intermediate,50597,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",12187,A,In vivo,Rattus norvegicus,10116.0,,,
13359,Autocuration,22224,,,Bioavailability was determined; extremely poor,17431,A,In vivo,,,,,
13360,Intermediate,50594,,,% bioavailability in mice after oral administration of prodrug,13318,A,In vivo,Mus musculus,10090.0,,,
13361,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13362,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13363,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13364,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13365,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13366,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13367,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13368,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13369,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13370,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13371,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13372,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13373,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13374,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13375,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13376,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13377,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13378,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13379,Autocuration,22224,,,IV clearance determined at an peroral dose of 15 mg/kg.,15173,A,In vivo,,,,,
13380,Expert,50064,,,Mouse oral clearance was measured against Hymenolepiasis nana.,7732,F,In vivo,Hymenolepis nana,102285.0,,,
13381,Expert,50545,,,Mouse oral clearance was measured against Nematospiroides dubius,7732,F,In vivo,Heligmosomoides polygyrus,6339.0,,,
13382,Autocuration,22224,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,7732,F,In vivo,,,,,
13383,Intermediate,50594,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,7732,A,In vivo,Mus musculus,10090.0,,,
13384,Autocuration,22224,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,7732,B,In vivo,,,,,
13385,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13386,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13387,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13388,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13389,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13390,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13391,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13392,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13393,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,8328,A,In vivo,,,,,
13394,Intermediate,50588,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,13376,A,In vivo,Canis lupus familiaris,9615.0,,,
13395,Intermediate,50797,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,13477,A,In vivo,Macaca mulatta,9544.0,,,
13396,Intermediate,50597,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,13477,A,In vivo,Rattus norvegicus,10116.0,,,
13397,Intermediate,50597,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,13477,A,In vivo,Rattus norvegicus,10116.0,,,
13398,Intermediate,50597,,,Plasma clearance was determined for the compound in rats,13313,A,In vivo,Rattus norvegicus,10116.0,,,
13399,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,12504,A,In vivo,Rattus norvegicus,10116.0,,,
13400,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,12504,A,In vivo,Rattus norvegicus,10116.0,,,
13401,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,12504,A,In vivo,Rattus norvegicus,10116.0,,,
13402,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,12504,A,In vivo,Rattus norvegicus,10116.0,,,
13403,Intermediate,50597,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,13129,A,In vivo,Rattus norvegicus,10116.0,,,
13404,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,7732,A,In vivo,Heligmosomoides polygyrus,6339.0,,,
13405,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,7732,A,In vivo,Heligmosomoides polygyrus,6339.0,,,
13406,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,7732,A,In vivo,Heligmosomoides polygyrus,6339.0,,,
13407,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,7732,A,In vivo,Heligmosomoides polygyrus,6339.0,,,
13408,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,7732,A,In vivo,Heligmosomoides polygyrus,6339.0,,,
13409,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,9278,A,In vivo,Rattus norvegicus,10116.0,,,
13410,Autocuration,22224,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,9278,A,In vivo,Rattus norvegicus,10116.0,,,
13411,Autocuration,22224,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,9278,A,In vivo,Rattus norvegicus,10116.0,,,
13412,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,9278,A,In vivo,Rattus norvegicus,10116.0,,,
13413,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 25 mg/kg os dosage,9278,A,In vivo,Rattus norvegicus,10116.0,,,
13414,Intermediate,50587,Urine,,Urinary clearance was determined at 100 mg/kg oral dosage in human,9278,A,In vivo,Homo sapiens,9606.0,,,
13415,Intermediate,50588,Urine,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,9278,A,In vivo,Canis lupus familiaris,9615.0,,,
13416,Intermediate,50588,Plasma,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,5932,A,In vivo,Canis lupus familiaris,9615.0,,,
13417,Intermediate,50597,Plasma,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,5932,A,In vivo,Rattus norvegicus,10116.0,,,
13418,Intermediate,50597,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,5182,A,In vivo,Rattus norvegicus,10116.0,,,
13419,Intermediate,50588,,,Clearance rate in dogs,10499,A,In vivo,Canis lupus familiaris,9615.0,,,
13420,Autocuration,22224,,,Compound was measured for intrinsic clearance,6051,A,In vitro,,,,,
13421,Autocuration,22229,,,Calculated partition coefficient (clogP),17508,P,,,,,,
13422,Autocuration,22229,,,Calculated partition coefficient (clogP),6228,P,,,,,,
13423,Autocuration,22229,,,Calculated partition coefficient (clogP),6231,P,,,,,,
13424,Autocuration,22229,,,Calculated partition coefficient (clogP),17740,P,,,,,,
13425,Autocuration,22229,,,Calculated partition coefficient (clogP),6495,P,,,,,,
13426,Autocuration,22229,,,Calculated partition coefficient (clogP),2171,P,,,,,,
13427,Autocuration,22224,,,Partition coefficient of the compound,3255,A,,,,,,
13428,Autocuration,22224,,,Permeability,6821,A,,,,,,
13429,Autocuration,22229,,,Calculated partition coefficient (clogP),2685,P,,,,,,
13430,Autocuration,22224,,,Partition coefficient (logD),17584,A,,,,,,
13431,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),13824,P,,,,,,
13432,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),13824,P,,,,,,
13433,Autocuration,22229,,,Calculated partition coefficient (clogP),16479,P,,,,,,
13434,Autocuration,22229,,,Calculated partition coefficient (clogP),11997,P,,,,,,
13435,Autocuration,22229,,,Calculated logarithm of partition coefficient (P) was determined,2988,P,,,,,,
13436,Autocuration,22229,,,Calculated partition coefficient (clogP),931,P,,,,,,
13437,Autocuration,22229,,,Calculated partition coefficient (clogP),4381,P,,,,,,
13438,Autocuration,22229,,,Calculated partition coefficient (clogP),4397,P,,,,,,
13439,Autocuration,22229,,,Calculated partition coefficient (clogP),5889,P,,,,,,
13440,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,6154,A,,,,,,
13441,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,6154,A,,,,,,
13442,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,6154,A,,,,,,
13443,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,6154,A,,,,,,
13444,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,6154,A,,,,,,
13445,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,6154,A,,,,,,
13446,Autocuration,22224,,,Percent degradation of compound at a pH of 1 over a 18 hr period,6887,A,,,,,,
13447,Autocuration,22224,,,Percent degradation of compound at pH of 1 over an 18 hr period,6887,A,,,,,,
13448,Autocuration,22224,,,Delta Logarithm of Partition Coefficient value was determined.,14116,A,,,,,,
13449,Autocuration,22224,,,Delta logPoct-cyc,11137,A,,,,,,
13450,Autocuration,22224,,,Lipophilicity estimated on reversed phase TLC,7230,P,,,,,,
13451,Autocuration,22224,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,15741,A,,,,,,
13452,Autocuration,22224,,,Delta logPoct-cyc,9663,A,,,,,,
13453,Autocuration,22229,,,Change in logarithm of partition coefficient of the compound,9663,P,,,,,,
13454,Autocuration,22224,,,Delta logD (pH 6.5),13807,A,,,,,,
13455,Autocuration,22224,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",13807,P,,,,,,
13456,Autocuration,22224,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,17425,A,,,,,,
13457,Autocuration,22224,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),12143,A,,,,,,
13458,Autocuration,22224,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,12608,A,,,,,,
13459,Autocuration,22224,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,12608,A,,,,,,
13460,Intermediate,50597,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,8649,A,,Rattus norvegicus,10116.0,,,
13461,Intermediate,50597,,,Amount of deuterium retained was reported after normal workup in rats,8649,A,,Rattus norvegicus,10116.0,,,
13462,Intermediate,50597,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,8649,A,,Rattus norvegicus,10116.0,,,
13463,Intermediate,50597,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,8649,A,,Rattus norvegicus,10116.0,,,
13464,Intermediate,50597,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,8649,A,,Rattus norvegicus,10116.0,,,
13465,Intermediate,50597,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,8649,A,,Rattus norvegicus,10116.0,,,
13466,Intermediate,50597,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,8649,A,,Rattus norvegicus,10116.0,,,
13467,Autocuration,22224,,,Compound was subjected to electrochemical oxidation,9659,A,,,,,,
13468,Autocuration,22224,,,Compound was subjected to photochemical oxidation,9659,A,,,,,,
13469,Autocuration,22224,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,9659,A,,,,,,
13470,Autocuration,22224,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,9659,A,,,,,,
13471,Autocuration,22224,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,9659,A,,,,,,
13472,Intermediate,50597,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,9607,A,,Rattus norvegicus,10116.0,,,
13473,Autocuration,22229,,,Dissociation constant (pKa),7057,P,,,,,,
13474,Autocuration,22224,,,Dissociation constant value of the compound; ND means not determined.,7057,P,,,,,,
13475,Intermediate,50597,Blood,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13476,Intermediate,50597,Blood,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13477,Intermediate,50597,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13478,Intermediate,50597,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13479,Intermediate,50597,Liver,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13480,Intermediate,50597,Liver,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13481,Intermediate,50597,Spleen,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13482,Intermediate,50597,Spleen,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13483,Intermediate,50597,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13484,Intermediate,50597,Urine,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13485,Intermediate,50597,Feces,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13486,Intermediate,50597,Urine,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,7911,A,,Rattus norvegicus,10116.0,,,
13487,Intermediate,50594,Cerebellum,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,13792,A,,Mus musculus,10090.0,,,
13488,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,13792,A,,Mus musculus,10090.0,,,
13489,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13490,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13491,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13492,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13493,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13494,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13495,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13496,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13497,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13498,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13499,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13500,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13501,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13502,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13503,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13504,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13505,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13506,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13507,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13508,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13509,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13510,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13511,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13512,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13513,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13514,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13515,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",8133,A,,Canis lupus familiaris,9615.0,,,
13516,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13517,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13518,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13519,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13520,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",8133,A,,Simiiformes,314293.0,,,
13521,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13522,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13523,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13524,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13525,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13526,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13527,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13528,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13529,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13530,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13531,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13532,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13533,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13534,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13535,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13536,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13537,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13538,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13539,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13540,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13541,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13542,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13543,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13544,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13545,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13546,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13547,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13548,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13549,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13550,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13551,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13552,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13553,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13554,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13555,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13556,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13557,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13558,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13559,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13560,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13561,Intermediate,50597,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,9025,A,In vivo,Rattus norvegicus,10116.0,,,
13562,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,9025,A,In vivo,Canis lupus familiaris,9615.0,,,
13563,Autocuration,22229,,,Calculated partition coefficient (clogP),6448,P,,,,,,
13564,Autocuration,22229,,,Calculated partition coefficient (clogP),17221,P,,,,,,
13565,Autocuration,22229,,,Calculated partition coefficient (clogP),6545,P,,,,,,
13566,Autocuration,22229,,,Calculated partition coefficient (clogP),577,P,,,,,,
13567,Autocuration,22229,,,Calculated partition coefficient (clogP),6285,P,,,,,,
13568,Autocuration,22229,,,Calculated partition coefficient (clogP),6500,P,,,,,,
13569,Autocuration,22229,,,Calculated partition coefficient (clogP),6716,P,,,,,,
13570,Autocuration,22229,,,Calculated partition coefficient (clogP),13658,P,,,,,,
13571,Autocuration,22229,,,Calculated partition coefficient (clogP),6549,P,,,,,,
13572,Autocuration,22229,,,Calculated partition coefficient (clogP) (MacLogP),14685,P,,,,,,
13573,Autocuration,22224,,,Partition coefficient (logP),6893,A,,,,,,
13574,Autocuration,22224,,,Kinetic parameter was determined,3687,A,,,,,,
13575,Autocuration,22229,,,Calculated partition coefficient (clogP),4207,P,,,,,,
13576,Autocuration,22229,,,Calculated partition coefficient (clogP),4626,P,,,,,,
13577,Autocuration,22224,,,Lipophilicity was determined,1021,P,,,,,,
13578,Autocuration,22224,,,Lipophilicity was determined,3777,P,,,,,,
13579,Autocuration,22224,,,Lipophilicity was determined,17533,P,,,,,,
13580,Autocuration,22229,,,Calculated partition coefficient (clogP),6524,P,,,,,,
13581,Autocuration,22224,,,Lipophilicity was determined,17533,P,,,,,,
13582,Autocuration,22224,,,Lipophilicity in octanol-water,6480,P,,,,,,
13583,Autocuration,22229,,,Calculated partition coefficient (clogP),17606,P,,,,,,
13584,Autocuration,22229,,,Octanol-water partition coefficient was determined,6863,P,,,,,,
13585,Autocuration,22224,,,Partition coefficient (logP),1356,A,,,,,,
13586,Autocuration,22229,,,Calculated partition coefficient (clogP),3326,P,,,,,,
13587,Autocuration,22224,,,Partition coefficient was determined; ND means not determined,1356,A,,,,,,
13588,Autocuration,22229,,,Calculated partition coefficient (clogP),12984,P,,,,,,
13589,Autocuration,22224,,,Partition coefficient of the compound,17363,A,,,,,,
13590,Autocuration,22224,,,Permeability was determined,6827,A,,,,,,
13591,Autocuration,22229,,,The compound was evaluated for the partition coefficient,261,P,,,,,,
13592,Autocuration,22224,,,Partition coefficient (logP),2685,A,,,,,,
13593,Autocuration,22224,,,The lipophilicity was reported,414,P,,,,,,
13594,Autocuration,22229,,,logarithm of the octanol-water partition coefficient for the compound,15769,P,,,,,,
13595,Autocuration,22224,,,Clogp value was determined,17248,A,,,,,,
13596,Autocuration,22224,,,Clp at a dose of 1.5 mg/kg,16935,A,In vivo,,,,,
13597,Autocuration,22224,,,Clp at a dose of 2.0 mg/kg,16935,A,In vivo,,,,,
13598,Autocuration,22224,Plasma,,"Clp, plasma clearance at a dose of 10 mg/kg",14832,A,In vivo,,,,,
13599,Autocuration,22224,Plasma,,"Clp, plasma clearance at a dose of 50 mg/kg",14832,A,In vivo,,,,,
13600,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat,2399,A,In vivo,Rattus norvegicus,10116.0,,,
13601,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat; Not determined,2399,A,In vivo,Rattus norvegicus,10116.0,,,
13602,Intermediate,50597,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,6227,A,In vivo,Rattus norvegicus,10116.0,,,
13603,Intermediate,50797,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,6227,A,In vivo,Macaca mulatta,9544.0,,,
13604,Autocuration,22224,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,5623,A,In vivo,,,,,
13605,Autocuration,22224,,,Plasma clearance determined,4854,A,In vivo,,,,,
13606,Intermediate,100712,,,Plasma clearance after iv administration at 3 mg/kg in hamster,4493,A,In vivo,Cricetinae,10026.0,,,
13607,Intermediate,100712,,,Plasma clearance after iv administration at 4 mg/kg in hamster,4493,A,In vivo,Cricetinae,10026.0,,,
13608,Intermediate,50597,,,Rate of clearance in rat was determined,14956,A,In vivo,Rattus norvegicus,10116.0,,,
13609,Intermediate,50597,Plasma,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
13610,Intermediate,50597,Plasma,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
13611,Intermediate,50597,Plasma,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
13612,Intermediate,50597,Plasma,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,15372,A,In vivo,Rattus norvegicus,10116.0,,,
13613,Autocuration,22224,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,15604,A,In vivo,Simiiformes,314293.0,,,
13614,Intermediate,50597,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,15604,A,In vivo,Rattus norvegicus,10116.0,,,
13615,Intermediate,50588,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,15604,A,In vivo,Canis lupus familiaris,9615.0,,,
13616,Intermediate,50597,,,Clpl value in rat,14964,A,In vivo,Rattus norvegicus,10116.0,,,
13617,Intermediate,50512,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,15240,A,In vivo,Cavia porcellus,10141.0,,,
13618,Intermediate,50597,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,16449,A,In vivo,Rattus norvegicus,10116.0,,,
13619,Intermediate,100710,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,16449,A,In vivo,Macaca fascicularis,9541.0,,,
13620,Autocuration,22224,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,12902,A,In vivo,,,,,
13621,Autocuration,22224,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,12902,A,In vivo,,,,,
13622,Autocuration,22224,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,12902,A,In vivo,,,,,
13623,Autocuration,22224,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,12902,A,In vivo,,,,,
13624,Autocuration,22224,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,12902,A,In vivo,,,,,
13625,Autocuration,22224,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,12902,A,In vivo,,,,,
13626,Autocuration,22224,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,12902,A,In vivo,,,,,
13627,Autocuration,22224,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,12902,A,In vivo,,,,,
13628,Autocuration,22224,Blood,,Cmax was calculated as maximum concentration reached in the blood,11149,A,In vivo,,,,,
13629,Autocuration,22224,Blood,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,11149,A,In vivo,,,,,
13630,Intermediate,50597,,,Cmax was determine after peroral administration at 10 mpk in Rat,5669,A,In vivo,Rattus norvegicus,10116.0,,,
13631,Intermediate,50797,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,5669,A,In vivo,Macaca mulatta,9544.0,,,
13632,Intermediate,50588,,,Cmax was determine after peroral administration at 10 mpk in dog,5669,A,In vivo,Canis lupus familiaris,9615.0,,,
13633,Intermediate,50597,,,Cmax was determine after peroral administration at 160 mpk in Rat,5669,A,In vivo,Rattus norvegicus,10116.0,,,
13634,Intermediate,50597,,,Cmax was determine after peroral administration at 20 mpk in Rat,5669,A,In vivo,Rattus norvegicus,10116.0,,,
13635,Intermediate,50597,,,Cmax was determine after peroral administration at 50 mpk in Rat,5669,A,In vivo,Rattus norvegicus,10116.0,,,
13636,Autocuration,22224,,,Cmax was determined,4236,A,In vivo,,,,,
13637,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,13792,A,,Mus musculus,10090.0,,,
13638,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,13792,A,,Mus musculus,10090.0,,,
13639,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,13792,A,,Mus musculus,10090.0,,,
13640,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,13792,A,,Mus musculus,10090.0,,,
13641,Intermediate,50594,Striatum,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,13792,A,,Mus musculus,10090.0,,,
13642,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,8418,A,,Rattus norvegicus,10116.0,,,
13643,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,8418,A,,Rattus norvegicus,10116.0,,,
13644,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,8418,A,,Rattus norvegicus,10116.0,,,
13645,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,8418,A,,Rattus norvegicus,10116.0,,,
13646,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,8418,A,,Rattus norvegicus,10116.0,,,
13647,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,8418,A,,Rattus norvegicus,10116.0,,,
13648,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,8418,A,,Rattus norvegicus,10116.0,,,
13649,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,8418,A,,Rattus norvegicus,10116.0,,,
13650,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,8418,A,,Rattus norvegicus,10116.0,,,
13651,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,8418,A,,Rattus norvegicus,10116.0,,,
13652,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,8418,A,,Rattus norvegicus,10116.0,,,
13653,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,8418,A,,Rattus norvegicus,10116.0,,,
13654,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,8418,A,,Rattus norvegicus,10116.0,,,
13655,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,8418,A,,Rattus norvegicus,10116.0,,,
13656,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,8418,A,,Rattus norvegicus,10116.0,,,
13657,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,8418,A,,Rattus norvegicus,10116.0,,,
13658,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,8418,A,,Rattus norvegicus,10116.0,,,
13659,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,8418,A,,Rattus norvegicus,10116.0,,,
13660,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,8418,A,,Rattus norvegicus,10116.0,,,
13661,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,8418,A,,Rattus norvegicus,10116.0,,,
13662,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,8418,A,,Rattus norvegicus,10116.0,,,
13663,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,8418,A,,Rattus norvegicus,10116.0,,,
13664,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,8418,A,,Rattus norvegicus,10116.0,,,
13665,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,8418,A,,Rattus norvegicus,10116.0,,,
13666,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,8418,A,,Rattus norvegicus,10116.0,,,
13667,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,8418,A,,Rattus norvegicus,10116.0,,,
13668,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,8418,A,,Rattus norvegicus,10116.0,,,
13669,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,8418,A,,Rattus norvegicus,10116.0,,,
13670,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,8418,A,,Rattus norvegicus,10116.0,,,
13671,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,8418,A,,Rattus norvegicus,10116.0,,,
13672,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,8418,A,,Rattus norvegicus,10116.0,,,
13673,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,8418,A,,Rattus norvegicus,10116.0,,,
13674,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,8418,A,,Rattus norvegicus,10116.0,,,
13675,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,8418,A,,Rattus norvegicus,10116.0,,,
13676,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,8418,A,,Rattus norvegicus,10116.0,,,
13677,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,8418,A,,Rattus norvegicus,10116.0,,,
13678,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,8418,A,,Rattus norvegicus,10116.0,,,
13679,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,8418,A,,Rattus norvegicus,10116.0,,,
13680,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13681,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13682,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",8133,A,,Rattus norvegicus,10116.0,,,
13683,Intermediate,50597,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13684,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
13685,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13686,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13687,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13688,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
13689,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13690,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
13691,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13692,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13693,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13694,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
13695,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13696,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
13697,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13698,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13699,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13700,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
13701,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13702,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,6996,A,,Rattus norvegicus,10116.0,,,
13703,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13704,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13705,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13706,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),6996,A,,Rattus norvegicus,10116.0,,,
13707,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),6996,A,,Rattus norvegicus,10116.0,,,
13708,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
13709,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13710,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
13711,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13712,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13713,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13714,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13715,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13716,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13717,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13718,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13719,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),6996,A,,Canis lupus familiaris,9615.0,,,
13720,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13721,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13722,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,6996,A,,Canis lupus familiaris,9615.0,,,
13723,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13724,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),6996,A,,Canis lupus familiaris,9615.0,,,
13725,Intermediate,50594,Zone of skin,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13726,Intermediate,50594,Zone of skin,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13727,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13728,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13729,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13730,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13731,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13732,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13733,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13734,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13735,Intermediate,50594,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13736,Intermediate,50594,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13737,Intermediate,50594,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13738,Intermediate,50594,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",9716,A,In vivo,Mus musculus,10090.0,,,
13739,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13740,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,12192,A,,Mus musculus,10090.0,,,
13741,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13742,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,12192,A,,Mus musculus,10090.0,,,
13743,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13744,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,12192,A,,Mus musculus,10090.0,,,
13745,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13746,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,12192,A,,Mus musculus,10090.0,,,
13747,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13748,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,12192,A,,Mus musculus,10090.0,,,
13749,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),12192,A,,Mus musculus,10090.0,,,
13750,Autocuration,22224,Feces,,Removal of 238-Plutonium(IV) in feces at 24 h,12192,A,,,,,,
13751,Autocuration,22224,Feces,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),12192,A,,,,,,
13752,Autocuration,22224,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,12192,A,,,,,,
13753,Autocuration,22224,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),12192,A,,,,,,
13754,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),12192,A,,,,,,
13755,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),12192,A,,,,,,
13756,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 h,12192,A,,,,,,
13757,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),12192,A,,,,,,
13758,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 h,12192,A,,,,,,
13759,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),12192,A,,,,,,
13760,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 h,12192,A,,,,,,
13761,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),12192,A,,,,,,
13762,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),12192,A,,,,,,
13763,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),12192,A,,,,,,
13764,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13765,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13766,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13767,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13768,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13769,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13770,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13771,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13772,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13773,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13774,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13775,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13776,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13777,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13778,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13779,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13780,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13781,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13782,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13783,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13784,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13785,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13786,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13787,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,11836,A,,Rattus norvegicus,10116.0,,,
13788,Intermediate,50597,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13789,Intermediate,50597,Uterus,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,11836,A,,Rattus norvegicus,10116.0,,,
13790,Autocuration,22224,,,Tested in vitro for intrinsic activity relative to quinpirole,12640,A,,,,,,
13791,Autocuration,22224,,,"Relative ion enhancement, determined in pulsed ultrafiltration",14218,A,,,,,,
13792,Autocuration,22224,,,% ionization at the pH 7.4 at 37 degree Centigrade,11296,A,,,,,,
13793,Autocuration,22224,,,Percentage ionization was measured,10929,A,,,,,,
13794,Intermediate,50591,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,13841,A,,Bos taurus,9913.0,,,
13795,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,10431,A,,,,,,
13796,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,10431,A,,,,,,
13797,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,10431,A,,,,,,
13798,Autocuration,22229,,,Compound was evaluated for the partition coefficient in octanol/water,8826,P,,,,,,
13799,Autocuration,22229,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),8826,P,,,,,,
13800,Autocuration,22224,,,Equilibrium constant measured by the pulse radiolysis at pH 7,9884,A,,,,,,
13801,Intermediate,50587,,,In vitro hydrolytic rate constant determined in human blood,9827,A,,Homo sapiens,9606.0,,,
13802,Intermediate,50587,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,10009,A,,Homo sapiens,9606.0,,,
13803,Autocuration,22224,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,10009,A,,,,,,
13804,Intermediate,50594,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,10009,A,,Mus musculus,10090.0,,,
13805,Intermediate,50594,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,10009,A,,Mus musculus,10090.0,,,
13806,Intermediate,50587,,,In vitro oxidation of compound in presence of human plasma,10009,A,,Homo sapiens,9606.0,,,
13807,Autocuration,22224,,,In vitro oxidation of compound in presence of hydrogen peroxide,10009,A,,,,,,
13808,Intermediate,50594,,,In vitro oxidation of compound in presence of mouse brain homogenate,10009,A,,Mus musculus,10090.0,,,
13809,Intermediate,50594,,,In vitro oxidation of compound in presence of mouse liver homogenate,10009,A,,Mus musculus,10090.0,,,
13810,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13811,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13812,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13813,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13814,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13815,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13816,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13817,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,11510,A,,Rattus norvegicus,10116.0,,,
13818,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13819,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13820,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13821,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13822,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13823,Intermediate,50597,Blood,,Biodistribution in rat blood at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13824,Intermediate,50597,Blood,,Biodistribution in rat blood at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13825,Intermediate,50597,Blood,,Biodistribution in rat blood at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13826,Intermediate,50597,Blood,,Biodistribution in rat blood at 3 hr after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13827,Intermediate,50597,Blood,,Biodistribution in rat blood at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13828,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13829,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13830,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13831,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13832,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13833,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13834,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 3 hr after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13835,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13836,Intermediate,50597,,,Biodistribution in rat cortex at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13837,Intermediate,50597,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13838,Intermediate,50597,,,Biodistribution in rat cortex at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13839,Intermediate,50597,,,Biodistribution in rat cortex at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13840,Intermediate,50597,,,Biodistribution in rat cortex at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13841,Intermediate,50597,,,Biodistribution in rat cortex at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13842,Intermediate,50597,,,Biodistribution in rat cortex at 3 hr after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13843,Intermediate,50597,,,Biodistribution in rat cortex at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13844,Intermediate,50597,Heart,,Biodistribution in rat heart at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13845,Intermediate,50597,Heart,,Biodistribution in rat heart at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13846,Intermediate,50597,Heart,,Biodistribution in rat heart at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13847,Intermediate,50597,Heart,,Biodistribution in rat heart at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13848,Intermediate,50597,Heart,,Biodistribution in rat heart at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13849,Intermediate,50597,Heart,,Biodistribution in rat heart at 3 hr after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13850,Intermediate,50597,Heart,,Biodistribution in rat heart at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13851,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13852,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13853,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13854,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13855,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13856,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13857,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13858,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13859,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13860,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13861,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13862,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13863,Intermediate,50597,Liver,,Biodistribution in rat liver at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13864,Intermediate,50597,Liver,,Biodistribution in rat liver at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13865,Intermediate,50597,Liver,,Biodistribution in rat liver at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13866,Intermediate,50597,Liver,,Biodistribution in rat liver at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13867,Intermediate,50597,Liver,,Biodistribution in rat liver at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13868,Intermediate,50597,Liver,,Biodistribution in rat liver at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13869,Intermediate,50597,Liver,,Biodistribution in rat liver at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13870,Intermediate,50597,Lung,,Biodistribution in rat lung at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13871,Intermediate,50597,Lung,,Biodistribution in rat lung at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13872,Intermediate,50597,Lung,,Biodistribution in rat lung at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13873,Intermediate,50597,Lung,,Biodistribution in rat lung at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13874,Intermediate,50597,Lung,,Biodistribution in rat lung at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13875,Intermediate,50597,Lung,,Biodistribution in rat lung at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
13876,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,12361,A,,Rattus norvegicus,10116.0,,,
13877,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,12361,A,,Rattus norvegicus,10116.0,,,
13878,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,12361,A,,Rattus norvegicus,10116.0,,,
13879,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,12361,A,,Rattus norvegicus,10116.0,,,
13880,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,12361,A,,Rattus norvegicus,10116.0,,,
13881,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,12361,A,,Rattus norvegicus,10116.0,,,
13882,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,12361,A,,Rattus norvegicus,10116.0,,,
13883,Intermediate,50597,Urine,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,12712,A,,Rattus norvegicus,10116.0,,,
13884,Intermediate,50597,Feces,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,7415,A,,Rattus norvegicus,10116.0,,,
13885,Intermediate,50597,Urine,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,7415,A,,Rattus norvegicus,10116.0,,,
13886,Intermediate,50597,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,7415,A,,Rattus norvegicus,10116.0,,,
13887,Intermediate,50597,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,7415,A,,Rattus norvegicus,10116.0,,,
13888,Intermediate,50597,Feces,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",7415,A,,Rattus norvegicus,10116.0,,,
13889,Intermediate,50597,Urine,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",7415,A,,Rattus norvegicus,10116.0,,,
13890,Intermediate,50597,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",7415,A,,Rattus norvegicus,10116.0,,,
13891,Intermediate,50594,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,8050,A,,Mus musculus,10090.0,,,
13892,Intermediate,50594,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,8050,A,,Mus musculus,10090.0,,,
13893,Intermediate,50594,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,8050,A,,Mus musculus,10090.0,,,
13894,Intermediate,50594,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,8050,A,,Mus musculus,10090.0,,,
13895,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,8050,A,,Mus musculus,10090.0,,,
13896,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,8050,A,,Mus musculus,10090.0,,,
13897,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,8050,A,,Mus musculus,10090.0,,,
13898,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,8050,A,,Mus musculus,10090.0,,,
13899,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,8050,A,,Mus musculus,10090.0,,,
13900,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,8050,A,,Mus musculus,10090.0,,,
13901,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,8050,A,,Mus musculus,10090.0,,,
13902,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,8050,A,,Mus musculus,10090.0,,,
13903,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,8050,A,,Mus musculus,10090.0,,,
13904,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,8050,A,,Mus musculus,10090.0,,,
13905,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,8050,A,,Mus musculus,10090.0,,,
13906,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,8050,A,,Mus musculus,10090.0,,,
13907,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13908,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13909,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13910,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13911,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13912,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13913,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13914,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13915,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13916,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13917,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13918,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13919,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13920,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13921,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13922,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13923,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
13924,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13925,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13926,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13927,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13928,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13929,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13930,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13931,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13932,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13933,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13934,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13935,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13936,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13937,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13938,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13939,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13940,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13941,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13942,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13943,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13944,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13945,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13946,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13947,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13948,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13949,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13950,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13951,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13952,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13953,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13954,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13955,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13956,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
13957,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13958,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
13959,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13960,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13961,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13962,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13963,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13964,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
13965,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13966,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13967,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13968,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13969,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13970,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13971,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13972,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13973,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13974,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13975,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13976,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13977,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13978,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13979,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13980,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
13981,Autocuration,22229,,,Octanol:water partition coefficient is evaluated,8362,P,,,,,,
13982,Autocuration,22224,,,Partition coefficient in 1-octanol/water system,8257,P,,,,,,
13983,Autocuration,22224,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,8257,P,,,,,,
13984,Autocuration,22224,,,Partition coefficient in octanol/water system was determined,9468,P,,,,,,
13985,Autocuration,22224,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,9468,P,,,,,,
13986,Autocuration,22224,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,10568,A,,,,,,
13987,Autocuration,22224,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",10568,A,,,,,,
13988,Autocuration,22224,,,Pseudo-first-order rate constant of the compound,15359,A,,,,,,
13989,Autocuration,22224,,,Pseudo-first-order rate constant with 1-min time point,15359,A,,,,,,
13990,Autocuration,22224,,,Pseudo-first-order rate constant without 1-min time point,15359,A,,,,,,
13991,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,10431,A,,,,,,
13992,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,10431,A,,,,,,
13993,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,10431,A,,,,,,
13994,Autocuration,22224,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,15704,A,,,,,,
13995,Autocuration,22224,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,15287,A,,,,,,
13996,Autocuration,22224,,,The efflux rate constant of the compound,7516,A,,,,,,
13997,Autocuration,22224,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,12973,A,,,,,,
13998,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,12973,A,,,,,,
13999,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,12973,F,,,,,,
14000,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,12973,A,,,,,,
14001,Autocuration,22224,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,8696,A,,,,,,
14002,Autocuration,22224,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,15052,A,,,,,,
14003,Autocuration,22224,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,15052,A,,,,,,
14004,Autocuration,22224,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),10503,A,,,,,,
14005,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14006,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14007,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14008,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14009,Autocuration,22224,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14010,Autocuration,22224,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,10503,A,,,,,,
14011,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14012,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14013,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14014,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14015,Intermediate,50597,Lung,,Biodistribution in rat lung at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14016,Intermediate,50597,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14017,Intermediate,50597,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14018,Intermediate,50597,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14019,Intermediate,50597,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14020,Intermediate,50597,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14021,Intermediate,50597,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14022,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14023,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14024,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14025,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14026,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14027,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14028,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 3 hr after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14029,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14030,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14031,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14032,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14033,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14034,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14035,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14036,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14037,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14038,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14039,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14040,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14041,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14042,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14043,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,13100,A,In vivo,Rattus norvegicus,10116.0,,,
14044,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",13331,A,,,,,,
14045,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",13331,A,,,,,,
14046,Autocuration,22224,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),13331,A,,,,,,
14047,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",13331,A,,,,,,
14048,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",13331,A,,,,,,
14049,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",13331,A,,,,,,
14050,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",13331,A,,,,,,
14051,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",13331,A,,,,,,
14052,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14053,Autocuration,22224,Urine,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,10086,F,,,,,,
14054,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14055,Autocuration,22224,Urine,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,10086,F,,,,,,
14056,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14057,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14058,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14059,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,10086,A,,Rattus norvegicus,10116.0,,,
14060,Intermediate,50597,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,13248,A,,Rattus norvegicus,10116.0,,,
14061,Intermediate,50597,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,13248,A,,Rattus norvegicus,10116.0,,,
14062,Intermediate,50587,Liver,,In vitro metabolism in human liver microsomes,14527,A,,Homo sapiens,9606.0,,,
14063,Intermediate,50587,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,3008,A,,Homo sapiens,9606.0,,,
14064,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14065,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14066,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14067,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14068,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14069,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14070,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14071,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14072,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14073,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14074,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14075,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14076,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14077,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14078,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14079,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14080,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14081,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14082,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14083,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14084,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14085,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14086,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14087,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14088,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14089,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14090,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14091,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14092,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14093,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14094,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14095,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14096,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14097,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14098,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14099,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14100,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14101,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14102,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14103,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14104,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14105,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14106,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14107,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14108,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14109,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14110,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14111,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",12017,A,In vivo,Rattus norvegicus,10116.0,,,
14112,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14113,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14114,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14115,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14116,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14117,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14118,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14119,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14120,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14121,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14122,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14123,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14124,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14125,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14126,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),14045,A,In vivo,Rattus norvegicus,10116.0,,,
14127,Intermediate,50594,,,Biodistribution in mice bladder plus excreted urine was determined,14045,A,In vivo,Mus musculus,10090.0,,,
14128,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14129,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14130,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14131,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14132,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 10 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14133,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 30 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14134,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14135,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 60 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14136,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14137,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14138,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14139,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14140,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14141,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14142,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14143,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14144,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 10 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14145,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",14045,A,,Mus musculus,10090.0,,,
14146,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14147,Intermediate,50594,Liver,,Biodistribution in mice liver at 60 minutes of post injection,14045,A,In vivo,Mus musculus,10090.0,,,
14148,Intermediate,50594,Lung,,Biodistribution in mice lungs at 10 min of post injection,14045,A,In vivo,Mus musculus,10090.0,,,
14149,Intermediate,50594,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14150,Intermediate,50594,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",14045,A,,Mus musculus,10090.0,,,
14151,Intermediate,50594,Lung,,Biodistribution in mice lungs at 60 min of post injection,14045,A,In vivo,Mus musculus,10090.0,,,
14152,Intermediate,50594,Spleen,,Percentage biodistribution in mouse spleen,14045,A,,Mus musculus,10090.0,,,
14153,Intermediate,50594,Stomach,,Percentage biodistribution in mouse stomach,14045,A,,Mus musculus,10090.0,,,
14154,Intermediate,50594,Urine,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,11745,A,,Mus musculus,10090.0,,,
14155,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,13257,A,In vivo,,,,,
14156,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,13257,A,In vivo,,,,,
14157,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,13257,A,In vivo,,,,,
14158,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,13257,A,In vivo,,,,,
14159,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,13257,A,In vivo,,,,,
14160,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,13257,A,In vivo,,,,,
14161,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,13257,A,In vivo,,,,,
14162,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,13257,A,In vivo,,,,,
14163,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
14164,Intermediate,50597,Serum,,Affinity for protein binding expressed as association constant in fresh rat serum,7095,A,,Rattus norvegicus,10116.0,,,
14165,Autocuration,22224,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,12185,A,,,,,,
14166,Autocuration,22224,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,12185,A,,,,,,
14167,Autocuration,22224,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,12185,A,,,,,,
14168,Autocuration,22224,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,12185,A,,,,,,
14169,Autocuration,22224,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,12686,A,,,,,,
14170,Autocuration,22224,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",12686,A,,,,,,
14171,Autocuration,22224,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,12686,A,,,,,,
14172,Autocuration,22224,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",12686,A,,,,,,
14173,Autocuration,22224,,,Apparent rate constant Koff for inactivation of dTMP synthase.,8057,A,,,,,,
14174,Autocuration,22224,,,The irreversible inhibitor activity by second order rate equation.,15778,A,,,,,,
14175,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,12375,A,,Rattus norvegicus,10116.0,,,
14176,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,12375,A,,Rattus norvegicus,10116.0,,,
14177,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,12375,A,,Rattus norvegicus,10116.0,,,
14178,Autocuration,22224,,,Dissociation rate calculated from the first-order equation using t1/2 value,13588,A,,,,,,
14179,Autocuration,22224,,,The compound was tested for Binding constant against DNA,15039,A,,,,,,
14180,Autocuration,22224,,,First order rate constant for cyclization of the compound,9500,A,,,,,,
14181,Autocuration,22224,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,10014,A,,,,,,
14182,Autocuration,22224,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,10014,A,,,,,,
14183,Autocuration,22224,,,Hydrolysis rate constant was determined,568,A,,,,,,
14184,Autocuration,22224,,,Observed first order rate constant,10026,A,,,,,,
14185,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,10281,A,,,,,,
14186,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,10281,A,,,,,,
14187,Autocuration,22224,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,9680,A,,,,,,
14188,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14189,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14190,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14191,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14192,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14193,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14194,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14195,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14196,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14197,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14198,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14199,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14200,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14201,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14202,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14203,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14204,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14205,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14206,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14207,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14208,Intermediate,50587,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,3008,A,,Homo sapiens,9606.0,,,
14209,Intermediate,50587,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,4509,A,,Homo sapiens,9606.0,,,
14210,Intermediate,50587,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,4509,A,,Homo sapiens,9606.0,,,
14211,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14212,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,8613,A,,Human herpesvirus 1,10298.0,,,
14213,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14214,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14215,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,8613,A,,Human herpesvirus 1,10298.0,,,
14216,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14217,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,8613,A,,Human herpesvirus 1,10298.0,,,
14218,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14219,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14220,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14221,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,8613,A,,Human herpesvirus 1,10298.0,,,
14222,Autocuration,22229,,,Calculated partition coefficient (clogP) (MlogP),6021,P,,,,,,
14223,Autocuration,22224,,,Equipotent potent ratio relative to carbachol (nicotinic activity),9348,A,,,,,,
14224,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",15592,A,,Canis lupus familiaris,9615.0,,,
14225,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",15592,A,,Canis lupus familiaris,9615.0,,,
14226,Autocuration,22229,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,15592,P,,,,,,
14227,Autocuration,22229,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,15592,P,,,,,,
14228,Autocuration,22229,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,15592,P,,,,,,
14229,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,15592,A,In vivo,Canis lupus familiaris,9615.0,,,
14230,Intermediate,50597,Serum,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,7095,A,,Rattus norvegicus,10116.0,,,
14231,Autocuration,22224,,,Area under the MAP curve measured over 5 min; ND means Not determined,16618,A,,,,,,
14232,Autocuration,22224,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,16835,P,,,,,,
14233,Autocuration,22229,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,15284,P,,,,,,
14234,Autocuration,22224,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,15750,A,,,,,,
14235,Intermediate,50597,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,16618,A,In vivo,Rattus norvegicus,10116.0,,,
14236,Autocuration,22224,,,Half life after oral tested,16618,A,In vivo,,,,,
14237,Intermediate,50597,Plasma,,Half life was determined in plasma of rat; NT indicates not tested,15812,A,,Rattus norvegicus,10116.0,,,
14238,Intermediate,50597,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,16618,A,In vivo,Rattus norvegicus,10116.0,,,
14239,Autocuration,22224,,,Oral bioavailability after oral tested,16618,A,In vivo,,,,,
14240,Intermediate,50597,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),13098,A,,Rattus norvegicus,10116.0,,,
14241,Intermediate,50597,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),13098,A,,Rattus norvegicus,10116.0,,,
14242,Intermediate,50597,Plasma,,half life was determined in plasma of rat; NT indicates not tested,15812,A,,Rattus norvegicus,10116.0,,,
14243,Intermediate,50597,Plasma,,half life was determined in plasma of rat; NT means not tested,15812,A,,Rattus norvegicus,10116.0,,,
14244,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,11510,A,,Rattus norvegicus,10116.0,,,
14245,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,11510,A,,Rattus norvegicus,10116.0,,,
14246,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,11510,A,,Rattus norvegicus,10116.0,,,
14247,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,11510,A,,Rattus norvegicus,10116.0,,,
14248,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,11510,A,,Rattus norvegicus,10116.0,,,
14249,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,11510,A,,Rattus norvegicus,10116.0,,,
14250,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,11510,A,,Rattus norvegicus,10116.0,,,
14251,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,11510,A,,Rattus norvegicus,10116.0,,,
14252,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,11510,A,,Rattus norvegicus,10116.0,,,
14253,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,11510,A,,Rattus norvegicus,10116.0,,,
14254,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,11510,A,,Rattus norvegicus,10116.0,,,
14255,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,11510,A,,Rattus norvegicus,10116.0,,,
14256,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,11510,A,,Rattus norvegicus,10116.0,,,
14257,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,11510,A,,Rattus norvegicus,10116.0,,,
14258,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,11510,A,,Rattus norvegicus,10116.0,,,
14259,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,11510,A,,Rattus norvegicus,10116.0,,,
14260,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,11510,A,,Rattus norvegicus,10116.0,,,
14261,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14262,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14263,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14264,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14265,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14266,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14267,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14268,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14269,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14270,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14271,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14272,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14273,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14274,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14275,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14276,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14277,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14278,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14279,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14280,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14281,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14282,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14283,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14284,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14285,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14286,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14287,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14288,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14289,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14290,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14291,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14292,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14293,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14294,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14295,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14296,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14297,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14298,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14299,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14300,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14301,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14302,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14303,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14304,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14305,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14306,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14307,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14308,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),13257,A,In vivo,,,,,
14309,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,13257,A,In vivo,,,,,
14310,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,13257,A,In vivo,,,,,
14311,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),13257,A,In vivo,,,,,
14312,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,13257,A,In vivo,,,,,
14313,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,13257,A,In vivo,,,,,
14314,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,13257,A,In vivo,,,,,
14315,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,13257,A,In vivo,,,,,
14316,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,13257,A,In vivo,,,,,
14317,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,13257,A,In vivo,,,,,
14318,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,13257,A,In vivo,,,,,
14319,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,13257,A,In vivo,,,,,
14320,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,13257,A,In vivo,,,,,
14321,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,13257,A,In vivo,,,,,
14322,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,13257,A,In vivo,,,,,
14323,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),13257,A,In vivo,,,,,
14324,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,13257,A,In vivo,,,,,
14325,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),13257,A,In vivo,,,,,
14326,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,13257,A,In vivo,,,,,
14327,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,13257,A,In vivo,,,,,
14328,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,13257,A,In vivo,,,,,
14329,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,13257,A,In vivo,,,,,
14330,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,13257,A,In vivo,,,,,
14331,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,13257,A,In vivo,,,,,
14332,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,13257,A,In vivo,,,,,
14333,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,13257,A,In vivo,,,,,
14334,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,13257,A,In vivo,,,,,
14335,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,13257,A,In vivo,,,,,
14336,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,13257,A,In vivo,,,,,
14337,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,13257,A,In vivo,,,,,
14338,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),13257,A,In vivo,,,,,
14339,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,13257,A,In vivo,,,,,
14340,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,13257,A,In vivo,,,,,
14341,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),13257,A,In vivo,,,,,
14342,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,13257,A,In vivo,,,,,
14343,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,13257,A,In vivo,,,,,
14344,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,13257,A,In vivo,,,,,
14345,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,13257,A,In vivo,,,,,
14346,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,13257,A,In vivo,,,,,
14347,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,13257,A,In vivo,,,,,
14348,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,13257,A,In vivo,,,,,
14349,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,13257,A,In vivo,,,,,
14350,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,13257,A,In vivo,,,,,
14351,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,13257,A,In vivo,,,,,
14352,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,2193,A,,,,,,
14353,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,2193,A,,,,,,
14354,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,2193,A,,,,,,
14355,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,2193,A,,,,,,
14356,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,2193,A,,,,,,
14357,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,2193,A,,,,,,
14358,Autocuration,22224,,,Hydrolysis rate constant was determined,568,A,,,,,,
14359,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",9680,A,,,,,,
14360,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",9680,A,,,,,,
14361,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",9680,A,,,,,,
14362,Autocuration,22224,,,Observed second order rate constant,10026,A,,,,,,
14363,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,10281,A,,,,,,
14364,Autocuration,22224,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,10014,A,,,,,,
14365,Autocuration,22224,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,10014,A,,,,,,
14366,Autocuration,22224,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",9680,A,,,,,,
14367,Autocuration,22224,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",9680,A,,,,,,
14368,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14369,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14370,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14371,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14372,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14373,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14374,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14375,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14376,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14377,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,13028,A,,,,,,
14378,Intermediate,50597,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,10014,A,,Rattus norvegicus,10116.0,,,
14379,Autocuration,22224,,,Association constant for compound at 31 degree C was determined,9962,A,,,,,,
14380,Autocuration,22224,,,Calculated antagonist equilibrium dissociation constant of the compound,12029,A,,,,,,
14381,Autocuration,22224,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,12029,A,,,,,,
14382,Intermediate,50512,Trachea,,Dissociation constants vs LTE4 on guinea pig trachea,10583,A,,Cavia porcellus,10141.0,,,
14383,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",568,A,,,,,,
14384,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",568,A,,,,,,
14385,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",568,A,,,,,,
14386,Autocuration,22224,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",568,A,,,,,,
14387,Autocuration,22224,,,Affinity constant KD value was derived from TMP,7493,A,,,,,,
14388,Autocuration,22224,,,Apparent dissociation (binding) rate constant was evaluated,8371,A,,,,,,
14389,Autocuration,22224,,,Dissociation constant (KD) of the compound,13114,P,,,,,,
14390,Autocuration,22224,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,15515,P,,,,,,
14391,Autocuration,22224,,,Dissociation constant from ESR titration experiments,522,P,,,,,,
14392,Autocuration,22224,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),13888,,,,,,,
14393,Autocuration,22224,,,Dissociation constant was evaluated.,2616,P,,,,,,
14394,Autocuration,22224,,,Dissociation constant was reported,3798,P,,,,,,
14395,Intermediate,50597,,,Dissociation constant was determined in rat pituitary cells.,8731,A,,Rattus norvegicus,10116.0,,,
14396,Autocuration,22224,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,11892,A,,,,,,
14397,Autocuration,22224,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,11892,A,,,,,,
14398,Autocuration,22224,,,Equilibrium dissociation constant of the compound,2582,A,,,,,,
14399,Autocuration,22224,,,Equilibrium dissociation constant was determined,11892,A,,,,,,
14400,Autocuration,22224,,,Kinetic constant KD was evaluated,13396,A,,,,,,
14401,Autocuration,22224,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,603,A,,,,,,
14402,Autocuration,22224,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,15673,A,,,,,,
14403,Autocuration,22224,,,Rate constant for hydrolysis in aqueous acetone.,10368,A,,,,,,
14404,Autocuration,22224,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,14228,A,,,,,,
14405,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,11510,A,,Rattus norvegicus,10116.0,,,
14406,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,11510,A,,Rattus norvegicus,10116.0,,,
14407,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,11510,A,,Rattus norvegicus,10116.0,,,
14408,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,11510,A,,Rattus norvegicus,10116.0,,,
14409,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,11510,A,,Rattus norvegicus,10116.0,,,
14410,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,11510,A,,Rattus norvegicus,10116.0,,,
14411,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,11510,A,,Rattus norvegicus,10116.0,,,
14412,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,11510,A,,Rattus norvegicus,10116.0,,,
14413,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,11510,A,,Rattus norvegicus,10116.0,,,
14414,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14415,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14416,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14417,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14418,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14419,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14420,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14421,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,11510,A,,Rattus norvegicus,10116.0,,,
14422,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14423,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14424,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14425,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14426,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14427,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14428,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14429,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14430,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14431,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14432,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14433,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14434,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14435,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14436,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14437,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14438,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14439,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14440,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14441,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14442,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,11510,A,,Rattus norvegicus,10116.0,,,
14443,Intermediate,50588,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,8310,A,,Canis lupus familiaris,9615.0,,,
14444,Intermediate,50588,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,8310,A,,Canis lupus familiaris,9615.0,,,
14445,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14446,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14447,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14448,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14449,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14450,Intermediate,50588,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,8310,A,,Canis lupus familiaris,9615.0,,,
14451,Intermediate,50594,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14452,Intermediate,50588,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,8310,A,,Canis lupus familiaris,9615.0,,,
14453,Intermediate,50588,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,8310,A,,Canis lupus familiaris,9615.0,,,
14454,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14455,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14456,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14457,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14458,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,8310,A,,Mus musculus,10090.0,,,
14459,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14460,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14461,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14462,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14463,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14464,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14465,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14466,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14467,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14468,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14469,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14470,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14471,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14472,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14473,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14474,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14475,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14476,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14477,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14478,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14479,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14480,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14481,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14482,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14483,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14484,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14485,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14486,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14487,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14488,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14489,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14490,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14491,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14492,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14493,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14494,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14495,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14496,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14497,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14498,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14499,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14500,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14501,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14502,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14503,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14504,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14505,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14506,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14507,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),13257,A,In vivo,,,,,
14508,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),13257,A,In vivo,,,,,
14509,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,13257,A,In vivo,,,,,
14510,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,13257,A,In vivo,,,,,
14511,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,13257,A,In vivo,,,,,
14512,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,13257,A,In vivo,,,,,
14513,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,13257,A,In vivo,,,,,
14514,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,13257,A,In vivo,,,,,
14515,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,13257,A,In vivo,,,,,
14516,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,13257,A,In vivo,,,,,
14517,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,13257,A,In vivo,,,,,
14518,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,13257,A,In vivo,,,,,
14519,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,13257,A,In vivo,,,,,
14520,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,13257,A,In vivo,,,,,
14521,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),13257,A,In vivo,,,,,
14522,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,13257,A,In vivo,,,,,
14523,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,13257,A,In vivo,,,,,
14524,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),13257,A,In vivo,,,,,
14525,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,13257,A,In vivo,,,,,
14526,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,13257,A,In vivo,,,,,
14527,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,13257,A,In vivo,,,,,
14528,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,13257,A,In vivo,,,,,
14529,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,13257,A,In vivo,,,,,
14530,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14531,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14532,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14533,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14534,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14535,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14536,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14537,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14538,Intermediate,50597,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14539,Intermediate,50597,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14540,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14541,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14542,Intermediate,50597,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14543,Intermediate,50597,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14544,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14545,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14546,Intermediate,50597,Cerebellum,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14547,Intermediate,50597,Cerebellum,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14548,Intermediate,50597,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14549,Intermediate,50597,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14550,Intermediate,50597,Hippocampus,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14551,Intermediate,50597,Hippocampus,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14552,Intermediate,50597,Hypothalamus,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14553,Intermediate,50597,Hypothalamus,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14554,Intermediate,50597,Cerebellum,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14555,Intermediate,50597,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14556,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,12404,A,,,,,,
14557,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",568,A,,,,,,
14558,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",568,A,,,,,,
14559,Autocuration,22224,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",568,A,,,,,,
14560,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,12404,A,,,,,,
14561,Intermediate,50212,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,7624,A,,Escherichia coli,562.0,,,
14562,Intermediate,50597,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",7624,A,,Rattus norvegicus,10116.0,,,
14563,Intermediate,50597,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",7624,A,,Rattus norvegicus,10116.0,,,
14564,Autocuration,22224,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",4643,A,,,,,,
14565,Autocuration,22224,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,11532,A,,,,,,
14566,Autocuration,22224,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,11018,A,,,,,,
14567,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",2276,A,,,,,,
14568,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",2276,A,,,,,,
14569,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",2276,A,,,,,,
14570,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",2276,A,,,,,,
14571,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",2276,A,,,,,,
14572,Autocuration,22224,,,Michaelis constant (KM) was evaluated,8949,A,,,,,,
14573,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,12404,A,,,,,,
14574,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,7625,B,,,,,,
14575,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,7625,B,,,,,,
14576,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,7625,B,,,,,,
14577,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,7625,B,,,,,,
14578,Autocuration,22224,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,12908,A,,,,,,
14579,Autocuration,22224,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,10368,A,,,,,,
14580,Autocuration,22224,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),13108,A,,,,,,
14581,Autocuration,22224,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),13108,A,,,,,,
14582,Autocuration,22224,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,15217,A,,,,,,
14583,Autocuration,22224,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,15217,A,,,,,,
14584,Autocuration,22224,,,Binding constant was determined,10933,A,,,,,,
14585,Autocuration,22224,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,2363,A,,,,,,
14586,Autocuration,22224,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,2363,A,,,,,,
14587,Autocuration,22224,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,2276,A,,,,,,
14588,Autocuration,22224,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,14915,P,,,,,,
14589,Autocuration,22224,,,Catalytic rate constant of the compound,8847,A,,,,,,
14590,Autocuration,22224,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,15357,B,,,,,,
14591,Autocuration,22224,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),2869,A,,,,,,
14592,Autocuration,22224,,,Catalytic rate constant against phospholipase A2 was determined,3484,A,,,,,,
14593,Autocuration,22224,,,"Compound was evaluated for catalytic constant, Kcat",1373,A,,,,,,
14594,Autocuration,22224,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,8142,A,,,,,,
14595,Autocuration,22224,,,Kcat calculated from 0.693/T1/2,14131,A,,,,,,
14596,Autocuration,22224,,,Kcat was determined,17269,A,,,,,,
14597,Autocuration,22224,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,3485,A,,,,,,
14598,Autocuration,22224,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,3485,A,,,,,,
14599,Autocuration,22224,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,3485,A,,,,,,
14600,Autocuration,22224,,,Kcat value was determined,5962,A,,,,,,
14601,Autocuration,22224,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,3133,A,,,,,,
14602,Autocuration,22224,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,3133,A,,,,,,
14603,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",2276,A,,,,,,
14604,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",2276,A,,,,,,
14605,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",2276,A,,,,,,
14606,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",2276,A,,,,,,
14607,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",2276,A,,,,,,
14608,Autocuration,22224,,,Kinetic parameter for rate of conversion to PABA was determined,4892,A,,,,,,
14609,Autocuration,22224,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,3133,A,,,,,,
14610,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",11488,A,,Rattus norvegicus,10116.0,,,
14611,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",11488,A,,Rattus norvegicus,10116.0,,,
14612,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",11488,A,,Rattus norvegicus,10116.0,,,
14613,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",11488,A,,Rattus norvegicus,10116.0,,,
14614,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",11488,A,,Rattus norvegicus,10116.0,,,
14615,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",11488,A,,Rattus norvegicus,10116.0,,,
14616,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14617,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14618,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14619,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14620,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14621,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14622,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14623,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14624,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14625,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14626,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14627,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14628,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14629,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14630,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14631,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14632,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14633,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,11488,A,,Rattus norvegicus,10116.0,,,
14634,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",7132,A,,Oryctolagus cuniculus,9986.0,,,
14635,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14636,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14637,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14638,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",7132,A,,Oryctolagus cuniculus,9986.0,,,
14639,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14640,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14641,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14642,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14643,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",7132,A,,Oryctolagus cuniculus,9986.0,,,
14644,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14645,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14646,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14647,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",7132,A,,Oryctolagus cuniculus,9986.0,,,
14648,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14649,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14650,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14651,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",7132,A,,Oryctolagus cuniculus,9986.0,,,
14652,Intermediate,50597,Blood,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14653,Intermediate,50597,Blood,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14654,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14655,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14656,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14657,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14658,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14659,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14660,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14661,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14662,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14663,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14664,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14665,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14666,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14667,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14668,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14669,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14670,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14671,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,12582,A,,Canis lupus familiaris,9615.0,,,
14672,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14673,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14674,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14675,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14676,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14677,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14678,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14679,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14680,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14681,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14682,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14683,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14684,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14685,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14686,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14687,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14688,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14689,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14690,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14691,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14692,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14693,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14694,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14695,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14696,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14697,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14698,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14699,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14700,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14701,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14702,Intermediate,50597,Hippocampus,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14703,Intermediate,50597,Hypothalamus,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14704,Intermediate,50597,Hypothalamus,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,15413,A,In vivo,Rattus norvegicus,10116.0,,,
14705,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14706,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14707,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14708,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14709,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14710,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14711,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14712,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14713,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14714,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14715,Intermediate,50597,Blood,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14716,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14717,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14718,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14719,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14720,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14721,Intermediate,50597,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14722,Intermediate,50597,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14723,Intermediate,50597,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14724,Intermediate,50597,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14725,Intermediate,50597,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14726,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14727,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14728,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14729,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14730,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14731,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14732,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14733,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14734,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14735,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14736,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14737,Intermediate,50597,Liver,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14738,Intermediate,50597,Liver,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14739,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14740,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14741,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14742,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14743,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14744,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14745,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14746,Autocuration,22224,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,3133,A,,,,,,
14747,Autocuration,22224,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,2742,A,,,,,,
14748,Autocuration,22224,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,2742,A,,,,,,
14749,Autocuration,22224,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,2742,A,,,,,,
14750,Autocuration,22224,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,2742,A,,,,,,
14751,Autocuration,22224,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,2742,A,,,,,,
14752,Autocuration,22224,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,2742,A,,,,,,
14753,Autocuration,22224,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,2742,A,,,,,,
14754,Autocuration,22224,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,2742,A,,,,,,
14755,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",2276,A,,,,,,
14756,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",2276,A,,,,,,
14757,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",2276,A,,,,,,
14758,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",2276,A,,,,,,
14759,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",2276,A,,,,,,
14760,Autocuration,22224,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",2276,A,,,,,,
14761,Autocuration,22224,,,Ratio of Kcat to that of Km was determined,17269,A,,,,,,
14762,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",2276,A,,,,,,
14763,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",2276,A,,,,,,
14764,Autocuration,22224,,,"Compound was evaluated for constant, Kd",15917,A,,,,,,
14765,Autocuration,22224,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,10933,A,,,,,,
14766,Autocuration,22224,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,10933,A,,,,,,
14767,Autocuration,22224,,,Dissociation Constant of compound determined,14293,A,,,,,,
14768,Autocuration,22224,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,6698,B,,,,,,
14769,Autocuration,22224,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,6698,B,,,,,,
14770,Autocuration,22224,,,Dissociation constant of compound with Fructose was determined,4318,P,,,,,,
14771,Autocuration,22224,,,Dissociation constant of compound with Fructose was determined; Not determined,4318,P,,,,,,
14772,Autocuration,22224,,,Dissociation constant of compound with Lactulose was determined,4318,P,,,,,,
14773,Autocuration,22224,,,Dissociation constant of compound with Lactulose was determined; Not determined,4318,P,,,,,,
14774,Autocuration,22224,,,Dissociation constant of the Compound,14959,P,,,,,,
14775,Autocuration,22224,,,Dissociation constant by non-linear regression analysis,5913,P,,,,,,
14776,Autocuration,22224,,,Dissociation constant was determined,14218,P,,,,,,
14777,Autocuration,22224,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,10689,P,,,,,,
14778,Autocuration,22224,,,Dissociation constant was determined,13925,P,,,,,,
14779,Autocuration,22224,,,Dissociation constant was determined,16359,P,,,,,,
14780,Intermediate,50597,Muscle tissue,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,10944,A,,Rattus norvegicus,10116.0,,,
14781,Autocuration,22224,,,The dissociation constant determined by fluorescence displacement assay,11080,A,,,,,,
14782,Autocuration,22224,,,kd value surface plasmon resonance (SPR) method,17805,A,,,,,,
14783,Intermediate,50597,Muscle tissue,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,10944,A,,Rattus norvegicus,10116.0,,,
14784,Autocuration,22224,,,First dissociation constant of the binding of compound to V30M TTR,16645,F,,,,,,
14785,Autocuration,22224,,,Second dissociation constant of the binding of compound to V30M TTR,16645,F,,,,,,
14786,Autocuration,22224,,,"Compound was evaluated for equilibrium constant, Ke",7793,A,,,,,,
14787,Autocuration,22224,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,12199,A,,,,,,
14788,Autocuration,22224,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,12199,A,,,,,,
14789,Autocuration,22224,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,9680,A,,,,,,
14790,Autocuration,22224,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,9680,A,,,,,,
14791,Autocuration,22224,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,9680,A,,,,,,
14792,Intermediate,50594,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,13758,A,,Mus musculus,10090.0,,,
14793,Intermediate,50594,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,13758,A,,Mus musculus,10090.0,,,
14794,Intermediate,50594,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,13758,A,,Mus musculus,10090.0,,,
14795,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,13758,A,,Mus musculus,10090.0,,,
14796,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,13758,A,,Mus musculus,10090.0,,,
14797,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,13758,A,,Mus musculus,10090.0,,,
14798,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,13758,A,,Mus musculus,10090.0,,,
14799,Intermediate,50594,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,13758,A,,Mus musculus,10090.0,,,
14800,Intermediate,50597,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,,Rattus norvegicus,10116.0,,,
14801,Intermediate,50597,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,14393,A,,Rattus norvegicus,10116.0,,,
14802,Intermediate,50597,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",15078,A,,Rattus norvegicus,10116.0,,,
14803,Intermediate,50597,Brain,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14804,Intermediate,50597,Brain,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14805,Intermediate,50597,Heart,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14806,Intermediate,50597,Heart,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14807,Intermediate,50597,Kidney,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14808,Intermediate,50597,Kidney,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14809,Intermediate,50597,Liver,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14810,Intermediate,50597,Liver,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14811,Intermediate,50597,Lung,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14812,Intermediate,50597,Lung,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14813,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14814,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14815,Intermediate,50597,Zone of skin,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14816,Intermediate,50597,Zone of skin,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14817,Intermediate,50597,Spleen,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14818,Intermediate,50597,Spleen,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,13925,A,In vivo,Rattus norvegicus,10116.0,,,
14819,Intermediate,50597,Blood,,Biodistribution of Compound in rat blood after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14820,Intermediate,50597,Blood,,Biodistribution of Compound in rat blood after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14821,Intermediate,50597,Brain,,Biodistribution of Compound in rat brain after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14822,Intermediate,50597,Brain,,Biodistribution of Compound in rat brain after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14823,Intermediate,50597,Heart,,Biodistribution of Compound in rat heart after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14824,Intermediate,50597,Heart,,Biodistribution of Compound in rat heart after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14825,Intermediate,50597,Liver,,Biodistribution of Compound in rat liver after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14826,Intermediate,50597,Liver,,Biodistribution of Compound in rat liver after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14827,Intermediate,50597,Lung,,Biodistribution of Compound in rat lung after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14828,Intermediate,50597,Lung,,Biodistribution of Compound in rat lung after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14829,Intermediate,50597,Muscle tissue,,Biodistribution of Compound in rat muscle after 15 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14830,Intermediate,50597,Muscle tissue,,Biodistribution of Compound in rat muscle after 2 minutes of administration,9712,A,In vivo,Rattus norvegicus,10116.0,,,
14831,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,13925,A,,Rattus norvegicus,10116.0,,,
14832,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,13925,A,,Rattus norvegicus,10116.0,,,
14833,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,13925,A,,Rattus norvegicus,10116.0,,,
14834,Intermediate,50597,,,Organ distribution in rat blood 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14835,Intermediate,50597,,,Organ distribution in rat blood 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14836,Intermediate,50597,,,Organ distribution in rat blood 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14837,Intermediate,50597,,,Organ distribution in rat blood 30 min after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14838,Intermediate,50597,,,Organ distribution in rat brain 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14839,Intermediate,50597,,,Organ distribution in rat brain 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14840,Intermediate,50597,,,Organ distribution in rat brain 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14841,Intermediate,50597,,,Organ distribution in rat heart 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14842,Intermediate,50597,,,Organ distribution in rat heart 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14843,Intermediate,50597,,,Organ distribution in rat heart 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14844,Intermediate,50597,,,Organ distribution in rat kidney 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14845,Intermediate,50597,,,Organ distribution in rat kidney 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14846,Intermediate,50597,,,Organ distribution in rat kidney 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14847,Intermediate,50597,Liver,,Organ distribution in rat liver 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14848,Intermediate,50597,Liver,,Organ distribution in rat liver 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14849,Intermediate,50597,Liver,,Organ distribution in rat liver 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14850,Intermediate,50597,,,Organ distribution in rat lung 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14851,Intermediate,50597,,,Organ distribution in rat lung 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14852,Intermediate,50597,,,Organ distribution in rat lung 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14853,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 2 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14854,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 2 hr after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14855,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 30 minutes after intravenous injection,6941,A,,Rattus norvegicus,10116.0,,,
14856,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),14439,A,In vivo,Mus musculus,10090.0,,,
14857,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),14439,A,In vivo,Mus musculus,10090.0,,,
14858,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),14439,A,In vivo,Mus musculus,10090.0,,,
14859,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14860,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14861,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14862,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14863,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14864,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14865,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14866,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14867,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14868,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14869,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14870,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14871,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14872,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14873,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14874,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14875,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14876,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14877,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14878,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14879,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14880,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14881,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14882,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14883,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14884,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14885,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14886,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14887,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14888,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,12582,A,,Rattus norvegicus,10116.0,,,
14889,Intermediate,50597,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",7415,A,,Rattus norvegicus,10116.0,,,
14890,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,7313,A,,,,,,
14891,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,7313,A,,,,,,
14892,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,7313,A,,,,,,
14893,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,7570,A,,,,,,
14894,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,7570,A,,,,,,
14895,Autocuration,22224,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,7570,A,,,,,,
14896,Autocuration,22224,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,7570,A,,,,,,
14897,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,7570,A,,,,,,
14898,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,7570,A,,,,,,
14899,Autocuration,22224,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,7570,A,,,,,,
14900,Autocuration,22224,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,7570,A,,,,,,
14901,Autocuration,22224,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,7570,A,,,,,,
14902,Autocuration,22224,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,7570,A,,,,,,
14903,Autocuration,22224,Adrenal cortex,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,7570,A,,,,,,
14904,Autocuration,22224,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,7570,A,,,,,,
14905,Autocuration,22224,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,7570,A,,,,,,
14906,Autocuration,22224,Adrenal cortex,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,7570,A,,,,,,
14907,Autocuration,22224,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,7570,A,,,,,,
14908,Autocuration,22224,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,7570,A,,,,,,
14909,Autocuration,22224,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",14122,A,In vivo,Canis lupus familiaris,9615.0,,,
14910,Autocuration,22224,,,Absolute bioavailability in male cynomolgus monkeys,16449,A,In vivo,Macaca fascicularis,9541.0,,,
14911,Autocuration,22224,,,Absolute bioavailability in maleSprague-Dawley rats,16449,A,In vivo,Rattus norvegicus,10116.0,,,
14912,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14913,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14914,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14915,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14916,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14917,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14918,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14919,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14920,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14921,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14922,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14923,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14924,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14925,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14926,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14927,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14928,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14929,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14930,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14931,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14932,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14933,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14934,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14935,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14936,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14937,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14938,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14939,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14940,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14941,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14942,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14943,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14944,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14945,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14946,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14947,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14948,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14949,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14950,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 120 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14951,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 24 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14952,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 4 hr,15045,A,In vivo,Mus musculus,10090.0,,,
14953,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14954,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14955,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14956,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14957,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14958,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14959,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14960,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),12017,A,In vivo,Rattus norvegicus,10116.0,,,
14961,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14962,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14963,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,12017,A,In vivo,Rattus norvegicus,10116.0,,,
14964,Intermediate,50597,,,The Kel values in female wistar rats.,14941,A,,Rattus norvegicus,10116.0,,,
14965,Autocuration,22224,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,4646,A,,,,,,
14966,Autocuration,22224,,,Hydrolysis rate constant of the compound,8847,A,,,,,,
14967,Autocuration,22229,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,11778,P,,,,,,
14968,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",2363,A,,,,,,
14969,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",2363,A,,,,,,
14970,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",2363,A,,,,,,
14971,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",2363,A,,,,,,
14972,Autocuration,22224,,,Apparent inactivation rate constant was evaluated,8371,A,,,,,,
14973,Autocuration,22224,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,14883,A,,,,,,
14974,Autocuration,22224,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,14883,A,,,,,,
14975,Autocuration,22224,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,4643,A,,,,,,
14976,Autocuration,22224,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,3519,A,,,,,,
14977,Autocuration,22224,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,10600,A,,,,,,
14978,Autocuration,22224,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,8501,F,,,,,,
14979,Autocuration,22224,,,Dissociation constant was determined,8505,P,,,,,,
14980,Autocuration,22224,,,Dissociation constant was determined,9778,P,,,,,,
14981,Autocuration,22224,,,Dissociation constant at pH 7.4,9778,P,,,,,,
14982,Autocuration,22224,,,Dissociation constant in presence of 1 mM dithiothreitol,9778,P,,,,,,
14983,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,13007,A,,,,,,
14984,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,13007,A,,,,,,
14985,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,13007,A,,,,,,
14986,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,13007,A,,,,,,
14987,Autocuration,22224,,,Kinetic constant for aromatization of androstenedione,11482,A,,,,,,
14988,Autocuration,22224,,,Kinetic constant for aromatization of testosterone,11482,A,,,,,,
14989,Autocuration,22224,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,2303,A,,,,,,
14990,Autocuration,22224,,,Local inhibition constant was determined,11964,A,,,,,,
14991,Intermediate,50347,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,3140,A,,Saccharomyces cerevisiae,4932.0,,,
14992,Autocuration,22224,,,Dissociation constant value of the compound,10650,P,,,,,,
14993,Autocuration,22224,Cornea,,In vitro permeability through cornea without epithelium,4667,A,,,,,,
14994,Autocuration,22224,Cornea,,In vitro permeability through intact cornea,4667,A,,,,,,
14995,Intermediate,50592,Cornea,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,9199,A,,Oryctolagus cuniculus,9986.0,,,
14996,Autocuration,22224,,,Rate of enzyme inactivation for the compound was determined,11966,A,,,,,,
14997,Autocuration,22224,Cornea,,In vitro permeability through cornea without epithelium,4667,A,,,,,,
14998,Autocuration,22224,Cornea,,In vitro permeability through intact cornea,4667,A,,,,,,
14999,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15000,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15001,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15002,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15003,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15004,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15005,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15006,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15007,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15008,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15009,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15010,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15011,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15012,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15013,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",8354,A,,,,,,
15014,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),14439,A,In vivo,Mus musculus,10090.0,,,
15015,Intermediate,50587,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,14439,A,In vivo,Homo sapiens,9606.0,,,
15016,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),14439,A,In vivo,Mus musculus,10090.0,,,
15017,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),14439,A,In vivo,Mus musculus,10090.0,,,
15018,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),14439,A,In vivo,Mus musculus,10090.0,,,
15019,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),14439,A,In vivo,Mus musculus,10090.0,,,
15020,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,14439,A,In vivo,Mus musculus,10090.0,,,
15021,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),14439,A,In vivo,Mus musculus,10090.0,,,
15022,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),14439,A,In vivo,Mus musculus,10090.0,,,
15023,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),14439,A,In vivo,Mus musculus,10090.0,,,
15024,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),14439,A,In vivo,Mus musculus,10090.0,,,
